
**CUMULATIVE SUPPLEMENT 10**
**October 2026**



# APPROVED DRUG PRODUCTS

## WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

## 46th EDITION


**Department of Health and Human Services**
**Food and Drug Administration**
**Office of Medical Products and Tobacco**
**Center for Drug Evaluation and Research**
**Office of Generic Drugs**
**Office of Generic Drug Regulatory Affairs**



**2026**

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Regulatory Affairs

**APPROVED DRUG PRODUCTS**
**with**
**THERAPEUTIC EQUIVALENCE EVALUATIONS**

**46th EDITION**

**Cumulative Supplement 10**
**October 2026**

**CONTENTS**

*PAGE*

# Contents


1.0 INTRODUCTION ..... v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT ..... vi
1.2 CUMULATIVE SUPPLEMENT CONTENT ..... vi
1.3 LEVOTHYROXINE SODIUM ..... vii
1.4 AVAILABILITY OF THE EDITION ..... viii
1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST ..... ix
1.6 CUMULATIVE SUPPLEMENT LEGEND ..... x

DRUG PRODUCT LISTS
Prescription Drug Product List ..... 1-1
OTC Drug Product List ..... 2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List ..... 3-1
Orphan Products Designations and Approvals List ..... 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ..... 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM
A. Patent and Exclusivity Lists ..... A-1
B. Patent and Exclusivity Terms ..... B-1

**APPROVED DRUG PRODUCTS**
**with**
**THERAPEUTIC EQUIVALENCE EVALUATIONS**

**46th EDITION**

**CUMULATIVE SUPPLEMENT 10**
**October 2026**

## 1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

## 1.3 LEVOTHYROXINE SODIUM[1]

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[2]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

| TE Code | Proprietary Name | Applicant | Strength | Appl No | RLD | RS |
|---|---|---|---|---|---|---|
| AB1 | UNITHROID | STEVENS J | 0.3MG | N021210 | RLD | RS |
| | | | | | | |

[1] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.
[2] Please consult the Active Section of the Orange Book for information on other strengths.

| | | | | | | |
|---|---|---|---|---|---|---|
| AB2 | ABBVIE INC | ABBVIE | 0.3MG | N021402 | RLD | RS |
| | | | | | | |
| AB3 | LEVOXYL | KING PHARMS | 0.2MG | N021301 | RLD | RS |
| | | | | | | |
| AB4 | THYRO-TABS | ALVOGEN INC | 0.3MG | N021116 | RLD | – |
| AB4 | LEVOTHYROXINE SODIUM[3] | MYLAN | 0.3MG | A076187 | – | RS |

## 1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
https://www.fda.gov/about-fda/reports-manuals-forms/forms.

[3] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

## 1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

| CATEGORIES COUNTED | DEC 2025 | MAR 2026 | JUN 2026 | SEP 2026 | DEC 2026 |
|---|---|---|---|---|---|
| DRUG PRODUCTS | 24120 | 24441 | 24637 | 24771 | |
| LISTED SINGLE SOURCE | 2765 (11.5%) | 2813 (11.5%) | 2807 (11.4%) | 2805 (11.3%) | |
| MULTISOURCE | 21355 (88.5%) | 21628 (88.5%) | 21830 (88.6%) | 21966 (88.7%) | |
| THERAPEUTICALLY EQUIVALENT | 21260 (87.1%) | 21534 (88.1%) | 21763 (88.3%) | 21908 (88.4%) | |
| NOT THERAPEUTICALLY EQUIVALENT | 95 (0.4%) | 94 (0.4%) | 67 (0.3%) | 58 (0.2%) | |

| | | | | |
|---|---|---|---|---|
| EXCEPTIONS[4] | 47 (0.2%) | 47 (0.2%) | 47 (0.2%) | 47 (0.2%) |
| NEW MOLECULAR ENTITIES APPROVED | 19 | 41 | 36 | 32 |
| NUMBER OF APPLICANTS | 1198 | 1198 | 1195 | 1163 |

## 1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

| | |
|---|---|
| NEWA | New drug product approval |
| NFTG | New first-time generic approval |
| CAHN[5] | Applicant holder firm name has changed |
| CAIN | Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. |
| CDFR | Change. Dosage Form; Route of Administration |
| CFTG | Change. A TE Code is added when a first time generic for an innovator is approved. |
| CMFD | Change. The product is moved from the Discontinued Section due to a change in marketing status. |
| CMKT | Change. RX to OTC marketing status switch. |
| CMS1 | Change. Miscellaneous addition to list. |
| CMS2 | Change. Miscellaneous deletion from list. |

[4] Amino acid containing products of varying composition (see Introduction, page xx of the List).
[5] The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

| | |
|---|---|
| CPOT | Change. Potency amount/unit. |
| CRLD | Change. Reference Listed Drug |
| CHRS | Change. Reference Standard |
| CTEC | Change. Therapeutic Equivalence Code. |
| CTNA | Change. Trade Name. |
| DISC | Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition. |

ABAMETAPIR

LOTION;TOPICAL

XEGLYZE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | LNHC | 0.74% | N206966 | 001 | Jul 24, 2020 | Apr | CAHN |

ABARELIX

POWDER;INTRAMUSCULAR

PLENAXIS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | SPECIALITY EUROPEAN | 100MG/VIAL | N021320 | 001 | Nov 25, 2003 | Jan | CDFR |

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | REGCON HOLDINGS | 500MG | A215086 | 001 | Mar 23, 2023 | Sep | CAHN |

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | APPCO | 333MG | A218984 | 001 | Mar 16, 2026 | Mar | NEWA |
| AB | SOMERSET THERAPS LLC | 333MG | A218984 | 001 | Mar 16, 2026 | Sep | CAHN |

ACARBOSE

TABLET;ORAL

ACARBOSE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | AVET LIFESCIENCES | 25MG | A202271 | 001 | Feb 07, 2012 | Jul | DISC |
| @ | | 50MG | A202271 | 002 | Feb 07, 2012 | Jul | DISC |
| @ | | 100MG | A202271 | 003 | Feb 07, 2012 | Jul | DISC |
| @ | NATCO PHARMA USA | 25MG | A091053 | 001 | Jan 06, 2011 | Mar | CAHN |
| @ | | 50MG | A091053 | 002 | Jan 06, 2011 | Mar | CAHN |
| @ | | 100MG | A091053 | 003 | Jan 06, 2011 | Mar | CAHN |

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP1 | APOTEX | 1GM/100ML (10MG/ML) | A205746 | 001 | Apr 18, 2023 | May | CAHN |

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | PHARMAZONE | 300MG;50MG | A214088 | 001 | Apr 07, 2022 | Sep | CAHN |
| AA | | 325MG;25MG | A214088 | 002 | Apr 07, 2022 | Sep | CAHN |
| AA | | 325MG;50MG | A214088 | 003 | Apr 07, 2022 | Sep | CAHN |
| AA | PHARMOBEDIENT | 300MG;50MG | A207386 | 001 | Nov 15, 2016 | Sep | CAHN |

BUTAPAP

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA ! | MIKART | 325MG;50MG | A089987 | 001 | Oct 26, 1992 | Mar | CAHN |
| AA ! | PHARMOBEDIENT | 325MG;50MG | A089987 | 001 | Oct 26, 1992 | Sep | CAHN |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | INGENUS PHARMS LLC | 300MG;50MG;40MG | A215047 | 001 | Nov 17, 2021 | Feb | CAHN |
| AA | PHARMAZONE | 300MG;50MG;40MG | A214087 | 001 | Aug 13, 2021 | Sep | CAHN |
| AA | | 325MG;50MG;40MG | A214087 | 002 | Aug 13, 2021 | Sep | CAHN |

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA ! | ABHAI LLC | 325MG;50MG;40MG | A211106 | 001 | Sep 26, 2018 | Jun | CHRS |
| @ | HIKMA | 325MG;50MG;40MG | A089718 | 001 | Jun 12, 1995 | Sep | CAHN |
| AA | PHARMOBEDIENT | 325MG;50MG;40MG | A089175 | 001 | Jan 21, 1987 | Sep | CAHN |
| @ | STRIDES PHARMA INTL | 325MG;50MG;40MG | A040511 | 001 | Aug 27, 2003 | Jun | DISC |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | QUAGEN | 325MG;50MG;40MG;30MG | A204649 | 001 | Jul 08, 2020 | Apr | CAHN |

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | ! | PAI HOLDINGS | 120MG/5ML;12MG/5ML | A087508 | 001 | | Sep CAHN |

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | | ADAPTIS | 300MG;15MG | A211610 | 001 | Jun 27, 2019 | Sep CAHN |
| | AA | | | 300MG;30MG | A211610 | 002 | Jun 27, 2019 | Sep CAHN |
| | AA | | | 300MG;60MG | A211610 | 003 | Jun 27, 2019 | Sep CAHN |

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AA | | GENUS | 325MG/15ML;7.5MG/15ML | A040894 | 001 | Jul 19, 2011 | Oct CAHN |
| >A> | AA | | PAI HOLDINGS | 325MG/15ML;7.5MG/15ML | A040894 | 001 | Jul 19, 2011 | Oct CAHN |
| | | @ | | 325MG/15ML;7.5MG/15ML | A200343 | 001 | Jan 25, 2012 | Sep CAHN |
| | | ! | PHARMOBEDIENT | 300MG/15ML;10MG/15ML | A040881 | 001 | Feb 25, 2010 | Sep CAHN |

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | | ADAPTIS | 300MG;5MG | A207509 | 001 | Oct 29, 2018 | Sep CAHN |
| | AA | | | 300MG;7.5MG | A207509 | 002 | Oct 29, 2018 | Sep CAHN |
| | AA | | | 300MG;10MG | A207509 | 003 | Oct 29, 2018 | Sep CAHN |
| | AA | | LANNETT CO INC | 300MG;5MG | A207171 | 001 | Jun 20, 2017 | Mar CMFD |
| | AA | | | 300MG;7.5MG | A207171 | 002 | Jun 20, 2017 | Mar CMFD |
| | AA | | | 300MG;10MG | A207171 | 003 | Jun 20, 2017 | Mar CMFD |
| | AA | | | 325MG;5MG | A207172 | 001 | Jun 22, 2017 | Mar CMFD |
| | AA | | | 325MG;7.5MG | A207172 | 002 | Jun 22, 2017 | Mar CMFD |
| | AA | | | 325MG;10MG | A207172 | 003 | Jun 22, 2017 | Mar CMFD |
| | | @ | PHARMAZONE | 325MG;5MG | A211690 | 001 | Feb 07, 2020 | Sep CAHN |
| | | @ | | 325MG;7.5MG | A211690 | 002 | Feb 07, 2020 | Sep CAHN |
| | | @ | | 325MG;10MG | A211690 | 003 | Feb 07, 2020 | Sep CAHN |
| | | @ | STRIDES PHARMA INTL | 325MG;5MG | A040655 | 001 | Jan 19, 2006 | Jan DISC |
| | | @ | | 325MG;7.5MG | A040656 | 001 | Jan 19, 2006 | Jan DISC |
| | | @ | | 325MG;10MG | A040355 | 001 | May 31, 2000 | Jan DISC |

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | | PHARMOBEDIENT | 300MG/5ML;10MG/5ML | A202142 | 001 | Nov 27, 2018 | Sep CAHN |

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | | LANNETT CO INC | 325MG;5MG | A207333 | 001 | Sep 25, 2017 | Feb CMFD |
| | AA | | | 325MG;10MG | A207333 | 002 | Sep 25, 2017 | Feb CMFD |
| | | @ | PHARMAZONE | 325MG;5MG | A207574 | 001 | Dec 13, 2016 | Sep CAHN |
| | | ! | PHARMOBEDIENT | 300MG;2.5MG | A040608 | 001 | Dec 30, 2005 | Sep CAHN |
| | | ! | | 300MG;5MG | A040608 | 002 | Dec 30, 2005 | Sep CAHN |
| | | ! | | 300MG;7.5MG | A040608 | 003 | Dec 30, 2005 | Sep CAHN |
| | | ! | | 300MG;10MG | A040608 | 004 | Dec 30, 2005 | Sep CAHN |

PERCOCET

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | ! | OZANTRI | 325MG;2.5MG | A040330 | 001 | Jun 25, 1999 | Apr CAHN |
| | AA | ! | | 325MG;5MG | A040330 | 002 | Jun 25, 1999 | Apr CAHN |
| | | @ + | | 325MG;5MG | A085106 | 002 | | Apr CAHN |
| | AA | ! | | 325MG;7.5MG | A040330 | 003 | Nov 23, 2001 | Apr CAHN |
| | AA | ! | | 325MG;10MG | A040330 | 004 | Nov 23, 2001 | Apr CAHN |

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | MICRO LABS LTD INDIA | 325MG;37.5MG | A201952 | 001 | Dec 14, 2012 | Jun DISC |
| | | @ | PHARMAZONE | 325MG;37.5MG | A078778 | 001 | Apr 07, 2014 | Sep CAHN |
| | | @ | SENORES PHARMS | 325MG;37.5MG | A078778 | 001 | Apr 07, 2014 | Jun CAHN |

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ADAPTIS | 125MG | A211556 | 001 | Oct 18, 2019 | Sep CAHN |
| | AB | | | 250MG | A211556 | 002 | Oct 18, 2019 | Sep CAHN |

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | COSETTE PHARMS NC | 2%;1% | A040609 | 001 | Feb 06, 2006 | May | CAHN |

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | APOTEX | 6GM/30ML (200MG/ML) | N021539 | 001 | Jan 23, 2004 | Jul | CAHN |

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | AZURITY | 0.4MG/INH | N202450 | 001 | Jul 23, 2012 | Jun | CAHN |
| | +! | | 0.4MG/INH | N202450 | 001 | Jul 23, 2012 | Mar | CAHN |

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | AZURITY | 0.4MG/INH;0.012MG/INH | N210595 | 001 | Mar 29, 2019 | Sep | DISC |
| | +! | | 0.4MG/INH;0.012MG/INH | N210595 | 001 | Mar 29, 2019 | Jul | CAHN |
| | +! | | 0.4MG/INH;0.012MG/INH | N210595 | 001 | Mar 29, 2019 | Mar | CAHN |

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | PHARMOBEDIENT | 200MG | A212173 | 001 | Sep 14, 2020 | Sep | CAHN |

OINTMENT;TOPICAL

ACYCLOVIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | 5% | A205591 | 001 | Nov 13, 2017 | May | CAHN |

TABLET;ORAL

ACYCLOVIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 400MG | A209366 | 001 | Oct 07, 2019 | Sep | CAHN |
| AB | | | 800MG | A209366 | 002 | Oct 07, 2019 | Sep | CAHN |
| AB | | PHARMOBEDIENT | 400MG | A210401 | 001 | Mar 07, 2018 | Sep | CAHN |
| AB | | | 800MG | A210401 | 002 | Mar 07, 2018 | Sep | CAHN |
| | @ | STRIDES PHARMA INTL | 400MG | A074946 | 001 | Nov 19, 1997 | Jan | DISC |
| | @ | | 800MG | A074946 | 002 | Nov 19, 1997 | Jan | DISC |

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | HAINAN POLY | EQ 50MG BASE/ML | A218111 | 001 | Jan 08, 2024 | Jul | CAHN |

ADAPALENE

GEL;TOPICAL

ADAPALENE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> AB | | ENCUBE | 0.3% | A200298 | 001 | Jun 14, 2012 | Oct | CAHN |
| >D> AB | | ENCUBE ETHICALS | 0.3% | A200298 | 001 | Jun 14, 2012 | Oct | CAHN |

SOLUTION;TOPICAL

ADAPALENE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | WAYLIS THERAP | 0.1% | A203981 | 001 | Sep 23, 2016 | Jan | CAHN |
| AB | | | 0.1% | A204593 | 001 | Jan 05, 2016 | Jan | CAHN |

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA LTD | 0.3%;2.5% | A217384 | 001 | Jul 22, 2026 | Jul | NEWA |
| >D> AB | | ENCUBE | 0.1%;2.5% | A206164 | 001 | May 23, 2018 | Oct | CAHN |
| >A> AB | | | 0.1%;2.5% | A206164 | 001 | May 23, 2018 | Oct | CAHN |
| AB | ! | SUN PHARMA CANADA | 0.1%;2.5% | A206959 | 001 | Jan 24, 2018 | Jun | CHRS |

EPIDUO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | GALDERMA LABS LP | 0.1%;2.5% | N022320 | 001 | Dec 08, 2008 | Jun | DISC |

AFATINIB DIMALEATE

TABLET;ORAL

AFATINIB DIMALEATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | APOTEX | EQ 20MG BASE | A210725 | 001 | Jul 14, 2026 | Jul | NFTG |
| AB | | | EQ 30MG BASE | A210725 | 002 | Jul 14, 2026 | Jul | NFTG |
| AB | | | EQ 40MG BASE | A210725 | 003 | Jul 14, 2026 | Jul | NFTG |
| AB | | HETERO LABS LTD V | EQ 20MG BASE | A210750 | 001 | Jul 14, 2026 | Jul | NFTG |

TABLET;ORAL
AFATINIB DIMALEATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | | EQ 30MG BASE | A210750 | 002 | Jul 14, 2026 | Jul NFTG |
| AB | | | EQ 40MG BASE | A210750 | 003 | Jul 14, 2026 | Jul NFTG |
| >A> AB | | MSN | EQ 20MG BASE | A210804 | 001 | Oct 21, 2026 | Oct NEWA |
| >A> AB | | | EQ 30MG BASE | A210804 | 002 | Oct 21, 2026 | Oct NEWA |
| >A> AB | | | EQ 40MG BASE | A210804 | 003 | Oct 21, 2026 | Oct NEWA |

GILOTRIF

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + | BOEHRINGER INGELHEIM | EQ 20MG BASE | N201292 | 001 | Jul 12, 2013 | Jul CFTG |
| AB | + | | EQ 30MG BASE | N201292 | 002 | Jul 12, 2013 | Jul CFTG |
| AB | +! | | EQ 40MG BASE | N201292 | 003 | Jul 12, 2013 | Jul CFTG |

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION
ALBUTEROL SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB3 | | CIPLA | EQ 0.09MG BASE/INH | A219409 | 001 | Apr 22, 2026 | Apr NFTG |

VENTOLIN HFA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB3 | +! | GLAXOSMITHKLINE | EQ 0.09MG BASE/INH | N020983 | 001 | Apr 19, 2001 | Apr CFTG |

SYRUP;ORAL
ALBUTEROL SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | COSETTE PHARMS NC | EQ 2MG BASE/5ML | A074454 | 001 | Sep 25, 1995 | May CAHN |

TABLET;ORAL
ALBUTEROL SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | ADAPTIS | EQ 2MG BASE | A213524 | 001 | Oct 08, 2020 | Sep CAHN |
| @ | | | EQ 4MG BASE | A213524 | 002 | Oct 08, 2020 | Sep CAHN |
| @ | | AIZANT | EQ 2MG BASE | A210948 | 001 | Mar 15, 2019 | Jul DISC |
| @ | | | EQ 4MG BASE | A210948 | 002 | Mar 15, 2019 | Jul DISC |
| @ | | NATCO PHARMA USA | EQ 2MG BASE | A072894 | 002 | Jan 17, 1991 | Jun DISC |
| AB | | | EQ 2MG BASE | A072894 | 002 | Jan 17, 1991 | Mar CAHN |
| @ | | | EQ 4MG BASE | A072894 | 001 | Jan 17, 1991 | Jun DISC |
| AB | ! | | EQ 4MG BASE | A072894 | 001 | Jan 17, 1991 | Mar CAHN |
| AB | ! | ZYDUS PHARMS | EQ 4MG BASE | A208884 | 002 | Oct 22, 2020 | Jun CHRS |

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL
ACLOVATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | | FOUGERA | 0.05% | N018707 | 001 | Dec 14, 1982 | Jul CAHN |

OINTMENT;TOPICAL
ACLOVATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | | FOUGERA | 0.05% | N018702 | 001 | Dec 14, 1982 | Jul CAHN |

ALENDRONATE SODIUM

SOLUTION;ORAL
ALENDRONATE SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | PRECISION DOSE INC | EQ 70MG BASE/75ML | A214523 | 001 | Sep 02, 2026 | Aug NEWA |

TABLET, EFFERVESCENT;ORAL
BINOSTO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | | RADIUS | EQ 70MG BASE | N202344 | 001 | Mar 12, 2012 | Jun DISC |

ALISKIREN HEMIFUMARATE

TABLET;ORAL
TEKTURNA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + | LXO IRELAND | EQ 150MG BASE | N021985 | 001 | Mar 05, 2007 | Jan CAHN |
| AB | +! | | EQ 300MG BASE | N021985 | 002 | Mar 05, 2007 | Jan CAHN |

ALLOPURINOL

TABLET;ORAL
LOPURIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | DR REDDYS | 100MG | A071587 | 002 | Apr 02, 1987 | Jul CMS1 |

ALOSETRON HYDROCHLORIDE

TABLET;ORAL
ALOSETRON HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | EQ 0.5MG BASE | A211621 | 001 | Sep 16, 2019 | Sep CAHN |
| AB | | | EQ 1MG BASE | A211621 | 002 | Sep 16, 2019 | Sep CAHN |

LOTRONEX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + | LEGACY | EQ 0.5MG BASE | N021107 | 002 | Dec 23, 2003 | Jun CAHN |
| AB | +! | | EQ 1MG BASE | N021107 | 001 | Feb 09, 2000 | Jun CAHN |

ALPELISIB

GRANULE;ORAL

VIJOICE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | NOVARTIS | 50MG/PACKET | N218466 | 001 | Apr 24, 2024 | Apr | CDFR |

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION;INTRAVENOUS

INFUVITE ADULT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | SANDOZ CANADA INC | 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML | N021163 | 001 | May 18, 2000 | Apr | CFTG |
| AP | +! | | 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML | N021163 | 002 | Jun 16, 2003 | Apr | CFTG |

MULTIPLE VITAMINS INJECTION ADULT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | APOTEX | 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML | A210273 | 001 | Apr 09, 2026 | Apr | NFTG |
| AP | | | 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML | A210672 | 001 | Apr 09, 2026 | Apr | NFTG |

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | STRIDES PHARMA INTL | 0.25MG | A090248 | 001 | Sep 17, 2010 | Jan | DISC |
| | @ | | 0.5MG | A090248 | 002 | Sep 17, 2010 | Jan | DISC |
| | @ | | 1MG | A090248 | 003 | Sep 17, 2010 | Jan | DISC |
| | @ | | 2MG | A090248 | 004 | Sep 17, 2010 | Jan | DISC |
| | @ | TP ANDA HOLDINGS | 0.25MG | A078491 | 001 | Sep 25, 2008 | Sep | CAHN |
| | @ | | 0.5MG | A078491 | 002 | Sep 25, 2008 | Sep | CAHN |
| | @ | | 1MG | A078491 | 003 | Sep 25, 2008 | Sep | CAHN |
| | @ | | 2MG | A078491 | 004 | Dec 12, 2008 | Sep | CAHN |
| AB | | UNICHEM | 0.25MG | A213204 | 001 | Jul 13, 2026 | Jul | NEWA |
| AB | | | 0.5MG | A213204 | 002 | Jul 13, 2026 | Jul | NEWA |
| AB | | | 1MG | A213204 | 003 | Jul 13, 2026 | Jul | NEWA |
| AB | | | 2MG | A213204 | 004 | Jul 13, 2026 | Jul | NEWA |

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ACTAVIS ELIZABETH | 0.5MG | A078056 | 001 | Feb 13, 2007 | Aug | DISC |
| | @ | | 1MG | A078056 | 002 | Feb 13, 2007 | Aug | DISC |
| | @ | | 2MG | A078056 | 003 | Feb 13, 2007 | Aug | DISC |
| | @ | | 3MG | A078056 | 004 | Feb 13, 2007 | Aug | DISC |

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ONESOURCE | 100MG | A211354 | 001 | Feb 18, 2022 | Jul | CAHN |

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | PHARMOBEDIENT | 50MG/5ML | A075819 | 001 | Sep 11, 2002 | Sep | CAHN |
| AA | | | 50MG/5ML | A214178 | 001 | Aug 20, 2021 | Sep | CAHN |
| AA | | POM PHARMA | 50MG/5ML | A214178 | 001 | Aug 20, 2021 | Apr | CAHN |

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | PHARMOBEDIENT | 100MG | A210215 | 001 | Mar 10, 2020 | Sep | CAHN |
| AB | | POM PHARMA | 100MG | A210215 | 001 | Mar 10, 2020 | Apr | CAHN |
| | @ | WATSON LABS INC | 100MG | A208096 | 001 | Dec 15, 2016 | Jul | DISC |

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | SUN PHARM | 5MG | A210784 | 001 | Mar 28, 2019 | May DISC |
| @ | | | 10MG | A210784 | 002 | Mar 28, 2019 | Jun DISC |

AMCINONIDE

CREAM;TOPICAL

AMCINONIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | GENUS LIFESCIENCES | 0.1% | A076065 | 001 | May 15, 2003 | Jun DISC |
| ! | | TARO PHARM INDS | 0.1% | A076229 | 001 | May 31, 2002 | Jun CTEC |
| AB ! | | | 0.1% | A076229 | 001 | May 31, 2002 | Jun CHRS |

AMIFAMPRIDINE PHOSPHATE

TABLET;ORAL

>A> AMIFAMPRIDINE PHOSPHATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> AB | | LUPIN | EQ 10MG BASE | A217996 | 001 | Oct 30, 2026 | Oct NFTG |

FIRDAPSE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >D> | +! | CATALYST PHARMS | EQ 10MG BASE | N208078 | 001 | Nov 28, 2018 | Oct CFTG |
| >A> AB | +! | | EQ 10MG BASE | N208078 | 001 | Nov 28, 2018 | Oct CFTG |

AMIFOSTINE

INJECTABLE;INJECTION

ETHYOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | LEGACY | 375MG/VIAL | N020221 | 002 | Sep 10, 1999 | Jun CAHN |
| +! | | | 500MG/VIAL | N020221 | 001 | Dec 08, 1995 | Jun CAHN |
| @ | | LEGACY PHARMA | 375MG/VIAL | N020221 | 002 | Sep 10, 1999 | Mar CAHN |
| @ + | | | 500MG/VIAL | N020221 | 001 | Dec 08, 1995 | Mar CAHN |
| +! | | | 500MG/VIAL | N020221 | 001 | Dec 08, 1995 | Mar CMFD |

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | ZENARA | 250MG/ML | A215374 | 001 | Aug 28, 2025 | Mar CAHN |

SOLUTION;ORAL

AMINOCAPROIC ACID

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | APOZEAL PHARMS | 0.25GM/ML | A213216 | 001 | May 19, 2025 | Jul CAHN |
| AA | | CARNEGIE | 0.25GM/ML | A214140 | 001 | Jan 26, 2021 | Feb CAHN |
| AA | | PHARMAZONE | 0.25GM/ML | A213216 | 001 | May 19, 2025 | Sep CAHN |

TABLET;ORAL

AMINOCAPROIC ACID

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CARNEGIE | 500MG | A213928 | 001 | Feb 12, 2021 | Feb CAHN |
| AB | | | 1GM | A213928 | 002 | Feb 12, 2021 | Feb CAHN |
| AB | | PHARMOBEDIENT | 500MG | A213928 | 001 | Feb 12, 2021 | Sep CAHN |
| AB | | | 1GM | A213928 | 002 | Feb 12, 2021 | Sep CAHN |
| AB | | RISING | 500MG | A213944 | 001 | Sep 14, 2022 | May CAHN |
| AB | | | 1GM | A213944 | 002 | Sep 14, 2022 | May CAHN |

AMINOPHYLLINE

SUPPOSITORY;RECTAL

TRUPHYLLINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | COSETTE PHARMS NC | 250MG | A085498 | 001 | Mar 23, 1983 | May CAHN |
| @ | | | 500MG | A085498 | 002 | Jan 03, 1983 | May CAHN |

TABLET;ORAL

AMINOPHYLLINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | HIKMA | 100MG | A084540 | 001 | | Sep CAHN |
| @ | | | 200MG | A085003 | 001 | | Sep CAHN |

AMISULPRIDE

SOLUTION;INTRAVENOUS

BARHEMSYS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | | LXO IRELAND | 5MG/2ML (2.5MG/ML) | N209510 | 001 | Feb 26, 2020 | Jun CAHN |
| +! | | | 10MG/4ML (2.5MG/ML) | N209510 | 002 | Sep 01, 2020 | Jun CAHN |

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE;ORAL

AMITRIPTYLINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> ! | | CMP DEV LLC | 40MG/ML | A219639 | 001 | Nov 05, 2026 | Oct NFTG |

TABLET;ORAL
AMITRIPTYLINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA USA | 10MG | A086009 | 002 | | Mar CMFD |
| AB | | | 25MG | A086009 | 003 | | Mar CMFD |
| AB | | | 50MG | A086009 | 001 | | Mar CMFD |
| AB | | | 75MG | A086009 | 004 | | Mar CMFD |
| AB | | | 100MG | A086009 | 005 | | Mar CMFD |
| AB | | | 150MG | A086009 | 006 | | Mar CMFD |
| AB | | RUBICON RESEARCH | 10MG | A215376 | 001 | May 01, 2023 | May CTEC |
| AB | | | 25MG | A215376 | 002 | May 01, 2023 | May CTEC |
| AB | | | 50MG | A215376 | 003 | May 01, 2023 | May CTEC |
| AB | | | 75MG | A215376 | 004 | May 01, 2023 | May CTEC |
| AB | | | 100MG | A215376 | 005 | May 01, 2023 | May CTEC |
| AB | | | 150MG | A215376 | 006 | May 01, 2023 | May CTEC |

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL
SDAMLO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | BRILLIAN PHARMA | EQ 2.5MG BASE/BOT | N219531 | 001 | Jul 24, 2025 | Jan CMFD |
| | +! | | EQ 5MG BASE/BOT | N219531 | 002 | Jul 24, 2025 | Jan CMFD |
| | +! | | EQ 10MG BASE/BOT | N219531 | 003 | Jul 24, 2025 | Jan CMFD |

TABLET;ORAL
AMLODIPINE BESYLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | GRAVITI PHARMS | EQ 2.5MG BASE | A201380 | 003 | Feb 17, 2026 | Feb NEWA |
| AB | | IPCA LABS LTD | EQ 2.5MG BASE | A210489 | 001 | Sep 22, 2026 | Sep NEWA |
| AB | | | EQ 5MG BASE | A210489 | 002 | Sep 22, 2026 | Sep NEWA |
| AB | | | EQ 10MG BASE | A210489 | 003 | Sep 22, 2026 | Sep NEWA |
| AB | | MACLEODS PHARMS | EQ 2.5MG BASE | A076719 | 001 | May 23, 2007 | Sep CAHN |
| AB | | | EQ 5MG BASE | A076719 | 002 | May 23, 2007 | Sep CAHN |
| AB | | | EQ 10MG BASE | A076719 | 003 | May 23, 2007 | Sep CAHN |
| | @ | STRIDES PHARMA | EQ 2.5MG BASE | A077516 | 001 | Jul 11, 2007 | Jun DISC |
| | @ | | EQ 5MG BASE | A077516 | 002 | Jul 11, 2007 | Jun DISC |
| | @ | | EQ 10MG BASE | A077516 | 003 | Jul 11, 2007 | Jun DISC |
| | @ | TEVA PHARMS INC | EQ 2.5MG BASE | A219686 | 001 | Jan 22, 2026 | Sep DISC |
| AB | | | EQ 2.5MG BASE | A219686 | 001 | Jan 22, 2026 | Jan NEWA |
| | @ | | EQ 5MG BASE | A219686 | 002 | Jan 22, 2026 | Sep DISC |
| AB | | | EQ 5MG BASE | A219686 | 002 | Jan 22, 2026 | Jan NEWA |
| | @ | | EQ 10MG BASE | A219686 | 003 | Jan 22, 2026 | Sep DISC |
| AB | | | EQ 10MG BASE | A219686 | 003 | Jan 22, 2026 | Jan NEWA |

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | APDM PHARMS | EQ 2.5MG BASE;EQ 10MG BASE | A207762 | 001 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 2.5MG BASE;EQ 20MG BASE | A207762 | 002 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 2.5MG BASE;EQ 40MG BASE | A207762 | 003 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 5MG BASE;EQ 10MG BASE | A207762 | 004 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 5MG BASE;EQ 20MG BASE | A207762 | 005 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 5MG BASE;EQ 40MG BASE | A207762 | 006 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 5MG BASE;EQ 80MG BASE | A207762 | 007 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 10MG BASE;EQ 10MG BASE | A207762 | 008 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 10MG BASE;EQ 20MG BASE | A207762 | 009 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 10MG BASE;EQ 40MG BASE | A207762 | 010 | Jan 11, 2019 | Jun CAHN |
| AB | | | EQ 10MG BASE;EQ 80MG BASE | A207762 | 011 | Jan 11, 2019 | Jun CAHN |
| AB | | NEOCUBES PHARMA | EQ 2.5MG BASE;EQ 10MG BASE | A207762 | 001 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 2.5MG BASE;EQ 20MG BASE | A207762 | 002 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 2.5MG BASE;EQ 40MG BASE | A207762 | 003 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 5MG BASE;EQ 10MG BASE | A207762 | 004 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 5MG BASE;EQ 20MG BASE | A207762 | 005 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 5MG BASE;EQ 40MG BASE | A207762 | 006 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 5MG BASE;EQ 80MG BASE | A207762 | 007 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 10MG BASE;EQ 10MG BASE | A207762 | 008 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 10MG BASE;EQ 20MG BASE | A207762 | 009 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 10MG BASE;EQ 40MG BASE | A207762 | 010 | Jan 11, 2019 | Sep CAHN |
| AB | | | EQ 10MG BASE;EQ 80MG BASE | A207762 | 011 | Jan 11, 2019 | Sep CAHN |

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | @ | AMNEAL | EQ 2.5MG BASE;10MG | A077215 | 001 | Dec 07, 2018 | Oct CMFD |
| >A> | AB | | | EQ 2.5MG BASE;10MG | A077215 | 001 | Dec 07, 2018 | Oct CMFD |
| >D> | | @ | | EQ 5MG BASE;10MG | A077215 | 002 | Dec 07, 2018 | Oct CMFD |
| >A> | AB | | | EQ 5MG BASE;10MG | A077215 | 002 | Dec 07, 2018 | Oct CMFD |

CAPSULE;ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | @ | | EQ 5MG BASE;20MG | A077215 | 003 | Dec 07, 2018 | Oct CMFD |
| >A> | AB | | | EQ 5MG BASE;20MG | A077215 | 003 | Dec 07, 2018 | Oct CMFD |
| >D> | | @ | | EQ 10MG BASE;20MG | A077215 | 004 | Dec 07, 2018 | Oct CMFD |
| >A> | AB | | | EQ 10MG BASE;20MG | A077215 | 004 | Dec 07, 2018 | Oct CMFD |
| | AB | ! | LUPIN PHARMS | EQ 10MG BASE;40MG | A078466 | 006 | Jul 05, 2011 | May CHRS |

LOTREL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | SANDOZ | EQ 2.5MG BASE;10MG | N020364 | 002 | Mar 03, 1995 | May DISC |
| @ + | | EQ 5MG BASE;10MG | N020364 | 003 | Mar 03, 1995 | May DISC |
| @ + | | EQ 5MG BASE;20MG | N020364 | 004 | Mar 03, 1995 | May DISC |
| @ + | | EQ 5MG BASE;40MG | N020364 | 007 | Apr 11, 2006 | May DISC |
| @ + | | EQ 10MG BASE;20MG | N020364 | 005 | Jun 20, 2002 | May DISC |
| @ + | | EQ 10MG BASE;40MG | N020364 | 006 | Apr 11, 2006 | May DISC |

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | TORRENT | EQ 5MG BASE;12.5MG;20MG | A203580 | 001 | Oct 26, 2016 | Aug CMFD |
| AB | | EQ 10MG BASE;12.5MG;40MG | A203580 | 004 | Oct 26, 2016 | Aug CMFD |
| AB | | EQ 10MG BASE;25MG;40MG | A203580 | 005 | Oct 26, 2016 | Aug CMFD |

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | LUPIN | EQ 5MG BASE;12.5MG;160MG | A200797 | 001 | Jun 03, 2015 | Jun DISC |
| @ | | EQ 5MG BASE;25MG;160MG | A200797 | 002 | Jun 03, 2015 | Jun DISC |
| @ | | EQ 10MG BASE;12.5MG;160MG | A200797 | 003 | Jun 03, 2015 | Jun DISC |
| @ | | EQ 10MG BASE;25MG;160MG | A200797 | 004 | Jun 03, 2015 | Jun DISC |
| @ | | EQ 10MG BASE;25MG;320MG | A200797 | 005 | Jun 03, 2015 | Jun DISC |

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET;ORAL
WIDAPLIK

| | | | | | | |
|---|---|---|---|---|---|---|
| @ + | AZURITY | EQ 1.25MG BASE;0.625MG;10MG | N219423 | 001 | Jun 05, 2025 | Jun DISC |
| +! | | EQ 1.25MG BASE;0.625MG;10MG | N219423 | 001 | Jun 05, 2025 | May CHRS |
| + | | EQ 1.25MG BASE;0.625MG;10MG | N219423 | 001 | Jun 05, 2025 | Mar CMFD |
| @ + | | EQ 2.5MG BASE;1.25MG;20MG | N219423 | 002 | Jun 05, 2025 | Jun DISC |
| + | | EQ 2.5MG BASE;1.25MG;20MG | N219423 | 002 | Jun 05, 2025 | Mar CMFD |
| @ + | | EQ 5MG BASE;2.5MG;40MG | N219423 | 003 | Jun 05, 2025 | Jun DISC |
| +! | | EQ 5MG BASE;2.5MG;40MG | N219423 | 003 | Jun 05, 2025 | Mar CMFD |

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL
TELMISARTAN AND AMLODIPINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | LUPIN | EQ 5MG BASE;40MG | A201586 | 001 | Jan 08, 2014 | Jan DISC |
| @ | | EQ 5MG BASE;80MG | A201586 | 003 | Jan 08, 2014 | Jan DISC |
| @ | | EQ 10MG BASE;40MG | A201586 | 002 | Jan 08, 2014 | Jan DISC |
| @ | | EQ 10MG BASE;80MG | A201586 | 004 | Jan 08, 2014 | Jan DISC |
| | MYLAN | EQ 5MG BASE;40MG | A202516 | 001 | Aug 26, 2014 | Feb CMFD |
| @ | | EQ 5MG BASE;40MG | A202516 | 001 | Aug 26, 2014 | Jan DISC |
| | | EQ 5MG BASE;80MG | A202516 | 003 | Aug 26, 2014 | Feb CMFD |
| @ | | EQ 5MG BASE;80MG | A202516 | 003 | Aug 26, 2014 | Jan DISC |
| | | EQ 10MG BASE;40MG | A202516 | 002 | Aug 26, 2014 | Feb CMFD |
| @ | | EQ 10MG BASE;40MG | A202516 | 002 | Aug 26, 2014 | Jan DISC |
| ! | | EQ 10MG BASE;80MG | A202516 | 004 | Aug 26, 2014 | Feb CMFD |
| @ | | EQ 10MG BASE;80MG | A202516 | 004 | Aug 26, 2014 | Jan DISC |

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL
AMLODIPINE BESYLATE AND VALSARTAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | CADILA PHARMS LTD | EQ 5MG BASE;160MG | A205797 | 001 | Oct 21, 2026 | Oct NEWA |
| >A> | AB | | EQ 5MG BASE;320MG | A205797 | 002 | Oct 21, 2026 | Oct NEWA |
| >A> | AB | | EQ 10MG BASE;160MG | A205797 | 003 | Oct 21, 2026 | Oct NEWA |
| >A> | AB | | EQ 10MG BASE;320MG | A205797 | 004 | Oct 21, 2026 | Oct NEWA |
| | | @ | LUPIN | EQ 5MG BASE;160MG | A090245 | 001 | Mar 30, 2015 | Apr DISC |
| | | @ | | EQ 5MG BASE;320MG | A090245 | 003 | Mar 30, 2015 | Apr DISC |
| | | @ | | EQ 10MG BASE;160MG | A090245 | 002 | Mar 30, 2015 | Apr DISC |
| | | @ | | EQ 10MG BASE;320MG | A090245 | 004 | Mar 30, 2015 | Apr DISC |

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | NUKEMED | 30mCi-300mCi/8ML (3.75-37.5mCi/ML) | A204455 | 001 | Apr 23, 2015 | Apr DISC |
| | ! | WA UNIV SCH MED | 37.5mCi-800mCi/10ML (3.75-80mCi/ML) | A204506 | 002 | Feb 13, 2026 | Feb NFTG |

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PADAGIS ISRAEL | EQ 12% BASE | A075774 | 001 | May 01, 2002 | Jan CHRS |
| AB | ! | SUN PHARMA CANADA | EQ 12% BASE | A075883 | 001 | Apr 10, 2003 | Jan CHRS |
| AB | | ZYDUS LIFESCIENCES | EQ 12% BASE | A217815 | 001 | Feb 12, 2026 | Feb NEWA |

LOTION;TOPICAL

AMMONIUM LACTATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ZYDUS LIFESCIENCES | EQ 12% BASE | A217758 | 001 | May 15, 2026 | May NEWA |

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CHARTWELL RX | 250MG | A061926 | 001 | | Aug CAHN |
| >A> | @ | | 250MG | A062853 | 001 | Dec 22, 1987 | Oct CAHN |
| >A> | @ | | 250MG | A063030 | 001 | Feb 28, 1989 | Oct CAHN |
| AB | ! | | 500MG | A061926 | 003 | | Aug CAHN |
| >A> | @ | | 500MG | A062854 | 001 | Dec 22, 1987 | Oct CAHN |
| >A> | @ | | 500MG | A063031 | 001 | Feb 28, 1989 | Oct CAHN |
| >D> | @ | TEVA | 250MG | A062853 | 001 | Dec 22, 1987 | Oct CAHN |
| >D> | @ | | 250MG | A063030 | 001 | Feb 28, 1989 | Oct CAHN |
| >D> | @ | | 500MG | A062854 | 001 | Dec 22, 1987 | Oct CAHN |
| >D> | @ | | 500MG | A063031 | 001 | Feb 28, 1989 | Oct CAHN |

FOR SUSPENSION;ORAL

AMOXICILLIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | CHARTWELL RX | 125MG/5ML | A061931 | 001 | | Aug CAHN |
| >A> | @ | | 125MG/5ML | A062946 | 001 | Nov 01, 1988 | Oct CAHN |
| AB | | | 200MG/5ML | A065119 | 001 | Dec 04, 2002 | Aug CAHN |
| AB | ! | | 250MG/5ML | A061931 | 002 | | Aug CAHN |
| >A> | @ | | 250MG/5ML | A063001 | 001 | Jan 06, 1989 | Oct CAHN |
| AB | ! | | 400MG/5ML | A065119 | 002 | Dec 04, 2002 | Aug CAHN |
| >D> | @ | TEVA | 125MG/5ML | A062946 | 001 | Nov 01, 1988 | Oct CAHN |
| >D> | @ | | 250MG/5ML | A063001 | 001 | Jan 06, 1989 | Oct CAHN |

AMOXICILLIN PEDIATRIC

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CHARTWELL RX | 50MG/ML | A061931 | 003 | Dec 01, 1982 | Aug CAHN |

TABLET;ORAL

AMOXICILLIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CHARTWELL RX | 500MG | A065056 | 001 | Sep 18, 2000 | Aug CAHN |
| AB | ! | | 875MG | A065056 | 002 | Sep 18, 2000 | Aug CAHN |

TABLET, CHEWABLE;ORAL

AMOXICILLIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | CHARTWELL RX | 125MG | A064013 | 002 | Sep 11, 1995 | Aug CAHN |
| >A> | @ | | 125MG | A064031 | 001 | Dec 19, 1996 | Oct CAHN |
| | ! | | 250MG | A064013 | 001 | Dec 22, 1992 | Aug CAHN |
| >A> | @ | | 250MG | A064031 | 002 | Dec 19, 1996 | Oct CAHN |
| >D> | @ | TEVA | 125MG | A064031 | 001 | Dec 19, 1996 | Oct CAHN |
| >D> | @ | | 250MG | A064031 | 002 | Dec 19, 1996 | Oct CAHN |

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CHARTWELL RX | 200MG/5ML;EQ 28.5MG BASE/5ML | A065089 | 001 | May 25, 2004 | Aug CAHN |
| AB | ! | | 400MG/5ML;EQ 57MG BASE/5ML | A065089 | 002 | May 25, 2004 | Aug CAHN |
| AB | ! | | 600MG/5ML;EQ 42.9MG BASE/5ML | A065162 | 001 | Mar 12, 2004 | Aug CAHN |
| | @ | MICRO LABS | 600MG/5ML;EQ 42.9MG BASE/5ML | A217805 | 001 | Dec 08, 2023 | Aug DISC |
| | @ | MICRO LABS LTD INDIA | 200MG/5ML;EQ 28.5MG BASE/5ML | A205187 | 001 | May 21, 2021 | Aug DISC |
| | @ | | 400MG/5ML;EQ 57MG BASE/5ML | A205187 | 002 | May 21, 2021 | Aug DISC |

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CHARTWELL RX | 500MG;EQ 125MG BASE | A065101 | 001 | Oct 30, 2002 | Aug CAHN |
| AB | | | 875MG;EQ 125MG BASE | A065096 | 001 | Oct 29, 2002 | Aug CAHN |
| AB | | REGCON HOLDINGS | 500MG;EQ 125MG BASE | A209992 | 001 | Sep 15, 2023 | Aug CAHN |
| AB | | | 875MG;EQ 125MG BASE | A209991 | 001 | Sep 15, 2023 | Aug CAHN |

TABLET, CHEWABLE;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | CHARTWELL RX | 200MG;EQ 28.5MG BASE | A065205 | 001 | Feb 09, 2005 | Aug | CAHN |
| | ! | | 400MG;EQ 57MG BASE | A065205 | 002 | Feb 09, 2005 | Aug | CAHN |

TABLET, EXTENDED RELEASE;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | SANDOZ | 1GM;EQ 62.5MG BASE | A090227 | 001 | Apr 21, 2010 | Jan | CTEC |

AUGMENTIN XR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | US ANTIBIOTICS | 1GM;EQ 62.5MG BASE | N050785 | 001 | Sep 25, 2002 | Jan | CMFD |

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AARXION ANDA HLDING | 1.25MG;1.25MG;1.25MG;1.25MG | A206721 | 001 | Nov 10, 2015 | Sep | CAHN |
| | @ | | 1.875MG;1.875MG;1.875MG;1.875MG | A206721 | 002 | Nov 10, 2015 | Sep | CAHN |
| | @ | | 2.5MG;2.5MG;2.5MG;2.5MG | A206721 | 003 | Nov 10, 2015 | Sep | CAHN |
| | @ | | 3.125MG;3.125MG;3.125MG;3.125MG | A206721 | 004 | Nov 10, 2015 | Sep | CAHN |
| | @ | | 3.75MG;3.75MG;3.75MG;3.75MG | A206721 | 005 | Nov 10, 2015 | Sep | CAHN |
| | @ | | 5MG;5MG;5MG;5MG | A206721 | 006 | Nov 10, 2015 | Sep | CAHN |
| | @ | | 7.5MG;7.5MG;7.5MG;7.5MG | A206721 | 007 | Nov 10, 2015 | Sep | CAHN |
| AB | | PHARMOBEDIENT | 1.25MG;1.25MG;1.25MG;1.25MG | A210293 | 001 | Apr 03, 2020 | Sep | CAHN |
| AB | | | 1.875MG;1.875MG;1.875MG;1.875MG | A210293 | 002 | Apr 03, 2020 | Sep | CAHN |
| AB | | | 2.5MG;2.5MG;2.5MG;2.5MG | A210293 | 003 | Apr 03, 2020 | Sep | CAHN |
| AB | | | 3.75MG;3.75MG;3.75MG;3.75MG | A210293 | 004 | Apr 03, 2020 | Sep | CAHN |
| AB | | | 5MG;5MG;5MG;5MG | A210293 | 005 | Apr 03, 2020 | Sep | CAHN |
| AB | | | 7.5MG;7.5MG;7.5MG;7.5MG | A210293 | 006 | Apr 03, 2020 | Sep | CAHN |

AMPHETAMINE SULFATE

TABLET;ORAL
AMPHETAMINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | INGENUS PHARMS LLC | 5MG | A213763 | 001 | Aug 24, 2020 | Feb | CAHN |
| | @ | | 10MG | A213763 | 002 | Aug 24, 2020 | Feb | CAHN |
| AA | | PHARMAZONE | 5MG | A212582 | 001 | Feb 04, 2020 | Sep | CAHN |
| AA | | | 5MG | A212901 | 001 | May 22, 2020 | Sep | CAHN |
| AA | | | 10MG | A212582 | 002 | Feb 04, 2020 | Sep | CAHN |
| AA | | | 10MG | A212901 | 002 | May 22, 2020 | Sep | CAHN |

AMPHOTERICIN B

INJECTABLE, LIPOSOMAL;INJECTION
AMPHOTERICIN B

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> AB | | QILU PHARM HAINAN | 50MG/VIAL | A220139 | 001 | Oct 14, 2026 | Oct | NEWA |

AMPICILLIN SODIUM

INJECTABLE;INJECTION
AMPICILLIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ACS DOBFAR SPA | EQ 10GM BASE/VIAL | A201404 | 001 | Dec 20, 2013 | Sep | CAHN |
| | @ | | EQ 125MG BASE/VIAL | A062797 | 001 | Jul 12, 1993 | Sep | CAHN |
| AP | | | EQ 250MG BASE/VIAL | A062719 | 001 | May 12, 1987 | Sep | CAHN |
| AP | | | EQ 500MG BASE/VIAL | A062719 | 003 | May 12, 1987 | Sep | CAHN |
| AP | | | EQ 1GM BASE/VIAL | A062719 | 002 | May 12, 1987 | Sep | CAHN |
| AP | | | EQ 2GM BASE/VIAL | A062797 | 002 | Jul 12, 1993 | Sep | CAHN |
| >A> | @ | CHARTWELL RX | EQ 125MG BASE/VIAL | A062816 | 001 | Oct 24, 1988 | Oct | CAHN |
| >A> | @ | | EQ 250MG BASE/VIAL | A062816 | 002 | Oct 24, 1988 | Oct | CAHN |
| >A> | @ | | EQ 500MG BASE/VIAL | A062816 | 003 | Oct 24, 1988 | Oct | CAHN |
| >A> | @ | | EQ 1GM BASE/VIAL | A062816 | 004 | Oct 24, 1988 | Oct | CAHN |
| >A> | @ | | EQ 2GM BASE/VIAL | A062816 | 005 | Oct 24, 1988 | Oct | CAHN |
| >A> | @ | | EQ 10GM BASE/VIAL | A062994 | 001 | Sep 15, 1988 | Oct | CAHN |
| >D> | @ | WATSON LABS INC | EQ 125MG BASE/VIAL | A062816 | 001 | Oct 24, 1988 | Oct | CAHN |
| >D> | @ | | EQ 250MG BASE/VIAL | A062816 | 002 | Oct 24, 1988 | Oct | CAHN |
| >D> | @ | | EQ 500MG BASE/VIAL | A062816 | 003 | Oct 24, 1988 | Oct | CAHN |
| >D> | @ | | EQ 1GM BASE/VIAL | A062816 | 004 | Oct 24, 1988 | Oct | CAHN |
| >D> | @ | | EQ 2GM BASE/VIAL | A062816 | 005 | Oct 24, 1988 | Oct | CAHN |
| >D> | @ | | EQ 10GM BASE/VIAL | A062994 | 001 | Sep 15, 1988 | Oct | CAHN |

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION
AMPICILLIN AND SULBACTAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ACS DOBFAR SPA | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065222 | 001 | Nov 29, 2005 | Sep | CAHN |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM | A065222 | 002 | Nov 29, 2005 | Sep | CAHN |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | INJECTABLE;INJECTION | | | | | | |
| | | AMPICILLIN AND SULBACTAM | | | | | | |
| | | | | BASE/VIAL | | | | |
| | AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A065314 | 001 | Nov 27, 2006 | Sep CAHN |
| | | @ | EUROFARMA | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065316 | 001 | Jun 29, 2007 | Feb CAHN |
| | | @ | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A065316 | 002 | Jun 29, 2007 | Feb CAHN |
| | | AMPICILLIN/AMPICILLIN TRIHYDRATE | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | AMPICILLIN TRIHYDRATE | | | | | | |
| >A> | | @ | CHARTWELL RX | EQ 250MG BASE | A060765 | 001 | | Oct CAHN |
| >A> | | @ | | EQ 500MG BASE | A060765 | 002 | | Oct CAHN |
| >D> | | @ | IVAX SUB TEVA PHARMS | EQ 250MG BASE | A060765 | 001 | | Oct CAHN |
| >D> | | @ | | EQ 500MG BASE | A060765 | 002 | | Oct CAHN |
| | | FOR SUSPENSION;ORAL | | | | | | |
| | | AMPICILLIN TRIHYDRATE | | | | | | |
| >A> | | @ | CHARTWELL RX | EQ 125MG BASE/5ML | A061370 | 001 | | Oct CAHN |
| >A> | | @ | | EQ 250MG BASE/5ML | A061370 | 002 | | Oct CAHN |
| >D> | | @ | TEVA | EQ 125MG BASE/5ML | A061370 | 001 | | Oct CAHN |
| >D> | | @ | | EQ 250MG BASE/5ML | A061370 | 002 | | Oct CAHN |
| | | AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID | | | | | | |
| | | FOR SUSPENSION;ORAL | | | | | | |
| | | PROBAMPACIN | | | | | | |
| | | @ | COSETTE PHARMS NC | EQ 3.5GM BASE/BOT;1GM/BOT | A061741 | 001 | | May CAHN |
| | | ANASTROZOLE | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | ANASTROZOLE | | | | | | |
| | AB | | PHARMOBEDIENT | 1MG | A206037 | 001 | Nov 09, 2018 | Sep CAHN |
| | | APALUTAMIDE | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | APALUTAMIDE | | | | | | |
| | AB | | ZYDUS LIFESCIENCES | 60MG | A217113 | 001 | Mar 17, 2025 | May CAHN |
| | | APREPITANT | | | | | | |
| | | EMULSION;INTRAVENOUS | | | | | | |
| | | APONVIE | | | | | | |
| | | +! | HERON THERAPS INC | 32MG/4.4ML (7.2MG/ML) | N216457 | 001 | Sep 16, 2022 | Mar CTEC |
| | AB | +! | | 32MG/4.4ML (7.2MG/ML) | N216457 | 001 | Sep 16, 2022 | Feb CFTG |
| | | APREPITANT | | | | | | |
| | | +! | AZURITY | 130MG/18ML (7.2MG/ML) | N218754 | 001 | Jun 16, 2026 | Jun NEWA |
| | | @ | MYLAN | 32MG/4.4ML (7.2MG/ML) | A218851 | 001 | Mar 05, 2026 | Mar DISC |
| | AB | | | 32MG/4.4ML (7.2MG/ML) | A218851 | 001 | Mar 05, 2026 | Feb NFTG |
| | | FOR SUSPENSION;ORAL | | | | | | |
| | | EMEND | | | | | | |
| | | @ + | MSD MERCK CO | 125MG/KIT | N207865 | 001 | Dec 17, 2015 | Sep DISC |
| | | ARFORMOTEROL TARTRATE | | | | | | |
| | | SOLUTION;INHALATION | | | | | | |
| | | ARFORMOTEROL TARTRATE | | | | | | |
| | AN | | ADAPTIS | EQ 0.015MG BASE/2ML | A213762 | 001 | Jun 22, 2021 | Sep CAHN |
| | AN | | PHARMAZONE | EQ 0.015MG BASE/2ML | A218380 | 001 | Feb 03, 2025 | Sep CAHN |
| | | @ | TEVA PHARMS USA | EQ 0.015MG BASE/2ML | A200293 | 001 | Nov 09, 2021 | Jun DISC |
| | | ARGATROBAN | | | | | | |
| | | INJECTABLE;INJECTION | | | | | | |
| | | ARGATROBAN | | | | | | |
| >D> | AP | ! | HOSPIRA | 250MG/2.5ML (100MG/ML) | A204120 | 001 | Sep 21, 2016 | Oct DISC |
| >A> | | @ | | 250MG/2.5ML (100MG/ML) | A204120 | 001 | Sep 21, 2016 | Oct DISC |
| >D> | AP | | MYLAN INSTITUTIONAL | 250MG/2.5ML (100MG/ML) | A202626 | 001 | Jun 30, 2014 | Oct CHRS |
| >A> | AP | ! | | 250MG/2.5ML (100MG/ML) | A202626 | 001 | Jun 30, 2014 | Oct CHRS |

ARIPIPRAZOLE

TABLET;ORAL

ARIPIPRAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | APOTEX | 2MG | A078583 | 001 | Jul 24, 2015 | Apr DISC |
| | @ | | 5MG | A078583 | 002 | Jul 24, 2015 | Apr DISC |
| | @ | | 10MG | A078583 | 003 | Jul 24, 2015 | Apr DISC |
| | @ | | 15MG | A078583 | 004 | Jul 24, 2015 | Apr DISC |
| | @ | | 20MG | A078583 | 005 | Jul 24, 2015 | Apr DISC |
| | @ | | 30MG | A078583 | 006 | Jul 24, 2015 | Apr DISC |

TABLET, ORALLY DISINTEGRATING;ORAL

ARIPIPRAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AUROBINDO PHARMA | 10MG | A216208 | 001 | Feb 18, 2026 | Aug DISC |
| AB | | | 10MG | A216208 | 001 | Feb 18, 2026 | Feb NEWA |
| | @ | | 15MG | A216208 | 002 | Feb 18, 2026 | Aug DISC |
| AB | | | 15MG | A216208 | 002 | Feb 18, 2026 | Feb NEWA |

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | COREPHARMA | 50MG | A201514 | 001 | Mar 25, 2019 | Jan CMFD |
| AB | | | 150MG | A201514 | 002 | Mar 25, 2019 | Jan CMFD |
| AB | | | 250MG | A201514 | 003 | Mar 25, 2019 | Jan CMFD |
| | @ | LUPIN | 50MG | A200751 | 001 | Nov 28, 2016 | Jun DISC |
| | @ | | 150MG | A200751 | 003 | Nov 28, 2016 | Jun DISC |
| | @ | | 200MG | A200751 | 004 | Nov 28, 2016 | Jun DISC |
| | @ | | 250MG | A200751 | 005 | Nov 28, 2016 | Jun DISC |
| AB | | MACLEODS PHARMS | 50MG | A201514 | 001 | Mar 25, 2019 | Sep CAHN |
| AB | | | 150MG | A201514 | 002 | Mar 25, 2019 | Sep CAHN |
| AB | | | 250MG | A201514 | 003 | Mar 25, 2019 | Sep CAHN |

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | INGENUS PHARMS LLC | 1MG/ML | A209315 | 001 | Nov 15, 2018 | Feb CAHN |
| | @ | | 2MG/ML | A209315 | 002 | Jan 14, 2021 | Feb CAHN |
| AP | | J MOLNER | 1MG/ML | A210802 | 001 | Nov 13, 2018 | Jun CAHN |

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYKLX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | AM GENOMICS | EQ 8% BASE | N218643 | 001 | Aug 15, 2025 | Feb DISC |
| | @ + | THEA PHARMA | EQ 8% BASE | N218643 | 001 | Aug 15, 2025 | Apr CAHN |

ASCORBIC ACID

SOLUTION;INTRAVENOUS

ASCORBIC ACID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | PHARMOBEDIENT | 25,000MG/50ML (500MG/ML) | A220172 | 001 | Jul 30, 2026 | Sep CAHN |
| AP | | STIRA | 25,000MG/50ML (500MG/ML) | A220172 | 001 | Jul 30, 2026 | Jul NEWA |
| | ! | ZYDUS PHARMS | 2,500MG/5ML (500MG/ML) | A220873 | 001 | Aug 20, 2026 | Aug NFTG |
| | ! | | 5,000MG/10ML (500MG/ML) | A220873 | 002 | Aug 20, 2026 | Aug NFTG |
| AP | | | 25,000MG/50ML (500MG/ML) | A220873 | 003 | Aug 20, 2026 | Aug NEWA |

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | SANDOZ CANADA INC | 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL; 0.14MG/VIAL;17MG/VIAL;1MG/VIAL ;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL | N021265 | 001 | Feb 21, 2001 | Apr CFTG |

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | SANDOZ CANADA INC | 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL; 0.14MG/VIAL;17MG/VIAL;1MG/VIAL ;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL | N021265 | 002 | Jan 29, 2004 | Apr CFTG |

MULTIPLE VITAMINS INJECTION PEDIATRIC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | APOTEX | 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL; 0.14MG/VIAL;17MG/VIAL; | A210671 | 001 | Apr 21, 2026 | Apr NFTG |

INJECTABLE;INTRAVENOUS

MULTIPLE VITAMINS INJECTION PEDIATRIC

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | 1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL | | | | | |

MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE)

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | APOTEX | 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL | A210456 | 001 | Apr 21, 2026 | Apr | NFTG |

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PLENVU

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | NORGINE | 7.54GM;140GM;2.2GM;48.11GM;5.2 GM;9GM | N209381 | 001 | May 04, 2018 | Sep | DISC |
| +! | | 7.54GM;140GM;2.2GM;48.11GM;5.2 GM;9GM | N209381 | 001 | May 04, 2018 | Aug | CAHN |

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB + | ABBVIE | EQ 2.5MG BASE | N022117 | 003 | Mar 12, 2015 | Mar | CAHN |
| AB + | | EQ 5MG BASE | N022117 | 001 | Aug 13, 2009 | Mar | CAHN |
| AB +! | | EQ 10MG BASE | N022117 | 002 | Aug 13, 2009 | Mar | CAHN |

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | HIKMA | 325MG;50MG;40MG | A086162 | 002 | Feb 16, 1984 | Sep | CAHN |

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | GENUS LIFESCIENCES | 325MG;200MG | A040116 | 001 | Apr 25, 1996 | Sep | CAHN |
| @ | INGENUS PHARMS LLC | 325MG;200MG | A040832 | 001 | Jan 07, 2010 | May | CAHN |
| @ | ZETA PHARMS | 325MG;200MG | A040116 | 001 | Apr 25, 1996 | Aug | CAHN |

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> @ | ALLIED | 325MG;400MG | A089657 | 001 | Nov 04, 1988 | Oct | CAHN |
| >D> @ | PAR PHARM | 325MG;400MG | A089657 | 001 | Nov 04, 1988 | Oct | CAHN |

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | EPIC PHARMA LLC | 325MG;4.8355MG | A040910 | 001 | Jul 16, 2020 | Apr | DISC |

PERCODAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | ENDO OPERATIONS | 325MG;4.8355MG | N007337 | 007 | Aug 05, 2005 | Apr | DISC |

ATENOLOL

TABLET;ORAL

ATENOLOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | IPCA LABS LTD | 25MG | A077877 | 001 | Dec 27, 2006 | Jan | CMFD |
| AB | | 50MG | A077877 | 002 | Dec 27, 2006 | Jan | CMFD |
| AB | | 100MG | A077877 | 003 | Dec 27, 2006 | Jan | CMFD |

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB ! | UNICHEM | 100MG;25MG | A213302 | 002 | Nov 25, 2020 | Apr | CHRS |

TENORETIC 100

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | TWI PHARMS | 100MG;25MG | N018760 | 001 | Jun 08, 1984 | Apr | DISC |

TENORETIC 50

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | TWI PHARMS | 50MG;25MG | N018760 | 002 | Jun 08, 1984 | Apr | DISC |

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | CREEKWOOD PHARMS | EQ 10MG BASE | A218875 | 001 | Jun 16, 2026 | Jun | NEWA |
| AB | | EQ 18MG BASE | A218875 | 002 | Jun 16, 2026 | Jun | NEWA |
| AB | | EQ 25MG BASE | A218875 | 003 | Jun 16, 2026 | Jun | NEWA |
| AB | | EQ 40MG BASE | A218875 | 004 | Jun 16, 2026 | Jun | NEWA |
| AB | | EQ 60MG BASE | A218875 | 005 | Jun 16, 2026 | Jun | NEWA |
| AB | | EQ 80MG BASE | A218875 | 006 | Jun 16, 2026 | Jun | NEWA |
| AB | | EQ 100MG BASE | A218875 | 007 | Jun 16, 2026 | Jun | NEWA |
| AB | PHARMAZONE | EQ 10MG BASE | A218875 | 001 | Jun 16, 2026 | Sep | CAHN |
| AB | | EQ 18MG BASE | A218875 | 002 | Jun 16, 2026 | Sep | CAHN |
| AB | | EQ 25MG BASE | A218875 | 003 | Jun 16, 2026 | Sep | CAHN |
| AB | | EQ 40MG BASE | A218875 | 004 | Jun 16, 2026 | Sep | CAHN |
| AB | | EQ 60MG BASE | A218875 | 005 | Jun 16, 2026 | Sep | CAHN |
| AB | | EQ 80MG BASE | A218875 | 006 | Jun 16, 2026 | Sep | CAHN |
| AB | | EQ 100MG BASE | A218875 | 007 | Jun 16, 2026 | Sep | CAHN |

SOLUTION;ORAL

ATONCY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | MAP77 | EQ 4MG BASE/ML | N220320 | 001 | Mar 20, 2026 | Mar | NEWA |

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | MICRO LABS LTD INDIA | EQ 10MG BASE | A205945 | 001 | Nov 07, 2019 | Aug | DISC |
| @ | | EQ 20MG BASE | A205945 | 002 | Nov 07, 2019 | Aug | DISC |
| @ | | EQ 40MG BASE | A205945 | 003 | Nov 07, 2019 | Aug | DISC |
| @ | | EQ 80MG BASE | A205945 | 004 | Nov 07, 2019 | Aug | DISC |
| AB | UMEDICA | EQ 10MG BASE | A213853 | 001 | Aug 19, 2020 | Jun | CTEC |
| AB | | EQ 20MG BASE | A213853 | 002 | Aug 19, 2020 | Jun | CTEC |
| AB | | EQ 40MG BASE | A213853 | 003 | Aug 19, 2020 | Jun | CTEC |
| AB | | EQ 80MG BASE | A213853 | 004 | Aug 19, 2020 | Jun | CTEC |

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LYPQOZET

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | PHARMOBEDIENT | EQ 10MG BASE;10MG | A206084 | 001 | Apr 26, 2017 | Jul | DISC |
| @ | | EQ 20MG BASE;10MG | A206084 | 002 | Apr 26, 2017 | Jul | DISC |
| @ | | EQ 40MG BASE;10MG | A206084 | 003 | Apr 26, 2017 | Jul | DISC |
| @ | | EQ 80MG BASE;10MG | A206084 | 004 | Apr 26, 2017 | Jul | DISC |

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP + | ACCORD HLTHCARE | 0.4MG/ML (0.4MG/ML) | N214652 | 001 | Sep 29, 2020 | Jul | CMFD |

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AT1 | EDENBRIDGE PHARMS | 1% | A219013 | 001 | Apr 15, 2026 | Apr | NEWA |
| AT1 | GLAND | 1% | A219996 | 001 | Jul 31, 2026 | Jul | NEWA |
| >A> AT1 | SENTISS PHARMA | 1% | A219628 | 001 | Oct 16, 2026 | Oct | NEWA |

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | LEGACY | 0.025MG;1MG | N017744 | 002 | | Jun | CAHN |

MOTOFEN HALF-STRENGTH

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | LEGACY | 0.025MG;0.5MG | N017744 | 001 | | Jun | CAHN |

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | HIKMA | 0.025MG;2.5MG | A087765 | 001 | Mar 15, 1982 | Sep | CAHN |
| @ | QUAGEN | 0.025MG;2.5MG | A085762 | 001 | | Apr | CAHN |
| @ | | 0.025MG;2.5MG | A210571 | 001 | Aug 31, 2018 | Feb | CAHN |

AURANOFIN

CAPSULE;ORAL

RIDAURA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | LEGACY | 3MG | N018689 | 001 | May 24, 1985 | Jun | CAHN |

AXITINIB

TABLET;ORAL

AXITINIB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | APOTEX | 1MG | A211650 | 001 | Oct 30, 2025 | Sep CMFD |
| | @ | | | 1MG | A211650 | 001 | Oct 30, 2025 | Apr DISC |
| AB | | | | 5MG | A211650 | 002 | Oct 30, 2025 | Sep CMFD |
| | @ | | | 5MG | A211650 | 002 | Oct 30, 2025 | Apr DISC |

INLYTA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | + | PF PRISM CV | 1MG | N202324 | 001 | Jan 27, 2012 | Sep CTEC |
| | | + | | 1MG | N202324 | 001 | Jan 27, 2012 | Apr CTEC |
| AB | | +! | | 5MG | N202324 | 002 | Jan 27, 2012 | Sep CTEC |
| | | +! | | 5MG | N202324 | 002 | Jan 27, 2012 | Apr CTEC |

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | | ADAPTIS | 100MG/VIAL | A207518 | 001 | Sep 29, 2016 | Aug CAHN |
| | @ | | AMNEAL | 100MG/VIAL | A211549 | 001 | Feb 03, 2022 | Apr DISC |
| AP | | | SOMERSET THERAPS LLC | 100MG/VIAL | A217453 | 001 | May 20, 2025 | Sep CAHN |

AZATHIOPRINE

TABLET;ORAL

IMURAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | + | LEGACY | 25MG | N016324 | 002 | | Jun CAHN |
| AB | | +! | | 50MG | N016324 | 001 | | Jun CAHN |

AZELAIC ACID

GEL;TOPICAL

AZELAIC ACID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | | | ENCUBE | 15% | A208724 | 001 | Nov 19, 2018 | Oct CAHN |
| >A> AB | | | | 15% | A208724 | 001 | Nov 19, 2018 | Oct CAHN |
| >D> AB | | | SUN PHARMA CANADA | 15% | A210549 | 001 | Aug 23, 2019 | Oct CHRS |
| >A> AB | | ! | | 15% | A210549 | 001 | Aug 23, 2019 | Oct CHRS |

FINACEA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | | +! | LEO PHARMA AS | 15% | N021470 | 001 | Dec 24, 2002 | Oct CHRS |
| >A> AB | | + | | 15% | N021470 | 001 | Dec 24, 2002 | Oct CHRS |

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

AZILSARTAN MEDOXOMIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | LUPIN | EQ 40MG MEDOXOMIL | A214489 | 001 | Jul 20, 2022 | Apr CMFD |
| AB | | | | EQ 80MG MEDOXOMIL | A214489 | 002 | Jul 20, 2022 | Apr CMFD |

EDARBI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | + | AZURITY | EQ 40MG MEDOXOMIL | N200796 | 001 | Feb 25, 2011 | Apr CTEC |
| AB | | +! | | EQ 80MG MEDOXOMIL | N200796 | 002 | Feb 25, 2011 | Apr CTEC |

AZITHROMYCIN

INJECTABLE;INJECTION

AZITHROMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ! | EUGIA PHARMA | EQ 500MG BASE/VIAL | A203294 | 001 | Jun 19, 2015 | Jul CHRS |
| AP | | | HAINAN POLY | EQ 500MG BASE/VIAL | A203412 | 001 | Oct 09, 2018 | Jul CAHN |

ZITHROMAX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | + | PFIZER | EQ 500MG BASE/VIAL | N050733 | 001 | Jan 30, 1997 | Jul DISC |

TABLET;ORAL

AZITHROMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | | CARLSBAD | EQ 250MG BASE | A211317 | 001 | Jul 26, 2022 | Feb CAHN |
| AB | | | | EQ 600MG BASE | A211068 | 001 | May 08, 2020 | Feb CAHN |
| | @ | | FOSUN PHARMA | EQ 500MG BASE | A211318 | 001 | Mar 17, 2021 | Sep CAHN |
| | @ | | STRIDES PHARMA | EQ 250MG BASE | A215772 | 001 | Jul 15, 2022 | Jun DISC |
| | @ | | | EQ 500MG BASE | A215773 | 001 | Jul 12, 2022 | Jun DISC |

AZTREONAM

INJECTABLE;INJECTION

AZACTAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | | LABS DELBERT | 500MG/VIAL | N050580 | 001 | Dec 31, 1986 | May CAHN |
| AP | | +! | | 1GM/VIAL | N050580 | 002 | Dec 31, 1986 | May CAHN |
| AP | | +! | | 2GM/VIAL | N050580 | 003 | Dec 31, 1986 | May CAHN |

AZTREONAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | | HIKMA | 1GM/VIAL | A207069 | 001 | Feb 05, 2026 | Feb DISC |
| AP | | | | 1GM/VIAL | A207069 | 001 | Feb 05, 2026 | Jan NEWA |
| | @ | | | 2GM/VIAL | A207069 | 002 | Feb 05, 2026 | Feb DISC |

INJECTABLE;INJECTION
AZTREONAM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | 2GM/VIAL | A207069 | 002 | Feb 05, 2026 | Jan | NEWA |

BACITRACIN

OINTMENT;OPHTHALMIC
BACITRACIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ PADAGIS US | 500 UNITS/GM | A061212 | 001 | | Mar | DISC |

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ PADAGIS US | 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A062166 | 002 | | Mar | DISC |

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ! BAUSCH AND LOMB INC | 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A064068 | 001 | Oct 30, 1995 | May | CAHN |

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AT | ! BAUSCH AND LOMB INC | 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A064064 | 001 | Oct 30, 1995 | May | CAHN |
| | @ PADAGIS US | 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A060764 | 002 | | Mar | DISC |

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ! BAUSCH AND LOMB | 500 UNITS/GM;10,000 UNITS/GM | A064046 | 001 | Jan 26, 1995 | Mar | CTEC |
| | ! BAUSCH AND LOMB INC | 500 UNITS/GM;10,000 UNITS/GM | A064046 | 001 | Jan 26, 1995 | May | CAHN |
| | @ PADAGIS US | 500 UNITS/GM;10,000 UNITS/GM | A065022 | 001 | Feb 27, 2002 | Mar | DISC |

BACLOFEN

GRANULE;ORAL
LYVISPAH

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + STRIDES PHARMA INTL | 5MG/PACKET | N215422 | 001 | Nov 22, 2021 | Apr | CDFR |
| >D> | @ + | 10MG/PACKET | N215422 | 002 | Nov 22, 2021 | Oct | CMFD |
| >A> | +! | 10MG/PACKET | N215422 | 002 | Nov 22, 2021 | Oct | CMFD |
| | @ + | 10MG/PACKET | N215422 | 002 | Nov 22, 2021 | Apr | CDFR |
| | @ + | 20MG/PACKET | N215422 | 003 | Nov 22, 2021 | Apr | CDFR |

GRANULES;ORAL
LYVISPAH

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + STRIDES PHARMA INTL | 5MG/PACKET | N215422 | 001 | Nov 22, 2021 | Jan | CAHN |
| | @ + | 10MG/PACKET | N215422 | 002 | Nov 22, 2021 | Jan | CAHN |
| | @ + | 20MG/PACKET | N215422 | 003 | Nov 22, 2021 | Jan | CAHN |

INJECTABLE;INTRATHECAL
BACLOFEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | MAIA PHARMS INC | 0.05MG/ML | A210048 | 003 | Jan 15, 2021 | Aug | CMS1 |
| | @ PHARMOBEDIENT | 0.5MG/ML | A209592 | 001 | Mar 21, 2018 | Sep | DISC |
| | @ | 1MG/ML | A209594 | 001 | Mar 06, 2018 | Sep | DISC |
| | @ | 2MG/ML | A209592 | 002 | Mar 21, 2018 | Sep | DISC |

SOLUTION;ORAL
OZOBAX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + ROSEMOUNT | 5MG/5ML | N208193 | 001 | Sep 18, 2019 | Aug | CAHN |

OZOBAX DS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | +! ROSEMOUNT | 10MG/5ML | N208193 | 002 | Oct 12, 2023 | Aug | CAHN |

TABLET;ORAL
BACLOFEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ADAPTIS | 5MG | A211555 | 003 | Nov 30, 2021 | Sep | CAHN |
| AB | | 10MG | A211555 | 001 | Feb 01, 2019 | Sep | CAHN |
| AB | | 20MG | A211555 | 002 | Feb 01, 2019 | Sep | CAHN |
| >A> | @ ALLIED | 10MG | A077181 | 001 | Jul 29, 2005 | Oct | CAHN |
| >A> | @ | 20MG | A077121 | 002 | Jul 29, 2005 | Oct | CAHN |
| AB | HIBROW HLTHCARE | 5MG | A211555 | 003 | Nov 30, 2021 | May | CTEC |
| AB | | 10MG | A211555 | 001 | Feb 01, 2019 | May | CTEC |
| AB | | 20MG | A211555 | 002 | Feb 01, 2019 | May | CTEC |
| | @ MICRO LABS | 5MG | A217687 | 001 | Nov 08, 2023 | Aug | DISC |
| | @ | 10MG | A217687 | 002 | Nov 08, 2023 | Aug | DISC |
| | @ | 20MG | A217687 | 003 | Nov 08, 2023 | Aug | DISC |

TABLET;ORAL
BACLOFEN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | PHARMOBEDIENT | 10MG | A074584 | 001 | Aug 19, 1996 | Sep CAHN |
| >D> | | @ | | 10MG | A077181 | 001 | Jul 29, 2005 | Oct CAHN |
| | AB | | | 20MG | A074584 | 002 | Aug 19, 1996 | Sep CAHN |
| >D> | | @ | | 20MG | A077121 | 002 | Jul 29, 2005 | Oct CAHN |
| | AB | | RUBICON RESEARCH | 5MG | A209102 | 001 | Nov 28, 2017 | Jan CHRS |
| | AB | | TP ANDA HOLDINGS | 10MG | A077088 | 002 | Oct 31, 2007 | Sep CAHN |
| | AB | | | 20MG | A077088 | 001 | Oct 31, 2007 | Sep CAHN |

BALOXAVIR MARBOXIL
TABLET;ORAL
BALOXAVIR MARBOXIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | NORWICH | 40MG | A217449 | 001 | Jun 17, 2026 | Jun NFTG |
| | AB | | | 80MG | A217449 | 002 | Jun 17, 2026 | Jun NFTG |

XOFLUZA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | + | GENENTECH INC | 40MG | N210854 | 002 | Oct 24, 2018 | Jun CFTG |
| | AB | +! | | 80MG | N210854 | 003 | Mar 18, 2021 | Jun CFTG |

BALSALAZIDE DISODIUM
CAPSULE;ORAL
BALSALAZIDE DISODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | CARNEGIE | 750MG | A219422 | 001 | Apr 03, 2025 | Feb CAHN |
| >A> | AB | | ESJAY PHARMA | 750MG | A077807 | 001 | Dec 28, 2007 | Oct CAHN |
| >D> | AB | | NOVITIUM PHARMA | 750MG | A077807 | 001 | Dec 28, 2007 | Oct CAHN |
| >D> | AB | | ZYDUS LIFESCIENCES | 750MG | A217592 | 001 | Jun 08, 2023 | Oct CHRS |
| >A> | AB | ! | | 750MG | A217592 | 001 | Jun 08, 2023 | Oct CHRS |
| >D> | | COLAZAL | | | | | | |
| >D> | AB | +! | VALEANT PHARMS INTL | 750MG | N020610 | 001 | Jul 18, 2000 | Oct DISC |
| >A> | | @ + | | 750MG | N020610 | 001 | Jul 18, 2000 | Oct DISC |

BAXDROSTAT
TABLET;ORAL
BAXFENDY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | ASTRAZENECA AB | 1MG | N219878 | 001 | May 15, 2026 | May NEWA |
| | | +! | | 2MG | N219878 | 002 | May 15, 2026 | May NEWA |

BECLOMETHASONE DIPROPIONATE
AEROSOL, METERED;INHALATION
BECLOMETHASONE DIPROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | ! | AMNEAL IRELAND LTD | 0.04MG/INH | A213811 | 001 | Dec 16, 2025 | Sep CTEC |
| | AB | ! | | 0.08MG/INH | A213811 | 002 | Dec 16, 2025 | Sep CTEC |
| | AB | | AUROLIFE PHARMA LLC | 0.04MG/INH | A214418 | 001 | Sep 14, 2026 | Sep NEWA |
| | AB | | | 0.08MG/INH | A214418 | 002 | Sep 14, 2026 | Sep NEWA |

BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE
AEROSOL, METERED;INHALATION
TRIMBOW

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | CHIESI | 0.086MG/INH;0.0049MG/INH;0.010 6MG/INH | N219622 | 001 | May 14, 2026 | Sep DISC |
| | | +! | | 0.086MG/INH;0.0049MG/INH;0.010 6MG/INH | N219622 | 001 | May 14, 2026 | May NEWA |
| | | @ + | | 0.172MG/INH;0.0049MG/INH;0.010 6MG/INH | N219622 | 002 | May 14, 2026 | Sep DISC |
| | | +! | | 0.172MG/INH;0.0049MG/INH;0.010 6MG/INH | N219622 | 002 | May 14, 2026 | May NEWA |

BELUMOSUDIL MESYLATE
TABLET;ORAL
REZUROCK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | +! | KADMON PHARMS LLC | EQ 200MG BASE | N214783 | 001 | Jul 16, 2021 | Oct CAHN |
| >A> | | +! | SANOFI-AVENTIS | EQ 200MG BASE | N214783 | 001 | Jul 16, 2021 | Oct CAHN |

BENAZEPRIL HYDROCHLORIDE
TABLET;ORAL
BENAZEPRIL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | MACLEODS PHARMS | 5MG | A077128 | 001 | Mar 08, 2006 | Sep CAHN |
| | AB | | | 10MG | A077128 | 002 | Mar 08, 2006 | Sep CAHN |
| | AB | | | 20MG | A077128 | 003 | Mar 08, 2006 | Sep CAHN |
| | AB | | | 40MG | A077128 | 004 | Mar 08, 2006 | Sep CAHN |

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | APOTEX | 5MG;6.25MG | A078794 | 001 | Aug 21, 2014 | Mar DISC |
| | @ | | 10MG;12.5MG | A078794 | 002 | Aug 21, 2014 | Mar DISC |
| | @ | | 20MG;12.5MG | A078794 | 003 | Aug 21, 2014 | Mar DISC |
| | @ | | 20MG;25MG | A078794 | 004 | Aug 21, 2014 | Mar DISC |
| AB | ! | SANDOZ | 20MG;25MG | A076631 | 004 | Feb 11, 2004 | Jan CHRS |

LOTENSIN HCT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + | VALIDUS PHARMS | 20MG;25MG | N020033 | 003 | May 19, 1992 | Jan CHRS |

BENDAMUSTINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

GOBARDEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | AVYXA HOLDINGS | 100MG/4ML (25MG/ML) | N219014 | 001 | Jul 03, 2025 | Sep CTNA |
| | +! | | 100MG/4ML (25MG/ML) | N219014 | 001 | Jul 03, 2025 | Mar CAHN |
| | +! | DR REDDYS | 100MG/4ML (25MG/ML) | N219014 | 001 | Jul 03, 2025 | Apr CMFD |

BENZONATATE

CAPSULE;ORAL

BENZONATATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | ASCENT PHARMS INC | 150MG | A211518 | 002 | Feb 22, 2019 | Apr CMFD |
| AA | | MARKSANS PHARMA | 100MG | A220298 | 001 | Mar 30, 2026 | Mar NEWA |
| AA | | | 200MG | A220298 | 002 | Mar 30, 2026 | Mar NEWA |
| >A> AA | | ONESOURCE | 100MG | A091133 | 001 | Jul 30, 2015 | Oct CAHN |
| >A> AA | | | 150MG | A091133 | 003 | Oct 20, 2026 | Oct CAHN |
| >A> AA | | | 200MG | A091133 | 002 | Jul 30, 2015 | Oct CAHN |
| >D> AA | | ONESOURCE SPECIALTY | 100MG | A091133 | 001 | Jul 30, 2015 | Oct CAHN |
| >A> AA | | | 150MG | A091133 | 003 | Oct 20, 2026 | Oct NEWA |
| >D> AA | | | 200MG | A091133 | 002 | Jul 30, 2015 | Oct CAHN |
| AA | | PHARMAZONE | 100MG | A220298 | 001 | Mar 30, 2026 | Sep CAHN |
| AA | | | 200MG | A220298 | 002 | Mar 30, 2026 | Sep CAHN |
| AA | ! | THEPHARMANETWORK LLC | 150MG | A040627 | 003 | Sep 24, 2014 | Apr CTEC |

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ACTAVIS LABS UT INC | 2.5%;EQ 1.2% BASE | A205128 | 001 | Jun 19, 2015 | Jul DISC |
| AB | | | 3.75%;EQ 1.2% BASE | A208757 | 001 | Aug 07, 2026 | Jul NEWA |
| >D> AB | | ENCUBE | 2.5%;EQ 1.2% BASE | A207194 | 001 | Aug 19, 2019 | Oct CAHN |
| >A> AB | | | 2.5%;EQ 1.2% BASE | A207194 | 001 | Aug 19, 2019 | Oct CAHN |
| >D> AB | | | 5%;EQ 1% BASE | A204087 | 001 | Jun 27, 2017 | Oct CAHN |
| >A> AB | | | 5%;EQ 1% BASE | A204087 | 001 | Jun 27, 2017 | Oct CAHN |
| >D> AB | | | 5%;1.2% | A212433 | 001 | Apr 28, 2021 | Oct CAHN |
| >A> AB | | | 5%;1.2% | A212433 | 001 | Apr 28, 2021 | Oct CAHN |

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

ERYTHROMYCIN AND BENZOYL PEROXIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | @ | ENCUBE | 5%;3% | A065112 | 001 | Mar 29, 2004 | Oct CAHN |
| >A> | @ | | 5%;3% | A065112 | 001 | Mar 29, 2004 | Oct CAHN |

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | AVET LIFESCIENCES | 50MG | A202061 | 001 | Jan 27, 2012 | Jun CMFD |

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | TP ANDA HOLDINGS | 0.5MG | A040706 | 002 | Feb 14, 2008 | Sep CAHN |
| | @ | | 1MG | A040706 | 003 | Feb 14, 2008 | Sep CAHN |
| | @ | | 2MG | A040706 | 001 | Feb 14, 2008 | Sep CAHN |

>A> BEPIROVIRSEN SODIUM

>A> SOLUTION;SUBCUTANEOUS

>A> HIBSAGO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | +! | GLAXOSMITHKLINE | EQ 150MG BASE/ML (EQ 150MG BASE/ML) | N221276 | 001 | Oct 20, 2026 | Oct NEWA |

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | APOTEX | 1.5% | A206066 | 001 | Mar 05, 2019 | Apr | DISC |

BEROTRALSTAT DIHYDROCHLORIDE

PELLETS;ORAL

ORLADEYO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | + | BIOCRYST | EQ 150MG BASE/PACKET | N219776 | 005 | Oct 15, 2026 | Oct | NEWA |

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL

BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA LTD | EQ 0.05% BASE | A219348 | 001 | Jan 26, 2026 | Jan | NEWA |
| AB | | COSETTE PHARMS NC | EQ 0.05% BASE | A210217 | 001 | Oct 12, 2018 | May | CAHN |
| AB | +! | FOUGERA | EQ 0.05% BASE | N019137 | 001 | Jun 26, 1984 | Jul | CAHN |

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | EQ 0.05% BASE | A071467 | 001 | Aug 10, 1987 | May | CAHN |
| | @ | | EQ 0.05% BASE | A071882 | 001 | Jun 06, 1988 | May | CAHN |

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | | ENCUBE | EQ 0.05% BASE | A206389 | 001 | Feb 13, 2018 | Oct | CAHN |
| >A> AB | | | EQ 0.05% BASE | A206389 | 001 | Feb 13, 2018 | Oct | CAHN |

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | FOUGERA | EQ 0.05% BASE | N019141 | 001 | Sep 04, 1984 | Aug | CAHN |

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | 0.064%;0.005% | A210765 | 001 | May 11, 2020 | May | CAHN |

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | INGENUS PHARMS LLC | 0.12% | A207144 | 001 | May 24, 2017 | Feb | CAHN |

LUXIQ

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | QUAGEN | 0.12% | N020934 | 001 | Feb 28, 1999 | Jul | CAHN |

CREAM;TOPICAL

BETA-VAL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | EQ 0.1% BASE | N018642 | 001 | Mar 24, 1983 | May | CAHN |

BETAMETHASONE VALERATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | FOUGERA | EQ 0.1% BASE | N018861 | 001 | Aug 31, 1983 | Jul | CAHN |

LOTION;TOPICAL

BETA-VAL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | EQ 0.1% BASE | A070072 | 001 | Jun 27, 1985 | May | CAHN |

BETAMETHASONE VALERATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | FOUGERA | EQ 0.1% BASE | N018866 | 001 | Aug 31, 1983 | Jul | CAHN |
| AB | | PHARMAZONE | EQ 0.1% BASE | A070052 | 001 | Jul 31, 1985 | Sep | CAHN |

OINTMENT;TOPICAL

BETA-VAL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | EQ 0.1% BASE | A070069 | 001 | Dec 19, 1985 | May | CAHN |

BETAMETHASONE VALERATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | FOUGERA | EQ 0.1% BASE | N018865 | 001 | Aug 31, 1983 | Jul | CAHN |

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | EUROFARMA | EQ 0.5% BASE | A075630 | 001 | Apr 12, 2001 | Feb | CAHN |

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 75MG | A203663 | 001 | Jun 16, 2020 | Aug | DISC |

BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM

TABLET;ORAL

BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | GILEAD SCIENCES INC | EQ 75MG BASE, EQ 50MG BASE; EQ 300MG BASE | N221443 | 001 | Aug 27, 2026 | Aug | NEWA |

BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM

TABLET;ORAL

BIXLENVO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | GILEAD SCIENCES INC | EQ 75MG BASE;EQ 50MG BASE | N221104 | 001 | Aug 27, 2026 | Aug | NEWA |

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | APOTEX | 0.03% | A201894 | 001 | Dec 01, 2014 | Apr | DISC |

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | INGENUS PHARMS LLC | 140MG;125MG;125MG | A217511 | 001 | Jul 03, 2023 | Feb | CAHN |

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | MICRO LABS | 5MG | A218303 | 001 | Mar 09, 2026 | Feb | NEWA |
| AB | | | 10MG | A218303 | 002 | Mar 09, 2026 | Feb | NEWA |
| | @ | NATCO PHARMA USA | 5MG | A075831 | 001 | Dec 14, 2005 | Mar | CAHN |
| | @ | | 10MG | A075831 | 002 | Dec 14, 2005 | Mar | CAHN |

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA LTD | 2.5MG;6.25MG | A217922 | 001 | Jan 21, 2026 | Jan | NEWA |
| AB | | | 5MG;6.25MG | A217922 | 002 | Jan 21, 2026 | Jan | NEWA |
| AB | | | 10MG;6.25MG | A217922 | 003 | Jan 21, 2026 | Jan | NEWA |
| AB | | UNIQUE PHARM | 2.5MG;6.25MG | A219489 | 001 | Mar 24, 2026 | Mar | NEWA |
| AB | | | 5MG;6.25MG | A219489 | 002 | Mar 24, 2026 | Mar | NEWA |
| AB | | | 10MG;6.25MG | A219489 | 003 | Mar 24, 2026 | Mar | NEWA |

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | HAINAN POLY | 250MG/VIAL | A213078 | 001 | May 28, 2021 | Jul | CAHN |

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | CAPLIN ONE LABS | 3.5MG/VIAL | A203654 | 001 | Jul 26, 2022 | Mar | DISC |
| AP | | | 3.5MG/VIAL | A203654 | 001 | Jul 26, 2022 | Jan | CAHN |
| AP | | SOMERSET THERAPS LLC | 3.5MG/VIAL | A211898 | 001 | Oct 11, 2022 | Sep | CAHN |

BOSENTAN

TABLET, FOR SUSPENSION;ORAL

BOSENTAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ZYDUS PHARMS | 32MG | A213981 | 001 | Feb 17, 2026 | Feb | NEWA |

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | PF PRISM CV | EQ 400MG BASE | N203341 | 003 | Oct 27, 2017 | Jun | CFTG |

BOSUTINIB MONOHYDRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | MSN | EQ 400MG BASE | A209624 | 001 | Jun 12, 2026 | Jun | NFTG |

BREPOCITINIB TOSYLATE

TABLET;ORAL

LISRAYA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | PRIOVANT THERAP | EQ 30MG BASE | N220106 | 001 | Aug 27, 2026 | Aug | NEWA |

BREXANOLONE

SOLUTION;INTRAVENOUS

ZULRESSO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | SAGE THERAP SUPERNUS | 100MG/20ML (5MG/ML) | N211371 | 001 | Jun 17, 2019 | Jun CAHN |

BRIGATINIB

TABLET;ORAL

ALUNBRIG

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | TAKEDA PHARMS USA | 90MG | N208772 | 002 | Apr 28, 2017 | Jan CHRS |
| | + | | 180MG | N208772 | 003 | Oct 02, 2017 | Jan CHRS |

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | ! | BAUSCH AND LOMB INC | 0.2% | A076260 | 001 | May 28, 2003 | May CAHN |
| AB | | GLAND | 0.1% | A219219 | 001 | Mar 11, 2026 | Feb NEWA |
| AB | | MANKIND PHARMA | 0.1% | A220398 | 001 | Apr 16, 2026 | Apr NEWA |
| AB | | MICRO LABS | 0.1% | A218558 | 001 | May 07, 2026 | Apr NEWA |
| AB | | UPSHER SMITH LABS | 0.1% | A217599 | 001 | Jul 30, 2025 | Aug CMFD |
| AT | | | 0.15% | A216772 | 001 | Jun 12, 2024 | Aug CMFD |

BRIMONIDINE TARTRATE; CARBACHOL

SOLUTION/DROPS;OPHTHALMIC

YUVEZZI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | VISUS | 0.1%;2.75% | N220142 | 001 | Jan 28, 2026 | Jan NEWA |

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | GLAND | 0.2%;EQ 0.5% BASE | A219166 | 001 | Jun 11, 2026 | Jun NEWA |
| >A> AB | | MICRO LABS | 0.2%;EQ 0.5% BASE | A217589 | 001 | Nov 06, 2026 | Oct NEWA |
| AB | | SABA ILAC SANAYIVE | 0.2%;EQ 0.5% BASE | A217934 | 001 | Jul 01, 2026 | Jun NEWA |

BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVARACETAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | HAINAN POLY | 50MG/5ML (10MG/ML) | A218249 | 001 | Feb 23, 2026 | Feb NFTG |
| AP | | MICRO LABS | 50MG/5ML (10MG/ML) | A214880 | 001 | Feb 23, 2026 | Feb NFTG |
| AP | | MSN | 50MG/5ML (10MG/ML) | A214924 | 001 | Feb 23, 2026 | Feb NFTG |
| AP | | SHANDONG | 50MG/5ML (10MG/ML) | A219766 | 001 | Jul 13, 2026 | Jul NEWA |

BRIVIACT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | UCB INC | 50MG/5ML (10MG/ML) | N205837 | 001 | May 12, 2016 | Feb CFTG |

SOLUTION;ORAL

BRIVARACETAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | ALKEM LABS LTD | 10MG/ML | A219772 | 001 | Feb 23, 2026 | Feb NEWA |
| AA | | AUROBINDO PHARMA | 10MG/ML | A220288 | 001 | Aug 10, 2026 | Jul NEWA |
| AA | | INDOCO | 10MG/ML | A220385 | 001 | Feb 23, 2026 | Feb NEWA |
| AA | | LUPIN | 10MG/ML | A220164 | 001 | Feb 23, 2026 | Feb NEWA |
| AA | | MSN | 10MG/ML | A214922 | 001 | Feb 19, 2026 | Feb NFTG |
| AA | | REGCON HOLDINGS | 10MG/ML | A220385 | 001 | Feb 23, 2026 | Mar CAHN |
| AA | | ZHEJIANG POLY PHARM | 10MG/ML | A218494 | 001 | Feb 23, 2026 | Feb NEWA |
| >A> AA | | ZYDUS LIFESCIENCES | 10MG/ML | A221301 | 001 | Oct 20, 2026 | Oct NEWA |

BRIVIACT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | +! | UCB INC | 10MG/ML | N205838 | 001 | May 12, 2016 | Feb CFTG |

TABLET;ORAL

BRIVARACETAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | APOTEX | 10MG | A214875 | 001 | Feb 23, 2026 | Feb NEWA |
| AB | | | 25MG | A214875 | 002 | Feb 23, 2026 | Feb NEWA |
| AB | | | 50MG | A214875 | 003 | Feb 23, 2026 | Feb NEWA |
| AB | | | 75MG | A214875 | 004 | Feb 23, 2026 | Feb NEWA |
| AB | | | 100MG | A214875 | 005 | Feb 23, 2026 | Feb NEWA |
| >A> AB | | APPCO | 10MG | A220832 | 001 | Nov 06, 2026 | Oct NEWA |
| >A> AB | | | 25MG | A220832 | 002 | Nov 06, 2026 | Oct NEWA |
| >A> AB | | | 50MG | A220832 | 003 | Nov 06, 2026 | Oct NEWA |
| >A> AB | | | 75MG | A220832 | 004 | Nov 06, 2026 | Oct NEWA |
| >A> AB | | | 100MG | A220832 | 005 | Nov 06, 2026 | Oct NEWA |
| AB | | AUROBINDO PHARMA LTD | 10MG | A214848 | 003 | Jul 13, 2026 | Jul NEWA |
| AB | | | 25MG | A214848 | 004 | Jul 13, 2026 | Jul NEWA |
| AB | | | 50MG | A214848 | 001 | Jan 06, 2023 | Jan CMFD |
| AB | | | 75MG | A214848 | 005 | Jul 13, 2026 | Jul NEWA |
| AB | | | 100MG | A214848 | 002 | Jan 06, 2023 | Jan CMFD |

TABLET;ORAL
BRIVARACETAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | BRECKENRIDGE | 10MG | A220470 | 001 | Feb 23, 2026 | Sep | CAHN |
| | @ | | 25MG | A220470 | 002 | Feb 23, 2026 | Sep | CAHN |
| | @ | | 50MG | A220470 | 003 | Feb 23, 2026 | Sep | CAHN |
| | @ | | 75MG | A220470 | 004 | Feb 23, 2026 | Sep | CAHN |
| | @ | | 100MG | A220470 | 005 | Feb 23, 2026 | Sep | CAHN |
| | @ | CENTAUR PHARMS PVT | 10MG | A220470 | 001 | Feb 23, 2026 | Aug | DISC |
| AB | | | 10MG | A220470 | 001 | Feb 23, 2026 | Feb | NEWA |
| | @ | | 25MG | A220470 | 002 | Feb 23, 2026 | Aug | DISC |
| AB | | | 25MG | A220470 | 002 | Feb 23, 2026 | Feb | NEWA |
| | @ | | 50MG | A220470 | 003 | Feb 23, 2026 | Aug | DISC |
| AB | | | 50MG | A220470 | 003 | Feb 23, 2026 | Feb | NEWA |
| | @ | | 75MG | A220470 | 004 | Feb 23, 2026 | Aug | DISC |
| AB | | | 75MG | A220470 | 004 | Feb 23, 2026 | Feb | NEWA |
| | @ | | 100MG | A220470 | 005 | Feb 23, 2026 | Aug | DISC |
| AB | | | 100MG | A220470 | 005 | Feb 23, 2026 | Feb | NEWA |
| AB | | SCIEGEN PHARMS | 10MG | A219952 | 001 | Jul 01, 2026 | Jun | NEWA |
| AB | | | 25MG | A219952 | 002 | Jul 01, 2026 | Jun | NEWA |
| AB | | | 50MG | A219952 | 003 | Jul 01, 2026 | Jun | NEWA |
| AB | | | 75MG | A219952 | 004 | Jul 01, 2026 | Jun | NEWA |
| AB | | | 100MG | A219952 | 005 | Jul 01, 2026 | Jun | NEWA |
| AB | | SUNSHINE | 10MG | A214748 | 001 | Jun 09, 2022 | Jan | CMFD |
| AB | | | 25MG | A214748 | 002 | Jun 09, 2022 | Jan | CMFD |
| AB | | | 50MG | A214748 | 003 | Jun 09, 2022 | Jan | CMFD |
| AB | | | 75MG | A214748 | 004 | Jun 09, 2022 | Jan | CMFD |
| AB | | | 100MG | A214748 | 005 | Jun 09, 2022 | Jan | CMFD |
| AB | | ZHEJIANG JUTAI PHARM | 25MG | A220136 | 001 | Sep 08, 2026 | Aug | NEWA |
| AB | | | 50MG | A220136 | 002 | Sep 08, 2026 | Aug | NEWA |
| AB | | | 100MG | A220136 | 003 | Sep 08, 2026 | Aug | NEWA |
| AB | | ZYDUS PHARMS | 10MG | A214501 | 001 | Oct 03, 2022 | May | CMFD |
| AB | | | 25MG | A214501 | 002 | Oct 03, 2022 | May | CMFD |
| AB | | | 50MG | A214501 | 003 | Oct 03, 2022 | May | CMFD |
| AB | | | 75MG | A214501 | 004 | Oct 03, 2022 | May | CMFD |
| AB | | | 100MG | A214501 | 005 | Oct 03, 2022 | May | CMFD |

BROMFENAC SODIUM
SOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | J MOLNER | EQ 0.09% ACID | A202030 | 001 | Jan 09, 2013 | Jul | CAHN |

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SYRUP;ORAL
BROMFED-DM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | PHARMOBEDIENT | 2MG/5ML;10MG/5ML;30MG/5ML | A088811 | 001 | Jun 07, 1985 | Jan | DISC |

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | ADAPTIS | 2MG/5ML;10MG/5ML;30MG/5ML | A211170 | 001 | Jun 16, 2020 | Sep | CAHN |

BUDESONIDE
SUSPENSION;INHALATION
PULMICORT RESPULES

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AN | +! | ASTRAZENECA | 0.25MG/2ML | N020929 | 001 | Aug 08, 2000 | Jan | CHRS |
| AN | +! | | 0.5MG/2ML | N020929 | 002 | Aug 08, 2000 | Jan | CHRS |

BUDESONIDE; FORMOTEROL FUMARATE
AEROSOL, METERED;INHALATION
SYMBICORT AEROSPHERE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | ASTRAZENECA | 0.08MG/INH;0.0048MG/INH | N216579 | 002 | Apr 27, 2026 | Apr | NEWA |

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE
AEROSOL, METERED;INHALATION
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | TEVA PHARMS USA INC | 0.08MG/INH;0.0045MG/INH | A212212 | 001 | Apr 23, 2026 | Apr | NEWA |
| AB | | | 0.16MG/INH;0.0045MG/INH | A212212 | 002 | Apr 23, 2026 | Apr | NEWA |

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE
AEROSOL, METERED;INHALATION

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | BREZTRI AEROSPHERE | | | | | | |
| >A> | +! | ASTRAZENECA AB | 0.16MG/INH;0.0048MG/INH;0.009MG/INH | N220290 | 001 | Oct 08, 2026 | Oct | NEWA |
| | +! | | 0.16MG/INH;0.0048MG/INH;0.018MG/INH | N212122 | 002 | Apr 27, 2026 | Apr | NEWA |
| >A> | +! | | 0.16MG/INH;0.0048MG/INH;0.018 | N220290 | 002 | Oct 08, 2026 | Oct | NEWA |

AEROSOL, METERED;INHALATION

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | | BREZTRI AEROSPHERE | | | | | |
| | | | | MG/INH | | | | |

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AP | | ADAPTIS | 0.25MG/ML | A220427 | 001 | Feb 26, 2026 | Oct CAHN |
| | AP | | | 0.25MG/ML | A220427 | 001 | Feb 26, 2026 | Sep CAHN |
| >A> | AP | | ANTHEA PHARMA | 0.25MG/ML | A220427 | 001 | Feb 26, 2026 | Oct CAHN |
| | AP | | | 0.25MG/ML | A220427 | 001 | Feb 26, 2026 | Feb NEWA |

TABLET;ORAL

BUMETANIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | MSN | 0.5MG | A215362 | 001 | Feb 05, 2026 | Jan NEWA |
| | AB | | | 1MG | A215362 | 002 | Feb 05, 2026 | Jan NEWA |
| | AB | | | 2MG | A215362 | 003 | Feb 05, 2026 | Jan NEWA |

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AP | | ADAPTIS | 0.25% | A220493 | 001 | Apr 22, 2026 | Oct CAHN |
| | AP | | | 0.25% | A220493 | 001 | Apr 22, 2026 | Sep CAHN |
| | AP | | | 0.25% | A220493 | 005 | Sep 11, 2026 | Sep NFTG |
| >D> | AP | | | 0.5% | A220493 | 002 | Apr 22, 2026 | Oct CAHN |
| | AP | | | 0.5% | A220493 | 002 | Apr 22, 2026 | Sep CAHN |
| | AP | | | 0.5% | A220493 | 004 | Sep 11, 2026 | Sep NFTG |
| >D> | AP | | | 0.75% | A220493 | 003 | Apr 22, 2026 | Oct CAHN |
| | AP | | | 0.75% | A220493 | 003 | Apr 22, 2026 | Sep CAHN |
| >A> | AP | | ANTHEA PHARMA | 0.25% | A220493 | 001 | Apr 22, 2026 | Oct CAHN |
| | AP | | | 0.25% | A220493 | 001 | Apr 22, 2026 | Apr NEWA |
| >A> | AP | | | 0.5% | A220493 | 002 | Apr 22, 2026 | Oct CAHN |
| | AP | | | 0.5% | A220493 | 002 | Apr 22, 2026 | Apr NEWA |
| >A> | AP | | | 0.75% | A220493 | 003 | Apr 22, 2026 | Oct CAHN |
| | AP | | | 0.75% | A220493 | 003 | Apr 22, 2026 | Apr NEWA |
| | AP | | HIKMA PHARMS | 0.25% | A204842 | 001 | Feb 11, 2021 | Sep CTNA |
| | AP | | | 0.5% | A204842 | 002 | Feb 11, 2021 | Sep CTNA |
| | AP | | | 0.75% | A204842 | 003 | Feb 11, 2021 | Sep CTNA |
| | | @ | MEITHEAL | 0.25% | A216039 | 001 | Jun 23, 2023 | Jul DISC |
| | | @ | | 0.25% | A216040 | 001 | Dec 27, 2023 | Jul DISC |
| | | @ | | 0.5% | A216039 | 002 | Jun 23, 2023 | Jul DISC |
| | | @ | | 0.5% | A216040 | 002 | Dec 27, 2023 | Jul DISC |
| | | @ | | 0.75% | A216040 | 003 | Dec 27, 2023 | Jul DISC |

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUTRANS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | + | KNOA PHARMA | 5MCG/HR | N021306 | 001 | Jun 30, 2010 | May CAHN |
| | AB | + | | 7.5MCG/HR | N021306 | 005 | Jun 30, 2014 | May CAHN |
| | AB | + | | 10MCG/HR | N021306 | 002 | Jun 30, 2010 | May CAHN |
| | AB | + | | 15MCG/HR | N021306 | 004 | Jul 25, 2013 | May CAHN |
| | AB | +! | | 20MCG/HR | N021306 | 003 | Jun 30, 2010 | May CAHN |

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

BRIXADI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | BRAEBURN | 8MG/0.16ML (50MG/ML) | N210136 | 001 | May 23, 2023 | Mar CHRS |
| | | +! | | 16MG/0.32ML (50MG/ML) | N210136 | 002 | May 23, 2023 | Mar CHRS |
| | | +! | | 24MG/0.48ML (50MG/ML) | N210136 | 003 | May 23, 2023 | Mar CHRS |
| | | +! | | 32MG/0.64ML (50MG/ML) | N210136 | 004 | May 23, 2023 | Mar CHRS |
| | | +! | | 64MG/0.18ML (356MG/ML) | N210136 | 005 | May 23, 2023 | Mar CHRS |
| | | +! | | 96MG/0.27ML (356MG/ML) | N210136 | 006 | May 23, 2023 | Mar CHRS |

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AP | | GLAND | EQ 0.3MG BASE/ML | A221145 | 001 | Oct 15, 2026 | Oct NEWA |

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | QUAGEN | EQ 2MG BASE | A201066 | 001 | Mar 06, 2015 | Jun CAHN |
| | | @ | | EQ 8MG BASE | A201066 | 002 | Mar 06, 2015 | Jun CAHN |
| | | | RUBICON RESEARCH | EQ 4MG BASE | A090279 | 003 | Jul 10, 2026 | Aug CHRS |
| | | ! | | EQ 4MG BASE | A090279 | 003 | Jul 10, 2026 | Jul NFTG |
| | | ! | | EQ 12MG BASE | A090279 | 004 | Jul 10, 2026 | Jul NFTG |

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ASCENT PHARMS INC | EQ 2MG BASE;EQ 0.5MG BASE | A219850 | 001 | Jan 21, 2026 | Jan NEWA |
| AB | | | EQ 4MG BASE;EQ 1MG BASE | A219850 | 002 | Jan 21, 2026 | Jan NEWA |
| AB | | | EQ 8MG BASE;EQ 2MG BASE | A219850 | 003 | Jan 21, 2026 | Jan NEWA |
| AB | | | EQ 12MG BASE;EQ 3MG BASE | A219850 | 004 | Jan 21, 2026 | Jan NEWA |

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | MICRO LABS | 75MG | A207403 | 001 | Apr 17, 2020 | Aug DISC |
| | @ | | 100MG | A207403 | 002 | Apr 17, 2020 | Aug DISC |
| AB | | PHARMAZONE | 75MG | A075584 | 001 | Feb 07, 2000 | Sep CAHN |
| AB | | | 100MG | A075584 | 002 | Feb 07, 2000 | Sep CAHN |
| AB | | SENORES PHARMS | 75MG | A075584 | 001 | Feb 07, 2000 | Feb CAHN |
| AB | | | 100MG | A075584 | 002 | Feb 07, 2000 | Feb CAHN |

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB3 | | AUROBINDO PHARMA LTD | 150MG | A216051 | 001 | Jul 21, 2026 | Jul NEWA |
| AB3 | | | 300MG | A216051 | 002 | Jul 21, 2026 | Jul NEWA |
| AB1 | | MACLEODS PHARMS | 100MG | A218567 | 001 | Jun 23, 2026 | Jun NEWA |
| AB1 | | | 150MG | A218567 | 002 | Jun 23, 2026 | Jun NEWA |
| AB1 | | | 200MG | A218567 | 003 | Jun 23, 2026 | Jun NEWA |
| AB1 | | YICHANG HUMANWELL | 100MG | A220529 | 001 | May 04, 2026 | Apr NEWA |
| AB1 | | | 150MG | A220529 | 002 | May 04, 2026 | Apr NEWA |
| AB1 | | | 200MG | A220529 | 003 | May 04, 2026 | Apr NEWA |

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

AUVELITY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | + | AXSOME | 105MG;30MG | N215430 | 002 | Apr 30, 2026 | Apr NEWA |

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | AZURITY | 90MG;8MG | N200063 | 001 | Sep 10, 2014 | Jul CAHN |

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL

BUCAPSOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | EPIC PHARMA LLC | 5MG | A218628 | 004 | Apr 29, 2026 | Apr NFTG |

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 5MG | A209696 | 001 | May 03, 2018 | Sep CAHN |
| AB | | | 7.5MG | A209696 | 002 | May 03, 2018 | Sep CAHN |
| AB | | | 10MG | A209696 | 003 | May 03, 2018 | Sep CAHN |
| AB | | | 15MG | A209696 | 004 | May 03, 2018 | Sep CAHN |
| AB | | | 30MG | A209696 | 005 | May 03, 2018 | Sep CAHN |
| | | EPIC PHARMA LLC | 2.5MG | A208972 | 006 | May 13, 2026 | May NEWA |
| AB | | | 5MG | A208972 | 001 | Apr 16, 2019 | May CTEC |
| AB | | | 7.5MG | A208972 | 002 | Apr 16, 2019 | May CTEC |
| AB | | | 10MG | A208972 | 003 | Apr 16, 2019 | May CTEC |
| | | | 12.5MG | A208972 | 007 | May 13, 2026 | May NEWA |
| AB | | | 15MG | A208972 | 004 | Apr 16, 2019 | May CTEC |
| AB | | | 30MG | A208972 | 005 | Apr 16, 2019 | May CTEC |
| AB | | INVENTIA HLTHCARE | 5MG | A209696 | 001 | May 03, 2018 | Jul CTEC |
| AB | | | 7.5MG | A209696 | 002 | May 03, 2018 | Jul CTEC |
| AB | | | 10MG | A209696 | 003 | May 03, 2018 | Jul CTEC |
| AB | | | 15MG | A209696 | 004 | May 03, 2018 | Jul CTEC |
| AB | | | 30MG | A209696 | 005 | May 03, 2018 | Jul CTEC |
| | @ | MYLAN | 7.5MG | A076008 | 002 | Jul 08, 2013 | Feb DISC |

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | ADAPTIS | 6MG/ML | A210931 | 001 | Apr 18, 2019 | Aug CAHN |
| | @ | MYLAN INSTITUTIONAL | 6MG/ML | A208536 | 001 | Nov 20, 2017 | Jun DISC |
| | @ | PRAXGEN | 6MG/ML | A205106 | 001 | Sep 21, 2018 | Jul CAHN |
| | @ | QUAGEN | 6MG/ML | A205106 | 001 | Sep 21, 2018 | Sep CAHN |

BUTABARBITAL SODIUM

TABLET;ORAL

SODIUM BUTABARBITAL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 15MG | A085418 | 001 | | | Sep CAHN |
| | @ | | 30MG | A085418 | 002 | | | Sep CAHN |
| | @ | WEST WARD | 30MG | A085418 | 002 | | | Aug CMS1 |

CABERGOLINE

TABLET;ORAL

CABERGOLINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | RENATA | 0.5MG | A220309 | 001 | Jun 15, 2026 | | Jun NEWA |

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

CABENUVA KIT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | VIIV HLTHCARE | 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) | N212888 | 001 | Jan 21, 2021 | | May CHRS |

CABOZANTINIB LAURYLSULFATE

CAPSULE;ORAL

OMCAZIO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | HANDA ONCOL | EQ 11.5MG BASE | N220613 | 001 | Sep 03, 2026 | | Sep NEWA |
| | + | | EQ 23MG BASE | N220613 | 002 | Sep 03, 2026 | | Sep NEWA |
| | +! | | EQ 34.5MG BASE | N220613 | 003 | Sep 03, 2026 | | Sep NEWA |

CABOZANTINIB S-MALATE

TABLET;ORAL

CABOMETYX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | EXELIXIS INC | EQ 20MG BASE | N208692 | 001 | Apr 25, 2016 | | Aug CFTG |
| AB | + | | EQ 40MG BASE | N208692 | 002 | Apr 25, 2016 | | Aug CFTG |
| AB | +! | | EQ 60MG BASE | N208692 | 003 | Apr 25, 2016 | | Aug CFTG |

CABOZANTINIB S-MALATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> AB | | CIPLA | EQ 20MG BASE | A217870 | 001 | Oct 16, 2026 | | Oct NEWA |
| >A> AB | | | EQ 40MG BASE | A217870 | 002 | Oct 16, 2026 | | Oct NEWA |
| >A> AB | | | EQ 60MG BASE | A217870 | 003 | Oct 16, 2026 | | Oct NEWA |
| AB | | MSN | EQ 20MG BASE | A213878 | 001 | Aug 14, 2026 | | Aug NFTG |
| AB | | | EQ 40MG BASE | A213878 | 002 | Aug 14, 2026 | | Aug NFTG |
| AB | | | EQ 60MG BASE | A213878 | 003 | Aug 14, 2026 | | Aug NFTG |

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 100MG;1MG | A040510 | 001 | Sep 17, 2004 | | Sep CAHN |
| | ! | MIKART | 100MG;1MG | A040590 | 001 | Sep 16, 2005 | | Mar CAHN |
| | ! | PHARMOBEDIENT | 100MG;1MG | A040590 | 001 | Sep 16, 2005 | | Sep CAHN |

CALCIPOTRIENE

SOLUTION;TOPICAL

CALCIPOTRIENE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | ! | COSETTE PHARMS NC | 0.005% | A078468 | 001 | Mar 24, 2011 | | May CAHN |

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> AP | | NANJING KING FRIEND | 200 IU/ML | A216996 | 001 | Oct 29, 2026 | | Oct NEWA |
| AP | | ZYDUS PHARMS | 200 IU/ML | A215864 | 001 | Mar 04, 2026 | | Feb NEWA |

SPRAY, METERED;NASAL

MIACALCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | ALLIED | 200 IU/SPRAY | N020313 | 002 | Aug 17, 1995 | | Jun CAHN |
| | @ + | SAPTALIS PHARMS | 200 IU/SPRAY | N020313 | 002 | Aug 17, 1995 | | Jul CAHN |

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | HUMANWELL PURACAP | 0.25MCG | A219796 | 001 | Feb 27, 2026 | | Feb NEWA |
| AB | | | 0.5MCG | A219796 | 002 | Feb 27, 2026 | | Feb NEWA |

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ADAPTIS | 667MG | A217205 | 001 | Mar 13, 2023 | Sep CAHN |
| | AB | | COHANCE LIFESCIENCES | 667MG | A211038 | 001 | Feb 21, 2020 | Sep CAHN |
| | | @ | LUPIN | 667MG | A202127 | 001 | Jul 09, 2015 | Mar DISC |

TABLET;ORAL

CALCIUM ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | PADAGIS US | 667MG | A091561 | 001 | Apr 13, 2011 | Mar DISC |

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | PHARMAZONE | 100MG/ML | A219342 | 001 | Nov 27, 2024 | Sep CAHN |
| | AP | | SQUARE PHARMS PLC | 100MG/ML | A217463 | 001 | Sep 29, 2025 | May CMFD |
| | | @ | | 100MG/ML | A217463 | 001 | Sep 29, 2025 | Mar DISC |

>A> SOLUTION;EXTRACORPOREAL

>A> CALREZDY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | +! | FRESENIUS MEDCL CARE | 14.7GM/1000ML (1500ML) | N219456 | 001 | Oct 19, 2026 | Oct NEWA |

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | FRESENIUS KABI USA | 20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML | A210332 | 001 | Mar 28, 2022 | May CMFD |

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | +! | OTSUKA ICU MEDCL | 20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML | N017608 | 001 | | May CHRS |

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | CAPLIN | 1GM/10ML (100MG/ML) | A218840 | 001 | May 04, 2026 | Apr NEWA |
| | AP | | | 5GM/50ML (100MG/ML) | A218840 | 002 | May 04, 2026 | Apr NEWA |
| | AP | | | 10GM/100ML (100MG/ML) | A218840 | 003 | May 04, 2026 | Apr NEWA |
| | | +! | HQ SPCLT PHARMA | 10GM/100ML (100MG/ML) | N210906 | 004 | Nov 18, 2025 | May NEWA |
| | AP | | NIVAGEN | 1GM/10ML (100MG/ML) | A213071 | 001 | Oct 14, 2022 | Aug CAHN |
| | AP | | | 5GM/50ML (100MG/ML) | A213071 | 002 | Oct 19, 2023 | Aug CAHN |
| | AP | | | 10GM/100ML (100MG/ML) | A213071 | 003 | Apr 30, 2024 | Aug CAHN |

CALCIUM GLUCONATE IN SODIUM CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | CIPLA | 1GM/50ML (20MG/ML) | A217891 | 001 | Sep 17, 2026 | Sep NEWA |
| | AP | | | 2GM/100ML (20MG/ML) | A217891 | 002 | Sep 17, 2026 | Sep NEWA |
| | AP | | MILLA PHARMS | 1GM/50ML (20MG/ML) | A219037 | 001 | Aug 28, 2026 | Aug NEWA |
| | AP | | | 2GM/100ML (20MG/ML) | A219037 | 002 | Aug 28, 2026 | Aug NEWA |

CAMIZESTRANT

TABLET;ORAL

ETCAMAH

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | ASTRAZENECA | 75MG | N220359 | 001 | Sep 04, 2026 | Sep NEWA |

CANAGLIFLOZIN

TABLET;ORAL

>D> CANAGLIFLOZIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | APOTEX | 100MG | A210449 | 001 | Apr 14, 2026 | Oct DISC |
| >A> | | @ | | 100MG | A210449 | 001 | Apr 14, 2026 | Oct DISC |
| | AB | | | 100MG | A210449 | 001 | Apr 14, 2026 | Apr NFTG |
| >D> | AB | | | 300MG | A210449 | 002 | Apr 14, 2026 | Oct DISC |
| >A> | | @ | | 300MG | A210449 | 002 | Apr 14, 2026 | Oct DISC |
| | AB | | | 300MG | A210449 | 002 | Apr 14, 2026 | Apr NFTG |
| | | @ | AUROBINDO PHARMA LTD | 100MG | A210386 | 001 | Apr 20, 2026 | Apr DISC |
| | AB | | | 100MG | A210386 | 001 | Apr 20, 2026 | Apr NEWA |
| | | @ | | 300MG | A210386 | 002 | Apr 20, 2026 | Apr DISC |
| | AB | | | 300MG | A210386 | 002 | Apr 20, 2026 | Apr NEWA |

INVOKANA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | + | JANSSEN PHARMS | 100MG | N204042 | 001 | Mar 29, 2013 | Oct CTEC |
| >A> | | + | | 100MG | N204042 | 001 | Mar 29, 2013 | Oct CTEC |
| | AB | + | | 100MG | N204042 | 001 | Mar 29, 2013 | Apr CFTG |
| >D> | AB | +! | | 300MG | N204042 | 002 | Mar 29, 2013 | Oct CTEC |
| >A> | | +! | | 300MG | N204042 | 002 | Mar 29, 2013 | Oct CTEC |
| | AB | +! | | 300MG | N204042 | 002 | Mar 29, 2013 | Apr CFTG |

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | PHARMAZONE | 16MG;12.5MG | A202965 | 001 | Jun 03, 2013 | Sep CAHN |
| | AB | | | 32MG;12.5MG | A202965 | 002 | Jun 03, 2013 | Sep CAHN |
| | AB | | | 32MG;25MG | A202965 | 003 | Jun 03, 2013 | Sep CAHN |
| | | @ | PHARMOBEDIENT | 32MG;12.5MG | A090704 | 002 | Dec 04, 2012 | Jul DISC |
| | | @ | | 32MG;25MG | A090704 | 003 | Dec 04, 2012 | Sep DISC |
| | AB | | SENORES PHARMS | 16MG;12.5MG | A202965 | 001 | Jun 03, 2013 | Jan CAHN |
| | AB | | | 32MG;12.5MG | A202965 | 002 | Jun 03, 2013 | Jan CAHN |
| | AB | | | 32MG;25MG | A202965 | 003 | Jun 03, 2013 | Jan CAHN |

CANGRELOR

POWDER;INTRAVENOUS

CANGRELOR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | MSN | 50MG/VIAL | A213703 | 001 | Jun 04, 2026 | May NEWA |

CAPECITABINE

TABLET;ORAL

CAPECITABINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | | | | | | | |
| >D> | AB | | ALKEM LABS LTD | 150MG | A207652 | 001 | Nov 24, 2017 | Oct CTNA |
| >D> | AB | | | 500MG | A207652 | 002 | Nov 24, 2017 | Oct CTNA |
| | AB | ! | DR REDDYS | 500MG | A204345 | 002 | Dec 04, 2020 | Jan CHRS |
| | AB | | SOMERSET THERAPS LLC | 150MG | A211724 | 001 | Apr 27, 2020 | Sep CAHN |
| | AB | | | 500MG | A211724 | 002 | Apr 27, 2020 | Sep CAHN |

XELODA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | + | CHEPLAPHARM | 150MG | N020896 | 001 | Apr 30, 1998 | Jan DISC |
| | @ | + | | 500MG | N020896 | 002 | Apr 30, 1998 | Jan DISC |

XORIDRONO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | | | | | | | |
| >A> | AB | | ALKEM LABS LTD | 150MG | A207652 | 001 | Nov 24, 2017 | Oct CTNA |
| >A> | AB | | | 500MG | A207652 | 002 | Nov 24, 2017 | Oct CTNA |

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | COSETTE PHARMS NC | 12.5MG | A074433 | 001 | Feb 13, 1996 | May CAHN |
| | | @ | | 12.5MG | A074462 | 001 | Feb 13, 1996 | May CAHN |
| | | @ | | 12.5MG | A074483 | 001 | Feb 13, 1996 | May CAHN |
| | | @ | | 25MG | A074433 | 002 | Feb 13, 1996 | May CAHN |
| | | @ | | 25MG | A074462 | 002 | Feb 13, 1996 | May CAHN |
| | | @ | | 25MG | A074483 | 002 | Feb 13, 1996 | May CAHN |
| | | @ | | 50MG | A074433 | 003 | Feb 13, 1996 | May CAHN |
| | | @ | | 50MG | A074462 | 003 | Feb 13, 1996 | May CAHN |
| | | @ | | 50MG | A074483 | 003 | Feb 13, 1996 | May CAHN |
| | | @ | | 100MG | A074433 | 004 | Feb 13, 1996 | May CAHN |
| | | @ | | 100MG | A074462 | 004 | Feb 13, 1996 | May CAHN |
| | | @ | | 100MG | A074483 | 004 | Feb 13, 1996 | May CAHN |
| | AB | | HIKMA | 12.5MG | A074505 | 001 | Feb 13, 1996 | Sep CAHN |
| | AB | | | 25MG | A074505 | 002 | Feb 13, 1996 | Sep CAHN |
| | AB | | | 50MG | A074505 | 003 | Feb 13, 1996 | Sep CAHN |
| | AB | ! | | 100MG | A074505 | 004 | Feb 13, 1996 | Sep CAHN |
| | AB | | MACLEODS PHARMS | 12.5MG | A074737 | 001 | Oct 28, 1998 | Sep CAHN |
| | AB | | | 25MG | A074737 | 002 | Oct 28, 1998 | Sep CAHN |
| | AB | | | 50MG | A074737 | 003 | Oct 28, 1998 | Sep CAHN |
| | AB | | | 100MG | A074737 | 004 | Oct 28, 1998 | Sep CAHN |
| | | @ | TP ANDA HOLDINGS | 12.5MG | A074418 | 001 | Feb 13, 1996 | Sep CAHN |
| | | @ | | 25MG | A074418 | 002 | Feb 13, 1996 | Sep CAHN |
| | | @ | | 50MG | A074418 | 003 | Feb 13, 1996 | Sep CAHN |
| | | @ | | 100MG | A074418 | 004 | Feb 13, 1996 | Sep CAHN |

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | COSETTE PHARMS NC | 25MG;15MG | A074827 | 001 | Dec 29, 1997 | May CAHN |
| | | @ | | 25MG;25MG | A074827 | 002 | Dec 29, 1997 | May CAHN |
| | | @ | | 50MG;15MG | A074827 | 004 | Dec 29, 1997 | May CAHN |
| | | @ | | 50MG;25MG | A074827 | 003 | Dec 29, 1997 | May CAHN |

CARBAMAZEPINE

TABLET;ORAL

CARBAMAZEPINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | APPCO | 200MG | A214328 | 001 | Aug 16, 2021 | Aug CAHN |
| | | @ | SOMERSET THERAPS LLC | 200MG | A214328 | 001 | Aug 16, 2021 | Sep CAHN |

EPITOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | TEVA | 200MG | A070541 | 001 | Sep 17, 1986 | Aug DISC |

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | ADAPTIS | 100MG | A218447 | 001 | Nov 02, 2026 | Oct NEWA |
| >A> | AB | | | 200MG | A218447 | 002 | Nov 02, 2026 | Oct NEWA |
| >A> | AB | | | 400MG | A218447 | 003 | Nov 02, 2026 | Oct NEWA |
| | AB | | INGENUS PHARMS LLC | 100MG | A216404 | 001 | Dec 02, 2022 | Feb CAHN |
| | AB | | | 200MG | A216404 | 002 | Dec 02, 2022 | Feb CAHN |
| | AB | | | 400MG | A216404 | 003 | Dec 02, 2022 | Feb CAHN |

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ALEMBIC | 12.5MG;200MG;50MG | A218535 | 001 | Feb 05, 2026 | Jan NEWA |
| | AB | | | 18.75MG;200MG;75MG | A218535 | 002 | Feb 05, 2026 | Jan NEWA |
| | AB | | | 25MG;200MG;100MG | A218535 | 003 | Feb 05, 2026 | Jan NEWA |
| | AB | | | 31.25MG;200MG;125MG | A218535 | 004 | Feb 05, 2026 | Jan NEWA |
| | AB | | | 37.5MG;200MG;150MG | A218535 | 005 | Feb 05, 2026 | Jan NEWA |
| | AB | | | 50MG;200MG;200MG | A218535 | 006 | Feb 05, 2026 | Jan NEWA |

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

>A>

CARBIDOPA AND LEVODOPA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | ACTAVIS LABS FL | 23.75MG;95MG | A208522 | 001 | Nov 02, 2026 | Oct NFTG |
| >A> | AB | | | 36.25MG;145MG | A208522 | 002 | Nov 02, 2026 | Oct NFTG |
| >A> | AB | | | 48.75MG;195MG | A208522 | 003 | Nov 02, 2026 | Oct NFTG |
| >A> | AB | | | 61.25MG;245MG | A208522 | 004 | Nov 02, 2026 | Oct NFTG |

RYTARY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | + | IMPAX | 23.75MG;95MG | N203312 | 001 | Jan 07, 2015 | Oct CFTG |
| >A> | AB | + | | 23.75MG;95MG | N203312 | 001 | Jan 07, 2015 | Oct CFTG |
| >D> | | + | | 36.25MG;145MG | N203312 | 002 | Jan 07, 2015 | Oct CFTG |
| >A> | AB | + | | 36.25MG;145MG | N203312 | 002 | Jan 07, 2015 | Oct CFTG |
| >D> | | + | | 48.75MG;195MG | N203312 | 003 | Jan 07, 2015 | Oct CFTG |
| >A> | AB | + | | 48.75MG;195MG | N203312 | 003 | Jan 07, 2015 | Oct CFTG |
| >D> | | +! | | 61.25MG;245MG | N203312 | 004 | Jan 07, 2015 | Oct CFTG |
| >A> | AB | +! | | 61.25MG;245MG | N203312 | 004 | Jan 07, 2015 | Oct CFTG |

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | SUN PHARM INDS | 25MG;100MG | A077828 | 001 | Aug 23, 2007 | Feb DISC |
| | | @ | | 50MG;200MG | A077828 | 002 | Aug 23, 2007 | Feb DISC |

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | GENUS | 4MG | A040442 | 001 | Mar 19, 2003 | Jul DISC |
| | | @ | GENUS LIFESCIENCES | 4MG | A040442 | 001 | Mar 19, 2003 | Sep CAHN |
| | AB | | LEADING | 6MG | A215476 | 001 | Dec 19, 2024 | Jun CTEC |
| | AB | ! | MIKART | 6MG | A207484 | 001 | May 31, 2016 | Jun CTEC |
| | | ! | MISSION PHARMACAL | 4MG | A090756 | 001 | May 27, 2011 | Jul CTEC |
| | AA | ! | | 4MG | A090756 | 001 | May 27, 2011 | Jul CHRS |
| | | @ | PHARMAZONE | 4MG | A090435 | 001 | Apr 15, 2010 | Sep CAHN |
| | AB | ! | PHARMOBEDIENT | 6MG | A207484 | 001 | May 31, 2016 | Sep CAHN |
| | | @ | ZETA PHARMS | 4MG | A040442 | 001 | Mar 19, 2003 | Aug CAHN |

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | INGENUS PHARMS LLC | 50MG/5ML (10MG/ML) | A208487 | 001 | Apr 26, 2017 | May CAHN |
| | | @ | | 150MG/15ML (10MG/ML) | A208487 | 002 | Apr 26, 2017 | May CAHN |
| | | @ | | 450MG/45ML (10MG/ML) | A208487 | 003 | Apr 26, 2017 | May CAHN |
| | | @ | | 600MG/60ML (10MG/ML) | A208487 | 004 | Apr 26, 2017 | May CAHN |
| | | @ | NOVAST LABS | 50MG/5ML (10MG/ML) | A208487 | 001 | Apr 26, 2017 | Feb DISC |
| | | @ | | 150MG/15ML (10MG/ML) | A208487 | 002 | Apr 26, 2017 | Feb DISC |
| | | @ | | 450MG/45ML (10MG/ML) | A208487 | 003 | Apr 26, 2017 | Feb DISC |
| | | @ | | 600MG/60ML (10MG/ML) | A208487 | 004 | Apr 26, 2017 | Feb DISC |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | INJECTABLE;INTRAVENOUS | | | | | | |
| | CARBOPLATIN | | | | | | |
| | @ QILU PHARM HAINAN | 50MG/5ML (10MG/ML) | A219999 | 001 | Feb 04, 2026 | Aug DISC |
| AP | | 50MG/5ML (10MG/ML) | A219999 | 001 | Feb 04, 2026 | Jan NEWA |
| | @ | 150MG/15ML (10MG/ML) | A219999 | 002 | Feb 04, 2026 | Aug DISC |
| AP | | 150MG/15ML (10MG/ML) | A219999 | 002 | Feb 04, 2026 | Jan NEWA |
| | @ | 450MG/45ML (10MG/ML) | A219999 | 003 | Feb 04, 2026 | Aug DISC |
| AP | | 450MG/45ML (10MG/ML) | A219999 | 003 | Feb 04, 2026 | Jan NEWA |
| | @ | 600MG/60ML (10MG/ML) | A219999 | 004 | Feb 04, 2026 | Aug DISC |
| AP | | 600MG/60ML (10MG/ML) | A219999 | 004 | Feb 04, 2026 | Jan NEWA |
| | CARBOPROST TROMETHAMINE | | | | | |
| | INJECTABLE;INJECTION | | | | | |
| | CARBOPROST TROMETHAMINE | | | | | |
| AP | SOMERSET THERAPS LLC | EQ 0.25MG BASE/ML | A219529 | 001 | May 27, 2026 | May NEWA |
| | CARFILZOMIB | | | | | |
| | POWDER;INTRAVENOUS | | | | | |
| | CARFILZOMIB | | | | | |
| AP | MSN | 60MG/VIAL | A209526 | 001 | Jul 20, 2026 | Jul NEWA |
| | CARIPRAZINE HYDROCHLORIDE | | | | | |
| | CAPSULE;ORAL | | | | | |
| | CARIPRAZINE HYDROCHLORIDE | | | | | |
| | @ AUROBINDO PHARMA LTD | EQ 1.5MG BASE | A213982 | 001 | Dec 16, 2025 | Jan DISC |
| | @ | EQ 3MG BASE | A213982 | 002 | Dec 16, 2025 | Jan DISC |
| | @ | EQ 6MG BASE | A213982 | 003 | Dec 16, 2025 | Jan DISC |
| | VRAYLAR | | | | | |
| | +! ABBVIE | EQ 1.5MG BASE | N204370 | 001 | Sep 17, 2015 | Jan CTEC |
| | + | EQ 3MG BASE | N204370 | 002 | Sep 17, 2015 | Jan CTEC |
| | + | EQ 6MG BASE | N204370 | 004 | Sep 17, 2015 | Jan CTEC |
| | CARISOPRODOL | | | | | |
| | TABLET;ORAL | | | | | |
| | CARISOPRODOL | | | | | |
| | @ HIKMA | 350MG | A040124 | 001 | Jan 24, 1996 | Sep CAHN |
| AA | INGENUS PHARMS LLC | 350MG | A040823 | 001 | Oct 22, 2008 | Feb CAHN |
| AA | PHARMAZONE | 350MG | A081025 | 001 | Apr 13, 1989 | Sep CAHN |
| AA | | 350MG | A211789 | 001 | Oct 20, 2021 | Sep CAHN |
| | CARMUSTINE | | | | | |
| | INJECTABLE;INJECTION | | | | | |
| | CARMUSTINE | | | | | |
| | @ INGENUS PHARMS LLC | 100MG/VIAL | A211011 | 001 | Jun 21, 2022 | May CAHN |
| | CARVEDILOL | | | | | |
| | TABLET;ORAL | | | | | |
| | CARVEDILOL | | | | | |
| | @ ALLIED | 3.125MG | A077316 | 001 | Sep 05, 2007 | Jun CAHN |
| | @ | 6.25MG | A077316 | 002 | Sep 05, 2007 | Jun CAHN |
| | @ | 12.5MG | A077316 | 003 | Sep 05, 2007 | Jun CAHN |
| | @ | 25MG | A077316 | 004 | Sep 05, 2007 | Jun CAHN |
| | @ LUPIN | 3.125MG | A078217 | 001 | Sep 05, 2007 | Feb DISC |
| | @ | 6.25MG | A078217 | 002 | Sep 05, 2007 | Feb DISC |
| | @ | 12.5MG | A078217 | 003 | Sep 05, 2007 | Feb DISC |
| | @ | 25MG | A078217 | 004 | Sep 05, 2007 | Feb DISC |
| | @ SCIEGEN PHARMS | 3.125MG | A077316 | 001 | Sep 05, 2007 | Jul CAHN |
| | @ | 6.25MG | A077316 | 002 | Sep 05, 2007 | Jul CAHN |
| | @ | 12.5MG | A077316 | 003 | Sep 05, 2007 | Jul CAHN |
| | @ | 25MG | A077316 | 004 | Sep 05, 2007 | Jul CAHN |
| | CASPOFUNGIN ACETATE | | | | | |
| | POWDER;INTRAVENOUS | | | | | |
| | CASPOFUNGIN ACETATE | | | | | |
| AP | ! GLAND | 50MG/VIAL | A207092 | 001 | Sep 29, 2017 | May CHRS |
| AP | ! | 70MG/VIAL | A207092 | 002 | Sep 29, 2017 | May CHRS |
| | @ HENGRUI PHARMA | 50MG/VIAL | A200833 | 001 | Jun 28, 2018 | May DISC |
| | @ | 70MG/VIAL | A200833 | 002 | Jun 28, 2018 | May DISC |

CEFAZOLIN SODIUM

POWDER;INTRAVENOUS

CEFAZOLIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | HQ SPCLT PHARMA | EQ 3GM BASE/VIAL | N211413 | 002 | Mar 08, 2024 | Feb | NEWA |

CEFEPIME HYDROCHLORIDE; ZIDEBACTAM

POWDER;INTRAVENOUS

ZAYNICH

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | WOCKHARDT BIO AG | EQ 2GM BASE/VIAL;1GM/VIAL | N220787 | 001 | May 29, 2026 | May | NEWA |

CEFIXIME

CAPSULE;ORAL

CEFIXIME

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA LTD | 400MG | A217607 | 001 | Mar 23, 2026 | Mar | NEWA |

FOR SUSPENSION;ORAL

CEFIXIME

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | FDC LTD | 100MG/5ML | A218691 | 001 | May 14, 2026 | May | NEWA |
| AB | | | 200MG/5ML | A218691 | 002 | May 14, 2026 | May | NEWA |

TABLET;ORAL

CEFIXIME

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | FDC LTD | 400MG | A206358 | 001 | Dec 17, 2024 | Jan | CMFD |

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CLAFORAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | STERIMAX | EQ 1GM BASE/VIAL | N050547 | 002 | | Sep | CMFD |

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS

CEFTAROLINE FOSAMIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | APOTEX | 400MG/VIAL | A208075 | 001 | Sep 21, 2021 | Jan | CMFD |
| AP | | | 600MG/VIAL | A208075 | 002 | Sep 21, 2021 | Jan | CMFD |

TEFLARO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | ABBVIE | 400MG/VIAL | N200327 | 001 | Oct 29, 2010 | Jan | CTEC |
| AP | +! | | 600MG/VIAL | N200327 | 002 | Oct 29, 2010 | Jan | CTEC |

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | SANDOZ INC | EQ 1GM BASE/VIAL | A065204 | 001 | May 03, 2005 | Apr | DISC |
| | @ | | EQ 2GM BASE/VIAL | A065204 | 002 | May 03, 2005 | Apr | DISC |

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | REGCON HOLDINGS | EQ 250MG BASE/VIAL | A210197 | 001 | Jan 12, 2024 | Aug | CAHN |
| | @ | | EQ 500MG BASE/VIAL | A210197 | 002 | Jan 12, 2024 | Aug | CAHN |
| | @ | | EQ 1GM BASE/VIAL | A210197 | 003 | Jan 12, 2024 | Aug | CAHN |
| | @ | | EQ 2GM BASE/VIAL | A210197 | 004 | Jan 12, 2024 | Aug | CAHN |

CELECOXIB

CAPSULE;ORAL

CELECOXIB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ALLIED | 50MG | A078857 | 001 | May 30, 2014 | Jun | CAHN |
| | @ | | 100MG | A078857 | 002 | Feb 11, 2015 | Jun | CAHN |
| | @ | | 200MG | A078857 | 003 | Feb 11, 2015 | Jun | CAHN |
| | @ | | 400MG | A078857 | 004 | Feb 11, 2015 | Jun | CAHN |
| | @ | PHARMAZONE | 50MG | A078857 | 001 | May 30, 2014 | Sep | CAHN |
| AB | | | 50MG | A210628 | 001 | Nov 27, 2019 | Sep | CAHN |
| | @ | | 100MG | A078857 | 002 | Feb 11, 2015 | Sep | CAHN |
| AB | | | 100MG | A210628 | 002 | Nov 27, 2019 | Sep | CAHN |
| | @ | | 200MG | A078857 | 003 | Feb 11, 2015 | Sep | CAHN |
| AB | | | 200MG | A210628 | 003 | Nov 27, 2019 | Sep | CAHN |
| | @ | | 400MG | A078857 | 004 | Feb 11, 2015 | Sep | CAHN |
| AB | | | 400MG | A210628 | 004 | Nov 27, 2019 | Sep | CAHN |
| AB | | PHARMOBEDIENT | 50MG | A211412 | 001 | Mar 06, 2020 | Sep | CAHN |
| AB | | | 100MG | A211412 | 002 | Mar 06, 2020 | Sep | CAHN |
| AB | | | 200MG | A211412 | 003 | Mar 06, 2020 | Sep | CAHN |
| AB | | | 400MG | A211412 | 004 | Mar 06, 2020 | Sep | CAHN |
| | @ | SENORES PHARMS | 50MG | A078857 | 001 | May 30, 2014 | Jul | CAHN |
| | @ | | 100MG | A078857 | 002 | Feb 11, 2015 | Jul | CAHN |
| | @ | | 200MG | A078857 | 003 | Feb 11, 2015 | Jul | CAHN |
| | @ | | 400MG | A078857 | 004 | Feb 11, 2015 | Jul | CAHN |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | CENTANAFADINE HYDROCHLORIDE | | | | | | |
| >A> | | CAPSULE, EXTENDED RELEASE;ORAL | | | | | | |
| >A> | | SIMTRIYO | | | | | | |
| >A> | + | OTSUKA | EQ 140MG BASE | N218145 | 001 | Oct 30, 2026 | Oct | NEWA |
| >A> | + | | EQ 210MG BASE | N218145 | 002 | Oct 30, 2026 | Oct | NEWA |
| >A> | +! | | EQ 280MG BASE | N218145 | 003 | Oct 30, 2026 | Oct | NEWA |
| | | CEPHALEXIN | | | | | | |
| | | FOR SUSPENSION;ORAL | | | | | | |
| | | CEPHALEXIN | | | | | | |
| AB | | AUROBINDO PHARMA | EQ 125MG BASE/5ML | A213568 | 001 | Jun 09, 2026 | May | NEWA |
| AB | | | EQ 250MG BASE/5ML | A213568 | 002 | Jun 09, 2026 | May | NEWA |
| | | TABLET;ORAL | | | | | | |
| | | CEPHALEXIN | | | | | | |
| AB | | TEVA | EQ 250MG BASE | A063024 | 002 | Jan 12, 1989 | Jun | CTEC |
| AB | ! | | EQ 500MG BASE | A063024 | 001 | Jan 12, 1989 | Jun | CTEC |
| | | CETIRIZINE HYDROCHLORIDE | | | | | | |
| | | SOLUTION;INTRAVENOUS | | | | | | |
| | | QUZYTTIR | | | | | | |
| | +! | ESTEVE | 10MG/ML (10MG/ML) | N211415 | 001 | Oct 04, 2019 | Apr | CAHN |
| | | SOLUTION;ORAL | | | | | | |
| | | CETIRIZINE HYDROCHLORIDE | | | | | | |
| | @ | PHARMAZONE | 5MG/5ML | A078757 | 001 | Aug 28, 2009 | Sep | CAHN |
| AA | | | 5MG/5ML | A078870 | 001 | Apr 27, 2009 | Sep | CAHN |
| AA | | RUBICON RESEARCH | 5MG/5ML | A220335 | 001 | Feb 25, 2026 | Feb | NEWA |
| | @ | TIME CAP LABS | 5MG/5ML | A078757 | 001 | Aug 28, 2009 | Mar | CAHN |
| | | CETRORELIX ACETATE | | | | | | |
| | | POWDER;SUBCUTANEOUS | | | | | | |
| | | CETRORELIX ACETATE | | | | | | |
| AP | | EPIC PHARMA LLC | EQ 0.25MG BASE/VIAL | A218740 | 001 | Apr 29, 2026 | May | CAHN |
| AP | | HUMANWELL | EQ 0.25MG BASE/VIAL | A218740 | 001 | Apr 29, 2026 | Apr | NEWA |
| | @ | TEVA PHARMS INC | EQ 0.25MG BASE/VIAL | A215737 | 001 | Aug 12, 2022 | Jul | DISC |
| | | CEVIMELINE HYDROCHLORIDE | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | CEVIMELINE HYDROCHLORIDE | | | | | | |
| AB | | ZYDUS LIFESCIENCES | 30MG | A220267 | 001 | Mar 11, 2026 | Feb | NEWA |
| >A> | | SOLUTION;ORAL | | | | | | |
| >A> | | EVOXAC | | | | | | |
| >A> | +! | COSETTE | 30MG/5ML | N221183 | 001 | Oct 15, 2026 | Oct | NEWA |
| | | CHLORDIAZEPOXIDE HYDROCHLORIDE | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | CHLORDIAZEPOXIDE HYDROCHLORIDE | | | | | | |
| AB | + | BARR | 5MG | A084768 | 001 | | Mar | CRLD |
| AB | + | | 10MG | A083116 | 001 | | Mar | CRLD |
| AB | +! | | 25MG | A084769 | 001 | | Mar | CRLD |
| | | LIBRIUM | | | | | | |
| AB | + | BAUSCH | 5MG | A085461 | 001 | | Feb | CAHN |
| AB | + | | 10MG | A085472 | 001 | | Feb | CAHN |
| | | CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE | | | | | | |
| AB | | MACLEODS PHARMS | 5MG;2.5MG | A215453 | 001 | Jul 29, 2022 | Sep | CAHN |
| | | CHLORHEXIDINE GLUCONATE | | | | | | |
| | | SOLUTION;DENTAL | | | | | | |
| | | PERIDEX | | | | | | |
| AT | +! | SOLVENTUM | 0.12% | N019028 | 001 | Aug 13, 1986 | May | CAHN |
| | | CHLOROPROCAINE HYDROCHLORIDE | | | | | | |
| | | SOLUTION;INTRATHECAL | | | | | | |
| | | CLOROTEKAL | | | | | | |
| >D> | @ + | B BRAUN MEDICAL | 50MG/5ML (10MG/ML) | N208791 | 001 | Sep 26, 2017 | Oct | CAHN |
| >A> | @ + | SINTETICA | 50MG/5ML (10MG/ML) | N208791 | 001 | Sep 26, 2017 | Oct | CAHN |

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | COHANCE LIFESCIENCES | 500MG | A214756 | 001 | Sep 03, 2021 | Sep CAHN |
| | @ | HIKMA | 250MG | A083082 | 001 | | Sep CAHN |
| | @ | | 500MG | A083082 | 002 | Sep 17, 1999 | Sep CAHN |

CHLOROTHIAZIDE

SUSPENSION;ORAL

DIURIL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | SALIX PHARMS | 250MG/5ML | N011870 | 001 | | Jan DISC |

TABLET;ORAL

CHLOROTHIAZIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 250MG | A086028 | 001 | Jul 14, 1982 | Sep CAHN |
| | @ | | 500MG | A087736 | 001 | Jul 14, 1982 | Sep CAHN |

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

CHLOROTHIAZIDE AND RESERPINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 250MG;0.125MG | A088365 | 002 | Dec 22, 1983 | Sep CAHN |
| | @ | | 250MG;0.125MG | A088365 | 002 | Dec 22, 1983 | Jul CMS1 |
| | @ | | 500MG;0.125MG | A088365 | 001 | Dec 22, 1983 | Sep CAHN |

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | APOZEAL PHARMS | 4MG/5ML;5MG/5ML;60MG/5ML | A206660 | 001 | May 15, 2017 | Jul CAHN |
| | @ | PADAGIS US | 4MG/5ML;5MG/5ML;60MG/5ML | A204627 | 001 | Apr 29, 2014 | Mar DISC |
| | @ | PHARMAZONE | 4MG/5ML;5MG/5ML;60MG/5ML | A206660 | 001 | May 15, 2017 | Sep CAHN |

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | ! | GENUS | 30MG/ML | A214542 | 001 | Jun 02, 2021 | Mar CTEC |
| AA | ! | | 100MG/ML | A214542 | 002 | Jun 02, 2021 | Mar CTEC |
| AA | | RUBICON | 30MG/ML | A216678 | 001 | Oct 10, 2025 | Mar CTEC |
| AA | | | 100MG/ML | A216678 | 002 | Oct 10, 2025 | Mar CTEC |
| AA | | RUBICON RESEARCH | 30MG/ML | A216678 | 001 | Oct 10, 2025 | May CAHN |
| AA | | | 100MG/ML | A216678 | 002 | Oct 10, 2025 | May CAHN |

SONAZINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | SAPTALIS PHARMS | 30MG/ML | A080983 | 004 | | Mar CMFD |
| AA | | | 100MG/ML | A080983 | 005 | | Mar CMFD |
| AA | | SCIEGEN PHARMS | 30MG/ML | A080983 | 004 | | Aug CAHN |
| AA | | | 100MG/ML | A080983 | 005 | | Aug CAHN |

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | MSN | 25MG/ML | A216092 | 001 | Jan 26, 2026 | Jan NEWA |
| AP | | REGCON HOLDINGS | 25MG/ML | A218229 | 001 | Sep 24, 2024 | Aug CAHN |
| AP | | RISING | 25MG/ML | A216724 | 001 | Dec 10, 2024 | Sep CAHN |

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CHARTWELL RX | 10MG | A212630 | 001 | Nov 29, 2021 | Sep CAHN |
| AB | | | 25MG | A212630 | 002 | Nov 29, 2021 | Sep CAHN |
| AB | | | 50MG | A212630 | 003 | Nov 29, 2021 | Sep CAHN |
| AB | | | 100MG | A212630 | 004 | Nov 29, 2021 | Sep CAHN |
| AB | | | 200MG | A212630 | 005 | Nov 29, 2021 | Sep CAHN |
| AB | | ZAMEER PHARMS | 10MG | A212630 | 001 | Nov 29, 2021 | Jan CAHN |
| AB | | | 25MG | A212630 | 002 | Nov 29, 2021 | Jan CAHN |
| AB | | | 50MG | A212630 | 003 | Nov 29, 2021 | Jan CAHN |
| AB | | | 100MG | A212630 | 004 | Nov 29, 2021 | Jan CAHN |
| AB | | | 200MG | A212630 | 005 | Nov 29, 2021 | Jan CAHN |

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 25MG | A211320 | 001 | Feb 09, 2022 | Sep CAHN |
| AB | | | 50MG | A211320 | 002 | Feb 09, 2022 | Sep CAHN |
| AB | ! | ALKEM LABS LTD | 50MG | A213412 | 002 | Feb 11, 2020 | Mar CHRS |
| | @ | COSETTE PHARMS NC | 50MG | A088651 | 001 | May 30, 1985 | May CAHN |
| AB | | INGENUS PHARMS LLC | 25MG | A206904 | 001 | Mar 30, 2017 | May CAHN |
| AB | | | 50MG | A206904 | 002 | Mar 30, 2017 | May CAHN |

TABLET;ORAL
CHLORTHALIDONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | MACLEODS PHARMS | 25MG | A212229 | 001 | Jul 01, 2026 | Jun NEWA |
| AB | | | 50MG | A212229 | 002 | Jul 01, 2026 | Jun NEWA |

THALITONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | | CASPER PHARMA LLC | 25MG | N019574 | 002 | Feb 12, 1992 | Jun DISC |

CHLORZOXAZONE

TABLET;ORAL
CHLORZOXAZONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | MACLEODS PHARMS | 250MG | A214702 | 001 | Apr 10, 2023 | Sep CAHN |
| AB | | | 375MG | A214941 | 001 | Oct 20, 2022 | Sep CAHN |
| AA | | | 500MG | A214941 | 002 | Oct 20, 2022 | Sep CAHN |
| AB | | | 750MG | A214941 | 003 | Oct 20, 2022 | Sep CAHN |
| AA | | PHARMAZONE | 250MG | A215158 | 001 | Jul 29, 2021 | Sep CAHN |
| AA | | | 500MG | A210961 | 001 | Jan 22, 2024 | Sep CAHN |
| @ | | | 500MG | A214365 | 001 | Apr 27, 2023 | Sep CAHN |
| AA | ! | PHARMOBEDIENT | 250MG | A207483 | 001 | Jun 24, 2016 | Sep CAHN |
| AB | ! | | 375MG | A040861 | 001 | Jun 01, 2010 | Sep CAHN |
| AB | ! | | 750MG | A040861 | 002 | Jun 01, 2010 | Sep CAHN |
| AA | | SENORES PHARMS | 500MG | A210961 | 001 | Jan 22, 2024 | Jan CAHN |

CHOLESTYRAMINE

POWDER;ORAL
CHOLESTYRAMINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AIPING PHARM INC | EQ 4GM RESIN/PACKET | A214877 | 001 | Jan 21, 2022 | Jun CMFD |
| AB | | | EQ 4GM RESIN/SCOOPFUL | A214877 | 002 | Jan 21, 2022 | Jun CMFD |
| AB | | MICRO LABS | EQ 4GM RESIN/PACKET | A219318 | 001 | Mar 05, 2026 | Feb NEWA |
| AB | | PHARMOBEDIENT | EQ 4GM RESIN/PACKET | A209597 | 001 | Mar 09, 2021 | Jan CAHN |
| AB | | | EQ 4GM RESIN/SCOOPFUL | A209597 | 002 | Mar 09, 2021 | Jan CAHN |

CHOLESTYRAMINE LIGHT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ZYDUS PHARMS | EQ 4GM RESIN/PACKET | A202902 | 002 | Apr 25, 2017 | Mar NEWA |

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | MICRO LABS | EQ 45MG FENOFIBRIC ACID | A213450 | 001 | Jun 16, 2020 | Aug DISC |
| @ | | | EQ 135MG FENOFIBRIC ACID | A213450 | 002 | Jun 16, 2020 | Aug DISC |

CHROMIC CHLORIDE

INJECTABLE;INJECTION
CHROMIC CHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | SOMERSET THERAPS LLC | EQ 0.004MG CHROMIUM/ML | A218538 | 001 | Nov 18, 2024 | Feb CAHN |

CICLESONIDE

AEROSOL, METERED;INHALATION
ALVESCO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | AZURITY | 0.08MG/INH | N021658 | 002 | Jan 10, 2008 | Jun CAHN |
| | +! | | 0.16MG/INH | N021658 | 003 | Jan 10, 2008 | Jun CAHN |

AEROSOL, METERED;NASAL
ZETONNA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | | AZURITY | 0.037MG/INH | N202129 | 001 | Jan 20, 2012 | Jun CAHN |
| @ + | | | 0.037MG/INH | N202129 | 001 | Jan 20, 2012 | Mar CAHN |

SPRAY, METERED;NASAL
OMNARIS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | AZURITY | 0.05MG/SPRAY | N022004 | 001 | Oct 20, 2006 | Jun CAHN |
| | +! | | 0.05MG/SPRAY | N022004 | 001 | Oct 20, 2006 | Mar CAHN |

CICLOPIROX

CREAM;TOPICAL
CICLOPIROX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | 0.77% | A078463 | 001 | Dec 20, 2010 | May CAHN |

LOPROX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | EUROFARMA | 0.77% | N018748 | 001 | Dec 30, 1982 | Feb CAHN |

SHAMPOO;TOPICAL
CICLOPIROX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >D> AT | | ENCUBE | 1% | A209975 | 001 | Apr 05, 2018 | Oct CAHN |
| >A> AT | | | 1% | A209975 | 001 | Apr 05, 2018 | Oct CAHN |

SOLUTION;TOPICAL
CICLOPIROX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | COSETTE PHARMS NC | 8% | A078233 | 001 | Sep 18, 2007 | May CAHN |
| >D> AT | | ENCUBE | 8% | A077687 | 001 | Sep 18, 2007 | Oct CAHN |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | SOLUTION;TOPICAL | | | | | | | |
| | | CICLOPIROX | | | | | | | |
| >A> | AT | | | 8% | A077687 | 001 | Sep 18, 2007 | Oct | CAHN |
| | | SUSPENSION;TOPICAL | | | | | | | |
| | | LOPROX | | | | | | | |
| | AB | +! | EUROFARMA | 0.77% | N019824 | 001 | Dec 30, 1988 | Feb | CAHN |
| | | CILASTATIN SODIUM; IMIPENEM; RELEBACTAM | | | | | | | |
| | | POWDER;INTRAVENOUS | | | | | | | |
| | | RECARBRIO | | | | | | | |
| | | @ + | MSD MERCK CO | EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIA | N212819 | 001 | Jul 16, 2019 | Sep | DISC |
| | | CILOSTAZOL | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | CILOSTAZOL | | | | | | | |
| | AB | | AUROBINDO PHARMA USA | 50MG | A077019 | 001 | Nov 23, 2004 | Sep | CMFD |
| | AB | | | 100MG | A077019 | 002 | Nov 23, 2004 | Sep | CMFD |
| | | CIMETIDINE HYDROCHLORIDE | | | | | | | |
| | | INJECTABLE;INJECTION | | | | | | | |
| | | CIMETIDINE HYDROCHLORIDE | | | | | | | |
| | | @ | HOSPIRA | EQ 300MG BASE/2ML | A074296 | 001 | Mar 28, 1997 | May | CAHN |
| | | CINACALCET HYDROCHLORIDE | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | CINACALCET HYDROCHLORIDE | | | | | | | |
| | | @ | HETERO LABS LTD V | EQ 30MG BASE | A209403 | 001 | Oct 07, 2020 | Feb | DISC |
| | | @ | | EQ 60MG BASE | A209403 | 002 | Oct 07, 2020 | Feb | DISC |
| | | @ | | EQ 90MG BASE | A209403 | 003 | Oct 07, 2020 | Feb | DISC |
| | | @ | STEVENS J | EQ 30MG BASE | A204364 | 001 | Dec 02, 2021 | Feb | CPOT |
| | | @ | | EQ 60MG BASE | A204364 | 002 | Dec 02, 2021 | Feb | CPOT |
| | | @ | | EQ 90MG BASE | A204364 | 003 | Dec 02, 2021 | Feb | CPOT |
| | | @ | SUN PHARM | EQ 60MG BASE | A207008 | 002 | Oct 11, 2018 | Jul | DISC |
| | | CIPEPOFOL | | | | | | | |
| | | EMULSION;INTRAVENOUS | | | | | | | |
| | | CYPSEDO | | | | | | | |
| | | +! | HAISCO | 50MG/20ML (2.5MG/ML) | N220482 | 001 | Aug 27, 2026 | Aug | NEWA |
| | | CIPROFLOXACIN HYDROCHLORIDE | | | | | | | |
| | | SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| | | CIPROFLOXACIN HYDROCHLORIDE | | | | | | | |
| | | @ | J MOLNER | EQ 0.3% BASE | A078598 | 001 | Jan 16, 2008 | Jul | CAHN |
| | | SOLUTION/DROPS;OTIC | | | | | | | |
| | | CIPROFLOXACIN HYDROCHLORIDE | | | | | | | |
| | AB | | ALEMBIC THERAP | EQ 0.2% BASE | A217887 | 001 | Nov 05, 2024 | May | CAHN |
| | | TABLET;ORAL | | | | | | | |
| | | CIPROFLOXACIN HYDROCHLORIDE | | | | | | | |
| | | @ | AMNEAL | EQ 250MG BASE | A075939 | 002 | Jun 09, 2004 | Mar | DISC |
| | | @ | | EQ 500MG BASE | A075939 | 003 | Jun 09, 2004 | Mar | DISC |
| | | @ | | EQ 750MG BASE | A075939 | 004 | Jun 09, 2004 | Mar | DISC |
| | | @ | HIKMA | EQ 250MG BASE | A076558 | 002 | Jun 09, 2004 | Jun | DISC |
| | | @ | | EQ 500MG BASE | A076558 | 003 | Jun 09, 2004 | Jun | DISC |
| | | @ | | EQ 750MG BASE | A076558 | 004 | Jun 09, 2004 | Jun | DISC |
| | AB | | PHARMOBEDIENT | EQ 250MG BASE | A208921 | 001 | Jun 22, 2018 | Sep | CAHN |
| | AB | | | EQ 500MG BASE | A208921 | 002 | Jun 22, 2018 | Sep | CAHN |
| | | CIPROFLOXACIN; DEXAMETHASONE | | | | | | | |
| | | SUSPENSION/DROPS;OTIC | | | | | | | |
| | | CIPROFLOXACIN AND DEXAMETHASONE | | | | | | | |
| >A> | AB | | ALEMBIC | 0.3%;0.1% | A217723 | 001 | Oct 15, 2026 | Oct | NEWA |
| | | CISATRACURIUM BESYLATE | | | | | | | |
| | | INJECTABLE;INJECTION | | | | | | | |
| | | CISATRACURIUM BESYLATE | | | | | | | |
| | | @ | HENGRUI PHARMA | EQ 2MG BASE/ML | A204960 | 003 | Aug 30, 2017 | Feb | DISC |
| | AP | | PIRAMAL | EQ 2MG BASE/ML | A212432 | 001 | Mar 11, 2022 | Apr | CMFD |
| | AP | | | EQ 10MG BASE/ML | A212432 | 002 | Mar 11, 2022 | Apr | CMFD |
| | | CISATRACURIUM BESYLATE PRESERVATIVE FREE | | | | | | | |
| | AP | | HAINAN POLY | EQ 2MG BASE/ML | A216539 | 001 | Aug 27, 2024 | Apr | CMFD |
| | AP | | | EQ 10MG BASE/ML | A216539 | 002 | Aug 27, 2024 | Apr | CMFD |

INJECTABLE;INJECTION
CISATRACURIUM BESYLATE PRESERVATIVE FREE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HENGRUI PHARMA | EQ 2MG BASE/ML | A | 204960 | 001 | Jan 27, 2017 | Feb DISC |
| | @ | | EQ 10MG BASE/ML | A | 204960 | 002 | Sep 19, 2017 | Feb DISC |

CISPLATIN
SOLUTION;INTRAVENOUS
AXYCIS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | +! | AVYXA HOLDINGS | 50MG/50ML (1MG/ML) | N | 220748 | 001 | Oct 29, 2026 | Oct NEWA |

CITALOPRAM HYDROBROMIDE
CAPSULE;ORAL
CITALOPRAM HYDROBROMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | ALMATICA | EQ 30MG BASE | N | 215428 | 001 | Jan 31, 2022 | Mar CFTG |
| AB | | AUROBINDO PHARMA LTD | EQ 30MG BASE | A | 219985 | 001 | Mar 13, 2026 | Mar NFTG |

TABLET;ORAL
CITALOPRAM HYDROBROMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AMNEAL PHARMS NY | EQ 10MG BASE | A | 077289 | 001 | Nov 30, 2006 | Feb DISC |
| | @ | | EQ 20MG BASE | A | 077289 | 002 | Nov 30, 2006 | Feb DISC |
| | @ | | EQ 40MG BASE | A | 077289 | 003 | Nov 30, 2006 | Feb DISC |
| | @ | COSETTE PHARMS NC | EQ 10MG BASE | A | 077048 | 001 | Nov 16, 2004 | May CAHN |
| | @ | | EQ 20MG BASE | A | 077048 | 002 | Nov 16, 2004 | May CAHN |
| | @ | | EQ 40MG BASE | A | 077048 | 003 | Nov 16, 2004 | May CAHN |

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE
GEL;VAGINAL
PHEXX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | EVOFEM INC | 1%;1.8%;0.4% | N | 208352 | 001 | May 22, 2020 | May CTNA |

CLADRIBINE
TABLET;ORAL
CLADRIBINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | HOPEWELL PHARMA | 10MG | A | 215547 | 001 | Mar 27, 2026 | Mar NEWA |

CLEMASTINE FUMARATE
SYRUP;ORAL
CLEMASTINE FUMARATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | GENUS LIFESCIENCES | EQ 0.5MG BASE/5ML | A | 074884 | 001 | Dec 17, 1997 | Sep CAHN |

CLINDAMYCIN HYDROCHLORIDE
CAPSULE;ORAL
CLINDAMYCIN HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | EQ 150MG BASE | A | 063029 | 001 | Sep 20, 1989 | Jun CAHN |
| | @ | | EQ 300MG BASE | A | 063029 | 002 | Aug 05, 2005 | Jun CAHN |

CLINDAMYCIN PALMITATE HYDROCHLORIDE
FOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AMNEAL PHARMS | EQ 75MG BASE/5ML | A | 203513 | 001 | Mar 13, 2014 | Apr DISC |
| AA | | APPCO | EQ 75MG BASE/5ML | A | 207047 | 001 | May 11, 2018 | May CAHN |
| | @ | PADAGIS US | EQ 75MG BASE/5ML | A | 090902 | 001 | Jul 07, 2010 | Mar DISC |
| AA | | SOMERSET THERAPS LLC | EQ 75MG BASE/5ML | A | 207047 | 001 | May 11, 2018 | Sep CAHN |

CLINDAMYCIN PHOSPHATE
AEROSOL, FOAM;TOPICAL
EVOCLIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | QUAGEN | 1% | N | 050801 | 001 | Oct 22, 2004 | Jul CAHN |

CREAM;VAGINAL
CLEOCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | PFIZER | EQ 2% BASE | N | 050680 | 002 | Mar 02, 1998 | Aug CHRS |

CLINDAMYCIN PHOSPHATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | FOUGERA PHARMS | EQ 2% BASE | A | 065139 | 001 | Dec 27, 2004 | Aug CHRS |

GEL;TOPICAL
CLINDAMYCIN PHOSPHATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB1 | | AMVIKA | EQ 1% BASE | A | 211872 | 001 | Jul 29, 2020 | Sep CAHN |
| AB1 | | AUROBINDO PHARMA LTD | EQ 1% BASE | A | 218942 | 001 | Mar 18, 2026 | Mar NEWA |
| >D> AB1 | | ENCUBE | EQ 1% BASE | A | 212438 | 001 | Mar 11, 2021 | Oct CAHN |
| >A> AB1 | | | EQ 1% BASE | A | 212438 | 001 | Mar 11, 2021 | Oct CAHN |
| AB1 | | SOLARIS PHARMA CORP | EQ 1% BASE | A | 211872 | 001 | Jul 29, 2020 | Feb CAHN |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | LOTION;TOPICAL | | | | | | | |
| | | CLINDAMYCIN PHOSPHATE | | | | | | | |
| >D> | AB | | ENCUBE | EQ 1% BASE | A215607 | 001 | Jan 18, 2022 | Oct | CAHN |
| >A> | AB | | | EQ 1% BASE | A215607 | 001 | Jan 18, 2022 | Oct | CAHN |
| | | SOLUTION;TOPICAL | | | | | | | |
| | | CLINDA-DERM | | | | | | | |
| | | @ | PADAGIS US | EQ 1% BASE | A063329 | 001 | Sep 30, 1992 | Mar | DISC |
| | | CLINDAMYCIN PHOSPHATE | | | | | | | |
| >A> | AT | | ENCUBE | EQ 1% BASE | A209914 | 001 | Jan 28, 2019 | Oct | CAHN |
| >D> | AT | | ENCUBE ETHICALS | EQ 1% BASE | A209914 | 001 | Jan 28, 2019 | Oct | CAHN |
| | | @ | INGENUS PHARMS LLC | EQ 1% BASE | A064108 | 001 | Sep 27, 1996 | Feb | CAHN |
| | AT | | RISING | EQ 1% BASE | A218300 | 001 | Mar 23, 2026 | Mar | NEWA |
| | | SWAB;TOPICAL | | | | | | | |
| | | CLINDAMYCIN PHOSPHATE | | | | | | | |
| | AT | | RISING | EQ 1% BASE | A218300 | 001 | Mar 23, 2026 | Jul | CDFR |
| | | CLINDETS | | | | | | | |
| | | @ | PERRIGO CO | EQ 1% BASE | A064136 | 001 | Sep 30, 1996 | Mar | DISC |
| | | CLINDAMYCIN PHOSPHATE; TRETINOIN | | | | | | | |
| | | GEL;TOPICAL | | | | | | | |
| | | CLINDAMYCIN PHOSPHATE AND TRETINOIN | | | | | | | |
| >D> | AB2 | | ENCUBE | 1.2%;0.025% | A216943 | 001 | Sep 01, 2023 | Oct | CAHN |
| >A> | AB2 | | | 1.2%;0.025% | A216943 | 001 | Sep 01, 2023 | Oct | CAHN |
| | | VELTIN | | | | | | | |
| | AB2 | +! | CHARTWELL RX | 1.2%;0.025% | N050803 | 001 | Jul 16, 2010 | Jun | CAHN |
| | | CLOBAZAM | | | | | | | |
| | | FILM;ORAL | | | | | | | |
| | | SYMPAZAN | | | | | | | |
| | | + | COSETTE | 5MG | N210833 | 001 | Nov 01, 2018 | Jun | CAHN |
| | | + | | 10MG | N210833 | 002 | Nov 01, 2018 | Jun | CAHN |
| | | +! | | 20MG | N210833 | 003 | Nov 01, 2018 | Jun | CAHN |
| | | TABLET;ORAL | | | | | | | |
| | | CLOBAZAM | | | | | | | |
| | AB | | PHARMAZONE | 10MG | A209808 | 001 | Oct 22, 2018 | Sep | CAHN |
| | AB | | | 20MG | A209808 | 002 | Oct 22, 2018 | Sep | CAHN |
| | AB | | SENORES PHARMS | 10MG | A209808 | 001 | Oct 22, 2018 | Sep | CAHN |
| | AB | | | 20MG | A209808 | 002 | Oct 22, 2018 | Sep | CAHN |
| | | CLOBETASOL PROPIONATE | | | | | | | |
| | | AEROSOL, FOAM;TOPICAL | | | | | | | |
| | | CLOBETASOL PROPIONATE | | | | | | | |
| | | @ | INGENUS PHARMS LLC | 0.05% | A206805 | 001 | Jul 31, 2017 | May | CAHN |
| | | OLUX | | | | | | | |
| | | @ + | QUAGEN | 0.05% | N021142 | 001 | May 26, 2000 | Jul | CAHN |
| | | OLUX E | | | | | | | |
| | | @ + | QUAGEN | 0.05% | N022013 | 001 | Jan 12, 2007 | Jul | CAHN |
| | | CREAM;TOPICAL | | | | | | | |
| | | CLOBETASOL PROPIONATE | | | | | | | |
| | | @ | AMNEAL | 0.05% | A211256 | 001 | Dec 26, 2018 | Sep | DISC |
| | | @ | COSETTE PHARMS NC | 0.05% | A074139 | 001 | Aug 03, 1994 | Jun | CAHN |
| >D> | AB1 | ! | ENCUBE | 0.05% | A212982 | 001 | Aug 28, 2020 | Oct | CAHN |
| >A> | AB1 | ! | | 0.05% | A212982 | 001 | Aug 28, 2020 | Oct | CAHN |
| | | TEMOVATE | | | | | | | |
| | | @ + | FOUGERA | 0.05% | N019322 | 001 | Dec 27, 1985 | Aug | CAHN |
| | | TEMOVATE E | | | | | | | |
| | | @ + | FOUGERA | 0.05% | N020340 | 001 | Jun 17, 1994 | Aug | CAHN |
| | | GEL;TOPICAL | | | | | | | |
| | | CLOBETASOL PROPIONATE | | | | | | | |
| >D> | | @ | ENCUBE | 0.05% | A208881 | 001 | Mar 06, 2017 | Oct | CAHN |
| >A> | | @ | | 0.05% | A208881 | 001 | Mar 06, 2017 | Oct | CAHN |
| | | @ | | 0.05% | A208881 | 001 | Mar 06, 2017 | May | CAHN |
| | AB | | FOUGERA PHARMS | 0.05% | A075368 | 001 | Feb 15, 2000 | Aug | CHRS |
| | AB | ! | PADAGIS US | 0.05% | A075027 | 001 | Oct 31, 1997 | Aug | CHRS |
| | | OINTMENT;TOPICAL | | | | | | | |
| | | CLOBETASOL PROPIONATE | | | | | | | |
| | AB | | COSETTE PHARMS NC | 0.05% | A074089 | 001 | Feb 16, 1994 | May | CAHN |
| >D> | AB | ! | ENCUBE | 0.05% | A211295 | 001 | Nov 15, 2019 | Oct | CAHN |
| >A> | AB | ! | | 0.05% | A211295 | 001 | Nov 15, 2019 | Oct | CAHN |
| | | TEMOVATE | | | | | | | |
| | | @ + | FOUGERA | 0.05% | N019323 | 001 | Dec 27, 1985 | Aug | CAHN |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | SOLUTION;TOPICAL | | | | | | | |
| | | CLOBETASOL PROPIONATE | | | | | | | |
| | @ | COSETTE PHARMS NC | 0.05% | | A074331 | 001 | Dec 15, 1995 | Jun | CAHN |
| >D> | AT | ENCUBE | 0.05% | | A076977 | 001 | Aug 05, 2005 | Oct | CAHN |
| >A> | AT | | 0.05% | | A076977 | 001 | Aug 05, 2005 | Oct | CAHN |
| | | TEMOVATE | | | | | | | |
| | @ + | FOUGERA | 0.05% | | N019966 | 001 | Feb 22, 1990 | Aug | CAHN |
| | | SPRAY;TOPICAL | | | | | | | |
| | | CLOBETASOL PROPIONATE | | | | | | | |
| | @ | PADAGIS US | 0.05% | | A090898 | 001 | Jun 16, 2011 | Mar | DISC |
| | | CLOCORTOLONE PIVALATE | | | | | | | |
| | | CREAM;TOPICAL | | | | | | | |
| | | CLOCORTOLONE PIVALATE | | | | | | | |
| AB | ! | TARO | 0.1% | | A206370 | 001 | Apr 21, 2020 | Aug | CHRS |
| | | CLODERM | | | | | | | |
| AB | + | LEGACY | 0.1% | | N017765 | 001 | | Aug | CHRS |
| AB | +! | | 0.1% | | N017765 | 001 | | Jun | CAHN |
| | | CLOFARABINE | | | | | | | |
| | | SOLUTION;INTRAVENOUS | | | | | | | |
| | | CLOFARABINE | | | | | | | |
| | @ | INGENUS PHARMS LLC | 20MG/20ML (1MG/ML) | | A210270 | 001 | Sep 14, 2018 | May | CAHN |
| | @ | MLV | 20MG/20ML (1MG/ML) | | A204029 | 001 | May 09, 2017 | Sep | CAHN |
| | @ | PHARMOBEDIENT | 20MG/20ML (1MG/ML) | | A208860 | 001 | Nov 06, 2017 | May | DISC |
| | | CLOMIPHENE CITRATE | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | CLOMID | | | | | | | |
| AB | ! | COSETTE | 50MG | | A075528 | 001 | Aug 30, 1999 | Jul | CTNA |
| | | CLOMIPHENE CITRATE | | | | | | | |
| AB | | ASCENT PHARMS INC | 50MG | | A220673 | 001 | May 15, 2026 | May | NEWA |
| AB | | RUBICON RESEARCH | 50MG | | A216545 | 001 | Nov 12, 2024 | May | CAHN |
| | | CLOMIPRAMINE HYDROCHLORIDE | | | | | | | |
| | | CAPSULE;ORAL | | | | | | | |
| | | CLOMIPRAMINE HYDROCHLORIDE | | | | | | | |
| AB | | LEADING | 25MG | | A211364 | 001 | Feb 07, 2020 | Aug | CAHN |
| AB | | | 50MG | | A211364 | 002 | Feb 07, 2020 | Aug | CAHN |
| AB | | | 75MG | | A211364 | 003 | Feb 07, 2020 | Aug | CAHN |
| | @ | MPP PHARMA | 25MG | | A213221 | 001 | Jun 22, 2020 | Sep | CAHN |
| | @ | | 50MG | | A213221 | 002 | Jun 22, 2020 | Sep | CAHN |
| | @ | | 75MG | | A213221 | 003 | Jun 22, 2020 | Sep | CAHN |
| | @ | TP ANDA HOLDINGS | 25MG | | A210653 | 001 | Apr 03, 2020 | Jul | DISC |
| | @ | | 50MG | | A210653 | 002 | Apr 03, 2020 | Jul | DISC |
| | @ | | 75MG | | A210653 | 003 | Apr 03, 2020 | Jul | DISC |
| | | CLONAZEPAM | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | CLONAZEPAM | | | | | | | |
| AB | | CHARTWELL RX | 0.5MG | | A074925 | 001 | Sep 30, 1997 | Jan | CMFD |
| AB | | | 1MG | | A074925 | 002 | Sep 30, 1997 | Jan | CMFD |
| AB | | | 2MG | | A074925 | 003 | Sep 30, 1997 | Jan | CMFD |
| | @ | QUAGEN | 0.5MG | | A074940 | 001 | Oct 30, 1997 | Apr | CAHN |
| | @ | | 1MG | | A074940 | 002 | Oct 30, 1997 | Apr | CAHN |
| | @ | | 2MG | | A074940 | 003 | Oct 30, 1997 | Apr | CAHN |
| | | RUBICON RESEARCH | 0.25MG | | A075468 | 004 | Jun 12, 2026 | Jul | NFTG |
| | | TABLET, ORALLY DISINTEGRATING;ORAL | | | | | | | |
| | | CLONAZEPAM | | | | | | | |
| AB | | RUBICON RESEARCH | 0.125MG | | A216988 | 001 | May 21, 2026 | May | NEWA |
| AB | | | 0.25MG | | A216988 | 002 | May 21, 2026 | May | NEWA |
| AB | | | 0.5MG | | A216988 | 003 | May 21, 2026 | May | NEWA |
| AB | | | 1MG | | A216988 | 004 | May 21, 2026 | May | NEWA |
| AB | | | 2MG | | A216988 | 005 | May 21, 2026 | May | NEWA |
| | | CLONIDINE | | | | | | | |
| | | SYSTEM;TRANSDERMAL | | | | | | | |
| | | CLONIDINE | | | | | | | |
| | @ | ADAPTIS | 0.1MG/24HR | | A076157 | 001 | Aug 18, 2009 | Sep | CAHN |
| | @ | | 0.2MG/24HR | | A076157 | 002 | Aug 18, 2009 | Sep | CAHN |
| | @ | | 0.3MG/24HR | | A076157 | 003 | Aug 18, 2009 | Sep | CAHN |
| | @ | DIFGEN PHARMS | 0.1MG/24HR | | A076157 | 001 | Aug 18, 2009 | Feb | CAHN |

SYSTEM;TRANSDERMAL
CLONIDINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | | 0.2MG/24HR | A076157 | 002 | Aug 18, 2009 | Feb CAHN |
| | @ | | 0.3MG/24HR | A076157 | 003 | Aug 18, 2009 | Feb CAHN |

TABLET, EXTENDED RELEASE;ORAL
NEXICLON XR

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | ROSEMOUNT | EQ 0.17MG BASE | N022500 | 001 | Dec 03, 2009 | Mar CAHN |
| | @ | | EQ 0.26MG BASE | N022500 | 002 | Dec 03, 2009 | Mar CAHN |

CLONIDINE HYDROCHLORIDE
INJECTABLE;INJECTION
CLONIDINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >D> AP | | XGEN PHARMS | 5MG/10ML (0.5MG/ML) | A203167 | 002 | Oct 29, 2013 | Oct DISC |
| >A> | @ | | 5MG/10ML (0.5MG/ML) | A203167 | 002 | Oct 29, 2013 | Oct DISC |

SOLUTION;ORAL
QLONILIK

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | CMP DEV LLC | 0.05MG/ML | N221094 | 001 | Jul 29, 2026 | Jul NEWA |

TABLET;ORAL
CLONIDINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ALEMBIC PHARMS LTD | 0.05MG | A091368 | 004 | Sep 17, 2026 | Sep NEWA |
| AB | ! | TP ANDA HOLDINGS | 0.05MG | A070923 | 004 | Apr 06, 2026 | Sep CTEC |
| | ! | | 0.05MG | A070923 | 004 | Apr 06, 2026 | Mar NFTG |

CLOPIDOGREL BISULFATE
TABLET;ORAL
CLOPIDOGREL BISULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | EQ 75MG BASE | A078004 | 001 | May 17, 2012 | Sep CAHN |

CLORAZEPATE DIPOTASSIUM
CAPSULE;ORAL
CLORAZEPATE DIPOTASSIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | NATCO PHARMA USA | 3.75MG | A071509 | 001 | Oct 19, 1987 | Mar CAHN |
| | @ | | 7.5MG | A071510 | 001 | Oct 19, 1987 | Mar CAHN |
| | @ | | 15MG | A071511 | 001 | Oct 19, 1987 | Mar CAHN |

TABLET;ORAL
CLORAZEPATE DIPOTASSIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | MACLEODS PHARMS | 3.75MG | A215566 | 001 | Jun 14, 2022 | Sep CAHN |
| AB | | | 7.5MG | A215566 | 002 | Jun 14, 2022 | Sep CAHN |
| AB | | | 15MG | A215566 | 003 | Jun 14, 2022 | Sep CAHN |

CLOTRIMAZOLE
TROCHE/LOZENGE;ORAL
CLOTRIMAZOLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | RISING | 10MG | A215641 | 001 | Feb 29, 2024 | Sep CAHN |

CLOXACILLIN SODIUM
CAPSULE;ORAL
CLOXACILLIN SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> | @ | CHARTWELL RX | EQ 250MG BASE | A062240 | 001 | | Oct CAHN |
| >A> | @ | | EQ 500MG BASE | A062240 | 002 | | Oct CAHN |
| >D> | @ | TEVA | EQ 250MG BASE | A062240 | 001 | | Oct CAHN |
| >D> | @ | | EQ 500MG BASE | A062240 | 002 | | Oct CAHN |

FOR SOLUTION;ORAL
CLOXACILLIN SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> | @ | CHARTWELL RX | EQ 125MG BASE/5ML | A062268 | 001 | | Oct CAHN |
| >A> | @ | | EQ 125MG BASE/5ML | A062978 | 001 | Apr 06, 1989 | Oct CAHN |
| >D> | @ | TEVA | EQ 125MG BASE/5ML | A062268 | 001 | | Oct CAHN |
| >D> | @ | | EQ 125MG BASE/5ML | A062978 | 001 | Apr 06, 1989 | Oct CAHN |

COBICISTAT
TABLET;ORAL
TYBOST

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | GILEAD SCIENCES INC | 150MG | N203094 | 001 | Sep 24, 2014 | Mar DISC |

COBICISTAT; DARUNAVIR ETHANOLATE
TABLET;ORAL
PREZCOBIX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | JANSSEN PRODS | 150MG;EQ 675MG BASE | N205395 | 002 | Mar 21, 2025 | Mar CHRS |

TABLET, FOR SUSPENSION;ORAL
PREZCOBIX PED

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | JANSSEN PRODS | 90MG;EQ 600MG BASE | N220092 | 001 | Feb 27, 2026 | Feb NEWA |

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | ! | PAI HOLDINGS | 10MG/5ML;5MG/5ML;6.25MG/5ML | A040660 | 001 | Dec 07, 2006 | May | CAHN |

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | ! | COSETTE PHARMS NC | 10MG/5ML;6.25MG/5ML | A200386 | 001 | Jun 29, 2012 | May | CAHN |

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | AVERION | 10MG/5ML;30MG/5ML;1.25MG/5ML | A088704 | 001 | Mar 22, 1985 | Sep | CAHN |

COLCHICINE

CAPSULE;ORAL

COLCHICINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | MICRO LABS | 0.6MG | A212880 | 001 | Feb 17, 2026 | Feb | NEWA |

MITIGARE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | HIKMA | 0.6MG | N204820 | 001 | Sep 26, 2014 | Sep | CAHN |

TABLET;ORAL

COLCHICINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | MACLEODS PHARMS | 0.6MG | A210633 | 001 | Feb 13, 2026 | Feb | NEWA |

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | INGENUS PHARMS LLC | 0.5MG;500MG | A040618 | 001 | May 13, 2008 | May | CAHN |

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 625MG | A212050 | 001 | Dec 04, 2020 | Sep | CAHN |

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

COLESTID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | PFIZER | 5GM/SCOOPFUL | N017563 | 003 | Sep 22, 1995 | May | CTEC |
| >D> | +! | | 5GM/PACKET | N017563 | 004 | Sep 22, 1995 | Oct | DISC |
| >A> | @ + | | 5GM/PACKET | N017563 | 004 | Sep 22, 1995 | Oct | DISC |
| | +! | | 5GM/PACKET | N017563 | 004 | Sep 22, 1995 | May | CTEC |

COLESTIPOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | IMPAX LABS | 5GM/SCOOPFUL | A077277 | 001 | May 02, 2006 | May | DISC |
| | @ | | 5GM/PACKET | A077277 | 002 | May 02, 2006 | May | DISC |

TABLET;ORAL

COLESTIPOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | MACLEODS PHARMS | 1GM | A220012 | 001 | Sep 15, 2025 | Aug | CAHN |

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | ! | XELLIA PHARMS APS | EQ 150MG BASE/VIAL | A205356 | 001 | May 29, 2015 | May | CHRS |

COLY-MYCIN M

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | PH HEALTH | EQ 150MG BASE/VIAL | N050108 | 002 | | May | DISC |

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

VAPRISOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | APOTEX | 20MG/4ML (5MG/ML) | N021697 | 001 | Dec 29, 2005 | Jul | CAHN |

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | APOTEX | 20MG/100ML (0.2MG/ML) | N021697 | 002 | Oct 08, 2008 | Jul | CAHN |

COPPER HISTIDINATE

POWDER;SUBCUTANEOUS

ZYCUBO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | SENTYNL THERAPS INC | 2.9MG/VIAL | N211241 | 001 | Jan 12, 2026 | Jan | NEWA |

CORTISONE ACETATE

TABLET;ORAL

CORTISONE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 25MG | A080776 | 002 | | | Sep CAHN |

CRISABOROLE

OINTMENT;TOPICAL

CRISABOROLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | MACLEODS PHARMS | 2% | A216242 | 001 | Sep 24, 2026 | | Sep NFTG |

EUCRISA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | ANACOR PHARMS INC | 2% | N207695 | 001 | Dec 14, 2016 | | Sep CFTG |

CROMOLYN SODIUM

SOLUTION;INHALATION

CROMOLYN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | MICRO LABS | 10MG/ML | A213658 | 001 | Apr 29, 2022 | | Aug DISC |
| AN | | SCIEGEN PHARMS | 10MG/ML | A075437 | 001 | Apr 21, 2000 | | Sep CAHN |

CROTAMITON

CREAM;TOPICAL

EURAX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | JOURNEY | 10% | N006927 | 001 | | | Apr CMFD |

LOTION;TOPICAL

CROTAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | LEGACY | 10% | A087204 | 001 | | | Jun CAHN |
| | | LEGACY PHARMA | 10% | A087204 | 001 | | | Apr CTEC |
| | ! | | 10% | A087204 | 001 | | | Apr CHRS |

EURAX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | JOURNEY | 10% | N009112 | 003 | | | Apr DISC |

CUPRIC CHLORIDE

INJECTABLE;INJECTION

CUPRIC CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AMNEAL | EQ 0.4MG COPPER/ML | A217287 | 001 | Jan 26, 2026 | | Mar DISC |
| AP | | | EQ 0.4MG COPPER/ML | A217287 | 001 | Jan 26, 2026 | | Jan NEWA |
| AP | | STIRA | EQ 0.4MG COPPER/ML | A217626 | 001 | Apr 30, 2024 | | Apr CAHN |

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ASPIRO | 1MG/ML | A219820 | 001 | Jul 08, 2026 | | Jun NEWA |
| AP | | H2-PHARMA | 1MG/ML | A209255 | 001 | Dec 18, 2018 | | Sep CAHN |
| | @ | PHARMOBEDIENT | 1MG/ML | A204829 | 001 | Jun 05, 2017 | | Sep DISC |

CYCLACILLIN

TABLET;ORAL

CYCLACILLIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | @ | CHARTWELL RX | 250MG | A062895 | 001 | Aug 04, 1988 | | Oct CAHN |
| >A> | @ | | 500MG | A062895 | 002 | Aug 04, 1988 | | Oct CAHN |
| >D> | @ | TEVA | 250MG | A062895 | 001 | Aug 04, 1988 | | Oct CAHN |
| >D> | @ | | 500MG | A062895 | 002 | Aug 04, 1988 | | Oct CAHN |

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AIPING PHARM INC | 5MG | A072854 | 002 | Feb 03, 2006 | | Sep CMFD |
| AB | | | 7.5MG | A072854 | 003 | May 13, 2026 | | May NEWA |
| AB | | | 10MG | A072854 | 001 | Nov 19, 1991 | | Sep CMFD |
| AB | | TP ANDA HOLDINGS | 5MG | A077209 | 002 | Feb 03, 2006 | | Sep CAHN |
| AB | | | 10MG | A077209 | 001 | Oct 04, 2005 | | Sep CAHN |

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PENTOLAIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | BAUSCH AND LOMB INC | 1% | A040075 | 001 | Apr 29, 1994 | | May CAHN |

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | AMNEAL PHARMS | 25MG | A210890 | 001 | Nov 02, 2026 | Oct NEWA |
| >A> | AB | | | 50MG | A210890 | 002 | Nov 02, 2026 | Oct NEWA |
| | AB | | PHARMAZONE | 25MG | A209872 | 001 | May 07, 2018 | Sep CAHN |
| | AB | | | 50MG | A209872 | 002 | May 07, 2018 | Sep CAHN |

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | HAINAN POLY | 500MG/VIAL | A218632 | 001 | Dec 26, 2024 | Aug CMFD |
| | | @ | | 500MG/VIAL | A218632 | 001 | Dec 26, 2024 | Jan DISC |
| | AP | | | 1GM/VIAL | A218632 | 002 | Dec 26, 2024 | Aug CMFD |
| | | @ | | 1GM/VIAL | A218632 | 002 | Dec 26, 2024 | Jan DISC |
| | AP | | | 2GM/VIAL | A218632 | 003 | Dec 26, 2024 | Aug CMFD |
| | | @ | | 2GM/VIAL | A218632 | 003 | Dec 26, 2024 | Jan DISC |

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | ! | PHARMAZONE | 250MG | A060593 | 001 | | Sep CAHN |

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB1 | | AUROBINDO PHARMA LTD | 25MG | A219652 | 001 | Sep 17, 2026 | Sep NEWA |
| | AB1 | | | 50MG | A219652 | 002 | Sep 17, 2026 | Sep NEWA |
| | AB1 | | | 100MG | A219652 | 003 | Sep 17, 2026 | Sep NEWA |
| | AB1 | | ONESOURCE | 25MG | A216046 | 001 | Aug 02, 2022 | Jul CAHN |
| | AB1 | | | 50MG | A216046 | 002 | Aug 02, 2022 | Jul CAHN |
| | AB1 | | | 100MG | A216046 | 003 | Aug 02, 2022 | Jul CAHN |

EMULSION;OPHTHALMIC

CYCLOSPORINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | AMNEAL | 0.05% | A211909 | 001 | Nov 28, 2025 | Sep DISC |
| | AB | | JIANGSU ANBISON | 0.05% | A219288 | 001 | Jun 01, 2026 | May NEWA |
| | AB | | TWI PHARMS | 0.05% | A209064 | 001 | Jan 21, 2026 | Jan NEWA |

INJECTABLE;INJECTION

CYCLOSPORINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | PADAGIS US | 50MG/ML | A065151 | 001 | Oct 07, 2003 | Mar DISC |

SOLUTION;ORAL

CYCLOSPORINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | @ | ESJAY PHARMA | 100MG/ML | A065167 | 001 | Jan 05, 2005 | Oct CAHN |
| >D> | | @ | PHARM ASSOC | 100MG/ML | A065167 | 001 | Jan 05, 2005 | Oct CAHN |

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | | PHARMAZONE | 2MG/5ML | A209108 | 001 | Oct 16, 2018 | Sep CAHN |
| | AA | | ST JOHN PHARM | 2MG/5ML | A209108 | 001 | Oct 16, 2018 | Jan CAHN |

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | ANVI | 4MG | A087129 | 001 | | Mar CAHN |
| | AA | | INGENUS PHARMS LLC | 4MG | A205087 | 001 | Sep 23, 2015 | Feb CAHN |
| | | @ | STRIDES PHARMA INTL | 4MG | A087129 | 001 | | Jun CAHN |
| | AA | | TP ANDA HOLDINGS | 4MG | A206553 | 001 | Nov 29, 2016 | Sep CAHN |

CYPROLARA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | ! | QUAGEN | 2MG | A212491 | 002 | Oct 02, 2026 | Sep NFTG |

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ELCYS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | EXELA PHARMA | 2500MG/50ML (50MG/ML) | N210660 | 002 | Dec 04, 2023 | Aug CMFD |

NOURESS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | BAXTER HLTHCARE CORP | 500MG/10ML (50MG/ML) | N212535 | 001 | Dec 13, 2019 | Sep CMFD |

DABIGATRAN ETEXILATE MESYLATE

PELLETS;ORAL

PRADAXA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | | | | | | | |
| >D> | | + | BOEHRINGER INGELHEIM | EQ 20MG BASE/PACKET | N214358 | 001 | Jun 21, 2021 | Oct DISC |
| >A> | | @ + | | EQ 20MG BASE/PACKET | N214358 | 001 | Jun 21, 2021 | Oct DISC |
| >D> | | + | | EQ 30MG BASE/PACKET | N214358 | 002 | Jun 21, 2021 | Oct DISC |
| >A> | | @ + | | EQ 30MG BASE/PACKET | N214358 | 002 | Jun 21, 2021 | Oct DISC |

PELLETS;ORAL
PRADAXA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | + | EQ 40MG BASE/PACKET | N214358 | 003 | Jun 21, 2021 | Oct DISC |
| >A> | | @ + | EQ 40MG BASE/PACKET | N214358 | 003 | Jun 21, 2021 | Oct DISC |
| >D> | | + | EQ 50MG BASE/PACKET | N214358 | 004 | Jun 21, 2021 | Oct DISC |
| >A> | | @ + | EQ 50MG BASE/PACKET | N214358 | 004 | Jun 21, 2021 | Oct DISC |
| >D> | | + | EQ 110MG BASE/PACKET | N214358 | 005 | Jun 21, 2021 | Oct DISC |
| >A> | | @ + | EQ 110MG BASE/PACKET | N214358 | 005 | Jun 21, 2021 | Oct DISC |
| >D> | | +! | EQ 150MG BASE/PACKET | N214358 | 006 | Jun 21, 2021 | Oct DISC |
| >A> | | @ + | EQ 150MG BASE/PACKET | N214358 | 006 | Jun 21, 2021 | Oct DISC |

DACOMITINIB

TABLET;ORAL
VIZIMPRO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | PFIZER | 15MG | N211288 | 001 | Sep 27, 2018 | Jul DISC |
| | @ + | | 30MG | N211288 | 002 | Sep 27, 2018 | Jul DISC |
| | @ + | | 45MG | N211288 | 003 | Sep 27, 2018 | Jul DISC |

DALBAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS
DALBAVANCIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | BE PHARMS | EQ 500MG BASE/VIAL | A219604 | 001 | Jun 04, 2026 | May NEWA |
| >A> AP | EMERGE BIOSCIENCE | EQ 500MG BASE/VIAL | A218929 | 001 | Nov 26, 2025 | Oct CAHN |
| >D> AP | KINDOS | EQ 500MG BASE/VIAL | A218929 | 001 | Nov 26, 2025 | Oct CAHN |
| AP | LONG GROVE PHARMS | EQ 500MG BASE/VIAL | A218602 | 001 | Feb 26, 2026 | Feb NEWA |

DAPAGLIFLOZIN

TABLET;ORAL
DAPAGLIFLOZIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | AIZANT | 5MG | A211523 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211523 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | AJANTA PHARMA LTD | 5MG | A211482 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211482 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | ALEMBIC | 5MG | A211560 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211560 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | ALKEM LABS LTD | 5MG | A211545 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211545 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | AUROBINDO PHARMA | 5MG | A211468 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211468 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | BIOCON PHARMA | 5MG | A211470 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211470 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | CIPLA | 5MG | A211535 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211535 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | INVENTIA | 5MG | A211156 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211156 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | LUPIN | 5MG | A211531 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211531 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | MACLEODS PHARMS | 5MG | A211506 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211506 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | MICRO LABS | 5MG | A211467 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211467 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | MSN | 5MG | A211478 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211478 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | SANDOZ | 5MG | A211312 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211312 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | TEVA PHARMS USA | 5MG | A211541 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211541 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | ZYDUS PHARMS | 5MG | A211582 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG | A211582 | 002 | Apr 06, 2026 | Mar NFTG |

FARXIGA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + | ASTRAZENECA AB | 5MG | N202293 | 001 | Jan 08, 2014 | Mar CFTG |
| AB | +! | | 10MG | N202293 | 002 | Jan 08, 2014 | Mar CFTG |

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ALKEM LABS LTD | 5MG;500MG | A211563 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 5MG;1GM | A211563 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG;500MG | A211563 | 003 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG;1GM | A211563 | 004 | Apr 06, 2026 | Mar NFTG |
| AB | AUROBINDO PHARMA | 5MG;500MG | A211489 | 001 | Apr 06, 2026 | Mar NFTG |
| AB | | 5MG;1GM | A211489 | 002 | Apr 06, 2026 | Mar NFTG |
| AB | | 10MG;500MG | A211489 | 003 | Apr 06, 2026 | Mar NFTG |

TABLET, EXTENDED RELEASE;ORAL
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | | 10MG;1GM | A211489 | 004 | Apr 06, 2026 | Mar NFTG |
| | | @ | CIPLA | 5MG;1GM | A211595 | 001 | Apr 06, 2026 | Sep DISC |
| | AB | | | 5MG;1GM | A211595 | 001 | Apr 06, 2026 | Mar NFTG |
| | | @ | CIPLA LTD | 5MG;500MG | A211536 | 001 | Apr 06, 2026 | Sep DISC |
| | AB | | | 5MG;500MG | A211536 | 001 | Apr 06, 2026 | Mar NFTG |
| | | @ | | 10MG;500MG | A211536 | 002 | Apr 06, 2026 | Sep DISC |
| | AB | | | 10MG;500MG | A211536 | 002 | Apr 06, 2026 | Mar NFTG |
| | | @ | | 10MG;1GM | A211536 | 003 | Apr 06, 2026 | Sep DISC |
| | AB | | | 10MG;1GM | A211536 | 003 | Apr 06, 2026 | Mar NFTG |
| | AB | | LUPIN | 5MG;500MG | A211579 | 001 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 5MG;1GM | A211579 | 002 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;500MG | A211579 | 003 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;1GM | A211579 | 004 | Apr 06, 2026 | Mar NFTG |
| | AB | | MACLEODS PHARMS | 5MG;500MG | A211559 | 001 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 5MG;1GM | A211559 | 002 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;500MG | A211559 | 003 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;1GM | A211559 | 004 | Apr 06, 2026 | Mar NFTG |
| | AB | | MICRO LABS | 5MG;500MG | A211466 | 001 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 5MG;1GM | A211466 | 002 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;500MG | A211466 | 003 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;1GM | A211466 | 004 | Apr 06, 2026 | Mar NFTG |
| | AB | | MSN | 5MG;500MG | A211479 | 001 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 5MG;1GM | A211479 | 002 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;500MG | A211479 | 003 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;1GM | A211479 | 004 | Apr 06, 2026 | Mar NFTG |
| | AB | | SUN PHARM | 5MG;1GM | A211491 | 001 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;500MG | A211491 | 002 | Apr 06, 2026 | Mar NFTG |
| | AB | | | 10MG;1GM | A211491 | 003 | Apr 06, 2026 | Mar NFTG |
| >D> | AB | | TEVA PHARMS USA INC | 2.5MG;1GM | A211583 | 001 | Apr 06, 2026 | Oct DISC |
| >A> | | @ | | 2.5MG;1GM | A211583 | 001 | Apr 06, 2026 | Oct DISC |
| | AB | | | 2.5MG;1GM | A211583 | 001 | Apr 06, 2026 | Mar NFTG |
| >D> | AB | | | 5MG;500MG | A211583 | 002 | Apr 06, 2026 | Oct DISC |
| >A> | | @ | | 5MG;500MG | A211583 | 002 | Apr 06, 2026 | Oct DISC |
| | AB | | | 5MG;500MG | A211583 | 002 | Apr 06, 2026 | Mar NFTG |
| >D> | AB | | | 5MG;1GM | A211583 | 003 | Apr 06, 2026 | Oct DISC |
| >A> | | @ | | 5MG;1GM | A211583 | 003 | Apr 06, 2026 | Oct DISC |
| | AB | | | 5MG;1GM | A211583 | 003 | Apr 06, 2026 | Mar NFTG |
| >D> | AB | | | 10MG;500MG | A211583 | 004 | Apr 06, 2026 | Oct DISC |
| >A> | | @ | | 10MG;500MG | A211583 | 004 | Apr 06, 2026 | Oct DISC |
| | AB | | | 10MG;500MG | A211583 | 004 | Apr 06, 2026 | Mar NFTG |
| >D> | AB | | | 10MG;1GM | A211583 | 005 | Apr 06, 2026 | Oct DISC |
| >A> | | @ | | 10MG;1GM | A211583 | 005 | Apr 06, 2026 | Oct DISC |
| | AB | | | 10MG;1GM | A211583 | 005 | Apr 06, 2026 | Mar NFTG |

XIGDUO XR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | + | ASTRAZENECA AB | 2.5MG;1GM | N205649 | 005 | Jul 28, 2017 | Oct CTEC |
| >A> | | + | | 2.5MG;1GM | N205649 | 005 | Jul 28, 2017 | Oct CTEC |
| | AB | + | | 2.5MG;1GM | N205649 | 005 | Jul 28, 2017 | Mar CFTG |
| | AB | + | | 5MG;500MG | N205649 | 001 | Oct 29, 2014 | Mar CFTG |
| | AB | + | | 5MG;1GM | N205649 | 002 | Oct 29, 2014 | Mar CFTG |
| | AB | + | | 10MG;500MG | N205649 | 003 | Oct 29, 2014 | Mar CFTG |
| | AB | +! | | 10MG;1GM | N205649 | 004 | Oct 29, 2014 | Mar CFTG |

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL
DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | ! | MSN | 10MG;EQ 5MG BASE | A211533 | 001 | Apr 06, 2026 | Mar NFTG |
| | AB | | TORRENT | 10MG;EQ 5MG BASE | A211537 | 001 | Apr 06, 2026 | Mar NFTG |

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | PHARMOBEDIENT | 0.5% | A204902 | 001 | May 30, 2019 | Sep CAHN |

DAPSONE

GEL;TOPICAL
DAPSONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ALEMBIC | 5% | A213414 | 001 | Jun 25, 2026 | Jun NEWA |
| | | @ | AMNEAL | 7.5% | A212701 | 001 | May 31, 2023 | Sep DISC |
| | | @ | CHARTWELL RX | 5% | A215087 | 001 | Oct 31, 2023 | May CAHN |
| | | @ | | 7.5% | A212657 | 001 | Nov 01, 2023 | May CAHN |
| | AB | | COSETTE PHARMS NC | 5% | A210178 | 001 | Mar 31, 2022 | May CAHN |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | GEL;TOPICAL | | | | | | |
| | | DAPSONE | | | | | | |
| >D> | AB | ENCUBE | 5% | A212383 | 001 | Oct 13, 2023 | Oct | CAHN |
| >A> | AB | | 5% | A212383 | 001 | Oct 13, 2023 | Oct | CAHN |
| | | TABLET;ORAL | | | | | | |
| | | DAPSONE | | | | | | |
| | AB | MACLEODS PHARMS | 25MG | A218335 | 001 | Jul 08, 2026 | Jun | NEWA |
| | AB | | 100MG | A218335 | 002 | Jul 08, 2026 | Jun | NEWA |
| | AB | ZYDUS LIFESCIENCES | 25MG | A220103 | 001 | Feb 26, 2026 | Feb | NEWA |
| | AB | | 100MG | A220103 | 002 | Feb 26, 2026 | Feb | NEWA |
| | | DAPTOMYCIN | | | | | | |
| | | POWDER;INTRAVENOUS | | | | | | |
| | | DAPTOMYCIN | | | | | | |
| | @ | HENGRUI PHARMA | 500MG/VIAL | A212022 | 001 | Aug 22, 2019 | Jan | DISC |
| | | DARAXONRASIB | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | RASONQUE | | | | | | |
| | + | REVOLUTION MEDICINES | 100MG | N220910 | 001 | Aug 26, 2026 | Aug | NEWA |
| | +! | | 150MG | N220910 | 002 | Aug 26, 2026 | Aug | NEWA |
| | | DARIFENACIN HYDROBROMIDE | | | | | | |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| | | DARIFENACIN HYDROBROMIDE | | | | | | |
| | AB | ALICORA | EQ 7.5MG BASE | A211045 | 001 | Jan 06, 2020 | Sep | CAHN |
| | AB | | EQ 15MG BASE | A211045 | 002 | Jan 06, 2020 | Sep | CAHN |
| | | DASATINIB | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | DASATINIB | | | | | | |
| | AB | MSN | 20MG | A219579 | 001 | Sep 11, 2026 | Sep | NEWA |
| | AB | | 50MG | A219579 | 002 | Sep 11, 2026 | Sep | NEWA |
| | AB | | 70MG | A219579 | 003 | Sep 11, 2026 | Sep | NEWA |
| | AB | | 80MG | A219579 | 004 | Sep 11, 2026 | Sep | NEWA |
| | AB | | 100MG | A219579 | 005 | Sep 11, 2026 | Sep | NEWA |
| | AB | | 140MG | A219579 | 006 | Sep 11, 2026 | Sep | NEWA |
| | | DASIGLUCAGON HYDROCHLORIDE | | | | | | |
| | | SOLUTION;SUBCUTANEOUS | | | | | | |
| | | ZEGALOGUE | | | | | | |
| | @ + | ZEALAND PHARMA | EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) | N214231 | 001 | Mar 22, 2021 | Feb | DISC |
| | | ZEGALOGUE (AUTOINJECTOR) | | | | | | |
| | @ + | ZEALAND PHARMA | EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) | N214231 | 002 | Mar 22, 2021 | Feb | DISC |
| | | DECITABINE | | | | | | |
| | | INJECTABLE;INTRAVENOUS | | | | | | |
| | | DECITABINE | | | | | | |
| | @ | INGENUS PHARMS LLC | 50MG/VIAL | A210984 | 001 | Sep 16, 2019 | Jun | CAHN |
| | AP | NIVAGEN | 50MG/VIAL | A212117 | 001 | Dec 07, 2020 | Aug | CAHN |
| | @ | NOVAST LABS | 50MG/VIAL | A210984 | 001 | Sep 16, 2019 | Feb | DISC |
| | AP | SOMERSET THERAPS LLC | 50MG/VIAL | A217814 | 001 | Dec 19, 2025 | Sep | CAHN |
| | | DEFERASIROX | | | | | | |
| | | GRANULE;ORAL | | | | | | |
| | | DEFERASIROX | | | | | | |
| | AB | PHARMAZONE | 90MG | A214559 | 001 | Mar 09, 2021 | Sep | CAHN |
| | AB | | 180MG | A214559 | 002 | Mar 09, 2021 | Sep | CAHN |
| | AB | | 360MG | A214559 | 003 | Mar 09, 2021 | Sep | CAHN |
| | | DEFERIPRONE | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | DEFERIPRONE | | | | | | |
| | AB | PHARMAZONE | 500MG | A220132 | 001 | Dec 11, 2025 | Sep | CAHN |
| | AB | | 1GM | A220132 | 002 | Dec 11, 2025 | Sep | CAHN |
| | | FERRIPROX | | | | | | |
| | @ + | CHIESI | 500MG | N021825 | 001 | Oct 14, 2011 | Apr | DISC |

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | HIKMA | 500MG/VIAL | A078086 | 001 | May 30, 2007 | Mar DISC |
| | | @ | | 2GM/VIAL | A078086 | 002 | May 30, 2007 | Mar DISC |
| >D> | AP | | HOSPIRA | 500MG/VIAL | A076019 | 001 | Mar 17, 2004 | Oct DISC |
| >A> | | @ | | 500MG/VIAL | A076019 | 001 | Mar 17, 2004 | Oct DISC |

DEFLAZACORT

SUSPENSION;ORAL

DEFLAZACORT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | BIOCON PHARMA | 22.75MG/ML | A220709 | 001 | May 28, 2026 | Jun CAHN |
| | AB | | CARNEGIE | 22.75MG/ML | A220709 | 001 | May 28, 2026 | May NEWA |
| | AB | | SUN PHARM INDS INC | 22.75MG/ML | A219930 | 001 | Jan 27, 2026 | Jan NEWA |

TABLET;ORAL

DEFLAZACORT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | HIKMA | 6MG | A220524 | 001 | Sep 18, 2026 | Sep NEWA |
| | AB | | | 18MG | A220524 | 002 | Sep 18, 2026 | Sep NEWA |
| | AB | | | 30MG | A220524 | 003 | Sep 18, 2026 | Sep NEWA |
| | AB | | | 36MG | A220524 | 004 | Sep 18, 2026 | Sep NEWA |
| >A> | AB | | TEVA PHARMS INC | 6MG | A217103 | 001 | Oct 19, 2026 | Oct NEWA |
| >A> | AB | | | 18MG | A217103 | 002 | Oct 19, 2026 | Oct NEWA |
| >A> | AB | | | 30MG | A217103 | 003 | Oct 19, 2026 | Oct NEWA |
| >A> | AB | | | 36MG | A217103 | 004 | Oct 19, 2026 | Oct NEWA |

DEHYDRATED ALCOHOL

SOLUTION;INTRA-ARTERIAL

ABLYSINOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | BPI LABS | 99% (1ML) | N207987 | 001 | Jun 21, 2018 | Jan CAIN |
| | AP | +! | | 99% (5ML) | N207987 | 002 | Jun 21, 2018 | Jan CAIN |

DEHYDRATED ALCOHOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | ACCORD HLTHCARE | 99% (5ML) | A217845 | 001 | Jun 23, 2025 | Jan CAIN |
| | AP | | BRECKENRIDGE | 99% (5ML) | A219444 | 001 | Jun 23, 2025 | Jan CAIN |
| | AP | | INGENUS PHARMS LLC | 99% (5ML) | A219569 | 001 | Jul 09, 2025 | Jan CAIN |
| | AP | | XGEN PHARMS | 99% (5ML) | A219400 | 001 | Jun 23, 2025 | Jan CAIN |

SOLUTION;INTRAVENOUS

DEHYDRATED ALCOHOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | BE PHARMS | 98% (5ML) | N214988 | 001 | Oct 23, 2025 | Jun CAHN |
| | | +! | ROYAL PHARMS | 98% (5ML) | N214988 | 001 | Oct 23, 2025 | Jan CAIN |

DESFLURANE

LIQUID;INHALATION

DESFLURANE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AN | | PIRAMAL CRITICAL | 100% | A090363 | 001 | Oct 05, 2026 | Sep NEWA |
| | | @ | SHANGHAI HENGRUI | 100% | A208234 | 001 | Feb 26, 2018 | Jun DISC |

SUPRANE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AN | +! | BAXTER HLTHCARE | 100% | N020118 | 001 | Sep 18, 1992 | Sep CTEC |
| | | +! | | 100% | N020118 | 001 | Sep 18, 1992 | Jun CTEC |

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | AMNEAL PHARMS CO | 10MG | A208105 | 001 | Mar 17, 2016 | Sep DISC |
| | | @ | | 25MG | A208105 | 002 | Mar 17, 2016 | Sep DISC |
| | | @ | | 50MG | A208105 | 003 | Mar 17, 2016 | Sep DISC |
| | | @ | | 75MG | A208105 | 004 | Mar 17, 2016 | Sep DISC |
| | | @ | | 100MG | A208105 | 005 | Mar 17, 2016 | Sep DISC |
| | | @ | | 150MG | A208105 | 006 | Mar 17, 2016 | Sep DISC |
| | | @ | HERITAGE | 10MG | A207433 | 001 | May 05, 2016 | Jan DISC |
| | | @ | | 25MG | A207433 | 002 | May 05, 2016 | Jan DISC |
| | | @ | | 50MG | A207433 | 003 | May 05, 2016 | Jan DISC |
| | | @ | | 75MG | A207433 | 004 | May 05, 2016 | Jan DISC |
| | | @ | | 100MG | A207433 | 005 | May 05, 2016 | Jan DISC |
| | | @ | | 150MG | A207433 | 006 | May 05, 2016 | Jan DISC |
| | AB | | INGENUS PHARMS LLC | 10MG | A204963 | 001 | Dec 26, 2017 | Feb CAHN |
| | AB | | | 25MG | A204963 | 002 | Dec 26, 2017 | Feb CAHN |
| | AB | | | 50MG | A204963 | 003 | Dec 26, 2017 | Feb CAHN |
| | AB | | | 75MG | A204963 | 004 | Dec 26, 2017 | Feb CAHN |
| | AB | ! | | 100MG | A204963 | 005 | Dec 26, 2017 | Jul CHRS |
| | AB | | | 100MG | A204963 | 005 | Dec 26, 2017 | Feb CAHN |
| | AB | | | 150MG | A204963 | 006 | Dec 26, 2017 | Feb CAHN |

TABLET;ORAL
NORPRAMIN
@ + VALIDUS PHARMS 10MG N014399 007 Feb 11, 1982 Jul DISC
@ + 25MG N014399 001 Jul DISC
@ + 50MG N014399 003 Jul DISC
@ + 75MG N014399 004 Jul DISC
@ + 100MG N014399 005 Jul DISC
@ + 150MG N014399 006 Jul DISC

DESLORATADINE
TABLET;ORAL
DESLORATADINE
AB NATCO PHARMA USA 5MG A078351 001 Feb 10, 2012 May CMFD
@ 5MG A078351 001 Feb 10, 2012 Mar CAHN

DESMOPRESSIN ACETATE
INJECTABLE;INJECTION
DDAVP
AP +! J MOLNER 0.004MG/ML N018938 001 Mar 30, 1984 Jun CAHN
@ 0.015MG/ML N018938 002 Apr 25, 1995 Jun CAHN
DESMOPRESSIN ACETATE
AP CAPLIN 0.004MG/ML A219981 001 Feb 27, 2026 Feb NEWA
SOLUTION;ORAL
DESMODA
+! ETON 0.05MG/ML N219873 001 Feb 25, 2026 Feb NEWA
SPRAY, METERED;NASAL
DESMOPRESSIN ACETATE
@ BAUSCH 0.01MG/SPRAY A074830 001 Jan 25, 1999 Aug DISC

DESOGESTREL; ETHINYL ESTRADIOL
TABLET;ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL
AB ANNORA PHARMA 0.15MG,N/A;0.02MG,0.01MG A219670 001 Jul 07, 2026 Jun NEWA
AB 0.15MG;0.03MG A219761 001 Mar 18, 2026 Mar NEWA

DESONIDE
AEROSOL, FOAM;TOPICAL
VERDESO
@ + GENUS 0.05% N021978 001 Sep 19, 2006 Apr CAHN
CREAM;TOPICAL
DESONIDE
AB COSETTE PHARMS NC 0.05% A074027 001 Sep 28, 1992 May CAHN
GEL;TOPICAL
DESONIDE
! PHARMAZONE 0.05% A202470 001 May 11, 2020 Sep CAHN
LOTION;TOPICAL
DESONIDE
>D> @ ENCUBE 0.05% A207855 001 Sep 28, 2017 Oct CAHN
>A> @ 0.05% A207855 001 Sep 28, 2017 Oct CAHN
@ 0.05% A207855 001 Sep 28, 2017 May CAHN
@ VERTICE 0.05% A207855 001 Sep 28, 2017 Apr CAHN
OINTMENT;TOPICAL
DESONIDE
>A> AB ENCUBE 0.05% A210998 001 Jan 30, 2019 Oct CAHN
>D> AB ENCUBE ETHICALS 0.05% A210998 001 Jan 30, 2019 Oct CAHN

DESOXIMETASONE
CREAM;TOPICAL
DESOXIMETASONE
@ ACTAVIS MID ATLANTIC 0.25% A205082 001 Sep 04, 2015 Aug DISC
@ COSETTE PHARMS NC 0.25% A209595 001 Mar 04, 2020 Jun CAHN
AB SCIEGEN PHARMS 0.05% A203787 001 Jan 06, 2017 Apr CMFD
AB 0.25% A203234 001 Jun 12, 2015 Apr CMFD
GEL;TOPICAL
DESOXIMETASONE
@ PADAGIS US 0.05% A077552 001 Jan 09, 2006 Mar DISC
OINTMENT;TOPICAL
DESOXIMETASONE
@ COSETTE PHARMS NC 0.25% A206740 001 Dec 23, 2016 Jun CAHN
>D> @ ENCUBE 0.25% A208101 001 Feb 25, 2016 Oct CAHN
>A> @ 0.25% A208101 001 Feb 25, 2016 Oct CAHN

OINTMENT;TOPICAL
DESOXIMETASONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | | 0.25% | A208101 | 001 | Feb 25, 2016 | May CAHN |

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PLATINUM | EQ 50MG BASE | A204805 | 001 | May 07, 2019 | Mar CAHN |
| AB | | | EQ 100MG BASE | A204805 | 002 | May 07, 2019 | Mar CAHN |
| AB | | YICHANG HUMANWELL | EQ 25MG BASE | A220460 | 001 | Mar 10, 2026 | Feb NEWA |
| AB | | | EQ 50MG BASE | A220460 | 002 | Mar 10, 2026 | Feb NEWA |
| AB | | | EQ 100MG BASE | A220460 | 003 | Mar 10, 2026 | Feb NEWA |

DEXAMETHASONE

CONCENTRATE;ORAL
DEXAMETHASONE INTENSOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | HIKMA | 1MG/ML | A088252 | 001 | Sep 01, 1983 | Jan CRLD |

ELIXIR;ORAL
DEXAMETHASONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | ! | PHARMAZONE | 0.5MG/5ML | A084754 | 001 | | Sep CAHN |
| AA | ! | SENORES PHARMS | 0.5MG/5ML | A084754 | 001 | | Sep CAHN |

SUSPENSION;INTRAOCULAR
DEXYCU KIT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | EYEPOINT PHARMS | 9% | N208912 | 001 | Feb 09, 2018 | Jul DISC |

TABLET;ORAL
DEXAMETHASONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | PANGEA | 0.25MG | A088149 | 001 | Apr 28, 1983 | Mar CMFD |
| AB | | SOLGEN | 0.5MG | A218372 | 001 | Sep 17, 2024 | Sep CAHN |
| AB | | | 0.75MG | A218372 | 002 | Sep 17, 2024 | Sep CAHN |
| AB | | | 1MG | A218372 | 003 | Sep 17, 2024 | Sep CAHN |
| AB | | | 1.5MG | A218372 | 004 | Sep 17, 2024 | Sep CAHN |
| AB | | | 2MG | A218372 | 005 | Sep 17, 2024 | Sep CAHN |
| AB | | | 4MG | A218372 | 006 | Sep 17, 2024 | Sep CAHN |
| AB | | | 6MG | A218372 | 007 | Sep 17, 2024 | Sep CAHN |

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | QUAGEN | EQ 4MG PHOSPHATE/ML | A214890 | 002 | Jul 28, 2023 | Sep CAHN |
| | @ | | EQ 10MG PHOSPHATE/ML | A214890 | 001 | Jul 07, 2023 | Sep CAHN |

SOLUTION/DROPS;OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ! | BAUSCH AND LOMB INC | EQ 0.1% PHOSPHATE | A040069 | 001 | Jul 26, 1996 | May CAHN |
| | @ | CAPLIN | EQ 0.1% PHOSPHATE | A088771 | 001 | Jan 16, 1985 | Jan CAHN |

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AT | | BAUSCH AND LOMB INC | 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A064063 | 001 | Jul 25, 1994 | May CAHN |
| | @ | PADAGIS US | 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A062938 | 001 | Jul 31, 1989 | Mar DISC |

SUSPENSION/DROPS;OPHTHALMIC
DEXASPORIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AT | | BAUSCH AND LOMB INC | 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A064135 | 001 | Sep 13, 1995 | May CAHN |

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC
TOBRAMYCIN AND DEXAMETHASONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | BAUSCH AND LOMB INC | 0.1%;0.3% | A064134 | 001 | Oct 27, 1999 | May CAHN |

DEXMEDETOMIDINE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL
IGALMI

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >D> | +! | BIOXCEL | EQ 0.12MG BASE | N215390 | 001 | Apr 05, 2022 | Oct CAHN |
| >D> | + | | EQ 0.18MG BASE | N215390 | 002 | Apr 05, 2022 | Oct CAHN |
| | + | | EQ 0.18MG BASE | N215390 | 002 | Apr 05, 2022 | Jan CHRS |
| >A> | +! | TEVA | EQ 0.12MG BASE | N215390 | 001 | Apr 05, 2022 | Oct CAHN |
| >A> | + | | EQ 0.18MG BASE | N215390 | 002 | Apr 05, 2022 | Oct CAHN |

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | BAXTER HLTHCARE CORP | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A208103 | 001 | Apr 15, 2026 | Sep | DISC |
| AP | | | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A208103 | 001 | Apr 15, 2026 | Apr | NEWA |
| | @ | CAPLIN | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A091465 | 001 | Jun 14, 2016 | Apr | DISC |
| AP | | | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A091465 | 001 | Jun 14, 2016 | Jan | CAHN |
| AP | | DR REDDYS | EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | A220315 | 001 | Feb 25, 2026 | Feb | NEWA |
| AP | | | EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | A220315 | 002 | Feb 25, 2026 | Feb | NEWA |
| | @ | HENGRUI PHARMA | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A209065 | 001 | Sep 19, 2017 | Jun | DISC |
| | @ | KNACK | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A218675 | 001 | Mar 09, 2026 | May | DISC |
| AP | | | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A218675 | 001 | Mar 09, 2026 | Feb | NEWA |
| AP | | NEPHRON | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A216254 | 001 | Sep 28, 2026 | Sep | NEWA |

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AUROLIFE PHARMA LLC | 5MG | A202580 | 002 | Aug 25, 2015 | Mar | CMS1 |
| | @ | | 10MG | A202580 | 003 | Aug 25, 2015 | Mar | CMS1 |
| | @ | | 15MG | A202580 | 004 | Aug 25, 2015 | Mar | CMS1 |
| | @ | | 20MG | A202580 | 005 | Dec 21, 2015 | Mar | CMS1 |
| | @ | | 25MG | A202580 | 006 | May 04, 2021 | Mar | CMS1 |
| | @ | | 35MG | A202580 | 007 | May 04, 2021 | Mar | CMS1 |
| | @ | | 40MG | A202580 | 008 | Aug 25, 2015 | Mar | CMS1 |
| AB | | PLATINUM | 5MG | A078992 | 001 | Nov 23, 2021 | Apr | CAHN |
| AB | | | 10MG | A078992 | 002 | Nov 23, 2021 | Apr | CAHN |
| AB | | | 15MG | A078992 | 003 | Nov 18, 2013 | Apr | CAHN |
| AB | | | 30MG | A078992 | 004 | Nov 18, 2013 | Apr | CAHN |
| AB | | | 20MG | A078992 | 005 | Nov 23, 2021 | Apr | CAHN |
| AB | | | 40MG | A078992 | 006 | Nov 23, 2021 | Apr | CAHN |

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL

AZSTARYS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | COMMAVE SUB | EQ 5.2MG BASE;EQ 26.1MG BASE | N212994 | 001 | May 07, 2021 | May | CAHN |
| | + | | EQ 7.8MG BASE;EQ 39.2MG BASE | N212994 | 002 | May 07, 2021 | May | CAHN |
| | +! | | EQ 10.4MG BASE;EQ 52.3MG BASE | N212994 | 003 | May 07, 2021 | May | CAHN |

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | PHARMAZONE | 5MG | A076137 | 001 | Jan 18, 2002 | Sep | CAHN |
| | @ | | 10MG | A076137 | 002 | Jan 18, 2002 | Sep | CAHN |
| | @ | | 15MG | A076137 | 003 | Jan 18, 2002 | Sep | CAHN |
| | @ | QUAGEN | 5MG | A206735 | 001 | Jan 27, 2016 | Apr | CAHN |
| | @ | | 10MG | A206735 | 002 | Jan 27, 2016 | Apr | CAHN |
| | @ | | 15MG | A206735 | 003 | Jan 27, 2016 | Apr | CAHN |
| | @ | STRIDES PHARMA INTL | 5MG | A205673 | 001 | Oct 31, 2017 | Jan | DISC |
| | @ | | 10MG | A205673 | 002 | Oct 31, 2017 | Jan | DISC |
| | @ | | 15MG | A205673 | 003 | Oct 31, 2017 | Jan | DISC |

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | PHARMAZONE | 5MG | A206095 | 001 | Aug 18, 2022 | Sep | CAHN |
| | @ | | 10MG | A206095 | 002 | Aug 18, 2022 | Sep | CAHN |
| | @ | SENORES PHARMS | 5MG | A206095 | 001 | Aug 18, 2022 | Sep | CAHN |
| | @ | | 10MG | A206095 | 002 | Aug 18, 2022 | Sep | CAHN |

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | COSETTE PHARMS NC | 15MG/5ML;6.25MG/5ML | A091687 | 001 | Jun 28, 2012 | May | CAHN |
| AA | | HETERO LABS LTD III | 15MG/5ML;6.25MG/5ML | A218264 | 001 | Mar 12, 2026 | Mar | NEWA |
| AA | | RUBICON RESEARCH | 15MG/5ML;6.25MG/5ML | A220869 | 001 | Jun 23, 2026 | Jun | NEWA |

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | SUN PHARM | 20MG;10MG | A204196 | 001 | Jun 03, 2026 | May | NEWA |

NUEDEXTA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | OTSUKA AMERICA PHARM | 20MG;10MG | N021879 | 001 | Oct 29, 2010 | May | CAHN |

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION;ORAL, RECTAL

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | ADAPTIS | 66%;10% | A214201 | 001 | Jun 27, 2022 | Aug | CAHN |
| AA | | GUARDIAN DRUG | 66%;10% | A214201 | 001 | Jun 27, 2022 | Aug | CAHN |

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | BAXTER HLTHCARE CORP | 10MG/2ML (5MG/ML) | A219882 | 001 | Jul 28, 2026 | Jul | NEWA |
| | ! | | 20MG/4ML (5MG/ML) | A219882 | 002 | Jul 28, 2026 | Jul | NFTG |
| AP | | LUPIN | 10MG/2ML (5MG/ML) | A220365 | 001 | Jul 27, 2026 | Jul | NEWA |

TABLET;ORAL

DIAZEPAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | STRIDES PHARMA INTL | 2MG | A077749 | 001 | Mar 31, 2006 | Jan | DISC |
| | @ | | 5MG | A077749 | 002 | Mar 31, 2006 | Jan | DISC |
| | @ | | 10MG | A077749 | 003 | Mar 31, 2006 | Jan | DISC |

DIAZOXIDE CHOLINE

TABLET, EXTENDED RELEASE;ORAL

VYKAT XR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | SOLENO | 25MG | N216665 | 001 | Mar 26, 2025 | Sep | CAHN |
| | + | | 75MG | N216665 | 002 | Mar 26, 2025 | Sep | CAHN |
| | +! | | 150MG | N216665 | 003 | Mar 26, 2025 | Sep | CAHN |

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ONESOURCE | 25MG | A210078 | 001 | Dec 03, 2019 | Jul | CAHN |

ZIPSOR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | ASSERTIO SPECLTY | 25MG | N022202 | 001 | Jun 16, 2009 | Feb | CAHN |
| AB | +! | COSETTE | 25MG | N022202 | 001 | Jun 16, 2009 | Jun | CAHN |

FOR SOLUTION;ORAL

CAMBIA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | ASSERTIO SPECLTY | 50MG | N022165 | 001 | Jun 17, 2009 | Feb | CAHN |
| AB | +! | COSETTE | 50MG | N022165 | 001 | Jun 17, 2009 | Jun | CAHN |

TABLET;ORAL

CATAFLAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> AB | | AMICI PHARMA | 25MG | A076561 | 002 | Jul 21, 2021 | Oct | CAHN |
| >A> AB | | | 50MG | A076561 | 001 | Mar 18, 2004 | Oct | CAHN |
| >D> AB | | PANGEA | 25MG | A076561 | 002 | Jul 21, 2021 | Oct | CAHN |
| AB | | | 25MG | A076561 | 002 | Jul 21, 2021 | Sep | CAHN |
| >D> AB | | | 50MG | A076561 | 001 | Mar 18, 2004 | Oct | CAHN |
| AB | | | 50MG | A076561 | 001 | Mar 18, 2004 | Sep | CAHN |

DICLOFENAC POTASSIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | INGENUS PHARMS LLC | 50MG | A215585 | 001 | Oct 08, 2021 | Feb | CAHN |
| AB | | PHARMAZONE | 25MG | A215787 | 002 | Nov 09, 2023 | Sep | CAHN |
| AB | | | 50MG | A215787 | 001 | Mar 15, 2023 | Sep | CAHN |
| AB | | RISING | 50MG | A075463 | 001 | Jul 26, 1999 | Jun | CAHN |
| | ! | RUBICON RESEARCH | 75MG | A075229 | 003 | Sep 18, 2026 | Sep | NFTG |

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ALEMBIC | 3% | A212351 | 001 | Jul 27, 2022 | Jun | CTEC |
| | @ | AMNEAL | 3% | A200936 | 001 | Oct 28, 2013 | Mar | DISC |

SOLARAZE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | FOUGERA | 3% | N021005 | 001 | Oct 16, 2000 | Jul | CAHN |

SOLUTION;INTRAVENOUS

ZUEINO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | ADVENTAPHARMA | 37.5MG/ML (37.5MG/ML) | N218379 | 001 | Sep 25, 2026 | Sep | NEWA |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | SOLUTION;TOPICAL | | | | | | |
| | | DICLOFENAC SODIUM | | | | | | |
| >D> | AB | ENCUBE | 2% | A217646 | 001 | Apr 09, 2025 | Oct | CAHN |
| >A> | AB | | 2% | A217646 | 001 | Apr 09, 2025 | Oct | CAHN |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| | | DICLOFENAC SODIUM | | | | | | |
| | AB | AUROBINDO PHARMA USA | 100MG | A076152 | 001 | Dec 13, 2001 | Jul | CMFD |
| | AB | INGENUS PHARMS LLC | 100MG | A216275 | 001 | Sep 23, 2022 | Feb | CAHN |
| | | DICLOXACILLIN SODIUM | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | DICLOXACILLIN SODIUM | | | | | | |
| | AB | CHARTWELL RX | EQ 250MG BASE | A062286 | 001 | Jun 03, 1982 | Aug | CAHN |
| | AB | ! | EQ 500MG BASE | A062286 | 002 | Jun 03, 1982 | Aug | CAHN |
| | | DICYCLOMINE HYDROCHLORIDE | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | DICYCLOMINE HYDROCHLORIDE | | | | | | |
| | AB | HIKMA | 10MG | A040204 | 001 | Feb 28, 1997 | Sep | CAHN |
| | AB | RUBICON RESEARCH | 10MG | A216515 | 001 | Jul 17, 2026 | Jul | NEWA |
| | AB | SOLGEN | 10MG | A216639 | 001 | Mar 24, 2023 | Sep | CAHN |
| | | INJECTABLE;INJECTION | | | | | | |
| | | DICYCLOMINE HYDROCHLORIDE | | | | | | |
| | @ | QUAGEN | 10MG/ML | A212058 | 001 | Apr 26, 2019 | Sep | CAHN |
| | | TABLET;ORAL | | | | | | |
| | | DICYCLOMINE HYDROCHLORIDE | | | | | | |
| | AB ! | AUROBINDO PHARMA USA | 20MG | A040317 | 001 | Sep 07, 1999 | Aug | CHRS |
| | AB | HIKMA | 20MG | A040161 | 001 | Oct 01, 1996 | Sep | CAHN |
| | AB | SOLGEN | 20MG | A216760 | 001 | Nov 28, 2022 | Sep | CAHN |
| | AB | WATSON LABS | 20MG | A085223 | 001 | Jul 30, 1986 | Aug | CHRS |
| | | DIFAMILAST | | | | | | |
| | | OINTMENT;TOPICAL | | | | | | |
| | | ADQUEY | | | | | | |
| | +! | ACROTECH BIOPHARMA | 1% | N219474 | 001 | Feb 12, 2026 | Feb | NEWA |
| | | DIFELIKEFALIN ACETATE | | | | | | |
| | | SOLUTION;INTRAVENOUS | | | | | | |
| | | DIFELIKEFALIN ACETATE | | | | | | |
| | AP | QILU PHARM HAINAN | EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML) | A220919 | 001 | Aug 31, 2026 | Aug | NFTG |
| | | KORSUVA | | | | | | |
| | AP +! | VIFOR INTL | EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML) | N214916 | 001 | Aug 23, 2021 | Aug | CFTG |
| | | DIFLUPREDNATE | | | | | | |
| | | EMULSION;OPHTHALMIC | | | | | | |
| | | DIFLUPREDNATE | | | | | | |
| | AB | ALEMBIC | 0.05% | A213774 | 001 | Jan 26, 2026 | Jan | NEWA |
| | @ | CIPLA | 0.05% | A211776 | 001 | Aug 09, 2021 | Aug | DISC |
| | | DIGOXIN | | | | | | |
| | | ELIXIR;ORAL | | | | | | |
| | | DIGOXIN | | | | | | |
| >A> | AA | AMICI PHARMA | 0.05MG/ML | A215209 | 001 | Mar 11, 2022 | Oct | CAHN |
| >D> | AA | PANGEA | 0.05MG/ML | A215209 | 001 | Mar 11, 2022 | Oct | CAHN |
| | AA | | 0.05MG/ML | A215209 | 001 | Mar 11, 2022 | Sep | CAHN |
| | | INJECTABLE;INJECTION | | | | | | |
| | | DIGOXIN | | | | | | |
| >D> | AP | SANDOZ | 0.25MG/ML | A040481 | 001 | Aug 21, 2003 | Oct | CHRS |
| >A> | AP ! | | 0.25MG/ML | A040481 | 001 | Aug 21, 2003 | Oct | CHRS |
| >D> | | LANOXIN | | | | | | |
| >D> | AP +! | AZURITY | 0.25MG/ML | N009330 | 002 | | Oct | DISC |
| >A> | @ + | | 0.25MG/ML | N009330 | 002 | | Oct | DISC |
| | AP +! | | 0.25MG/ML | N009330 | 002 | | Jul | CAHN |
| | AP +! | | 0.25MG/ML | N009330 | 002 | | Mar | CAHN |
| >D> | | LANOXIN PEDIATRIC | | | | | | |
| >D> | +! | AZURITY | 0.1MG/ML | N009330 | 004 | | Oct | DISC |
| >A> | @ + | | 0.1MG/ML | N009330 | 004 | | Oct | DISC |
| | +! | | 0.1MG/ML | N009330 | 004 | | Jul | CAHN |
| | +! | | 0.1MG/ML | N009330 | 004 | | Mar | CAHN |

TABLET;ORAL
DIGOXIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | HIKMA | 0.125MG | A077002 | 002 | Oct 30, 2007 | Sep | CAHN |
| AB | | | 0.25MG | A077002 | 001 | Oct 30, 2007 | Sep | CAHN |
| | @ | SUN PHARM INDS INC | 0.125MG | A076363 | 001 | Jan 31, 2003 | May | DISC |
| | @ | | 0.25MG | A076363 | 002 | Jan 31, 2003 | May | DISC |

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION
DIHYDROERGOTAMINE MESYLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | PADAGIS US | 1MG/ML | A040475 | 001 | Apr 28, 2003 | Mar | DISC |

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
CARDIZEM CD

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB3 | + | BAUSCH | 360MG | N020062 | 005 | Aug 24, 1999 | Jul | CHRS |

DILTIAZEM HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB3 | | MACLEODS PHARMS | 120MG | A218744 | 001 | Feb 27, 2026 | Feb | NEWA |
| AB3 | | | 180MG | A218744 | 002 | Feb 27, 2026 | Feb | NEWA |
| AB3 | | | 240MG | A218744 | 003 | Feb 27, 2026 | Feb | NEWA |
| AB3 | | | 300MG | A218744 | 004 | Feb 27, 2026 | Feb | NEWA |
| AB3 | | | 360MG | A218744 | 005 | Feb 27, 2026 | Feb | NEWA |
| AB3 | ! | NOVAST LABS | 360MG | A208783 | 005 | Jun 14, 2019 | Jul | CHRS |

TABLET;ORAL
DILTIAZEM HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ADAPTIS | 30MG | A211596 | 001 | Nov 18, 2019 | Aug | CAHN |
| | @ | | 60MG | A211596 | 002 | Nov 18, 2019 | Aug | CAHN |
| | @ | | 90MG | A211596 | 003 | Nov 18, 2019 | Aug | CAHN |
| | @ | | 120MG | A211596 | 004 | Nov 18, 2019 | Aug | CAHN |
| AB | | YICHANG HUMANWELL | 30MG | A220590 | 001 | Sep 25, 2026 | Sep | NEWA |
| AB | | | 60MG | A220590 | 002 | Sep 25, 2026 | Sep | NEWA |
| AB | | | 90MG | A220590 | 003 | Sep 25, 2026 | Sep | NEWA |
| AB | | | 120MG | A220590 | 004 | Sep 25, 2026 | Sep | NEWA |
| AB | | ZYDUS LIFESCIENCES | 30MG | A219253 | 001 | Aug 08, 2025 | May | CMFD |
| | @ | | 30MG | A219253 | 001 | Aug 08, 2025 | Jan | DISC |
| AB | | | 60MG | A219253 | 002 | Aug 08, 2025 | May | CMFD |
| | @ | | 60MG | A219253 | 002 | Aug 08, 2025 | Jan | DISC |
| AB | | | 90MG | A219253 | 003 | Aug 08, 2025 | May | CMFD |
| | @ | | 90MG | A219253 | 003 | Aug 08, 2025 | Jan | DISC |
| AB | | | 120MG | A219253 | 004 | Aug 08, 2025 | May | CMFD |
| | @ | | 120MG | A219253 | 004 | Aug 08, 2025 | Jan | DISC |

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | @ | CHARTWELL RX | 120MG | A210285 | 001 | Dec 21, 2021 | Oct | CAHN |
| >A> | @ | | 240MG | A210285 | 002 | Dec 21, 2021 | Oct | CAHN |
| | @ | MYLAN | 120MG | A210531 | 001 | Aug 17, 2020 | Mar | DISC |
| | @ | | 240MG | A210531 | 002 | Aug 17, 2020 | Mar | DISC |
| >D> | @ | SAWAI USA | 120MG | A210285 | 001 | Dec 21, 2021 | Oct | CAHN |
| >D> | @ | | 240MG | A210285 | 002 | Dec 21, 2021 | Oct | CAHN |

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL
DIMETHYL SULFOXIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | PHARMOBEDIENT | 50% | A220173 | 001 | Jul 07, 2026 | Sep | CAHN |
| AT | | RENOVA PHARMS | 50% | A220173 | 001 | Jul 07, 2026 | Jul | CAHN |
| AT | | STIRA | 50% | A220173 | 001 | Jul 07, 2026 | Jun | NEWA |

RIMSO-50

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | +! | MYLAN INSTITUTIONAL | 50% | N017788 | 001 | | Jun | CTEC |

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 50MG | A083567 | 001 | | Sep | CAHN |

ELIXIR;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | ANNORA PHARMA | 12.5MG/5ML | A219470 | 001 | Jun 17, 2026 | Jun | NEWA |
| AA | +! | PHARM ASSOC | 12.5MG/5ML | A087513 | 001 | Feb 10, 1982 | Jun | CTEC |

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | ! | AVET LIFESCIENCES | 50MG/ML | A205337 | 001 | Nov 14, 2025 | Sep | CHRS |

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | PHARMOBEDIENT | 50MG/ML | A040498 | 001 | Jul 12, 2005 | Sep DISC |

DISOPYRAMIDE PHOSPHATE
CAPSULE, EXTENDED RELEASE;ORAL
NORPACE CR

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | PFIZER | EQ 100MG BASE | N018655 | 001 | Jul 20, 1982 | Sep DISC |
| @ + | | EQ 150MG BASE | N018655 | 002 | Jul 20, 1982 | Sep DISC |

DISULFIRAM
TABLET;ORAL
DISULFIRAM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | NATCO PHARMA USA | 250MG | A203916 | 001 | Mar 04, 2015 | Mar CAHN |
| @ | | 500MG | A203916 | 002 | Mar 04, 2015 | Mar CAHN |

DIVALPROEX SODIUM
TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | LUPIN | EQ 125MG VALPROIC ACID | A078790 | 001 | Jul 29, 2008 | May DISC |
| @ | | EQ 250MG VALPROIC ACID | A078790 | 002 | Jul 29, 2008 | May DISC |
| @ | | EQ 500MG VALPROIC ACID | A078790 | 003 | Jul 29, 2008 | May DISC |

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | COSETTE PHARMS NC | EQ 500MG VALPROIC ACID | A078700 | 001 | Aug 03, 2009 | Jun CAHN |

DOBUTAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | HAINAN POLY | EQ 12.5MG BASE/ML | A216131 | 001 | Dec 21, 2022 | Jul CAHN |

SOLUTION;INTRAVENOUS
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | BAXTER HLTHCARE | EQ 50MG BASE/100ML | N020255 | 001 | Oct 19, 1993 | Sep CDFR |
| AP | +! | | EQ 100MG BASE/100ML | N020255 | 003 | Oct 19, 1993 | Sep CDFR |
| AP | +! | | EQ 200MG BASE/100ML | N020255 | 004 | Oct 19, 1993 | Sep CDFR |
| AP | +! | | EQ 400MG BASE/100ML | N020255 | 005 | Oct 19, 1993 | Sep CDFR |
| AP | +! | HOSPIRA | EQ 50MG BASE/100ML | N020201 | 003 | Oct 19, 1993 | Sep CDFR |
| AP | +! | | EQ 100MG BASE/100ML | N020201 | 002 | Oct 19, 1993 | Sep CDFR |
| AP | +! | | EQ 200MG BASE/100ML | N020201 | 001 | Oct 19, 1993 | Sep CDFR |
| AP | +! | | EQ 400MG BASE/100ML | N020201 | 006 | Jul 07, 1994 | Sep CDFR |

DOCETAXEL
INJECTABLE;INJECTION
DOCETAXEL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ADAPTIS | 20MG/ML (20MG/ML) | A210327 | 001 | May 16, 2019 | Aug CAHN |
| AP | | | 80MG/4ML (20MG/ML) | A210327 | 002 | May 16, 2019 | Aug CAHN |
| AP | | | 160MG/8ML (20MG/ML) | A210327 | 003 | May 16, 2019 | Aug CAHN |
| | @ | GUANGDONG SUNHO | 20MG/ML (20MG/ML) | A213768 | 001 | May 13, 2025 | Jul DISC |
| | @ | | 80MG/4ML (20MG/ML) | A213768 | 002 | May 13, 2025 | Jul DISC |
| | @ | INGENUS PHARMS LLC | 20MG/2ML (10MG/ML) | A207563 | 001 | Aug 31, 2017 | Feb CAHN |
| | @ | | 80MG/8ML (10MG/ML) | A207563 | 002 | Aug 31, 2017 | Feb DISC |
| AP | | | 80MG/8ML (10MG/ML) | A207563 | 002 | Aug 31, 2017 | Feb CAHN |
| | @ | | 160MG/16ML (10MG/ML) | A207563 | 003 | Aug 31, 2017 | Feb DISC |
| AP | | | 160MG/16ML (10MG/ML) | A207563 | 003 | Aug 31, 2017 | Feb CAHN |

SOLUTION;INTRAVENOUS
BEIZRAY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | ZHUHAI | 20MG/ML (20MG/ML) | N218711 | 002 | Dec 10, 2025 | Jul NEWA |

DOFETILIDE
CAPSULE;ORAL
DOFETILIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ANDAS 5 HOLDING | 0.125MG | A212496 | 001 | Jul 29, 2026 | Aug CAHN |
| AB | | | 0.25MG | A212496 | 002 | Jul 29, 2026 | Aug CAHN |
| AB | | | 0.5MG | A212496 | 003 | Jul 29, 2026 | Aug CAHN |
| | @ | APPCO | 0.125MG | A215323 | 001 | Apr 14, 2022 | Jun CAHN |
| | @ | | 0.25MG | A215323 | 002 | Apr 14, 2022 | Jun CAHN |
| | @ | | 0.5MG | A215323 | 003 | Apr 14, 2022 | Jun CAHN |
| | @ | INGENUS PHARMS LLC | 0.125MG | A212410 | 001 | Dec 27, 2019 | Feb CAHN |
| | @ | | 0.25MG | A212410 | 002 | Dec 27, 2019 | Feb CAHN |
| | @ | | 0.5MG | A212410 | 003 | Dec 27, 2019 | Feb CAHN |
| AB | | INNOGENIX INC | 0.125MG | A212496 | 001 | Jul 29, 2026 | Jul NEWA |
| AB | | | 0.25MG | A212496 | 002 | Jul 29, 2026 | Jul NEWA |

CAPSULE;ORAL
DOFETILIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | | 0.5MG | A212496 | 003 | Jul 29, 2026 | Jul NEWA |
| | @ | SOMERSET THERAPS LLC | 0.125MG | A215323 | 001 | Apr 14, 2022 | Sep CAHN |
| | @ | | 0.25MG | A215323 | 002 | Apr 14, 2022 | Sep CAHN |
| | @ | | 0.5MG | A215323 | 003 | Apr 14, 2022 | Sep CAHN |
| | @ | STRIDES PHARMA INTL | 0.125MG | A208519 | 001 | Oct 09, 2018 | Jan DISC |
| | @ | | 0.25MG | A208519 | 002 | Oct 09, 2018 | Jan DISC |
| | @ | | 0.5MG | A208519 | 003 | Oct 09, 2018 | Jan DISC |

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | LUPIN | 23MG | A202782 | 001 | Oct 30, 2015 | Feb DISC |
| | @ | STRIDES PHARMA | 5MG | A078662 | 001 | May 31, 2011 | Jun DISC |
| | @ | | 10MG | A078662 | 002 | May 31, 2011 | Jun DISC |

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> AB | | STRIDES PHARMA INTL | 10MG;14MG | A208359 | 001 | Oct 13, 2026 | Oct NEWA |
| >A> AB | | | 10MG;28MG | A208359 | 002 | Oct 13, 2026 | Oct NEWA |

DORAVIRINE; ISLATRAVIR

TABLET;ORAL
IDVYNSO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | MSD | 100MG;0.25MG | N216964 | 001 | Apr 20, 2026 | Apr NEWA |

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AT2 | | ALEMBIC THERAP | EQ 2% BASE;EQ 0.5% BASE | A216308 | 001 | Feb 18, 2025 | May CAHN |
| AT1 | | RUBICON RESEARCH | EQ 2% BASE;EQ 0.5% BASE | A078201 | 001 | Oct 28, 2008 | Aug CMFD |

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL
DOXEPIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | LEADING | EQ 10MG BASE | A211619 | 001 | Mar 09, 2021 | Aug CAHN |
| AB | | | EQ 25MG BASE | A211619 | 002 | Mar 09, 2021 | Aug CAHN |
| AB | | | EQ 50MG BASE | A211619 | 003 | Mar 09, 2021 | Aug CAHN |
| AB | | | EQ 75MG BASE | A211619 | 004 | Mar 09, 2021 | Aug CAHN |
| AB | | | EQ 100MG BASE | A211619 | 005 | Mar 09, 2021 | Aug CAHN |
| | @ | MICRO LABS | EQ 10MG BASE | A217688 | 001 | Jun 27, 2023 | Aug DISC |
| | @ | | EQ 25MG BASE | A217688 | 002 | Jun 27, 2023 | Aug DISC |
| | @ | | EQ 50MG BASE | A217688 | 003 | Jun 27, 2023 | Aug DISC |
| | @ | | EQ 75MG BASE | A217688 | 004 | Jun 27, 2023 | Aug DISC |
| | @ | | EQ 100MG BASE | A217688 | 005 | Jun 27, 2023 | Aug DISC |
| | @ | PH HEALTH | EQ 150MG BASE | A071422 | 006 | Nov 09, 1987 | Jul DISC |
| AB | | UNIQUE | EQ 10MG BASE | A217975 | 001 | Aug 21, 2023 | Mar CAHN |
| AB | | | EQ 25MG BASE | A217975 | 002 | Aug 21, 2023 | Mar CAHN |
| AB | | | EQ 50MG BASE | A217975 | 003 | Aug 21, 2023 | Mar CAHN |
| AB | | | EQ 75MG BASE | A217975 | 004 | Aug 21, 2023 | Mar CAHN |
| AB | | | EQ 100MG BASE | A217975 | 005 | Aug 21, 2023 | Mar CAHN |
| AB | ! | VELZEN PHARMA PVT | EQ 150MG BASE | A211618 | 001 | Mar 01, 2021 | Jul CHRS |

CREAM;TOPICAL
DOXEPIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | SUN PHARMA CANADA | 5% | A213919 | 001 | Apr 28, 2026 | Apr NEWA |

TABLET;ORAL
DOXEPIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | MSN | EQ 3MG BASE | A214823 | 001 | Apr 03, 2023 | Sep CTEC |
| AB | | | EQ 6MG BASE | A214823 | 002 | Apr 03, 2023 | Sep CTEC |

DOXERCALCIFEROL

INJECTABLE;INJECTION
DOXERCALCIFEROL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | CAPLIN | 4MCG/2ML (2MCG/ML) | A200926 | 001 | Feb 04, 2014 | Apr DISC |
| AP | | | 4MCG/2ML (2MCG/ML) | A200926 | 001 | Feb 04, 2014 | Jan CAHN |
| | @ | | 2MCG/ML (2MCG/ML) | A200926 | 002 | Sep 04, 2014 | Apr DISC |
| | | | 2MCG/ML (2MCG/ML) | A200926 | 002 | Sep 04, 2014 | Apr NEWA |
| | @ | EUGIA PHARMA | 4MCG/2ML (2MCG/ML) | A213717 | 002 | Jan 24, 2022 | Mar DISC |
| | @ | HIKMA | 4MCG/2ML (2MCG/ML) | A091101 | 001 | Aug 30, 2013 | Mar DISC |

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | QILU PHARM HAINAN | 20MG/10ML (2MG/ML) | A219881 | 001 | Feb 03, 2026 | Jan NEWA |
| AB | | | 50MG/25ML (2MG/ML) | A219881 | 002 | Feb 03, 2026 | Jan NEWA |

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AIPING PHARM INC | 40MG | A219978 | 001 | Oct 01, 2025 | Jan CAHN |
| | @ | COSETTE PHARMS NC | EQ 50MG BASE | A204446 | 001 | May 28, 2015 | Jun CAHN |
| | @ | | EQ 75MG BASE | A204446 | 002 | May 28, 2015 | Jun CAHN |
| | @ | | EQ 100MG BASE | A204446 | 003 | May 28, 2015 | Jun CAHN |

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | HIKMA | EQ 20MG BASE | A065103 | 001 | May 13, 2005 | Sep CAHN |
| AB | | | EQ 50MG BASE | A062396 | 002 | Nov 07, 1984 | Sep CAHN |
| AB | ! | | EQ 100MG BASE | A062396 | 001 | May 07, 1984 | Sep CAHN |

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | AVET LIFESCIENCES | EQ 100MG BASE/VIAL | A203276 | 001 | Feb 19, 2026 | Feb DISC |
| AP | | | EQ 100MG BASE/VIAL | A203276 | 001 | Feb 19, 2026 | Feb NEWA |
| >A> AP | | EMERGE BIOSCIENCE | EQ 100MG BASE/VIAL | A218053 | 001 | Oct 28, 2024 | Oct CAHN |
| AP | | HAINAN POLY | EQ 100MG BASE/VIAL | A217685 | 001 | Jun 21, 2024 | Jul CAHN |
| AP | | | EQ 200MG BASE/VIAL | A217685 | 002 | Jun 21, 2024 | Jul CAHN |
| >D> AP | | KINDOS | EQ 100MG BASE/VIAL | A218053 | 001 | Oct 28, 2024 | Oct CAHN |
| AP | | PHARMOBEDIENT | EQ 100MG BASE/VIAL | A217078 | 001 | Feb 21, 2025 | Jun CAHN |

TABLET;ORAL

DOXYCYCLINE HYCLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | APOTEX | EQ 75MG BASE | A209243 | 001 | Apr 15, 2019 | Jan DISC |
| | @ | | EQ 150MG BASE | A209243 | 002 | Apr 15, 2019 | Jan DISC |
| | @ | ARTHUR GRP | EQ 100MG BASE | A212487 | 001 | Mar 30, 2022 | Jul CAHN |
| AB | | HIKMA | EQ 100MG BASE | A065095 | 001 | Jul 02, 2003 | Sep CAHN |
| | @ | PHARMOBEDIENT | EQ 100MG BASE | A213475 | 001 | Mar 10, 2021 | Sep CAHN |
| | @ | QUAGEN | EQ 100MG BASE | A212487 | 001 | Mar 30, 2022 | Sep CAHN |

TABLET, DELAYED RELEASE;ORAL

DORYX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | MAYNE PHARMA | EQ 80MG BASE | N050795 | 004 | Apr 11, 2013 | Apr DISC |
| | @ + | | EQ 200MG BASE | N050795 | 005 | Apr 11, 2013 | Apr DISC |

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PHARMOBEDIENT | 10MG;10MG | A207825 | 001 | Jul 06, 2020 | Jun DISC |

DRONABINOL

CAPSULE;ORAL

DRONABINOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | RHODES | 2.5MG | A078292 | 001 | Jun 27, 2008 | May CAHN |
| | @ | | 5MG | A078292 | 002 | Jun 27, 2008 | May CAHN |
| | @ | | 10MG | A078292 | 003 | Jun 27, 2008 | May CAHN |

SOLUTION;ORAL

SYNDROS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | WELLHOUSE PHARMA | 5MG/ML | N205525 | 001 | Mar 23, 2017 | Jan CAHN |

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

DRONEDARONE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | LUPIN | EQ 400MG BASE | A205904 | 001 | Jan 31, 2024 | Mar DISC |

MULTAQ

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | SANOFI AVENTIS US | EQ 400MG BASE | N022425 | 001 | Jul 01, 2009 | Mar CTEC |

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | 100MG | A215265 | 001 | Nov 01, 2021 | Sep CAHN |
| AB | | | 200MG | A215265 | 002 | Nov 01, 2021 | Sep CAHN |
| AB | | | 300MG | A215265 | 003 | Nov 01, 2021 | Sep CAHN |
| AB | | SENORES PHARMS | 100MG | A215265 | 001 | Nov 01, 2021 | Sep CAHN |

CAPSULE;ORAL
DROXIDOPA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | | 200MG | A215265 | 002 | Nov 01, 2021 | Sep CAHN |
| AB | | | 300MG | A215265 | 003 | Nov 01, 2021 | Sep CAHN |

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | ALLIED | EQ 20MG BASE | A090780 | 001 | Oct 28, 2015 | Sep CAHN |
| | @ | | EQ 30MG BASE | A090780 | 002 | Oct 28, 2015 | Sep CAHN |
| | @ | | EQ 60MG BASE | A090780 | 003 | Oct 28, 2015 | Sep CAHN |
| | +! | ALMATICA | EQ 80MG BASE | N219131 | 001 | Feb 27, 2026 | Feb NEWA |
| | + | | EQ 90MG BASE | N219131 | 002 | Feb 27, 2026 | Feb NEWA |
| | + | | EQ 120MG BASE | N219131 | 003 | Feb 27, 2026 | Feb NEWA |
| | @ | EVEREST LIFESCIENCES | EQ 20MG BASE | A090780 | 001 | Oct 28, 2015 | Sep CAHN |
| | @ | | EQ 30MG BASE | A090780 | 002 | Oct 28, 2015 | Sep CAHN |
| | @ | | EQ 60MG BASE | A090780 | 003 | Oct 28, 2015 | Sep CAHN |
| | @ | MARKSANS PHARMA | EQ 20MG BASE | A090723 | 001 | Dec 11, 2013 | Sep CAHN |
| | @ | | EQ 30MG BASE | A090723 | 002 | Dec 11, 2013 | Sep CAHN |
| | @ | | EQ 60MG BASE | A090723 | 003 | Dec 11, 2013 | Sep CAHN |
| | @ | PHARMAZONE | EQ 20MG BASE | A090723 | 001 | Dec 11, 2013 | Sep CAHN |
| | @ | | EQ 30MG BASE | A090723 | 002 | Dec 11, 2013 | Sep CAHN |
| | @ | | EQ 60MG BASE | A090723 | 003 | Dec 11, 2013 | Sep CAHN |

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | MARKSANS PHARMA | 0.5MG | A204376 | 001 | Apr 07, 2017 | Sep CAHN |
| AB | | ONESOURCE | 0.5MG | A204262 | 001 | Nov 20, 2015 | Jul CAHN |
| AB | | PHARMAZONE | 0.5MG | A204376 | 001 | Apr 07, 2017 | Sep CAHN |

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PH HEALTH | 0.5MG;0.4MG | A202509 | 001 | Feb 26, 2014 | Aug DISC |

ECONAZOLE NITRATE

CREAM;TOPICAL
ECONAZOLE NITRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA USA | 1% | A210364 | 001 | Apr 18, 2018 | Mar CMFD |
| >D> AB | | ENCUBE | 1% | A076574 | 001 | Dec 17, 2004 | Oct CAHN |
| >A> AB | | | 1% | A076574 | 001 | Dec 17, 2004 | Oct CAHN |
| AB | | | 1% | A076574 | 001 | Dec 17, 2004 | Jun CMFD |

EDARAVONE

SOLUTION;INTRAVENOUS
EDARAVONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | DR REDDYS | 60MG/100ML (0.6MG/ML) | A215917 | 001 | May 06, 2024 | Apr DISC |
| | @ | GLAND | 60MG/100ML (0.6MG/ML) | A216199 | 002 | May 06, 2024 | Apr DISC |
| | @ | PHARMOBEDIENT | 30MG/100ML (0.3MG/ML) | A217565 | 001 | Oct 31, 2024 | Jun DISC |
| | @ | | 60MG/100ML (0.6MG/ML) | A217565 | 002 | Oct 31, 2024 | Jun DISC |
| | ! | | 60MG/100ML (0.6MG/ML) | A217565 | 002 | Oct 31, 2024 | Apr CTEC |
| AP | | ZYDUS PHARMS | 30MG/100ML (0.3MG/ML) | A218349 | 001 | Jul 22, 2026 | Jul NEWA |

RADICAVA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | SHIONOGI | 30MG/100ML (0.3MG/ML) | N209176 | 001 | May 05, 2017 | Apr CAHN |
| | @ + | | 60MG/100ML (0.6MG/ML) | N209176 | 002 | Nov 15, 2018 | Apr DISC |
| AP | + | | 60MG/100ML (0.6MG/ML) | N209176 | 002 | Nov 15, 2018 | Apr CAHN |

SUSPENSION;ORAL
RADICAVA ORS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | SHIONOGI | 105MG/5ML | N215446 | 001 | May 12, 2022 | Apr CAHN |

EFAVIRENZ

TABLET;ORAL
EFAVIRENZ

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PHARMOBEDIENT | 600MG | A204869 | 001 | Mar 12, 2018 | Jul DISC |

EFINACONAZOLE

SOLUTION;TOPICAL
EFINACONAZOLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | ALEMBIC | 10% | A212027 | 001 | Feb 23, 2026 | Aug DISC |
| AB | | | 10% | A212027 | 001 | Feb 23, 2026 | Feb NEWA |
| AB | | NIVAGEN PHARMS INC | 10% | A211969 | 001 | Jun 21, 2021 | Mar CAHN |

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | CARLSBAD | EQ 20MG BASE | A209680 | 001 | Jul 13, 2020 | | Feb CAHN |
| @ | | EQ 40MG BASE | A209680 | 002 | Jul 13, 2020 | | Feb CAHN |

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

GRANULE;ORAL

TRIKAFTA (COPACKAGED)

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| + | VERTEX PHARMS INC | 80MG, 60MG, 40MG;59.5MG | N217660 | 001 | Apr 26, 2023 | | Apr CDFR |
| +! | | 100MG, 75MG, 50MG;75MG | N217660 | 002 | Apr 26, 2023 | | Apr CDFR |

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | CIPLA | EQ 84MG BASE | A212369 | 001 | Dec 10, 2024 | | Feb DISC |

ELTROMBOPAG OLAMINE

TABLET;ORAL

ELTROMBOPAG OLAMINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ACTAVIS LABS FL | EQ 50MG ACID | A208815 | 001 | Jun 17, 2026 | | Jun NEWA |
| AB | AIZANT | EQ 12.5MG ACID | A220660 | 001 | Apr 28, 2026 | | Apr NEWA |
| AB | | EQ 25MG ACID | A220660 | 002 | Apr 28, 2026 | | Apr NEWA |
| AB | | EQ 50MG ACID | A220660 | 003 | Apr 28, 2026 | | Apr NEWA |
| AB | | EQ 75MG ACID | A220660 | 004 | Apr 28, 2026 | | Apr NEWA |
| AB | AMNEAL | EQ 12.5MG ACID | A212884 | 001 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 25MG ACID | A212884 | 003 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 50MG ACID | A212884 | 002 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 75MG ACID | A212884 | 004 | Jan 14, 2026 | | Jan NEWA |
| AB | BIOCON PHARMA | EQ 12.5MG ACID | A220660 | 001 | Apr 28, 2026 | | May CAHN |
| AB | | EQ 25MG ACID | A220660 | 002 | Apr 28, 2026 | | May CAHN |
| AB | | EQ 50MG ACID | A220660 | 003 | Apr 28, 2026 | | May CAHN |
| AB | | EQ 75MG ACID | A220660 | 004 | Apr 28, 2026 | | May CAHN |
| >A> AB | CHANGZHOU PHARM | EQ 12.5MG ACID | A221019 | 001 | Nov 05, 2026 | | Oct NEWA |
| >A> AB | | EQ 25MG ACID | A221019 | 002 | Nov 05, 2026 | | Oct NEWA |
| >A> AB | | EQ 50MG ACID | A221019 | 003 | Nov 05, 2026 | | Oct NEWA |
| >A> AB | | EQ 75MG ACID | A221019 | 004 | Nov 05, 2026 | | Oct NEWA |
| AB | DR REDDYS | EQ 12.5MG ACID | A219121 | 001 | Mar 16, 2026 | | Mar NEWA |
| AB | | EQ 25MG ACID | A219121 | 002 | Mar 16, 2026 | | Mar NEWA |
| AB | | EQ 50MG ACID | A219121 | 003 | Mar 16, 2026 | | Mar NEWA |
| AB | | EQ 75MG ACID | A219121 | 004 | Mar 16, 2026 | | Mar NEWA |
| AB | HIKMA | EQ 12.5MG ACID | A220033 | 001 | Apr 08, 2026 | | Apr CAHN |
| AB | | EQ 25MG ACID | A220033 | 002 | Apr 08, 2026 | | Apr CAHN |
| AB | | EQ 50MG ACID | A220033 | 003 | Apr 08, 2026 | | Apr CAHN |
| AB | | EQ 75MG ACID | A220033 | 004 | Apr 08, 2026 | | Apr CAHN |
| AB | MSN | EQ 12.5MG ACID | A220250 | 001 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 25MG ACID | A220250 | 002 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 50MG ACID | A220250 | 003 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 75MG ACID | A220250 | 004 | Jan 14, 2026 | | Jan NEWA |
| AB | SOMERSET THERAPS LLC | EQ 12.5MG ACID | A219638 | 001 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 25MG ACID | A219638 | 002 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 50MG ACID | A219638 | 003 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 75MG ACID | A219638 | 004 | Jan 14, 2026 | | Jan NEWA |
| AB | TEVA PHARMS USA | EQ 12.5MG ACID | A209938 | 001 | Jul 13, 2026 | | Jul NEWA |
| AB | | EQ 25MG ACID | A209938 | 002 | Jul 13, 2026 | | Jul NEWA |
| AB | | EQ 75MG ACID | A209938 | 003 | Jul 13, 2026 | | Jul NEWA |
| AB | ZENARA | EQ 12.5MG ACID | A220033 | 001 | Apr 08, 2026 | | Mar NEWA |
| AB | | EQ 25MG ACID | A220033 | 002 | Apr 08, 2026 | | Mar NEWA |
| AB | | EQ 50MG ACID | A220033 | 003 | Apr 08, 2026 | | Mar NEWA |
| AB | | EQ 75MG ACID | A220033 | 004 | Apr 08, 2026 | | Mar NEWA |
| AB | ZYDUS PHARMS | EQ 12.5MG ACID | A216281 | 001 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 25MG ACID | A216281 | 002 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 50MG ACID | A216281 | 003 | Jan 14, 2026 | | Jan NEWA |
| AB | | EQ 75MG ACID | A216281 | 004 | Jan 14, 2026 | | Jan NEWA |

ELUXADOLINE

TABLET;ORAL

ELUXADOLINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | AUROBINDO PHARMA | 75MG | A213511 | 001 | Jun 02, 2026 | | Jun DISC |
| AB | | 75MG | A213511 | 001 | Jun 02, 2026 | | May NEWA |
| @ | | 100MG | A213511 | 002 | Jun 02, 2026 | | Jun DISC |
| AB | | 100MG | A213511 | 002 | Jun 02, 2026 | | May NEWA |

TABLET;ORAL
VIBERZI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | ABBVIE | 75MG | N206940 | 001 | May 27, 2015 | Jun CTEC |
| AB | + | | 75MG | N206940 | 001 | May 27, 2015 | May CTEC |
| AB | + | | 75MG | N206940 | 001 | May 27, 2015 | May CTEC |
| | +! | | 100MG | N206940 | 002 | May 27, 2015 | Jun CTEC |
| AB | +! | | 100MG | N206940 | 002 | May 27, 2015 | May CTEC |
| AB | +! | | 100MG | N206940 | 002 | May 27, 2015 | May CTEC |

EMPAGLIFLOZIN
TABLET;ORAL
EMPAGLIFLOZIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | INVAGEN PHARMS | 10MG | A212330 | 001 | Sep 22, 2026 | Sep NEWA |
| AB | | | 25MG | A212330 | 002 | Sep 22, 2026 | Sep NEWA |

JARDIANCE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + | BOEHRINGER INGELHEIM | 10MG | N204629 | 001 | Aug 01, 2014 | Sep CTEC |
| AB | +! | | 25MG | N204629 | 002 | Aug 01, 2014 | Sep CTEC |

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
TABLET;ORAL
EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | APOTEX | 200MG;EQ 25MG BASE;EQ 25MG BASE | A214095 | 001 | Jan 30, 2026 | Jul DISC |
| AB | | | 200MG;EQ 25MG BASE;EQ 25MG BASE | A214095 | 001 | Jan 30, 2026 | Jan NFTG |

ODEFSEY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | GILEAD SCIENCES INC | 200MG;EQ 25MG BASE;EQ 25MG BASE | N208351 | 001 | Mar 01, 2016 | Jul CTEC |
| AB | +! | | 200MG;EQ 25MG BASE;EQ 25MG BASE | N208351 | 001 | Mar 01, 2016 | Jan CFTG |

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | LAURUS | 200MG;EQ 25MG BASE;300MG | A220232 | 001 | Mar 04, 2026 | Feb NEWA |

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
TABLET;ORAL
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | CIPLA LTD | 200MG;EQ 25MG BASE | A214059 | 001 | Nov 05, 2026 | Oct NEWA |
| | | @ | LUPIN | 200MG;EQ 25MG BASE | A213926 | 001 | Dec 13, 2024 | Mar DISC |
| | AB | | MACLEODS PHARMS | 200MG;EQ 25MG BASE | A214216 | 001 | Apr 07, 2026 | Mar NEWA |
| | AB | | NATCO | 200MG;EQ 25MG BASE | A214173 | 001 | Aug 26, 2026 | Aug NEWA |

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PHARMOBEDIENT | 200MG;300MG | A206436 | 001 | Apr 09, 2018 | Jun DISC |

ENALAPRIL MALEATE
TABLET;ORAL
ENALAPRIL MALEATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | 2.5MG | A075483 | 001 | Aug 22, 2000 | Sep CAHN |
| AB | | | 5MG | A075483 | 002 | Aug 22, 2000 | Sep CAHN |
| AB | | | 10MG | A075483 | 003 | Aug 22, 2000 | Sep CAHN |
| AB | | | 20MG | A075483 | 004 | Aug 22, 2000 | Sep CAHN |

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | 5MG;12.5MG | A075727 | 001 | Sep 18, 2001 | Jun CAHN |
| | @ | | 10MG;25MG | A075727 | 002 | Sep 18, 2001 | Jun CAHN |
| AB | | PHARMAZONE | 5MG;12.5MG | A075909 | 001 | Oct 15, 2001 | Sep CAHN |
| AB | | | 10MG;25MG | A075909 | 002 | Oct 15, 2001 | Sep CAHN |

ENLICITIDE DECANOATE
TABLET;ORAL
LIPFENDRA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | MSD | EQ 20MG BASE | N220848 | 001 | Jul 15, 2026 | Jul NEWA |

ENSIFENTRINE

SUSPENSION;INHALATION

OHTUVAYRE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | MSD | 3MG/2.5ML | N217389 | 001 | Jun 26, 2024 | Apr | CAHN |

ENSITRELVIR

TABLET;ORAL

XOCOVA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | SHIONOGI | 125MG | N220442 | 001 | May 29, 2026 | May | NEWA |

ENTECAVIR

TABLET;ORAL

ENTECAVIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | PHARMADAX | 0.5MG | A212106 | 001 | Aug 10, 2020 | Mar | CAHN |
| | @ | | 1MG | A212106 | 002 | Aug 10, 2020 | Mar | CAHN |

ENZALUTAMIDE

TABLET;ORAL

ENZALUTAMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | SANDOZ | 40MG | A216068 | 001 | Apr 20, 2026 | Apr | NFTG |
| AB | | | 80MG | A216068 | 002 | Apr 20, 2026 | Apr | NFTG |

XTANDI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | ASTELLAS | 40MG | N213674 | 001 | Aug 04, 2020 | Apr | CFTG |
| AB | +! | | 80MG | N213674 | 002 | Aug 04, 2020 | Apr | CFTG |

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | BAXTER HLTHCARE CORP | 50MG/ML (50MG/ML) | A216740 | 001 | Jul 08, 2026 | Jun | NEWA |
| | @ | CIVICA | 50MG/ML (50MG/ML) | A215593 | 001 | Dec 23, 2025 | Jun | DISC |
| AP2 | | FRESENIUS KABI USA | 50MG/10ML (5MG/ML) | A219991 | 001 | Mar 19, 2026 | Mar | NEWA |

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | APOTEX | 0.05% | A090919 | 001 | Oct 31, 2011 | Apr | DISC |
| | ! | SOMERSET THERAPS LLC | 0.05% | A090951 | 001 | Oct 31, 2011 | Apr | CTEC |

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | APOTEX | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A220657 | 001 | Sep 15, 2026 | Sep | CAHN |
| | +! | BAXTER HLTHCARE CORP | 1MG/ML (1MG/ML) | N220626 | 001 | Mar 30, 2026 | Mar | NEWA |
| | +! | | 30MG/30ML (1MG/ML) | N220626 | 002 | Mar 30, 2026 | Mar | NEWA |
| AP | +! | BPI LABS | 1MG/ML (1MG/ML) | N205029 | 005 | Mar 04, 2024 | May | CFTG |
| AP | | DEVA HLDING | 1MG/ML (1MG/ML) | A217426 | 001 | Jul 31, 2026 | Jul | NEWA |
| AP | | DIFGEN PHARMS | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A220657 | 001 | Sep 15, 2026 | Sep | NEWA |
| AP | | GLAND | 1MG/ML (1MG/ML) | A219239 | 003 | Sep 22, 2026 | Sep | NEWA |
| >A> AP | | | EQ 30MG BASE/30ML (EQ 1MG BASE/ML) | A220400 | 001 | Oct 26, 2026 | Oct | NEWA |
| AP | | HIKMA | 1MG/ML (1MG/ML) | A220562 | 001 | May 29, 2026 | May | NFTG |
| AP | | ZYDUS PHARMS | EQ 30MG BASE/30ML (EQ 1MG BASE/ML) | A219832 | 001 | Sep 14, 2026 | Sep | NEWA |

SOLUTION;INTRAVENOUS

EPINEPHRINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | HOSPIRA | 1MG/10ML (0.1MG/ML) | N209359 | 001 | Nov 05, 2019 | Jun | DISC |

EPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | BAXTER HLTHCARE CORP | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | N218475 | 002 | Mar 16, 2026 | Mar | NEWA |
| >A> | +! | | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | N218475 | 003 | Oct 19, 2026 | Oct | NEWA |
| | @ + | | EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) | N218475 | 001 | Feb 28, 2025 | Jun | DISC |

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

SOLUTION;INJECTION

FLAVALTA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | DEPROCO | EQ 0.017MG BASE/1.7ML (EQ 0.01MG BASE/ML);34MG/1.7ML (20MG/ML) | N216564 | 001 | Mar 19, 2026 | Mar | NEWA |

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | WEST-WARD PHARMS INT | 0.01MG/ML;1% | A080406 | 001 | | Apr | CRLD |

EPLERENONE

TABLET;ORAL

EPLERENONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ANDAS 5 HOLDING | 25MG | A203896 | 001 | Feb 02, 2017 | Aug | CAHN |
| | @ | | 50MG | A203896 | 002 | Feb 02, 2017 | Aug | CAHN |
| AB | | EVEREST LIFESCIENCES | 25MG | A207842 | 001 | Oct 25, 2021 | Sep | CAHN |
| AB | | | 50MG | A207842 | 002 | Oct 25, 2021 | Sep | CAHN |
| | @ | INNOGENIX | 25MG | A203896 | 001 | Feb 02, 2017 | May | CAHN |
| | @ | | 50MG | A203896 | 002 | Feb 02, 2017 | May | CAHN |
| AB | | PHARMAZONE | 25MG | A212765 | 001 | Aug 10, 2020 | Sep | CAHN |
| AB | | | 50MG | A212765 | 002 | Aug 10, 2020 | Sep | CAHN |
| AB | | SENORES PHARMS | 25MG | A212765 | 001 | Aug 10, 2020 | Sep | CAHN |
| AB | | | 50MG | A212765 | 002 | Aug 10, 2020 | Sep | CAHN |

EPLONTERSEN SODIUM

SOLUTION;SUBCUTANEOUS

WAINUA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | ASTRAZENECA AB | EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) | N217388 | 002 | Apr 15, 2026 | Apr | NEWA |

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | MEITHEAL | EQ 0.5MG BASE/VIAL | A078396 | 001 | Apr 23, 2008 | Jun | DISC |
| | @ | | EQ 1.5MG BASE/VIAL | A078396 | 002 | Apr 23, 2008 | Jun | DISC |

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | HAINAN POLY | 2MG/ML | A209864 | 001 | Jan 25, 2019 | Jul | CAHN |
| AP | | | 75MG/100ML | A209864 | 002 | Jan 25, 2019 | Jul | CAHN |
| AP | | QUAGEN | 2MG/ML | A213081 | 001 | Sep 07, 2021 | Sep | CAHN |
| AP | | | 75MG/100ML | A213081 | 002 | Apr 20, 2022 | Sep | CAHN |

ERGOCALCIFEROL

CAPSULE;ORAL

ERGOCALCIFEROL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | ! | ONESOURCE | 50,000 IU | A090455 | 001 | Aug 03, 2010 | Jul | CAHN |

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOMAR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | PANGEA | 2MG | A087693 | 001 | Feb 24, 1983 | Jul | CRLD |

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

ERIBULIN MESYLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | FORMOSA LABS | 1MG/2ML (0.5MG/ML) | A219054 | 001 | Mar 16, 2026 | Mar | NEWA |
| >A> AP | | KINDOS | 1MG/2ML (0.5MG/ML) | A218930 | 001 | Oct 19, 2026 | Oct | NEWA |
| AP | | NATCO | 1MG/2ML (0.5MG/ML) | A217085 | 001 | Jun 01, 2026 | May | NEWA |
| AP | | XGEN PHARMS | 1MG/2ML (0.5MG/ML) | A219054 | 001 | Mar 16, 2026 | Mar | CAHN |

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | EQ 25MG BASE | A211960 | 001 | Nov 05, 2019 | Aug | CAHN |
| AB | | | EQ 100MG BASE | A211960 | 002 | Nov 05, 2019 | Aug | CAHN |
| AB | | | EQ 150MG BASE | A211960 | 003 | Nov 05, 2019 | Aug | CAHN |

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYTHROMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | CARNEGIE | 250MG | A062746 | 001 | Dec 22, 1986 | Feb CAHN |
| AB | | | PHARMOBEDIENT | 250MG | A062746 | 001 | Dec 22, 1986 | Sep CAHN |

GEL;TOPICAL

ERYTHROMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | @ | ENCUBE | 2% | A208154 | 001 | Jul 19, 2017 | Oct CAHN |
| >A> | | @ | | 2% | A208154 | 001 | Jul 19, 2017 | Oct CAHN |

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | ! | BAUSCH AND LOMB INC | 0.5% | A064067 | 001 | Jul 29, 1994 | May CAHN |

ILOTYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | DISTA | 0.5% | N050368 | 001 | | Jul CRLD |

SOLUTION;TOPICAL

ERYTHROMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | @ | ENCUBE | 2% | A208100 | 001 | Nov 20, 2017 | Oct CAHN |
| >A> | | @ | | 2% | A208100 | 001 | Nov 20, 2017 | Oct CAHN |
| | | @ | | 2% | A208100 | 001 | Nov 20, 2017 | May CAHN |

TABLET;ORAL

ERYTHROMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | CARNEGIE | 250MG | A061621 | 001 | | Feb CAHN |
| AB | | | | 500MG | A061621 | 002 | | Feb CAHN |

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | CARNEGIE | 250MG | A062298 | 001 | | Feb CAHN |
| AB | | | | 333MG | A062298 | 003 | Mar 29, 1982 | Feb CAHN |
| AB | | ! | | 500MG | A062298 | 002 | | Feb CAHN |
| AB | | | PHARMOBEDIENT | 250MG | A062298 | 001 | | Sep CAHN |
| AB | | | | 333MG | A062298 | 003 | Mar 29, 1982 | Sep CAHN |
| AB | | ! | | 500MG | A062298 | 002 | | Sep CAHN |

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | COSETTE PHARMS NC | EQ 125MG BASE/5ML | A062169 | 001 | Oct 17, 1990 | Jun CAHN |
| | | @ | | EQ 250MG BASE/5ML | A062169 | 002 | Oct 17, 1990 | Jun CAHN |

ERYTHROMYCIN ETHYLSUCCINATE

TABLET;ORAL

E.E.S. 400

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | CARNEGIE | EQ 400MG BASE | A061905 | 001 | | Feb CAHN |
| BX | | ! | | EQ 400MG BASE | A061905 | 002 | Aug 12, 1982 | Feb CAHN |
| | | @ | PHARMOBEDIENT | EQ 400MG BASE | A061905 | 001 | | Sep CAHN |
| BX | | ! | | EQ 400MG BASE | A061905 | 002 | Aug 12, 1982 | Sep CAHN |

ERYTHROMYCIN ETHYLSUCCINATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| BX | | ! | CARNEGIE | EQ 400MG BASE | A061904 | 001 | | Feb CAHN |

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | MICRO LABS | EQ 5MG BASE | A091655 | 001 | Apr 22, 2026 | Aug DISC |
| AB | | | | EQ 5MG BASE | A091655 | 001 | Apr 22, 2026 | Apr NEWA |
| | | @ | | EQ 10MG BASE | A091655 | 002 | Apr 22, 2026 | Aug DISC |
| AB | | | | EQ 10MG BASE | A091655 | 002 | Apr 22, 2026 | Apr NEWA |
| | | @ | | EQ 20MG BASE | A091655 | 003 | Apr 22, 2026 | Aug DISC |
| AB | | | | EQ 20MG BASE | A091655 | 003 | Apr 22, 2026 | Apr NEWA |

ESLICARBAZEPINE ACETATE

TABLET;ORAL

ESLICARBAZEPINE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | AUROBINDO PHARMA | 200MG | A216481 | 001 | Aug 05, 2026 | Jul NEWA |
| AB | | | | 400MG | A216481 | 002 | Aug 05, 2026 | Jul NEWA |
| AB | | | | 600MG | A216481 | 003 | Aug 05, 2026 | Jul NEWA |
| AB | | | | 800MG | A216481 | 004 | Aug 05, 2026 | Jul NEWA |

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | CISEN | EQ 20MG BASE | A213158 | 001 | Sep 22, 2020 | May DISC |
| | | @ | | EQ 40MG BASE | A213158 | 002 | Sep 22, 2020 | May DISC |
| >D> | | @ | HEC PHARM | EQ 20MG BASE | A207265 | 002 | May 18, 2018 | Oct CMFD |
| >A> | AB | | | EQ 20MG BASE | A207265 | 002 | May 18, 2018 | Oct CMFD |
| >D> | | @ | | EQ 40MG BASE | A207265 | 001 | May 18, 2018 | Oct CMFD |
| >A> | AB | | | EQ 40MG BASE | A207265 | 001 | May 18, 2018 | Oct CMFD |

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | NOVITIUM PHARMA | EQ 20MG BASE/PACKET | A218687 | 001 | Sep 25, 2026 | Sep NEWA |
| AB | | | | EQ 40MG BASE/PACKET | A218687 | 002 | Sep 25, 2026 | Sep NEWA |

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ! | HAINAN POLY | EQ 40MG BASE/VIAL | A215732 | 001 | Feb 10, 2022 | Jul CAHN |
| AP | | | REGCON HOLDINGS | EQ 40MG BASE/VIAL | A207181 | 001 | Mar 06, 2017 | Aug CAHN |

ESTRADIOL

CREAM;VAGINAL

ESTRACE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | +! | ABBVIE | 0.01% | A086069 | 001 | Jan 31, 1984 | Mar CAHN |

ESTRADIOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | ENCUBE | 0.01% | A209767 | 001 | Mar 05, 2018 | Oct CAHN |
| >A> | AB | | | 0.01% | A209767 | 001 | Mar 05, 2018 | Oct CAHN |

GEL;TRANSDERMAL

ESTRADIOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | AMVIKA | 0.1% (0.25GM/PACKET) | A217863 | 001 | Jul 12, 2024 | Sep CAHN |
| AB | | | | 0.1% (0.5GM/PACKET) | A217863 | 002 | Jul 12, 2024 | Sep CAHN |
| AB | | | | 0.1% (0.75GM/PACKET) | A217863 | 003 | Jul 12, 2024 | Sep CAHN |
| AB | | | | 0.1% (1GM/PACKET) | A217863 | 004 | Jul 12, 2024 | Sep CAHN |
| AB | | | | 0.1% (1.25GM/PACKET) | A217863 | 005 | Jul 12, 2024 | Sep CAHN |
| >D> | AB | | ENCUBE | 0.1% (0.25GM/PACKET) | A218507 | 001 | Mar 05, 2025 | Oct CAHN |
| >A> | AB | | | 0.1% (0.25GM/PACKET) | A218507 | 001 | Mar 05, 2025 | Oct CAHN |
| >D> | AB | | | 0.1% (0.5GM/PACKET) | A218507 | 002 | Mar 05, 2025 | Oct CAHN |
| >A> | AB | | | 0.1% (0.5GM/PACKET) | A218507 | 002 | Mar 05, 2025 | Oct CAHN |
| >D> | AB | | | 0.1% (0.75GM/PACKET) | A218507 | 003 | Mar 05, 2025 | Oct CAHN |
| >A> | AB | | | 0.1% (0.75GM/PACKET) | A218507 | 003 | Mar 05, 2025 | Oct CAHN |
| >D> | AB | | | 0.1% (1.25GM/PACKET) | A218507 | 005 | Mar 05, 2025 | Oct CAHN |
| >A> | AB | | | 0.1% (1.25GM/PACKET) | A218507 | 005 | Mar 05, 2025 | Oct CAHN |
| >D> | AB | | | 0.1% (1GM/PACKET) | A218507 | 004 | Mar 05, 2025 | Oct CAHN |
| >A> | AB | | | 0.1% (1GM/PACKET) | A218507 | 004 | Mar 05, 2025 | Oct CAHN |
| AB | | | SOLARIS PHARMA CORP | 0.1% (0.25GM/PACKET) | A217863 | 001 | Jul 12, 2024 | Feb CAHN |
| AB | | | | 0.1% (0.5GM/PACKET) | A217863 | 002 | Jul 12, 2024 | Feb CAHN |
| AB | | | | 0.1% (0.75GM/PACKET) | A217863 | 003 | Jul 12, 2024 | Feb CAHN |
| AB | | | | 0.1% (1GM/PACKET) | A217863 | 004 | Jul 12, 2024 | Feb CAHN |
| AB | | | | 0.1% (1.25GM/PACKET) | A217863 | 005 | Jul 12, 2024 | Feb CAHN |
| AB | | | XIROMED | 0.1% (0.25GM/PACKET) | A211783 | 001 | Aug 10, 2022 | Jan CAHN |
| AB | | | | 0.1% (0.5GM/PACKET) | A211783 | 002 | Aug 10, 2022 | Jan CAHN |
| AB | | | | 0.1% (1GM/PACKET) | A211783 | 003 | Aug 10, 2022 | Jan CAHN |

GEL, METERED;TRANSDERMAL

ESTRADIOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | ENCUBE | 0.06% (1.25GM/ACTIVATION) | A218214 | 001 | May 11, 2026 | Oct CAHN |
| >A> | AB | | | 0.06% (1.25GM/ACTIVATION) | A218214 | 001 | May 11, 2026 | Oct CAHN |
| AB | | | | 0.06% (1.25GM/ACTIVATION) | A218214 | 001 | May 11, 2026 | May NEWA |
| AB | | | LONG GROVE PHARMS | 0.06% (1.25GM/ACTIVATION) | A215096 | 001 | Feb 02, 2026 | Jan NEWA |
| | | @ | PADAGIS US | 0.06% (1.25GM/ACTIVATION) | A215096 | 001 | Feb 02, 2026 | Jun DISC |
| AB | | | | 0.06% (1.25GM/ACTIVATION) | A215096 | 001 | Feb 02, 2026 | May CAHN |

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | MILLICENT MFG PR | EQ 0.05MG BASE/24HR | N021367 | 001 | Mar 20, 2003 | Jan CAHN |
| | | +! | | EQ 0.1MG BASE/24HR | N021367 | 002 | Mar 20, 2003 | Jan CAHN |

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA PRO

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | +! | BAYER HLTHCARE | 0.045MG/24HR;0.015MG/24HR | N | 021258 | 001 | Nov 21, 2003 | Oct CFTG |
| >A> | AB | +! | | 0.045MG/24HR;0.015MG/24HR | N | 021258 | 001 | Nov 21, 2003 | Oct CFTG |

>A> ESTRADIOL AND LEVONORGESTREL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | ZYDUS PHARMS | 0.045MG/24HR;0.015MG/24HR | A | 220407 | 001 | Oct 19, 2026 | Oct NFTG |

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | +! | NOVEN PHARMS INC | 0.05MG/24HR;0.14MG/24HR | N | 020870 | 001 | Aug 07, 1998 | Mar CHRS |

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | LUPIN LTD | 1MG | A | 091124 | 001 | Sep 13, 2011 | Apr DISC |
| | | @ | | 2MG | A | 091124 | 002 | Sep 13, 2011 | Apr DISC |
| | | @ | | 3MG | A | 091124 | 003 | Sep 13, 2011 | Apr DISC |

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | ! | XIROMED | 0.05MG;1MG | A | 204704 | 001 | Feb 09, 2016 | Apr CHRS |

KELNOR 1/50

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | WATSON LABS | 0.05MG;1MG | A | 072723 | 001 | Dec 30, 1991 | Apr DISC |

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM;TRANSDERMAL

TWIRLA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | +! | AGILE | 0.01MG/24HR;0.04MG/24HR | N | 204017 | 001 | Feb 14, 2020 | Jun CPOT |

TABLET;ORAL

QUARTETTE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | +! | TEVA BRANDED PHARM | 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A | N | 204061 | 001 | Mar 28, 2013 | Mar CAHN |

TABLET;ORAL-28

MYZILRA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | PH HEALTH | 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG | A | 077502 | 001 | Nov 23, 2011 | Apr DISC |

ETHINYL ESTRADIOL; NORELGESTROMIN

SYSTEM;TRANSDERMAL

GWYN LO

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | +! | VIATRIS SPECIALTY | 0.02MG/24HR;0.22MG/24HR | N | 219990 | 001 | Jul 28, 2026 | Jul NEWA |

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

GILDAGIA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | PH HEALTH | 0.035MG;0.4MG | A | 078376 | 001 | Nov 06, 2012 | Apr DISC |

TABLET, CHEWABLE;ORAL

>A> GENERESS FE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | @ + | TEVA BRANDED PHARM | 0.025MG;0.8MG | N | 022573 | 001 | Dec 22, 2010 | Oct CTNA |

>D> NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | @ + | TEVA BRANDED PHARM | 0.025MG;0.8MG | N | 022573 | 001 | Dec 22, 2010 | Oct CTNA |

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

GILDESS 24 FE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | PH HEALTH | 0.02MG;1MG | A | 090293 | 001 | Dec 01, 2014 | Apr DISC |

LO JUNEL FE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | TEVA PHARMS INC | 0.01MG,0.01MG;1MG,N/A | A | 219324 | 001 | Jun 22, 2026 | Jun NEWA |

LO LOESTRIN FE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | +! | APIL | 0.01MG,0.01MG;1MG,N/A | N | 022501 | 001 | Oct 21, 2010 | Jun CTEC |

TABLET, ORALLY DISINTEGRATING;ORAL

FEMLYV

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | +! | MILLICENT MFG PR | 0.02MG;1MG | N | 218718 | 001 | Jul 22, 2024 | Jun CAHN |

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ANNORA PHARMA | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | A220876 | 001 | Sep 23, 2026 | Sep | NEWA |

PREVIFEM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | PH HEALTH | 0.035MG;0.25MG | A076334 | 001 | Jan 09, 2004 | Apr | DISC |

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | HERITAGE PHARMS INC | 250MG | A200892 | 001 | Sep 25, 2012 | Apr | DISC |
| AB | | ONESOURCE | 250MG | A211928 | 001 | Feb 19, 2019 | Jul | CAHN |

ETODOLAC

TABLET;ORAL

ETODOLAC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA LTD | 400MG | A214872 | 001 | Jul 15, 2026 | Jul | NEWA |
| AB | | | 500MG | A214872 | 002 | Jul 15, 2026 | Jul | NEWA |
| @ | | PHARMACO | 400MG | A210704 | 001 | Dec 16, 2020 | Sep | DISC |
| @ | | | 500MG | A210704 | 002 | Dec 16, 2020 | Sep | DISC |
| @ | | PHARMAZONE | 400MG | A074839 | 001 | Jul 11, 1997 | Sep | CAHN |
| @ | | SENORES PHARMS | 400MG | A074839 | 001 | Jul 11, 1997 | Jan | CAHN |
| @ | | TP ANDA HOLDINGS | 400MG | A074819 | 001 | Feb 28, 1997 | Sep | CAHN |
| @ | | | 500MG | A074819 | 002 | Apr 28, 1998 | Sep | CAHN |

ETOPOSIDE

CAPSULE;ORAL

ETOPOSIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | MYLAN | 50MG | A075635 | 001 | Sep 19, 2001 | Jan | CTEC |

VEPESID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | ONESOURCE SPECIALTY | 50MG | N019557 | 001 | Dec 30, 1986 | Jan | CMFD |

INJECTABLE;INJECTION

ETOPOSIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | NATCO PHARMA USA | 20MG/ML | A203507 | 001 | Nov 20, 2017 | Mar | CAHN |
| @ | | | 20MG/ML | A204927 | 001 | Oct 31, 2017 | Mar | CAHN |

INJECTABLE;INTRAVENOUS

AVOPEF

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| +! | | AVYXA HOLDINGS | 100MG/5ML (20MG/ML) | N220200 | 001 | Feb 13, 2026 | Feb | NEWA |

SOLUTION;INTRAVENOUS

AVOPEF

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| +! | | AVYXA HOLDINGS | 100MG/5ML (20MG/ML) | N220200 | 001 | Feb 13, 2026 | Mar | CDFR |
| +! | | | 500MG/25ML (20MG/ML) | N220200 | 002 | Jun 24, 2026 | Jun | NEWA |

ETRAVIRINE

TABLET;ORAL

ETRAVIRINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | PHARMOBEDIENT | 100MG | A215402 | 001 | Apr 13, 2022 | Sep | CAHN |
| AB | | | 200MG | A215402 | 002 | Apr 13, 2022 | Sep | CAHN |

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | ALKEM LABS LTD | 1MG | A214138 | 004 | Nov 26, 2021 | May | CHRS |
| AB | | APOTEX | 2.5MG | A218488 | 001 | May 12, 2026 | May | NEWA |
| AB | | | 5MG | A218488 | 002 | May 12, 2026 | May | NEWA |
| AB | | | 7.5MG | A218488 | 003 | May 12, 2026 | May | NEWA |
| AB | | | 10MG | A218488 | 004 | May 12, 2026 | May | NEWA |
| AB | | EUGIA PHARMA | 0.25MG | A219533 | 001 | Feb 25, 2026 | Feb | NEWA |
| AB | | | 0.5MG | A219533 | 002 | Feb 25, 2026 | Feb | NEWA |
| AB | | | 0.75MG | A219533 | 003 | Feb 25, 2026 | Feb | NEWA |
| AB | | | 1MG | A219533 | 004 | Feb 25, 2026 | Feb | NEWA |
| AB | | I3 PHARMS | 0.25MG | A219464 | 001 | Jun 30, 2026 | Jun | NEWA |
| AB | | | 0.5MG | A219464 | 002 | Jun 30, 2026 | Jun | NEWA |
| AB | | | 0.75MG | A219464 | 003 | Jun 30, 2026 | Jun | NEWA |
| AB | | | 1MG | A219464 | 004 | Jun 30, 2026 | Jun | NEWA |
| AB | | NEOCUBES PHARMA | 2.5MG | A219955 | 001 | Oct 30, 2025 | Sep | CAHN |
| AB | | | 5MG | A219955 | 002 | Oct 30, 2025 | Sep | CAHN |
| AB | | | 7.5MG | A219955 | 003 | Oct 30, 2025 | Sep | CAHN |
| AB | | | 10MG | A219955 | 004 | Oct 30, 2025 | Sep | CAHN |
| >D> AB | | PH HEALTH | 0.25MG | A205775 | 001 | Oct 18, 2021 | Oct | DISC |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | TABLET;ORAL | | | | | | |
| | | EVEROLIMUS | | | | | | |
| >A> | | @ | 0.25MG | A205775 | 001 | Oct 18, 2021 | Oct DISC | |
| >D> | AB | | 0.5MG | A205775 | 002 | Oct 18, 2021 | Oct DISC | |
| >A> | | @ | 0.5MG | A205775 | 002 | Oct 18, 2021 | Oct DISC | |
| >D> | AB | | 0.75MG | A205775 | 003 | Oct 18, 2021 | Oct DISC | |
| >A> | | @ | 0.75MG | A205775 | 003 | Oct 18, 2021 | Oct DISC | |
| >D> | AB | | 1MG | A205775 | 004 | Oct 18, 2021 | Oct DISC | |
| >A> | | @ | 1MG | A205775 | 004 | Oct 18, 2021 | Oct DISC | |
| | | @ | 2.5MG | A207934 | 001 | Dec 09, 2019 | Jan DISC | |
| | | @ | 5MG | A207934 | 002 | Dec 09, 2019 | Jan DISC | |
| | | @ | 7.5MG | A207934 | 003 | Dec 09, 2019 | Jan DISC | |
| | | @ | 10MG | A207934 | 004 | Dec 09, 2020 | Jan DISC | |
| | AB | PHARMAZONE | 0.25MG | A219464 | 001 | Jun 30, 2026 | Sep CAHN | |
| | AB | | 0.5MG | A219464 | 002 | Jun 30, 2026 | Sep CAHN | |
| | AB | | 0.75MG | A219464 | 003 | Jun 30, 2026 | Sep CAHN | |
| | AB | | 1MG | A219464 | 004 | Jun 30, 2026 | Sep CAHN | |
| | | ZORTRESS | | | | | | |
| | AB | + NOVARTIS | 1MG | N021560 | 004 | Aug 10, 2018 | May CHRS | |
| | | TABLET, FOR SUSPENSION;ORAL | | | | | | |
| | | EVEROLIMUS | | | | | | |
| | AB | BIOCON PHARMA | 2MG | A217216 | 001 | Jan 09, 2026 | Jan NEWA | |
| | AB | | 3MG | A217216 | 002 | Jan 09, 2026 | Jan NEWA | |
| | AB | | 5MG | A217216 | 003 | Jan 09, 2026 | Jan NEWA | |
| | AB | NOVITIUM PHARMA | 2MG | A220597 | 001 | Sep 21, 2026 | Sep NEWA | |
| | AB | | 3MG | A220597 | 002 | Sep 21, 2026 | Sep NEWA | |
| | AB | | 5MG | A220597 | 003 | Sep 21, 2026 | Sep NEWA | |
| | | EXEMESTANE | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | EXEMESTANE | | | | | | |
| >D> | | @ EIRGEN | 25MG | A200898 | 001 | Jul 28, 2014 | Oct CMFD | |
| >A> | AB | | 25MG | A200898 | 001 | Jul 28, 2014 | Oct CMFD | |
| | | @ | 25MG | A200898 | 001 | Jul 28, 2014 | Jul CAHN | |
| | | EXENATIDE SYNTHETIC | | | | | | |
| | | INJECTABLE;SUBCUTANEOUS | | | | | | |
| | | EXENATIDE SYNTHETIC | | | | | | |
| | | @ AMNEAL | 300MCG/1.2ML (250MCG/ML) | A206697 | 001 | Nov 19, 2024 | Sep DISC | |
| | | @ | 600MCG/2.4ML (250MCG/ML) | A206697 | 002 | Nov 19, 2024 | Sep DISC | |
| | | EZETIMIBE | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | EZETIMIBE | | | | | | |
| | | @ WATSON LABS INC | 10MG | A200831 | 001 | Jun 12, 2017 | Aug DISC | |
| | | EZETIMIBE; SIMVASTATIN | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | EZETIMIBE AND SIMVASTATIN | | | | | | |
| | | @ WATSON LABS INC | 10MG;10MG | A202968 | 001 | Apr 26, 2017 | Feb DISC | |
| | | @ | 10MG;20MG | A202968 | 002 | Apr 26, 2017 | Feb DISC | |
| | | @ | 10MG;40MG | A202968 | 003 | Apr 26, 2017 | Feb DISC | |
| | | @ | 10MG;80MG | A202968 | 004 | Apr 26, 2017 | Feb DISC | |
| | | FAMCICLOVIR | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | FAMCICLOVIR | | | | | | |
| | | @ APOTEX | 125MG | A091480 | 001 | Jul 22, 2011 | Jul DISC | |
| | | @ | 250MG | A091480 | 002 | Jul 22, 2011 | Jul DISC | |
| | | @ | 500MG | A091480 | 003 | Jul 22, 2011 | Jul DISC | |
| | | FAMOTIDINE | | | | | | |
| | | FOR SUSPENSION;ORAL | | | | | | |
| | | FAMOTIDINE | | | | | | |
| | AB | CARNEGIE | 40MG/5ML | A217137 | 001 | Jul 07, 2023 | Feb CAHN | |
| | AB | CONTRACT PHARMACAL | 40MG/5ML | A219603 | 001 | Mar 09, 2026 | Feb NEWA | |
| | AB | PHARMAZONE | 40MG/5ML | A217605 | 001 | Jan 16, 2024 | Sep CAHN | |
| | | INJECTABLE;INJECTION | | | | | | |
| | | FAMOTIDINE | | | | | | |
| | AP | LUPIN | 10MG/ML | A217432 | 001 | May 12, 2026 | May NEWA | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | SOLUTION;INTRAVENOUS | | | | | | |
| | | FAMOTIDINE | | | | | | |
| | @ + | SAGENT | 20MG/5ML (4MG/ML) | N219935 | 001 | Jul 16, 2025 | Jul DISC |
| | @ + | | 40MG/10ML (4MG/ML) | N219935 | 002 | Jul 16, 2025 | Jul DISC |
| | @ + | | 200MG/50ML (4MG/ML) | N219935 | 003 | Jul 16, 2025 | Jul DISC |
| | | TABLET;ORAL | | | | | | |
| | | FAMOTIDINE | | | | | | |
| | AB | VKT PHARMA | 20MG | A215630 | 001 | Jan 07, 2022 | Jan CAHN |
| | AB | | 40MG | A215630 | 002 | Jan 07, 2022 | Jan CAHN |
| | | TABLET, ORALLY DISINTEGRATING;ORAL | | | | | | |
| | | PEPCID RPD | | | | | | |
| | @ + | MERCK | 20MG | N020752 | 001 | May 28, 1998 | Jun CRLD |
| | @ + | | 40MG | N020752 | 002 | May 28, 1998 | Jun CRLD |
| | | FAMOTIDINE; IBUPROFEN | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | IBUPROFEN AND FAMOTIDINE | | | | | | |
| | AB | ZYDUS LIFESCIENCES | 26.6MG;800MG | A218684 | 001 | Feb 20, 2025 | Feb CAHN |
| | | FELODIPINE | | | | | | |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| | | FELODIPINE | | | | | | |
| >D> | AB | PH HEALTH | 2.5MG | A200815 | 001 | Oct 28, 2011 | Oct DISC |
| >A> | @ | | 2.5MG | A200815 | 001 | Oct 28, 2011 | Oct DISC |
| >D> | AB | | 5MG | A200815 | 002 | Oct 28, 2011 | Oct DISC |
| >A> | @ | | 5MG | A200815 | 002 | Oct 28, 2011 | Oct DISC |
| >D> | AB | | 10MG | A200815 | 003 | Oct 28, 2011 | Oct DISC |
| >A> | @ | | 10MG | A200815 | 003 | Oct 28, 2011 | Oct DISC |
| | AB | PHARMOBEDIENT | 2.5MG | A210847 | 001 | Oct 26, 2018 | Sep CAHN |
| | AB | | 5MG | A210847 | 002 | Oct 26, 2018 | Sep CAHN |
| | AB | | 10MG | A210847 | 003 | Oct 26, 2018 | Sep CAHN |
| | | FENOFIBRATE | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | FENOFIBRATE (MICRONIZED) | | | | | | |
| | @ | INGENUS PHARMS LLC | 67MG | A207564 | 001 | Apr 19, 2019 | May CAHN |
| | @ | | 134MG | A207564 | 002 | Apr 19, 2019 | May CAHN |
| | @ | | 200MG | A207564 | 003 | Apr 19, 2019 | May CAHN |
| | @ | RHODES PHARMS | 67MG | A075753 | 001 | Sep 03, 2002 | Aug DISC |
| | @ | | 134MG | A075753 | 002 | Apr 09, 2002 | Aug DISC |
| | @ | | 200MG | A075753 | 003 | Apr 09, 2002 | Aug DISC |
| | | LIPOFEN | | | | | | |
| | @ + | CIPHER PHARMS INC | 100MG | N021612 | 002 | Jan 11, 2006 | Jan CRLD |
| | | TABLET;ORAL | | | | | | |
| | | FENOFIBRATE | | | | | | |
| | AB | MACLEODS PHARMS | 54MG | A210379 | 001 | Jan 21, 2026 | Jan NEWA |
| | AB | | 160MG | A210379 | 002 | Jan 21, 2026 | Jan NEWA |
| | | TRIGLIDE | | | | | | |
| | @ | JAGOTEC | 50MG | N021350 | 001 | May 07, 2005 | Jan CAHN |
| | @ + | | 160MG | N021350 | 002 | May 07, 2005 | Jan CAHN |
| | | FENOFIBRIC ACID | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | FIBRICOR | | | | | | |
| | @ + | ROSEMOUNT | 35MG | N022418 | 001 | Aug 14, 2009 | Mar CAHN |
| | @ + | | 105MG | N022418 | 002 | Aug 14, 2009 | Mar CAHN |
| | | FENOPROFEN CALCIUM | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | FENOPROFEN CALCIUM | | | | | | |
| | AB | MISEMER | EQ 200MG BASE | A215548 | 001 | May 16, 2023 | Sep CMFD |
| | AB | | EQ 300MG BASE | A215548 | 002 | May 16, 2023 | Jul CMFD |
| >D> | @ | | EQ 400MG BASE | A215548 | 003 | May 16, 2023 | Oct CMFD |
| >A> | AB | | EQ 400MG BASE | A215548 | 003 | May 16, 2023 | Oct CMFD |
| | AB | RISING | EQ 200MG BASE | A214475 | 002 | Jul 26, 2024 | Sep CTEC |
| | AB | | EQ 300MG BASE | A214475 | 003 | Jul 26, 2024 | Jul CTEC |
| >D> | ! | | EQ 400MG BASE | A214475 | 001 | Jul 18, 2022 | Oct CTEC |
| >A> | AB ! | | EQ 400MG BASE | A214475 | 001 | Jul 18, 2022 | Oct CTEC |

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | HIKMA | EQ 0.025MG BASE/0.5ML | N019101 | 002 | Jan 20, 2023 | Sep DISC |

FERRIC CARBOXYMALTOSE

SOLUTION;INTRAVENOUS

FERRIC CARBOXYMALTOSE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | MYLAN | 100MG IRON/2ML (50MG IRON/ML) | A217769 | 001 | Jun 25, 2026 | Jun NFTG |
| AP | | | 1GM IRON/20ML (50MG IRON/ML) | A217076 | 001 | Jun 25, 2026 | Jun NFTG |
| AP | | MYLAN LABS LTD | 750MG IRON/15ML (50MG IRON/ML) | A212572 | 001 | Jun 25, 2026 | Jun NFTG |

INJECTAFER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | AM REGENT | 750MG IRON/15ML (50MG IRON/ML) | N203565 | 001 | Jul 25, 2013 | Jun CFTG |
| AP | +! | | 100MG IRON/2ML (50MG IRON/ML) | N203565 | 004 | Feb 04, 2022 | Jun CFTG |
| | + | | 500MG IRON/10ML (50MG IRON/ML) | N203565 | 002 | Oct 08, 2020 | Aug CHRS |
| AP | + | | 1GM IRON/20ML (50MG IRON/ML) | N203565 | 003 | Apr 28, 2021 | Aug CHRS |
| AP | +! | | 1GM IRON/20ML (50MG IRON/ML) | N203565 | 003 | Apr 28, 2021 | Jun CFTG |

FERRIC CITRATE

TABLET;ORAL

AURYXIA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | KERYX BIOPHARMS | EQ 210MG IRON | N205874 | 001 | Sep 05, 2014 | Feb CFTG |

FERRIC CITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | TEVA PHARMS USA | EQ 210MG IRON | A212563 | 001 | Mar 11, 2026 | Feb NFTG |

FERRIC OXYHYDROXIDE

TABLET, CHEWABLE;ORAL

VELPHORO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | + | VIFOR FRESENIUS | EQ 250MG IRON | N205109 | 002 | Oct 13, 2026 | Oct NEWA |

FERUMOXYTOL

SOLUTION;INTRAVENOUS

FERABRIGHT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | AZURITY | EQ 300MG IRON/10ML (EQ 30MG IRON/ML) | N219868 | 001 | Oct 16, 2025 | Aug CHRS |
| | +! | | EQ 300MG IRON/10ML (EQ 30MG IRON/ML) | N219868 | 001 | Oct 16, 2025 | Jul CAHN |
| | +! | | EQ 300MG IRON/10ML (EQ 30MG IRON/ML) | N219868 | 001 | Oct 16, 2025 | Apr CAHN |
| | +! | | EQ 510MG IRON/17ML (EQ 30MG IRON/ML) | N219868 | 002 | Oct 16, 2025 | Jul CAHN |
| | +! | | EQ 510MG IRON/17ML (EQ 30MG IRON/ML) | N219868 | 002 | Oct 16, 2025 | Apr CAHN |

FERAHEME

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | AZURITY | EQ 510MG IRON/17ML (EQ 30MG IRON/ML) | N022180 | 001 | Jun 30, 2009 | Jul CAHN |
| AB | +! | | EQ 510MG IRON/17ML (EQ 30MG IRON/ML) | N022180 | 001 | Jun 30, 2009 | Apr CAHN |

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | DR REDDYS LABS LTD | 30MG | A076502 | 001 | Apr 11, 2006 | Mar DISC |
| | @ | | 60MG | A076502 | 002 | Apr 11, 2006 | Mar DISC |
| | @ | | 180MG | A076502 | 003 | Apr 11, 2006 | Mar DISC |
| | @ | RISING | 60MG | A077081 | 003 | Apr 11, 2008 | Mar DISC |
| | @ | | 180MG | A077081 | 001 | Apr 16, 2007 | Mar DISC |
| | @ | TEVA | 30MG | A076447 | 001 | Sep 01, 2005 | Mar DISC |
| | @ | | 60MG | A076447 | 002 | Sep 01, 2005 | Mar DISC |
| | @ | | 180MG | A076447 | 003 | Sep 01, 2005 | Mar DISC |

FIDAXOMICIN

TABLET;ORAL

FIDAXOMICIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | APOTEX | 200MG | A219559 | 001 | Feb 02, 2026 | Jan NEWA |
| AB | HIKMA | 200MG | A219737 | 001 | Oct 07, 2026 | Sep NEWA |
| AB | SANDOZ | 200MG | A220465 | 001 | Aug 13, 2026 | Jul NEWA |
| AB | TORRENT | 200MG | A220374 | 001 | Jan 27, 2026 | Jan NEWA |

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | FONSECA BIOSCIENCES | 0.3% | N206307 | 001 | Dec 17, 2014 | Apr CMFD |

FINERENONE

TABLET;ORAL

KERENDIA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | + | BAYER HLTHCARE | 20MG | N215341 | 002 | Jul 09, 2021 | May CHRS |
| | +! | | 40MG | N215341 | 003 | Jul 11, 2025 | May CHRS |

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ALEMBIC | EQ 0.5MG BASE | A207974 | 001 | Apr 24, 2026 | Apr NEWA |

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | MICRO LABS | 50MG | A218093 | 001 | Apr 22, 2026 | Aug CAHN |
| AB | | | 100MG | A218093 | 002 | Apr 22, 2026 | Aug CAHN |
| AB | | | 150MG | A218093 | 003 | Apr 22, 2026 | Aug CAHN |
| AB | | OMSAV PHARMA | 50MG | A218093 | 001 | Apr 22, 2026 | Apr NEWA |
| AB | | | 100MG | A218093 | 002 | Apr 22, 2026 | Apr NEWA |
| AB | | | 150MG | A218093 | 003 | Apr 22, 2026 | Apr NEWA |

FLORBETABEN F-18

SOLUTION;INTRAVENOUS

NEURACEQ

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | LANTHEUS | 1.4-135mCi/ML | N204677 | 001 | Mar 19, 2014 | Mar CAHN |

FLORETYROSINE F-18

SOLUTION;INTRAVENOUS

PIXCLARA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | TELIX | 5-300mCi/ML | N218592 | 001 | Sep 11, 2026 | Sep NEWA |

FLORQUINITAU F-18

SOLUTION;INTRAVENOUS

TAUKLARIFY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | CERVEAU LANTHEUS | 1-40mCi/ML | N220496 | 001 | Aug 13, 2026 | Aug NEWA |

FLUCONAZOLE

TABLET;ORAL

FLUCONAZOLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | ANI PHARMS | 50MG | A078423 | 001 | Mar 07, 2011 | Sep DISC |
| AB | | UNIQUE | 50MG | A076957 | 001 | Sep 28, 2005 | Mar CAHN |
| AB | | | 100MG | A076957 | 002 | Sep 28, 2005 | Mar CAHN |
| AB | | | 150MG | A076957 | 004 | Feb 27, 2017 | Mar CAHN |
| AB | | | 200MG | A076957 | 003 | Sep 28, 2005 | Mar CAHN |

FLUCYTOSINE

CAPSULE;ORAL

FLUCYTOSINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PHARMOBEDIENT | 250MG | A218005 | 001 | Jul 23, 2025 | Sep CAHN |
| AB | | | 500MG | A218005 | 002 | Jul 23, 2025 | Sep CAHN |

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | CAPLIN ONE LABS | 50MG/2ML (25MG/ML) | N022137 | 001 | Sep 21, 2007 | Jan CAHN |
| | ! | HISUN PHARM HANGZHOU | 50MG/2ML (25MG/ML) | A220196 | 001 | Jul 23, 2026 | Jul NEWA |
| | @ | PHARMAZONE | 50MG/2ML (25MG/ML) | A200647 | 001 | Dec 21, 2011 | Sep CAHN |

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | BARBARA ANN KARMANOS | 20-300mCi/ML | A204385 | 001 | Oct 29, 2014 | Sep CAHN |
| | @ | NUKEMED | 4-500mCi/ML | A203911 | 001 | Apr 22, 2015 | Apr DISC |
| | @ | PHARMALOGIC | 20-300mCi/ML | A204264 | 001 | Dec 18, 2014 | Jun DISC |

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 0.1MG | A220308 | 001 | Feb 10, 2026 | Sep | CAHN |
| AB | | HIBROW HLTHCARE | 0.1MG | A220308 | 001 | Feb 10, 2026 | Jan | NEWA |

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | HIKMA | 0.5MG/5ML (0.1MG/ML) | A076787 | 002 | Oct 12, 2004 | Mar | DISC |
| @ | | | 1MG/10ML (0.1MG/ML) | A076787 | 001 | Oct 12, 2004 | Mar | DISC |

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | COSETTE PHARMS NC | 0.01% | A089526 | 001 | Jul 26, 1988 | May | CAHN |
| @ | | | 0.025% | A089525 | 001 | Jul 26, 1988 | Jun | CAHN |
| @ | | | 0.025% | A089525 | 001 | Jul 26, 1988 | May | CAHN |
| AT | | | 0.025% | A210747 | 001 | Nov 05, 2018 | May | CAHN |

SYNALAR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | +! | EUROFARMA | 0.01% | N012787 | 004 | | Feb | CAHN |
| AT | +! | | 0.025% | N012787 | 002 | | Feb | CAHN |
| AT | +! | | 0.025% | N012787 | 005 | | Feb | CAHN |

SYNALAR-HP

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | EUROFARMA | 0.2% | N016161 | 002 | | Feb | CAHN |

IMPLANT;INTRAVITREAL

RETISERT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | | BAUSCH AND LOMB | 0.59MG | N021737 | 001 | Apr 08, 2005 | Jun | DISC |

YUTIQ

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | | ALIMERA SCIENCES INC | 0.18MG | N210331 | 001 | Oct 12, 2018 | Sep | DISC |

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | COSETTE PHARMS NC | 0.025% | A089524 | 001 | Jul 26, 1988 | May | CAHN |

SYNALAR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | +! | EUROFARMA | 0.025% | N013960 | 001 | | Feb | CAHN |

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | COSETTE PHARMS NC | 0.01% | A207441 | 001 | Sep 28, 2016 | Jun | CAHN |
| >A> AT | | ENCUBE | 0.01% | A209913 | 001 | Feb 13, 2019 | Oct | CAHN |
| >D> AT | | ENCUBE ETHICALS | 0.01% | A209913 | 001 | Feb 13, 2019 | Oct | CAHN |

SYNALAR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | +! | EUROFARMA | 0.01% | N015296 | 001 | | Feb | CAHN |

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| ! | | EUROFARMA | 0.025%;EQ 3.5MG BASE/GM | A060700 | 001 | | Feb | CAHN |

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB1 | | COSETTE PHARMS NC | 0.05% | A073085 | 001 | Feb 14, 1992 | May | CAHN |
| >D> AB1 | | ENCUBE | 0.05% | A211410 | 001 | Oct 16, 2018 | Oct | CAHN |
| >A> AB1 | | | 0.05% | A211410 | 001 | Oct 16, 2018 | Oct | CAHN |
| >D> | @ | | 0.1% | A211758 | 001 | Apr 03, 2019 | Oct | CAHN |
| >A> | @ | | 0.1% | A211758 | 001 | Apr 03, 2019 | Oct | CAHN |
| | @ | | 0.1% | A211758 | 001 | Apr 03, 2019 | May | CAHN |
| >D> AB | | ZYDUS LIFESCIENCES | 0.1% | A208989 | 001 | Feb 10, 2020 | Oct | CHRS |
| >A> AB | ! | | 0.1% | A208989 | 001 | Feb 10, 2020 | Oct | CHRS |

FLUOCINONIDE EMULSIFIED BASE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB2 | | COSETTE PHARMS NC | 0.05% | A074204 | 001 | Jun 13, 1995 | May | CAHN |

>D> VANOS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | +! | BAUSCH | 0.1% | N021758 | 001 | Feb 11, 2005 | Oct | DISC |
| >A> | @ + | | 0.1% | N021758 | 001 | Feb 11, 2005 | Oct | DISC |

GEL;TOPICAL

FLUOCINONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | COSETTE PHARMS NC | 0.05% | A072537 | 001 | Feb 07, 1989 | Jun | CAHN |

SOLUTION;TOPICAL

FLUOCINONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | COSETTE PHARMS NC | 0.05% | A071535 | 001 | Dec 02, 1988 | Jun | CAHN |

SOLUTION;TOPICAL
FLUOCINONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AT | | ENCUBE | 0.05% | A209699 | 001 | Nov 29, 2018 | Oct CAHN |
| >D> | AT | | ENCUBE ETHICALS | 0.05% | A209699 | 001 | Nov 29, 2018 | Oct CAHN |
| | AT | | SCIEGEN PHARMS | 0.05% | A207554 | 001 | Mar 18, 2019 | May CMFD |

FLUORESCEIN SODIUM
INJECTABLE;INTRAVENOUS
FLUORESCEIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | BPI LABS | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A220046 | 001 | Apr 30, 2026 | Apr NEWA |
| | | @ | NEXUS | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | A215709 | 002 | Sep 25, 2023 | May DISC |
| | | | | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | A215709 | 002 | Sep 25, 2023 | Apr CHRS |
| | AP | | ZYDUS LIFESCIENCES | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A218651 | 001 | Jun 01, 2026 | May NEWA |
| | | ! | | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | A218651 | 002 | Jun 01, 2026 | May NEWA |

FLUOROMETHOLONE
SUSPENSION/DROPS;OPHTHALMIC
FLUOROMETHOLONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | DIFGEN PHARMS | 0.1% | A218819 | 001 | Feb 12, 2026 | Jan NEWA |
| | AB | | SANDOZ | 0.1% | A218819 | 001 | Feb 12, 2026 | May CAHN |

FLUOROURACIL
CREAM;TOPICAL
FLUOROURACIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | ENCUBE | 5% | A216942 | 001 | Feb 12, 2025 | Oct CAHN |
| >A> | AB | | | 5% | A216942 | 001 | Feb 12, 2025 | Oct CAHN |

INJECTABLE;INJECTION
FLUOROURACIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | INGENUS PHARMS LLC | 500MG/10ML (50MG/ML) | A209219 | 001 | Dec 12, 2019 | May CAHN |
| | | @ | | 1GM/20ML (50MG/ML) | A209219 | 002 | Dec 12, 2019 | May CAHN |
| | | @ | | 2.5GM/50ML (50MG/ML) | A209271 | 002 | Dec 11, 2019 | May CAHN |
| | | @ | | 5GM/100ML (50MG/ML) | A209271 | 001 | Dec 11, 2019 | May CAHN |

SOLUTION;INTRAVENOUS
FAVLYXA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | AVYXA HOLDINGS | 250MG/10ML (25MG/ML) | N220201 | 001 | Feb 20, 2026 | Feb NEWA |
| | | +! | | 2.5GM/100ML (25MG/ML) | N220201 | 002 | Jul 06, 2026 | Jul NEWA |

SOLUTION;TOPICAL
FLUOROURACIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AT | | ENCUBE | 5% | A215612 | 001 | Nov 02, 2023 | Oct CAHN |
| >A> | AT | | | 5% | A215612 | 001 | Nov 02, 2023 | Oct CAHN |

FLUOXETINE HYDROCHLORIDE
CAPSULE;ORAL
FLUOXETINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | ! | AUROBINDO PHARMA | EQ 40MG BASE | A078619 | 003 | Jan 31, 2008 | May CHRS |
| | | @ | MICRO LABS | EQ 10MG BASE | A216232 | 001 | Mar 29, 2022 | Aug DISC |
| | | @ | | EQ 20MG BASE | A216232 | 002 | Mar 29, 2022 | Aug DISC |
| | | @ | | EQ 40MG BASE | A216232 | 003 | Mar 29, 2022 | Aug DISC |
| | AB1 | | PHARMAZONE | EQ 10MG BASE | A075049 | 001 | Aug 02, 2001 | Sep CAHN |
| | AB1 | | | EQ 10MG BASE | A075465 | 001 | Jan 29, 2002 | Sep CAHN |
| | AB1 | | | EQ 20MG BASE | A075049 | 002 | Jan 29, 2002 | Sep CAHN |
| | AB1 | | | EQ 20MG BASE | A075465 | 002 | Jan 29, 2002 | Sep CAHN |
| | AB | | | EQ 40MG BASE | A075049 | 003 | Jan 29, 2002 | Sep CAHN |
| | AB | | | EQ 40MG BASE | A075465 | 003 | Aug 02, 2001 | Sep CAHN |
| | AB1 | | SENORES PHARMS | EQ 10MG BASE | A075049 | 001 | Aug 02, 2001 | Feb CAHN |
| | AB1 | | | EQ 20MG BASE | A075049 | 002 | Jan 29, 2002 | Feb CAHN |
| | AB | | | EQ 40MG BASE | A075049 | 003 | Jan 29, 2002 | Feb CAHN |
| | | @ | STRIDES PHARMA INTL | EQ 10MG BASE | A076922 | 001 | Dec 16, 2004 | Jan DISC |
| | | @ | | EQ 20MG BASE | A076922 | 002 | Dec 16, 2004 | Jan DISC |
| | | @ | | EQ 40MG BASE | A076922 | 003 | Dec 16, 2004 | Jan DISC |

PROZAC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | ELI LILLY AND CO | EQ 10MG BASE | N018936 | 006 | Dec 23, 1992 | May DISC |
| | | @ + | | EQ 20MG BASE | N018936 | 001 | Dec 29, 1987 | May DISC |
| | | @ + | | EQ 40MG BASE | N018936 | 003 | Jun 15, 1999 | May DISC |

SOLUTION;ORAL
FLUOXETINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | ! | AUROBINDO PHARMA | EQ 20MG BASE/5ML | A079209 | 001 | Mar 20, 2009 | Apr CHRS |
| | | @ | PHARM ASSOC | EQ 20MG BASE/5ML | A076015 | 001 | Jan 30, 2002 | Apr DISC |

TABLET;ORAL
FLUOXETINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | EQ 60MG BASE | A209695 | 001 | Nov 20, 2017 | Sep | CAHN |
| | @ | LUPIN | EQ 60MG BASE | A211632 | 001 | Feb 08, 2019 | Mar | DISC |

FLUPHENAZINE HYDROCHLORIDE
TABLET;ORAL
FLUPHENAZINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | BRECKENRIDGE | 1MG | A216891 | 001 | Nov 15, 2022 | Feb | DISC |
| | @ | | 2.5MG | A216891 | 002 | Nov 15, 2022 | Feb | DISC |
| | @ | | 5MG | A216891 | 003 | Nov 15, 2022 | Feb | DISC |
| | @ | | 10MG | A216891 | 004 | Nov 15, 2022 | Feb | DISC |
| AB | | CHARTWELL RX | 1MG | A215141 | 001 | Oct 20, 2021 | Sep | CAHN |
| AB | | | 2.5MG | A215141 | 002 | Oct 20, 2021 | Sep | CAHN |
| AB | | | 5MG | A215141 | 003 | Oct 20, 2021 | Sep | CAHN |
| AB | | | 10MG | A215141 | 004 | Oct 20, 2021 | Sep | CAHN |
| AB | | ZAMEER PHARMS | 1MG | A215141 | 001 | Oct 20, 2021 | Jan | CAHN |
| AB | | | 2.5MG | A215141 | 002 | Oct 20, 2021 | Jan | CAHN |
| AB | | | 5MG | A215141 | 003 | Oct 20, 2021 | Jan | CAHN |
| AB | | | 10MG | A215141 | 004 | Oct 20, 2021 | Jan | CAHN |

FLURAZEPAM HYDROCHLORIDE
CAPSULE;ORAL
FLURAZEPAM HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 15MG | A071108 | 002 | Dec 08, 1986 | Sep | CAHN |
| | @ | | 30MG | A071108 | 001 | Dec 08, 1986 | Sep | CAHN |
| | @ | HIKMA INTL PHARMS | 15MG | A071108 | 002 | Dec 08, 1986 | Feb | CMS1 |

FLURBIPROFEN
TABLET;ORAL
FLURBIPROFEN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | GENUS | 100MG | A074431 | 001 | May 31, 1995 | Aug | CAHN |

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE
POWDER;INHALATION
BREO ELLIPTA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | GLAXO GRP LTD | 0.05MG/INH;EQ 0.025MG BASE/INH | N204275 | 003 | May 12, 2023 | Jan | CHRS |

FLUTICASONE PROPIONATE
AEROSOL, METERED;INHALATION
FLOVENT HFA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | GLAXO GRP LTD | 0.044MG/INH | N021433 | 003 | May 14, 2004 | Feb | CFTG |
| >D> | +! | | 0.11MG/INH | N021433 | 002 | May 14, 2004 | Oct | CFTG |
| >A> AB | +! | | 0.11MG/INH | N021433 | 002 | May 14, 2004 | Oct | CFTG |
| >D> | +! | | 0.22MG/INH | N021433 | 001 | May 14, 2004 | Oct | CFTG |
| >A> AB | +! | | 0.22MG/INH | N021433 | 001 | May 14, 2004 | Oct | CFTG |

FLUTICASONE PROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | GLENMARK SPECLT | 0.044MG/INH | A219602 | 001 | Mar 03, 2026 | Feb | NFTG |
| >A> AB | | TEVA PHARMS USA INC | 0.11MG/INH | A209917 | 001 | Nov 03, 2026 | Oct | NFTG |
| >A> AB | | | 0.22MG/INH | A209917 | 002 | Nov 03, 2026 | Oct | NFTG |

CREAM;TOPICAL
CUTIVATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | FOUGERA | 0.05% | N019958 | 001 | Dec 18, 1990 | Aug | CAHN |

FLUTICASONE PROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | 0.05% | A077055 | 001 | Jun 30, 2006 | May | CAHN |
| >D> AB | | ENCUBE | 0.05% | A076633 | 001 | May 14, 2004 | Oct | CAHN |
| >A> AB | | | 0.05% | A076633 | 001 | May 14, 2004 | Oct | CAHN |

LOTION;TOPICAL
CUTIVATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | FOUGERA | 0.05% | N021152 | 001 | Mar 31, 2005 | Aug | CAHN |

OINTMENT;TOPICAL
CUTIVATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | FOUGERA | 0.005% | N019957 | 001 | Dec 14, 1990 | Jul | CAHN |

FLUTICASONE PROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | 0.005% | A077168 | 001 | Mar 03, 2006 | May | CAHN |

SPRAY, METERED;NASAL
FLUTICASONE PROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | GLENMARK PHARMS LTD | 0.05MG/SPRAY | A219232 | 001 | Aug 18, 2026 | Aug | NEWA |
| AB | | GLENMARK SPECLT | 0.05MG/SPRAY | A219232 | 001 | Aug 18, 2026 | Aug | CAHN |

XHANCE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | PARATEK PHARMS | 0.093MG/SPRAY | N209022 | 001 | Sep 18, 2017 | May | CPOT |

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

AIRDUO RESPICLICK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | TEVA PHARM | 0.055MG/INH;EQ 0.014MG BASE/INH | N208799 | 001 | Jan 27, 2017 | Jan | CHRS |
| | +! | | 0.113MG/INH;EQ 0.014MG BASE/INH | N208799 | 002 | Jan 27, 2017 | Jan | CHRS |

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | CIPLA | 0.1MG/INH;EQ 0.05MG BASE/INH | A213087 | 001 | Jul 27, 2026 | Jul | NEWA |
| AB | | | 0.25MG/INH;EQ 0.05MG BASE/INH | A213087 | 002 | Jul 27, 2026 | Jul | NEWA |
| AB | | | 0.5MG/INH;EQ 0.05MG BASE/INH | A213087 | 003 | Jul 27, 2026 | Jul | NEWA |
| AB | | RESPIRENT PHARMS | 0.1MG/INH;EQ 0.05MG BASE/INH | A214464 | 001 | Jan 12, 2026 | Jun | CMFD |
| | @ | | 0.1MG/INH;EQ 0.05MG BASE/INH | A214464 | 001 | Jan 12, 2026 | Mar | DISC |
| AB | | | 0.1MG/INH;EQ 0.05MG BASE/INH | A214464 | 001 | Jan 12, 2026 | Jan | NEWA |
| AB | | | 0.25MG/INH;EQ 0.05MG BASE/INH | A214464 | 002 | Jan 12, 2026 | Jun | CMFD |
| | @ | | 0.25MG/INH;EQ 0.05MG BASE/INH | A214464 | 002 | Jan 12, 2026 | Mar | DISC |
| AB | | | 0.25MG/INH;EQ 0.05MG BASE/INH | A214464 | 002 | Jan 12, 2026 | Jan | NEWA |

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | APPCO | 100MG | A220328 | 001 | Apr 30, 2026 | Apr | NEWA |
| AB | | | 150MG | A220328 | 002 | Apr 30, 2026 | Apr | NEWA |
| AB | | MICRO LABS | 100MG | A220768 | 001 | Jun 23, 2026 | Jun | NEWA |
| AB | | | 150MG | A220768 | 002 | Jun 23, 2026 | Jun | NEWA |
| AB | | ZYDUS PHARMS | 100MG | A220447 | 001 | Jul 21, 2026 | Jul | NEWA |
| AB | | | 150MG | A220447 | 002 | Jul 21, 2026 | Jul | NEWA |

TABLET;ORAL

LUVOX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | ANI PHARMS | 100MG | N021519 | 003 | Dec 20, 2007 | Aug | CHRS |

FOLIC ACID

SOLUTION;ORAL

QUIOFIC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | CMP DEV LLC | 0.2MG/ML | N216395 | 001 | Jan 26, 2026 | Jan | NEWA |
| | +! | SOLUBIOMIX | 0.2MG/ML | N216395 | 001 | Jan 26, 2026 | Mar | CAHN |

TABLET;ORAL

FOLIC ACID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 1MG | A080600 | 001 | | Sep | CAHN |
| AA | + | WATSON LABS | 1MG | A080680 | 001 | | Feb | CHRS |

FONDAPARINUX SODIUM

SOLUTION;SUBCUTANEOUS

ARIXTRA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | MYLAN IRELAND LTD | 2.5MG/0.5ML (2.5MG/0.5ML) | N021345 | 001 | Dec 07, 2001 | Mar | CPOT |
| AP | +! | | 2.5MG/0.5ML | N021345 | 001 | Dec 07, 2001 | Jan | CDFR |
| AP | +! | | 5MG/0.4ML (5MG/0.4ML) | N021345 | 002 | May 28, 2004 | Mar | CPOT |
| AP | +! | | 5MG/0.4ML | N021345 | 002 | May 28, 2004 | Jan | CDFR |
| AP | +! | | 7.5MG/0.6ML (7.5MG/0.6ML) | N021345 | 003 | May 28, 2004 | Mar | CPOT |
| AP | +! | | 7.5MG/0.6ML | N021345 | 003 | May 28, 2004 | Jan | CDFR |
| AP | +! | | 10MG/0.8ML (10MG/0.8ML) | N021345 | 004 | May 28, 2004 | Mar | CPOT |
| AP | +! | | 10MG/0.8ML | N021345 | 004 | May 28, 2004 | Jan | CDFR |

FONDAPARINUX SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | BRIGHTGENE | 2.5MG/0.5ML (2.5MG/0.5ML) | A218312 | 001 | Dec 18, 2024 | Mar | CPOT |
| | @ | | 2.5MG/0.5ML | A218312 | 001 | Dec 18, 2024 | Jan | CDFR |
| AP | | DR REDDYS LABS LTD | 2.5MG/0.5ML (2.5MG/0.5ML) | A091316 | 001 | Jul 11, 2011 | Mar | CPOT |
| AP | | | 2.5MG/0.5ML | A091316 | 001 | Jul 11, 2011 | Jan | CDFR |
| AP | | | 5MG/0.4ML (5MG/0.4ML) | A091316 | 002 | Jul 11, 2011 | Mar | CPOT |
| AP | | | 5MG/0.4ML | A091316 | 002 | Jul 11, 2011 | Jan | CDFR |
| AP | | | 7.5MG/0.6ML (7.5MG/0.6ML) | A091316 | 003 | Jul 11, 2011 | Mar | CPOT |
| AP | | | 7.5MG/0.6ML | A091316 | 003 | Jul 11, 2011 | Jan | CDFR |
| AP | | | 10MG/0.8ML (10MG/0.8ML) | A091316 | 004 | Jul 11, 2011 | Mar | CPOT |
| AP | | | 10MG/0.8ML | A091316 | 004 | Jul 11, 2011 | Jan | CDFR |
| AP | | EUGIA PHARMA | 2.5MG/0.5ML (2.5MG/0.5ML) | A206918 | 001 | Dec 26, 2017 | Mar | CPOT |
| AP | | | 2.5MG/0.5ML | A206918 | 001 | Dec 26, 2017 | Jan | CDFR |
| AP | | | 5MG/0.4ML (5MG/0.4ML) | A206918 | 002 | Dec 26, 2017 | Mar | CPOT |
| AP | | | 5MG/0.4ML | A206918 | 002 | Dec 26, 2017 | Jan | CDFR |
| AP | | | 7.5MG/0.6ML (7.5MG/0.6ML) | A206918 | 003 | Dec 26, 2017 | Mar | CPOT |
| AP | | | 7.5MG/0.6ML | A206918 | 003 | Dec 26, 2017 | Jan | CDFR |
| AP | | | 10MG/0.8ML (10MG/0.8ML) | A206918 | 004 | Dec 26, 2017 | Mar | CPOT |
| AP | | | 10MG/0.8ML | A206918 | 004 | Dec 26, 2017 | Jan | CDFR |
| | @ | HANGZHOU ZHONGMEI | 2.5MG/0.5ML (2.5MG/0.5ML) | A216493 | 001 | Aug 19, 2024 | Mar | CPOT |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | SOLUTION;SUBCUTANEOUS | | | | | | |
| | FONDAPARINUX SODIUM | | | | | | |
| | @ | 2.5MG/0.5ML | A216493 | 001 | Aug 19, 2024 | Jan | CDFR |
| | @ | 5MG/0.4ML (5MG/0.4ML) | A216493 | 002 | Aug 19, 2024 | Mar | CPOT |
| | @ | 5MG/0.4ML | A216493 | 002 | Aug 19, 2024 | Jan | CDFR |
| | @ | 7.5MG/0.6ML (7.5MG/0.6ML) | A216493 | 003 | Aug 19, 2024 | Mar | CPOT |
| | @ | 7.5MG/0.6ML | A216493 | 003 | Aug 19, 2024 | Jan | CDFR |
| | @ | 10MG/0.8ML (10MG/0.8ML) | A216493 | 004 | Aug 19, 2024 | Mar | CPOT |
| | @ | 10MG/0.8ML | A216493 | 004 | Aug 19, 2024 | Jan | CDFR |
| | @ HENGRUI PHARMA | 2.5MG/0.5ML (2.5MG/0.5ML) | A206812 | 001 | May 15, 2018 | Jun | DISC |
| AP | | 2.5MG/0.5ML (2.5MG/0.5ML) | A206812 | 001 | May 15, 2018 | Mar | CPOT |
| AP | | 2.5MG/0.5ML | A206812 | 001 | May 15, 2018 | Jan | CDFR |
| | @ | 5MG/0.4ML (5MG/0.4ML) | A206812 | 002 | May 15, 2018 | Jun | DISC |
| AP | | 5MG/0.4ML (5MG/0.4ML) | A206812 | 002 | May 15, 2018 | Mar | CPOT |
| AP | | 5MG/0.4ML | A206812 | 002 | May 15, 2018 | Jan | CDFR |
| | @ | 7.5MG/0.6ML (7.5MG/0.6ML) | A206812 | 003 | May 15, 2018 | Jun | DISC |
| AP | | 7.5MG/0.6ML (7.5MG/0.6ML) | A206812 | 003 | May 15, 2018 | Mar | CPOT |
| AP | | 7.5MG/0.6ML | A206812 | 003 | May 15, 2018 | Jan | CDFR |
| | @ | 10MG/0.8ML (10MG/0.8ML) | A206812 | 004 | May 15, 2018 | Jun | DISC |
| AP | | 10MG/0.8ML (10MG/0.8ML) | A206812 | 004 | May 15, 2018 | Mar | CPOT |
| AP | | 10MG/0.8ML | A206812 | 004 | May 15, 2018 | Jan | CDFR |
| AP | SCINOPHARM TAIWAN | 2.5MG/0.5ML (2.5MG/0.5ML) | A208615 | 001 | Nov 14, 2018 | Mar | CPOT |
| AP | | 2.5MG/0.5ML | A208615 | 001 | Nov 14, 2018 | Jan | CDFR |
| AP | | 5MG/0.4ML (5MG/0.4ML) | A208615 | 002 | Nov 14, 2018 | Mar | CPOT |
| AP | | 5MG/0.4ML | A208615 | 002 | Nov 14, 2018 | Jan | CDFR |
| AP | | 7.5MG/0.6ML (7.5MG/0.6ML) | A208615 | 003 | Nov 14, 2018 | Mar | CPOT |
| AP | | 7.5MG/0.6ML | A208615 | 003 | Nov 14, 2018 | Jan | CDFR |
| AP | | 10MG/0.8ML (10MG/0.8ML) | A208615 | 004 | Nov 14, 2018 | Mar | CPOT |
| AP | | 10MG/0.8ML | A208615 | 004 | Nov 14, 2018 | Jan | CDFR |
| | FOSAPREPITANT DIMEGLUMINE | | | | | | |
| | POWDER;INTRAVENOUS | | | | | | |
| | FOSAPREPITANT DIMEGLUMINE | | | | | | |
| | @ BAXTER HLTHCARE CORP | EQ 150MG BASE/VIAL | A211860 | 001 | Sep 05, 2019 | May | DISC |
| | @ CAPLIN | EQ 150MG BASE/VIAL | A203939 | 001 | Dec 08, 2020 | Jan | CAHN |
| | @ CHARTWELL RX | EQ 150MG BASE/VIAL | A212957 | 002 | Aug 20, 2020 | Jul | CAHN |
| | @ QUAGEN | EQ 150MG BASE/VIAL | A211624 | 001 | Sep 05, 2019 | Sep | CAHN |
| | @ | EQ 150MG BASE/VIAL | A213199 | 001 | Oct 04, 2021 | Sep | CAHN |
| | NAVITRUX | | | | | | |
| | +! AVYXA HOLDINGS | EQ 150MG BASE/VIAL | N220436 | 001 | Jun 24, 2026 | Jun | NEWA |
| | FOSCARNET SODIUM | | | | | | |
| | SOLUTION;INTRAVENOUS | | | | | | |
| | FOSCARNET SODIUM | | | | | | |
| AP | CAPLIN | 6GM/250ML (24MG/ML) | A220068 | 001 | May 13, 2026 | May | NEWA |
| | FOSFOMYCIN TROMETHAMINE | | | | | | |
| | FOR SOLUTION;ORAL | | | | | | |
| | FOSFOMYCIN TROMETHAMINE | | | | | | |
| AA | AUCTA | EQ 3GM BASE/PACKET | A217772 | 001 | Apr 09, 2026 | Mar | NEWA |
| AA | NOVITIUM PHARMA | EQ 3GM BASE/PACKET | A210426 | 001 | Aug 12, 2026 | Jul | NEWA |
| | FOSTAMATINIB DISODIUM | | | | | | |
| | TABLET;ORAL | | | | | | |
| | FOSTAMATINIB DISODIUM | | | | | | |
| AB | ANNORA PHARMA | EQ 100MG BASE | A217329 | 001 | Jun 17, 2026 | Jun | NFTG |
| AB | | EQ 150MG BASE | A217329 | 002 | Jun 17, 2026 | Jun | NFTG |
| | TAVALISSE | | | | | | |
| AB | + RIGEL PHARMS | EQ 100MG BASE | N209299 | 001 | Apr 17, 2018 | Jun | CFTG |
| AB | +! | EQ 150MG BASE | N209299 | 002 | Apr 17, 2018 | Jun | CFTG |
| | FROVATRIPTAN SUCCINATE | | | | | | |
| | TABLET;ORAL | | | | | | |
| | FROVA | | | | | | |
| | @ + ENDO OPERATIONS | EQ 2.5MG BASE | N021006 | 001 | Nov 08, 2001 | Feb | DISC |
| | FROVATRIPTAN SUCCINATE | | | | | | |
| AB | ! RENATA | EQ 2.5MG BASE | A213891 | 001 | Apr 06, 2022 | Feb | CHRS |

FULVESTRANT

SOLUTION;INTRAMUSCULAR

CLIGAVYX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | AVYXA HOLDINGS | 250MG/5ML (50MG/ML) | N210063 | 001 | Aug 19, 2019 | Jun | CMFD |
| | @ | | 250MG/5ML (50MG/ML) | N210063 | 001 | Aug 19, 2019 | Apr | CTNA |

FULVESTRANT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | EUGIA PHARMA | 250MG/5ML (50MG/ML) | A215169 | 001 | Jun 30, 2023 | Mar | DISC |
| >A> AO | | SINOPEP ALLSINO | 250MG/5ML (50MG/ML) | A216722 | 001 | Oct 28, 2026 | Oct | NEWA |

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | AMNEAL PHARMS CO | 10MG/ML | A207552 | 001 | Jul 20, 2016 | Jul | DISC |
| AP | | MICRO LABS | 10MG/ML | A218188 | 001 | Jan 08, 2026 | Jan | NEWA |

SOLUTION;SUBCUTANEOUS

FUROSCIX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| +! | | SCPHARMACEUTICALS | 80MG/10ML (8MG/ML) | N209988 | 001 | Oct 07, 2022 | Jul | CAHN |

FUROSCIX READYFLOW (AUTOINJECTOR)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| +! | | SCPHARMACEUTICALS | 80MG/ML (80MG/ML) | N209988 | 002 | Jul 23, 2026 | Jul | NEWA |

FUTIBATINIB

TABLET;ORAL

LYTGOBI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | | TAIHO ONCOLOGY | 16MG | N214801 | 002 | Jul 28, 2025 | May | DISC |

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | ALLIED | 100MG | A090158 | 001 | Feb 14, 2011 | Jun | CAHN |
| @ | | | 300MG | A090158 | 002 | Feb 14, 2011 | Jun | CAHN |
| @ | | | 400MG | A090158 | 003 | Feb 14, 2011 | Jun | CAHN |
| AB | | PHARMAZONE | 100MG | A090007 | 001 | Jul 21, 2011 | Sep | CAHN |
| @ | | | 100MG | A090158 | 001 | Feb 14, 2011 | Sep | CAHN |
| AB | | | 100MG | A219319 | 001 | Aug 07, 2025 | Sep | CAHN |
| AB | | | 200MG | A219319 | 004 | May 14, 2026 | Sep | CAHN |
| AB | | | 300MG | A090007 | 002 | Jul 21, 2011 | Sep | CAHN |
| @ | | | 300MG | A090158 | 002 | Feb 14, 2011 | Sep | CAHN |
| AB | | | 300MG | A219319 | 002 | Aug 07, 2025 | Sep | CAHN |
| AB | | | 400MG | A090007 | 003 | Jul 21, 2011 | Sep | CAHN |
| @ | | | 400MG | A090158 | 003 | Feb 14, 2011 | Sep | CAHN |
| AB | | | 400MG | A219319 | 003 | Aug 07, 2025 | Sep | CAHN |
| AB | | PHARMOBEDIENT | 100MG | A217546 | 001 | May 12, 2023 | Sep | CAHN |
| AB | | | 300MG | A217546 | 002 | May 12, 2023 | Sep | CAHN |
| AB | | | 400MG | A217546 | 003 | May 12, 2023 | Sep | CAHN |
| AB | | PRINSTON | 100MG | A219814 | 001 | Mar 06, 2026 | Feb | NEWA |
| AB | | | 300MG | A219814 | 002 | Mar 06, 2026 | Feb | NEWA |
| AB | | | 400MG | A219814 | 003 | Mar 06, 2026 | Feb | NEWA |
| @ | | SENORES PHARMS | 100MG | A090158 | 001 | Feb 14, 2011 | Jul | CAHN |
| AB | | | 200MG | A219319 | 004 | May 14, 2026 | May | NEWA |
| @ | | | 300MG | A090158 | 002 | Feb 14, 2011 | Jul | CAHN |
| @ | | | 400MG | A090158 | 003 | Feb 14, 2011 | Jul | CAHN |

RELGAABI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | SCIEGEN PHARMS | 100MG | A204989 | 001 | Feb 18, 2016 | Mar | CTNA |
| AB | | | 200MG | A204989 | 004 | Mar 06, 2026 | May | CFTG |
| | | | 200MG | A204989 | 004 | Mar 06, 2026 | Mar | CTNA |
| | | | 200MG | A204989 | 004 | Mar 06, 2026 | Feb | NEWA |
| AB | | | 300MG | A204989 | 002 | Feb 18, 2016 | Mar | CTNA |
| AB | | | 400MG | A204989 | 003 | Feb 18, 2016 | Mar | CTNA |

SOLUTION;ORAL

GABAPENTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AA | | ACELLA PHARMS LLC | 250MG/5ML | A076403 | 001 | May 01, 2012 | Oct | CHRS |
| >A> AA | ! | | 250MG/5ML | A076403 | 001 | May 01, 2012 | Oct | CHRS |

NEURONTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AA | +! | VIATRIS | 250MG/5ML | N021129 | 001 | Mar 02, 2000 | Oct | CHRS |
| >A> AA | + | | 250MG/5ML | N021129 | 001 | Mar 02, 2000 | Oct | CHRS |

TABLET;ORAL

GABAPENTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB2 | | ABON PHARMS LLC | 600MG | A203643 | 001 | Sep 09, 2024 | Sep | CAHN |
| AB2 | | ACTAVIS ELIZABETH | 300MG | A203611 | 001 | Jun 23, 2026 | Jun | NEWA |
| AB2 | | | 600MG | A203611 | 002 | Jun 23, 2026 | Jun | NEWA |
| AB2 | | EPIC PHARMA LLC | 300MG | A216252 | 001 | Feb 26, 2024 | May | CAHN |

TABLET;ORAL
GABAPENTIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB2 | | 600MG | A216252 | 002 | Feb 26, 2024 | | May CAHN |
| AB2 | MLV | 600MG | A203643 | 001 | Sep 09, 2024 | | Sep CAHN |
| @ | PHARMAZONE | 600MG | A076877 | 001 | Jul 06, 2006 | | Sep CAHN |
| @ | | 800MG | A076877 | 002 | Jul 06, 2006 | | Sep CAHN |
| AB1 | PHARMOBEDIENT | 600MG | A217965 | 001 | Apr 08, 2024 | | Sep CAHN |
| AB1 | | 800MG | A217965 | 002 | Apr 08, 2024 | | Sep CAHN |

GADOBUTROL
SOLUTION;INTRAVENOUS
GADOBUTROL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | HENGRUI PHARMA | 1.20944GM/2ML (604.72MG/ML) | A216081 | 003 | Nov 17, 2022 | | Jun DISC |
| @ | | 4.5354GM/7.5ML (604.72MG/ML) | A216081 | 004 | Nov 17, 2022 | | Jun DISC |
| @ | | 6.0472GM/10ML (604.72MG/ML) | A216081 | 005 | Nov 17, 2022 | | Jun DISC |
| @ | | 9.0708GM/15ML (604.72MG/ML) | A216081 | 006 | Nov 17, 2022 | | Jun DISC |
| AP | VIWIT PHARM | 4.5354GM/7.5ML (604.72MG/ML) | A219287 | 001 | Jun 11, 2026 | | Jun NEWA |
| AP | | 6.0472GM/10ML (604.72MG/ML) | A219287 | 002 | Jun 11, 2026 | | Jun NEWA |
| AP | | 9.0708GM/15ML (604.72MG/ML) | A219287 | 003 | Jun 11, 2026 | | Jun NEWA |
| AP | ZENARA | 1.20944GM/2ML (604.72MG/ML) | A219146 | 001 | Jun 08, 2026 | | May NEWA |
| AP | | 4.5354GM/7.5ML (604.72MG/ML) | A219146 | 002 | Jun 08, 2026 | | May NEWA |
| AP | | 6.0472GM/10ML (604.72MG/ML) | A219146 | 003 | Jun 08, 2026 | | May NEWA |
| AP | | 9.0708GM/15ML (604.72MG/ML) | A219146 | 004 | Jun 08, 2026 | | May NEWA |
| AP | | 18.1416GM/30ML (604.72MG/ML) | A219146 | 005 | Jun 08, 2026 | | May NEWA |
| AP | | 39.3068GM/65ML (604.72MG/ML) | A219146 | 006 | Jun 08, 2026 | | May NEWA |

PIXXOSCAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | GE HLTHCARE | 1.20944GM/2ML (604.72MG/ML) | A215957 | 001 | Jun 29, 2026 | | Jun NEWA |
| AP | | 4.5354GM/7.5ML (604.72MG/ML) | A215957 | 002 | Jun 29, 2026 | | Jun NEWA |
| AP | | 6.0472GM/10ML (604.72MG/ML) | A215957 | 003 | Jun 29, 2026 | | Jun NEWA |
| AP | | 9.0708GM/15ML (604.72MG/ML) | A215957 | 004 | Jun 29, 2026 | | Jun NEWA |

GADOQUATRANE
SOLUTION;INTRAVENOUS
AMBELVIST

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | BAYER HEALTHCARE | 0.5158GM/2ML (257.9MG/ML) | N219627 | 001 | Jun 12, 2026 | | Jun NEWA |
| +! | | 1.93425GM/7.5ML (257.9MG/ML) | N219627 | 002 | Jun 12, 2026 | | Jun NEWA |
| +! | | 2.579GM/10ML (257.9MG/ML) | N219627 | 003 | Jun 12, 2026 | | Jun NEWA |
| +! | | 3.8685GM/15ML (257.9MG/ML) | N219627 | 004 | Jun 12, 2026 | | Jun NEWA |
| +! | | 7.737GM/30ML (257.9MG/ML) | N219627 | 005 | Jun 12, 2026 | | Jun NEWA |
| +! | | 16.7635GM/65ML (257.9MG/ML) | N219627 | 006 | Jun 12, 2026 | | Jun NEWA |

GADOTERATE MEGLUMINE
SOLUTION;INTRAVENOUS
GADOTERATE MEGLUMINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | VIWIT PHARM | 3.769GM/10ML (376.9MG/ML) | A219286 | 001 | Aug 10, 2026 | | Jul NEWA |
| AP | | 5.6535GM/15ML (376.9MG/ML) | A219286 | 002 | Aug 10, 2026 | | Jul NEWA |
| AP | | 7.538GM/20ML (376.9MG/ML) | A219286 | 003 | Aug 10, 2026 | | Jul NEWA |

GALANTAMINE HYDROBROMIDE
TABLET;ORAL
GALANTAMINE HYDROBROMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | PHARMAZONE | EQ 4MG BASE | A077593 | 001 | Sep 11, 2008 | | Sep CAHN |
| AB | | EQ 8MG BASE | A077593 | 002 | Sep 11, 2008 | | Sep CAHN |
| AB | | EQ 12MG BASE | A077593 | 003 | Sep 11, 2008 | | Sep CAHN |
| AB | SENORES PHARMS | EQ 4MG BASE | A077593 | 001 | Sep 11, 2008 | | Jan CAHN |
| AB | | EQ 8MG BASE | A077593 | 002 | Sep 11, 2008 | | Jan CAHN |
| AB | | EQ 12MG BASE | A077593 | 003 | Sep 11, 2008 | | Jan CAHN |

GALLIUM DOTATATE GA-68
POWDER;INTRAVENOUS
NETSPOT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | NOVARTIS | 2.1-5.5mCi/ML | N208547 | 001 | Jun 01, 2016 | | Jun CAHN |

GALLIUM GA-68 GOZETOTIDE
SOLUTION;INTRAVENOUS
GALLIUM GA 68 GOZETOTIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | RADIOMEDIX | 0.5-5mCi/ML | A216410 | 001 | Jun 08, 2026 | | May NEWA |
| AP +! | UNIV OF CA SAN FRAN | 0.5-5mCi/mL | N212643 | 001 | Dec 01, 2020 | | May CFTG |

GALLIUM GA-68 GOZETOTIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | IONETIX | 0.5-5mCi/mL | A219189 | 001 | May 14, 2026 | | May NFTG |

GANAXOLONE

SUSPENSION;ORAL

ZTALMY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | IMMEDICA PHARMA | 50MG/ML | N215904 | 001 | Jun 01, 2022 | Mar | CAHN |

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

GANCICLOVIR SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | HAINAN POLY | EQ 500MG BASE/VIAL | A204204 | 001 | Nov 08, 2018 | Jul | CAHN |

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | TRIS PHARMA INC | 250MCG/0.5ML | A219454 | 001 | Jun 27, 2025 | Mar | DISC |

GEDATOLISIB

POWDER;INTRAVENOUS

REVTORPYK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | CELCUITY | 180MG/VIAL | N219908 | 001 | Jul 14, 2026 | Jul | NEWA |

GEFITINIB

TABLET;ORAL

GEFITINIB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | APOTEX | 250MG | A209532 | 001 | Sep 23, 2022 | Jan | DISC |
| | @ | CIPLA | 250MG | A211826 | 001 | May 16, 2025 | Apr | DISC |

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ADAPTIS | EQ 200MG BASE/VIAL | A207575 | 001 | Feb 22, 2019 | Aug | CAHN |
| AP | | | 200MG/5.26ML (38MG/ML) | A210991 | 001 | Oct 04, 2019 | Aug | CAHN |
| AP | | | EQ 1GM BASE/VIAL | A207575 | 002 | Feb 22, 2019 | Aug | CAHN |
| AP | | | 1GM/26.3ML (38MG/ML) | A210991 | 002 | Oct 04, 2019 | Aug | CAHN |
| AP | | | 2GM/52.6ML (38MG/ML) | A210991 | 003 | Oct 04, 2019 | Aug | CAHN |
| | @ | INGENUS PHARMS LLC | 200MG/5.26ML (38MG/ML) | A210383 | 001 | Feb 14, 2019 | May | CAHN |
| | @ | | 1GM/26.3ML (38MG/ML) | A210383 | 002 | Feb 14, 2019 | May | CAHN |
| | @ | | 2GM/52.6ML (38MG/ML) | A210383 | 003 | Feb 14, 2019 | May | CAHN |
| | @ | NOVAST LABS | 200MG/5.26ML (38MG/ML) | A210383 | 001 | Feb 14, 2019 | Feb | DISC |
| | @ | | 1GM/26.3ML (38MG/ML) | A210383 | 002 | Feb 14, 2019 | Feb | DISC |
| | @ | | 2GM/52.6ML (38MG/ML) | A210383 | 003 | Feb 14, 2019 | Feb | DISC |

SOLUTION;INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | ACCORD HLTHCARE | 1GM/10ML (100MG/ML) | N209604 | 002 | Aug 03, 2017 | May | DISC |
| | @ + | | 1.5GM/15ML (100MG/ML) | N209604 | 003 | Aug 03, 2017 | May | DISC |
| | @ + | | 2GM/20ML (100MG/ML) | N209604 | 004 | Aug 03, 2017 | May | DISC |
| | @ + | | 200MG/2ML (100MG/ML) | N209604 | 001 | Aug 03, 2017 | May | DISC |

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | COSETTE PHARMS NC | EQ 0.1% BASE | A064056 | 001 | Apr 29, 1994 | May | CAHN |

OINTMENT;OPHTHALMIC

GENTAMICIN SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | SCIEGEN PHARMS | EQ 0.3% BASE | A065024 | 001 | Jul 30, 2004 | Sep | CAHN |

OINTMENT;TOPICAL

GENTAMICIN SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | COSETTE PHARMS NC | EQ 0.1% BASE | A064054 | 001 | Apr 29, 1994 | May | CAHN |
| >D> | @ | ENCUBE | EQ 0.1% BASE | A209233 | 001 | Dec 31, 2018 | Oct | CMFD |
| >A> AT | | | EQ 0.1% BASE | A209233 | 001 | Dec 31, 2018 | Oct | CMFD |
| >A> AT | | | EQ 0.1% BASE | A209233 | 001 | Dec 31, 2018 | Oct | CAHN |

SOLUTION/DROPS;OPHTHALMIC

GENTAMICIN SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | BAUSCH AND LOMB INC | EQ 0.3% BASE | A064048 | 001 | May 11, 1994 | May | CAHN |
| | @ | PADAGIS US | EQ 0.3% BASE | A065121 | 001 | Jan 30, 2004 | Mar | DISC |

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

GLATIRAMER ACETATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | HYBIO | 20MG/ML | A213382 | 001 | Feb 11, 2026 | Jan NEWA |
| AP | | | 40MG/ML | A214022 | 001 | Feb 11, 2026 | Jan NEWA |
| AP | | SYNTHON BV | 20MG/ML | A203857 | 001 | Sep 25, 2024 | Jun CAHN |
| AP | | | 40MG/ML | A206873 | 001 | Sep 25, 2024 | Jun CAHN |

GLECAPREVIR; PIBRENTASVIR

PELLETS;ORAL

MAVYRET

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | ABBVIE | 50MG/PACKET;20MG/PACKET | N215110 | 001 | Jun 10, 2021 | Mar CPOT |

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PHARMAZONE | 1MG | A076802 | 001 | Oct 06, 2005 | Sep CAHN |
| | @ | | 2MG | A076802 | 002 | Oct 06, 2005 | Sep CAHN |
| | @ | | 4MG | A076802 | 003 | Oct 06, 2005 | Sep CAHN |

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AIPING PHARM INC | 2.5MG | A074305 | 003 | Sep 23, 2026 | Sep NEWA |
| AB | | | 5MG | A074305 | 001 | Apr 07, 1995 | Jul CMFD |
| AB | | | 10MG | A074305 | 002 | Apr 07, 1995 | Jul CMFD |
| AB | | GRAVITI PHARMS | 5MG | A219159 | 001 | Mar 04, 2026 | Feb NEWA |
| AB | | | 10MG | A219159 | 002 | Mar 04, 2026 | Feb NEWA |
| AB | | RUBICON RESEARCH | 2.5MG | A214874 | 001 | Oct 03, 2023 | Sep CTEC |
| | ! | | 15MG | A214874 | 004 | Feb 04, 2026 | Jan NFTG |

GLUCAGON

SOLUTION;INTRAVENOUS

GVOKE VIALDX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | XERIS | 1MG/0.2ML (1MG/0.2ML) | N212097 | 006 | Mar 14, 2025 | May DISC |

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | IMPAX | 1.25MG;250MG | A076345 | 001 | Feb 18, 2004 | Mar CAHN |
| AB | | | 2.5MG;500MG | A076345 | 002 | Feb 18, 2004 | Mar CAHN |
| AB | | | 5MG;500MG | A076345 | 003 | Feb 18, 2004 | Mar CAHN |

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

GLYCEROL PHENYLBUTYRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | AUROBINDO PHARMA | 1.1GM/ML | A220313 | 001 | Apr 15, 2026 | Apr NEWA |
| AA | | ESJAY PHARMA | 1.1GM/ML | A220579 | 001 | Jul 28, 2026 | Jul NEWA |
| AA | | LUPIN | 1.1GM/ML | A207694 | 001 | Apr 30, 2026 | Apr NEWA |
| AA | | MSN | 1.1GM/ML | A219540 | 001 | Apr 15, 2026 | Apr NEWA |
| AA | | NAVINTA LLC | 1.1GM/ML | A220568 | 001 | Apr 23, 2026 | Apr NEWA |
| AA | | PAI HOLDINGS | 1.1GM/ML | A220579 | 001 | Jul 28, 2026 | Aug CAHN |
| AA | | TEVA PHARMS INC | 1.1GM/ML | A218738 | 001 | Apr 15, 2026 | Apr NEWA |

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | NIVAGEN | 0.2MG/ML | A212591 | 001 | Oct 13, 2021 | Aug CAHN |
| AP | | NIVAGEN PHARMS INC | 0.2MG/ML | A212591 | 001 | Oct 13, 2021 | Apr CAHN |

SOLUTION;ORAL

GLYCOPYRROLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | COHANCE LIFESCIENCES | 1MG/5ML | A212467 | 001 | Jul 05, 2022 | Sep CAHN |
| AA | | QUAGEN | 1MG/5ML | A216910 | 001 | May 18, 2026 | May NEWA |

TABLET;ORAL

GLYCOPYRROLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 1MG | A040836 | 001 | Mar 05, 2009 | Sep CAHN |
| | @ | | 2MG | A040836 | 002 | Mar 05, 2009 | Sep CAHN |
| AA | | TP ANDA HOLDINGS | 1MG | A090020 | 001 | Oct 19, 2011 | Sep CAHN |
| AA | | | 2MG | A090020 | 002 | Oct 19, 2011 | Sep CAHN |

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

PREVDUO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | AZURITY | 0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML) | N216903 | 001 | Feb 23, 2023 | Jun DISC |

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

GLYCOPYRRONIUM TOSYLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | PADAGIS US | EQ 2.4% BASE | A214448 | 001 | Apr 03, 2026 | Apr DISC |
| AB | | | EQ 2.4% BASE | A214448 | 001 | Apr 03, 2026 | Mar NFTG |

QBREXZA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | JOURNEY | EQ 2.4% BASE | N210361 | 001 | Jun 28, 2018 | Apr CTEC |
| AB | +! | | EQ 2.4% BASE | N210361 | 001 | Jun 28, 2018 | Mar CFTG |

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | ! | BAUSCH AND LOMB INC | 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML | A064047 | 001 | Jan 31, 1996 | May CAHN |

NEOSPORIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | MONARCH PHARMS | 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML | A060582 | 001 | | Jan DISC |

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | APOTEX | 3.1MG/24HR | N022198 | 001 | Sep 12, 2008 | Jul CAHN |

INJECTABLE;SUBCUTANEOUS

SUSTOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | HERON THERAPS INC | 10MG/0.4ML (10MG/0.4ML) | N022445 | 001 | Aug 09, 2016 | Sep DISC |

GRANISETRON HYDROCHLORIDE

SOLUTION;ORAL

GRANISETRON HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | PHARMOBEDIENT | EQ 2MG BASE/10ML | A219282 | 001 | Mar 17, 2025 | Sep CAHN |

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | 125MG/5ML | A065438 | 001 | Oct 08, 2010 | May CAHN |

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ASCENT PHARMS INC | EQ 1MG BASE | A220675 | 001 | Mar 24, 2026 | Mar NEWA |
| AB | | | EQ 2MG BASE | A220675 | 002 | Mar 24, 2026 | Mar NEWA |
| AB | | PHARMAZONE | EQ 1MG BASE | A216828 | 001 | Oct 05, 2023 | Sep CAHN |
| AB | | | EQ 2MG BASE | A216828 | 002 | Oct 05, 2023 | Sep CAHN |
| AB | | RUBICON RESEARCH | EQ 1MG BASE | A216762 | 001 | Oct 17, 2023 | Mar CTEC |
| AB | | | EQ 2MG BASE | A216762 | 002 | Oct 17, 2023 | Mar CTEC |

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | | TWI PHARMS | EQ 1MG BASE | A201408 | 001 | Jun 02, 2015 | Oct DISC |
| >A> | @ | | EQ 1MG BASE | A201408 | 001 | Jun 02, 2015 | Oct DISC |
| >D> AB | | | EQ 2MG BASE | A201408 | 002 | Jun 02, 2015 | Oct DISC |
| >A> | @ | | EQ 2MG BASE | A201408 | 002 | Jun 02, 2015 | Oct DISC |
| >D> AB | | | EQ 3MG BASE | A201408 | 003 | Jun 02, 2015 | Oct DISC |
| >A> | @ | | EQ 3MG BASE | A201408 | 003 | Jun 02, 2015 | Oct DISC |
| >D> AB | | | EQ 4MG BASE | A201408 | 004 | Jun 02, 2015 | Oct DISC |
| >A> | @ | | EQ 4MG BASE | A201408 | 004 | Jun 02, 2015 | Oct DISC |

HALCINONIDE

SOLUTION;TOPICAL

HALCINONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AT | ! | ENCUBE | 0.1% | A217671 | 001 | May 29, 2024 | Oct CAHN |
| >A> AT | ! | | 0.1% | A217671 | 001 | May 29, 2024 | Oct CAHN |

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

HALOBETASOL PROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | PADAGIS ISRAEL | 0.05% | A215266 | 001 | Aug 11, 2023 | Feb | CTEC |
| AB | ! | | 0.05% | A215266 | 001 | Aug 11, 2023 | Feb | CHRS |

LEXETTE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | MAYNE PHARMA | 0.05% | N210566 | 001 | May 24, 2018 | Feb | DISC |

CREAM;TOPICAL

HALOBETASOL PROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | COSETTE PHARMS NC | 0.05% | A078162 | 001 | Apr 24, 2007 | May | CAHN |

LOTION;TOPICAL

ULTRAVATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | LACER PHARMA | 0.05% | N208183 | 001 | Nov 06, 2015 | Aug | CMFD |
| | @ + | | 0.05% | N208183 | 001 | Nov 06, 2015 | Aug | DISC |

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | 0.05% | A077109 | 001 | Jun 14, 2005 | May | CAHN |
| | @ | | 0.05% | A077721 | 001 | Sep 07, 2006 | Jun | CAHN |
| >D> AB | | ENCUBE | 0.05% | A209978 | 001 | Mar 20, 2018 | Oct | CAHN |
| >A> AB | | | 0.05% | A209978 | 001 | Mar 20, 2018 | Oct | CAHN |
| AB | | | 0.05% | A209978 | 001 | Mar 20, 2018 | Jun | CMFD |

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AIPING PHARM INC | 0.5MG | A071130 | 004 | Apr 08, 2026 | Mar | NEWA |
| AB | | | 1MG | A071130 | 005 | Apr 08, 2026 | Mar | NEWA |
| AB | | | 20MG | A071130 | 006 | Apr 08, 2026 | Mar | NEWA |
| AB | | AJANTA PHARMA LTD | 0.5MG | A218210 | 001 | Sep 14, 2026 | Sep | NEWA |
| AB | | | 1MG | A218210 | 002 | Sep 14, 2026 | Sep | NEWA |
| AB | | | 2MG | A218210 | 003 | Sep 14, 2026 | Sep | NEWA |
| AB | | | 5MG | A218210 | 004 | Sep 14, 2026 | Sep | NEWA |
| AB | | | 10MG | A218210 | 005 | Sep 14, 2026 | Sep | NEWA |
| AB | | | 20MG | A218210 | 006 | Sep 14, 2026 | Sep | NEWA |
| AB | | ALEMBIC | 1MG | A214470 | 001 | Jun 04, 2026 | May | NEWA |
| AB | | | 2MG | A214470 | 002 | Jun 04, 2026 | May | NEWA |
| AB | | | 5MG | A214470 | 003 | Jun 04, 2026 | May | NEWA |
| AB | | | 10MG | A214470 | 004 | Jun 04, 2026 | May | NEWA |
| AB | | | 20MG | A214470 | 005 | Jun 04, 2026 | May | NEWA |
| AB | | MYLAN | 2MG | A070278 | 001 | Jun 10, 1986 | Jul | CHRS |
| | @ | | 10MG | A070278 | 002 | Jul 16, 2009 | Aug | DISC |
| | @ | | 20MG | A070278 | 003 | Jul 16, 2009 | Apr | DISC |
| AB | | SCIEGEN PHARMS | 0.5MG | A071173 | 002 | Jan 02, 1987 | Sep | CAHN |
| AB | | | 1MG | A071173 | 003 | Jan 02, 1987 | Sep | CAHN |
| AB | | | 2MG | A071173 | 004 | Jan 02, 1987 | Sep | CAHN |
| AB | | | 5MG | A071173 | 005 | Jan 07, 1988 | Sep | CAHN |
| AB | | | 10MG | A071173 | 001 | Jan 07, 1988 | Sep | CAHN |
| AB | | | 20MG | A071173 | 006 | Jan 07, 1988 | Sep | CAHN |
| AB | ! | ZYDUS PHARMS USA | 2MG | A077580 | 006 | Jan 17, 2023 | Jul | CHRS |

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 5,000 UNITS/0.5ML | N017037 | 013 | Apr 07, 1986 | Sep | DISC |

HEPARIN SODIUM PRESERVATIVE FREE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | PFIZER | 1,000 UNITS/ML | N201370 | 004 | Jul 21, 2011 | Feb | CMFD |

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | APOZEAL PHARMS | 1.5MG/5ML;5MG/5ML | A204765 | 001 | Mar 06, 2017 | Jul | CAHN |
| | @ | PADAGIS US | 1.5MG/5ML;5MG/5ML | A205731 | 001 | Feb 15, 2017 | Mar | DISC |
| | @ | PAI HOLDINGS | 1.5MG/5ML;5MG/5ML | A040613 | 001 | Feb 08, 2008 | Sep | CAHN |
| | @ | PHARMAZONE | 1.5MG/5ML;5MG/5ML | A204765 | 001 | Mar 06, 2017 | Sep | CAHN |
| | @ | PHARMOBEDIENT | 1.5MG/5ML;5MG/5ML | A088008 | 001 | Mar 03, 1983 | Jun | DISC |

TABLET;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | PHARMAZONE | 1.5MG;5MG | A220509 | 001 | Sep 22, 2026 | Sep | CAHN |
| AA | | SENORES PHARMS | 1.5MG;5MG | A220509 | 001 | Sep 22, 2026 | Sep | NEWA |

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AP | | EMERGE BIOSCIENCE | 20MG/ML | A217501 | 001 | Jun 02, 2025 | Oct CAHN |
| >D> | AP | | KINDOS | 20MG/ML | A217501 | 001 | Jun 02, 2025 | Oct CAHN |

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | HERITAGE | 10MG | A086242 | 001 | Feb 04, 2010 | Mar DISC |
| | | @ | | 25MG | A086242 | 003 | | Mar DISC |
| | | @ | | 50MG | A086242 | 002 | | Mar DISC |
| | | @ | | 100MG | A086242 | 004 | Feb 04, 2010 | Mar DISC |
| | | @ | STRIDES PHARMA INTL | 10MG | A087836 | 001 | Oct 05, 1982 | Jan DISC |
| | | @ | | 25MG | A086961 | 002 | | Jan DISC |
| | | @ | | 50MG | A086962 | 001 | | Jan DISC |
| | | @ | | 100MG | A088391 | 001 | Sep 27, 1983 | Jan DISC |

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | STRIDES PHARMA INTL | 25MG;25MG | A088957 | 001 | Oct 21, 1985 | Jan DISC |
| | | @ | | 50MG;50MG | A088946 | 001 | Oct 21, 1985 | Jan DISC |

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | INGENUS PHARMS LLC | 37.5MG;20MG | A215586 | 001 | Apr 06, 2022 | Feb CAHN |
| | AB | | PHARMAZONE | 37.5MG;20MG | A215988 | 001 | Jan 17, 2024 | Sep CAHN |

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | HIKMA | 12.5MG | A077885 | 001 | Nov 26, 2007 | Sep CAHN |

SOLUTION;ORAL

HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | ! | RUBICON RESEARCH | 50MG/5ML | A218248 | 001 | Oct 07, 2026 | Sep NEWA |

TABLET;ORAL

HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | HIKMA | 25MG | A084878 | 002 | Jul 12, 2006 | Sep CAHN |
| | | @ | | 50MG | A084878 | 001 | | Sep CAHN |
| | | @ | TP ANDA HOLDINGS | 100MG | A087060 | 001 | | Sep CAHN |

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | CHARTWELL RX | 12.5MG;150MG | A201524 | 001 | Feb 27, 2013 | Apr CAHN |
| | | @ | | 12.5MG;300MG | A201524 | 002 | Feb 27, 2013 | Apr CAHN |
| | | @ | HIKMA | 12.5MG;150MG | A090351 | 001 | Oct 15, 2012 | Jun DISC |
| | | @ | | 12.5MG;300MG | A090351 | 002 | Oct 15, 2012 | Jun DISC |
| | | @ | | 25MG;300MG | A090351 | 003 | Jun 08, 2017 | Jun DISC |

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | HIKMA | 12.5MG;10MG | A076265 | 001 | Jul 08, 2002 | Sep CAHN |
| | | @ | | 12.5MG;20MG | A076265 | 002 | Jul 08, 2002 | Sep CAHN |
| | | @ | | 25MG;20MG | A076265 | 003 | Jul 08, 2002 | Sep CAHN |
| | AB | | MACLEODS PHARMS | 12.5MG;10MG | A076674 | 001 | Oct 05, 2004 | Sep CAHN |
| | AB | | | 12.5MG;20MG | A076674 | 002 | Oct 05, 2004 | Sep CAHN |
| | AB | | | 25MG;20MG | A076674 | 003 | Oct 05, 2004 | Sep CAHN |

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | HETERO LABS LTD V | 12.5MG;50MG | A219869 | 001 | May 27, 2026 | May NEWA |
| | AB | | | 12.5MG;100MG | A219869 | 002 | May 27, 2026 | May NEWA |
| | AB | | | 25MG;100MG | A219869 | 003 | May 27, 2026 | May NEWA |

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | STRIDES PHARMA INTL | 15MG;250MG | A070614 | 002 | Feb 02, 1987 | Jan | CMS1 |
| | @ | | 25MG;250MG | A070614 | 003 | Feb 02, 1987 | Jan | CMS1 |
| | @ | | 30MG;500MG | A070614 | 004 | Feb 02, 1987 | Jan | CMS1 |

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ALEMBIC | 25MG;100MG | A202870 | 002 | Nov 06, 2013 | Feb | CHRS |
| AB | ! | MYLAN | 50MG;100MG | A076792 | 003 | Aug 20, 2004 | Feb | CHRS |
| AB | | PHARMAZONE | 25MG;50MG | A215789 | 001 | Jan 08, 2025 | Sep | CAHN |
| AB | | | 25MG;100MG | A215789 | 002 | Jan 08, 2025 | Sep | CAHN |

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | MICRO LABS | 12.5MG;20MG | A206371 | 001 | Apr 13, 2026 | Apr | NEWA |
| AB | | | 12.5MG;40MG | A206371 | 002 | Apr 13, 2026 | Apr | NEWA |
| AB | | | 25MG;40MG | A206371 | 003 | Apr 13, 2026 | Apr | NEWA |
| AB | | PHARMAZONE | 12.5MG;20MG | A208847 | 001 | Sep 17, 2019 | Sep | CAHN |
| AB | | | 12.5MG;40MG | A208847 | 003 | Sep 17, 2019 | Sep | CAHN |
| AB | | | 25MG;40MG | A208847 | 002 | Sep 17, 2019 | Sep | CAHN |
| AB | | SCIEGEN PHARMS | 12.5MG;20MG | A208465 | 001 | Mar 31, 2026 | Mar | NEWA |
| AB | | | 12.5MG;40MG | A208465 | 002 | Mar 31, 2026 | Mar | NEWA |
| AB | | | 25MG;40MG | A208465 | 003 | Mar 31, 2026 | Mar | NEWA |

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | RUBICON RESEARCH | 25MG;25MG | A220884 | 001 | Sep 10, 2026 | Aug | NEWA |

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | LUPIN | 12.5MG;40MG | A091351 | 001 | Aug 07, 2014 | Jun | DISC |
| | @ | | 12.5MG;80MG | A091351 | 002 | Aug 07, 2014 | Jun | DISC |
| | @ | | 25MG;80MG | A091351 | 003 | Aug 07, 2014 | Jun | DISC |

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | LUPIN LTD | 12.5MG;80MG | A078946 | 003 | Mar 21, 2013 | May | DISC |
| | @ | | 12.5MG;160MG | A078946 | 004 | Mar 21, 2013 | May | DISC |
| | @ | | 12.5MG;320MG | A078946 | 001 | Mar 21, 2013 | May | DISC |
| | @ | | 25MG;160MG | A078946 | 005 | Mar 21, 2013 | May | DISC |
| | @ | | 25MG;320MG | A078946 | 002 | Mar 21, 2013 | May | DISC |
| AB | | SCIEGEN PHARMS | 12.5MG;80MG | A204687 | 001 | Apr 23, 2026 | Apr | NEWA |
| AB | | | 12.5MG;160MG | A204687 | 002 | Apr 23, 2026 | Apr | NEWA |
| AB | | | 12.5MG;320MG | A204687 | 003 | Apr 23, 2026 | Apr | NEWA |
| AB | | | 25MG;160MG | A204687 | 004 | Apr 23, 2026 | Apr | NEWA |
| AB | | | 25MG;320MG | A204687 | 005 | Apr 23, 2026 | Apr | NEWA |

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA ER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | KNOA PHARMA | 20MG | N206627 | 001 | Nov 20, 2014 | May | CAHN |
| AB | + | | 30MG | N206627 | 002 | Nov 20, 2014 | May | CAHN |
| AB | + | | 40MG | N206627 | 003 | Nov 20, 2014 | May | CAHN |
| AB | + | | 60MG | N206627 | 004 | Nov 20, 2014 | May | CAHN |
| AB | + | | 80MG | N206627 | 005 | Nov 20, 2014 | May | CAHN |
| AB | + | | 100MG | N206627 | 006 | Nov 20, 2014 | May | CAHN |
| @ | + | | 120MG | N206627 | 007 | Nov 20, 2014 | May | CAHN |

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AMNEAL PHARMS NY | 2.5MG;200MG | A076642 | 003 | Oct 19, 2007 | Sep | CTNA |
| | | | 10MG;200MG | A076642 | 004 | Oct 19, 2007 | Sep | CTNA |
| | | | 10MG;200MG | A076642 | 004 | Oct 19, 2007 | May | CMFD |

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | SOLUTION;ORAL | | | | | | |
| | | HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | | |
| | | @ | APOZEAL PHARMS | 5MG/5ML;60MG/5ML | A206661 | 001 | Jan 23, 2019 | Jul CAHN |
| | | @ | PHARMAZONE | 5MG/5ML;60MG/5ML | A206661 | 001 | Jan 23, 2019 | Sep CAHN |

HYDROCORTISONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | CREAM;TOPICAL | | | | | | |
| | | ANUSOL HC | | | | | | |
| | | @ | SALIX PHARMS | 2.5% | A088250 | 001 | Jun 06, 1984 | Aug DISC |
| | | HYDROCORTISONE | | | | | | |
| | | @ | ACTAVIS MID ATLANTIC | 2.5% | A089682 | 001 | Mar 10, 1988 | Jun DISC |
| >D> | AT | | ENCUBE | 2.5% | A203810 | 001 | Jul 23, 2018 | Oct CAHN |
| >A> | AT | | | 2.5% | A203810 | 001 | Jul 23, 2018 | Oct CAHN |
| | AT | | | 2.5% | A203810 | 001 | Jul 23, 2018 | Jul CMFD |
| | | GRANULE;ORAL | | | | | | |
| | | ALKINDI SPRINKLE | | | | | | |
| | | +! | ETON | 0.5MG | N213876 | 001 | Sep 29, 2020 | Aug CHRS |
| | | LOTION;TOPICAL | | | | | | |
| | | ALA-SCALP | | | | | | |
| | | + | LEGACY | 2% | A083231 | 001 | | Jun CAHN |
| | | HYDROCORTISONE | | | | | | |
| >D> | | @ | ENCUBE | 2.5% | A203804 | 001 | Jul 27, 2018 | Oct CAHN |
| >A> | | @ | | 2.5% | A203804 | 001 | Jul 27, 2018 | Oct CAHN |
| | AT | | RISING | 2.5% | A218298 | 001 | Jul 16, 2026 | Jul NEWA |
| | | STIE-CORT | | | | | | |
| | AT | ! | PADAGIS US | 2.5% | A089074 | 001 | Nov 26, 1985 | Jul CTEC |
| | | OINTMENT;TOPICAL | | | | | | |
| | | HYDROCORTISONE IN ABSORBASE | | | | | | |
| | AT | | PHARMOBEDIENT | 1% | A088138 | 001 | Sep 06, 1985 | Sep CAHN |
| | | TABLET;ORAL | | | | | | |
| | | HYDROCORTISONE | | | | | | |
| | AB | | ADAPTIS | 5MG | A217160 | 001 | Nov 25, 2024 | Sep CAHN |
| | AB | | | 10MG | A217160 | 002 | Nov 25, 2024 | Sep CAHN |
| | AB | | | 20MG | A217160 | 003 | Nov 25, 2024 | Sep CAHN |
| | AB | | APPCO | 5MG | A220329 | 001 | Feb 25, 2026 | Feb NEWA |
| | AB | | | 10MG | A220329 | 002 | Feb 25, 2026 | Feb NEWA |
| | AB | | | 20MG | A220329 | 003 | Feb 25, 2026 | Feb NEWA |
| | | @ | HIKMA | 5MG | A083365 | 002 | Feb 23, 2015 | Sep CAHN |
| | | @ | | 10MG | A083365 | 003 | Feb 23, 2015 | Sep CAHN |
| | | @ | | 20MG | A083365 | 001 | | Sep CAHN |

HYDROCORTISONE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | CREAM;TOPICAL | | | | | | |
| | | MICORT-HC | | | | | | |
| | | @ | LEGACY | 2% | A040398 | 001 | Mar 29, 2002 | Jun CAHN |
| | | | | 2.5% | A040396 | 001 | Feb 27, 2001 | Jun CAHN |
| | | OINTMENT;OPHTHALMIC | | | | | | |
| | | HYDROCORTISONE ACETATE | | | | | | |
| | | @ | SCIEGEN PHARMS | 0.5% | A080828 | 001 | | Sep CAHN |

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | CREAM;TOPICAL | | | | | | |
| | | PRAMOSONE | | | | | | |
| | | | LEGACY | 0.5%;1% | A083778 | 001 | | Jun CAHN |
| | | | | 1%;1% | A085368 | 001 | | Jun CAHN |
| | | LOTION;TOPICAL | | | | | | |
| | | PRAMOSONE | | | | | | |
| | | | LEGACY | 1%;1% | A085980 | 001 | | Jun CAHN |
| | | | | 2.5%;1% | A085979 | 001 | | Jun CAHN |

HYDROCORTISONE BUTYRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | OINTMENT;TOPICAL | | | | | | |
| | | HYDROCORTISONE BUTYRATE | | | | | | |
| | | ! | TARO | 0.1% | A076842 | 001 | Dec 27, 2004 | Feb CTEC |
| | AB | ! | | 0.1% | A076842 | 001 | Dec 27, 2004 | Feb CHRS |
| | | LOCOID | | | | | | |
| | | @ + | PRECISION DERMAT | 0.1% | N018652 | 001 | Oct 29, 1982 | Feb DISC |

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

HYDROCORTISONE SODIUM SUCCINATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | APOTEX | EQ 100MG BASE/VIAL | A219856 | 001 | Feb 05, 2026 | Jan NEWA |
| | AP | | ZYDUS PHARMS | EQ 100MG BASE/VIAL | A217191 | 001 | May 07, 2026 | Apr NEWA |

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | COSETTE PHARMS NC | 0.2% | A074489 | 001 | Aug 12, 1998 | Jun CAHN |
| | AB | | | 0.2% | A213724 | 001 | Feb 11, 2021 | May CAHN |
| >A> | AB | | ENCUBE | 0.2% | A211047 | 001 | Nov 04, 2021 | Oct CAHN |
| >D> | AB | | ENCUBE ETHICALS | 0.2% | A211047 | 001 | Nov 04, 2021 | Oct CAHN |
| | | @ | PADAGIS ISRAEL | 0.2% | A075666 | 001 | May 24, 2000 | Mar DISC |

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | COSETTE PHARMS NC | 0.2% | A211764 | 001 | Mar 04, 2020 | May CAHN |

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AT | ! | BAUSCH AND LOMB INC | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A064053 | 001 | Dec 29, 1995 | May CAHN |
| | AT | | ORBICULAR PHARM TECH | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A220938 | 001 | Aug 27, 2026 | Aug NEWA |

SUSPENSION/DROPS;OTIC

CASPORYN HC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AT | + | CASPER PHARMA LLC | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | N060613 | 001 | | Aug CHRS |

OTICAIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AT | ! | BAUSCH AND LOMB INC | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A064065 | 001 | Aug 28, 1996 | Aug CHRS |
| | AT | | | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A064065 | 001 | Aug 28, 1996 | May CAHN |

HYDROCORTISONE; UREA

CREAM;TOPICAL

ALPHADERM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | BIOGLAN | 1%;10% | A086008 | 001 | | May CRLD |

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID-HP

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | +! | FRESENIUS KABI USA | 10MG/ML | N019034 | 001 | Jan 11, 1984 | Apr CMFD |

HYDROMORPHONE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | HOSPIRA INC | 0.25MG/0.5ML | N200403 | 005 | Mar 03, 2023 | Aug CRLD |
| | | + | | 0.5MG/0.5ML | N200403 | 004 | Jun 13, 2022 | Aug CRLD |
| | AP | + | | 1MG/ML | N200403 | 001 | Dec 01, 2011 | Aug CRLD |
| | AP | + | | 2MG/ML | N200403 | 002 | Dec 01, 2011 | Aug CRLD |
| | AP | + | | 4MG/ML | N200403 | 003 | Dec 01, 2011 | Aug CRLD |

SOLUTION;ORAL

HYDROMORPHONE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | PAI HOLDINGS | 5MG/5ML | A207108 | 001 | Apr 22, 2020 | Sep CAHN |

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | HIKMA | 200MG | A040760 | 001 | Aug 15, 2007 | Sep CAHN |
| | AB | | PHARMAZONE | 200MG | A212902 | 001 | May 14, 2020 | Sep CAHN |
| | AB | | SENORES PHARMS | 200MG | A212902 | 001 | May 14, 2020 | Jan CAHN |

HYDROXYUREA

CAPSULE;ORAL

DROXIA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | WAYLIS THERAP | 200MG | N016295 | 002 | Feb 25, 1998 | Jul CMFD |
| | | + | | 300MG | N016295 | 003 | Feb 25, 1998 | Jul CMFD |
| | | + | | 400MG | N016295 | 004 | Feb 25, 1998 | Jul CMFD |

TABLET;ORAL

HYDROXYUREA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | ESJAY PHARMA | 100MG | A220300 | 001 | Nov 03, 2026 | Oct NFTG |
| >A> | AB | | | 1GM | A220300 | 002 | Nov 03, 2026 | Oct NFTG |

TABLET;ORAL
SIKLOS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | + | THERAVIA | 100MG | N208843 | 001 | Dec 21, 2017 | Oct CFTG |
| >A> | AB | + | | 100MG | N208843 | 001 | Dec 21, 2017 | Oct CFTG |
| >D> | | +! | | 1GM | N208843 | 002 | Dec 21, 2017 | Oct CFTG |
| >A> | AB | +! | | 1GM | N208843 | 002 | Dec 21, 2017 | Oct CFTG |

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL
HYDROXYZINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | | PHARMAZONE | 10MG/5ML | A210634 | 001 | Feb 26, 2019 | Sep CAHN |
| | AA | | RUBICON RESEARCH | 10MG/5ML | A219561 | 001 | Sep 11, 2026 | Sep NEWA |
| | AA | | SAPTALIS PHARMS | 10MG/5ML | A220271 | 001 | Jun 11, 2026 | May NEWA |
| | AA | | SCIEGEN PHARMS | 10MG/5ML | A220271 | 001 | Jun 11, 2026 | Aug CAHN |

TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | AMNEAL PHARM | 10MG | A040808 | 001 | Sep 24, 2008 | Apr DISC |
| | | @ | | 25MG | A040808 | 002 | Sep 24, 2008 | Apr DISC |
| | | @ | | 50MG | A040808 | 003 | Sep 24, 2008 | Apr DISC |

HYDROXYZINE PAMOATE

CAPSULE;ORAL
VISTARIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | PFIZER | EQ 25MG HYDROCHLORIDE | N011459 | 002 | | Aug DISC |
| | | @ + | | EQ 50MG HYDROCHLORIDE | N011459 | 004 | | Aug DISC |

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS
IBANDRONATE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | CHEMI SPA | EQ 3MG BASE/3ML | A202235 | 001 | Sep 02, 2014 | May DISC |
| | | @ | PHARMOBEDIENT | EQ 3MG BASE/3ML | A202671 | 001 | Sep 02, 2014 | Jun DISC |

IBERDOMIDE HYDROCHLORIDE

CAPSULE;ORAL
ZENBEXUS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | BRISTOL MYERS SQUIBB | EQ 0.75MG BASE | N221075 | 001 | Aug 13, 2026 | Aug NEWA |
| | | +! | | EQ 1MG BASE | N221075 | 002 | Aug 13, 2026 | Aug NEWA |

IBRUTINIB

CAPSULE;ORAL
IBRUTINIB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | HETERO LABS LTD V | 140MG | A211182 | 001 | Sep 08, 2026 | Aug NEWA |

IMBRUVICA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | +! | PHARMACYCLICS LLC | 140MG | N205552 | 001 | Nov 13, 2013 | Aug CTEC |

IBUPROFEN

SOLUTION;INTRAVENOUS
CALDOLOR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | APOTEX | 400MG/4ML (100MG/ML) | N022348 | 001 | Jun 11, 2009 | Jul CAHN |
| | | +! | | 800MG/8ML (100MG/ML) | N022348 | 002 | Jun 11, 2009 | Jul CAHN |
| | | +! | | 800MG/200ML (4MG/ML) | N022348 | 003 | Jan 25, 2019 | Jul CAHN |

TABLET;ORAL
IBUPROFEN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | ALLIED | 400MG | A070045 | 001 | Sep 24, 1985 | Jul CAHN |
| | | @ | | 600MG | A070057 | 001 | Sep 24, 1985 | Jul CAHN |
| | | @ | | 800MG | A071999 | 001 | Dec 03, 1987 | Jul CAHN |
| | | @ | PHARMAZONE | 400MG | A070045 | 001 | Sep 24, 1985 | Sep CAHN |
| | AB | | | 400MG | A090796 | 001 | Dec 21, 2010 | Sep CAHN |
| | | @ | | 600MG | A070057 | 001 | Sep 24, 1985 | Sep CAHN |
| | AB | | | 600MG | A090796 | 002 | Dec 21, 2010 | Sep CAHN |
| | | @ | | 800MG | A071999 | 001 | Dec 03, 1987 | Sep CAHN |
| | AB | | | 800MG | A090796 | 003 | Dec 21, 2010 | Sep CAHN |
| | | @ | SENORES PHARMS | 400MG | A070045 | 001 | Sep 24, 1985 | Jul CAHN |
| | | @ | | 600MG | A070057 | 001 | Sep 24, 1985 | Jul CAHN |
| | | @ | | 800MG | A071999 | 001 | Dec 03, 1987 | Jul CAHN |

IBUTILIDE FUMARATE

INJECTABLE;INJECTION
IBUTILIDE FUMARATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | PHARMOBEDIENT | 0.1MG/ML | A090643 | 001 | Jan 11, 2010 | Sep DISC |

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA LTD | 1GM | A218949 | 001 | Jun 24, 2026 | Jun | NEWA |
| AB | | ONESOURCE | 500MG | A217844 | 001 | Sep 22, 2023 | Jul | CAHN |
| AB | | | 1GM | A217844 | 002 | Sep 22, 2023 | Jul | CAHN |
| AB | | TORRENT | 1GM | A218994 | 001 | Dec 20, 2024 | Apr | CAHN |

ICOTROKINRA HYDROCHLORIDE

TABLET;ORAL

ICOTYDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | JANSSEN BIOTECH | EQ 200MG BASE | N220149 | 001 | Mar 17, 2026 | Mar | NEWA |

IDELALISIB

TABLET;ORAL

IDELALISIB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | NATCO | 100MG | A216921 | 001 | Feb 17, 2026 | Sep | DISC |
| AB | | | 100MG | A216921 | 001 | Feb 17, 2026 | Feb | NFTG |
| | @ | | 150MG | A216921 | 002 | Feb 17, 2026 | Sep | DISC |
| AB | | | 150MG | A216921 | 002 | Feb 17, 2026 | Feb | NFTG |

ZYDELIG

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | GILEAD SCIENCES INC | 100MG | N205858 | 001 | Jul 23, 2014 | Sep | CTEC |
| AB | + | | 100MG | N205858 | 001 | Jul 23, 2014 | Feb | CFTG |
| | +! | | 150MG | N205858 | 002 | Jul 23, 2014 | Sep | CTEC |
| AB | +! | | 150MG | N205858 | 002 | Jul 23, 2014 | Feb | CFTG |

ILOPERIDONE

TABLET;ORAL

ILOPERIDONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ADAPTIS | 1MG | A207231 | 001 | Nov 28, 2016 | Sep | CAHN |
| | @ | | 2MG | A207231 | 002 | Nov 28, 2016 | Sep | CAHN |
| | @ | | 4MG | A207231 | 003 | Nov 28, 2016 | Sep | CAHN |
| | @ | | 6MG | A207231 | 004 | Nov 28, 2016 | Sep | CAHN |
| | @ | | 8MG | A207231 | 005 | Nov 28, 2016 | Sep | CAHN |
| | @ | | 10MG | A207231 | 006 | Nov 28, 2016 | Sep | CAHN |
| | @ | | 12MG | A207231 | 007 | Nov 28, 2016 | Sep | CAHN |

ILOPROST

SOLUTION;INHALATION

ILOPROST

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | BELOTECA | 10MCG/ML (10MCG/ML) | A214997 | 001 | Jul 10, 2026 | Jul | NFTG |
| | ! | | 20MCG/ML (20MCG/ML) | A214997 | 002 | Jul 10, 2026 | Jul | NFTG |
| | ! | REGCON HOLDINGS | 10MCG/ML (10MCG/ML) | A214997 | 001 | Jul 10, 2026 | Aug | CAHN |
| | ! | | 20MCG/ML (20MCG/ML) | A214997 | 002 | Jul 10, 2026 | Aug | CAHN |

IMATINIB MESYLATE

TABLET;ORAL

GLEEVEC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | NOVARTIS | EQ 100MG BASE | N021588 | 001 | Apr 18, 2003 | Mar | CHRS |
| AB | + | | EQ 400MG BASE | N021588 | 002 | Apr 18, 2003 | Mar | CHRS |

IMATINIB MESYLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | @ | ESJAY PHARMA | EQ 100MG BASE | A205990 | 001 | Feb 08, 2019 | Oct | CAHN |
| >A> | @ | | EQ 400MG BASE | A205990 | 002 | Feb 08, 2019 | Oct | CAHN |
| >D> | @ | NOVITIUM PHARMA | EQ 100MG BASE | A205990 | 001 | Feb 08, 2019 | Oct | CAHN |
| >D> | @ | | EQ 400MG BASE | A205990 | 002 | Feb 08, 2019 | Oct | CAHN |
| | @ | SUN PHARM | EQ 100MG BASE | A078340 | 001 | Dec 03, 2015 | Feb | DISC |
| | @ | | EQ 400MG BASE | A078340 | 002 | Dec 03, 2015 | Feb | DISC |

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | 5% | A200481 | 001 | Apr 18, 2011 | Jun | CAHN |
| >D> | @ | ENCUBE | 5% | A091044 | 001 | Feb 28, 2011 | Oct | CAHN |
| >A> | @ | | 5% | A091044 | 001 | Feb 28, 2011 | Oct | CAHN |

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

INDIUM IN-111 PENTETREOTIDE KIT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | SUN PHARM INDS INC | 3mCi/ML | A212785 | 001 | Jul 01, 2024 | Apr | DISC |

OCTREOSCAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | CURIUM | 3mCi/ML | N020314 | 001 | Jun 02, 1994 | Apr | CTEC |

INDOCYANINE GREEN

INJECTABLE;INJECTION

IC-GREEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ! | RENEW PHARMS | 10MG/VIAL | N011525 | 003 | | May CMFD |

INDOCYANINE GREEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | ZYDUS LIFESCIENCES | 25MG/VIAL | A219139 | 001 | Aug 03, 2026 | Jul NEWA |

SOLUTION;INTRAVENOUS, INTERSTITIAL

ZYOGREEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | PROVEPHARM SAS | 25MG/10ML (2.5MG/ML) | N218579 | 001 | Jul 10, 2026 | Jul NEWA |

INDOMETHACIN

SUPPOSITORY;RECTAL

INDOCIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | COSETTE | 50MG | N017814 | 001 | Aug 13, 1984 | Jun CAHN |

SUSPENSION;ORAL

INDOCIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | COSETTE | 25MG/5ML | N018332 | 001 | Oct 10, 1985 | Jun CAHN |

IOHEXOL

SOLUTION;INJECTION, ORAL

IOHEXOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | AMNEAL | 75.5% | A217737 | 002 | Jun 25, 2026 | Jun NFTG |

OMNIPAQUE 350

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | +! | GE HEALTHCARE | 75.5% | N018956 | 004 | Dec 26, 1985 | Jun CFTG |

IOMEPROL

SOLUTION;INTRA-ARTERIAL

IOMERVU

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | BRACCO | 35GM IODINE/100ML (350MG IODINE/ML) | N216016 | 007 | Nov 27, 2024 | Feb CMFD |
| | +! | | 40GM IODINE/100ML (400MG IODINE/ML) | N216016 | 011 | Nov 27, 2024 | Feb CMFD |
| | +! | | 70GM IODINE/200ML (350MG IODINE/ML) | N216016 | 009 | Nov 27, 2024 | Feb CMFD |
| | +! | | 80GM IODINE/200ML (400MG IODINE/ML) | N216016 | 013 | Nov 27, 2024 | Feb CMFD |

SOLUTION;INTRAVENOUS

IOMERVU

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | BRACCO | 35GM IODINE/100ML (350MG IODINE/ML) | N216017 | 007 | Nov 27, 2024 | Feb CMFD |
| | +! | | 40GM IODINE/100ML (400MG IODINE/ML) | N216017 | 011 | Nov 27, 2024 | Feb CMFD |
| | +! | | 70GM IODINE/200ML (350MG IODINE/ML) | N216017 | 009 | Nov 27, 2024 | Feb CMFD |
| | +! | | 80GM IODINE/200ML (400MG IODINE/ML) | N216017 | 013 | Nov 27, 2024 | Feb CMFD |

IOPAMIDOL

>A> SOLUTION;ORAL

>A> ISOVUE READI

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> | +! | BRACCO | 9MG IODINE/ML | N220583 | 001 | Oct 09, 2026 | Oct NEWA |

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION

CONRAY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | LIEBEL-FLARSHEIM | 60% | N013295 | 001 | | Sep DISC |

IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

ATROVENT HFA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | BOEHRINGER INGELHEIM | 0.021MG/INH | N021527 | 001 | Nov 27, 2004 | Feb CFTG |

IPRATROPIUM BROMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ARMSTRONG PHARMS | 0.021MG/INH | A217953 | 001 | Feb 23, 2026 | Feb NFTG |

IRBESARTAN

TABLET;ORAL

IRBESARTAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PHARMOBEDIENT | 75MG | A200461 | 001 | Sep 27, 2012 | Sep CAHN |
| | @ | | 150MG | A200461 | 002 | Sep 27, 2012 | Sep CAHN |
| | @ | | 300MG | A200461 | 003 | Sep 27, 2012 | Sep CAHN |

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | ADAPTIS | 40MG/2ML (20MG/ML) | A208718 | 001 | Dec 28, 2018 | Aug CAHN |
| AP | | | 100MG/5ML (20MG/ML) | A208718 | 002 | Dec 28, 2018 | Aug CAHN |
| AP | | | 300MG/15ML (20MG/ML) | A208718 | 003 | Aug 16, 2019 | Aug CAHN |
| | @ | INGENUS PHARMS LLC | 40MG/2ML (20MG/ML) | A206935 | 001 | May 26, 2017 | Sep DISC |
| AP | | | 40MG/2ML (20MG/ML) | A206935 | 001 | May 26, 2017 | May CAHN |
| | @ | | 100MG/5ML (20MG/ML) | A206935 | 002 | May 26, 2017 | Sep DISC |
| AP | | | 100MG/5ML (20MG/ML) | A206935 | 002 | May 26, 2017 | May CAHN |

IRON SUCROSE

INJECTABLE;INTRAVENOUS

IRON SUCROSE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | MYLAN LABS LTD | EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML) | A212559 | 001 | Aug 08, 2025 | Sep DISC |

ISONIAZID

TABLET;ORAL

ISONIAZID

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | GENUS LIFESCIENCES | 100MG | A080936 | 001 | | Sep CAHN |
| | @ | | 300MG | A080937 | 002 | | Sep CAHN |
| | @ | HIKMA | 100MG | A080212 | 001 | | Sep CAHN |
| | @ | | 300MG | A080212 | 002 | | Sep CAHN |
| | @ | HIKMA INTL PHARMS | 300MG | A080212 | 002 | | Jul CMS1 |
| | @ | ZETA PHARMS | 100MG | A080936 | 001 | | Aug CAHN |
| | @ | | 300MG | A080937 | 002 | | Aug CAHN |

ISONIAZID; RIFAMPIN

CAPSULE;ORAL

RIFAMPIN AND ISONIAZID

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 150MG;300MG | A065221 | 001 | Jul 29, 2005 | Sep CAHN |

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | ASPIRO | 0.2MG/ML | A220299 | 001 | May 18, 2026 | May NEWA |
| AP | | J MOLNER | 0.2MG/ML | A211237 | 001 | May 19, 2021 | Jun CAHN |

ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | HIKMA | 5MG | A088088 | 003 | Oct 29, 1987 | Sep CAHN |
| AB | | | 10MG | A088088 | 002 | Oct 29, 1987 | Sep CAHN |
| AB | | | 20MG | A088088 | 001 | Nov 02, 1987 | Sep CAHN |
| | @ | | 30MG | A040591 | 001 | Jan 10, 2007 | Sep CAHN |
| AB | | RUBICON RESEARCH | 5MG | A215723 | 001 | Jul 08, 2022 | May CAHN |
| AB | | | 10MG | A215723 | 002 | Jul 08, 2022 | May CAHN |
| AB | | | 20MG | A215723 | 003 | Jul 08, 2022 | May CAHN |
| AB | | | 30MG | A215723 | 004 | Jul 08, 2022 | May CAHN |
| AB | | | 40MG | A215723 | 005 | Jul 08, 2022 | May CAHN |

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 2.5MG | A086055 | 002 | Oct 29, 1987 | Sep CAHN |
| | @ | | 5MG | A086055 | 001 | Nov 02, 1987 | Sep CAHN |

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ANI PHARMS | 10MG | A075147 | 002 | Mar 27, 2026 | Apr NEWA |
| AB | | | 20MG | A075147 | 001 | Nov 27, 1998 | Mar CMFD |
| | @ | HIKMA | 20MG | A075361 | 001 | Oct 05, 2000 | Sep CAHN |

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 30MG | A076813 | 002 | Mar 30, 2006 | Sep CAHN |
| | @ | | 60MG | A076813 | 001 | Jan 07, 2005 | Sep CAHN |

ISOSULFAN BLUE

SOLUTION;SUBCUTANEOUS

ISOSULFAN BLUE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | | EUGIA PHARMA | 50MG/5ML (10MG/ML) | A206831 | 001 | Feb 02, 2016 | May CMFD |
| | | ! | MYLAN INSTITUTIONAL | 10MG/ML (10MG/ML) | A090874 | 002 | Jan 28, 2026 | Jan NFTG |
| | | ! | | 30MG/3ML (10MG/ML) | A090874 | 003 | Jan 28, 2026 | Jan NFTG |
| AP | | | SABA ILAY SANAYI | 50MG/5ML (10MG/ML) | A210714 | 001 | Jan 16, 2019 | Jun CMFD |
| AP | | | SOMERSET THERAPS LLC | 50MG/5ML (10MG/ML) | A210558 | 001 | Jul 12, 2019 | May CMFD |

ISOTRETINOIN

CAPSULE;ORAL

ISOTRETINOIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | AMNEAL PHARMS NY | 10MG | A216097 | 001 | Oct 07, 2025 | Mar DISC |
| | | @ | | 20MG | A216097 | 002 | Oct 07, 2025 | Mar DISC |
| | | @ | | 25MG | A216097 | 003 | Oct 07, 2025 | Mar DISC |
| | | @ | | 30MG | A216097 | 004 | Oct 07, 2025 | Mar DISC |
| | | @ | | 35MG | A216097 | 005 | Oct 07, 2025 | Mar DISC |
| | | @ | | 40MG | A216097 | 006 | Oct 07, 2025 | Mar DISC |
| AB1 | | | AUROBINDO PHARMA LTD | 20MG | A220336 | 001 | Sep 10, 2026 | Aug NEWA |
| AB1 | | | | 30MG | A220336 | 002 | Sep 10, 2026 | Aug NEWA |
| AB1 | | | | 40MG | A220336 | 003 | Sep 10, 2026 | Aug NEWA |

IVABRADINE

SOLUTION;ORAL

CORLANOR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | AMGEN INC | 5MG/5ML (1MG/ML) | N209964 | 001 | Apr 22, 2019 | Mar DISC |

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | AMGEN INC | EQ 5MG BASE | N206143 | 001 | Apr 15, 2015 | Jan DISC |
| | | @ + | | EQ 7.5MG BASE | N206143 | 002 | Apr 15, 2015 | Jan DISC |

IVABRADINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ! | INGENUS PHARMS LLC | EQ 7.5MG BASE | A214051 | 002 | Dec 30, 2021 | Jan CHRS |

IVERMECTIN

TABLET;ORAL

IVERMECTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | AJANTA PHARMA LTD | 3MG | A218509 | 001 | Apr 07, 2026 | Mar NEWA |
| AB | | | E5 PHARMA | 3MG | A216808 | 001 | Mar 09, 2026 | Feb NEWA |
| AB | | | PHARMAZONE | 3MG | A218324 | 001 | Oct 16, 2024 | Sep CAHN |
| AB | | | ZYDUS LIFESCIENCES | 3MG | A216863 | 001 | Feb 26, 2026 | Feb NEWA |

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | CAPLIN | EQ 10MG BASE/ML | A217858 | 001 | Aug 07, 2025 | Apr DISC |

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

KETAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AP | | AMNEAL | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | A220380 | 001 | Nov 04, 2026 | Oct NEWA |
| >A> | | ! | | EQ 50MG BASE/ML (EQ 50MG BASE/ML) | A220380 | 002 | Nov 04, 2026 | Oct NFTG |
| >D> | | ! | BAXTER HLTHCARE CORP | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | A219684 | 002 | Aug 11, 2026 | Oct CTEC |
| >A> | AP | ! | | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | A219684 | 002 | Aug 11, 2026 | Oct CTEC |
| | | ! | | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | A219684 | 002 | Aug 11, 2026 | Jul NFTG |
| | | @ | | EQ 100MG BASE/10ML (EQ 10MG BASE/ML) | A219684 | 001 | Sep 17, 2025 | May DISC |
| >A> | AP | | NEURORX | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | A220602 | 001 | Oct 28, 2026 | Oct NEWA |

KETOCONAZOLE

CREAM;TOPICAL

KETOCONAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | ! | ENCUBE | 2% | A212443 | 001 | May 20, 2021 | Oct CAHN |
| >A> | AB | ! | | 2% | A212443 | 001 | May 20, 2021 | Oct CAHN |
| | | @ | PADAGIS US | 2% | A215185 | 001 | Nov 17, 2021 | Jan DISC |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | SHAMPOO;TOPICAL | | | | | | |
| | | KETOCONAZOLE | | | | | | |
| | AB | | COSETTE PHARMS NC | 2% | A076942 | 001 | Apr 11, 2005 | May CAHN |
| | | TABLET;ORAL | | | | | | |
| | | KETOCONAZOLE | | | | | | |
| | AB | | PHARMAZONE | 200MG | A075912 | 001 | Jan 10, 2002 | Sep CAHN |
| | | KETOROLAC TROMETHAMINE | | | | | | |
| | | INJECTABLE;INJECTION | | | | | | |
| | | KETOROLAC TROMETHAMINE | | | | | | |
| >D> | AP | | ADAPTIS | 15MG/ML | A221041 | 001 | Sep 25, 2026 | Oct CAHN |
| | AP | | | 15MG/ML | A221041 | 001 | Sep 25, 2026 | Sep NEWA |
| >D> | AP | | | 30MG/ML | A221041 | 002 | Sep 25, 2026 | Oct CAHN |
| | AP | | | 30MG/ML | A221041 | 002 | Sep 25, 2026 | Sep NEWA |
| >A> | AP | | ANTHEA PHARMA | 15MG/ML | A221041 | 001 | Sep 25, 2026 | Oct CAHN |
| >A> | AP | | | 30MG/ML | A221041 | 002 | Sep 25, 2026 | Oct CAHN |
| | AP | | SHANDONG | 30MG/ML | A218355 | 001 | Sep 23, 2026 | Sep NEWA |
| | | SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| | | ACULAR LS | | | | | | |
| | | + | ABBVIE | 0.4% | N021528 | 001 | May 30, 2003 | Apr CTEC |
| | | KETOROLAC TROMETHAMINE | | | | | | |
| | | @ | APOTEX | 0.4% | A077308 | 001 | Nov 05, 2009 | Apr DISC |
| | | SPRAY, METERED;NASAL | | | | | | |
| | | SPRIX | | | | | | |
| | | +! | COSETTE | 15.75MG/SPRAY | N022382 | 001 | May 14, 2010 | Jun CAHN |
| | | TABLET;ORAL | | | | | | |
| | | KETOROLAC TROMETHAMINE | | | | | | |
| | AB | | PHARMAZONE | 10MG | A215788 | 001 | Mar 23, 2022 | Sep CAHN |
| | | L-GLUTAMINE | | | | | | |
| | | FOR SOLUTION;ORAL | | | | | | |
| | | L-GLUTAMINE | | | | | | |
| | AA | | ANNORA PHARMA | 5GM/PACKET | A219722 | 001 | May 26, 2026 | May NEWA |
| | AA | | PHARMOBEDIENT | 5GM/PACKET | A219750 | 001 | May 14, 2026 | Sep CAHN |
| | AA | | RENOVA PHARMS | 5GM/PACKET | A219750 | 001 | May 14, 2026 | May CAHN |
| | AA | | STIRA | 5GM/PACKET | A219750 | 001 | May 14, 2026 | May NEWA |
| | | LABETALOL HYDROCHLORIDE | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | LABETALOL HYDROCHLORIDE | | | | | | |
| | AB | | ADAPTIS | 100MG | A207863 | 001 | Feb 04, 2019 | Sep CAHN |
| | AB | | | 200MG | A207863 | 002 | Feb 04, 2019 | Sep CAHN |
| | AB | | | 300MG | A207863 | 003 | Feb 04, 2019 | Sep CAHN |
| | AB | | APPCO | 400MG | A209603 | 004 | Oct 18, 2024 | Mar CTEC |
| | AB | | HERITAGE PHARMA | 400MG | A074787 | 004 | Mar 26, 2026 | Mar NEWA |
| | AB | | INNOGENIX | 100MG | A075215 | 001 | Jul 29, 1999 | Jul CAHN |
| | AB | | | 200MG | A075215 | 002 | Jul 29, 1999 | Jul CAHN |
| | AB | | | 300MG | A075215 | 003 | Jul 29, 1999 | Jul CAHN |
| | | @ | PH HEALTH | 100MG | A200908 | 001 | Jul 10, 2012 | Jul DISC |
| | | @ | | 200MG | A200908 | 002 | Jul 10, 2012 | Jul DISC |
| | | @ | | 300MG | A200908 | 003 | Jul 10, 2012 | Jul DISC |
| | AB | | UNICHEM | 100MG | A212719 | 001 | Aug 08, 2022 | Sep CMFD |
| | AB | | | 200MG | A212719 | 002 | Aug 08, 2022 | Sep CMFD |
| | AB | | | 300MG | A212719 | 003 | Aug 08, 2022 | Sep CMFD |
| | AB | ! | ZYDUS PHARMS | 200MG | A207743 | 002 | Sep 19, 2017 | Jul CHRS |
| | | LACOSAMIDE | | | | | | |
| | | SOLUTION;INTRAVENOUS | | | | | | |
| | | LACOSAMIDE | | | | | | |
| | AP | | ANTHEA PHARMA | 200MG/20ML (10MG/ML) | A220268 | 001 | Jan 21, 2026 | Jan NEWA |
| | AP | | GLENMARK PHARMS | 200MG/20ML (10MG/ML) | A220268 | 001 | Jan 21, 2026 | Mar CAHN |
| | AP | | OP NANOPHARMA | 200MG/20ML (10MG/ML) | A218706 | 001 | May 23, 2025 | Sep CAHN |
| | | SOLUTION;ORAL | | | | | | |
| | | LACOSAMIDE | | | | | | |
| | | @ | ADAPTIS | 10MG/ML | A220366 | 001 | May 21, 2026 | Sep CAHN |
| | | @ | APOTEX | 10MG/ML | A206355 | 001 | Sep 26, 2022 | Feb DISC |
| | AA | | INDOCO | 10MG/ML | A220386 | 001 | Jan 29, 2026 | Jan NEWA |
| | AA | | PHARMAZONE | 10MG/ML | A216461 | 001 | Feb 06, 2023 | Sep CAHN |
| | AA | | PROD DEVELOPMENT | 10MG/ML | A217596 | 001 | Jun 15, 2026 | Jun NEWA |
| | AA | | REGCON HOLDINGS | 10MG/ML | A220386 | 001 | Jan 29, 2026 | Jan CAHN |
| | AA | | SENORES PHARMS | 10MG/ML | A216461 | 001 | Feb 06, 2023 | Sep CAHN |
| | | @ | STERANCO HLTHCARE | 10MG/ML | A220366 | 001 | May 21, 2026 | Jul DISC |

SOLUTION;ORAL
LACOSAMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | | 10MG/ML | A220366 | 001 | May 21, 2026 | May NEWA |

TABLET;ORAL
LACOSAMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | 50MG | A218014 | 001 | Apr 02, 2024 | Sep CAHN |
| AB | | | 100MG | A218014 | 002 | Apr 02, 2024 | Sep CAHN |
| AB | | | 150MG | A218014 | 003 | Apr 02, 2024 | Sep CAHN |
| AB | | | 200MG | A218014 | 004 | Apr 02, 2024 | Sep CAHN |
| AB | | SENORES PHARMS | 50MG | A218014 | 001 | Apr 02, 2024 | Sep CAHN |
| AB | | | 100MG | A218014 | 002 | Apr 02, 2024 | Sep CAHN |
| AB | | | 150MG | A218014 | 003 | Apr 02, 2024 | Sep CAHN |
| AB | | | 200MG | A218014 | 004 | Apr 02, 2024 | Sep CAHN |

LACTULOSE

FOR SOLUTION;ORAL
LACTULOSE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | ! | APOTEX | 10GM/PACKET | A074712 | 001 | Dec 10, 1997 | Jul CAHN |
| AA | ! | | 20GM/PACKET | A074712 | 002 | Dec 10, 1997 | Jul CAHN |

SOLUTION;ORAL
LACTULOSE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | PHARMAZONE | 10GM/15ML | A207786 | 001 | Jun 11, 2018 | Sep CAHN |

SOLUTION;ORAL, RECTAL
LACTULOSE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | APOZEAL PHARMS | 10GM/15ML | A203762 | 001 | Mar 27, 2015 | Jul CAHN |
| AA | | PHARMAZONE | 10GM/15ML | A203762 | 001 | Mar 27, 2015 | Sep CAHN |

LAMIVUDINE

TABLET;ORAL
LAMIVUDINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | LUPIN | 150MG | A205217 | 001 | Dec 18, 2014 | Jan DISC |
| @ | | | 300MG | A205217 | 002 | Dec 18, 2014 | Jan DISC |

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL
LAMIVUDINE AND ZIDOVUDINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | PHARMOBEDIENT | 150MG;300MG | A079128 | 001 | May 13, 2015 | Jul DISC |

LAMOTRIGINE

TABLET;ORAL
LAMICTAL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + | GLAXOSMITHKLINE LLC | 25MG | N020241 | 005 | Dec 27, 1994 | Jun CHRS |

LAMOTRIGINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ! | ALEMBIC PHARMS LTD | 25MG | A090607 | 001 | Jan 13, 2011 | Jun CHRS |
| @ | | LUPIN LTD | 25MG | A078691 | 001 | Jun 01, 2010 | Apr DISC |
| @ | | | 100MG | A078691 | 002 | Jun 01, 2010 | Apr DISC |
| @ | | | 150MG | A078691 | 003 | Jun 01, 2010 | Apr DISC |
| @ | | | 200MG | A078691 | 004 | Jun 01, 2010 | Apr DISC |

TABLET, EXTENDED RELEASE;ORAL
LAMOTRIGINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | PH HEALTH | 25MG | A201791 | 001 | Jan 18, 2013 | Apr DISC |
| @ | | | 50MG | A201791 | 002 | Jan 18, 2013 | Apr DISC |
| @ | | | 100MG | A201791 | 003 | Jan 18, 2013 | Apr DISC |
| @ | | | 200MG | A201791 | 004 | Jan 18, 2013 | Apr DISC |
| @ | | | 250MG | A201791 | 005 | Jan 18, 2013 | Apr DISC |
| @ | | | 300MG | A201791 | 006 | Jan 18, 2013 | Apr DISC |
| AB | | PHARMOBEDIENT | 25MG | A213949 | 001 | Dec 08, 2021 | Sep CAHN |
| AB | | | 50MG | A213949 | 002 | Dec 08, 2021 | Sep CAHN |
| AB | | | 100MG | A213949 | 003 | Dec 08, 2021 | Sep CAHN |
| AB | | | 200MG | A213949 | 004 | Dec 08, 2021 | Sep CAHN |
| AB | | | 250MG | A213949 | 005 | Dec 08, 2021 | Sep CAHN |
| AB | | | 300MG | A213949 | 006 | Dec 08, 2021 | Sep CAHN |

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ALEMBIC | 25MG | A217278 | 001 | Feb 25, 2026 | Feb NEWA |
| AB | | | 50MG | A217278 | 002 | Feb 25, 2026 | Feb NEWA |
| AB | | | 100MG | A217278 | 003 | Feb 25, 2026 | Feb NEWA |
| AB | | | 200MG | A217278 | 004 | Feb 25, 2026 | Feb NEWA |
| AB | | J MOLNER | 25MG | A214124 | 001 | Feb 03, 2022 | Jun CAHN |
| AB | | | 50MG | A214124 | 002 | Feb 03, 2022 | Jun CAHN |
| AB | | | 100MG | A214124 | 003 | Feb 03, 2022 | Jun CAHN |
| AB | | | 200MG | A214124 | 004 | Feb 03, 2022 | Jun CAHN |

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | TORRENT | 25MG | A217100 | 001 | Jan 08, 2026 | Jan NEWA |
| AB | | | 50MG | A217100 | 002 | Jan 08, 2026 | Jan NEWA |
| AB | | | 100MG | A217100 | 003 | Jan 08, 2026 | Jan NEWA |
| AB | | | 200MG | A217100 | 004 | Jan 08, 2026 | Jan NEWA |

LAMOTRIGINE HEMIFUMARATE

SUSPENSION;ORAL
LAMLIQUE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | AZURITY | EQ 5MG BASE/ML | N221109 | 001 | Sep 25, 2026 | Sep NEWA |
| | +! | | EQ 25MG BASE/ML | N221109 | 002 | Sep 25, 2026 | Sep NEWA |

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS
LANREOTIDE ACETATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AMNEAL | EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) | A218217 | 001 | Sep 18, 2026 | Sep NEWA |
| | @ | INVAGEN PHARMS | EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) | A217193 | 001 | May 21, 2024 | Sep DISC |
| | @ + | | EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) | N215395 | 001 | Dec 17, 2021 | Sep DISC |
| | @ | | EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) | A217193 | 002 | May 21, 2024 | Sep DISC |
| | @ + | | EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) | N215395 | 002 | Dec 17, 2021 | Sep DISC |
| | @ | | EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) | A217193 | 003 | May 21, 2024 | Sep DISC |
| | @ + | | EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) | N215395 | 003 | Dec 17, 2021 | Sep DISC |

SOMATULINE DEPOT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | IPSEN PHARMA | EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) | N022074 | 001 | Aug 30, 2007 | Sep CTEC |
| | +! | | EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) | N022074 | 002 | Aug 30, 2007 | Sep CTEC |

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 15MG | A205868 | 001 | Aug 30, 2017 | Sep CAHN |
| AB | | | 30MG | A205868 | 002 | Aug 30, 2017 | Sep CAHN |

LASMIDITAN SUCCINATE

TABLET;ORAL
REYVOW

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | ELI LILLY AND CO | EQ 50MG BASE | N211280 | 001 | Jan 31, 2020 | Jun DISC |
| | @ + | | EQ 100MG BASE | N211280 | 002 | Jan 31, 2020 | Jun DISC |

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | CARNEGIE | 0.005% | A202077 | 001 | Feb 11, 2013 | Feb CAHN |
| AT | | J MOLNER | 0.005% | A200925 | 001 | Mar 22, 2011 | Jul CAHN |
| | @ | MANKIND PHARMA | 0.005% | A220360 | 001 | Dec 17, 2025 | Jun DISC |

LEDIPASVIR; SOFOSBUVIR

PELLETS;ORAL
HARVONI

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | + | GILEAD SCIENCES INC | 33.75MG/PACKET;150MG/PACKET | N212477 | 001 | Aug 28, 2019 | Jul CPOT |
| | +! | | 45MG/PACKET;200MG/PACKET | N212477 | 002 | Aug 28, 2019 | Jul CPOT |

LEFLUNOMIDE

TABLET;ORAL
ARAVA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | SANOFI AVENTIS US | 100MG | N020905 | 003 | Sep 10, 1998 | Jun DISC |

LENALIDOMIDE

CAPSULE;ORAL
LENALIDOMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ALVOGEN | 2.5MG | A210480 | 005 | Mar 06, 2023 | Jan CAHN |
| AB | | | 5MG | A210480 | 001 | Aug 31, 2022 | Jan CAHN |
| AB | | | 10MG | A210480 | 002 | Aug 31, 2022 | Jan CAHN |
| AB | | | 15MG | A210480 | 003 | Aug 31, 2022 | Jan CAHN |
| AB | | | 20MG | A210480 | 006 | Mar 06, 2023 | Jan CAHN |

CAPSULE;ORAL
LENALIDOMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | | 25MG | A210480 | 004 | Aug 31, 2022 | Jan CAHN |
| AB | | CIPLA | 5MG | A213165 | 001 | Feb 02, 2026 | Jan NEWA |
| AB | | | 10MG | A213165 | 002 | Feb 02, 2026 | Jan NEWA |
| AB | | | 15MG | A213165 | 003 | Feb 02, 2026 | Jan NEWA |
| AB | | | 20MG | A213165 | 004 | Feb 02, 2026 | Jan NEWA |
| AB | | | 25MG | A213165 | 005 | Feb 02, 2026 | Jan NEWA |
| | @ | TORRENT | 2.5MG | A213405 | 005 | Feb 10, 2026 | Mar DISC |
| AB | | | 2.5MG | A213405 | 005 | Feb 10, 2026 | Jan NEWA |
| | @ | | 5MG | A213405 | 006 | Feb 10, 2026 | Mar DISC |
| AB | | | 5MG | A213405 | 006 | Feb 10, 2026 | Jan NEWA |
| | @ | | 15MG | A213405 | 004 | Nov 04, 2025 | Mar DISC |

LENIOLISIB PHOSPHATE
TABLET;ORAL
JOENJA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | + | PHARMING | EQ 40MG BASE | N217759 | 002 | Sep 11, 2026 | Sep NEWA |
| | + | | EQ 50MG BASE | N217759 | 003 | Sep 11, 2026 | Sep NEWA |

LETROZOLE
TABLET;ORAL
LETROZOLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CARNEGIE | 2.5MG | A091191 | 001 | Jun 03, 2011 | Aug CMFD |
| AB | | PHARMOBEDIENT | 2.5MG | A091191 | 001 | Jun 03, 2011 | Sep CAHN |
| AB | | | 2.5MG | A205869 | 001 | Nov 14, 2018 | Sep CAHN |
| AB | | ZYDUS LIFESCIENCES | 2.5MG | A220438 | 001 | Sep 14, 2026 | Sep NEWA |

LEUCOVORIN CALCIUM
FOR SOLUTION;ORAL
LEUCOVORIN CALCIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | HOSPIRA | EQ 60MG BASE/VIAL | N008107 | 003 | Jan 30, 1987 | Jul CRLD |

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> AP | | GLAND | EQ 500MG BASE/VIAL | A218200 | 002 | Oct 14, 2026 | Oct NEWA |

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
LEUCOVORIN CALCIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | INGENUS PHARMS LLC | EQ 500MG BASE/50ML (EQ 10MG BASE/ML) | A210917 | 001 | Nov 23, 2018 | Feb CAHN |

VYKOURA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | AVYXA HOLDINGS | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | N220406 | 001 | Feb 03, 2026 | Feb NEWA |
| | +! | | EQ 350MG BASE/35ML (EQ 10MG BASE/ML) | N220406 | 002 | Feb 03, 2026 | Feb NEWA |
| | +! | | EQ 500MG BASE/50ML (EQ 10MG BASE/ML) | N220406 | 003 | Feb 03, 2026 | Feb NEWA |

TABLET;ORAL
LEUCOVORIN CALCIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | HIKMA | EQ 25MG BASE | A072736 | 001 | Feb 22, 1993 | May CHRS |
| AB | | INGENUS PHARMS LLC | EQ 5MG BASE | A211132 | 001 | Jul 30, 2020 | Apr CAHN |
| AB | | | EQ 10MG BASE | A211132 | 002 | Jul 30, 2020 | Apr CAHN |
| AB | | | EQ 15MG BASE | A211132 | 003 | Jul 30, 2020 | Apr CAHN |
| AB | ! | | EQ 25MG BASE | A211132 | 004 | Jul 30, 2020 | May CHRS |
| AB | | | EQ 25MG BASE | A211132 | 004 | Jul 30, 2020 | Apr CAHN |

LEUPROLIDE ACETATE
SOLUTION;SUBCUTANEOUS
LEUPROLIDE ACETATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | SOMERSET THERAPS LLC | 14MG/2.8ML (1MG/0.2ML) | A213829 | 001 | Aug 13, 2021 | Feb CAHN |

VOBRIG

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | SUN PHARM | 28MG/2.8ML (10MG/ML) | N213225 | 001 | Aug 26, 2026 | Sep DISC |
| | +! | | 28MG/2.8ML (10MG/ML) | N213225 | 001 | Aug 26, 2026 | Aug NEWA |

LEUPROLIDE MESYLATE
EMULSION;SUBCUTANEOUS
CAMCEVI ETM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | ACCORD | EQ 21MG BASE | N219745 | 001 | Aug 25, 2025 | Jan CAHN |

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| AN | NEPHRON | EQ 0.021% BASE | A215217 | 001 | May 26, 2026 | May NEWA |
| AN | | EQ 0.042% BASE | A215217 | 002 | May 26, 2026 | May NEWA |

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM

| | | | | | | |
|---|---|---|---|---|---|---|
| AP | BAXTER HLTHCARE CORP | 500MG/5ML (100MG/ML) | A208458 | 001 | Aug 06, 2026 | Jul NEWA |
| @ | KNACK | 500MG/5ML (100MG/ML) | A215465 | 001 | Dec 02, 2025 | May DISC |

LEVETIRACETAM IN SODIUM CHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| AP | MYLAN LABS LTD | 500MG/100ML (5MG/ML) | A218364 | 001 | May 08, 2026 | May NEWA |
| AP | | 1GM/100ML (10MG/ML) | A218364 | 002 | May 08, 2026 | May NEWA |
| AP | | 1.5GM/100ML (15MG/ML) | A218364 | 003 | May 08, 2026 | May NEWA |

SOLUTION;ORAL

LEVETIRACETAM

| | | | | | | |
|---|---|---|---|---|---|---|
| AA | ADAPTIS | 100MG/ML | A218080 | 001 | Nov 21, 2025 | Aug CAHN |
| AA | ANDA REPOSITORY | 100MG/ML | A218080 | 001 | Nov 21, 2025 | Mar CAHN |
| AA | GUARDIAN DRUG | 100MG/ML | A218080 | 001 | Nov 21, 2025 | Aug CAHN |
| @ | STRIDES PHARMA | 100MG/ML | A078582 | 001 | Jan 15, 2009 | Jun DISC |

TABLET;ORAL

LEVETIRACETAM

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | NOVAX | 250MG | A078869 | 001 | Mar 13, 2009 | Jul CAHN |
| AB | | 500MG | A078869 | 002 | Mar 13, 2009 | Jul CAHN |
| AB | | 750MG | A078869 | 003 | Mar 13, 2009 | Jul CAHN |
| AB | | 1GM | A078869 | 004 | Mar 13, 2009 | Jul CAHN |
| AB | PHARMAZONE | 250MG | A076920 | 001 | Jan 15, 2009 | Sep CAHN |
| AB | | 500MG | A076920 | 002 | Jan 15, 2009 | Sep CAHN |
| AB | | 750MG | A076920 | 003 | Jan 15, 2009 | Sep CAHN |
| AB | | 1GM | A078904 | 001 | Jan 15, 2009 | Sep CAHN |
| AB | SENORES PHARMS | 250MG | A076920 | 001 | Jan 15, 2009 | Jan CAHN |
| AB | | 500MG | A076920 | 002 | Jan 15, 2009 | Jan CAHN |
| AB | | 750MG | A076920 | 003 | Jan 15, 2009 | Jan CAHN |
| AB | | 1GM | A078904 | 001 | Jan 15, 2009 | Jan CAHN |

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

| | | | | | | |
|---|---|---|---|---|---|---|
| @ | ALICORA | 500MG | A201464 | 001 | May 25, 2012 | Sep CAHN |
| @ | | 750MG | A201464 | 002 | May 25, 2012 | Sep CAHN |
| AB | YABAO PHARM | 500MG | A212688 | 002 | May 05, 2023 | Sep CAHN |
| AB | | 750MG | A212688 | 001 | Jun 11, 2020 | Sep CAHN |

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| AT | BAUSCH AND LOMB INC | 0.5% | A074326 | 001 | Mar 04, 1994 | May CAHN |

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

| | | | | | | |
|---|---|---|---|---|---|---|
| AP | BAXTER HLTHCARE CORP | 200MG/ML | A217896 | 001 | Jul 02, 2026 | Jun NEWA |
| AP | GLAND | 200MG/ML | A220181 | 001 | Sep 30, 2026 | Sep NEWA |

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

| | | | | | | |
|---|---|---|---|---|---|---|
| @ | MICRO LABS LTD INDIA | 1.5% | A205600 | 001 | Feb 27, 2019 | Aug DISC |

TABLET;ORAL

LEVOFLOXACIN

| | | | | | | |
|---|---|---|---|---|---|---|
| @ | LUPIN | 250MG | A078424 | 001 | Jun 20, 2011 | May DISC |
| @ | | 500MG | A078424 | 002 | Jun 20, 2011 | May DISC |
| @ | | 750MG | A078424 | 003 | Jun 20, 2011 | May DISC |

LEVOLEUCOVORIN CALCIUM

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

| | | | | | | |
|---|---|---|---|---|---|---|
| @ | AMNEAL | EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) | A207548 | 001 | Sep 08, 2017 | Mar DISC |
| @ | INGENUS PHARMS LLC | EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) | A210623 | 001 | May 03, 2018 | May CAHN |
| @ | | EQ 250MG BASE/25ML (EQ 10MG | A210623 | 002 | May 03, 2018 | May CAHN |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | SOLUTION;INTRAVENOUS | | | | | | |
| | | LEVOLEUCOVORIN CALCIUM | | | | | | |
| | | @ QUAGEN | EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) | A213797 | 001 | Nov 02, 2021 | Sep | CAHN |
| | | LEVOTHYROXINE SODIUM | | | | | | |
| | | POWDER;INTRAVENOUS | | | | | | |
| | | LEVOTHYROXINE SODIUM | | | | | | |
| | | @ PIRAMAL CRITICAL | 100MCG/VIAL | A206163 | 001 | Jun 29, 2016 | Jul | DISC |
| | | @ | 500MCG/VIAL | A206163 | 002 | Jun 29, 2016 | Jul | DISC |
| | | SOLUTION;INTRAVENOUS | | | | | | |
| | | LEVOTHYROXINE SODIUM | | | | | | |
| | | @ + HIKMA | 100MCG/ML | N214253 | 001 | May 17, 2021 | Sep | DISC |
| | | SOLUTION;ORAL | | | | | | |
| | | ERMEZA | | | | | | |
| | | @ + MYLAN | 150MCG/5ML | N215809 | 001 | Apr 29, 2022 | Aug | DISC |
| | | LEVOTHYROXINE SODIUM ** | | | | | | |
| | | **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | EUTHYROX | | | | | | |
| | | @ EMD SERONO INC | 0.025MG | N021292 | 001 | May 31, 2002 | Apr | DISC |
| | | @ | 0.05MG | N021292 | 002 | May 31, 2002 | Apr | DISC |
| | | @ | 0.075MG | N021292 | 003 | May 31, 2002 | Apr | DISC |
| | | @ | 0.088MG | N021292 | 004 | May 31, 2002 | Apr | DISC |
| | | @ | 0.1MG | N021292 | 005 | May 31, 2002 | Apr | DISC |
| | | @ | 0.112MG | N021292 | 006 | May 31, 2002 | Apr | DISC |
| | | @ | 0.125MG | N021292 | 007 | May 31, 2002 | Apr | DISC |
| | | @ | 0.137MG | N021292 | 008 | May 31, 2002 | Apr | DISC |
| | | @ | 0.15MG | N021292 | 009 | May 31, 2002 | Apr | DISC |
| | | @ | 0.175MG | N021292 | 010 | May 31, 2002 | Apr | DISC |
| | | @ | 0.2MG | N021292 | 011 | May 31, 2002 | Apr | DISC |
| | | LEVOTHYROXINE SODIUM | | | | | | |
| | AB2 | ALEMBIC | 0.025MG | A216370 | 001 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.05MG | A216370 | 002 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.075MG | A216370 | 003 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.088MG | A216370 | 004 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.1MG | A216370 | 005 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.112MG | A216370 | 006 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.125MG | A216370 | 007 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.137MG | A216370 | 008 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.15MG | A216370 | 009 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.175MG | A216370 | 010 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.2MG | A216370 | 011 | May 20, 2026 | May | NEWA |
| | AB2 | | 0.3MG | A216370 | 012 | May 20, 2026 | May | NEWA |
| | | LIDOCAINE | | | | | | |
| | | OINTMENT;TOPICAL | | | | | | |
| | | LIDOCAINE | | | | | | |
| | AT | ALEMBIC | 5% | A211469 | 001 | Nov 23, 2018 | May | CTEC |
| | | @ COSETTE PHARMS NC | 5% | A211019 | 001 | Dec 12, 2018 | Jun | CAHN |
| >D> | AT | ENCUBE | 5% | A205318 | 001 | Feb 01, 2016 | Oct | CAHN |
| >A> | AT | | 5% | A205318 | 001 | Feb 01, 2016 | Oct | CAHN |
| | AT | | 5% | A205318 | 001 | Feb 01, 2016 | Jun | CMFD |
| | | @ H2-PHARMA | 5% | A208822 | 001 | Sep 25, 2017 | Sep | CAHN |
| | | @ QUAGEN | 5% | A212486 | 001 | Oct 17, 2019 | Sep | CAHN |
| | | PATCH;TOPICAL | | | | | | |
| | | LIDOCAINE | | | | | | |
| >A> | AB | ARYEH | 5% | A202346 | 001 | Aug 07, 2015 | Oct | CAHN |
| | AB | INVAGEN PHARMS | 5% | A207059 | 001 | Feb 09, 2026 | Sep | CAHN |
| >D> | AB | PHARMOBEDIENT | 5% | A202346 | 001 | Aug 07, 2015 | Oct | CAHN |
| >A> | AB | PRINSTON | 5% | A202346 | 001 | Aug 07, 2015 | Oct | CAHN |
| | AB | USPHARMA | 5% | A207059 | 001 | Feb 09, 2026 | Mar | CMFD |
| | | @ | 5% | A207059 | 001 | Feb 09, 2026 | Feb | DISC |
| | AB | | 5% | A207059 | 001 | Feb 09, 2026 | Jan | NEWA |

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | | ADAPTIS | 1% | A219535 | 001 | Apr 02, 2025 | Oct | CAHN |
| | AP | | | 1% | A219535 | 001 | Apr 02, 2025 | Sep | CAHN |
| >D> | AP | | | 2% | A219535 | 002 | Feb 06, 2026 | Oct | CAHN |
| | AP | | | 2% | A219535 | 002 | Feb 06, 2026 | Sep | CAHN |
| >A> | AP | | ANTHEA PHARMA | 1% | A219535 | 001 | Apr 02, 2025 | Oct | CAHN |
| >A> | AP | | | 2% | A219535 | 002 | Feb 06, 2026 | Oct | CAHN |
| | AP | | | 2% | A219535 | 002 | Feb 06, 2026 | Jan | NEWA |
| | AP | | HERITAGE | 1% | A215132 | 001 | Jun 09, 2022 | Sep | CAHN |
| | AP | | PHARMOBEDIENT | 1% | A214267 | 001 | Sep 19, 2022 | Sep | CAHN |
| | AP | | | 2% | A214267 | 002 | Sep 19, 2022 | Sep | CAHN |
| | AP | | | 4% | A214269 | 001 | May 05, 2022 | Sep | CAHN |
| | AP | | VIWIT PHARM | 1% | A220071 | 001 | Mar 19, 2026 | Mar | NEWA |
| | AP | | | 2% | A220071 | 002 | Mar 19, 2026 | Mar | NEWA |

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | CHARTWELL RX | 2% | A090665 | 001 | Sep 27, 2010 | May | CAHN |

JELLY;TOPICAL

LIDOCAINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | COSETTE PHARMS NC | 2% | A081318 | 001 | Apr 29, 1993 | Jun | CAHN |

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AT | | QUAGEN | 2% | A218676 | 001 | Mar 20, 2026 | Mar | NEWA |

SYSTEM;INTRADERMAL

ZINGO

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | POWDER PHARMS | 0.5MG | N022114 | 001 | Aug 16, 2007 | Jul | DISC |

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | ENCUBE | 2.5%;2.5% | A076320 | 001 | Aug 27, 2003 | Oct | CAHN |
| >A> | AB | | | 2.5%;2.5% | A076320 | 001 | Aug 27, 2003 | Oct | CAHN |

LINACLOTIDE

CAPSULE;ORAL

LINACLOTIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | ACTAVIS LABS FL | 72MCG | A211255 | 001 | Sep 24, 2026 | Sep | NFTG |

LINZESS

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | +! | ABBVIE | 72MCG | N202811 | 003 | Jan 25, 2017 | Sep | CFTG |

LINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | TEVA PHARMS USA | 5MG | A208433 | 001 | May 27, 2026 | May | NEWA |

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | | HAINAN POLY | EQ 300MG BASE/ML | A216662 | 001 | Dec 21, 2022 | Sep | CMFD |
| | | @ | | EQ 300MG BASE/ML | A216662 | 001 | Dec 21, 2022 | Jul | CAHN |
| | AP | | QUAGEN | EQ 300MG BASE/ML | A212770 | 001 | Mar 12, 2021 | Sep | CAHN |

LINERIXIBAT

TABLET;ORAL

LYNAVOY

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | +! | GLAXOSMITHKLINE | 40MG | N220295 | 001 | Mar 17, 2026 | Mar | NEWA |
| | | +! | INTERCEPT | 40MG | N220295 | 001 | Mar 17, 2026 | May | CAHN |

LINEZOLID

SOLUTION;INTRAVENOUS

LINEZOLID

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | | SEROVIA | 200MG/100ML (2MG/ML) | A205154 | 001 | Dec 06, 2017 | Aug | CAHN |
| | AP | | | 600MG/300ML (2MG/ML) | A205154 | 002 | Dec 06, 2017 | Aug | CAHN |
| | AP | | STERISCIENCE | 200MG/100ML (2MG/ML) | A205154 | 001 | Dec 06, 2017 | Sep | CAHN |
| | AP | | | 600MG/300ML (2MG/ML) | A205154 | 002 | Dec 06, 2017 | Sep | CAHN |

TABLET;ORAL

LINEZOLID

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | MACLEODS PHARMS | 600MG | A210378 | 001 | Oct 10, 2024 | Aug | CMFD |

LIRAFUGRATINIB HYDROCHLORIDE

CAPSULE;ORAL

LYRFIGTU

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | + | ELEVAR | EQ 20MG BASE | N220425 | 001 | Sep 23, 2026 | Sep NEWA |
| | +! | | EQ 30MG BASE | N220425 | 002 | Sep 23, 2026 | Sep NEWA |

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS

LIRAGLUTIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP1 | | BIOCON PHARMA | 18MG/3ML (6MG/ML) | A215245 | 001 | Mar 11, 2026 | Feb NEWA |
| AP2 | | | 18MG/3ML (6MG/ML) | A217063 | 001 | Feb 24, 2026 | Feb NEWA |
| >A> AP1 | | EMERGE BIOSCIENCE | 18MG/3ML (6MG/ML) | A218115 | 001 | Apr 02, 2025 | Oct CAHN |
| AP1 | | FRESENIUS KABI USA | 18MG/3ML (6MG/ML) | A212552 | 001 | Mar 30, 2026 | Mar NEWA |
| AP1 | | MYLAN INSTITUTIONAL | 18MG/3ML (6MG/ML) | A213155 | 001 | Jun 15, 2026 | Jun NEWA |
| >D> AP1 | | NANJING KING FRIEND | 18MG/3ML (6MG/ML) | A218115 | 001 | Apr 02, 2025 | Oct CAHN |
| AP2 | | ORBICULAR | 18MG/3ML (6MG/ML) | A217234 | 001 | Feb 24, 2026 | Feb NEWA |
| AP1 | | | 18MG/3ML (6MG/ML) | A217590 | 001 | Jan 14, 2026 | Jan NEWA |
| AP1 | | SANDOZ | 18MG/3ML (6MG/ML) | A212972 | 001 | Jul 01, 2026 | Jun NEWA |

LISINOPRIL

SOLUTION;ORAL

LISINOPRIL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | ANNORA PHARMA | 1MG/ML | A218419 | 001 | Aug 20, 2026 | Aug NFTG |

QBRELIS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | +! | AZURITY | 1MG/ML | N208401 | 001 | Jul 29, 2016 | Aug CFTG |

TABLET;ORAL

LISINOPRIL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | HERITAGE | 2.5MG | A076102 | 001 | Sep 30, 2002 | Sep CAHN |
| AB | | | 5MG | A076102 | 002 | Sep 30, 2002 | Sep CAHN |
| AB | | | 10MG | A076102 | 003 | Sep 30, 2002 | Sep CAHN |
| AB | | | 20MG | A076102 | 004 | Sep 30, 2002 | Sep CAHN |
| AB | | | 30MG | A076102 | 005 | Sep 30, 2002 | Sep CAHN |
| AB | | | 40MG | A076102 | 006 | Sep 30, 2002 | Sep CAHN |
| | @ | HIKMA | 2.5MG | A076063 | 001 | Jul 01, 2002 | Sep CAHN |
| | @ | | 5MG | A076063 | 002 | Jul 01, 2002 | Sep CAHN |
| | @ | | 10MG | A076063 | 003 | Jul 01, 2002 | Sep CAHN |
| | @ | | 20MG | A076063 | 004 | Jul 01, 2002 | Sep CAHN |
| | @ | | 30MG | A076063 | 006 | Jun 27, 2003 | Sep CAHN |
| | @ | | 40MG | A076063 | 005 | Jul 01, 2002 | Sep CAHN |

LITHIUM CARBONATE

TABLET;ORAL

LITHIUM CARBONATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 300MG | A078715 | 001 | Dec 28, 2010 | Sep CAHN |
| | +! | | 300MG | N018558 | 001 | Jan 29, 1982 | Jul CTEC |
| | @ | SUN PHARM INDS INC | 300MG | A091027 | 001 | Jun 24, 2010 | Jul DISC |

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | PAI HOLDINGS PHARM | EQ 300MG CARBONATE/5ML | A070755 | 001 | May 21, 1986 | Mar CMFD |

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | + | CHIESI | EQ 2MG BASE | N203858 | 007 | Feb 25, 2026 | Feb NEWA |
| | +! | | EQ 30MG BASE | N203858 | 004 | Apr 23, 2015 | Mar CHRS |

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | MICRO LABS | 25MG | A091541 | 001 | Sep 24, 2012 | Aug DISC |
| | @ | | 50MG | A091541 | 002 | Sep 24, 2012 | Aug DISC |
| | @ | | 100MG | A091541 | 003 | Sep 24, 2012 | Aug DISC |

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | SUN PHARM | 0.5% | A215384 | 001 | Aug 09, 2023 | Jul DISC |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | SUSPENSION/DROPS;OPHTHALMIC | | | | | | | |
| >D> | | INVELTYS | | | | | | | |
| >D> | | +! | ALCON LABS INC | 1% | N210565 | 001 | Aug 22, 2018 | Oct | DISC |
| >A> | | @ + | | 1% | N210565 | 001 | Aug 22, 2018 | Oct | DISC |
| | | LOVASTATIN | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | LOVASTATIN | | | | | | | |
| | AB | | MACLEODS PHARMS | 10MG | A077748 | 001 | Feb 28, 2007 | Sep | CAHN |
| | AB | | | 20MG | A077748 | 002 | Feb 28, 2007 | Sep | CAHN |
| | AB | | | 40MG | A077748 | 003 | Feb 28, 2007 | Sep | CAHN |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| | | ALTOPREV | | | | | | | |
| | | @ | AZURITY | 10MG | N021316 | 001 | Jun 26, 2002 | Jul | CAHN |
| | | @ | | 10MG | N021316 | 001 | Jun 26, 2002 | Mar | CAHN |
| | | @ + | | 20MG | N021316 | 002 | Jun 26, 2002 | Jul | CAHN |
| | | @ + | | 20MG | N021316 | 002 | Jun 26, 2002 | Mar | CAHN |
| | | @ + | | 40MG | N021316 | 003 | Jun 26, 2002 | Jul | CAHN |
| | | @ + | | 40MG | N021316 | 003 | Jun 26, 2002 | Mar | CAHN |
| | | @ + | | 60MG | N021316 | 004 | Jun 26, 2002 | Jul | CAHN |
| | | @ + | | 60MG | N021316 | 004 | Jun 26, 2002 | Mar | CAHN |
| | | LUBIPROSTONE | | | | | | | |
| | | CAPSULE;ORAL | | | | | | | |
| | | LUBIPROSTONE | | | | | | | |
| | AB | | AMNEAL | 8MCG | A209450 | 001 | Nov 30, 2021 | Jan | CMFD |
| | AB | | | 24MCG | A209450 | 002 | Nov 30, 2021 | Jan | CMFD |
| >A> | AB | | HUMANWELL PURACAP | 8MCG | A221049 | 001 | Oct 14, 2026 | Oct | NEWA |
| >A> | AB | | | 24MCG | A221049 | 002 | Oct 14, 2026 | Oct | NEWA |
| | | LURASIDONE HYDROCHLORIDE | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | LURASIDONE HYDROCHLORIDE | | | | | | | |
| >A> | AB | | HERITAGE | 20MG | A208058 | 001 | Sep 04, 2019 | Oct | CAHN |
| >A> | AB | | | 40MG | A208058 | 002 | Sep 04, 2019 | Oct | CAHN |
| >A> | AB | | | 60MG | A208058 | 003 | Sep 04, 2019 | Oct | CAHN |
| >A> | AB | | | 80MG | A208058 | 004 | Sep 04, 2019 | Oct | CAHN |
| >A> | AB | | | 120MG | A208058 | 005 | Feb 28, 2023 | Oct | CAHN |
| >D> | AB | | HERITAGE PHARMA AVET | 20MG | A208058 | 001 | Sep 04, 2019 | Oct | CAHN |
| >D> | AB | | | 40MG | A208058 | 002 | Sep 04, 2019 | Oct | CAHN |
| >D> | AB | | | 60MG | A208058 | 003 | Sep 04, 2019 | Oct | CAHN |
| >D> | AB | | | 80MG | A208058 | 004 | Sep 04, 2019 | Oct | CAHN |
| >D> | AB | | | 120MG | A208058 | 005 | Feb 28, 2023 | Oct | CAHN |
| | | LUTETIUM LU 177 DOTATATE | | | | | | | |
| | | SOLUTION;INTRAVENOUS | | | | | | | |
| | | LUTATHERA | | | | | | | |
| | AP | +! | AAA USA INC | 10mCi/ML | N208700 | 001 | Jan 26, 2018 | Sep | CFTG |
| | | LUTETIUM LU-177 DOTATATE | | | | | | | |
| | | SOLUTION;INTRAVENOUS | | | | | | | |
| | | BEXLUTRY | | | | | | | |
| | | +! | CURIUM | 10mCi/ML | N218525 | 001 | Sep 14, 2026 | Sep | NEWA |
| | | BRAVNETSA | | | | | | | |
| | AP | | LANTHEUS MEDICAL | 10mCi/ML | A217060 | 001 | Sep 21, 2026 | Sep | NFTG |
| | | LUTATHERA | | | | | | | |
| | AP | +! | AAA USA INC | 10mCi/ML | N208700 | 001 | Jan 26, 2018 | Sep | CAIN |
| | | MACIMORELIN ACETATE | | | | | | | |
| | | FOR SOLUTION;ORAL | | | | | | | |
| | | MACRILEN | | | | | | | |
| | | @ + | AETERNA ZENTARIS | EQ 60MG BASE/POUCH | N205598 | 001 | Dec 20, 2017 | Jan | CAHN |
| | | MACITENTAN | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | MACITENTAN | | | | | | | |
| | AB | | AMNEAL | 10MG | A211000 | 001 | Jun 08, 2026 | May | NEWA |
| | AB | | APOTEX | 10MG | A211195 | 001 | Jan 09, 2024 | Mar | CMFD |
| | AB | | LEPU PHARM | 10MG | A211026 | 001 | Dec 03, 2025 | Aug | CAHN |
| | AB | | MYLAN | 10MG | A211161 | 001 | Dec 03, 2025 | May | CMFD |
| | AB | | SEASONS BIOTECH | 10MG | A211026 | 001 | Dec 03, 2025 | Apr | CMFD |
| | AB | | TEVA PHARMS USA INC | 10MG | A211187 | 001 | Jun 08, 2026 | May | NEWA |

TABLET;ORAL
MACITENTAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | TORRENT | 10MG | A211107 | 001 | Aug 05, 2024 | Apr CMFD |
| AB | | ZYDUS LIFESCIENCES | 10MG | A211224 | 001 | Apr 06, 2021 | Apr CMFD |

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL
MAFENIDE ACETATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | INGENUS PHARMS LLC | 5% | A206716 | 001 | Jul 31, 2017 | Feb CAHN |

MAGNESIUM SULFATE

INJECTABLE;INJECTION
MAGNESIUM SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ! | BAXTER HLTHCARE CORP | 3GM/100ML (30MG/ML) | A211966 | 004 | Jan 08, 2026 | Jan NFTG |

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PHARMOBEDIENT | 1GM/100ML | A209932 | 001 | Sep 10, 2018 | Sep DISC |

MAGNESIUM SULFATE IN PLASTIC CONTAINER

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | ! | FRESENIUS KABI USA | 4GM/100ML (40MG/ML) | A206485 | 001 | Mar 15, 2016 | Sep CHRS |
| AP | ! | | 4GM/50ML (80MG/ML) | A206485 | 002 | Mar 15, 2016 | Sep CHRS |
| AP | ! | | 2GM/50ML (40MG/ML) | A206485 | 003 | Mar 15, 2016 | Sep CHRS |
| AP | ! | | 20GM/500ML (40MG/ML) | A206485 | 004 | Mar 15, 2016 | Sep CHRS |
| AP | ! | | 40GM/1000ML (40MG/ML) | A206485 | 005 | Mar 15, 2016 | Sep CHRS |
| AP | + | HOSPIRA | 4GM/100ML (40MG/ML) | N020309 | 001 | Jun 24, 1994 | Sep CHRS |
| | @ + | | 4GM/50ML (80MG/ML) | N020309 | 002 | Jun 24, 1994 | Sep DISC |
| | @ | MYLAN LABS LTD | 2GM/50ML (40MG/ML) | A209911 | 001 | Sep 14, 2018 | Mar DISC |
| | @ | PHARMOBEDIENT | 2GM/50ML (40MG/ML) | A209911 | 001 | Sep 14, 2018 | Aug CAHN |
| | @ | | 4GM/100ML (40MG/ML) | A209911 | 002 | Sep 14, 2018 | Aug CAHN |

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | ADAPTIS | 1GM/2ML (500MG/ML) | A217461 | 001 | Jul 09, 2026 | Sep CAHN |
| AP | | | 5GM/10ML (500MG/ML) | A217461 | 002 | Jul 09, 2026 | Sep CAHN |
| AP | | | 10GM/20ML (500MG/ML) | A217461 | 003 | Jul 09, 2026 | Sep CAHN |
| AP | | | 25GM/50ML (500MG/ML) | A217461 | 004 | Jul 09, 2026 | Sep CAHN |
| AP | | SQUARE PHARMS PLC | 1GM/2ML (500MG/ML) | A217461 | 001 | Jul 09, 2026 | Jul NEWA |
| AP | | | 5GM/10ML (500MG/ML) | A217461 | 002 | Jul 09, 2026 | Jul NEWA |
| AP | | | 10GM/20ML (500MG/ML) | A217461 | 003 | Jul 09, 2026 | Jul NEWA |
| AP | | | 25GM/50ML (500MG/ML) | A217461 | 004 | Jul 09, 2026 | Jul NEWA |

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

TABLET;ORAL
SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | LUPIN | 0.225GM;0.188GM;1.479GM | A216095 | 001 | May 28, 2026 | May NFTG |

SUTAB

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | AZURITY | 0.225GM;0.188GM;1.479GM | N213135 | 001 | Nov 10, 2020 | May CFTG |

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | MACLEODS PHARMS LTD | 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT | A219429 | 001 | Aug 31, 2026 | Aug NEWA |

MALATHION

LOTION;TOPICAL
MALATHION

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ! | COHANCE LIFESCIENCES | 0.5% | A091559 | 001 | May 23, 2012 | Sep CAHN |

MARALIXIBAT CHLORIDE

TABLET;ORAL
LIVMARLI

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | MIRUM | EQ 10MG BASE | N219485 | 001 | Apr 10, 2025 | Aug CHRS |
| | +! | | EQ 15MG BASE | N219485 | 002 | Apr 10, 2025 | Aug CHRS |
| | +! | | EQ 20MG BASE | N219485 | 003 | Apr 10, 2025 | Aug CHRS |

MARAVIROC

TABLET;ORAL
MARAVIROC

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | 150MG | A217114 | 001 | Aug 17, 2023 | Sep CAHN |
| AB | | | 300MG | A217114 | 002 | Aug 17, 2023 | Sep CAHN |
| AB | | RHODES PHARMS | 150MG | A216143 | 001 | Nov 04, 2025 | Sep CMFD |
| | @ | | 150MG | A216143 | 001 | Nov 04, 2025 | Apr DISC |
| AB | | | 300MG | A216143 | 002 | Nov 04, 2025 | Sep CMFD |
| | @ | | 300MG | A216143 | 002 | Nov 04, 2025 | Apr DISC |

MAVACAMTEN

CAPSULE;ORAL

CAMZYOS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | BRISTOL | 1MG | N214998 | 005 | Sep 30, 2026 | Sep NEWA |

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | | HERITAGE | 50MG | A205136 | 003 | Feb 22, 2019 | Jun CMFD |
| | AA | | PHARMAZONE | 12.5MG | A087128 | 002 | | Sep CAHN |
| | AA | | | 25MG | A087128 | 001 | | Sep CAHN |
| | AA | | QUAGEN | 25MG | A084092 | 003 | May 22, 1989 | Aug CAHN |
| | AA | | SENORES PHARMS | 12.5MG | A087128 | 002 | | Feb CAHN |
| | AA | | | 25MG | A087128 | 001 | | Feb CAHN |

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | EMERGE BIOSCIENCE | 150MG/ML | A076553 | 001 | Jul 28, 2004 | Oct CAHN |
| >D> | AB | | HONG KONG | 150MG/ML | A076553 | 001 | Jul 28, 2004 | Oct CAHN |

MELOXICAM

SOLUTION;INTRAVENOUS

XIFYRM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | AZURITY | 30MG/ML (30MG/ML) | N218395 | 001 | Jun 05, 2025 | Sep DISC |

SUSPENSION;ORAL

MELOXICAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | +! | AVONDALE PHARMS | 7.5MG/5ML | N021530 | 001 | Jun 01, 2004 | Oct CFTG |
| >A> | AB | +! | | 7.5MG/5ML | N021530 | 001 | Jun 01, 2004 | Oct CFTG |
| >A> | AB | | NOVITIUM PHARMA | 7.5MG/5ML | A220010 | 001 | Oct 15, 2026 | Oct NFTG |

TABLET;ORAL

MELOXICAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | MACLEODS PHARMS | 7.5MG | A077882 | 001 | Jul 20, 2006 | Sep CAHN |
| | AB | | | 15MG | A077882 | 002 | Jul 20, 2006 | Sep CAHN |
| | | @ | ZENNOVA | 7.5MG | A077933 | 001 | Jul 19, 2006 | Jul CAHN |
| | | @ | | 15MG | A077933 | 002 | Jul 19, 2006 | Jul CAHN |

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | INGENUS PHARMS LLC | EQ 50MG BASE/VIAL | A210947 | 001 | Feb 18, 2020 | May CAHN |
| | AP | | QUAGEN | EQ 50MG BASE/VIAL | A211463 | 001 | Sep 13, 2019 | Sep CAHN |

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | H2-PHARMA | 7MG | A213985 | 001 | Oct 11, 2022 | Aug CAHN |
| | AB | | | 14MG | A213985 | 002 | Oct 11, 2022 | Aug CAHN |
| | AB | | | 21MG | A213985 | 004 | Feb 06, 2024 | Aug CAHN |
| | AB | | | 28MG | A213985 | 003 | Oct 11, 2022 | Aug CAHN |

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | APOZEAL PHARMS | 2MG/ML | A205446 | 001 | Dec 07, 2015 | Jul CAHN |
| | AA | | MEDLEY PHARMS | 2MG/ML | A210319 | 001 | Aug 31, 2020 | Mar CAHN |
| | | @ | PHARMAZONE | 2MG/ML | A205446 | 001 | Dec 07, 2015 | Sep CAHN |
| | AA | | | 2MG/ML | A210319 | 001 | Aug 31, 2020 | Sep CAHN |

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | ! | DR REDDYS LABS LTD | 10MG | A090048 | 002 | Apr 14, 2010 | Mar CHRS |
| | | @ | PHARMAZONE | 5MG | A090073 | 001 | Sep 04, 2015 | Sep CAHN |
| | | @ | | 10MG | A090073 | 002 | Sep 04, 2015 | Sep CAHN |
| | AB | | PHARMOBEDIENT | 5MG | A212947 | 001 | Apr 03, 2020 | Sep CAHN |
| | AB | | | 10MG | A212947 | 002 | Apr 03, 2020 | Sep CAHN |
| | AB | | RENATA | 5MG | A209527 | 001 | May 07, 2018 | Feb CAHN |
| | AB | | | 10MG | A209527 | 002 | May 07, 2018 | Feb CAHN |
| | AB | | SOMERSET THERAPS LLC | 5MG | A209527 | 001 | May 07, 2018 | Sep CAHN |
| | AB | | | 10MG | A209527 | 002 | May 07, 2018 | Sep CAHN |
| | | @ | STRIDES PHARMA | 5MG | A202350 | 001 | May 23, 2017 | Jun DISC |
| | | @ | | 10MG | A202350 | 002 | May 23, 2017 | Jun DISC |

NAMENDA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | ABBVIE | 5MG | N021487 | 001 | Oct 16, 2003 | Mar DISC |

TABLET;ORAL
NAMENDA
@ + 10MG N021487 002 Oct 16, 2003 Mar DISC

MEPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
POLOCAINE
! FRESENIUS KABI USA 1% A089407 001 Dec 01, 1986 Jan CHRS
! 2% A089410 001 Dec 01, 1986 Jan CHRS
POLOCAINE-MPF
! FRESENIUS KABI USA 1% A089406 001 Dec 01, 1986 Jan CHRS
! 1.5% A089408 001 Dec 01, 1986 Jan CHRS
! 2% A089409 001 Dec 01, 1986 Jan CHRS

MERCAPTOPURINE
TABLET;ORAL
MERCAPTOPURINE
@ MYLAN 50MG A040594 001 Jul 01, 2005 Jun DISC

MEROPENEM
POWDER;INTRAVENOUS
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
+! B BRAUN MEDICAL 500MG/VIAL N202106 001 Apr 30, 2015 Jun CHRS
+ 500MG/VIAL N202106 001 Apr 30, 2015 Jun CRLD
+! 1GM/VIAL N202106 002 Apr 30, 2015 Jun CHRS
+ 1GM/VIAL N202106 002 Apr 30, 2015 Jun CRLD

MESALAMINE
CAPSULE, EXTENDED RELEASE;ORAL
MESALAMINE
AB DIFGEN PHARMS 250MG A219997 001 Mar 10, 2026 Feb NFTG
AB 500MG A219997 002 Mar 10, 2026 Feb NEWA
AB SANDOZ 250MG A219997 001 Mar 10, 2026 Jul CAHN
AB 500MG A219997 002 Mar 10, 2026 Jul CAHN
PENTASA
AB + TAKEDA PHARMS USA 250MG N020049 001 May 10, 1993 Feb CFTG
ENEMA;RECTAL
MESALAMINE
>D> AB ENCUBE 4GM/60ML A216941 001 May 30, 2023 Oct CAHN
>A> AB 4GM/60ML A216941 001 May 30, 2023 Oct CAHN
AB KLM LABS PVT 4GM/60ML A220016 001 Mar 31, 2026 Mar NEWA
SFROWASA
@ + MYLAN SPECIALITY LP 4GM/60ML N019618 002 Jun 20, 2008 Aug DISC
SUPPOSITORY;RECTAL
MESALAMINE
AB J MOLNER 1GM A208362 001 Jun 21, 2019 Jun CAHN
TABLET, DELAYED RELEASE;ORAL
MESALAMINE
>A> AB SCIEGEN PHARMS 1.2GM A217736 001 Oct 14, 2026 Oct NEWA

MESNA
INJECTABLE;INTRAVENOUS
MESNA
AP EUGIA PHARMA 100MG/ML A220518 001 Jan 27, 2026 Jan NEWA
TABLET;ORAL
MESNA
AB INGENUS PHARMS LLC 400MG A218871 001 Jan 13, 2025 Feb CAHN

METAPROTERENOL SULFATE
SYRUP;ORAL
METAPROTERENOL SULFATE
@ COSETTE PHARMS NC 10MG/5ML A072761 001 Feb 27, 1992 Jun CAHN

METAXALONE
TABLET;ORAL
METAXALONE
@ INGENUS PHARMS LLC 800MG A213836 001 Oct 21, 2020 Feb CAHN

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | CHARTWELL | 625MG | A075972 | 005 | Jan 24, 2002 | Jan CTEC |
| | AB | | | 750MG | A075972 | 004 | Jan 24, 2002 | Jan CTEC |
| | AB | | PHARMAZONE | 500MG | A076033 | 001 | Jan 24, 2002 | Sep CAHN |
| | AB | | | 500MG | A090888 | 001 | Mar 12, 2012 | Sep CAHN |
| | AB | | | 850MG | A076033 | 002 | Jan 24, 2002 | Sep CAHN |
| | AB | | | 850MG | A090888 | 002 | Mar 12, 2012 | Sep CAHN |
| | AB | | | 1GM | A076033 | 003 | Jan 24, 2002 | Sep CAHN |
| | AB | | | 1GM | A090888 | 003 | Mar 12, 2012 | Sep CAHN |
| | AB | | SCIEGEN PHARMS | 625MG | A203769 | 004 | Feb 09, 2026 | Jan NEWA |
| | AB | | | 750MG | A203769 | 005 | Feb 09, 2026 | Jan NEWA |

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB1 | | ADAPTIS | 500MG | A201991 | 001 | Jan 18, 2012 | Sep CAHN |
| | | @ | ALLIED | 500MG | A215629 | 001 | Jun 20, 2023 | Apr CAHN |
| | | @ | | 1GM | A215629 | 002 | Jun 20, 2023 | Apr CAHN |
| | | @ | AMNEAL PHARMS NY | 500MG | A078596 | 001 | Jan 03, 2008 | Mar DISC |
| | | @ | | 750MG | A078596 | 002 | Jan 03, 2008 | Mar DISC |
| | | @ | APOTEX | 500MG | A213356 | 001 | Dec 13, 2021 | Feb DISC |
| | | @ | | 1GM | A213356 | 002 | Dec 13, 2021 | Feb DISC |
| >D> | AB2 | | MYLAN PHARMS INC | 500MG | A200690 | 001 | Aug 01, 2012 | Oct DISC |
| >A> | | @ | | 500MG | A200690 | 001 | Aug 01, 2012 | Oct DISC |
| >D> | AB2 | | | 1GM | A200690 | 002 | Aug 01, 2012 | Oct DISC |
| >A> | | @ | | 1GM | A200690 | 002 | Aug 01, 2012 | Oct DISC |
| | AB1 | | PHARMAZONE | 500MG | A090295 | 001 | Apr 29, 2016 | Sep CAHN |
| | | @ | | 500MG | A215629 | 001 | Jun 20, 2023 | Sep CAHN |
| | AB | | | 750MG | A090295 | 002 | Apr 29, 2016 | Sep CAHN |
| | | @ | | 1GM | A215629 | 002 | Jun 20, 2023 | Sep CAHN |
| | AB1 | | PLATINUM | 500MG | A202306 | 001 | Feb 23, 2017 | Apr CAHN |
| | AB | | | 750MG | A202306 | 002 | Feb 23, 2017 | Apr CAHN |
| | | @ | RK PHARMA | 500MG | A215629 | 001 | Jun 20, 2023 | Jan DISC |
| | | @ | | 1GM | A215629 | 002 | Jun 20, 2023 | Jan DISC |
| | | @ | SENORES PHARMS | 500MG | A215629 | 001 | Jun 20, 2023 | Apr CAHN |
| | | @ | | 1GM | A215629 | 002 | Jun 20, 2023 | Apr CAHN |

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | APOTEX | 500MG;EQ 50MG BASE | A202426 | 001 | Apr 30, 2026 | Apr NEWA |
| | AB | | | 1GM;EQ 50MG BASE | A202426 | 002 | Apr 30, 2026 | Apr NEWA |

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | + | MSD SUB MERCK | 500MG;EQ 50MG BASE | N202270 | 001 | Feb 02, 2012 | May CTEC |
| | AB | + | | 1GM;EQ 50MG BASE | N202270 | 002 | Feb 02, 2012 | May CTEC |
| | AB | +! | | 1GM;EQ 100MG BASE | N202270 | 003 | Feb 02, 2012 | May CTEC |

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | PH HEALTH | 500MG;EQ 50MG BASE | A204144 | 001 | Jun 04, 2025 | May CMFD |
| | AB | | | 1GM;EQ 50MG BASE | A204144 | 002 | Jun 04, 2025 | May CMFD |
| | AB | | | 1GM;EQ 100MG BASE | A204144 | 003 | Jun 04, 2025 | May CMFD |

METHADONE HYDROCHLORIDE

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | | VISTAPHARM LLC | 5MG/5ML | A090707 | 001 | Jun 30, 2010 | Feb CMFD |

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | AJANTA PHARMA LTD | 25MG | A217408 | 001 | Feb 09, 2026 | Jan NEWA |
| | AB | | | 50MG | A217408 | 002 | Feb 09, 2026 | Jan NEWA |
| | AB | | PHARMOBEDIENT | 25MG | A040062 | 001 | Jan 27, 1994 | Sep CAHN |
| | | @ | | 25MG | A040102 | 001 | Aug 28, 1996 | Sep CAHN |
| | AB | ! | | 50MG | A040062 | 002 | Jan 27, 1994 | Sep CAHN |
| | | @ | | 50MG | A040102 | 002 | Aug 28, 1996 | Sep CAHN |
| | | @ | POM PHARMA | 25MG | A040102 | 001 | Aug 28, 1996 | Apr CAHN |
| | | @ | | 50MG | A040102 | 002 | Aug 28, 1996 | Apr CAHN |

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | INGENUS PHARMS LLC | 1GM | A210068 | 001 | Nov 27, 2020 | Feb CAHN |

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | HAINAN POLY | 1GM/10ML (100MG/ML) | A208116 | 001 | Jan 19, 2017 | Jul CAHN |

SUSPENSION;ORAL

ATMEKSI

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | ROSEMONT PHARMS | 750MG/5ML | N219843 | 001 | Jul 30, 2025 | May CAHN |

TABLET;ORAL

METHOCARBAMOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | DBL PHARMS | 500MG | A203550 | 001 | Feb 08, 2017 | Mar CAHN |
| AA | | | 750MG | A203550 | 002 | Feb 08, 2017 | Mar CAHN |
| | @ | HIKMA | 500MG | A085123 | 002 | | Sep CAHN |
| | @ | | 750MG | A085123 | 001 | | Sep CAHN |
| | @ | HIKMA INTL PHARMS | 500MG | A085123 | 002 | | Jun CMS1 |
| AA | | HLTHCARE | 500MG | A203550 | 001 | Feb 08, 2017 | Aug CAHN |
| AA | | | 500MG | A203550 | 001 | Feb 08, 2017 | Feb CAHN |
| AA | | | 750MG | A203550 | 002 | Feb 08, 2017 | Aug CAHN |
| AA | | | 750MG | A203550 | 002 | Feb 08, 2017 | Feb CAHN |
| AA | | PHARMAZONE | 500MG | A212623 | 001 | Apr 30, 2021 | Sep CAHN |
| AA | | | 750MG | A212623 | 002 | Apr 30, 2021 | Sep CAHN |
| AA | | PHARMOBEDIENT | 500MG | A203550 | 001 | Feb 08, 2017 | Sep CAHN |
| AA | | | 750MG | A203550 | 002 | Feb 08, 2017 | Sep CAHN |
| AB | | | 1GM | A212707 | 001 | Jun 12, 2023 | Sep CAHN |

METHOTREXATE

SOLUTION;SUBCUTANEOUS

OTREXUP

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | + | COSETTE | 7.5MG/0.4ML (7.5MG/0.4ML) | N204824 | 005 | Nov 07, 2014 | Jun CAHN |
| @ | + | | 10MG/0.4ML (10MG/0.4ML) | N204824 | 001 | Oct 11, 2013 | Jun CAHN |
| @ | + | | 12.5MG/0.4ML (12.5MG/0.4ML) | N204824 | 006 | Mar 24, 2016 | Jun CAHN |
| @ | + | | 15MG/0.4ML (15MG/0.4ML) | N204824 | 002 | Oct 11, 2013 | Jun CAHN |
| @ | + | | 17.5MG/0.4ML (17.5MG/0.4ML) | N204824 | 007 | Mar 24, 2016 | Jun CAHN |
| @ | + | | 20MG/0.4ML (20MG/0.4ML) | N204824 | 003 | Oct 11, 2013 | Jun CAHN |
| @ | + | | 22.5MG/0.4ML (22.5MG/0.4ML) | N204824 | 008 | Mar 24, 2016 | Jun CAHN |
| @ | + | | 25MG/0.4ML (25MG/0.4ML) | N204824 | 004 | Oct 11, 2013 | Jun CAHN |

OTREXUP PFS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | + | COSETTE | 10MG/0.4ML (10MG/0.4ML) | N204824 | 009 | May 31, 2017 | Jun CAHN |
| @ | + | | 15MG/0.6ML (15MG/0.6ML) | N204824 | 010 | May 31, 2017 | Jun CAHN |
| @ | + | | 17.5MG/0.7ML (17.5MG/0.7ML) | N204824 | 011 | May 31, 2017 | Jun CAHN |
| @ | + | | 20MG/0.8ML (20MG/0.8ML) | N204824 | 012 | May 31, 2017 | Jun CAHN |
| @ | + | | 22.5MG/0.9ML (22.5MG/0.9ML) | N204824 | 013 | May 31, 2017 | Jun CAHN |
| @ | + | | 25MG/ML (25MG/ML) | N204824 | 014 | May 31, 2017 | Jun CAHN |

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | ALEMBIC | EQ 50MG BASE/2ML (EQ 25MG BASE/ML) | A220225 | 001 | Apr 15, 2026 | Apr NEWA |
| AP | | | EQ 1GM BASE/40ML (EQ 25MG BASE/ML) | A220225 | 002 | Apr 15, 2026 | Apr NEWA |
| AP | | HETERO LABS LTD VI | EQ 50MG BASE/2ML (EQ 25MG BASE/ML) | A219865 | 001 | Apr 30, 2026 | Apr NEWA |
| AP | ! | HIKMA | EQ 200MG BASE/8ML (EQ 25MG BASE/ML) | A089342 | 001 | Sep 16, 1986 | Apr CTEC |

METHOTREXATE SODIUM PRESERVATIVE FREE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | CAPLIN ONE LABS | EQ 50MG BASE/2ML (EQ 25MG BASE/ML) | A090039 | 001 | Mar 31, 2009 | Mar DISC |
| AP | | | EQ 50MG BASE/2ML (EQ 25MG BASE/ML) | A090039 | 001 | Mar 31, 2009 | Jan CAHN |
| @ | | | EQ 250MG BASE/10ML (EQ 25MG BASE/ML) | A090039 | 002 | Mar 31, 2009 | Mar DISC |
| AP | | | EQ 250MG BASE/10ML (EQ 25MG BASE/ML) | A090039 | 002 | Mar 31, 2009 | Jan CAHN |
| @ | | | EQ 1GM BASE/40ML (EQ 25MG BASE/ML) | A090029 | 001 | Mar 31, 2009 | Mar DISC |
| AP | | | EQ 1GM BASE/40ML (EQ 25MG BASE/ML) | A090029 | 001 | Mar 31, 2009 | Jan CAHN |
| AP | | EUGIA PHARMA SPECLTS | EQ 50MG BASE/2ML (EQ 25MG BASE/ML) | A201529 | 001 | Mar 29, 2012 | Apr CMFD |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | INJECTABLE;INJECTION | | | | | | |
| | | METHOTREXATE SODIUM PRESERVATIVE FREE | | | | | | |
| AP | | | EQ 100MG BASE/4ML (EQ 25MG BASE/ML) | A201529 | 002 | Mar 29, 2012 | Apr | CMFD |
| AP | | | EQ 200MG BASE/8ML (EQ 25MG BASE/ML) | A201529 | 003 | Mar 29, 2012 | Apr | CMFD |
| AP | | | EQ 250MG BASE/10ML (EQ 25MG BASE/ML) | A201529 | 004 | Mar 29, 2012 | Apr | CMFD |
| | | TABLET;ORAL | | | | | | |
| | | METHOTREXATE SODIUM | | | | | | |
| | @ | DAITO | EQ 2.5MG BASE | A213362 | 001 | Aug 07, 2023 | Mar | DISC |
| | | METHOXSALEN | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | METHOXSALEN | | | | | | |
| AB | | ONESOURCE | 10MG | A202687 | 001 | Jun 05, 2014 | Jul | CAHN |
| | | METHSCOPOLAMINE BROMIDE | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | PAMINE | | | | | | |
| | @ | FOUGERA | 2.5MG | N008848 | 001 | | Jul | CAHN |
| | | PAMINE FORTE | | | | | | |
| | @ | FOUGERA | 5MG | N008848 | 002 | Mar 25, 2003 | Jul | CAHN |
| | | METHYLDOPA | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | METHYLDOPA | | | | | | |
| | @ | QUAGEN | 125MG | A070535 | 001 | Jan 02, 1987 | Apr | CAHN |
| | @ | | 250MG | A070536 | 001 | Jan 02, 1987 | Apr | CAHN |
| | @ | | 500MG | A070537 | 001 | Jan 02, 1987 | Apr | CAHN |
| | | METHYLENE BLUE | | | | | | |
| | | SOLUTION;INTRAVENOUS | | | | | | |
| | | METHYLENE BLUE | | | | | | |
| | ! | ZYDUS LIFESCIENCES | 5MG/ML (5MG/ML) | A215636 | 003 | Feb 02, 2026 | Jan | NFTG |
| | ! | | 100MG/10ML (10MG/ML) | A215636 | 004 | Mar 31, 2026 | Mar | NFTG |
| | | METHYLPHENIDATE | | | | | | |
| | | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | | | | | | |
| | | COTEMPLA XR-ODT | | | | | | |
| AB | + | NEOS THERAPS INC | 8.6MG | N205489 | 001 | Jun 19, 2017 | May | CTEC |
| AB | + | | 17.3MG | N205489 | 002 | Jun 19, 2017 | May | CTEC |
| AB | +! | | 25.9MG | N205489 | 003 | Jun 19, 2017 | May | CTEC |
| | | METHYLPHENIDATE | | | | | | |
| AB | | ACTAVIS ELIZABETH | 8.6MG | A210924 | 001 | Jun 19, 2020 | May | CMFD |
| AB | | | 17.3MG | A210924 | 002 | Jun 19, 2020 | May | CMFD |
| AB | | | 25.9MG | A210924 | 003 | Jun 19, 2020 | May | CMFD |
| | | METHYLPHENIDATE HYDROCHLORIDE | | | | | | |
| | | CAPSULE, EXTENDED RELEASE;ORAL | | | | | | |
| | | ADHANSIA XR | | | | | | |
| | @ + | KNOA PHARMA | 25MG | N212038 | 001 | Feb 27, 2019 | May | CAHN |
| | @ + | | 35MG | N212038 | 002 | Feb 27, 2019 | May | CAHN |
| | @ + | | 45MG | N212038 | 003 | Feb 27, 2019 | May | CAHN |
| | @ + | | 55MG | N212038 | 004 | Feb 27, 2019 | May | CAHN |
| | @ + | | 70MG | N212038 | 005 | Feb 27, 2019 | May | CAHN |
| | @ + | | 85MG | N212038 | 006 | Feb 27, 2019 | May | CAHN |
| | | METADATE CD | | | | | | |
| AB2 | + | LANNETT | 10MG | N021259 | 003 | May 27, 2003 | Aug | CAHN |
| AB2 | + | | 10MG | N021259 | 003 | May 27, 2003 | Jun | CAHN |
| AB2 | + | | 20MG | N021259 | 001 | Apr 03, 2001 | Aug | CAHN |
| AB2 | + | | 20MG | N021259 | 001 | Apr 03, 2001 | Jun | CAHN |
| AB2 | + | | 30MG | N021259 | 002 | Jun 19, 2003 | Aug | CAHN |
| AB2 | + | | 30MG | N021259 | 002 | Jun 19, 2003 | Jun | CAHN |
| AB2 | + | | 40MG | N021259 | 004 | Feb 19, 2006 | Aug | CAHN |
| AB2 | + | | 40MG | N021259 | 004 | Feb 19, 2006 | Jun | CAHN |
| AB2 | + | | 50MG | N021259 | 005 | Feb 19, 2006 | Aug | CAHN |
| AB2 | + | | 50MG | N021259 | 005 | Feb 19, 2006 | Jun | CAHN |
| AB2 | +! | | 60MG | N021259 | 006 | Feb 19, 2006 | Aug | CAHN |
| AB2 | +! | | 60MG | N021259 | 006 | Feb 19, 2006 | Jun | CAHN |
| | | METHYLPHENIDATE HYDROCHLORIDE | | | | | | |
| AB1 | | DR REDDYS LABS SA | 60MG | A078458 | 004 | Jun 23, 2016 | Feb | CHRS |
| AB1 | ! | GRANULES | 60MG | A211796 | 005 | May 23, 2019 | Feb | CHRS |

SOLUTION;ORAL
METHYLPHENIDATE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | ADAPTIS | 5MG/5ML | A210139 | 001 | Oct 03, 2018 | Sep CAHN |
| AA | | | 10MG/5ML | A210139 | 002 | Oct 03, 2018 | Sep CAHN |

TABLET;ORAL
METHYLPHENIDATE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | MPP PHARMA | 5MG | A207587 | 001 | Mar 03, 2017 | Sep CMFD |
| AB | | | 10MG | A207587 | 002 | Mar 03, 2017 | Sep CMFD |
| AB | | | 20MG | A207587 | 003 | Mar 03, 2017 | Sep CMFD |

TABLET, CHEWABLE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | QUAGEN | 2.5MG | A204954 | 001 | Jan 26, 2017 | Apr CAHN |
| | @ | | 5MG | A204954 | 002 | Jan 26, 2017 | Apr CAHN |
| | @ | | 10MG | A204954 | 003 | Jan 26, 2017 | Apr CAHN |

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | SPECGX LLC | 27MG | A202608 | 001 | Dec 28, 2012 | Jun DISC |
| | @ | | 36MG | A202608 | 002 | Dec 28, 2012 | Jun DISC |
| | @ | | 54MG | A202608 | 003 | Dec 28, 2012 | Jun DISC |
| | @ | SUN PHARM INDS INC | 18MG | A205135 | 001 | Aug 19, 2020 | Jul DISC |
| | @ | | 27MG | A205135 | 002 | Aug 19, 2020 | Jul DISC |
| | @ | | 36MG | A205135 | 003 | Aug 19, 2020 | Jul DISC |
| | @ | | 54MG | A205135 | 004 | Aug 19, 2020 | Jul DISC |

METHYLPREDNISOLONE

TABLET;ORAL
METHYLPREDNISOLONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | INGENUS PHARMS LLC | 4MG | A210985 | 001 | Jan 09, 2019 | Feb CAHN |
| | @ | QUAGEN | 4MG | A212262 | 001 | Jun 27, 2019 | Sep CAHN |

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE ACETATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CAPLIN | 40MG/ML | A220556 | 001 | Jan 26, 2026 | Jan NEWA |
| AB | | | 80MG/ML | A220556 | 002 | Jan 26, 2026 | Jan NEWA |
| AB | | EMERGE BIOSCIENCE | 40MG/ML | A040557 | 001 | Feb 23, 2005 | Aug CAHN |
| AB | | | 80MG/ML | A040557 | 002 | Feb 23, 2005 | Aug CAHN |
| >A> AB | | GLAND | 40MG/ML | A219662 | 001 | Nov 02, 2026 | Oct NEWA |
| >A> AB | | | 80MG/ML | A219662 | 002 | Nov 02, 2026 | Oct NEWA |

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | BAXTER HLTHCARE CORP | EQ 5MG BASE/ML | A217072 | 001 | Sep 11, 2026 | Sep NEWA |
| AP | | FRESENIUS KABI USA | EQ 5MG BASE/ML | A091392 | 001 | Apr 19, 2013 | Jun CMFD |

SOLUTION;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | ! | PAI HOLDINGS | EQ 5MG BASE/5ML | A072744 | 001 | May 28, 1991 | May CAHN |

SPRAY, METERED;NASAL
GIMOTI

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | QOL MEDCL | EQ 15MG BASE/SPRAY | N209388 | 001 | Jun 19, 2020 | Feb CAHN |

TABLET;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | STRIDES PHARMA INTL | EQ 10MG BASE | A070581 | 001 | Oct 17, 1985 | Jan DISC |

METOLAZONE

TABLET;ORAL
METOLAZONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ACERTIS PHARMS | 2.5MG | A218606 | 001 | Apr 17, 2024 | Aug CAHN |
| AB | | | 5MG | A218606 | 002 | Apr 17, 2024 | Aug CAHN |
| AB | | | 10MG | A218606 | 003 | Apr 17, 2024 | Aug CAHN |
| | @ | MICRO LABS | 2.5MG | A217563 | 001 | Nov 06, 2024 | Aug DISC |
| | @ | | 5MG | A217563 | 002 | Nov 06, 2024 | Aug DISC |
| | @ | | 10MG | A217563 | 003 | Nov 06, 2024 | Aug DISC |

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ALICORA | EQ 25MG TARTRATE | A203028 | 001 | Mar 31, 2020 | Sep CAHN |
| AB | | | EQ 50MG TARTRATE | A203028 | 002 | Mar 31, 2020 | Sep CAHN |
| AB | | | EQ 100MG TARTRATE | A203699 | 001 | Mar 30, 2020 | Sep CAHN |
| AB | | | EQ 200MG TARTRATE | A203699 | 002 | Mar 30, 2020 | Sep CAHN |

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | | MYLAN PHARMS INC | EQ 25MG TARTRATE | A202033 | 001 | Dec 15, 2011 | Jun DISC |
| | @ | | | EQ 50MG TARTRATE | A202033 | 002 | Dec 15, 2011 | Jun DISC |
| | @ | | | EQ 100MG TARTRATE | A202033 | 003 | Dec 15, 2011 | May DISC |
| | @ | | | EQ 200MG TARTRATE | A202033 | 004 | Dec 15, 2011 | Mar DISC |
| AB | | | ZHEJIANG JUTAI PHARM | EQ 25MG TARTRATE | A214110 | 004 | May 15, 2026 | May NEWA |

METOPROLOL TARTRATE
TABLET;ORAL
METOPROLOL TARTRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | ADAPTIS | 50MG | A074453 | 001 | Apr 27, 1995 | Sep CAHN |
| AB | | | | 100MG | A074453 | 002 | Apr 27, 1995 | Sep CAHN |

METRONIDAZOLE
CREAM;TOPICAL
METRONIDAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | COSETTE PHARMS NC | 0.75% | A077549 | 001 | Dec 19, 2007 | May CAHN |

GEL;TOPICAL
METRONIDAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ! | COSETTE PHARMS NC | 0.75% | A078178 | 001 | Jan 19, 2011 | May CAHN |
| AB | | | | 1% | A216692 | 001 | Jan 23, 2023 | May CAHN |
| >D> AB | | | ENCUBE | 0.75% | A077547 | 001 | Jul 13, 2006 | Oct CAHN |
| >A> AB | | | | 0.75% | A077547 | 001 | Jul 13, 2006 | Oct CAHN |
| AB | | | ZYDUS LIFESCIENCES | 0.75% | A220095 | 001 | Feb 13, 2026 | Feb NEWA |

GEL;VAGINAL
METRONIDAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | AMVIKA | 0.75% | A213648 | 001 | Oct 14, 2021 | Sep CAHN |
| AB | | | AUROBINDO PHARMA LTD | 0.75% | A218485 | 001 | Sep 25, 2026 | Sep NEWA |
| AB | | | COSETTE PHARMS NC | 0.75% | A216323 | 001 | Jul 12, 2023 | May CAHN |
| >D> | @ | | ENCUBE | 0.75% | A077264 | 001 | Oct 31, 2006 | Oct CAHN |
| >A> | @ | | | 0.75% | A077264 | 001 | Oct 31, 2006 | Oct CAHN |
| >D> AB | | ! | | 0.75% | A215610 | 001 | Jun 16, 2023 | Oct CAHN |
| >A> AB | | ! | | 0.75% | A215610 | 001 | Jun 16, 2023 | Oct CAHN |
| >D> | @ | | | 1.3% | A216795 | 001 | Mar 18, 2024 | Oct CAHN |
| >A> | @ | | | 1.3% | A216795 | 001 | Mar 18, 2024 | Oct CAHN |

NUVESSA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | ALEMBIC THERAP | 1.3% | N205223 | 001 | Mar 24, 2014 | May CAHN |

INJECTABLE;INJECTION
METRO I.V. IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | | B BRAUN | 500MG/100ML | N018900 | 001 | Sep 29, 1983 | Jan DISC |

METRONIDAZOLE IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ! | INFORLIFE | 500MG/100ML | A206191 | 001 | Feb 25, 2019 | Jan CHRS |

MEXILETINE HYDROCHLORIDE
CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | INGENUS PHARMS LLC | 150MG | A214352 | 001 | Jan 25, 2021 | Feb CAHN |
| AB | | | | 200MG | A214352 | 002 | Jan 25, 2021 | Feb CAHN |
| AB | | | | 250MG | A214352 | 003 | Jan 25, 2021 | Feb CAHN |
| AB | | | MACLEODS PHARMS | 150MG | A219987 | 001 | Mar 23, 2026 | Mar NEWA |
| AB | | | | 200MG | A219987 | 002 | Mar 23, 2026 | Mar NEWA |
| AB | | | | 250MG | A219987 | 003 | Mar 23, 2026 | Mar NEWA |
| AB | | | PHARMAZONE | 150MG | A214089 | 001 | Oct 01, 2021 | Sep CAHN |
| AB | | | | 200MG | A214089 | 002 | Oct 01, 2021 | Sep CAHN |
| AB | | | | 250MG | A214089 | 003 | Oct 01, 2021 | Sep CAHN |
| AB | | | ZYDUS PHARMS | 150MG | A214598 | 001 | Sep 23, 2026 | Sep NEWA |
| AB | | | | 200MG | A214598 | 002 | Sep 23, 2026 | Sep NEWA |
| AB | | | | 250MG | A214598 | 003 | Sep 23, 2026 | Sep NEWA |

MICAFUNGIN SODIUM
INJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | | ASPIRO | EQ 50MG BASE/VIAL | A220296 | 001 | Mar 17, 2026 | Mar NEWA |
| AP | | | | EQ 100MG BASE/VIAL | A220296 | 002 | Mar 17, 2026 | Mar NEWA |
| AP | | | HISUN PHARM HANGZHOU | EQ 50MG BASE/VIAL | A219712 | 001 | Jan 21, 2026 | Jan NEWA |
| AP | | | | EQ 100MG BASE/VIAL | A219712 | 002 | Jan 21, 2026 | Jan NEWA |
| AP | | | YICHANG HUMANWELL | EQ 50MG BASE/VIAL | A219518 | 001 | Feb 24, 2026 | Feb NEWA |
| AP | | | | EQ 100MG BASE/VIAL | A219518 | 002 | Feb 24, 2026 | Feb NEWA |

POWDER;INTRAVENOUS
MICAFUNGIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | | PH HEALTH | EQ 50MG BASE/VIAL | N212156 | 001 | Jun 16, 2021 | Aug DISC |

POWDER;INTRAVENOUS
MICAFUNGIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | | EQ 100MG BASE/VIAL | N212156 | 002 | Jun 16, 2021 | Aug DISC |

MIDODRINE HYDROCHLORIDE

TABLET;ORAL
MIDODRINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ! | AUROBINDO PHARMA LTD | 5MG | A212774 | 002 | Aug 10, 2020 | Sep CHRS |
| | @ | IMPAX PHARMS | 2.5MG | A076449 | 001 | May 27, 2004 | Apr DISC |
| | @ | | 5MG | A076449 | 002 | May 27, 2004 | Apr DISC |
| | @ | | 10MG | A076449 | 003 | Dec 16, 2005 | Apr DISC |
| AB | | UNIQUE | 2.5MG | A207613 | 001 | Nov 02, 2018 | Mar CAHN |
| AB | | | 5MG | A207613 | 002 | Nov 02, 2018 | Mar CAHN |
| AB | | | 10MG | A207613 | 003 | Nov 02, 2018 | Mar CAHN |

ORVATEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | BEIJING YILING | 5MG | A076725 | 002 | Nov 03, 2004 | Sep CHRS |

MIGLITOL

TABLET;ORAL
MIGLITOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ! | ORIENT PHARMA | 25MG | A203965 | 001 | Feb 24, 2015 | Mar CAHN |
| | | | 50MG | A203965 | 002 | Feb 24, 2015 | Mar CAHN |
| | | | 100MG | A203965 | 003 | Feb 24, 2015 | Mar CAHN |

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL
MILNACIPRAN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AMNEAL PHARMS | 12.5MG | A205081 | 001 | Apr 22, 2016 | Jan CMFD |
| AB | | | 25MG | A205081 | 002 | Apr 22, 2016 | Jan CMFD |
| AB | | | 50MG | A205081 | 003 | Apr 22, 2016 | Jan CMFD |
| AB | | | 100MG | A205081 | 004 | Apr 22, 2016 | Jan CMFD |
| AB | | BRECKENRIDGE | 12.5MG | A205071 | 001 | Jan 27, 2016 | Jan CMFD |
| AB | | | 25MG | A205071 | 002 | Jan 27, 2016 | Jan CMFD |
| AB | | | 50MG | A205071 | 003 | Jan 27, 2016 | Jan CMFD |
| AB | | | 100MG | A205071 | 004 | Jan 27, 2016 | Jan CMFD |
| AB | | HETERO LABS LTD V | 12.5MG | A205147 | 001 | Oct 03, 2024 | Feb CMFD |
| AB | | | 25MG | A205147 | 002 | Oct 03, 2024 | Feb CMFD |
| AB | | | 50MG | A205147 | 003 | Oct 03, 2024 | Feb CMFD |
| AB | | | 100MG | A205147 | 004 | Oct 03, 2024 | Feb CMFD |
| AB | | MACLEODS PHARMS | 12.5MG | A210944 | 001 | Sep 15, 2026 | Sep NEWA |
| AB | | | 25MG | A210944 | 002 | Sep 15, 2026 | Sep NEWA |
| AB | | | 50MG | A210944 | 003 | Sep 15, 2026 | Sep NEWA |
| AB | | | 100MG | A210944 | 004 | Sep 15, 2026 | Sep NEWA |
| AB | | STRIDES PHARMA | 12.5MG | A207399 | 001 | Sep 15, 2026 | Sep NEWA |
| AB | | | 25MG | A207399 | 002 | Sep 15, 2026 | Sep NEWA |
| AB | | | 50MG | A207399 | 003 | Sep 15, 2026 | Sep NEWA |
| AB | | | 100MG | A207399 | 004 | Sep 15, 2026 | Sep NEWA |

SAVELLA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + | ABBVIE | 12.5MG | N022256 | 001 | Jan 14, 2009 | Jan CTEC |
| AB | + | | 25MG | N022256 | 002 | Jan 14, 2009 | Jan CTEC |
| AB | +! | | 50MG | N022256 | 003 | Jan 14, 2009 | Jan CTEC |
| AB | + | | 100MG | N022256 | 004 | Jan 14, 2009 | Jan CTEC |

MILRINONE LACTATE

INJECTABLE;INJECTION
MILRINONE LACTATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | HIKMA | EQ 1MG BASE/ML | A075530 | 001 | May 28, 2002 | Mar DISC |

MILSAPERIDONE

TABLET;ORAL
BYSANTI

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | | VANDA PHARMS INC | 1MG | N220358 | 001 | Feb 20, 2026 | Feb NEWA |
| + | | | 2MG | N220358 | 002 | Feb 20, 2026 | Feb NEWA |
| + | | | 4MG | N220358 | 003 | Feb 20, 2026 | Feb NEWA |
| + | | | 6MG | N220358 | 004 | Feb 20, 2026 | Feb NEWA |
| + | | | 8MG | N220358 | 005 | Feb 20, 2026 | Feb NEWA |
| + | | | 10MG | N220358 | 006 | Feb 20, 2026 | Feb NEWA |
| + | | | 12MG | N220358 | 007 | Feb 20, 2026 | Feb NEWA |

MILTEFOSINE

CAPSULE;ORAL

IMPAVIDO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | +! | ETON | 50MG | N204684 | 001 | Mar 19, 2014 | Oct CAHN |
| >D> | | +! | KNIGHT THERAPS | 50MG | N204684 | 001 | Mar 19, 2014 | Oct CAHN |

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | LUPIN | EQ 45MG BASE | A091424 | 001 | Nov 30, 2011 | Apr CAHN |
| | AB | | | EQ 55MG BASE | A091424 | 002 | Nov 30, 2011 | Apr CAHN |
| | AB | | | EQ 90MG BASE | A091424 | 003 | Nov 30, 2011 | Apr CAHN |
| | AB | | | EQ 135MG BASE | A091424 | 004 | Nov 30, 2011 | Apr CAHN |

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MIRABEGRON

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ALKEM LABS LTD | 8MG/ML | A219323 | 001 | Jan 20, 2026 | Jan NFTG |

MYRBETRIQ GRANULES

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | +! | APGDI | 8MG/ML | N213801 | 001 | Mar 25, 2021 | Jan CFTG |

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | CREEKWOOD PHARMS | 25MG | A219599 | 001 | Oct 07, 2026 | Sep NEWA |
| | AB | | | 50MG | A219599 | 002 | Oct 07, 2026 | Sep NEWA |
| | AB | | DEVA HOLDING AS | 25MG | A219941 | 001 | May 01, 2026 | Apr NEWA |
| | AB | | | 50MG | A219941 | 002 | May 01, 2026 | Apr NEWA |

MIRDAMETINIB

TABLET, FOR SUSPENSION;ORAL

GOMEKLI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | SPRINGWORKS | 3MG | N219379 | 002 | Jul 28, 2026 | Jul NEWA |
| | | + | | 4MG | N219379 | 003 | Jul 28, 2026 | Jul NEWA |

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | ALLIED | 15MG | A076176 | 001 | Jun 19, 2003 | Jun CAHN |
| | | @ | | 30MG | A076176 | 002 | Jun 19, 2003 | Jun CAHN |
| | | @ | | 45MG | A076176 | 003 | Jun 19, 2003 | Jun CAHN |
| | AB | | MICRO LABS | 7.5MG | A220104 | 001 | May 19, 2026 | May NEWA |
| | AB | | | 15MG | A220104 | 002 | May 19, 2026 | May NEWA |
| | AB | | | 30MG | A220104 | 003 | May 19, 2026 | May NEWA |
| | AB | | | 45MG | A220104 | 004 | May 19, 2026 | May NEWA |
| | AB | | NOVITIUM PHARMA | 7.5MG | A219919 | 001 | Feb 02, 2026 | Jan NEWA |
| | AB | | | 15MG | A219919 | 002 | Feb 02, 2026 | Jan NEWA |
| | AB | | | 30MG | A219919 | 003 | Feb 02, 2026 | Jan NEWA |
| | AB | | | 45MG | A219919 | 004 | Feb 02, 2026 | Jan NEWA |
| | | @ | PHARMAZONE | 15MG | A076176 | 001 | Jun 19, 2003 | Sep CAHN |
| | | @ | | 30MG | A076176 | 002 | Jun 19, 2003 | Sep CAHN |
| | | @ | | 45MG | A076176 | 003 | Jun 19, 2003 | Sep CAHN |
| | | @ | SENORES PHARMS | 15MG | A076176 | 001 | Jun 19, 2003 | Jul CAHN |
| | | @ | | 30MG | A076176 | 002 | Jun 19, 2003 | Jul CAHN |
| | | @ | | 45MG | A076176 | 003 | Jun 19, 2003 | Jul CAHN |
| | AB | | SUN PHARM INDS INC | 7.5MG | A076541 | 004 | Apr 22, 2004 | Aug CHRS |

MISOPROSTOL

TABLET;ORAL

MISOPROSTOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | MICRO LABS | 0.1MG | A216872 | 001 | Oct 17, 2022 | Aug DISC |
| | | @ | | 0.2MG | A216872 | 002 | Oct 17, 2022 | Aug DISC |

MITAPIVAT SULFATE

TABLET;ORAL

AQVESME

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | AGIOS PHARMS INC | EQ 100MG BASE | N216196 | 004 | Dec 23, 2025 | Jan NEWA |

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | ADAPTIS | 5MG/VIAL | A202670 | 001 | Oct 13, 2017 | Sep CAHN |
| AP | | | 20MG/VIAL | A202670 | 002 | Oct 13, 2017 | Sep CAHN |
| AP | | | 40MG/VIAL | A203386 | 001 | Oct 13, 2017 | Sep CAHN |

MODAFINIL

TABLET;ORAL

MODAFINIL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | LUPIN | 100MG | A208343 | 001 | Sep 03, 2026 | Aug NEWA |
| AB | | | 200MG | A208343 | 002 | Sep 03, 2026 | Aug NEWA |

MOMETASONE FUROATE

CREAM;TOPICAL

MOMETASONE FUROATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ! | COSETTE PHARMS NC | 0.1% | A077447 | 001 | May 22, 2006 | May CAHN |

IMPLANT;IMPLANTATION

SINUVA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | INTERSECT ENT INC | 1.35MG | N209310 | 001 | Dec 08, 2017 | Mar CHRS |

LOTION;TOPICAL

MOMETASONE FUROATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | 0.1% | A077678 | 001 | Nov 21, 2007 | Jun CAHN |
| >D> AB | | ENCUBE | 0.1% | A076499 | 001 | Nov 21, 2007 | Oct CAHN |
| >A> AB | | | 0.1% | A076499 | 001 | Nov 21, 2007 | Oct CAHN |

OINTMENT;TOPICAL

MOMETASONE FUROATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | 0.1% | A077401 | 001 | Jun 20, 2006 | May CAHN |
| >D> AB | | ENCUBE | 0.1% | A076481 | 001 | Nov 14, 2003 | Oct CAHN |
| >A> AB | | | 0.1% | A076481 | 001 | Nov 14, 2003 | Oct CAHN |
| AB | | | 0.1% | A076481 | 001 | Nov 14, 2003 | Apr CMFD |

SPRAY, METERED;NASAL

MOMETASONE FUROATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | NASPRESS | 0.05MG/SPRAY | A211706 | 001 | May 15, 2025 | Aug CMFD |

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ! | AJANTA PHARMA LTD | EQ 4MG BASE/PACKET | A203438 | 001 | Jul 31, 2015 | May CHRS |

SINGULAIR

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | ORGANON | EQ 4MG BASE/PACKET | N021409 | 001 | Jul 26, 2002 | May DISC |

TABLET;ORAL

MONTELUKAST SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AIPING PHARM INC | EQ 10MG BASE | A200889 | 001 | Aug 03, 2012 | Sep CAHN |

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | AMNEAL PHARMS | EQ 4MG BASE | A205107 | 001 | Sep 04, 2020 | Mar DISC |
| | @ | | EQ 5MG BASE | A205107 | 002 | Sep 04, 2020 | Mar DISC |
| AB | | PHARMAZONE | EQ 4MG BASE | A201581 | 001 | Aug 06, 2012 | Sep CAHN |
| AB | | | EQ 5MG BASE | A201581 | 002 | Aug 06, 2012 | Sep CAHN |
| AB | | SENORES PHARMS | EQ 4MG BASE | A201581 | 001 | Aug 06, 2012 | Jan CAHN |
| AB | | | EQ 5MG BASE | A201581 | 002 | Aug 06, 2012 | Jan CAHN |

SINGULAIR

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | ORGANON | EQ 4MG BASE | N020830 | 002 | Mar 03, 2000 | Jun DISC |

MORPHINE SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | FRESENIUS KABI USA | 1MG/0.5ML (1MG/0.5ML) | N204223 | 006 | May 29, 2026 | Sep DISC |
| | +! | | 1MG/0.5ML (1MG/0.5ML) | N204223 | 006 | May 29, 2026 | Sep NEWA |

SOLUTION;ORAL

MORPHINE SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PADAGIS US | 100MG/5ML | A201574 | 001 | Aug 06, 2012 | Mar DISC |
| AA | | QUAGEN | 10MG/5ML | A213892 | 001 | Jul 07, 2026 | Jun NEWA |
| AA | | | 20MG/5ML | A213892 | 002 | Jul 07, 2026 | Jun NEWA |
| AA | | | 100MG/5ML | A213892 | 003 | Jul 07, 2026 | Jun NEWA |
| | @ | TRIS PHARMA INC | 10MG/5ML | A203518 | 001 | May 12, 2015 | Mar DISC |

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | ACTAVIS ELIZABETH | 15MG | A203849 | 001 | Apr 06, 2015 | Aug DISC |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| | | MORPHINE SULFATE | | | | | | |
| | | @ | | 30MG | A203849 | 002 | Apr 06, 2015 | Aug DISC |
| | | @ | | 60MG | A203849 | 003 | Apr 06, 2015 | Aug DISC |
| | | @ | | 100MG | A203849 | 004 | Apr 06, 2015 | Aug DISC |
| | | @ | | 200MG | A203849 | 005 | Apr 06, 2015 | Aug DISC |
| | AB | ! | RHODES PHARMS | 100MG | A074769 | 001 | Jul 02, 1998 | Sep CHRS |
| | | @ | STRIDES PHARMA INTL | 15MG | A075295 | 001 | Oct 28, 1998 | Jan DISC |
| | | @ | | 30MG | A075295 | 002 | Oct 28, 1998 | Jan DISC |
| | | @ | | 60MG | A075295 | 003 | Oct 28, 1998 | Jan DISC |
| | | @ | | 100MG | A075295 | 004 | Sep 15, 2000 | Jan DISC |
| | | @ | | 200MG | A075295 | 005 | Sep 15, 2000 | Jan DISC |
| | | MS CONTIN | | | | | | |
| | AB | + | KNOA PHARMA | 15MG | N019516 | 003 | Sep 12, 1989 | May CAHN |
| | AB | + | | 30MG | N019516 | 001 | May 29, 1987 | May CAHN |
| | AB | + | | 60MG | N019516 | 002 | Apr 08, 1988 | May CAHN |
| | | @ + | | 100MG | N019516 | 004 | Jan 16, 1990 | Sep DISC |
| | AB | +! | | 100MG | N019516 | 004 | Jan 16, 1990 | May CAHN |
| | | @ + | | 200MG | N019516 | 005 | Nov 08, 1993 | Sep DISC |
| | AB | + | | 200MG | N019516 | 005 | Nov 08, 1993 | May CAHN |
| | | MOXIFLOXACIN HYDROCHLORIDE | | | | | | |
| | | SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| | | MOXIFLOXACIN HYDROCHLORIDE | | | | | | |
| | | @ | FDC LTD | EQ 0.5% BASE | A219475 | 001 | Aug 04, 2025 | Feb DISC |
| | | TABLET;ORAL | | | | | | |
| | | MOXIFLOXACIN HYDROCHLORIDE | | | | | | |
| | AB | | MACLEODS PHARMS | EQ 400MG BASE | A209143 | 001 | Mar 02, 2026 | Feb NEWA |
| | | @ | TORRENT | EQ 400MG BASE | A200160 | 001 | Apr 03, 2014 | Apr DISC |
| | | MUPIROCIN | | | | | | |
| | | OINTMENT;TOPICAL | | | | | | |
| | | CENTANY | | | | | | |
| | | @ | PADAGIS US | 2% | N050788 | 001 | Dec 04, 2002 | Mar DISC |
| | | MUPIROCIN | | | | | | |
| >D> | AB | | ENCUBE | 2% | A217943 | 001 | May 13, 2025 | Oct CAHN |
| >A> | AB | | | 2% | A217943 | 001 | May 13, 2025 | Oct CAHN |
| | | MUPIROCIN CALCIUM | | | | | | |
| | | CREAM;TOPICAL | | | | | | |
| | | MUPIROCIN | | | | | | |
| | AB | | ALEMBIC | EQ 2% BASE | A213053 | 001 | Nov 16, 2021 | Jul CTEC |
| >D> | AB | | ENCUBE | EQ 2% BASE | A213076 | 001 | Aug 31, 2021 | Oct CAHN |
| >A> | AB | | | EQ 2% BASE | A213076 | 001 | Aug 31, 2021 | Oct CAHN |
| | | MUPIROCIN CALCIUM | | | | | | |
| | AB | | ZYDUS LIFESCIENCES | EQ 2% BASE | A218361 | 001 | Sep 29, 2026 | Sep NEWA |
| | | MYCOPHENOLATE MOFETIL | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | MYCOPHENOLATE MOFETIL | | | | | | |
| | | @ | HIKMA | 250MG | A065410 | 001 | Jul 29, 2008 | Jun DISC |
| | | @ | MYLAN | 250MG | A065520 | 001 | May 04, 2009 | May DISC |
| | | FOR SUSPENSION;ORAL | | | | | | |
| | | MYCOPHENOLATE MOFETIL | | | | | | |
| | AB | | CONCORD BIOTECH LTD | 200MG/ML | A218566 | 001 | Jun 01, 2026 | May NEWA |
| | AB | | NEOCUBES PHARMA | 200MG/ML | A218566 | 001 | Jun 01, 2026 | Sep CAHN |
| | AB | | QUAGEN | 200MG/ML | A214525 | 001 | Jul 29, 2021 | Jul CAHN |
| | | TABLET;ORAL | | | | | | |
| | | MYCOPHENOLATE MOFETIL | | | | | | |
| | | @ | HIKMA | 500MG | A065413 | 001 | Jul 29, 2008 | Jun DISC |
| | | @ | MYLAN | 500MG | A065521 | 001 | May 04, 2009 | Jun DISC |
| | | MYCOPHENOLATE SODIUM | | | | | | |
| | | TABLET, DELAYED RELEASE;ORAL | | | | | | |
| | | MYCOPHENOLATE SODIUM | | | | | | |
| | | @ | RK PHARMA | EQ 180MG BASE | A091248 | 002 | Jan 08, 2014 | Jan DISC |
| | | @ | | EQ 360MG BASE | A091248 | 001 | Jan 08, 2014 | Jan DISC |
| | | @ | TWI PHARMS | EQ 180MG BASE | A214289 | 001 | Nov 03, 2021 | Mar DISC |
| | | @ | | EQ 360MG BASE | A214289 | 002 | Nov 03, 2021 | Mar DISC |

NABUMETONE

TABLET;ORAL

NABUMETONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | ! | LGM PHARMA | 1GM | A203166 | 003 | Aug 30, 2019 | Jan CHRS |
| | | @ | PHARMAZONE | 500MG | A090427 | 001 | Dec 30, 2011 | Sep CAHN |
| | | @ | | 750MG | A090427 | 002 | Dec 30, 2011 | Sep CAHN |
| | | @ | SENORES PHARMS | 500MG | A090427 | 001 | Dec 30, 2011 | Jun CAHN |
| | | @ | | 750MG | A090427 | 002 | Dec 30, 2011 | Jun CAHN |
| | | @ | TP ANDA HOLDINGS | 500MG | A079093 | 001 | Feb 27, 2009 | Sep CAHN |
| | | @ | | 750MG | A079093 | 002 | Feb 27, 2009 | Sep CAHN |

NADOLOL

TABLET;ORAL

NADOLOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | APPCO | 20MG | A212856 | 001 | Sep 13, 2019 | Aug CAHN |
| | AB | | | 40MG | A212856 | 002 | Sep 13, 2019 | Aug CAHN |
| | AB | | | 80MG | A212856 | 003 | Sep 13, 2019 | Aug CAHN |
| | | @ | INGENUS PHARMS LLC | 20MG | A210786 | 001 | Jun 01, 2018 | May CAHN |
| | | @ | | 40MG | A210786 | 002 | Jun 01, 2018 | May CAHN |
| | | @ | | 80MG | A210786 | 003 | Jun 01, 2018 | May CAHN |
| | AB | | SOMERSET THERAPS LLC | 20MG | A212856 | 001 | Sep 13, 2019 | Sep CAHN |
| | AB | | | 40MG | A212856 | 002 | Sep 13, 2019 | Sep CAHN |
| | AB | | | 80MG | A212856 | 003 | Sep 13, 2019 | Sep CAHN |

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | ACS DOBFAR SPA | EQ 1GM BASE/VIAL | A090002 | 001 | Jun 30, 2011 | Sep CAHN |
| | AP | | | EQ 2GM BASE/VIAL | A090002 | 002 | Jun 30, 2011 | Sep CAHN |
| >A> | | @ | CHARTWELL RX | EQ 500MG BASE/VIAL | A062844 | 001 | Oct 26, 1988 | Oct CAHN |
| >A> | | @ | | EQ 1GM BASE/VIAL | A062844 | 002 | Oct 26, 1988 | Oct CAHN |
| >A> | | @ | | EQ 1.5GM BASE/VIAL | A062844 | 003 | Oct 26, 1988 | Oct CAHN |
| >A> | | @ | | EQ 2GM BASE/VIAL | A062844 | 004 | Oct 26, 1988 | Oct CAHN |
| >A> | | @ | | EQ 4GM BASE/VIAL | A062844 | 005 | Oct 26, 1988 | Oct CAHN |
| >A> | | @ | | EQ 10GM BASE/VIAL | A063008 | 001 | Sep 29, 1988 | Oct CAHN |
| >A> | AP | | ONESOURCE SPECIALTY | EQ 10GM BASE/VIAL | A203830 | 001 | Sep 25, 2026 | Oct CAHN |
| >D> | AP | | STERISCIENCE | EQ 10GM BASE/VIAL | A203830 | 001 | Sep 25, 2026 | Oct CAHN |
| | AP | | | EQ 10GM BASE/VIAL | A203830 | 001 | Sep 25, 2026 | Sep NEWA |
| >D> | | @ | WATSON LABS INC | EQ 500MG BASE/VIAL | A062844 | 001 | Oct 26, 1988 | Oct CAHN |
| >D> | | @ | | EQ 1GM BASE/VIAL | A062844 | 002 | Oct 26, 1988 | Oct CAHN |
| >D> | | @ | | EQ 1.5GM BASE/VIAL | A062844 | 003 | Oct 26, 1988 | Oct CAHN |
| >D> | | @ | | EQ 2GM BASE/VIAL | A062844 | 004 | Oct 26, 1988 | Oct CAHN |
| >D> | | @ | | EQ 4GM BASE/VIAL | A062844 | 005 | Oct 26, 1988 | Oct CAHN |
| >D> | | @ | | EQ 10GM BASE/VIAL | A063008 | 001 | Sep 29, 1988 | Oct CAHN |

NALLPEN IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | BAXTER HLTHCARE | EQ 20MG BASE/ML | N050655 | 001 | Oct 31, 1989 | Jul DISC |

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | AMNEAL | 2% | A206960 | 001 | Apr 10, 2017 | Feb DISC |

NAFTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | LEGACY | 1% | N019599 | 001 | Feb 29, 1988 | Jun CAHN |
| | AB | +! | | 2% | N019599 | 002 | Jan 13, 2012 | Jun CAHN |

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | AMNEAL | 1% | A206165 | 001 | Mar 20, 2019 | Mar DISC |

NAFTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | LEGACY | 1% | N019356 | 001 | Jun 18, 1990 | Jun CAHN |
| | AB | +! | | 2% | N204286 | 001 | Jun 27, 2013 | Jun CAHN |
| | | @ + | LEGACY PHARMA | 1% | N019356 | 001 | Jun 18, 1990 | Jun DISC |
| | | +! | | 1% | N019356 | 001 | Jun 18, 1990 | Mar CTEC |

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALMEFENE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | ! | KNOA PHARMA | EQ 2MG BASE/2ML (EQ 1MG BASE/ML) | A212955 | 001 | Feb 08, 2022 | May CAHN |

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

ZURNAI (AUTOINJECTOR)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | KNOA PHARMA | EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML) | N218590 | 001 | Aug 07, 2024 | May CAHN |

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | STERINOVA INC | 0.4MG/ML | A219942 | 001 | Aug 18, 2026 | Aug NEWA |
| AP | | | 1MG/ML | A219942 | 002 | Aug 18, 2026 | Aug NEWA |

SPRAY;NASAL

KLOXXADO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | HIKMA | 4MG/SPRAY | N212045 | 002 | Aug 25, 2025 | Sep DISC |

REZENOPY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | SCIENTURE | 10MG/SPRAY | N215487 | 001 | Apr 19, 2024 | Jan CMFD |

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | NOVITIUM PHARMA | 50MG | A075434 | 001 | Mar 08, 2000 | Sep CMFD |

NAPROXEN

SUSPENSION;ORAL

NAPROXEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | AUROBINDO PHARMA | 25MG/ML | A216504 | 001 | Oct 03, 2025 | Mar DISC |

TABLET;ORAL

NAPROXEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 250MG | A076494 | 001 | Jan 14, 2004 | Sep CAHN |
| | @ | | 375MG | A076494 | 002 | Jan 14, 2004 | Sep CAHN |
| | @ | | 500MG | A076494 | 003 | Jan 14, 2004 | Sep CAHN |
| AB | | MARKSANS PHARMA | 250MG | A091416 | 001 | Feb 14, 2011 | Sep CAHN |
| AB | | | 375MG | A091416 | 002 | Feb 14, 2011 | Sep CAHN |
| AB | | | 500MG | A091416 | 003 | Feb 14, 2011 | Sep CAHN |
| AB | | PHARMAZONE | 250MG | A091416 | 001 | Feb 14, 2011 | Sep CAHN |
| AB | | | 375MG | A091416 | 002 | Feb 14, 2011 | Sep CAHN |
| AB | | | 500MG | A091416 | 003 | Feb 14, 2011 | Sep CAHN |

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | AZURITY | 60MG;EQ 10MG BASE | N021926 | 002 | May 14, 2015 | Jul CAHN |
| AB | +! | | 500MG;EQ 85MG BASE | N021926 | 001 | Apr 15, 2008 | Jul CAHN |

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PADAGIS US | EQ 1MG BASE | A091326 | 001 | Jul 08, 2010 | Mar DISC |
| | @ | | EQ 2.5MG BASE | A091326 | 002 | Jul 08, 2010 | Mar DISC |

NAVEPEGRITIDE

POWDER;SUBCUTANEOUS

YUVIWEL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | ASCENDIS | 1.3MG/VIAL | N219164 | 001 | Feb 27, 2026 | Feb NEWA |
| | +! | | 2.8MG/VIAL | N219164 | 002 | Feb 27, 2026 | Feb NEWA |
| | +! | | 5.5MG/VIAL | N219164 | 003 | Feb 27, 2026 | Feb NEWA |

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | TORRENT | EQ 2.5MG BASE | A203966 | 001 | Mar 02, 2018 | Mar DISC |
| | @ | | EQ 5MG BASE | A203966 | 002 | Mar 02, 2018 | Mar DISC |
| | @ | | EQ 10MG BASE | A203966 | 003 | Mar 02, 2018 | Mar DISC |
| | @ | | EQ 20MG BASE | A203966 | 004 | Mar 02, 2018 | Mar DISC |

NELARABINE

INJECTABLE;INTRAVENOUS

NELARABINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | PHARMOBEDIENT | 250MG/50ML (5MG/ML) | A216510 | 001 | Sep 05, 2024 | Aug CAHN |

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | AMVIKA | 500MG | A065220 | 001 | Jul 28, 2006 | Sep CAHN |
| AA | | SOLARIS PHARMA CORP | 500MG | A065220 | 001 | Jul 28, 2006 | Apr CAHN |

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | WATSON LABS | EQ 40MG BASE/ML;200,000 UNITS/ML | A062664 | 001 | Apr 08, 1986 | Jan DISC |
| | | ! | XGEN PHARMS | EQ 40MG BASE/ML;200,000 UNITS/ML | A065106 | 001 | Jan 31, 2006 | Jan CTEC |
| | AT | ! | | EQ 40MG BASE/ML;200,000 UNITS/ML | A065106 | 001 | Jan 31, 2006 | Jan CHRS |
| | | ! | | EQ 40MG BASE/ML;200,000 UNITS/ML | A065108 | 001 | Jan 31, 2006 | Jan CTEC |
| | AT | ! | | EQ 40MG BASE/ML;200,000 UNITS/ML | A065108 | 001 | Jan 31, 2006 | Jan CHRS |

NEOSPORIN G.U. IRRIGANT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | MONARCH PHARMS | EQ 40MG BASE/ML;200,000 UNITS/ML | A060707 | 001 | | Jan DISC |

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | EXELA PHARMA | 5MG/5ML (1MG/ML) | N204078 | 003 | Oct 27, 2023 | Jun DISC |

NEOSTIGMINE METHYLSULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | AMNEAL | 5MG/10ML (0.5MG/ML) | A210051 | 001 | Jun 15, 2018 | Sep DISC |
| | | @ | | 10MG/10ML (1MG/ML) | A210051 | 002 | Jun 15, 2018 | Sep DISC |
| | | @ | HIKMA | 3MG/3ML (1MG/ML) | A216206 | 001 | Jul 13, 2022 | Mar DISC |
| | AP | | J MOLNER | 5MG/10ML (0.5MG/ML) | A210989 | 001 | Aug 22, 2018 | Jul CAHN |
| | AP | | | 10MG/10ML (1MG/ML) | A210989 | 002 | Aug 22, 2018 | Jul CAHN |
| | AP | | NIVAGEN | 5MG/10ML (0.5MG/ML) | A212627 | 001 | Nov 03, 2022 | Aug CAHN |
| | AP | | | 10MG/10ML (1MG/ML) | A212627 | 002 | Nov 03, 2022 | Aug CAHN |
| | AP | | NIVAGEN PHARMS INC | 5MG/10ML (0.5MG/ML) | A212627 | 001 | Nov 03, 2022 | Mar CAHN |
| | AP | | | 10MG/10ML (1MG/ML) | A212627 | 002 | Nov 03, 2022 | Mar CAHN |

NIACIN

TABLET;ORAL

NIACIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | @ | HIKMA | 500MG | A083718 | 001 | | Oct CAHN |
| >A> | | @ | | 500MG | A083718 | 001 | | Oct CAHN |

TABLET, EXTENDED RELEASE;ORAL

NIACIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ADAPTIS | 500MG | A213090 | 001 | Aug 25, 2023 | Sep CAHN |
| | AB | | | 750MG | A213090 | 002 | Aug 25, 2023 | Sep CAHN |
| | AB | | | 1GM | A213090 | 003 | Aug 25, 2023 | Sep CAHN |
| | AB | | QUAGEN | 500MG | A203899 | 001 | Jun 16, 2017 | Jul CAHN |
| | AB | | | 1GM | A203899 | 002 | Jun 16, 2017 | Jul CAHN |

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | CHARTWELL RX | 20MG | A218638 | 001 | Jun 25, 2025 | Jul CAHN |
| | | @ | | 30MG | A218638 | 002 | Jun 25, 2025 | Jul CAHN |
| | | @ | NAVINTA LLC | 20MG | A218638 | 001 | Jun 25, 2025 | Mar DISC |
| | | @ | | 30MG | A218638 | 002 | Jun 25, 2025 | Mar DISC |
| | AB | | PHARMAZONE | 20MG | A215377 | 001 | Jul 17, 2023 | Sep CAHN |
| | AB | | | 30MG | A215377 | 002 | Jul 17, 2023 | Sep CAHN |
| | AB | | SENORES PHARMS | 20MG | A215377 | 001 | Jul 17, 2023 | Jan CAHN |
| | AB | | | 30MG | A215377 | 002 | Jul 17, 2023 | Jan CAHN |

INJECTABLE;INJECTION

CARDENE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | + | CHIESI | 25MG/10ML (2.5MG/ML) | N019734 | 001 | Jan 30, 1992 | Jan CMFD |

NICARDIPINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AP | | MEITHEAL | 25MG/10ML (2.5MG/ML) | A216819 | 001 | Aug 20, 2025 | Oct CAHN |
| >D> | AP | | NANJING KING FRIEND | 25MG/10ML (2.5MG/ML) | A216819 | 001 | Aug 20, 2025 | Oct CAHN |
| | AP | | SOMERSET THERAPS LLC | 25MG/10ML (2.5MG/ML) | A090664 | 001 | Nov 17, 2009 | Jan CAHN |

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | FRESENIUS KABI USA | 20MG/200ML (0.1MG/ML) | A219334 | 001 | Aug 04, 2026 | Jul NEWA |
| | AP | | | 40MG/200ML (0.2MG/ML) | A219334 | 002 | Aug 04, 2026 | Jul NEWA |

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | HERITAGE PHARMA | 10MG | | A202644 | 001 | Apr 25, 2013 | Mar CHRS |

PROCARDIA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | | PFIZER | 10MG | | N018482 | 001 | | Mar DISC |

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB2 | | AUROBINDO PHARMA USA | 30MG | | A090649 | 001 | Jun 21, 2010 | Sep CMFD |
| AB2 | | | 60MG | | A090649 | 002 | Jun 21, 2010 | Sep CMFD |
| AB2 | | | 90MG | | A090649 | 003 | Jun 21, 2010 | Sep CMFD |
| AB2 | ! | NOVAST LABS | 90MG | | A210614 | 003 | Mar 12, 2019 | Apr CHRS |
| @ | | PHARMADAX | 30MG | | A216019 | 001 | Nov 18, 2022 | Mar CAHN |
| @ | | | 60MG | | A216019 | 002 | Nov 18, 2022 | Mar CAHN |

PROCARDIA XL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | | PFIZER | 90MG | | N019684 | 003 | Sep 06, 1989 | Apr DISC |

NILOTINIB

TABLET, ORALLY DISINTEGRATING;ORAL

CAVHANZA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| + | | CYCLE | 60MG | | N217379 | 001 | May 29, 2026 | Aug CAHN |
| +! | | | 80MG | | N217379 | 002 | May 29, 2026 | Aug CAHN |
| + | | FLEX PHARMA | 60MG | | N217379 | 001 | May 29, 2026 | May NEWA |
| +! | | | 80MG | | N217379 | 002 | May 29, 2026 | May NEWA |

NILOTINIB D-TARTRATE

CAPSULE;ORAL

NILOTINIB D-TARTRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | | CIPLA | EQ 50MG BASE | | N218922 | 001 | Feb 19, 2025 | Aug DISC |
| @ + | | | EQ 150MG BASE | | N218922 | 002 | Feb 19, 2025 | Aug DISC |
| @ + | | | EQ 200MG BASE | | N218922 | 003 | Feb 19, 2025 | Aug DISC |

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | TEVA PHARMS INC | EQ 50MG BASE | | A219134 | 001 | Jun 26, 2026 | Jun NEWA |
| AB | | | EQ 150MG BASE | | A219134 | 002 | Jun 26, 2026 | Jun NEWA |
| AB | | | EQ 200MG BASE | | A219134 | 003 | Jun 26, 2026 | Jun NEWA |

NILUTAMIDE

TABLET;ORAL

NILANDRON

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | | ADVANZ PHARMA | 150MG | | N020169 | 002 | Apr 30, 1999 | Apr DISC |

NILUTAMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | ANI PHARMS | 150MG | | A207631 | 001 | Jul 15, 2016 | Apr CTEC |
| AB | ! | | 150MG | | A207631 | 001 | Jul 15, 2016 | Apr CHRS |

NINTEDANIB ESYLATE

CAPSULE;ORAL

NINTEDANIB ESYLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | APOTEX | EQ 100MG BASE | | A219227 | 001 | Apr 02, 2026 | Mar NFTG |
| AB | | | EQ 150MG BASE | | A219227 | 002 | Apr 02, 2026 | Mar NFTG |
| AB | | BIOCON PHARMA | EQ 100MG BASE | | A220118 | 001 | Aug 19, 2026 | Aug NEWA |
| AB | | | EQ 150MG BASE | | A220118 | 002 | Aug 19, 2026 | Aug NEWA |
| AB | | CIPLA | EQ 100MG BASE | | A212609 | 001 | Apr 02, 2026 | Mar NFTG |
| AB | | | EQ 150MG BASE | | A212609 | 002 | Apr 02, 2026 | Mar NFTG |
| AB | | DEXCEL | EQ 100MG BASE | | A219819 | 001 | Apr 02, 2026 | Mar NFTG |
| AB | | | EQ 150MG BASE | | A219819 | 002 | Apr 02, 2026 | Mar NFTG |
| AB | | DR REDDYS | EQ 100MG BASE | | A219283 | 001 | Apr 02, 2026 | Mar NFTG |
| AB | | | EQ 150MG BASE | | A219283 | 002 | Apr 02, 2026 | Mar NFTG |
| AB | | GLENMARK PHARMS LTD | EQ 100MG BASE | | A212555 | 001 | Jul 09, 2026 | Jul NEWA |
| AB | | | EQ 150MG BASE | | A212555 | 002 | Jul 09, 2026 | Jul NEWA |
| AB | | HUMANWELL PURACAP | EQ 100MG BASE | | A218472 | 001 | Jul 09, 2026 | Jun NEWA |
| AB | | | EQ 150MG BASE | | A218472 | 002 | Jul 09, 2026 | Jun NEWA |
| AB | | MACLEODS PHARMS | EQ 100MG BASE | | A219926 | 001 | Aug 03, 2026 | Jul NEWA |
| AB | | | EQ 150MG BASE | | A219926 | 002 | Aug 03, 2026 | Jul NEWA |
| AB | | SANDOZ | EQ 100MG BASE | | A216915 | 001 | Apr 02, 2026 | Mar NFTG |
| AB | | | EQ 150MG BASE | | A216915 | 002 | Apr 02, 2026 | Mar NFTG |

OFEV

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | BOEHRINGER INGELHEIM | EQ 100MG BASE | | N205832 | 001 | Oct 15, 2014 | Mar CFTG |
| AB | +! | | EQ 150MG BASE | | N205832 | 002 | Oct 15, 2014 | Mar CFTG |

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL

OGSIVEO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | SPRINGWORKS | EQ 50MG BASE | N217677 | 001 | Nov 27, 2023 | Mar DISC |

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AMTA | 8.5MG | A216606 | 001 | Apr 10, 2023 | Apr CMFD |
| | ! | | 17MG | A216606 | 002 | Dec 12, 2025 | Jun CTEC |
| AB | ! | | 17MG | A216606 | 002 | Dec 12, 2025 | Jun CHRS |
| | @ | MYLAN | 8.5MG | A091001 | 001 | Jan 26, 2011 | Apr DISC |
| | @ | | 17MG | A091001 | 002 | Jan 26, 2011 | Apr DISC |
| | @ | | 20MG | A079051 | 001 | Jul 25, 2008 | Apr DISC |
| | @ | | 25.5MG | A091001 | 003 | Jan 26, 2011 | Apr DISC |
| | @ | | 30MG | A079051 | 002 | Jul 25, 2008 | Apr DISC |
| | @ | | 34MG | A091001 | 004 | Jan 26, 2011 | Feb DISC |
| | @ | | 40MG | A079051 | 003 | Jul 25, 2008 | Apr DISC |

SULAR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | AZURITY | 8.5MG | N020356 | 008 | Jan 02, 2008 | Jun CAHN |
| | +! | | 8.5MG | N020356 | 008 | Jan 02, 2008 | Apr CTEC |
| AB | +! | | 8.5MG | N020356 | 008 | Jan 02, 2008 | Apr CTEC |
| AB | +! | | 8.5MG | N020356 | 008 | Jan 02, 2008 | Feb CAHN |
| | @ + | | 10MG | N020356 | 001 | Feb 02, 1995 | Jun CAHN |
| | @ + | | 10MG | N020356 | 001 | Feb 02, 1995 | Feb CAHN |
| | @ + | | 17MG | N020356 | 007 | Jan 02, 2008 | Jun CAHN |
| | @ + | | 17MG | N020356 | 007 | Jan 02, 2008 | Jun DISC |
| AB | +! | | 17MG | N020356 | 007 | Jan 02, 2008 | Feb CAHN |
| AB | +! | | 17MG | N020356 | 007 | Jan 02, 2008 | Feb CAHN |
| AB | +! | | 17MG | N020356 | 007 | Jan 02, 2008 | Feb CAHN |
| AB | +! | | 17MG | N020356 | 007 | Jan 02, 2008 | Feb CAHN |
| | @ + | | 20MG | N020356 | 002 | Feb 02, 1995 | Jun CAHN |
| | @ + | | 20MG | N020356 | 002 | Feb 02, 1995 | Feb CAHN |
| | @ + | | 25.5MG | N020356 | 006 | Jan 02, 2008 | Jun CAHN |
| | @ + | | 25.5MG | N020356 | 006 | Jan 02, 2008 | Feb CAHN |
| | @ + | | 30MG | N020356 | 003 | Feb 02, 1995 | Jun CAHN |
| | @ + | | 30MG | N020356 | 003 | Feb 02, 1995 | Feb CAHN |
| | @ + | | 34MG | N020356 | 005 | Jan 02, 2008 | Jun CAHN |
| | @ + | | 34MG | N020356 | 005 | Jan 02, 2008 | Jun DISC |
| | +! | | 34MG | N020356 | 005 | Jan 02, 2008 | Feb CAHN |
| | @ + | | 40MG | N020356 | 004 | Feb 02, 1995 | Jun CAHN |
| | @ + | | 40MG | N020356 | 004 | Feb 02, 1995 | Feb CAHN |
| | +! | COVIS | 34MG | N020356 | 005 | Jan 02, 2008 | Feb CTEC |

NITRIC OXIDE

GAS;INHALATION

NOXIVENT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | VERO BIOTECH INC | 100PPM | A207141 | 001 | Oct 02, 2018 | Mar CAHN |
| AA | | | 800PPM | A207141 | 002 | Oct 02, 2018 | Mar CAHN |

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AMNEAL PHARMS | 25MG/5ML | A201679 | 001 | May 11, 2011 | Apr DISC |

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | ALMATICA | 25MG | N016620 | 003 | | Aug DISC |
| | @ + | | 50MG | N016620 | 001 | | Aug DISC |
| | @ + | | 100MG | N016620 | 002 | | Aug DISC |

NITROFURANTOIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | MANKIND PHARMA | 100MG | A217272 | 003 | Mar 21, 2023 | Aug CHRS |
| | @ | PHARMOBEDIENT | 25MG | A074336 | 001 | Jan 25, 1995 | Sep CAHN |
| | @ | | 50MG | A074336 | 002 | Jan 25, 1995 | Sep CAHN |
| | @ | | 100MG | A074336 | 003 | Jan 25, 1995 | Sep CAHN |
| | @ | POM PHARMA | 25MG | A074336 | 001 | Jan 25, 1995 | Apr CAHN |
| | @ | | 50MG | A074336 | 002 | Jan 25, 1995 | Apr CAHN |
| | @ | | 100MG | A074336 | 003 | Jan 25, 1995 | Apr CAHN |

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | CREEKWOOD PHARMS | 75MG;25MG | A220269 | 001 | Apr 07, 2026 | Mar NEWA |
| | AB | | MICRO LABS | 75MG;25MG | A217073 | 001 | Nov 03, 2023 | Aug CAHN |
| | AB | | PHARMAZONE | 75MG;25MG | A220269 | 001 | Apr 07, 2026 | Sep CAHN |

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | USPHARMA | 0.1MG/HR | N020145 | 001 | Apr 04, 1995 | Jan CHRS |
| | | + | | 0.2MG/HR | N020145 | 002 | Apr 04, 1995 | Jan CHRS |
| | | + | | 0.3MG/HR | N020145 | 003 | Apr 04, 1995 | Jan CHRS |
| | | + | | 0.6MG/HR | N020145 | 005 | Apr 04, 1995 | Jan CHRS |
| | | + | | 0.8MG/HR | N020145 | 006 | Apr 04, 1995 | Jan CHRS |

NITROGLYCERIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB2 | | MYLAN TECHNOLOGIES | 0.1MG/HR | A074559 | 004 | Feb 06, 1998 | Jan CHRS |
| | AB2 | | | 0.2MG/HR | A074559 | 003 | Aug 30, 1996 | Jan CHRS |
| | AB2 | | | 0.6MG/HR | A074559 | 001 | Aug 30, 1996 | Jan CHRS |

OINTMENT;INTRA-ANAL

NITROGLYCERIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | AMVIKA | 0.4% | A218756 | 001 | Dec 18, 2025 | Sep CAHN |
| | AB | ! | COSETTE | 0.4% | A216103 | 001 | Feb 16, 2024 | Mar CHRS |
| | AB | ! | COSETTE PHARMS NC | 0.4% | A216103 | 001 | Feb 16, 2024 | May CAHN |
| >D> | AB | | ENCUBE | 0.4% | A216452 | 001 | Dec 16, 2024 | Oct CAHN |
| >A> | AB | | | 0.4% | A216452 | 001 | Dec 16, 2024 | Oct CAHN |
| | AB | | PADAGIS ISRAEL | 0.4% | A214565 | 001 | Jul 06, 2026 | Jun NEWA |

RECTIV

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | ABBVIE | 0.4% | N021359 | 001 | Jun 21, 2011 | Mar DISC |

OINTMENT;TRANSDERMAL

NITROGLYCERIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | ENCUBE | 2% | A218235 | 001 | Apr 15, 2025 | Oct CAHN |
| >A> | AB | | | 2% | A218235 | 001 | Apr 15, 2025 | Oct CAHN |

SPRAY, METERED;SUBLINGUAL

NITROGLYCERIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | EPIC PHARMA LLC | 0.4MG/SPRAY | A204681 | 001 | Aug 21, 2026 | Sep CAHN |
| | AB | | SOCORRO N1 | 0.4MG/SPRAY | A204681 | 001 | Aug 21, 2026 | Aug NEWA |

TABLET;SUBLINGUAL

NITROGLYCERIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | PHARMOBEDIENT | 0.3MG | A218583 | 001 | Oct 15, 2024 | Sep CAHN |
| | AB | | | 0.4MG | A218583 | 002 | Oct 15, 2024 | Sep CAHN |
| | AB | | | 0.6MG | A218583 | 003 | Oct 15, 2024 | Sep CAHN |

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AP | | ADAPTIS | EQ 1MG BASE/ML | A219924 | 001 | Nov 25, 2025 | Oct CAHN |
| | AP | | | EQ 1MG BASE/ML | A219924 | 001 | Nov 25, 2025 | Sep CAHN |
| | | @ | AMNEAL | EQ 1MG BASE/ML | A210839 | 001 | Dec 17, 2018 | Jul DISC |
| >A> | AP | | ANTHEA PHARMA | EQ 1MG BASE/ML | A219924 | 001 | Nov 25, 2025 | Oct CAHN |
| | AP | | NEPHRON | EQ 1MG BASE/ML | A216272 | 001 | Jun 11, 2026 | May NEWA |

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | BAXTER HLTHCARE CORP | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | N214313 | 004 | Feb 06, 2026 | Feb NEWA |
| | | +! | | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | N214313 | 005 | Feb 06, 2026 | Feb NEWA |
| | | +! | | EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) | N214313 | 006 | Feb 06, 2026 | Feb NEWA |

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | +! | BAXTER HLTHCARE CORP | EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) | N214313 | 003 | Nov 21, 2023 | Mar CFTG |
| | AP | | SAGENT | EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) | A220483 | 001 | Mar 26, 2026 | Mar NFTG |

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | INGENUS PHARMS LLC | 5MG | A206490 | 001 | Nov 05, 2018 | Feb CAHN |

NUSINERSEN SODIUM

SOLUTION;INTRATHECAL

SPINRAZA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | BIOGEN | EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) | N209531 | 001 | Dec 23, 2016 | May | CAHN |
| | +! | | EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML) | N209531 | 002 | Mar 27, 2026 | May | CAHN |
| | +! | | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | N209531 | 003 | Mar 27, 2026 | May | CAHN |
| | +! | BIOGEN IDEC | EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML) | N209531 | 002 | Mar 27, 2026 | Apr | NEWA |
| | +! | | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | N209531 | 003 | Mar 27, 2026 | Apr | NEWA |

NYSTATIN

CREAM;TOPICAL

NYSTATIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | COSETTE PHARMS NC | 100,000 UNITS/GM | A061966 | 001 | | May | CAHN |

SUSPENSION;ORAL

NILSTAT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | + | CHARTWELL MOLECULES | 100,000 UNITS/ML | N050299 | 001 | | Mar | CMFD |

NYSTATIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ADAPTIS | 100,000 UNITS/ML | A220367 | 001 | Feb 05, 2026 | Sep | CAHN |
| | @ | COSETTE PHARMS NC | 100,000 UNITS/ML | A062776 | 001 | Dec 17, 1987 | Jun | CAHN |
| AA | ! | PHARMAZONE | 100,000 UNITS/ML | A214346 | 001 | Mar 10, 2022 | Sep | CAHN |
| AA | | SCIEGEN PHARMS | 100,000 UNITS/ML | A062832 | 001 | Dec 27, 1991 | Jan | CAHN |
| | @ | STERANCO HLTHCARE | 100,000 UNITS/ML | A220367 | 001 | Feb 05, 2026 | Jul | DISC |
| AA | | | 100,000 UNITS/ML | A220367 | 001 | Feb 05, 2026 | Jan | NEWA |

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | 100,000 UNITS/GM;0.1% | A062367 | 001 | May 28, 1985 | Jun | CAHN |

OINTMENT;TOPICAL

MYKACET

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | 100,000 UNITS/GM;0.1% | A062733 | 001 | Mar 06, 1987 | Jun | CAHN |

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | QUAGEN | EQ 0.1MG BASE/ML | A217860 | 001 | May 02, 2024 | Sep | CAHN |

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | MICRO LABS | 0.3% | A218557 | 001 | Apr 08, 2026 | Mar | NEWA |

SOLUTION/DROPS;OTIC

OFLOXACIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | ! | BAUSCH AND LOMB INC | 0.3% | A076128 | 001 | Mar 17, 2008 | May | CAHN |

OLANZAPINE

POWDER;INTRAMUSCULAR

OLANZAPINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | | ADAPTIS | 10MG/VIAL | A220323 | 001 | Mar 05, 2026 | Oct | CAHN |
| | AP | | | 10MG/VIAL | A220323 | 001 | Mar 05, 2026 | Sep | CAHN |
| | AP | | AM REGENT | 10MG/VIAL | A201741 | 001 | Mar 20, 2012 | Jan | CDFR |
| >A> | AP | | ANTHEA PHARMA | 10MG/VIAL | A220323 | 001 | Mar 05, 2026 | Oct | CAHN |
| | AP | | | 10MG/VIAL | A220323 | 001 | Mar 05, 2026 | Feb | NEWA |
| | AP | | ASPIRO | 10MG/VIAL | A217466 | 001 | Mar 22, 2023 | Jan | CDFR |
| | AP | | EUGIA PHARMA | 10MG/VIAL | A210968 | 001 | Oct 22, 2020 | Jan | CDFR |
| | AP | | OMNIVIUM PHARMS | 10MG/VIAL | A219048 | 001 | Jan 23, 2026 | Jan | NEWA |
| | AP | | QILU | 10MG/VIAL | A218116 | 001 | May 16, 2025 | Jan | CDFR |
| | AP | | SANDOZ INC | 10MG/VIAL | A201588 | 001 | Oct 24, 2011 | Jan | CDFR |
| | AP | | UBI | 10MG/VIAL | A211072 | 001 | Jun 11, 2025 | Jan | CDFR |

ZYPREXA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | +! | CHEPLAPHARM | 10MG/VIAL | N021253 | 001 | Mar 29, 2004 | Jan | CDFR |
| >A> | | | POWDER;SUBCUTANEOUS | | | | | | |
| >A> | | | WELTRUZA | | | | | | |
| >A> | | + | TEVA | 318MG/VIAL | N219007 | 001 | Oct 08, 2026 | Oct | NEWA |
| >A> | | + | | 425MG/VIAL | N219007 | 002 | Oct 08, 2026 | Oct | NEWA |
| >A> | | +! | | 531MG/VIAL | N219007 | 003 | Oct 08, 2026 | Oct | NEWA |

TABLET;ORAL
OLANZAPINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | SUNSHINE | 2.5MG | A206238 | 001 | Nov 19, 2018 | Feb CMFD |
| AB | | | 5MG | A206238 | 002 | Nov 19, 2018 | Feb CMFD |
| AB | | | 7.5MG | A206238 | 003 | Nov 19, 2018 | Feb CMFD |
| AB | | | 10MG | A206238 | 004 | Nov 19, 2018 | Feb CMFD |
| AB | | | 15MG | A206238 | 005 | Nov 19, 2018 | Feb CMFD |
| AB | | | 20MG | A206238 | 006 | Nov 19, 2018 | Feb CMFD |
| AB | | TORRENT PHARMS LTD | 2.5MG | A091434 | 001 | Apr 23, 2012 | Jan CMFD |
| AB | | | 5MG | A091434 | 002 | Apr 23, 2012 | Jan CMFD |
| AB | | | 7.5MG | A091434 | 003 | Apr 23, 2012 | Jan CMFD |
| AB | | | 10MG | A091434 | 004 | Apr 23, 2012 | Jan CMFD |
| AB | | | 15MG | A091434 | 005 | Apr 23, 2012 | Jan CMFD |
| AB | | | 20MG | A091434 | 006 | Apr 23, 2012 | Jan CMFD |

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | PHARMOBEDIENT | 5MG | A202285 | 001 | May 12, 2014 | Sep DISC |
| | @ | | 10MG | A202285 | 002 | May 12, 2014 | Sep DISC |
| | @ | | 15MG | A202285 | 003 | May 12, 2014 | Sep DISC |
| | @ | | 20MG | A202285 | 004 | May 12, 2014 | Sep DISC |

OLEZARSEN SODIUM

SOLUTION;SUBCUTANEOUS
TRYNGOLZA (AUTOINJECTOR)

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | IONIS PHARMS INC | EQ 50MG BASE/0.8ML (EQ 50MG BASE/0.8ML) | N218614 | 002 | Jun 24, 2026 | Jul NEWA |

OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 5MG | A208659 | 001 | May 18, 2020 | Sep CAHN |
| AB | | | 20MG | A208659 | 002 | May 18, 2020 | Sep CAHN |
| AB | | | 40MG | A208659 | 003 | May 18, 2020 | Sep CAHN |
| | @ | MICRO LABS | 5MG | A206372 | 001 | Sep 17, 2019 | Aug DISC |
| | @ | | 20MG | A206372 | 002 | Sep 17, 2019 | Aug DISC |
| | @ | | 40MG | A206372 | 003 | Sep 17, 2019 | Aug DISC |
| AB | | PHARMAZONE | 5MG | A207135 | 001 | Jul 18, 2019 | Sep CAHN |
| AB | | | 20MG | A207135 | 002 | Jul 18, 2019 | Sep CAHN |
| AB | | | 40MG | A207135 | 003 | Jul 18, 2019 | Sep CAHN |

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | REGCON HOLDINGS | EQ 0.7% BASE | A208637 | 001 | Feb 19, 2020 | Sep CAHN |

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | AMNEAL PHARMS | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A204940 | 001 | Nov 27, 2015 | Apr DISC |
| | @ | APOTEX | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A090973 | 001 | Sep 30, 2014 | Apr DISC |
| | @ | ONESOURCE | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A091018 | 001 | Jun 24, 2014 | Jul CAHN |
| AB | | | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A203893 | 001 | Sep 19, 2017 | Jul CAHN |
| AB | | PHARMOBEDIENT | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A091028 | 001 | Apr 07, 2014 | Sep CAHN |
| AB | | | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A212504 | 001 | Aug 19, 2020 | Sep CAHN |
| AB | | RENOVA PHARMS | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A091028 | 001 | Apr 07, 2014 | Aug CAHN |
| | @ | SOFGEN PHARMS | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A211355 | 001 | Jul 10, 2019 | Aug DISC |

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ALLIED | 10MG | | A205070 | 001 | Jun 29, 2018 | Jun CAHN |
| | @ | | 20MG | | A205070 | 002 | Jun 29, 2018 | Jun CAHN |
| | @ | | 40MG | | A205070 | 003 | Jun 29, 2018 | Jun CAHN |
| AB | ! | GLENMARK PHARMS LTD | 20MG | | A091672 | 002 | Oct 31, 2014 | Apr CHRS |
| AB | ! | | 40MG | | A091672 | 003 | Oct 31, 2014 | Apr CHRS |
| | @ | PHARMAZONE | 10MG | | A205070 | 001 | Jun 29, 2018 | Sep CAHN |
| | @ | | 20MG | | A205070 | 002 | Jun 29, 2018 | Sep CAHN |
| | @ | | 40MG | | A205070 | 003 | Jun 29, 2018 | Sep CAHN |
| AB | | SANDOZ | 20MG | | A075757 | 002 | Jan 28, 2003 | Apr CHRS |
| AB | | | 40MG | | A076515 | 001 | Jan 21, 2009 | Apr CHRS |
| | @ | SENORES PHARMS | 10MG | | A205070 | 001 | Jun 29, 2018 | Jul CAHN |
| | @ | | 20MG | | A205070 | 002 | Jun 29, 2018 | Jul CAHN |
| | @ | | 40MG | | A205070 | 003 | Jun 29, 2018 | Jul CAHN |

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | AZURITY | EQ 2.5MG BASE/PACKET | | N022056 | 001 | Mar 20, 2008 | Jul CAHN |
| | + | | EQ 2.5MG BASE/PACKET | | N022056 | 001 | Mar 20, 2008 | Feb CAHN |
| | +! | | EQ 10MG BASE/PACKET | | N022056 | 002 | Mar 20, 2008 | Jul CAHN |
| | +! | | EQ 10MG BASE/PACKET | | N022056 | 002 | Mar 20, 2008 | Feb CAHN |

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 20MG;1.1GM | | A212587 | 001 | Apr 30, 2020 | Aug CAHN |
| AB | | | 40MG;1.1GM | | A212587 | 002 | Apr 30, 2020 | Aug CAHN |
| AB | | GUARDIAN DRUG | 20MG;1.1GM | | A212587 | 001 | Apr 30, 2020 | Aug CAHN |
| AB | | | 40MG;1.1GM | | A212587 | 002 | Apr 30, 2020 | Aug CAHN |

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | CHARTWELL MOLECULES | 16MG | | A077406 | 001 | Dec 26, 2006 | Aug CHRS |

ONDANSETRON HYDROCHLORIDE

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | PHARM ASSOC | EQ 4MG BASE/5ML | | A078127 | 001 | Jun 25, 2007 | Feb CMFD |

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | EQ 4MG BASE | | A077545 | 001 | Sep 06, 2007 | Sep CAHN |
| | @ | | EQ 8MG BASE | | A077545 | 002 | Sep 06, 2007 | Sep CAHN |
| | @ | | EQ 24MG BASE | | A077545 | 003 | Sep 06, 2007 | Sep CAHN |

ORFORGLIPRON CALCIUM

TABLET;ORAL

FOUNDAYO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | ELI LILLY AND CO | EQ 0.8MG BASE | | N220934 | 001 | Apr 01, 2026 | Apr NEWA |
| | + | | EQ 2.5MG BASE | | N220934 | 002 | Apr 01, 2026 | Apr NEWA |
| | + | | EQ 5.5MG BASE | | N220934 | 003 | Apr 01, 2026 | Apr NEWA |
| | + | | EQ 9MG BASE | | N220934 | 004 | Apr 01, 2026 | Apr NEWA |
| | + | | EQ 14.5MG BASE | | N220934 | 005 | Apr 01, 2026 | Apr NEWA |
| | +! | | EQ 17.2MG BASE | | N220934 | 006 | Apr 01, 2026 | Apr NEWA |

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | CEDIPROF INC | EQ 30MG BASE | | A217451 | 001 | Dec 03, 2024 | Apr DISC |
| | @ | | EQ 45MG BASE | | A217451 | 002 | Dec 03, 2024 | Apr DISC |
| | @ | | EQ 75MG BASE | | A217451 | 003 | Dec 03, 2024 | Apr DISC |
| | @ | UPSHER SMITH LABS | EQ 30MG BASE | | A213437 | 001 | Jan 22, 2026 | Apr DISC |
| AB | | | EQ 30MG BASE | | A213437 | 001 | Jan 22, 2026 | Jan NEWA |
| | @ | | EQ 45MG BASE | | A213437 | 002 | Jan 22, 2026 | Apr DISC |
| AB | | | EQ 45MG BASE | | A213437 | 002 | Jan 22, 2026 | Jan NEWA |
| | @ | | EQ 75MG BASE | | A213437 | 003 | Jan 22, 2026 | Apr DISC |
| AB | | | EQ 75MG BASE | | A213437 | 003 | Jan 22, 2026 | Jan NEWA |

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ALEMBIC | EQ 6MG BASE/ML | A218307 | 001 | Jun 25, 2026 | Jun NEWA |
| | @ | AMNEAL PHARMS NY | EQ 6MG BASE/ML | A210186 | 001 | Feb 27, 2018 | May DISC |

OSILODROSTAT PHOSPHATE

TABLET;ORAL
ISTURISA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | RECORDATI RARE | EQ 5MG BASE | N212801 | 002 | Mar 06, 2020 | Jun CHRS |

OXACILLIN SODIUM

FOR SOLUTION;ORAL
OXACILLIN SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> | @ | CHARTWELL RX | EQ 250MG BASE/5ML | A062252 | 001 | | Oct CAHN |
| >D> | @ | TEVA | EQ 250MG BASE/5ML | A062252 | 001 | | Oct CAHN |

INJECTABLE;INJECTION
BACTOCILL IN PLASTIC CONTAINER

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | BAXTER HLTHCARE | EQ 20MG BASE/ML | N050640 | 001 | Oct 26, 1989 | Jul DISC |

OXACILLIN SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | ACS DOBFAR SPA | EQ 125MG BASE/VIAL | A062798 | 003 | Dec 11, 1995 | Sep CAHN |
| | @ | | EQ 250MG BASE/VIAL | A062798 | 004 | Dec 11, 1995 | Sep CAHN |
| | @ | | EQ 500MG BASE/VIAL | A062798 | 005 | Dec 11, 1995 | Sep CAHN |
| | @ | | EQ 1GM BASE/VIAL | A062798 | 001 | Dec 11, 1995 | Sep CAHN |
| | @ | | EQ 2GM BASE/VIAL | A062798 | 002 | Dec 11, 1995 | Sep CAHN |
| >A> | @ | CHARTWELL RX | EQ 250MG BASE/VIAL | A062856 | 001 | Oct 26, 1988 | Oct CAHN |
| >A> | @ | | EQ 500MG BASE/VIAL | A062856 | 002 | Oct 26, 1988 | Oct CAHN |
| >A> | @ | | EQ 1GM BASE/VIAL | A062856 | 003 | Oct 26, 1988 | Oct CAHN |
| >A> | @ | | EQ 2GM BASE/VIAL | A062856 | 004 | Oct 26, 1988 | Oct CAHN |
| >A> | @ | | EQ 4GM BASE/VIAL | A062856 | 005 | Oct 26, 1988 | Oct CAHN |
| >A> | @ | | EQ 10GM BASE/VIAL | A062984 | 001 | Sep 29, 1988 | Oct CAHN |
| >D> | @ | WATSON LABS INC | EQ 250MG BASE/VIAL | A062856 | 001 | Oct 26, 1988 | Oct CAHN |
| >D> | @ | | EQ 500MG BASE/VIAL | A062856 | 002 | Oct 26, 1988 | Oct CAHN |
| >D> | @ | | EQ 1GM BASE/VIAL | A062856 | 003 | Oct 26, 1988 | Oct CAHN |
| >D> | @ | | EQ 2GM BASE/VIAL | A062856 | 004 | Oct 26, 1988 | Oct CAHN |
| >D> | @ | | EQ 4GM BASE/VIAL | A062856 | 005 | Oct 26, 1988 | Oct CAHN |
| >D> | @ | | EQ 10GM BASE/VIAL | A062984 | 001 | Sep 29, 1988 | Oct CAHN |

OXALIPLATIN

INJECTABLE;INTRAVENOUS
OXALIPLATIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | ACTAVIS | 50MG/10ML (5MG/ML) | A204880 | 001 | Mar 05, 2018 | Apr DISC |
| | @ | | 100MG/20ML (5MG/ML) | A204880 | 002 | Mar 05, 2018 | Apr DISC |
| | @ | HENGRUI PHARMA | 50MG/10ML (5MG/ML) | A203869 | 001 | Jun 18, 2014 | Apr DISC |
| | @ | | 100MG/20ML (5MG/ML) | A203869 | 002 | Jun 18, 2014 | Apr DISC |
| | @ | INGENUS PHARMS LLC | 50MG/10ML (5MG/ML) | A207562 | 001 | Oct 16, 2018 | May CAHN |
| | @ | | 100MG/20ML (5MG/ML) | A207562 | 002 | Oct 16, 2018 | May CAHN |
| | @ | NOVAST LABS | 100MG/20ML (5MG/ML) | A207562 | 002 | Oct 16, 2018 | Apr DISC |
| AP | | SHANDONG | 50MG/10ML (5MG/ML) | A219765 | 001 | Jan 15, 2026 | Jan NEWA |
| AP | | | 100MG/20ML (5MG/ML) | A219765 | 002 | Jan 15, 2026 | Jan NEWA |
| | @ + | TEVA PHARMS | 50MG/10ML (5MG/ML) | N022160 | 001 | Aug 07, 2009 | Apr DISC |
| | @ + | | 100MG/20ML (5MG/ML) | N022160 | 002 | Aug 07, 2009 | Apr DISC |

OXAPROZIN

TABLET;ORAL
DAYPRO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | PFIZER | 600MG | N018841 | 004 | Oct 29, 1992 | Jun DISC |

OXAPROZIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ! | DR REDDYS LABS LTD | 600MG | A075855 | 001 | Jan 31, 2001 | Jun CHRS |

OXCARBAZEPINE

SUSPENSION;ORAL
OXCARBAZEPINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | ADAPTIS | 300MG/5ML | A220281 | 001 | Mar 09, 2026 | Sep CAHN |
| AB | | MSN | 300MG/5ML | A209020 | 001 | May 29, 2026 | May NEWA |
| AB | | PHARMAZONE | 300MG/5ML | A217782 | 001 | Feb 14, 2024 | Sep CAHN |
| AB | | SENORES PHARMS | 300MG/5ML | A217782 | 001 | Feb 14, 2024 | Sep CAHN |
| | @ | STERANCO HLTHCARE | 300MG/5ML | A220281 | 001 | Mar 09, 2026 | Jul DISC |
| AB | | | 300MG/5ML | A220281 | 001 | Mar 09, 2026 | Feb NEWA |

TABLET;ORAL
OXCARBAZEPINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | EPIC PHARMA LLC | 150MG | A219556 | 001 | Mar 02, 2026 | Feb NEWA |
| AB | | | 300MG | A219556 | 002 | Mar 02, 2026 | Feb NEWA |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | TABLET;ORAL | | | | | | |
| | | OXCARBAZEPINE | | | | | | |
| | AB | | 600MG | A219556 | 003 | Mar 02, 2026 | Feb | NEWA |
| | AB | UMEDICA LABS PVT | 150MG | A218341 | 001 | Apr 29, 2026 | Apr | NEWA |
| | AB | | 300MG | A218341 | 002 | Apr 29, 2026 | Apr | NEWA |
| | AB | | 600MG | A218341 | 003 | Apr 29, 2026 | Apr | NEWA |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| | | OXCARBAZEPINE | | | | | | |
| >D> | | @ AUROBINDO PHARMA LTD | 150MG | A219241 | 001 | Apr 30, 2025 | Oct | CMFD |
| >A> | AB | | 150MG | A219241 | 001 | Apr 30, 2025 | Oct | CMFD |
| >D> | | @ | 300MG | A219241 | 002 | Apr 30, 2025 | Oct | CMFD |
| >A> | AB | | 300MG | A219241 | 002 | Apr 30, 2025 | Oct | CMFD |
| >D> | | @ | 600MG | A219241 | 003 | Apr 30, 2025 | Oct | CMFD |
| >A> | AB | | 600MG | A219241 | 003 | Apr 30, 2025 | Oct | CMFD |
| | | OXICONAZOLE NITRATE | | | | | | |
| | | CREAM;TOPICAL | | | | | | |
| | | OXISTAT | | | | | | |
| | AB | +! FOUGERA | EQ 1% BASE | N019828 | 001 | Dec 30, 1988 | Aug | CAHN |
| | | LOTION;TOPICAL | | | | | | |
| | | OXISTAT | | | | | | |
| | | @ + ANI PHARMS | EQ 1% BASE | N020209 | 001 | Sep 30, 1992 | Apr | DISC |
| | | OXYBUTYNIN CHLORIDE | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | OXYBUTYNIN CHLORIDE | | | | | | |
| | | @ ADAPTIS | 5MG | A211062 | 001 | Feb 06, 2019 | Sep | CAHN |
| | AB | AVET LIFESCIENCES | 5MG | A211682 | 001 | May 10, 2019 | May | CMFD |
| | AB | HERITAGE PHARMA AVET | 5MG | A211682 | 001 | May 10, 2019 | Jun | CAHN |
| | AB | ! NOVITIUM PHARMA | 5MG | A209823 | 001 | Oct 23, 2017 | Jan | CHRS |
| | AB | ! RISING | 2.5MG | A209025 | 002 | Feb 07, 2023 | Feb | CTEC |
| | AB | STRIDES PHARMA INTL | 2.5MG | A075079 | 002 | Mar 10, 2026 | Feb | NEWA |
| | AB | | 5MG | A075079 | 001 | Oct 31, 1997 | Jan | CHRS |
| | AB | TP ANDA HOLDINGS | 2.5MG | A210125 | 002 | Jul 21, 2026 | Jul | NEWA |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| | | OXYBUTYNIN CHLORIDE | | | | | | |
| | AB | ACCORD HLTHCARE | 15MG | A207138 | 003 | Feb 29, 2016 | Jan | CHRS |
| | AB | ! ZYDUS PHARMS | 15MG | A202332 | 003 | Jun 26, 2017 | Jan | CHRS |
| | | OXYCODONE HYDROCHLORIDE | | | | | | |
| | | SOLUTION;ORAL | | | | | | |
| | | OXYCODONE HYDROCHLORIDE | | | | | | |
| | AA | ADAPTIS | 5MG/5ML | A207511 | 001 | Nov 23, 2016 | Sep | CAHN |
| | AA | | 100MG/5ML | A209897 | 001 | Sep 06, 2017 | Sep | CAHN |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| | | OXYCONTIN | | | | | | |
| | | + KNOA PHARMA | 10MG | N022272 | 001 | Apr 05, 2010 | May | CAHN |
| | | + | 15MG | N022272 | 002 | Apr 05, 2010 | May | CAHN |
| | | + | 20MG | N022272 | 003 | Apr 05, 2010 | May | CAHN |
| | | + | 30MG | N022272 | 004 | Apr 05, 2010 | May | CAHN |
| | | +! | 40MG | N022272 | 005 | Apr 05, 2010 | May | CAHN |
| | | + | 60MG | N022272 | 006 | Apr 05, 2010 | May | CAHN |
| | | + | 80MG | N022272 | 007 | Apr 05, 2010 | May | CAHN |
| | | OXYMETAZOLINE HYDROCHLORIDE | | | | | | |
| | | CREAM;TOPICAL | | | | | | |
| | | OXYMETAZOLINE HYDROCHLORIDE | | | | | | |
| | AB | SUN PHARMA CANADA | 1% | A213584 | 001 | Oct 04, 2021 | May | CMFD |
| | | RHOFADE | | | | | | |
| | AB | +! MAYNE PHARMA | 1% | N208552 | 001 | Jan 18, 2017 | May | CTEC |
| | | OXYTETRACYCLINE HYDROCHLORIDE | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | OXYTETRACYCLINE HYDROCHLORIDE | | | | | | |
| | | @ HIKMA | EQ 250MG BASE | A060770 | 001 | | Sep | CAHN |

OZENOXACIN

CREAM;TOPICAL

XEPI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ + | LNHC | 1% | N208945 | 001 | Dec 11, 2017 | Jan CAHN |

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | NATCO PHARMA USA | 6MG/ML | A091540 | 001 | Sep 29, 2011 | Mar CAHN |

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 1.5MG | A204452 | 001 | Jun 12, 2019 | Sep CAHN |
| AB | | | 3MG | A204452 | 002 | Jun 12, 2019 | Sep CAHN |
| AB | | | 6MG | A204452 | 003 | Jun 12, 2019 | Sep CAHN |
| AB | | | 9MG | A204452 | 004 | Jun 12, 2019 | Sep CAHN |
| AB | | AJANTA PHARMA LTD | 3MG | A218514 | 002 | Jun 26, 2024 | Mar CMFD |
| AB | | | 6MG | A218514 | 003 | Jun 26, 2024 | Mar CMFD |
| AB | | | 9MG | A218514 | 004 | Jun 26, 2024 | Mar CMFD |
| | @ | APOTEX | 3MG | A203279 | 001 | Jan 26, 2026 | Apr DISC |
| AB | | | 3MG | A203279 | 001 | Jan 26, 2026 | Jan NEWA |
| | @ | | 6MG | A203279 | 002 | Jan 26, 2026 | Apr DISC |
| AB | | | 6MG | A203279 | 002 | Jan 26, 2026 | Jan NEWA |
| | @ | | 9MG | A203279 | 003 | Jan 26, 2026 | Apr DISC |
| AB | | | 9MG | A203279 | 003 | Jan 26, 2026 | Jan NEWA |
| AB | | I3 PHARMS | 1.5MG | A205402 | 001 | May 07, 2026 | May NEWA |
| AB | | | 3MG | A205402 | 002 | May 07, 2026 | May NEWA |
| AB | | | 6MG | A205402 | 003 | May 07, 2026 | May NEWA |
| AB | | | 9MG | A205402 | 004 | May 07, 2026 | May NEWA |
| AB | | PHARMAZONE | 1.5MG | A205402 | 001 | May 07, 2026 | Sep CAHN |
| AB | | | 1.5MG | A218755 | 001 | Sep 04, 2025 | Sep CAHN |
| AB | | | 3MG | A205402 | 002 | May 07, 2026 | Sep CAHN |
| AB | | | 3MG | A218755 | 002 | Sep 04, 2025 | Sep CAHN |
| AB | | | 6MG | A205402 | 003 | May 07, 2026 | Sep CAHN |
| AB | | | 6MG | A218755 | 003 | Sep 04, 2025 | Sep CAHN |
| AB | | | 9MG | A205402 | 004 | May 07, 2026 | Sep CAHN |
| AB | | | 9MG | A218755 | 004 | Sep 04, 2025 | Sep CAHN |
| | @ | RK PHARMA | 1.5MG | A203802 | 001 | Sep 24, 2015 | Jan DISC |
| | @ | | 3MG | A203802 | 002 | Sep 24, 2015 | Jan DISC |
| | @ | | 6MG | A203802 | 003 | Sep 24, 2015 | Jan DISC |
| | @ | | 9MG | A203802 | 004 | Sep 24, 2015 | Jan DISC |

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA HAFYERA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | JANSSEN PHARMS | 1.092GM/3.5ML (312MG/ML) | N207946 | 005 | Aug 30, 2021 | Jan CHRS |
| +! | | 1.560GM/5ML (312MG/ML) | N207946 | 006 | Aug 30, 2021 | Jan CHRS |

INVEGA SUSTENNA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | JANSSEN PHARMS | 39MG/0.25ML (39MG/0.25ML) | N022264 | 001 | Jul 31, 2009 | Mar CHRS |
| +! | | 78MG/0.5ML (78MG/0.5ML) | N022264 | 002 | Jul 31, 2009 | Mar CHRS |
| +! | | 117MG/0.75ML (117MG/0.75ML) | N022264 | 003 | Jul 31, 2009 | Mar CHRS |
| +! | | 234MG/1.5ML (156MG/ML) | N022264 | 005 | Jul 31, 2009 | Mar CHRS |

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | BAXTER HLTHCARE CORP | EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | A206916 | 001 | Nov 12, 2021 | Jun DISC |
| @ | INGENUS PHARMS LLC | EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | A208789 | 001 | May 22, 2020 | May CAHN |

PALOPEGTERIPARATIDE

SOLUTION;SUBCUTANEOUS

YORVIPATH

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | ASCENDIS PHARMA BONE | EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | N216490 | 002 | Aug 09, 2024 | May CHRS |
| +! | | EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | N216490 | 003 | Aug 09, 2024 | May CHRS |

PALOVAROTENE

CAPSULE;ORAL

SOHONOS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | IPSEN | 2.5MG | N215559 | 003 | Aug 16, 2023 | Aug DISC |

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | ANNORA PHARMA | EQ 40MG BASE | A216139 | 001 | Oct 27, 2023 | Oct CHRS |
| >A> | AB | ! | | EQ 40MG BASE | A216139 | 001 | Oct 27, 2023 | Oct CHRS |
| >D> | | PROTONIX | | | | | | |
| >D> | AB | +! | WYETH PHARMS | EQ 40MG BASE | N022020 | 001 | Nov 14, 2007 | Oct DISC |
| >A> | | @ + | | EQ 40MG BASE | N022020 | 001 | Nov 14, 2007 | Oct DISC |

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | PHARMOBEDIENT | EQ 40MG BASE/VIAL | A208580 | 001 | May 04, 2018 | Jan CAHN |
| | AP | | SHUANGCHENG | EQ 40MG BASE/VIAL | A219973 | 001 | Apr 22, 2026 | Apr NEWA |

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | AUROBINDO PHARMA LTD | EQ 40MG BASE | A202038 | 002 | Sep 28, 2012 | Oct CHRS |
| >A> | AB | ! | | EQ 40MG BASE | A202038 | 002 | Sep 28, 2012 | Oct CHRS |
| >D> | | PROTONIX | | | | | | |
| >D> | AB | + | WYETH PHARMS | EQ 20MG BASE | N020987 | 002 | Jun 12, 2001 | Oct DISC |
| >A> | | @ + | | EQ 20MG BASE | N020987 | 002 | Jun 12, 2001 | Oct DISC |
| >D> | AB | +! | | EQ 40MG BASE | N020987 | 001 | Feb 02, 2000 | Oct DISC |
| >A> | | @ + | | EQ 40MG BASE | N020987 | 001 | Feb 02, 2000 | Oct DISC |

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | PHARMAZONE | 1MCG | A204948 | 001 | Oct 07, 2016 | Sep CAHN |
| | AB | | | 2MCG | A204948 | 002 | Oct 07, 2016 | Sep CAHN |
| | AB | | | 4MCG | A204948 | 003 | Oct 07, 2016 | Sep CAHN |

ZEMPLAR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | ABBVIE | 2MCG | N021606 | 002 | May 26, 2005 | Apr DISC |

SOLUTION;INTRAVENOUS

PARICALCITOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | CAPLIN | 0.002MG/ML (0.002MG/ML) | A204910 | 001 | Aug 17, 2016 | Apr DISC |
| | @ | | 0.005MG/ML (0.005MG/ML) | A204910 | 002 | Aug 17, 2016 | Apr DISC |
| | @ | | 0.01MG/2ML (0.005MG/ML) | A204910 | 003 | Aug 17, 2016 | Apr DISC |
| | @ | EUGIA PHARMA | 0.002MG/ML (0.002MG/ML) | A205982 | 001 | Oct 09, 2018 | Jan DISC |
| | @ | | 0.005MG/ML (0.005MG/ML) | A205982 | 002 | Oct 09, 2018 | Jan DISC |
| | @ | | 0.01MG/2ML (0.005MG/ML) | A205982 | 003 | Oct 09, 2018 | Jan DISC |

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ANNORA PHARMA | EQ 10MG BASE/5ML | A219954 | 001 | Mar 05, 2026 | Feb NEWA |
| | AB | ! | NOVITIUM PHARMA | EQ 10MG BASE/5ML | A215003 | 001 | Sep 03, 2021 | Feb CTEC |

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | PHARMOBEDIENT | EQ 10MG BASE | A211248 | 001 | Nov 02, 2021 | Sep CAHN |
| | AB | | | EQ 20MG BASE | A211248 | 002 | Nov 02, 2021 | Sep CAHN |
| | AB | | | EQ 30MG BASE | A211248 | 003 | Nov 02, 2021 | Sep CAHN |
| | AB | | | EQ 40MG BASE | A211248 | 004 | Nov 02, 2021 | Sep CAHN |

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ALEMBIC | EQ 12.5MG BASE | A217280 | 003 | Mar 26, 2026 | Mar NEWA |
| | | @ | LUPIN | EQ 12.5MG BASE | A204134 | 001 | Jan 20, 2017 | Jun DISC |
| | | @ | | EQ 25MG BASE | A204134 | 002 | Jan 20, 2017 | Jun DISC |
| | | @ | | EQ 37.5MG BASE | A204134 | 003 | Jan 20, 2017 | Jun DISC |

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | +! | LEGACY | EQ 7.5MG BASE | N204516 | 001 | Jun 28, 2013 | Jun CAHN |

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | APOTEX | EQ 1GM BASE/VIAL | A209085 | 001 | May 25, 2022 | Jul DISC |
| >D> | AP | | NANG KUANG PHARM CO | EQ 100MG BASE/VIAL | A207352 | 001 | May 25, 2022 | Oct DISC |
| >A> | | @ | | EQ 100MG BASE/VIAL | A207352 | 001 | May 25, 2022 | Oct DISC |
| >D> | AP | | | EQ 500MG BASE/VIAL | A207352 | 002 | May 25, 2022 | Oct DISC |
| >A> | | @ | | EQ 500MG BASE/VIAL | A207352 | 002 | May 25, 2022 | Oct DISC |
| | AP | | SOMERSET THERAPS LLC | EQ 100MG BASE/VIAL | A211899 | 001 | May 25, 2022 | Sep CAHN |
| | AP | | | EQ 500MG BASE/VIAL | A211899 | 002 | May 25, 2022 | Sep CAHN |

PENCICLOVIR

CREAM;TOPICAL

PENCICLOVIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | TORRENT | 1% | A216981 | 001 | Aug 07, 2023 | Sep DISC |

PENICILLIN G POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | @ | CHARTWELL RX | 200,000 UNITS/5ML | A060307 | 002 | | Oct CAHN |
| >A> | | @ | | 400,000 UNITS/5ML | A060307 | 004 | | Oct CAHN |
| >D> | | @ | TEVA | 200,000 UNITS/5ML | A060307 | 002 | | Oct CAHN |
| >D> | | @ | | 400,000 UNITS/5ML | A060307 | 004 | | Oct CAHN |

PENICILLIN-2

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | @ | CHARTWELL RX | 250,000 UNITS/5ML | A060307 | 003 | | Oct CAHN |
| >D> | | @ | TEVA | 250,000 UNITS/5ML | A060307 | 003 | | Oct CAHN |

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | ACS DOBFAR SPA | 5,000,000 UNITS/VIAL | A065448 | 001 | Aug 18, 2009 | Sep CAHN |
| | AP | | | 20,000,000 UNITS/VIAL | A065448 | 002 | Aug 18, 2009 | Sep CAHN |
| >A> | | @ | CHARTWELL RX | 1,000,000 UNITS/VIAL | A062991 | 001 | Sep 13, 1988 | Oct CAHN |
| >A> | | @ | | 5,000,000 UNITS/VIAL | A062991 | 002 | Sep 13, 1988 | Oct CAHN |
| >A> | | @ | | 10,000,000 UNITS/VIAL | A062991 | 003 | Sep 13, 1988 | Oct CAHN |
| >A> | | @ | | 20,000,000 UNITS/VIAL | A062991 | 004 | Sep 13, 1988 | Oct CAHN |
| >D> | | @ | WATSON LABS INC | 1,000,000 UNITS/VIAL | A062991 | 001 | Sep 13, 1988 | Oct CAHN |
| >D> | | @ | | 5,000,000 UNITS/VIAL | A062991 | 002 | Sep 13, 1988 | Oct CAHN |
| >D> | | @ | | 10,000,000 UNITS/VIAL | A062991 | 003 | Sep 13, 1988 | Oct CAHN |
| >D> | | @ | | 20,000,000 UNITS/VIAL | A062991 | 004 | Sep 13, 1988 | Oct CAHN |

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | BAXTER HLTHCARE | 20,000 UNITS/ML | N050638 | 001 | Jun 25, 1990 | Sep DISC |

TABLET;ORAL

PENICILLIN G POTASSIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | @ | CHARTWELL RX | 200,000 UNITS | A060306 | 001 | | Oct CAHN |
| >A> | | @ | | 250,000 UNITS | A060306 | 002 | | Oct CAHN |
| >A> | | @ | | 400,000 UNITS | A060073 | 004 | | Oct CAHN |
| >A> | | @ | | 400,000 UNITS | A060306 | 003 | | Oct CAHN |
| >A> | | @ | | 500,000 UNITS | A060306 | 004 | | Oct CAHN |
| >D> | | @ | IVAX SUB TEVA PHARMS | 400,000 UNITS | A060073 | 004 | | Oct CAHN |
| >D> | | @ | TEVA | 200,000 UNITS | A060306 | 001 | | Oct CAHN |
| >D> | | @ | | 250,000 UNITS | A060306 | 002 | | Oct CAHN |
| >D> | | @ | | 400,000 UNITS | A060306 | 003 | | Oct CAHN |
| >D> | | @ | | 500,000 UNITS | A060306 | 004 | | Oct CAHN |

PENICILLIN G SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | @ | CHARTWELL RX | 5,000,000 UNITS/VIAL | A063014 | 001 | Sep 13, 1988 | Oct CAHN |
| >D> | | @ | WATSON LABS INC | 5,000,000 UNITS/VIAL | A063014 | 001 | Sep 13, 1988 | Oct CAHN |

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN-VK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | | CHARTWELL RX | EQ 125MG BASE/5ML | A060456 | 001 | | Aug CAHN |
| | | ! | | EQ 250MG BASE/5ML | A060456 | 002 | | Aug CAHN |

TABLET;ORAL

PENICILLIN V POTASSIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | @ | CHARTWELL RX | EQ 125MG BASE | A060518 | 001 | | Oct CAHN |
| >A> | | @ | | EQ 250MG BASE | A060518 | 002 | | Oct CAHN |
| >A> | | @ | | EQ 500MG BASE | A060518 | 003 | | Oct CAHN |
| >D> | | @ | IVAX SUB TEVA PHARMS | EQ 125MG BASE | A060518 | 001 | | Oct CAHN |
| >D> | | @ | | EQ 250MG BASE | A060518 | 002 | | Oct CAHN |

TABLET;ORAL
PENICILLIN V POTASSIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | @ | | EQ 500MG BASE | A060518 | 003 | | Oct CAHN |

PENICILLIN-VK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | CHARTWELL RX | EQ 250MG BASE | A060711 | 002 | | Aug CAHN |
| | AB | | | EQ 500MG BASE | A060711 | 003 | | Aug CAHN |

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION
PENTAMIDINE ISETHIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AN | | PAI HOLDINGS | 300MG/VIAL | A206667 | 001 | Apr 24, 2019 | Apr CAHN |

INJECTABLE;INJECTION
PENTAMIDINE ISETHIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | | PAI HOLDINGS | 300MG/VIAL | A206666 | 001 | Sep 28, 2017 | Apr CAHN |
| | | @ | PHARMOBEDIENT | 300MG/VIAL | A206982 | 001 | Mar 17, 2022 | Apr DISC |

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
TRENTAL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | + | VALIDUS PHARMS | 400MG | N018631 | 001 | Aug 30, 1984 | Aug CMFD |

PERAMPANEL

SUSPENSION;ORAL
PERAMPANEL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | TARO | 0.5MG/ML | A219052 | 001 | Jun 15, 2026 | Jun NEWA |

TABLET;ORAL
PERAMPANEL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | AUROBINDO PHARMA LTD | 2MG | A220492 | 001 | Oct 02, 2026 | Sep NEWA |
| | AB | | | 4MG | A220492 | 002 | Oct 02, 2026 | Sep NEWA |
| | AB | | | 6MG | A220492 | 003 | Oct 02, 2026 | Sep NEWA |
| | AB | | | 8MG | A220492 | 004 | Oct 02, 2026 | Sep NEWA |
| | AB | | | 10MG | A220492 | 005 | Oct 02, 2026 | Sep NEWA |
| | AB | | | 12MG | A220492 | 006 | Oct 02, 2026 | Sep NEWA |

PERMETHRIN

CREAM;TOPICAL
PERMETHRIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | ACTAVIS LABS | 5% | A074806 | 001 | Jan 23, 1998 | Aug DISC |
| | AB | | DR REDDYS LABS EU | 5% | A209732 | 001 | Aug 01, 2023 | Jun CMFD |
| >A> | AB | | ENCUBE | 5% | A211303 | 001 | Apr 03, 2019 | Oct CAHN |
| >D> | AB | | ENCUBE ETHICALS | 5% | A211303 | 001 | Apr 03, 2019 | Oct CAHN |

PERPHENAZINE

TABLET;ORAL
PERPHENAZINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | SOMERSET THERAPS LLC | 2MG | A210163 | 001 | May 18, 2022 | Sep CAHN |
| | AB | | | 4MG | A210163 | 002 | May 18, 2022 | Sep CAHN |
| | AB | | | 8MG | A210163 | 003 | May 18, 2022 | Sep CAHN |
| | AB | | | 16MG | A210163 | 004 | May 18, 2022 | Sep CAHN |

PHENOBARBITAL SODIUM

POWDER;INTRAVENOUS
SEZABY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | +! | SPARC | 100MG/VIAL | N215910 | 001 | Nov 17, 2022 | Oct CAHN |
| >D> | | +! | SUN PHARM INDS INC | 100MG/VIAL | N215910 | 001 | Nov 17, 2022 | Oct CAHN |

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL
PHENOXYBENZAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | AMNEAL | 10MG | A212568 | 001 | Oct 27, 2020 | Oct DISC |
| >A> | | @ | | 10MG | A212568 | 001 | Oct 27, 2020 | Oct DISC |

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL
PHENTERMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | INGENUS PHARMS LLC | 37.5MG | A091451 | 001 | Sep 21, 2012 | Feb CAHN |

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP1 | | BAXTER HLTHCARE CORP | 10MG/ML (10MG/ML) | A217032 | 001 | Apr 03, 2026 | Mar | NEWA |
| AP1 | | | 50MG/5ML (10MG/ML) | A217032 | 002 | Apr 03, 2026 | Mar | NEWA |
| AP1 | | | 100MG/10ML (10MG/ML) | A217032 | 003 | Apr 03, 2026 | Mar | NEWA |
| AP1 | | HAINAN POLY | 10MG/ML (10MG/ML) | A218412 | 001 | Mar 14, 2024 | Jan | CMFD |
| AP1 | | | 50MG/5ML (10MG/ML) | A218412 | 002 | Mar 14, 2024 | Jan | CMFD |
| AP1 | | | 100MG/10ML (10MG/ML) | A218412 | 003 | Mar 14, 2024 | Jan | CMFD |
| AP2 | | NEPHRON | 10MG/ML (10MG/ML) | A215268 | 001 | Sep 24, 2026 | Sep | NEWA |

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | ! | PAI HOLDINGS | 5MG/5ML;6.25MG/5ML | A040654 | 001 | Dec 07, 2006 | May | CAHN |

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | MANKIND PHARMA | 100MG EXTENDED | A219773 | 001 | Jan 02, 2026 | Jul | DISC |

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB1 | | ALEMBIC | 1MG/0.5ML | A216444 | 001 | Sep 08, 2025 | Mar | CTEC |
| AB1 | | AMNEAL | 1MG/0.5ML | A216601 | 001 | Nov 04, 2025 | Mar | CTEC |
| AB1 | | | 10MG/ML | A217734 | 001 | Jun 01, 2026 | May | NEWA |
| AB2 | | BAXTER HLTHCARE CORP | 1MG/0.5ML | A216852 | 001 | Feb 26, 2026 | Mar | CTEC |
| AB | | | 1MG/0.5ML | A216852 | 001 | Feb 26, 2026 | Feb | NEWA |
| AB2 | ! | CIPLA | 1MG/0.5ML | A214596 | 001 | Apr 22, 2022 | Mar | CTEC |
| AB1 | | | 1MG/0.5ML | A214966 | 001 | Jan 03, 2025 | Mar | CTEC |
| AB1 | | DR REDDYS | 1MG/0.5ML | A215820 | 001 | May 15, 2026 | May | NEWA |
| AB1 | +! | INTL MEDICATION | 1MG/0.5ML | A083722 | 001 | | Mar | CTEC |
| >D> AB2 | | LUPIN | 1MG/0.5ML | A219175 | 001 | Sep 30, 2026 | Oct | CTEC |
| >A> AB1 | | | 1MG/0.5ML | A219175 | 001 | Sep 30, 2026 | Oct | CTEC |
| AB2 | | | 1MG/0.5ML | A219175 | 001 | Sep 30, 2026 | Sep | NEWA |
| AB1 | | ORBICULAR | 1MG/0.5ML | A216298 | 001 | Mar 13, 2026 | Mar | CTEC |
| AB | | | 1MG/0.5ML | A216298 | 001 | Mar 13, 2026 | Mar | NEWA |
| AB1 | | SUNNY | 10MG/ML | A215090 | 001 | Jan 09, 2026 | Jan | NEWA |

TABLET;ORAL

PHYTONADIONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | NOVAX | 5MG | A220454 | 001 | Feb 26, 2026 | Jul | CAHN |
| AB | | SINOTHERAPEUTICS INC | 5MG | A220454 | 001 | Feb 26, 2026 | Feb | NEWA |
| AB | | TP ANDA HOLDINGS | 5MG | A213336 | 001 | Oct 12, 2023 | Sep | CAHN |

PIFLUFOLASTAT F-18

SOLUTION;INTRAVENOUS

PYLARIFY TRUVU

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | APHELION | 1mCi/mL-120mCi/mL | N220089 | 001 | Mar 06, 2026 | Mar | NEWA |

PILOCARPINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | AMNEAL | 1.25% | A217733 | 001 | Apr 28, 2025 | Apr | CTEC |
| AB | ! | | 1.25% | A217733 | 001 | Apr 28, 2025 | Apr | CHRS |
| AT | | FDC LTD | 1% | A217052 | 001 | Oct 02, 2025 | Aug | CMFD |
| | @ | | 1% | A217052 | 001 | Oct 02, 2025 | May | DISC |
| AT | | | 2% | A217052 | 002 | Oct 02, 2025 | Aug | CMFD |
| | @ | | 2% | A217052 | 002 | Oct 02, 2025 | May | DISC |
| AT | | | 4% | A217052 | 003 | Oct 02, 2025 | Aug | CMFD |
| | @ | | 4% | A217052 | 003 | Oct 02, 2025 | May | DISC |

VUITY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | ABBVIE | 1.25% | N214028 | 001 | Oct 28, 2021 | Apr | DISC |

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA USA | 5MG | A212377 | 001 | Aug 13, 2019 | Jan | CAHN |
| AB | | | 7.5MG | A212377 | 002 | Aug 13, 2019 | Jan | CAHN |
| | @ | PADAGIS US | 5MG | A076746 | 001 | Nov 16, 2004 | Mar | DISC |
| AB | | QUAGEN | 5MG | A212377 | 001 | Aug 13, 2019 | Jul | CAHN |
| AB | | | 7.5MG | A212377 | 002 | Aug 13, 2019 | Jul | CAHN |

PIMOZIDE

TABLET;ORAL

PIMOZIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | NOVITIUM PHARMA | 1MG | A219897 | 001 | Apr 13, 2026 | Apr NEWA |
| AB | | | 2MG | A219897 | 002 | Apr 13, 2026 | Apr NEWA |
| AB | | PH HEALTH | 1MG | A204521 | 001 | Sep 28, 2015 | Apr CTEC |
| AB | ! | | 2MG | A204521 | 002 | Sep 28, 2015 | Apr CTEC |

PINDOLOL

TABLET;ORAL

PINDOLOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | ANI PHARMS | 5MG | A073609 | 002 | Mar 29, 1993 | Sep DISC |
| @ | | | 10MG | A073609 | 001 | Mar 29, 1993 | Sep DISC |
| @ | | COSETTE PHARMS NC | 5MG | A073661 | 001 | Oct 31, 1993 | Jun CAHN |
| @ | | | 5MG | A073687 | 001 | Feb 26, 1993 | Jun CAHN |
| @ | | | 5MG | A074123 | 001 | Apr 17, 1997 | Jun CAHN |
| @ | | | 10MG | A073661 | 002 | Oct 31, 1993 | Jun CAHN |
| @ | | | 10MG | A073687 | 002 | Feb 26, 1993 | Jun CAHN |
| @ | | | 10MG | A074123 | 002 | Apr 17, 1997 | Jun CAHN |

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | SOLGEN | EQ 15MG BASE | A210165 | 001 | Jan 22, 2021 | Sep CAHN |
| AB | | | EQ 30MG BASE | A210165 | 002 | Jan 22, 2021 | Sep CAHN |
| AB | | | EQ 45MG BASE | A210165 | 003 | Jan 22, 2021 | Sep CAHN |

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >D> | | PIPERACILLIN | | | | | |
| >D> | ! | ACS DOBFAR SPA | EQ 2GM BASE/VIAL | A065114 | 001 | Nov 14, 2003 | Oct DISC |
| >A> | @ | | EQ 2GM BASE/VIAL | A065114 | 001 | Nov 14, 2003 | Oct DISC |
| | ! | | EQ 2GM BASE/VIAL | A065114 | 001 | Nov 14, 2003 | Sep CAHN |
| >D> | ! | | EQ 3GM BASE/VIAL | A065114 | 002 | Nov 14, 2003 | Oct DISC |
| >A> | @ | | EQ 3GM BASE/VIAL | A065114 | 002 | Nov 14, 2003 | Oct DISC |
| | ! | | EQ 3GM BASE/VIAL | A065114 | 002 | Nov 14, 2003 | Sep CAHN |
| >D> | ! | | EQ 4GM BASE/VIAL | A065114 | 003 | Nov 14, 2003 | Oct DISC |
| >A> | @ | | EQ 4GM BASE/VIAL | A065114 | 003 | Nov 14, 2003 | Oct DISC |
| | ! | | EQ 4GM BASE/VIAL | A065114 | 003 | Nov 14, 2003 | Sep CAHN |
| >D> | ! | | EQ 40GM BASE/VIAL | A065157 | 001 | Jul 12, 2004 | Oct DISC |
| >A> | @ | | EQ 40GM BASE/VIAL | A065157 | 001 | Jul 12, 2004 | Oct DISC |
| | ! | | EQ 40GM BASE/VIAL | A065157 | 001 | Jul 12, 2004 | Sep CAHN |

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | ACS DOBFAR SPA | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL | A065523 | 001 | May 31, 2011 | Sep CAHN |
| AP | | | EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL | A065523 | 002 | May 31, 2011 | Sep CAHN |
| AP | | | EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | A065523 | 003 | May 31, 2011 | Sep CAHN |
| AP | | | EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | A090498 | 001 | May 31, 2011 | Sep CAHN |
| @ | | SANDOZ | EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL | A065363 | 001 | Oct 21, 2010 | Apr DISC |
| @ | | | EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL | A065363 | 002 | Oct 21, 2010 | Apr DISC |
| @ | | | EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | A065363 | 003 | Oct 21, 2010 | Apr DISC |

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | LEGACY | 267MG | N022535 | 001 | Oct 15, 2014 | Jun CAHN |

PIRFENIDONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >D> AB | | AUROBINDO PHARMA | 267MG | A212597 | 001 | Apr 20, 2026 | Oct DISC |
| >A> | @ | | 267MG | A212597 | 001 | Apr 20, 2026 | Oct DISC |
| AB | | | 267MG | A212597 | 001 | Apr 20, 2026 | Apr NEWA |

TABLET;ORAL

ESBRIET

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + | LEGACY | 267MG | N208780 | 001 | Jan 11, 2017 | Jun CAHN |
| @ | + | | 534MG | N208780 | 002 | Jan 11, 2017 | Jun CAHN |

TABLET;ORAL
ESBRIET
AB +! 801MG N208780 003 Jan 11, 2017 Jun CAHN

PIROXICAM
CAPSULE;ORAL
PIROXICAM
@ UNICHEM 10MG A208340 001 Apr 13, 2017 May DISC
@ 20MG A208340 002 Apr 13, 2017 May DISC

PITOLISANT HYDROCHLORIDE
TABLET;ORAL
PITOLISANT HYDROCHLORIDE
>A> AB ANNORA PHARMA EQ 4.45MG BASE A218832 001 Oct 08, 2026 Oct NEWA
>A> AB EQ 17.8MG BASE A218832 002 Oct 08, 2026 Oct NEWA
AB LUPIN EQ 4.45MG BASE A218846 001 Aug 14, 2026 Aug NEWA
AB EQ 17.8MG BASE A218846 002 Aug 14, 2026 Aug NEWA
AB MSN EQ 4.45MG BASE A218873 001 Aug 14, 2026 Aug NEWA
AB EQ 17.8MG BASE A218873 002 Aug 14, 2026 Aug NEWA
AB NOVITIUM PHARMA EQ 4.45MG BASE A218495 001 Jul 21, 2026 Jul NFTG
AB EQ 17.8MG BASE A218495 002 Jul 21, 2026 Jul NFTG
WAKIX
AB + HARMONY EQ 4.45MG BASE N211150 001 Aug 14, 2019 Jul CFTG
AB +! EQ 17.8MG BASE N211150 002 Aug 14, 2019 Jul CFTG

PIVMECILLINAM HYDROCHLORIDE
TABLET;ORAL
PIVYA
+! ALEMBIC THERAP EQ 185MG BASE N216483 001 Apr 24, 2024 Jan CAHN

PLAZOMICIN SULFATE
SOLUTION;INTRAVENOUS
ZEMDRI
@ + CIPLA USA EQ 500MG BASE/10ML (EQ 50MG BASE/ML) N210303 001 Jun 25, 2018 May DISC

PLERIXAFOR
SOLUTION;SUBCUTANEOUS
PLERIXAFOR
@ TEVA PHARMS USA INC 24MG/1.2ML (20MG/ML) A205197 001 Jul 24, 2023 Mar DISC

PODOFILOX
GEL;TOPICAL
CONDYLOX
@ + ALLERGAN 0.5% N020529 001 Mar 13, 1997 Jan DISC
PODOFILOX
! PADAGIS US 0.5% A211871 001 Nov 22, 2023 Jan CHRS
0.5% A211871 001 Nov 22, 2023 Jan CTEC
SOLUTION;TOPICAL
CONDYLOX
@ + TEVA BRANDED PHARM 0.5% N019795 001 Dec 13, 1990 Apr DISC
AT +! 0.5% N019795 001 Dec 13, 1990 Feb CAHN
PODOFILOX
! PADAGIS US 0.5% A075600 001 Jan 29, 2002 Apr CTEC
AT ! 0.5% A075600 001 Jan 29, 2002 Apr CHRS

POLIDOCANOL
SOLUTION;INTRAVENOUS
VARITHENA
>A> @ + BOSTON 77.5MG/7.75ML (10MG/ML) N205098 002 Dec 21, 2017 Oct CAHN
>A> +! 180MG/18ML (10MG/ML) N205098 001 Nov 25, 2013 Oct CAHN
>D> @ + BOSTON SCITFC 77.5MG/7.75ML (10MG/ML) N205098 002 Dec 21, 2017 Oct CAHN
@ + 77.5MG/7.75ML (10MG/ML) N205098 002 Dec 21, 2017 May CAHN
>D> +! 180MG/18ML (10MG/ML) N205098 001 Nov 25, 2013 Oct CAHN
+! 180MG/18ML (10MG/ML) N205098 001 Nov 25, 2013 May CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
FOR SOLUTION;ORAL
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE
@ PHARMAZONE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT A090409 001 Apr 02, 2010 Sep CAHN

FOR SOLUTION;ORAL
TRILYTE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | AUROBINDO PHARMA USA | 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT | A076491 | 001 | Feb 05, 2004 | Apr | CMFD |

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS
FOR SOLUTION;ORAL
COLYTE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | QUAGEN | 120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET | N018983 | 005 | Oct 26, 1984 | Apr | CRLD |
| | @ + | | 227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET | N018983 | 004 | Oct 26, 1984 | Apr | CRLD |
| | @ + | | 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT | N018983 | 010 | Jan 31, 1989 | Apr | CRLD |
| | @ + | | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | N018983 | 007 | Jun 12, 1987 | Apr | CRLD |
| | @ + | | 360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET | N018983 | 006 | Oct 26, 1984 | Apr | CRLD |
| | @ + | STRIDES PHARMA INTL | 120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET | N018983 | 005 | Oct 26, 1984 | Apr | CAHN |
| | @ + | | 227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET | N018983 | 004 | Oct 26, 1984 | Apr | CAHN |
| | @ + | | 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT | N018983 | 010 | Jan 31, 1989 | Apr | CAHN |
| | @ + | | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | N018983 | 007 | Jun 12, 1987 | Apr | CAHN |
| | @ + | | 360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET | N018983 | 006 | Oct 26, 1984 | Apr | CAHN |

COLYTE WITH FLAVOR PACKS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | QUAGEN | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | N018983 | 012 | Oct 08, 1998 | Apr | CRLD |
| | @ + | STRIDES PHARMA INTL | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | N018983 | 012 | Oct 08, 1998 | Apr | CAHN |

COLYTE-FLAVORED

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | QUAGEN | 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT | N018983 | 008 | Nov 14, 1991 | Apr | CRLD |
| | @ + | | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | N018983 | 009 | Nov 14, 1991 | Apr | CRLD |
| | @ + | STRIDES PHARMA INTL | 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT | N018983 | 008 | Nov 14, 1991 | Apr | CAHN |
| | @ + | | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | N018983 | 009 | Nov 14, 1991 | Apr | CAHN |

PEG 3350 AND ELECTROLYTES

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | NOVEL LABS INC | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | A090186 | 001 | Jun 01, 2009 | Apr | CHRS |
| | @ | PHARMAZONE | 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT | A090928 | 001 | Jan 28, 2010 | Sep | CAHN |

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE
SOLUTION/DROPS;OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | BAUSCH AND LOMB INC | 10,000 UNITS/ML;EQ 1MG BASE/ML | A064120 | 001 | Feb 14, 1997 | May | CAHN |

POMALIDOMIDE
CAPSULE;ORAL
POMALIDOMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | APOTEX | 1MG | A210164 | 001 | Jun 11, 2024 | Jan | CMFD |
| AB | | 2MG | A210164 | 002 | Jun 11, 2024 | Jan | CMFD |
| AB | | 3MG | A210164 | 003 | Jun 11, 2024 | Jan | CMFD |
| AB | | 4MG | A210164 | 004 | Jun 11, 2024 | Jan | CMFD |
| AB | BRECKENRIDGE | 1MG | A210111 | 001 | Oct 30, 2020 | Jan | CMFD |
| AB | | 2MG | A210111 | 002 | Oct 30, 2020 | Jan | CMFD |
| AB | | 3MG | A210111 | 003 | Oct 30, 2020 | Jan | CMFD |
| AB | | 4MG | A210111 | 004 | Oct 30, 2020 | Jan | CMFD |
| AB | CIPLA | 1MG | A219718 | 001 | Aug 31, 2026 | Aug | NEWA |
| AB | | 2MG | A219718 | 002 | Aug 31, 2026 | Aug | NEWA |
| AB | | 3MG | A219718 | 003 | Aug 31, 2026 | Aug | NEWA |
| AB | | 4MG | A219718 | 004 | Aug 31, 2026 | Aug | NEWA |
| AB | DR REDDYS | 1MG | A213234 | 001 | Aug 31, 2026 | Aug | NEWA |
| AB | | 2MG | A213234 | 002 | Aug 31, 2026 | Aug | NEWA |
| AB | | 3MG | A213234 | 003 | Aug 31, 2026 | Aug | NEWA |

CAPSULE;ORAL
POMALIDOMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | 4MG | A213234 | 004 | Aug 31, 2026 | Aug | NEWA |
| AB | EUGIA PHARMA | 1MG | A210249 | 001 | Oct 30, 2020 | Jan | CMFD |
| AB | | 2MG | A210249 | 002 | Oct 30, 2020 | Jan | CMFD |
| AB | | 3MG | A210249 | 003 | Oct 30, 2020 | Jan | CMFD |
| AB | | 4MG | A210249 | 004 | Oct 30, 2020 | Jan | CMFD |
| AB | HETERO LABS LTD V | 1MG | A210236 | 001 | Sep 26, 2024 | Jan | CMFD |
| AB | | 2MG | A210236 | 002 | Sep 26, 2024 | Jan | CMFD |
| AB | | 3MG | A210236 | 003 | Sep 26, 2024 | Jan | CMFD |
| AB | | 4MG | A210236 | 004 | Sep 26, 2024 | Jan | CMFD |
| AB | MSN | 2MG | A210245 | 001 | Sep 02, 2026 | Aug | NEWA |
| AB | | 3MG | A210245 | 002 | Sep 02, 2026 | Aug | NEWA |
| AB | | 4MG | A210245 | 003 | Sep 02, 2026 | Aug | NEWA |
| AB | SANDOZ | 1MG | A220741 | 001 | Aug 31, 2026 | Aug | NEWA |
| AB | | 2MG | A220741 | 002 | Aug 31, 2026 | Aug | NEWA |
| AB | | 3MG | A220741 | 003 | Aug 31, 2026 | Aug | NEWA |
| AB | | 4MG | A220741 | 004 | Aug 31, 2026 | Aug | NEWA |
| AB | SPIL | 1MG | A210232 | 001 | Aug 31, 2026 | Aug | NEWA |
| AB | | 2MG | A210232 | 002 | Aug 31, 2026 | Aug | NEWA |
| AB | | 3MG | A210232 | 003 | Aug 31, 2026 | Aug | NEWA |
| AB | | 4MG | A210232 | 004 | Aug 31, 2026 | Aug | NEWA |
| AB | TEVA PHARMS USA | 1MG | A209956 | 001 | May 04, 2022 | Jan | CMFD |
| AB | | 2MG | A209956 | 002 | May 04, 2022 | Jan | CMFD |
| AB | | 3MG | A209956 | 003 | May 04, 2022 | Jan | CMFD |
| AB | | 4MG | A209956 | 004 | May 04, 2022 | Jan | CMFD |

POMALYST

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | + BRISTOL | 1MG | N204026 | 001 | Feb 08, 2013 | Jan | CTEC |
| AB | + | 2MG | N204026 | 002 | Feb 08, 2013 | Jan | CTEC |
| AB | + | 3MG | N204026 | 003 | Feb 08, 2013 | Jan | CTEC |
| AB | +! | 4MG | N204026 | 004 | Feb 08, 2013 | Jan | CTEC |

PONATINIB HYDROCHLORIDE

TABLET;ORAL
ICLUSIG

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! TAKEDA PHARMS USA | EQ 10MG BASE | N203469 | 004 | Dec 18, 2020 | Jan | CHRS |
| | + | EQ 45MG BASE | N203469 | 002 | Dec 14, 2012 | Jan | CHRS |

PONESIMOD

TABLET;ORAL
PONVORY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! VANDA PHARMS INC | 2MG; 3MG; 4MG; 5MG; 6MG; 7MG; 8MG; 9MG; 10MG | N213498 | 001 | Mar 18, 2021 | Sep | CPOT |

POSACONAZOLE

SOLUTION;INTRAVENOUS
NOXAFIL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + MERCK SHARP DOHME | 300MG/16.7ML (18MG/ML) | N205596 | 001 | Mar 13, 2014 | Jan | DISC |

POSACONAZOLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | ! GLAND | 300MG/16.7ML (18MG/ML) | A217553 | 001 | Dec 26, 2023 | Jan | CHRS |

TABLET, DELAYED RELEASE;ORAL
POSACONAZOLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | APOTEX | 100MG | A213331 | 001 | Jun 29, 2026 | Jun | NEWA |
| AB | PHARMAZONE | 100MG | A216488 | 001 | Aug 28, 2023 | Sep | CAHN |
| AB | SOMERSET THERAPS LLC | 100MG | A216326 | 001 | Jun 20, 2023 | Aug | CAHN |
| AB | WELDING | 100MG | A216326 | 001 | Jun 20, 2023 | Apr | CAHN |

POTASSIUM ACETATE

INJECTABLE;INJECTION
POTASSIUM ACETATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ EXELA PHARMA | 2MEQ/ML | A206203 | 001 | Dec 29, 2015 | Jan | DISC |

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ PADAGIS US | 8MEQ | A200185 | 001 | May 18, 2011 | Mar | DISC |
| | @ | 10MEQ | A200185 | 002 | May 18, 2011 | Mar | DISC |

FOR SOLUTION;ORAL
POKONZA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | + GENUS | 15MEQ | N208019 | 004 | Nov 12, 2025 | Apr | NEWA |

POTASSIUM CHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | ADAPTIS | 20MEQ | A219009 | 001 | Jul 11, 2025 | Aug | CAHN |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | FOR SOLUTION;ORAL | | | | | | |
| | POTASSIUM CHLORIDE | | | | | | |
| | @ + GENUS | 40MEQ | N208019 | 003 | Aug 25, 2023 | Jun | DISC |
| AA | GUARDIAN DRUG | 20MEQ | A219009 | 001 | Jul 11, 2025 | Aug | CAHN |
| | INJECTABLE;INJECTION | | | | | | |
| | POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER | | | | | | |
| | @ + BAXTER HLTHCARE | 2.24GM/100ML | N019904 | 003 | Dec 26, 1989 | Mar | DISC |
| | SOLUTION;ORAL | | | | | | |
| | POTASSIUM CHLORIDE | | | | | | |
| AA | ADAPTIS | 20MEQ/15ML | A214892 | 001 | Dec 30, 2022 | Aug | CAHN |
| AA | | 40MEQ/15ML | A214892 | 002 | Dec 30, 2022 | Aug | CAHN |
| | @ APOTEX | 20MEQ/15ML | A211067 | 001 | Aug 08, 2018 | May | DISC |
| | @ | 40MEQ/15ML | A211067 | 002 | Aug 08, 2018 | May | DISC |
| AA | GUARDIAN DRUG | 20MEQ/15ML | A214892 | 001 | Dec 30, 2022 | Aug | CAHN |
| AA | | 40MEQ/15ML | A214892 | 002 | Dec 30, 2022 | Aug | CAHN |
| | @ STRIDES PHARMA | 20MEQ/15ML | A211665 | 002 | Jan 16, 2024 | Jun | DISC |
| | TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| | KLOR-CON | | | | | | |
| AB2 | TWI PHARMS | 8MEQ | A218979 | 001 | Oct 28, 2024 | Aug | CTNA |
| AB2 | | 10MEQ | A218979 | 002 | Oct 28, 2024 | Aug | CTNA |
| | POTASSIUM CHLORIDE | | | | | | |
| | @ GLENMARK PHARMS LTD | 10MEQ | A203562 | 001 | Jul 26, 2016 | Sep | DISC |
| | @ | 20MEQ | A203562 | 002 | Jul 26, 2016 | Sep | DISC |
| | POTASSIUM CITRATE | | | | | | |
| | TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| | POTASSIUM CITRATE | | | | | | |
| AB | ADAPTIS | 5MEQ | A214426 | 001 | Feb 19, 2021 | Sep | CAHN |
| AB | | 10MEQ | A214426 | 002 | Feb 19, 2021 | Sep | CAHN |
| AB | | 15MEQ | A214426 | 003 | Feb 19, 2021 | Sep | CAHN |
| | POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC | | | | | | |
| | SOLUTION;INTRAVENOUS | | | | | | |
| | POTASSIUM PHOSPHATES | | | | | | |
| AP | CAPLIN | 1.18GM/5ML (236MG/ML);1.12GM/5ML | A220373 | 001 | Mar 12, 2026 | Mar | NEWA |
| AP | | 3.54GM/15ML (236MG/ML);3.36GM/15ML | A220373 | 002 | Mar 12, 2026 | Mar | NEWA |
| AP | | 11.8GM/50ML (236MG/ML);11.2GM/50ML | A220373 | 003 | Mar 12, 2026 | Mar | NEWA |
| | PRALIDOXIME CHLORIDE | | | | | | |
| | INJECTABLE;INJECTION | | | | | | |
| | PROTOPAM CHLORIDE | | | | | | |
| | @ BAXTER HLTHCARE CORP | 300MG/ML | N018799 | 001 | Dec 13, 1982 | Jun | CTNA |
| | PRASUGREL HYDROCHLORIDE | | | | | | |
| | TABLET;ORAL | | | | | | |
| | PRASUGREL | | | | | | |
| | @ PHARMAZONE | EQ 5MG BASE | A205926 | 001 | Jul 07, 2020 | Sep | CAHN |
| | @ | EQ 10MG BASE | A205926 | 002 | Jul 07, 2020 | Sep | CAHN |
| | @ SENORES PHARMS | EQ 5MG BASE | A205926 | 001 | Jul 07, 2020 | Jan | CAHN |
| | @ | EQ 10MG BASE | A205926 | 002 | Jul 07, 2020 | Jan | CAHN |
| | PRAVASTATIN SODIUM | | | | | | |
| | TABLET;ORAL | | | | | | |
| | PRAVASTATIN SODIUM | | | | | | |
| AB | PHARMAZONE | 10MG | A077491 | 002 | Oct 23, 2006 | Sep | CAHN |
| AB | | 20MG | A077491 | 003 | Oct 23, 2006 | Sep | CAHN |
| | ! | 30MG | A077491 | 005 | Aug 06, 2026 | Sep | CAHN |
| AB | | 40MG | A077491 | 004 | Oct 23, 2006 | Sep | CAHN |
| | ! | 60MG | A077491 | 006 | Aug 06, 2026 | Sep | CAHN |
| AB | | 80MG | A077491 | 001 | Feb 11, 2008 | Sep | CAHN |
| AB | SENORES PHARMS | 10MG | A077491 | 002 | Oct 23, 2006 | Feb | CAHN |
| AB | | 20MG | A077491 | 003 | Oct 23, 2006 | Feb | CAHN |
| | ! | 30MG | A077491 | 005 | Aug 06, 2026 | Sep | CHRS |
| | | 30MG | A077491 | 005 | Aug 06, 2026 | Jul | NEWA |
| AB | | 40MG | A077491 | 004 | Oct 23, 2006 | Feb | CAHN |
| | ! | 60MG | A077491 | 006 | Aug 06, 2026 | Sep | CHRS |
| | | 60MG | A077491 | 006 | Aug 06, 2026 | Jul | NFTG |
| AB | | 80MG | A077491 | 001 | Feb 11, 2008 | Feb | CAHN |

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

PREDNISOLONE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | UPSHER SMITH LABS | 1% | A212778 | 001 | Sep 28, 2026 | Sep NEWA |

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PEDIAPRED

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | +! | PAI HOLDINGS | EQ 5MG BASE/5ML | N019157 | 001 | May 28, 1986 | Apr CAHN |

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | ! | BAUSCH AND LOMB INC | EQ 0.9% PHOSPHATE | A040070 | 001 | Jul 29, 1994 | May CAHN |

PREDNISONE

TABLET;ORAL

PREDNISONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | PHARMAZONE | 5MG | A212629 | 001 | Dec 05, 2023 | Sep CAHN |
| AB | | | | 10MG | A212629 | 002 | Dec 05, 2023 | Sep CAHN |
| AB | | | | 20MG | A212629 | 003 | Dec 05, 2023 | Sep CAHN |
| | | @ | QUAGEN | 1MG | A211496 | 001 | Dec 28, 2018 | Sep CAHN |
| | | @ | | 2.5MG | A210525 | 004 | Dec 07, 2018 | Sep CAHN |
| | | @ | | 5MG | A210525 | 005 | Dec 07, 2018 | Sep CAHN |
| | | @ | | 10MG | A210525 | 001 | Dec 04, 2018 | Sep CAHN |
| | | @ | | 20MG | A210525 | 002 | Dec 04, 2018 | Sep CAHN |
| | | @ | | 50MG | A210525 | 003 | Dec 04, 2018 | Sep CAHN |
| >D> | AB | | STRIDES PHARMA | 2.5MG | A208412 | 004 | Nov 20, 2020 | Oct CHRS |
| >A> | AB | ! | | 2.5MG | A208412 | 004 | Nov 20, 2020 | Oct CHRS |
| >D> | AB | | | 5MG | A208412 | 005 | Nov 20, 2020 | Oct CHRS |
| >A> | AB | ! | | 5MG | A208412 | 005 | Nov 20, 2020 | Oct CHRS |
| >D> | AB | | | 10MG | A208412 | 001 | Feb 11, 2021 | Oct CHRS |
| >A> | AB | ! | | 10MG | A208412 | 001 | Feb 11, 2021 | Oct CHRS |
| >D> | AB | | | 20MG | A208412 | 002 | Feb 11, 2021 | Oct CHRS |
| >A> | AB | ! | | 20MG | A208412 | 002 | Feb 11, 2021 | Oct CHRS |
| >D> | AB | | | 50MG | A208412 | 003 | Jan 11, 2022 | Oct CHRS |
| >A> | AB | ! | | 50MG | A208412 | 003 | Jan 11, 2022 | Oct CHRS |

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | | DR REDDYS | 1MG | A219477 | 001 | Oct 01, 2025 | Jun CHRS |
| | | ! | | 5MG | A218035 | 001 | Jun 26, 2026 | Jun NEWA |

PREGABALIN

CAPSULE;ORAL

PREGABALIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | CAPLIN | 25MG | A218529 | 001 | Feb 24, 2026 | Sep CAHN |
| AB | | | | 50MG | A218529 | 002 | Feb 24, 2026 | Sep CAHN |
| AB | | | | 75MG | A218529 | 003 | Feb 24, 2026 | Sep CAHN |
| AB | | | | 100MG | A218529 | 004 | Feb 24, 2026 | Sep CAHN |
| AB | | | | 150MG | A218529 | 005 | Feb 24, 2026 | Sep CAHN |
| AB | | | | 200MG | A218529 | 006 | Feb 24, 2026 | Sep CAHN |
| AB | | | | 225MG | A218529 | 007 | Feb 24, 2026 | Sep CAHN |
| AB | | | | 300MG | A218529 | 008 | Feb 24, 2026 | Sep CAHN |
| AB | | | FOURRTS LABS | 25MG | A218529 | 001 | Feb 24, 2026 | Feb NEWA |
| AB | | | | 50MG | A218529 | 002 | Feb 24, 2026 | Feb NEWA |
| AB | | | | 75MG | A218529 | 003 | Feb 24, 2026 | Feb NEWA |
| AB | | | | 100MG | A218529 | 004 | Feb 24, 2026 | Feb NEWA |
| AB | | | | 150MG | A218529 | 005 | Feb 24, 2026 | Feb NEWA |
| AB | | | | 200MG | A218529 | 006 | Feb 24, 2026 | Feb NEWA |
| AB | | | | 225MG | A218529 | 007 | Feb 24, 2026 | Feb NEWA |
| AB | | | | 300MG | A218529 | 008 | Feb 24, 2026 | Feb NEWA |
| AB | | | MARKSANS PHARMA | 25MG | A216197 | 001 | Jul 18, 2022 | Sep CAHN |
| AB | | | | 50MG | A216197 | 002 | Jul 18, 2022 | Sep CAHN |
| AB | | | | 75MG | A216197 | 003 | Jul 18, 2022 | Sep CAHN |
| AB | | | | 100MG | A216197 | 004 | Jul 18, 2022 | Sep CAHN |
| AB | | | | 150MG | A216197 | 005 | Jul 18, 2022 | Sep CAHN |
| AB | | | | 200MG | A216197 | 006 | Jul 18, 2022 | Sep CAHN |
| AB | | | | 225MG | A216197 | 007 | Jul 18, 2022 | Sep CAHN |
| AB | | | | 300MG | A216197 | 008 | Jul 18, 2022 | Sep CAHN |
| AB | | | PHARMAZONE | 25MG | A212988 | 001 | Mar 08, 2022 | Sep CAHN |
| AB | | | | 25MG | A216197 | 001 | Jul 18, 2022 | Sep CAHN |
| AB | | | | 50MG | A212988 | 002 | Mar 08, 2022 | Sep CAHN |
| AB | | | | 50MG | A216197 | 002 | Jul 18, 2022 | Sep CAHN |
| AB | | | | 75MG | A212988 | 003 | Mar 08, 2022 | Sep CAHN |

CAPSULE;ORAL
PREGABALIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | 75MG | A216197 | 003 | Jul 18, 2022 | Sep | CAHN |
| AB | | 100MG | A212988 | 004 | Mar 08, 2022 | Sep | CAHN |
| AB | | 100MG | A216197 | 004 | Jul 18, 2022 | Sep | CAHN |
| AB | | 150MG | A212988 | 005 | Mar 08, 2022 | Sep | CAHN |
| AB | | 150MG | A216197 | 005 | Jul 18, 2022 | Sep | CAHN |
| AB | | 200MG | A212988 | 006 | Mar 08, 2022 | Sep | CAHN |
| AB | | 200MG | A216197 | 006 | Jul 18, 2022 | Sep | CAHN |
| AB | | 225MG | A212988 | 007 | Mar 08, 2022 | Sep | CAHN |
| AB | | 225MG | A216197 | 007 | Jul 18, 2022 | Sep | CAHN |
| AB | | 300MG | A212988 | 008 | Mar 08, 2022 | Sep | CAHN |
| AB | | 300MG | A216197 | 008 | Jul 18, 2022 | Sep | CAHN |
| AB | PHARMOBEDIENT | 75MG | A210891 | 001 | Sep 30, 2019 | Sep | CAHN |
| AB | | 300MG | A210891 | 002 | Sep 30, 2019 | Sep | CAHN |
| AB | RENATA | 50MG | A210585 | 001 | Dec 26, 2019 | Feb | CAHN |
| AB | | 75MG | A210585 | 002 | Dec 26, 2019 | Feb | CAHN |
| AB | | 100MG | A210585 | 003 | Dec 26, 2019 | Feb | CAHN |
| AB | | 150MG | A210585 | 004 | Dec 26, 2019 | Feb | CAHN |
| AB | | 200MG | A210585 | 005 | Dec 26, 2019 | Feb | CAHN |
| AB | | 300MG | A210585 | 006 | Dec 26, 2019 | Feb | CAHN |
| AB | SOMERSET THERAPS LLC | 50MG | A210585 | 001 | Dec 26, 2019 | Sep | CAHN |
| AB | | 75MG | A210585 | 002 | Dec 26, 2019 | Sep | CAHN |
| AB | | 100MG | A210585 | 003 | Dec 26, 2019 | Sep | CAHN |
| AB | | 150MG | A210585 | 004 | Dec 26, 2019 | Sep | CAHN |
| AB | | 200MG | A210585 | 005 | Dec 26, 2019 | Sep | CAHN |
| AB | | 300MG | A210585 | 006 | Dec 26, 2019 | Sep | CAHN |
| @ | STRIDES PHARMA | 25MG | A215755 | 001 | Apr 26, 2023 | Jun | DISC |
| @ | | 50MG | A215755 | 002 | Apr 26, 2023 | Jun | DISC |
| @ | | 75MG | A215755 | 003 | Apr 26, 2023 | Jun | DISC |
| @ | | 100MG | A215755 | 004 | Apr 26, 2023 | Jun | DISC |
| @ | | 150MG | A215755 | 005 | Apr 26, 2023 | Jun | DISC |
| @ | | 200MG | A215755 | 006 | Apr 26, 2023 | Jun | DISC |
| @ | | 225MG | A215755 | 007 | Apr 26, 2023 | Jun | DISC |
| @ | | 300MG | A215755 | 008 | Apr 26, 2023 | Jun | DISC |
| AB | TRIS PHARMA INC | 25MG | A214322 | 008 | Sep 26, 2024 | Sep | CAHN |
| AB | | 50MG | A214322 | 001 | Jul 15, 2021 | Sep | CAHN |
| AB | | 75MG | A214322 | 002 | Jul 15, 2021 | Sep | CAHN |
| AB | | 100MG | A214322 | 003 | Jul 15, 2021 | Sep | CAHN |
| AB | | 150MG | A214322 | 004 | Jul 15, 2021 | Sep | CAHN |
| AB | | 200MG | A214322 | 005 | Jul 15, 2021 | Sep | CAHN |
| AB | | 225MG | A214322 | 006 | Jul 15, 2021 | Sep | CAHN |
| AB | | 300MG | A214322 | 007 | Jul 15, 2021 | Sep | CAHN |
| @ | UNICHEM | 25MG | A219593 | 001 | Apr 30, 2026 | Sep | DISC |
| AB | | 25MG | A219593 | 001 | Apr 30, 2026 | Apr | NEWA |
| @ | | 50MG | A219593 | 002 | Apr 30, 2026 | Sep | DISC |
| AB | | 50MG | A219593 | 002 | Apr 30, 2026 | Apr | NEWA |
| @ | | 75MG | A219593 | 003 | Apr 30, 2026 | Sep | DISC |
| AB | | 75MG | A219593 | 003 | Apr 30, 2026 | Apr | NEWA |
| @ | | 100MG | A219593 | 004 | Apr 30, 2026 | Sep | DISC |
| AB | | 100MG | A219593 | 004 | Apr 30, 2026 | Apr | NEWA |
| @ | | 150MG | A219593 | 005 | Apr 30, 2026 | Sep | DISC |
| AB | | 150MG | A219593 | 005 | Apr 30, 2026 | Apr | NEWA |
| @ | | 200MG | A219593 | 006 | Apr 30, 2026 | Sep | DISC |
| AB | | 200MG | A219593 | 006 | Apr 30, 2026 | Apr | NEWA |
| @ | | 225MG | A219593 | 007 | Apr 30, 2026 | Sep | DISC |
| AB | | 225MG | A219593 | 007 | Apr 30, 2026 | Apr | NEWA |
| @ | | 300MG | A219593 | 008 | Apr 30, 2026 | Sep | DISC |
| AB | | 300MG | A219593 | 008 | Apr 30, 2026 | Apr | NEWA |

SOLUTION;ORAL
PREGABALIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | ANDA REPOSITORY | 20MG/ML | A212604 | 001 | Feb 18, 2022 | Aug | CAHN |
| AA | PATRIN | 20MG/ML | A212604 | 001 | Feb 18, 2022 | Mar | CAHN |

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | AIPING PHARM INC | 165MG | A217857 | 002 | Jun 24, 2026 | Jun | NEWA |

PRIMAQUINE PHOSPHATE

TABLET;ORAL
PRIMAQUINE PHOSPHATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | INGENUS PHARMS LLC | EQ 15MG BASE | A206043 | 001 | Jun 23, 2016 | Feb | CAHN |

PRIMIDONE
TABLET;ORAL
PRIMIDONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | CARNEGIE | 50MG | A218366 | 001 | Jan 23, 2024 | Feb CAHN |
| AB | | | 250MG | A218366 | 002 | Jan 23, 2024 | Feb CAHN |
| | @ | HIKMA | 50MG | A040667 | 001 | Jul 27, 2006 | Sep CAHN |
| | @ | | 250MG | A040667 | 002 | Jul 27, 2006 | Sep CAHN |

>A> PRITELIVIR MESYLATE
>A> TABLET;ORAL
>A> HOVILPRI

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> | +! | AICURIS ANTI-INFECT | EQ 100MG BASE | N221154 | 001 | Oct 09, 2026 | Oct NEWA |

PROCAINAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION
PROCAINAMIDE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | ! | GLAND | 100MG/ML | A218135 | 001 | Jul 22, 2024 | Jan CHRS |
| AP | ! | | 500MG/ML | A218135 | 002 | Jul 22, 2024 | Jan CHRS |
| AP | | HOSPIRA | 100MG/ML | A089069 | 001 | Feb 12, 1986 | Jan CHRS |
| | @ | | 500MG/ML | A089070 | 001 | Feb 12, 1986 | Jan DISC |

PROCHLORPERAZINE
SUPPOSITORY;RECTAL
PROCHLORPERAZINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ! | COSETTE PHARMS NC | 25MG | A040058 | 001 | Nov 24, 1993 | May CAHN |

PROCHLORPERAZINE EDISYLATE
INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | AMNEAL | EQ 5MG BASE/ML | A214192 | 001 | Nov 28, 2022 | Feb DISC |

PROGESTERONE
GEL;VAGINAL
CRINONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | ABBVIE | 4% | N020701 | 001 | Jul 31, 1997 | Apr DISC |

INJECTABLE;INJECTION
PROGESTERONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AO | | ACCORD HLTHCARE | 50MG/ML | A217707 | 001 | Nov 21, 2023 | Jul CMFD |

INSERT;VAGINAL
PROGESTERONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | GLENMARK PHARMS | 100MG | A216363 | 001 | Apr 08, 2026 | Apr CAHN |
| AB | | GLENMARK PHARMS LTD | 100MG | A216363 | 001 | Apr 08, 2026 | Mar NEWA |
| >A> AB | | NOVAST LABS | 100MG | A219588 | 001 | Oct 16, 2026 | Oct NEWA |

PROMETHAZINE HYDROCHLORIDE
SUPPOSITORY;RECTAL
PHENERGAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | PHARMOBEDIENT | 12.5MG | N010926 | 002 | | May CAHN |
| | @ + | | 25MG | N010926 | 001 | | May CAHN |

PROMETHAZINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | COSETTE PHARMS NC | 12.5MG | A040428 | 002 | Mar 31, 2003 | May CAHN |
| AB | ! | | 25MG | A040428 | 001 | Feb 05, 2002 | May CAHN |

PROMETHEGAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ! | COSETTE PHARMS NC | 50MG | A087165 | 001 | Aug 14, 1987 | May CAHN |

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | COSETTE PHARMS NC | 6.25MG/5ML | A091675 | 001 | Jun 28, 2012 | May CAHN |

PROPAFENONE HYDROCHLORIDE
TABLET;ORAL
PROPAFENONE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | WATSON LABS | 150MG | A075203 | 001 | Oct 24, 2000 | Jul DISC |
| | @ | | 225MG | A075203 | 002 | Oct 24, 2000 | Jul DISC |

PROPARACAINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
PROPARACAINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AT | ! | BAUSCH AND LOMB INC | 0.5% | A040074 | 001 | Sep 29, 1995 | May CAHN |

PROPOFOL

INJECTABLE;INJECTION

PROPOFOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | ADAPTIS | 10MG/ML | A220857 | 001 | Jul 14, 2026 | Oct CAHN |
| | AB | | | 10MG/ML | A220857 | 001 | Jul 14, 2026 | Sep CAHN |
| >A> | AB | | ANTHEA PHARMA | 10MG/ML | A220857 | 001 | Jul 14, 2026 | Oct CAHN |
| | AB | | | 10MG/ML | A220857 | 001 | Jul 14, 2026 | Jul NEWA |
| >A> | AB | | BAXTER HLTHCARE CORP | 10MG/ML | A203421 | 001 | Nov 03, 2026 | Oct NEWA |
| | AB | | EMERGE BIOSCIENCE | 10MG/ML | A217945 | 001 | Dec 02, 2025 | May CAHN |

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | CHARTWELL RX | 60MG | A078022 | 001 | Feb 15, 2007 | May CAHN |
| | | @ | | 80MG | A078022 | 002 | Feb 15, 2007 | May CAHN |
| | | @ | | 120MG | A078022 | 003 | Feb 15, 2007 | May CAHN |
| | | @ | | 160MG | A078022 | 004 | Feb 15, 2007 | May CAHN |
| | AB | | CREEKWOOD PHARMS | 60MG | A219460 | 001 | Aug 14, 2026 | Aug NEWA |
| | AB | | | 80MG | A219460 | 002 | Aug 14, 2026 | Aug NEWA |
| | AB | | | 120MG | A219460 | 003 | Aug 14, 2026 | Aug NEWA |
| | AB | | | 160MG | A219460 | 004 | Aug 14, 2026 | Aug NEWA |
| | AB | | IPCA LABS LTD | 60MG | A203103 | 001 | May 01, 2026 | Apr NEWA |
| | AB | | | 80MG | A203103 | 002 | May 01, 2026 | Apr NEWA |
| | AB | | | 120MG | A203103 | 003 | May 01, 2026 | Apr NEWA |
| | AB | | | 160MG | A203103 | 004 | May 01, 2026 | Apr NEWA |
| | AB | | MICRO LABS | 60MG | A217238 | 001 | Jun 24, 2026 | Jun NEWA |
| | AB | | | 80MG | A217238 | 002 | Jun 24, 2026 | Jun NEWA |
| | AB | | | 120MG | A217238 | 003 | Jun 24, 2026 | Jun NEWA |
| | AB | | | 160MG | A217238 | 004 | Jun 24, 2026 | Jun NEWA |

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | ALLIED | 1MG/ML | A076400 | 001 | Feb 26, 2003 | Apr CAHN |
| | | @ | SCIEGEN PHARMS | 1MG/ML | A076400 | 001 | Feb 26, 2003 | Aug CAHN |

SOLUTION;ORAL

HEMANGEOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | ETON | 4.28MG/ML | N205410 | 001 | Mar 14, 2014 | Mar CAHN |

PROPRANOLOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | ! | HIKMA | 20MG/5ML | A070690 | 002 | May 15, 1987 | May CTEC |
| | | ! | | 20MG/5ML | A070690 | 002 | May 15, 1987 | Feb CMS1 |
| | AA | | PAI HOLDINGS | 20MG/5ML | A219165 | 001 | Jun 10, 2026 | May NEWA |

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | MANKIND PHARMA | 10MG | A216663 | 001 | Jan 27, 2026 | Jan NEWA |
| | AB | | | 20MG | A216663 | 002 | Jan 27, 2026 | Jan NEWA |
| | AB | | | 40MG | A216663 | 003 | Jan 27, 2026 | Jan NEWA |
| | AB | | | 60MG | A216663 | 004 | Jan 27, 2026 | Jan NEWA |
| | AB | | | 80MG | A216663 | 005 | Jan 27, 2026 | Jan NEWA |
| >A> | AB | | SENORES PHARMS | 10MG | A216072 | 001 | Oct 26, 2026 | Oct NEWA |
| >A> | AB | | | 20MG | A216072 | 002 | Oct 26, 2026 | Oct NEWA |
| >A> | AB | | | 40MG | A216072 | 003 | Oct 26, 2026 | Oct NEWA |
| >A> | AB | | | 60MG | A216072 | 004 | Oct 26, 2026 | Oct NEWA |
| >A> | AB | | | 80MG | A216072 | 005 | Oct 26, 2026 | Oct NEWA |

PRUCALOPRIDE SUCCINATE

TABLET;ORAL

PRUCALOPRIDE SUCCINATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | AJANTA PHARMA LTD | EQ 1MG BASE | A219220 | 001 | Jan 16, 2026 | Jan NEWA |
| | AB | | | EQ 2MG BASE | A219220 | 002 | Jan 16, 2026 | Jan NEWA |
| | AB | | ALEMBIC | EQ 1MG BASE | A219234 | 001 | Jul 27, 2026 | Jul NEWA |
| | AB | | | EQ 2MG BASE | A219234 | 002 | Jul 27, 2026 | Jul NEWA |
| | AB | | BIONPHARMA | EQ 1MG BASE | A219216 | 001 | Jun 24, 2025 | Aug CAHN |
| | AB | | | EQ 2MG BASE | A219216 | 002 | Jun 24, 2025 | Aug CAHN |
| | AB | | MICRO LABS | EQ 1MG BASE | A219180 | 001 | Jun 29, 2026 | Jun NEWA |
| | AB | | | EQ 2MG BASE | A219180 | 002 | Jun 29, 2026 | Jun NEWA |
| | | @ | TEVA PHARMS INC | EQ 1MG BASE | A219071 | 001 | Feb 05, 2026 | Aug DISC |
| | AB | | | EQ 1MG BASE | A219071 | 001 | Feb 05, 2026 | Jan NEWA |
| | | @ | | EQ 2MG BASE | A219071 | 002 | Feb 05, 2026 | Aug DISC |
| | AB | | | EQ 2MG BASE | A219071 | 002 | Feb 05, 2026 | Jan NEWA |

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

MESTINON

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | BAUSCH | 180MG | N011665 | 001 | | | Aug CHRS |

PYRIDOSTIGMINE BROMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | ALVOGEN | 180MG | A204737 | 001 | Jun 26, 2015 | | Aug CHRS |
| | @ | IMPAX LABS INC | 180MG | A203184 | 001 | Sep 15, 2015 | | Jan DISC |

PYRIMETHAMINE

TABLET;ORAL

PYRIMETHAMINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | 25MG | A207127 | 001 | Feb 28, 2020 | | Sep CAHN |

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | SUN PHARM | EQ 25MG BASE | A201190 | 001 | Mar 27, 2012 | | Apr DISC |
| | @ | | EQ 50MG BASE | A201190 | 002 | Mar 27, 2012 | | Sep DISC |
| | @ | | EQ 100MG BASE | A201190 | 003 | Mar 27, 2012 | | Sep DISC |
| | @ | | EQ 300MG BASE | A201190 | 005 | Mar 27, 2012 | | Sep DISC |
| | @ | | EQ 400MG BASE | A201190 | 006 | Mar 27, 2012 | | Apr DISC |

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ALICORA | EQ 50MG BASE | A206260 | 001 | May 09, 2017 | | Sep CAHN |
| | @ | | EQ 150MG BASE | A206260 | 002 | May 09, 2017 | | Sep CAHN |
| | @ | | EQ 200MG BASE | A206260 | 003 | May 09, 2017 | | Sep CAHN |
| | @ | | EQ 300MG BASE | A206260 | 004 | May 09, 2017 | | Sep CAHN |
| | @ | | EQ 400MG BASE | A206260 | 005 | May 09, 2017 | | Sep CAHN |
| AB | | PLATINUM | EQ 50MG BASE | A202939 | 001 | May 09, 2017 | | Apr CAHN |
| AB | | | EQ 150MG BASE | A202939 | 002 | May 09, 2017 | | Apr CAHN |
| AB | | | EQ 200MG BASE | A202939 | 003 | May 09, 2017 | | Apr CAHN |
| AB | | | EQ 300MG BASE | A202939 | 004 | May 09, 2017 | | Apr CAHN |
| AB | | | EQ 400MG BASE | A202939 | 005 | May 09, 2017 | | Apr CAHN |

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | | CHARTWELL RX | EQ 40MG BASE | A076803 | 004 | Mar 02, 2005 | | Oct CHRS |
| >A> AB | ! | | EQ 40MG BASE | A076803 | 004 | Mar 02, 2005 | | Oct CHRS |
| >D> AB | | LUPIN | EQ 5MG BASE | A077690 | 001 | Jun 20, 2006 | | Oct DISC |
| >A> | @ | | EQ 5MG BASE | A077690 | 001 | Jun 20, 2006 | | Oct DISC |
| >D> AB | | | EQ 10MG BASE | A077690 | 002 | Jun 20, 2006 | | Oct DISC |
| >A> | @ | | EQ 10MG BASE | A077690 | 002 | Jun 20, 2006 | | Oct DISC |
| >D> AB | | | EQ 20MG BASE | A077690 | 003 | Jun 20, 2006 | | Oct DISC |
| >A> | @ | | EQ 20MG BASE | A077690 | 003 | Jun 20, 2006 | | Oct DISC |
| >D> AB | ! | | EQ 40MG BASE | A077690 | 004 | Jun 20, 2006 | | Oct DISC |
| >A> | @ | | EQ 40MG BASE | A077690 | 004 | Jun 20, 2006 | | Oct DISC |

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 324MG | A212589 | 001 | Sep 17, 2021 | | Sep CAHN |

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 200MG | A083862 | 001 | | | Sep CAHN |

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | 300MG | A040045 | 001 | Jun 30, 1994 | | Jun CAHN |

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | INGENUS PHARMS LLC | 324MG | A204372 | 001 | Jul 22, 2015 | | May CAHN |

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA USA | 20MG | A205761 | 001 | Feb 17, 2017 | Jan CAHN |
| AB | | QUAGEN | 20MG | A205761 | 001 | Feb 17, 2017 | Jul CAHN |

RALTEGRAVIR POTASSIUM

TABLET;ORAL

ISENTRESS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | MSD SUB MERCK | EQ 400MG BASE | N022145 | 001 | Oct 12, 2007 | Aug CTEC |

RALTEGRAVIR POTASSIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | HETERO LABS LTD III | EQ 400MG BASE | A203540 | 001 | Dec 19, 2024 | Aug CMFD |

RAMELTEON

TABLET;ORAL

RAMELTEON

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 8MG | A215485 | 001 | Jun 04, 2026 | Sep CAHN |
| AB | | AUROBINDO PHARMA LTD | 8MG | A215972 | 001 | Jul 10, 2023 | Feb CTEC |
| AB | | HIBROW HLTHCARE | 8MG | A215485 | 001 | Jun 04, 2026 | May NEWA |
| AB | | PHARMAZONE | 8MG | A212650 | 001 | Apr 10, 2020 | Sep CAHN |
| AB | | XIROMED | 8MG | A216209 | 001 | Nov 25, 2022 | Mar CTEC |

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | 1.25MG | A078191 | 001 | Jun 18, 2008 | Sep CAHN |
| AB | | | 2.5MG | A078191 | 002 | Jun 18, 2008 | Sep CAHN |
| AB | | | 5MG | A078191 | 003 | Jun 18, 2008 | Sep CAHN |
| AB | | | 10MG | A078191 | 004 | Jun 18, 2008 | Sep CAHN |
| AB | | SENORES PHARMS | 1.25MG | A078191 | 001 | Jun 18, 2008 | Jan CAHN |
| AB | | | 2.5MG | A078191 | 002 | Jun 18, 2008 | Jan CAHN |
| AB | | | 5MG | A078191 | 003 | Jun 18, 2008 | Jan CAHN |
| AB | | | 10MG | A078191 | 004 | Jun 18, 2008 | Jan CAHN |
| AB | | SOLGEN | 1.25MG | A079116 | 001 | Jun 20, 2008 | Sep CAHN |
| AB | | | 2.5MG | A079116 | 002 | Jun 20, 2008 | Sep CAHN |
| AB | | | 5MG | A079116 | 003 | Jun 20, 2008 | Sep CAHN |
| AB | | | 10MG | A079116 | 004 | Jun 20, 2008 | Sep CAHN |

SOLUTION;ORAL

VOSTALLY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | | ROSEMONT PHARMS | 1MG/ML | N219757 | 001 | Jul 23, 2025 | Apr DISC |
| | +! | | 1MG/ML | N219757 | 001 | Jul 23, 2025 | Feb CAHN |

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | RISING | EQ 150MG BASE | A075564 | 001 | Oct 27, 2000 | Mar CAHN |
| @ | | | EQ 300MG BASE | A075564 | 002 | Oct 27, 2000 | Mar CAHN |

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | VKT PHARMA | EQ 300MG BASE | A211289 | 002 | Jan 31, 2019 | Oct CHRS |
| >A> | AB | ! | | EQ 300MG BASE | A211289 | 002 | Jan 31, 2019 | Oct CHRS |

RANOLAZINE

GRANULE, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | | SPIL | 500MG | N216018 | 001 | Feb 28, 2022 | Apr CDFR |
| @ + | | | 1GM | N216018 | 002 | Feb 28, 2022 | Apr CDFR |

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | ACTAVIS ELIZABETH | 500MG | A208862 | 001 | May 28, 2019 | Jun DISC |
| @ | | | 1GM | A208862 | 002 | May 28, 2019 | Jun DISC |
| @ | | MICRO LABS | 500MG | A211745 | 001 | Feb 27, 2020 | Aug DISC |
| @ | | | 1GM | A211745 | 002 | Feb 27, 2020 | Aug DISC |
| AB | | PHARMAZONE | 500MG | A213517 | 001 | Apr 27, 2022 | Sep CAHN |
| AB | | | 1GM | A213517 | 002 | Apr 27, 2022 | Sep CAHN |
| AB | | PIRAMAL | 500MG | A213085 | 001 | Jul 25, 2023 | Feb CMFD |
| AB | | | 1GM | A213085 | 002 | Jul 25, 2023 | Feb CMFD |
| AB | | QUAGEN | 500MG | A212781 | 001 | Mar 23, 2020 | Sep CAHN |
| AB | | | 1GM | A212781 | 002 | Mar 23, 2020 | Sep CAHN |
| AB | | UMEDICA | 500MG | A214551 | 001 | Aug 05, 2026 | Jul NEWA |
| AB | | | 1GM | A214551 | 002 | Aug 05, 2026 | Jul NEWA |

REGADENOSON

SOLUTION;INTRAVENOUS

REGADENOSON

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | GE HEALTHCARE | 0.4MG/5ML (0.08MG/ML) | A215955 | 001 | Aug 05, 2024 | Feb DISC |
| | @ | MYLAN | 0.4MG/5ML (0.08MG/ML) | A213856 | 001 | Apr 04, 2023 | Jul DISC |

RELACORILANT

CAPSULE;ORAL

LIFYORLI (COPACKAGED)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | CORCEPT THERAP | 100MG;25MG | N220641 | 001 | Mar 25, 2026 | Mar NEWA |

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | NIVAGEN | EQ 1MG BASE/VIAL | A215635 | 001 | Jun 28, 2024 | Aug CAHN |
| AP | | | EQ 2MG BASE/VIAL | A215635 | 002 | Jun 28, 2024 | Aug CAHN |
| AP | | | EQ 5MG BASE/VIAL | A215635 | 003 | Jun 28, 2024 | Aug CAHN |

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | PADAGIS US | 0.5MG | A201189 | 001 | Jul 17, 2013 | Mar DISC |
| | @ | | 1MG | A201189 | 002 | Jan 22, 2014 | Mar DISC |
| | @ | | 2MG | A201189 | 003 | Jan 22, 2014 | Mar DISC |

RESERPINE

TABLET;ORAL

RESERPINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | 0.1MG | A080975 | 001 | | Sep CAHN |
| | @ | | 0.25MG | A080975 | 002 | | Sep CAHN |
| | @ | | 1MG | A080975 | 003 | | Sep CAHN |

SERPALAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | @ | LANNETT | 0.1MG | N010124 | 001 | | Oct CAHN |
| >A> | @ | | 0.1MG | N010124 | 001 | | Oct CAHN |
| >D> | @ | | 0.25MG | N010124 | 002 | | Oct CAHN |
| >A> | @ | | 0.25MG | N010124 | 002 | | Oct CAHN |

RIBAVIRIN

FOR SOLUTION;INHALATION

RIBAVIRIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | CHARTWELL RX | 6GM/VIAL | A207366 | 001 | Oct 06, 2016 | Jul CAHN |
| | @ | NAVINTA LLC | 6GM/VIAL | A207366 | 001 | Oct 06, 2016 | Mar DISC |

RIFABUTIN

CAPSULE;ORAL

RIFABUTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | I3 PHARMS | 150MG | A212430 | 001 | Mar 19, 2026 | Mar NEWA |
| AB | | PHARMAZONE | 150MG | A212430 | 001 | Mar 19, 2026 | Sep CAHN |
| AB | | ZYDUS LIFESCIENCES | 150MG | A219519 | 001 | Aug 21, 2026 | Aug NEWA |

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | NOVITIUM PHARMA | 150MG | A219918 | 001 | Jun 29, 2026 | Jun NEWA |
| AB | | | 300MG | A219918 | 002 | Jun 29, 2026 | Jun NEWA |

RIMACTANE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | TP ANDA HOLDINGS | 300MG | N050429 | 001 | | Sep CAHN |

RIFAPENTINE

TABLET;ORAL

PRIFTIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | SANOFI AVENTIS US | 150MG | N021024 | 001 | Jun 22, 1998 | Jun CFTG |

RIFAPENTINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | MACLEODS PHARMS | 150MG | A217042 | 001 | Jun 23, 2026 | Jun NFTG |

RIFAXIMIN

TABLET;ORAL

RIFAXIMIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ACTAVIS LABS FL INC | 550MG | A208959 | 001 | Mar 19, 2026 | Mar NFTG |

XIFAXAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | SALIX PHARMS | 550MG | N021361 | 002 | Mar 24, 2010 | Mar CFTG |

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

EDURANT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | JANSSEN PRODS | EQ 25MG BASE | N202022 | 001 | May 20, 2011 | Jan CFTG |

RILPIVIRINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | LAURUS | EQ 25MG BASE | A219788 | 001 | Jul 10, 2026 | Jul NEWA |
| AB | | SOMERSET THERAPS LLC | EQ 25MG BASE | A218798 | 001 | Jan 29, 2026 | Jan NFTG |

RILUZOLE

TABLET;ORAL

RILUTEK

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | + | AZURITY | 50MG | N020599 | 001 | Dec 12, 1995 | Jul CAHN |
| @ | + | | 50MG | N020599 | 001 | Dec 12, 1995 | Mar CAHN |

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | + | SHANDONG LUYE | 37.5MG | N212849 | 003 | Jan 13, 2023 | Jun DISC |
| @ | + | | 50MG | N212849 | 004 | Jan 13, 2023 | Jun DISC |

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

PERSERIS KIT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | + | INDIVIOR | 90MG | N210655 | 001 | Jul 27, 2018 | Jun DISC |
| @ | + | | 120MG | N210655 | 002 | Jul 27, 2018 | Jun DISC |

POWDER;INTRAMUSCULAR

RISPERDAL CONSTA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | JANSSEN PHARMS | 12.5MG/VIAL | N021346 | 004 | Apr 12, 2007 | Jan CHRS |
| AB | + | | 12.5MG/VIAL | N021346 | 004 | Apr 12, 2007 | Jan CDFR |
| AB | +! | | 25MG/VIAL | N021346 | 001 | Oct 29, 2003 | Jan CDFR |
| AB | +! | | 37.5MG/VIAL | N021346 | 002 | Oct 29, 2003 | Jan CHRS |
| AB | + | | 37.5MG/VIAL | N021346 | 002 | Oct 29, 2003 | Jan CDFR |
| AB | +! | | 50MG/VIAL | N021346 | 003 | Oct 29, 2003 | Jan CHRS |
| AB | + | | 50MG/VIAL | N021346 | 003 | Oct 29, 2003 | Jan CDFR |

RISPERIDONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AMNEAL | 12.5MG/VIAL | A218586 | 001 | Sep 02, 2025 | Jan CDFR |
| AB | | | 25MG/VIAL | A218586 | 002 | Sep 02, 2025 | Jan CDFR |
| AB | | | 37.5MG/VIAL | A218586 | 003 | Sep 02, 2025 | Jan CDFR |
| AB | | | 50MG/VIAL | A218586 | 004 | Sep 02, 2025 | Jan CDFR |
| AB | | NANOMI | 25MG/VIAL | A211220 | 001 | Sep 02, 2025 | Jan CDFR |
| AB | | | 37.5MG/VIAL | A211220 | 002 | Sep 02, 2025 | Jan CDFR |
| AB | | | 50MG/VIAL | A211220 | 003 | Sep 02, 2025 | Jan CDFR |
| AB | | TEVA PHARMS USA INC | 12.5MG/VIAL | A214068 | 001 | Dec 05, 2023 | Jan CDFR |
| AB | | | 25MG/VIAL | A214068 | 002 | Dec 05, 2023 | Jan CDFR |
| AB | | | 37.5MG/VIAL | A214068 | 003 | Dec 05, 2023 | Jan CDFR |
| AB | | | 50MG/VIAL | A214068 | 004 | Dec 05, 2023 | Jan CDFR |

SOLUTION;ORAL

RISPERIDONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | | PHARMAZONE | 1MG/ML | A078909 | 001 | Jul 29, 2009 | Sep CAHN |

TABLET;ORAL

RISPERIDONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | AMNEAL | 0.25MG | A078071 | 001 | Jun 17, 2009 | Aug DISC |
| @ | | | 0.5MG | A078071 | 002 | Jun 17, 2009 | Aug DISC |
| @ | | | 1MG | A078071 | 003 | Jun 17, 2009 | Aug DISC |
| @ | | | 2MG | A078071 | 004 | Jun 17, 2009 | Aug DISC |
| @ | | | 3MG | A078071 | 005 | Jun 17, 2009 | Aug DISC |
| @ | | | 4MG | A078071 | 006 | Jun 17, 2009 | Aug DISC |
| @ | | NATCO PHARMA USA | 0.25MG | A076288 | 001 | Sep 15, 2008 | Mar CAHN |
| @ | | | 0.5MG | A076288 | 002 | Sep 15, 2008 | Mar CAHN |
| @ | | | 1MG | A076288 | 003 | Sep 15, 2008 | Mar CAHN |
| @ | | | 2MG | A076288 | 004 | Sep 15, 2008 | Mar CAHN |
| @ | | | 3MG | A076288 | 005 | Sep 15, 2008 | Mar CAHN |
| @ | | | 4MG | A076288 | 006 | Sep 15, 2008 | Mar CAHN |

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | | NATCO PHARMA USA | 0.25MG | A091537 | 006 | Feb 12, 2013 | Mar CAHN |

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | | 0.5MG | A091537 | 001 | Mar 30, 2011 | Mar CAHN |
| | | @ | | 1MG | A091537 | 002 | Mar 30, 2011 | Mar CAHN |
| | | @ | | 2MG | A091537 | 003 | Mar 30, 2011 | Mar CAHN |
| | | @ | | 3MG | A091537 | 004 | Mar 30, 2011 | Mar CAHN |
| | | @ | | 4MG | A091537 | 005 | Mar 30, 2011 | Mar CAHN |
| | AB | | PH HEALTH | 0.25MG | A077494 | 001 | Apr 30, 2009 | Sep CTEC |
| | AB | | PHARMAZONE | 0.25MG | A077328 | 006 | Sep 22, 2026 | Sep CAHN |
| | AB | | | 0.5MG | A077328 | 001 | Feb 24, 2009 | Sep CAHN |
| | AB | | | 1MG | A077328 | 002 | Oct 05, 2009 | Sep CAHN |
| | AB | | | 2MG | A077328 | 003 | Feb 24, 2009 | Sep CAHN |
| | AB | | | 3MG | A077328 | 004 | Nov 30, 2009 | Sep CAHN |
| | AB | | | 4MG | A077328 | 005 | Nov 30, 2009 | Sep CAHN |
| | AB | | SENORES PHARMS | 0.25MG | A077328 | 006 | Sep 22, 2026 | Sep NEWA |

RITONAVIR
TABLET;ORAL
NORVIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | + | ABBVIE | 100MG | N022417 | 001 | Feb 10, 2010 | Jan CHRS |

RITONAVIR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | AMNEAL | 100MG | A208890 | 001 | Sep 17, 2018 | Mar DISC |
| | AB | ! | AURO BINDO PHARMA LTD | 100MG | A206614 | 001 | Sep 17, 2018 | Jan CHRS |

RIVAROXABAN
FOR SUSPENSION;ORAL
RIVAROXABAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | APOTEX | 1MG/ML | A218427 | 001 | Mar 02, 2026 | Sep DISC |
| | AB | | | 1MG/ML | A218427 | 001 | Mar 02, 2026 | Feb NEWA |
| >D> | AB | | LUPIN | 1MG/ML | A218195 | 001 | Sep 25, 2025 | Oct CHRS |
| >A> | AB | ! | | 1MG/ML | A218195 | 001 | Sep 25, 2025 | Oct CHRS |
| >D> | | XARELTO | | | | | | |
| >D> | AB | +! | JANSSEN PHARMS | 1MG/ML | N215859 | 001 | Dec 20, 2021 | Oct DISC |
| >A> | | @ + | | 1MG/ML | N215859 | 001 | Dec 20, 2021 | Oct DISC |

SUSPENSION;ORAL
>A> YULZETY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | + | ROSEMONT PHARMS | 2MG/ML | N221033 | 001 | Oct 16, 2026 | Oct NEWA |
| >A> | | +! | | 4MG/ML | N221033 | 002 | Oct 16, 2026 | Oct NEWA |

TABLET;ORAL
RIVAROXABAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | APOTEX | 10MG | A208579 | 001 | Nov 14, 2025 | Apr DISC |
| | | @ | | 15MG | A208579 | 002 | Nov 14, 2025 | Apr DISC |
| | | @ | | 20MG | A208579 | 003 | Nov 14, 2025 | Apr DISC |
| | BX | | BIOCON PHARMA | 2.5MG | A218107 | 001 | May 14, 2025 | Feb CTEC |
| | BX | | | 10MG | A218107 | 002 | May 14, 2025 | Feb CTEC |
| | BX | | | 15MG | A218107 | 003 | May 14, 2025 | Feb CTEC |
| | BX | | | 20MG | A218107 | 004 | May 14, 2025 | Feb CTEC |
| | AB | | EPIC PHARMA LLC | 2.5MG | A216255 | 001 | Aug 19, 2026 | Aug NEWA |
| | AB | | | 10MG | A216255 | 002 | Aug 19, 2026 | Aug NEWA |
| | AB | | | 15MG | A216255 | 003 | Aug 19, 2026 | Aug NEWA |
| | AB | | | 20MG | A216255 | 004 | Aug 19, 2026 | Aug NEWA |
| | AB | | INVAGEN PHARMS | 2.5MG | A218768 | 001 | Feb 20, 2026 | Feb NEWA |
| | AB | | MANKIND PHARMA | 2.5MG | A220874 | 001 | Jul 01, 2026 | Jun NEWA |
| | AB | | | 10MG | A220874 | 002 | Jul 01, 2026 | Jun NEWA |
| | AB | | | 15MG | A220874 | 003 | Jul 01, 2026 | Jun NEWA |
| | AB | | | 20MG | A220874 | 004 | Jul 01, 2026 | Jun NEWA |
| | AB | | MICRO LABS | 2.5MG | A208334 | 001 | Jun 30, 2026 | Jun NEWA |
| | AB | | | 10MG | A208334 | 002 | Jun 30, 2026 | Jun NEWA |
| | AB | | | 15MG | A208334 | 003 | Jun 30, 2026 | Jun NEWA |
| | AB | | | 20MG | A208334 | 004 | Jun 30, 2026 | Jun NEWA |
| >A> | AB | | TEVA PHARMS USA | 2.5MG | A212247 | 001 | Oct 27, 2026 | Oct NEWA |
| >A> | AB | | | 10MG | A212247 | 002 | Oct 27, 2026 | Oct NEWA |
| >A> | AB | | | 15MG | A212247 | 003 | Oct 27, 2026 | Oct NEWA |
| >A> | AB | | | 20MG | A212247 | 004 | Oct 27, 2026 | Oct NEWA |

RIZATRIPTAN BENZOATE
FILM;ORAL
RIZAFILM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | @ + | GENSCO | EQ 5MG BASE | N205394 | 002 | Feb 26, 2026 | Oct CMFD |
| >A> | | +! | | EQ 5MG BASE | N205394 | 002 | Feb 26, 2026 | Oct CMFD |
| | | @ + | | EQ 5MG BASE | N205394 | 002 | Feb 26, 2026 | Jul DISC |
| | | +! | | EQ 5MG BASE | N205394 | 002 | Feb 26, 2026 | Feb NEWA |
| | | +! | | EQ 10MG BASE | N205394 | 001 | Apr 14, 2023 | Sep CMFD |

TABLET;ORAL
RIZATRIPTAN BENZOATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | EQ 5MG BASE | A202047 | 001 | Dec 31, 2012 | Sep | CAHN |
| AB | | | EQ 10MG BASE | A202047 | 002 | Dec 31, 2012 | Sep | CAHN |
| | @ | PHARMOBEDIENT | EQ 5MG BASE | A201993 | 001 | Dec 31, 2012 | Feb | DISC |
| | @ | | EQ 10MG BASE | A201993 | 002 | Dec 31, 2012 | Feb | DISC |

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ASPIRO | 50MG/5ML (10MG/ML) | A220124 | 001 | Mar 04, 2026 | Feb | NEWA |
| AP | | | 100MG/10ML (10MG/ML) | A220124 | 002 | Mar 04, 2026 | Feb | NEWA |
| AP | | BAXTER HLTHCARE CORP | 50MG/5ML (10MG/ML) | A219260 | 001 | Sep 18, 2026 | Sep | NEWA |
| AP | | | 100MG/10ML (10MG/ML) | A219260 | 002 | Sep 18, 2026 | Sep | NEWA |
| | @ | KNACK | 50MG/5ML (10MG/ML) | A213476 | 001 | Jan 06, 2026 | May | DISC |
| | @ | | 100MG/10ML (10MG/ML) | A213476 | 002 | Jan 06, 2026 | May | DISC |

ROFLUMILAST

TABLET;ORAL
ROFLUMILAST

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | 250MCG | A208236 | 002 | Oct 19, 2023 | Sep | CAHN |
| AB | | | 500MCG | A208236 | 001 | Oct 03, 2018 | Sep | CAHN |
| | @ | PHARMOBEDIENT | 500MCG | A208257 | 001 | Jul 13, 2018 | Feb | DISC |
| AB | | SENORES PHARMS | 250MCG | A208236 | 002 | Oct 19, 2023 | Feb | CMFD |
| AB | | | 500MCG | A208236 | 001 | Oct 03, 2018 | Feb | CMFD |

ROMIDEPSIN

POWDER;INTRAVENOUS
ROMIDEPSIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> AP | | ZYDUS PHARMS | 10MG/VIAL | A220783 | 001 | Oct 19, 2026 | Oct | NEWA |

SOLUTION;INTRAVENOUS
ROMIDEPSIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | AMNEAL | 27.5MG/5.5ML (5MG/ML) | A219099 | 001 | Jun 02, 2026 | May | NFTG |

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | EQ 0.25MG BASE | A077460 | 001 | May 05, 2008 | Jun | CAHN |
| | @ | | EQ 0.5MG BASE | A077460 | 002 | May 05, 2008 | Jun | CAHN |
| | @ | | EQ 1MG BASE | A077460 | 003 | May 05, 2008 | Jun | CAHN |
| | @ | | EQ 2MG BASE | A077460 | 004 | May 05, 2008 | Jun | CAHN |
| | @ | | EQ 3MG BASE | A077460 | 005 | May 05, 2008 | Jun | CAHN |
| | @ | | EQ 4MG BASE | A077460 | 006 | May 05, 2008 | Jun | CAHN |
| | @ | | EQ 5MG BASE | A077460 | 007 | May 19, 2008 | Jun | CAHN |

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
ROPIVACAINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AP | | ADAPTIS | 20MG/10ML (2MG/ML) | A219883 | 004 | Oct 08, 2025 | Oct | CAHN |
| AP | | | 20MG/10ML (2MG/ML) | A219883 | 004 | Oct 08, 2025 | Sep | CAHN |
| >D> AP | | | 40MG/20ML (2MG/ML) | A219883 | 001 | Mar 21, 2025 | Oct | CAHN |
| AP | | | 40MG/20ML (2MG/ML) | A219883 | 001 | Mar 21, 2025 | Sep | CAHN |
| >D> AP | | | 100MG/20ML (5MG/ML) | A219883 | 005 | Oct 08, 2025 | Oct | CAHN |
| AP | | | 100MG/20ML (5MG/ML) | A219883 | 005 | Oct 08, 2025 | Sep | CAHN |
| >D> AP | | | 150MG/30ML (5MG/ML) | A219883 | 002 | Mar 21, 2025 | Oct | CAHN |
| AP | | | 150MG/30ML (5MG/ML) | A219883 | 002 | Mar 21, 2025 | Sep | CAHN |
| >D> AP | | | 200MG/20ML (10MG/ML) | A219883 | 003 | Mar 21, 2025 | Oct | CAHN |
| AP | | | 200MG/20ML (10MG/ML) | A219883 | 003 | Mar 21, 2025 | Sep | CAHN |
| >A> AP | | ANTHEA PHARMA | 20MG/10ML (2MG/ML) | A219883 | 004 | Oct 08, 2025 | Oct | CAHN |
| >A> AP | | | 40MG/20ML (2MG/ML) | A219883 | 001 | Mar 21, 2025 | Oct | CAHN |
| >A> AP | | | 100MG/20ML (5MG/ML) | A219883 | 005 | Oct 08, 2025 | Oct | CAHN |
| >A> AP | | | 150MG/30ML (5MG/ML) | A219883 | 002 | Mar 21, 2025 | Oct | CAHN |
| >A> AP | | | 200MG/20ML (10MG/ML) | A219883 | 003 | Mar 21, 2025 | Oct | CAHN |
| >A> AP | | EMERGE BIOSCIENCE | 20MG/10ML (2MG/ML) | A218713 | 001 | Jul 30, 2024 | Oct | CAHN |
| >A> AP | | | 40MG/20ML (2MG/ML) | A218713 | 002 | Jul 30, 2024 | Oct | CAHN |
| >A> AP | | | 100MG/20ML (5MG/ML) | A218713 | 003 | Jul 30, 2024 | Oct | CAHN |
| >A> AP | | | 100MG/10ML (10MG/ML) | A218713 | 004 | Jul 30, 2024 | Oct | CAHN |
| >A> AP | | | 150MG/30ML (5MG/ML) | A218713 | 005 | Jul 30, 2024 | Oct | CAHN |
| >A> AP | | | 150MG/20ML (7.5MG/ML) | A218713 | 006 | Jul 30, 2024 | Oct | CAHN |
| >A> AP | | | 200MG/20ML (10MG/ML) | A218713 | 007 | Jul 30, 2024 | Oct | CAHN |
| >D> AP | | KINDOS | 20MG/10ML (2MG/ML) | A218713 | 001 | Jul 30, 2024 | Oct | CAHN |
| >D> AP | | | 40MG/20ML (2MG/ML) | A218713 | 002 | Jul 30, 2024 | Oct | CAHN |
| >D> AP | | | 100MG/20ML (5MG/ML) | A218713 | 003 | Jul 30, 2024 | Oct | CAHN |

SOLUTION;INJECTION
ROPIVACAINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >D> AP | | 100MG/10ML (10MG/ML) | A218713 | 004 | Jul 30, 2024 | Oct | CAHN |
| >D> AP | | 150MG/30ML (5MG/ML) | A218713 | 005 | Jul 30, 2024 | Oct | CAHN |
| >D> AP | | 150MG/20ML (7.5MG/ML) | A218713 | 006 | Jul 30, 2024 | Oct | CAHN |
| >D> AP | | 200MG/20ML (10MG/ML) | A218713 | 007 | Jul 30, 2024 | Oct | CAHN |

ROSUVASTATIN CALCIUM

TABLET;ORAL
ROSUVASTATIN CALCIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | ANVI | EQ 5MG BASE | A079161 | 001 | Jul 19, 2016 | Mar | CAHN |
| @ | | EQ 10MG BASE | A079161 | 002 | Jul 19, 2016 | Mar | CAHN |
| @ | | EQ 20MG BASE | A079161 | 003 | Jul 19, 2016 | Mar | CAHN |
| @ | | EQ 40MG BASE | A079161 | 004 | Jul 19, 2016 | Mar | CAHN |
| @ | STRIDES PHARMA INTL | EQ 5MG BASE | A079161 | 001 | Jul 19, 2016 | Jun | CAHN |
| @ | | EQ 10MG BASE | A079161 | 002 | Jul 19, 2016 | Jun | CAHN |
| @ | | EQ 20MG BASE | A079161 | 003 | Jul 19, 2016 | Jun | CAHN |
| @ | | EQ 40MG BASE | A079161 | 004 | Jul 19, 2016 | Jun | CAHN |
| AB | SUNSHINE | EQ 5MG BASE | A210667 | 001 | Apr 01, 2020 | Jun | CMFD |
| AB | | EQ 10MG BASE | A210667 | 002 | Apr 01, 2020 | Jun | CMFD |
| AB | | EQ 20MG BASE | A210667 | 003 | Apr 01, 2020 | Jun | CMFD |
| AB | | EQ 40MG BASE | A210667 | 004 | Apr 01, 2020 | Jun | CMFD |

RUFINAMIDE

TABLET;ORAL
RUFINAMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ALLIED | 200MG | A205095 | 001 | May 16, 2016 | Jun | CAHN |
| AB | | 400MG | A205095 | 002 | May 16, 2016 | Jun | CAHN |
| AB | SCIEGEN PHARMS | 200MG | A205095 | 001 | May 16, 2016 | Jul | CAHN |
| AB | | 400MG | A205095 | 002 | May 16, 2016 | Jul | CAHN |

RUSFERTIDE ACETATE

POWDER;SUBCUTANEOUS
MIMRYLO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | TAKEDA PHARMS AM | EQ 9.5MG BASE/VIAL | N220605 | 001 | Aug 28, 2026 | Aug | NEWA |
| +! | | EQ 19MG BASE/VIAL | N220605 | 002 | Aug 28, 2026 | Aug | NEWA |
| +! | | EQ 28MG BASE/VIAL | N220605 | 003 | Aug 28, 2026 | Aug | NEWA |
| +! | | EQ 41MG BASE/VIAL | N220605 | 004 | Aug 28, 2026 | Aug | NEWA |
| +! | | EQ 54MG BASE/VIAL | N220605 | 005 | Aug 28, 2026 | Aug | NEWA |

RUXOLITINIB PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL
JAKAFI XR

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| + | INCYTE CORP | EQ 11MG BASE | N217180 | 001 | May 01, 2026 | May | NEWA |
| + | | EQ 22MG BASE | N217180 | 002 | May 01, 2026 | May | NEWA |
| + | | EQ 33MG BASE | N217180 | 003 | May 01, 2026 | May | NEWA |
| + | | EQ 44MG BASE | N217180 | 004 | May 01, 2026 | May | NEWA |
| +! | | EQ 55MG BASE | N217180 | 005 | May 01, 2026 | May | NEWA |

SACUBITRIL; VALSARTAN

TABLET;ORAL
SACUBITRIL AND VALSARTAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | AUROBINDO PHARMA LTD | 24MG;26MG | A213631 | 001 | Sep 02, 2026 | Aug | NEWA |
| AB | | 49MG;51MG | A213631 | 002 | Sep 02, 2026 | Aug | NEWA |
| AB | | 97MG;103MG | A213631 | 003 | Sep 02, 2026 | Aug | NEWA |
| AB | SOMERSET THERAPS LLC | 24MG;26MG | A219983 | 001 | Jan 20, 2026 | Jan | NEWA |
| AB | | 49MG;51MG | A219983 | 002 | Jan 20, 2026 | Jan | NEWA |
| AB | | 97MG;103MG | A219983 | 003 | Jan 20, 2026 | Jan | NEWA |
| AB | UMEDICA | 24MG;26MG | A219946 | 001 | Aug 04, 2026 | Jul | NEWA |
| AB | | 49MG;51MG | A219946 | 002 | Aug 04, 2026 | Jul | NEWA |
| AB | | 97MG;103MG | A219946 | 003 | Aug 04, 2026 | Jul | NEWA |

SAFINAMIDE MESYLATE

TABLET;ORAL
SAFINAMIDE MESYLATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | PHARMAZONE | EQ 50MG BASE | A215913 | 001 | Jun 13, 2025 | Sep | CAHN |
| AB | | EQ 100MG BASE | A215913 | 002 | Jun 13, 2025 | Sep | CAHN |
| AB | SENORES PHARMS | EQ 50MG BASE | A215913 | 001 | Jun 13, 2025 | Sep | CAHN |
| AB | | EQ 100MG BASE | A215913 | 002 | Jun 13, 2025 | Sep | CAHN |

SAPROPTERIN DIHYDROCHLORIDE

FOR SOLUTION;ORAL

KUVAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | +! | BIOMARIN PHARM | 100MG/PACKET | N205065 | 001 | Dec 19, 2013 | Jun CDFR |
| AB | | +! | | 500MG/PACKET | N205065 | 002 | Oct 27, 2015 | Jun CDFR |

SAPROPTERIN DIHYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | ANNORA PHARMA | 100MG/PACKET | A215420 | 001 | Aug 18, 2022 | Jun CDFR |
| AB | | | | 500MG/PACKET | A215420 | 002 | Aug 18, 2022 | Jun CDFR |
| AB | | | DR REDDYS | 100MG/PACKET | A209452 | 001 | Mar 30, 2021 | Jun CDFR |
| AB | | | | 500MG/PACKET | A215798 | 001 | May 13, 2022 | Jun CDFR |
| AB | | | HOPEWELL PHARMA | 100MG/PACKET | A216432 | 001 | Sep 03, 2025 | Sep CAHN |
| AB | | | | 500MG/PACKET | A216432 | 002 | Sep 03, 2025 | Sep CAHN |
| AB | | | MICRO LABS | 100MG/PACKET | A219511 | 001 | Jan 08, 2026 | Jun CDFR |
| AB | | | | 500MG/PACKET | A219511 | 002 | Jan 08, 2026 | Jun CDFR |
| AB | | | PH HEALTH | 100MG/PACKET | A207207 | 001 | Aug 20, 2019 | Jun CDFR |
| AB | | | | 500MG/PACKET | A210027 | 001 | Aug 20, 2019 | Jun CDFR |
| AB | | | TP ANDA HOLDINGS | 100MG/PACKET | A216432 | 001 | Sep 03, 2025 | Jun CDFR |
| AB | | | | 500MG/PACKET | A216432 | 002 | Sep 03, 2025 | Jun CDFR |

ZELVYSIA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | AUCTA | 100MG/PACKET | A218645 | 001 | Apr 29, 2025 | Jun CDFR |
| AB | | | | 500MG/PACKET | A218645 | 002 | Apr 29, 2025 | Jun CDFR |

POWDER;ORAL

KUVAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | +! | BIOMARIN PHARM | 500MG/PACKET | N205065 | 002 | Oct 27, 2015 | Jan CHRS |

SAPROPTERIN DIHYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | MICRO LABS | 100MG/PACKET | A219511 | 001 | Jan 08, 2026 | Jan NEWA |
| AB | | | | 500MG/PACKET | A219511 | 002 | Jan 08, 2026 | Jan NEWA |

TABLET;ORAL

SAPROPTERIN DIHYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | HIKMA | 100MG | A218797 | 001 | Jun 11, 2025 | Jun CAHN |

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | DIFGEN PHARMS | 1MG/72HR | A078830 | 001 | Jan 30, 2015 | Oct CAHN |
| >D> | AB | | PADAGIS US | 1MG/72HR | A078830 | 001 | Jan 30, 2015 | Oct CAHN |

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | COSETTE PHARMS NC | 5MG | A074744 | 001 | Jan 27, 1997 | Jun CAHN |
| | | @ | | 5MG | A074756 | 001 | Nov 25, 1998 | Jun CAHN |
| AB | | | PHARMAZONE | 5MG | A074672 | 001 | Apr 01, 1997 | Sep CAHN |

TABLET, ORALLY DISINTEGRATING;ORAL

ZELAPAR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | BAUSCH | 1.25MG | N021479 | 001 | Jun 14, 2006 | Sep DISC |

SELENIOUS ACID

SOLUTION;INTRAVENOUS

SELENIOUS ACID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | CIPLA | EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML) | A218661 | 001 | Jul 21, 2025 | Jan DISC |
| | | @ | | EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML) | A218661 | 002 | Jul 21, 2025 | Jan DISC |
| AP | | | EMERGE BIOSCIENCE | EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML) | A219472 | 001 | Feb 03, 2026 | Aug CAHN |
| AP | | | KINDOS | EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML) | A219472 | 001 | Feb 03, 2026 | Jan NEWA |
| AP | | | STIRA | EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML) | A218536 | 001 | Dec 31, 2025 | Apr CAHN |
| AP | | | | EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML) | A218536 | 002 | Dec 31, 2025 | Apr CAHN |
| AP | | | ZYDUS PHARMS | EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML) | A219322 | 001 | Jun 30, 2026 | Jun NEWA |
| AP | | | | EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML) | A219322 | 002 | Jun 30, 2026 | Jun NEWA |
| AP | | | | EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML) | A219322 | 003 | Jun 30, 2026 | Jun NEWA |

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | COSETTE PHARMS NC | 2.5% | A086209 | 001 | | | Jun CAHN |

SELEXIPAG

TABLET;ORAL

SELEXIPAG

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | RK PHARMA | 0.2MG | A214055 | 001 | Apr 16, 2026 | Apr NEWA |
| AB | | | 0.4MG | A214055 | 002 | Apr 16, 2026 | Apr NEWA |
| AB | | | 0.6MG | A214055 | 003 | Apr 16, 2026 | Apr NEWA |
| AB | | | 0.8MG | A214055 | 004 | Apr 16, 2026 | Apr NEWA |
| AB | | | 1MG | A214055 | 005 | Apr 16, 2026 | Apr NEWA |
| AB | | | 1.2MG | A214055 | 006 | Apr 16, 2026 | Apr NEWA |
| AB | | | 1.4MG | A214055 | 007 | Apr 16, 2026 | Apr NEWA |
| AB | | | 1.6MG | A214055 | 008 | Apr 16, 2026 | Apr NEWA |

UPTRAVI

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | + | ACTELION | 0.1MG | N207947 | 010 | May 23, 2026 | Jun NEWA |
| | + | | 0.15MG | N207947 | 011 | May 23, 2026 | Jun NEWA |
| AB | + | | 1MG | N207947 | 005 | Dec 21, 2015 | Apr CTEC |
| AB | + | | 1.2MG | N207947 | 006 | Dec 21, 2015 | Apr CTEC |

SELUMETINIB SULFATE

GRANULE;ORAL

KOSELUGO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | ASTRAZENECA | EQ 5MG BASE | N219943 | 001 | Sep 10, 2025 | May CHRS |
| | + | | EQ 7.5MG BASE | N219943 | 002 | Sep 10, 2025 | May CHRS |

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

OZEMPIC

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | NOVO | 0.25MG/0.5ML (0.25MG/0.5ML) | N209637 | 005 | May 05, 2026 | May NEWA |
| | +! | | 0.5MG/0.5ML (0.5MG/0.5ML) | N209637 | 006 | May 05, 2026 | May NEWA |
| | +! | | 1MG/0.5ML (1MG/0.5ML) | N209637 | 007 | May 05, 2026 | May NEWA |

WEGOVY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | NOVO | 0.25MG/0.5ML (0.25MG/0.5ML) | N215256 | 007 | May 05, 2026 | May NEWA |
| | +! | | 0.5MG/0.5ML (0.5MG/0.5ML) | N215256 | 008 | May 05, 2026 | May NEWA |
| | +! | | 1MG/0.5ML (1MG/0.5ML) | N215256 | 009 | May 05, 2026 | May NEWA |
| | +! | | 1.7MG/0.75ML (1.7MG/0.75ML) | N215256 | 010 | May 05, 2026 | May NEWA |
| | +! | | 2.4MG/0.75ML (2.4MG/0.75ML) | N215256 | 011 | May 05, 2026 | May NEWA |

WEGOVY FLEXTOUCH

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | NOVO | 9.6MG/3ML (3.2MG/ML) | N215256 | 012 | Jun 18, 2026 | Jun NEWA |

WEGOVY HD

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | NOVO | 7.2MG/0.75ML (7.2MG/0.75ML) | N215256 | 006 | Mar 19, 2026 | Mar NEWA |

TABLET;ORAL

OZEMPIC

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | NOVO | 1.5MG | N213051 | 004 | Dec 09, 2024 | Mar CTNA |
| | +! | | 4MG | N213051 | 005 | Dec 09, 2024 | Mar CTNA |
| | +! | | 9MG | N213051 | 006 | Dec 09, 2024 | Mar CTNA |

WEGOVY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | NOVO | 1.5MG | N218316 | 001 | Dec 22, 2025 | Mar CHRS |
| | +! | | 4MG | N218316 | 002 | Dec 22, 2025 | Mar CHRS |
| | +! | | 9MG | N218316 | 003 | Dec 22, 2025 | Mar CHRS |

SERTRALINE HYDROCHLORIDE

CAPSULE;ORAL

SERTRALINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AMNEAL | EQ 150MG BASE | A219655 | 001 | Jan 28, 2026 | Mar CAHN |
| AB | | | EQ 200MG BASE | A219655 | 002 | Jan 28, 2026 | Mar CAHN |
| AB | | APPCO | EQ 150MG BASE | A218712 | 001 | Jan 20, 2026 | Jan NEWA |
| AB | | | EQ 200MG BASE | A218712 | 002 | Jan 20, 2026 | Jan NEWA |
| AB | | NOVITIUM PHARMA | EQ 150MG BASE | A219714 | 001 | Jan 20, 2026 | Jan NEWA |
| AB | | | EQ 200MG BASE | A219714 | 002 | Jan 20, 2026 | Jan NEWA |
| AB | | SKG PHARMA | EQ 150MG BASE | A219655 | 001 | Jan 28, 2026 | Jan NEWA |
| AB | | | EQ 200MG BASE | A219655 | 002 | Jan 28, 2026 | Jan NEWA |
| AB | | UMEDICA | EQ 150MG BASE | A218342 | 001 | Jan 20, 2026 | Jan NEWA |
| AB | | | EQ 200MG BASE | A218342 | 002 | Jan 20, 2026 | Jan NEWA |
| AB | | ZYDUS LIFESCIENCES | EQ 150MG BASE | A220275 | 001 | Jan 29, 2026 | Jan NEWA |
| AB | | | EQ 200MG BASE | A220275 | 002 | Jan 29, 2026 | Jan NEWA |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | TABLET;ORAL | | | | | | |
| | SERTRALINE HYDROCHLORIDE | | | | | | |
| | @ APPCO | EQ 25MG BASE | A077713 | 001 | Feb 06, 2007 | Jan | CAHN |
| | @ | EQ 50MG BASE | A077713 | 002 | Feb 06, 2007 | Jan | CAHN |
| | @ | EQ 100MG BASE | A077713 | 003 | Feb 06, 2007 | Jan | CAHN |
| | | EQ 150MG BASE | A077713 | 004 | Sep 25, 2026 | Sep | NEWA |
| | | EQ 200MG BASE | A077713 | 005 | Sep 25, 2026 | Sep | NEWA |
| | ! ASCENT PHARMS INC | EQ 75MG BASE | A214790 | 004 | Aug 10, 2026 | Jul | NFTG |
| AB | MACLEODS PHARMS | EQ 25MG BASE | A076882 | 001 | Feb 06, 2007 | Sep | CAHN |
| AB | | EQ 50MG BASE | A076882 | 002 | Feb 06, 2007 | Sep | CAHN |
| AB | | EQ 100MG BASE | A076882 | 003 | Feb 06, 2007 | Sep | CAHN |
| | @ TP ANDA HOLDINGS | EQ 25MG BASE | A077713 | 001 | Feb 06, 2007 | Sep | CAHN |
| AB | | EQ 25MG BASE | A078175 | 001 | Jul 21, 2010 | Sep | CAHN |
| | @ | EQ 50MG BASE | A077713 | 002 | Feb 06, 2007 | Sep | CAHN |
| AB | | EQ 50MG BASE | A078175 | 002 | Jul 21, 2010 | Sep | CAHN |
| | @ | EQ 100MG BASE | A077713 | 003 | Feb 06, 2007 | Sep | CAHN |
| AB | | EQ 100MG BASE | A078175 | 003 | Jul 21, 2010 | Sep | CAHN |
| | | EQ 150MG BASE | A077713 | 004 | Sep 25, 2026 | Sep | CAHN |
| | | EQ 200MG BASE | A077713 | 005 | Sep 25, 2026 | Sep | CAHN |
| | SEVELAMER CARBONATE | | | | | | |
| | FOR SUSPENSION;ORAL | | | | | | |
| | RENVELA | | | | | | |
| | @ + GENZYME | 800MG/PACKET | N022318 | 001 | Aug 12, 2009 | Jun | DISC |
| | @ + | 2.4GM/PACKET | N022318 | 002 | Feb 18, 2009 | Jun | DISC |
| | SEVELAMER CARBONATE | | | | | | |
| AB | ! STRIDES PHARMA INTL | 2.4GM/PACKET | A211917 | 002 | Sep 08, 2023 | Jun | CHRS |
| | TABLET;ORAL | | | | | | |
| | RENVELA | | | | | | |
| | @ + SANOFI | 800MG | N022127 | 001 | Oct 19, 2007 | Jun | DISC |
| | SEVELAMER CARBONATE | | | | | | |
| AB | ! AUROBINDO PHARMA | 800MG | A207179 | 001 | Jul 17, 2017 | Jun | CHRS |
| | @ MICRO LABS | 800MG | A215537 | 001 | Feb 07, 2022 | Aug | DISC |
| AB | QUAGEN | 800MG | A200959 | 001 | Mar 20, 2018 | Sep | CAHN |
| | SILDENAFIL CITRATE | | | | | | |
| | FOR SUSPENSION;ORAL | | | | | | |
| | REVATIO | | | | | | |
| | @ + VIATRIS | EQ 10MG BASE/ML | N203109 | 001 | Aug 30, 2012 | Mar | DISC |
| | SILDENAFIL CITRATE | | | | | | |
| AB | ! AUROBINDO PHARMA LTD | EQ 10MG BASE/ML | A214773 | 001 | Dec 23, 2022 | Mar | CHRS |
| | TABLET;ORAL | | | | | | |
| | SILDENAFIL CITRATE | | | | | | |
| | @ TEVA PHARMS | EQ 20MG BASE | A078380 | 001 | Jan 07, 2013 | Apr | DISC |
| | SILODOSIN | | | | | | |
| | CAPSULE;ORAL | | | | | | |
| | SILODOSIN | | | | | | |
| AB | PHARMAZONE | 4MG | A213230 | 001 | Jan 03, 2022 | Sep | CAHN |
| AB | | 8MG | A213230 | 002 | Jan 03, 2022 | Sep | CAHN |
| | SIMVASTATIN | | | | | | |
| | TABLET;ORAL | | | | | | |
| | SIMVASTATIN | | | | | | |
| | @ MICRO LABS | 5MG | A090383 | 001 | Sep 16, 2011 | Aug | DISC |
| | @ | 10MG | A090383 | 002 | Sep 16, 2011 | Aug | DISC |
| | @ | 20MG | A090383 | 003 | Sep 16, 2011 | Aug | DISC |
| | @ | 40MG | A090383 | 004 | Sep 16, 2011 | Aug | DISC |
| | @ | 80MG | A090383 | 005 | Sep 16, 2011 | Aug | DISC |
| AB | PHARMOBEDIENT | 10MG | A211394 | 001 | Nov 27, 2024 | Sep | CAHN |
| AB | | 20MG | A211394 | 002 | Nov 27, 2024 | Sep | CAHN |
| AB | | 40MG | A211394 | 003 | Nov 27, 2024 | Sep | CAHN |
| AB | | 80MG | A211394 | 004 | Nov 27, 2024 | Sep | CAHN |
| AB | TP ANDA HOLDINGS | 5MG | A078735 | 001 | Aug 30, 2010 | Sep | CAHN |
| AB | | 10MG | A078735 | 002 | Aug 30, 2010 | Sep | CAHN |
| AB | | 20MG | A078735 | 003 | Aug 30, 2010 | Sep | CAHN |
| AB | | 40MG | A078735 | 004 | Aug 30, 2010 | Sep | CAHN |
| AB | | 80MG | A078735 | 005 | Aug 30, 2010 | Sep | CAHN |

SIPONIMOD

TABLET;ORAL

MAYZENT

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | + | NOVARTIS | EQ 0.25MG BASE | N209884 | 001 | Mar 26, 2019 | Oct | CTEC |
| >A> | AB | + | | EQ 0.25MG BASE | N209884 | 001 | Mar 26, 2019 | Oct | CTEC |
| | | + | | EQ 0.25MG BASE | N209884 | 001 | Mar 26, 2019 | Mar | CTEC |
| | AB | + | | EQ 0.25MG BASE | N209884 | 001 | Mar 26, 2019 | Feb | CTEC |
| >D> | | + | | EQ 1MG BASE | N209884 | 003 | Aug 24, 2021 | Oct | CTEC |
| >A> | AB | + | | EQ 1MG BASE | N209884 | 003 | Aug 24, 2021 | Oct | CTEC |
| | | + | | EQ 1MG BASE | N209884 | 003 | Aug 24, 2021 | Mar | CTEC |
| | AB | + | | EQ 1MG BASE | N209884 | 003 | Aug 24, 2021 | Feb | CTEC |
| >D> | | +! | | EQ 2MG BASE | N209884 | 002 | Mar 26, 2019 | Oct | CTEC |
| >A> | AB | +! | | EQ 2MG BASE | N209884 | 002 | Mar 26, 2019 | Oct | CTEC |
| | | +! | | EQ 2MG BASE | N209884 | 002 | Mar 26, 2019 | Mar | CTEC |
| | AB | +! | | EQ 2MG BASE | N209884 | 002 | Mar 26, 2019 | Feb | CTEC |

SIPONIMOD

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | AUROBINDO PHARMA LTD | EQ 0.25MG BASE | A218459 | 001 | Mar 06, 2026 | Mar | DISC |
| | AB | | | EQ 0.25MG BASE | A218459 | 001 | Mar 06, 2026 | Feb | NEWA |
| | | @ | | EQ 1MG BASE | A218459 | 002 | Mar 06, 2026 | Mar | DISC |
| | AB | | | EQ 1MG BASE | A218459 | 002 | Mar 06, 2026 | Feb | NEWA |
| | | @ | | EQ 2MG BASE | A218459 | 003 | Mar 06, 2026 | Mar | DISC |
| | AB | | | EQ 2MG BASE | A218459 | 003 | Mar 06, 2026 | Feb | NEWA |
| >A> | AB | | CIPLA | EQ 0.25MG BASE | A218228 | 001 | Oct 29, 2026 | Oct | NEWA |
| >A> | AB | | | EQ 1MG BASE | A218228 | 002 | Oct 29, 2026 | Oct | NEWA |
| >A> | AB | | | EQ 2MG BASE | A218228 | 003 | Oct 29, 2026 | Oct | NEWA |

SIROLIMUS

POWDER;INTRAVENOUS

FYARRO

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | +! | AADI | 100MG/VIAL | N213312 | 001 | Nov 22, 2021 | Apr | CAHN |

SITAGLIPTIN HYDROCHLORIDE

SOLUTION;ORAL

BRYNOVIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ + | AZURITY | EQ 25MG BASE/ML | N219122 | 001 | Jan 16, 2025 | Sep | DISC |

SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUVIA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | + | MSD | EQ 25MG BASE | N021995 | 001 | Oct 16, 2006 | May | CAHN |
| | AB | + | | EQ 50MG BASE | N021995 | 002 | Oct 16, 2006 | May | CAHN |
| | AB | +! | | EQ 100MG BASE | N021995 | 003 | Oct 16, 2006 | May | CAHN |

SITAGLIPTIN PHOSPHATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | APOTEX | EQ 25MG BASE | A202425 | 001 | Jan 20, 2026 | Jan | NEWA |
| | AB | | | EQ 50MG BASE | A202425 | 002 | Jan 20, 2026 | Jan | NEWA |
| | AB | | | EQ 100MG BASE | A202425 | 003 | Jan 20, 2026 | Jan | NEWA |
| | AB | | SANDOZ | EQ 25MG BASE | A202387 | 001 | Jan 14, 2026 | Jan | NEWA |
| | AB | | | EQ 50MG BASE | A202387 | 002 | Jan 14, 2026 | Jan | NEWA |
| | AB | | | EQ 100MG BASE | A202387 | 003 | Jan 14, 2026 | Jan | NEWA |

SODIUM ACETATE

SOLUTION;INTRAVENOUS

SODIUM ACETATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | | AMNEAL | 40MEQ/20ML (2MEQ/ML) | A218469 | 003 | Mar 02, 2026 | Feb | NEWA |
| | AP | | DR REDDYS | 100MEQ/50ML (2MEQ/ML) | A220274 | 001 | Apr 17, 2026 | Aug | CAHN |
| | AP | | | 200MEQ/100ML (2MEQ/ML) | A220274 | 002 | Apr 17, 2026 | Aug | CAHN |
| | AP | | EXTROVIS | 100MEQ/50ML (2MEQ/ML) | A220274 | 001 | Apr 17, 2026 | Apr | NEWA |
| | AP | | | 200MEQ/100ML (2MEQ/ML) | A220274 | 002 | Apr 17, 2026 | Apr | NEWA |

SODIUM BICARBONATE

SOLUTION;INTRAVENOUS

SODIUM BICARBONATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | | ADAPTIS | 50MEQ/50ML (1MEQ/ML) | A219701 | 001 | Jun 26, 2025 | Oct | CAHN |
| | AP | | | 50MEQ/50ML (1MEQ/ML) | A219701 | 001 | Jun 26, 2025 | Sep | CAHN |
| | AP | | AMNEAL | 50MEQ/50ML (1MEQ/ML) | A217523 | 001 | Jan 13, 2026 | Jan | NEWA |
| | | +! | | 150MEQ/1000ML (0.15MEQ/ML) | N220790 | 001 | Jul 09, 2026 | Jul | NEWA |
| >A> | AP | | ANTHEA PHARMA | 50MEQ/50ML (1MEQ/ML) | A219701 | 001 | Jun 26, 2025 | Oct | CAHN |
| | AP | | ASPIRO | 5MEQ/10ML (0.5MEQ/ML) | A220788 | 001 | Apr 15, 2026 | Apr | NEWA |
| | AP | | | 10MEQ/10ML (1MEQ/ML) | A220788 | 002 | Apr 15, 2026 | Apr | NEWA |
| | AP | | | 50MEQ/50ML (1MEQ/ML) | A220788 | 003 | Apr 15, 2026 | Apr | NEWA |
| | | +! | BAXTER HLTHCARE CORP | 150MEQ/1000ML (0.15MEQ/ML) | N218524 | 001 | Aug 14, 2026 | Aug | NEWA |
| | AP | | MILLA PHARMS | 50MEQ/50ML (1MEQ/ML) | A219089 | 001 | Jul 08, 2026 | Jun | NEWA |

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | NUKEMED | 10-200mCi/ML | A203912 | 001 | Apr 22, 2015 | Apr DISC |

SODIUM GLYCEROPHOSPHATE

SOLUTION;INTRAVENOUS

GLYCOPHOS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | FRESENIUS KABI USA | 4.32GM/20ML (216MG/ML) | N220381 | 001 | Jul 29, 2026 | Jul NEWA |
| | +! | | 21.6GM/100ML (216MG/ML) | N220381 | 002 | Jul 29, 2026 | Jul NEWA |

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | HAINAN POLY | 25MG/ML | A214199 | 001 | Aug 25, 2020 | Jul CAHN |
| | @ | PHARMOBEDIENT | 25MG/ML | A209584 | 001 | Aug 10, 2018 | Sep DISC |

SOLUTION;INTRAVENOUS

SODIUM NITROPRUSSIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | HAINAN POLY | 10MG/50ML (0.2MG/ML) | A215846 | 001 | Aug 26, 2022 | Jul CAHN |
| AP | | | 20MG/100ML (0.2MG/ML) | A215846 | 002 | Aug 26, 2022 | Jul CAHN |
| AP | | | 50MG/100ML (0.5MG/ML) | A215846 | 003 | Aug 26, 2022 | Jul CAHN |

SODIUM OXYBATE

FOR SUSPENSION, EXTENDED RELEASE;ORAL

LUMRYZ

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | ALKERMES INC | 4.5GM/PACKET | N214755 | 001 | May 01, 2023 | Aug CAHN |
| | + | | 6GM/PACKET | N214755 | 002 | May 01, 2023 | Aug CAHN |
| | + | | 7.5GM/PACKET | N214755 | 003 | May 01, 2023 | Aug CAHN |
| | + | | 9GM/PACKET | N214755 | 004 | May 01, 2023 | Aug CAHN |

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | HORIZON THERAP US | 3GM/TEASPOONFUL | N020573 | 001 | Apr 30, 1996 | Jan DISC |

SODIUM PHENYLBUTYRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | PH HEALTH | 3GM/TEASPOONFUL | A203918 | 001 | Jun 15, 2016 | Jun CTEC |
| AB | ! | | 3GM/TEASPOONFUL | A203918 | 001 | Jun 15, 2016 | Jan CHRS |
| | @ | SIGMAPHARM LABS LLC | 3GM/TEASPOONFUL | A202819 | 001 | Mar 22, 2013 | Jun DISC |

TABLET;ORAL

BUPHENYL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | HORIZON THERAP US | 500MG | N020572 | 001 | May 13, 1996 | Jan DISC |

SODIUM PHENYLBUTYRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | NAVINTA LLC | 500MG | A220418 | 001 | Feb 17, 2026 | Feb NEWA |
| AB | ! | PH HEALTH | 500MG | A204395 | 001 | Apr 15, 2016 | Jan CHRS |

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SOLUTION;INTRAVENOUS

SODIUM PHOSPHATES

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> AP | | AMNEAL | 4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML) | A218274 | 001 | Oct 15, 2026 | Oct NEWA |
| AP | | CAPLIN | 1.34GM/5ML;1.38GM/5ML (268MG/ML; 276MG/ML) | A220683 | 001 | Feb 23, 2026 | Feb NEWA |
| AP | | | 4.02GM/15ML;4.14GM/15ML (268MG/ML; 276MG/ML) | A220683 | 002 | Feb 23, 2026 | Feb NEWA |
| AP | | | 13.4GM/50ML;13.8GM/50ML (268MG/ML; 276MG/ML) | A220683 | 003 | Feb 23, 2026 | Feb NEWA |

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION;ORAL

LOKELMA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | ASTRAZENECA | 5GM/PACKET | N207078 | 001 | May 18, 2018 | Jul CFTG |
| AB | +! | | 10GM/PACKET | N207078 | 002 | May 18, 2018 | Jul CFTG |

SODIUM ZIRCONIUM CYCLOSILICATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | LUPIN | 5GM/PACKET | A217549 | 001 | Aug 07, 2026 | Jul NFTG |
| AB | | | 10GM/PACKET | A217549 | 002 | Aug 07, 2026 | Jul NFTG |

SOFOSBUVIR; VELPATASVIR

PELLETS;ORAL

EPCLUSA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | GILEAD SCIENCES INC | 150MG/PACKET;37.5MG/PACKET | N | 214187 | 001 | Jun 10, 2021 | Jul CPOT |
| | +! | | 200MG/PACKET;50MG/PACKET | N | 214187 | 002 | Jun 10, 2021 | Jul CPOT |

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | SUNSHINE | 5MG | A | 213346 | 001 | Apr 13, 2020 | May CMFD |
| AB | | | 10MG | A | 213346 | 002 | Apr 13, 2020 | May CMFD |

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SOLRIAMFETOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ALKEM LABS LTD | EQ 75MG BASE | A | 218722 | 001 | Jun 17, 2026 | Jun NFTG |
| AB | | | EQ 150MG BASE | A | 218722 | 002 | Jun 17, 2026 | Jun NFTG |
| >D> AB | | AURORBINDO PHARMA LTD | EQ 75MG BASE | A | 218725 | 001 | Oct 06, 2026 | Oct DISC |
| >A> | @ | | EQ 75MG BASE | A | 218725 | 001 | Oct 06, 2026 | Oct DISC |
| AB | | | EQ 75MG BASE | A | 218725 | 001 | Oct 06, 2026 | Sep NEWA |
| >D> AB | | | EQ 150MG BASE | A | 218725 | 002 | Oct 06, 2026 | Oct DISC |
| >A> | @ | | EQ 150MG BASE | A | 218725 | 002 | Oct 06, 2026 | Oct DISC |
| AB | | | EQ 150MG BASE | A | 218725 | 002 | Oct 06, 2026 | Sep NEWA |
| AB | | HIKMA | EQ 75MG BASE | A | 218016 | 001 | Jun 17, 2026 | Jun NFTG |
| AB | | | EQ 150MG BASE | A | 218016 | 002 | Jun 17, 2026 | Jun NFTG |

SUNOSI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | AXSOME MALTA | EQ 75MG BASE | N | 211230 | 001 | Jun 17, 2019 | Jun CFTG |
| AB | +! | | EQ 150MG BASE | N | 211230 | 002 | Jun 17, 2019 | Jun CFTG |

SONROTOCLAX

TABLET;ORAL

BEQALZI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | BEONE MEDICINES USA | 1MG | N | 220711 | 001 | May 13, 2026 | May NEWA |
| | + | | 5MG | N | 220711 | 002 | May 13, 2026 | May NEWA |
| | +! | | 20MG | N | 220711 | 003 | May 13, 2026 | Jun CHRS |
| | + | | 20MG | N | 220711 | 003 | May 13, 2026 | May NEWA |
| | + | | 80MG | N | 220711 | 004 | May 13, 2026 | Jun CHRS |
| | +! | | 80MG | N | 220711 | 004 | May 13, 2026 | May NEWA |

SOTALOL HYDROCHLORIDE

TABLET;ORAL

BETAPACE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | LEGACY | 80MG | N | 019865 | 001 | Oct 30, 1992 | Jun CAHN |
| AB | + | | 120MG | N | 019865 | 005 | Apr 20, 1994 | Jun CAHN |
| AB | +! | | 160MG | N | 019865 | 002 | Oct 30, 1992 | Jun CAHN |
| AB | + | | 240MG | N | 019865 | 003 | Oct 30, 1992 | Jun CAHN |
| | @ | | 320MG | N | 019865 | 004 | Oct 30, 1992 | Jun CAHN |

BETAPACE AF

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | LEGACY | 40MG | N | 021151 | 006 | Apr 02, 2003 | Jul CAHN |
| | @ | | 60MG | N | 021151 | 007 | Apr 02, 2003 | Jul CAHN |
| AB | + | | 80MG | N | 021151 | 001 | Feb 22, 2000 | Jul CAHN |
| | @ | | 100MG | N | 021151 | 005 | Mar 14, 2003 | Jul CAHN |
| AB | + | | 120MG | N | 021151 | 002 | Feb 22, 2000 | Jul CAHN |
| AB | +! | | 160MG | N | 021151 | 003 | Feb 22, 2000 | Jul CAHN |

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AMNEAL | 20MG/ML | A | 211432 | 001 | Nov 16, 2018 | Jul DISC |
| AP | | J MOLNER | 20MG/ML | A | 210231 | 001 | Jun 04, 2018 | Jun CAHN |
| AP | | NIVAGEN | 20MG/ML | A | 211625 | 001 | May 19, 2020 | Aug CAHN |
| AP | | NIVAGEN PHARMS INC | 20MG/ML | A | 211625 | 001 | May 19, 2020 | Apr CAHN |

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | ! | FRESENIUS KABI USA | 100MG/5ML (20MG/ML) | A | 217884 | 001 | Feb 11, 2025 | Mar CHRS |
| | @ + | HIKMA | 100MG/5ML (20MG/ML) | N | 215143 | 001 | Aug 20, 2021 | Mar DISC |

SUCRALFATE

SUSPENSION;ORAL

CARAFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ + | ABBVIE | 1GM/10ML | N019183 | 001 | Dec 16, 1993 | Jun | DISC |

SUCRALFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | CHARTWELL RX | 1GM/10ML | A211780 | 001 | Apr 14, 2025 | Jun | CAHN |
| AB | | COSETTE PHARMS NC | 1GM/10ML | A217126 | 001 | Nov 13, 2024 | May | CAHN |
| | @ | MYLAN | 1GM/10ML | A212913 | 001 | Sep 12, 2022 | Sep | DISC |
| >A> AB | | NOVITIUM PHARMA | 1GM/10ML | A216758 | 001 | Oct 13, 2026 | Oct | NEWA |
| AB | ! | VISTAPHARM LLC | 1GM/10ML | A211884 | 001 | Mar 15, 2022 | Jun | CHRS |

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTANIL CITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | HIKMA | EQ 0.05MG BASE/ML | A074413 | 001 | Dec 15, 1995 | Mar | DISC |

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

BRIDION

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | +! | MSD SUB MERCK | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | N022225 | 002 | Dec 15, 2015 | Jul | CHRS |

SUGAMMADEX SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | DR REDDYS | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214236 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214236 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | FRESENIUS KABI USA | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A219448 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | GLAND | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214364 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214364 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | HIKMA | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A218727 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A218728 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A218728 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | LUPIN | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214338 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214338 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | MANKIND PHARMA | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214230 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214230 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | MSN | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214368 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214368 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | MYLAN | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A213915 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A213915 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | QILU PHARM HAINAN | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A215575 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A215575 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | SANDOZ | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214311 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214311 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | SHANDONG | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A215701 | 001 | Oct 06, 2026 | Sep | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A215701 | 002 | Oct 06, 2026 | Sep | NEWA |
| AP | | STERISCIENCE | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A218814 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A218814 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | SUN PHARM INDS INC | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214319 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214319 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | TAMARANG | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A215260 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A215260 | 002 | Jul 28, 2026 | Jul | NEWA |

SOLUTION;INTRAVENOUS
SUGAMMADEX SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | TEVA PHARMS USA INC | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214126 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214126 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | ZENARA | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214306 | 001 | Jul 28, 2026 | Jul | NEWA |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214306 | 002 | Jul 28, 2026 | Jul | NEWA |
| AP | | ZYDUS PHARMS | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | A214290 | 001 | Oct 04, 2023 | May | CMFD |
| AP | | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | A214290 | 002 | Oct 04, 2023 | May | CMFD |

SULCONAZOLE NITRATE
SOLUTION;TOPICAL
EXELDERM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | + | JOURNEY | 1% | N018738 | 001 | Aug 30, 1985 | Jul | DISC |

SULFACETAMIDE SODIUM
OINTMENT;OPHTHALMIC
SULFACETAMIDE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | PADAGIS US | 10% | A080029 | 001 | | | Mar DISC |

SOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | ! | BAUSCH AND LOMB | 10% | A040066 | 001 | Dec 28, 1994 | May | CAHN |

SULFAMETHOXAZOLE; TRIMETHOPRIM
INJECTABLE;INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | PHARMOBEDIENT | 80MG/ML;16MG/ML | A206607 | 001 | Aug 30, 2017 | Sep | DISC |
| AP | ! | SOMERSET | 80MG/ML;16MG/ML | A212231 | 001 | Jun 26, 2019 | Sep | CHRS |

TABLET;ORAL
BACTRIM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | + | SUN PHARM INDUSTRIES | 400MG;80MG | N017377 | 001 | | | Oct DISC |
| >A> | @ + | | 400MG;80MG | N017377 | 001 | | | Oct DISC |

BACTRIM DS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | +! | SUN PHARM INDUSTRIES | 800MG;160MG | N017377 | 002 | | | Oct DISC |
| >A> | @ + | | 800MG;160MG | N017377 | 002 | | | Oct DISC |

SULFAMETHOXAZOLE AND TRIMETHOPRIM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | | AUROBINDO PHARMA | 800MG;160MG | A090624 | 002 | Feb 16, 2010 | Oct | CHRS |
| >A> AB | ! | | 800MG;160MG | A090624 | 002 | Feb 16, 2010 | Oct | CHRS |

SULFANILAMIDE
CREAM;VAGINAL
SULFANILAMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | COSETTE PHARMS NC | 15% | A088718 | 001 | Sep 19, 1985 | Jun | CAHN |

SULFISOXAZOLE
TABLET;ORAL
SULFISOXAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | HIKMA | 500MG | A080379 | 001 | | | Sep CAHN |

SUMATRIPTAN SUCCINATE
INJECTABLE;SUBCUTANEOUS
ALSUMA (AUTOINJECTOR)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | MERIDIAN MEDCL | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N022377 | 001 | Jun 29, 2010 | Sep | CTNA |

IMITREX STATDOSE (AUTOINJECTOR)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | GLAXOSMITHKLINE | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | N020080 | 002 | Feb 01, 2006 | Sep | CTNA |
| AB | +! | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N020080 | 003 | Dec 23, 1996 | Sep | CTNA |

SUMATRIPTAN SUCCINATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | ONESOURCE SPECIALTY | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090314 | 001 | Jun 10, 2010 | Jun | DISC |
| AP | | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090314 | 001 | Jun 10, 2010 | Feb | CMFD |
| @ | | PHARMOBEDIENT | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A203322 | 001 | Apr 14, 2014 | Aug | CAHN |

SUMATRIPTAN SUCCINATE (AUTOINJECTOR)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ALEMBIC | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A213518 | 001 | Nov 06, 2025 | Sep | CTNA |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | INJECTABLE;SUBCUTANEOUS | | | | | | | |
| | SUMATRIPTAN SUCCINATE (AUTOINJECTOR) | | | | | | | |
| AB | | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A213518 | 002 | Nov 06, 2025 | Sep CTNA |
| | @ | ANTARES PHARMA INC | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A078319 | 001 | Dec 10, 2015 | Sep CTNA |
| | @ | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A078319 | 002 | Dec 10, 2015 | Sep CTNA |
| AB | | DR REDDYS | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090495 | 001 | Jan 29, 2014 | Sep CTNA |
| AB | | ONESOURCE SPECIALTY | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090314 | 002 | Jan 30, 2026 | Jun NEWA |
| AB | | SUN PHARM | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090358 | 001 | Jun 21, 2011 | Sep CTNA |
| | POWDER;NASAL | | | | | | |
| | ONZETRA XSAIL | | | | | | |
| | @ + | AZURITY | EQ 11MG BASE | N206099 | 001 | Jan 27, 2016 | Sep DISC |
| | +! | | EQ 11MG BASE | N206099 | 001 | Jan 27, 2016 | Jul CAHN |
| | SOLUTION;SUBCUTANEOUS | | | | | | |
| | ALSUMA (AUTOINJECTOR) | | | | | | |
| | @ | MERIDIAN MEDCL | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N022377 | 001 | Jun 29, 2010 | Sep CDFR |
| | IMITREX | | | | | | |
| | @ + | GLAXOSMITHKLINE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N020080 | 001 | Dec 28, 1992 | Sep CDFR |
| | IMITREX STATDOSE (AUTOINJECTOR) | | | | | | |
| AB | +! | GLAXOSMITHKLINE | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | N020080 | 002 | Feb 01, 2006 | Sep CDFR |
| AB | +! | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N020080 | 003 | Dec 23, 1996 | Sep CDFR |
| | SUMATRIPTAN SUCCINATE | | | | | | |
| | @ | BAXTER HLTHCARE CORP | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A207101 | 001 | Jan 19, 2023 | Sep CDFR |
| AP | | CAPLIN | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A213998 | 001 | Jul 13, 2021 | Sep CDFR |
| AP | ! | EUGIA PHARMA | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A202758 | 001 | Apr 23, 2013 | Sep CDFR |
| AP | | FRESENIUS KABI USA | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A079242 | 001 | Mar 02, 2009 | Sep CDFR |
| | @ | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A079240 | 002 | Sep 18, 2009 | Sep CDFR |
| | @ | | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A079240 | 001 | Sep 18, 2009 | Sep CDFR |
| AP | | HIKMA | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A079123 | 001 | Feb 06, 2009 | Sep CDFR |
| AP | | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A200183 | 001 | Sep 16, 2013 | Sep CDFR |
| | @ | ONESOURCE SPECIALTY | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090314 | 001 | Jun 10, 2010 | Sep CDFR |
| | @ | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090641 | 001 | Jul 28, 2010 | Sep CDFR |
| AP | | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A215651 | 001 | Nov 21, 2024 | Sep CDFR |
| | @ | PH HEALTH | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A077332 | 001 | Oct 09, 2009 | Sep CDFR |
| | @ | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A077871 | 001 | Jul 09, 2009 | Sep CDFR |
| | @ | PHARMOBEDIENT | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A203322 | 001 | Apr 14, 2014 | Sep CDFR |
| | @ | SANDOZ | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A078067 | 002 | Feb 06, 2009 | Sep CDFR |
| | @ | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A078067 | 001 | Feb 06, 2009 | Sep CDFR |
| | @ | TEVA PARENTERAL | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A078318 | 001 | Feb 06, 2009 | Sep CDFR |
| | @ | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A078318 | 002 | Feb 06, 2009 | Sep CDFR |
| | @ | TEVA PHARMS USA | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A077907 | 001 | Feb 06, 2009 | Sep CDFR |
| AP | | WOCKHARDT BIO AG | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A078593 | 001 | Feb 06, 2009 | Sep CDFR |
| | @ | ZYDUS | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090310 | 001 | Aug 11, 2010 | Sep CDFR |
| | SUMATRIPTAN SUCCINATE (AUTOINJECTOR) | | | | | | |
| AB | | ALEMBIC | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A213518 | 001 | Nov 06, 2025 | Sep CDFR |
| AB | | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A213518 | 002 | Nov 06, 2025 | Sep CDFR |
| | @ | ANTARES PHARMA INC | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A078319 | 001 | Dec 10, 2015 | Sep CDFR |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | SOLUTION;SUBCUTANEOUS | | | | | | | |
| | | SUMATRIPTAN SUCCINATE (AUTOINJECTOR) | | | | | | | |
| | | @ | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A078319 | 002 | Dec 10, 2015 | Sep | CDFR |
| | AB | | DR REDDYS | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090495 | 001 | Jan 29, 2014 | Sep | CDFR |
| | AB | | ONESOURCE SPECIALTY | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090314 | 002 | Jan 30, 2026 | Sep | CDFR |
| | AB | | SUN PHARM | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090358 | 001 | Jun 21, 2011 | Sep | CDFR |
| | | SUMAVEL DOSEPRO | | | | | | | |
| | | @ + | ENDO OPERATIONS | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | N022239 | 002 | Nov 26, 2013 | Sep | CDFR |
| | | @ + | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N022239 | 001 | Jul 15, 2009 | Sep | CDFR |
| | | ZEMBRACE SYMTOUCH (AUTOINJECTOR) | | | | | | | |
| | | +! | TONIX MEDS | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | N208223 | 001 | Jan 28, 2016 | Sep | CHRS |
| | | + | | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | N208223 | 001 | Jan 28, 2016 | Sep | CTNA |
| | | SUNVOZERTINIB | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | ZEGFROVY | | | | | | | |
| | | + | DIZAL | 150MG | N219839 | 001 | Jul 02, 2025 | Jul | CAHN |
| | | +! | | 200MG | N219839 | 002 | Jul 02, 2025 | Jul | CAHN |
| | | TACROLIMUS | | | | | | | |
| | | OINTMENT;TOPICAL | | | | | | | |
| | | TACROLIMUS | | | | | | | |
| >D> | BX | | ENCUBE | 0.1% | A212387 | 001 | Oct 10, 2023 | Oct | CAHN |
| >A> | BX | | | 0.1% | A212387 | 001 | Oct 10, 2023 | Oct | CAHN |
| | | TADALAFIL | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | TADALAFIL | | | | | | | |
| | AB1 | | JUBILANT GENERICS | 2.5MG | A210329 | 001 | May 15, 2026 | May | NEWA |
| | AB1 | | | 5MG | A210329 | 002 | May 15, 2026 | May | NEWA |
| | AB1 | | | 10MG | A210329 | 003 | May 15, 2026 | May | NEWA |
| | AB1 | | | 20MG | A210329 | 004 | May 15, 2026 | May | NEWA |
| | AB2 | | | 20MG | A210592 | 001 | Aug 17, 2026 | Aug | NEWA |
| | | @ | PHARMOBEDIENT | 5MG | A206957 | 001 | Apr 29, 2019 | Aug | CAHN |
| | AB1 | | RISING | 2.5MG | A217606 | 001 | Aug 13, 2024 | Sep | CAHN |
| | AB1 | | | 5MG | A217606 | 002 | Aug 13, 2024 | Sep | CAHN |
| | AB1 | | | 10MG | A217606 | 003 | Aug 13, 2024 | Sep | CAHN |
| | AB1 | | | 20MG | A217606 | 004 | Aug 13, 2024 | Sep | CAHN |
| | | ! | TORRENT | 40MG | A212062 | 002 | May 20, 2026 | May | NFTG |
| | | TAFAMIDIS MEGLUMINE | | | | | | | |
| | | CAPSULE;ORAL | | | | | | | |
| >A> | | TAFAMIDIS MEGLUMINE | | | | | | | |
| >A> | | ! | AUROBINDO PHARMA LTD | 20MG | A218617 | 001 | Nov 06, 2026 | Oct | NFTG |
| | | VYNDAQEL | | | | | | | |
| | | @ + | FOLDRX PHARMS | 20MG | N211996 | 001 | May 03, 2019 | Jan | DISC |
| | | TAMSULOSIN HYDROCHLORIDE | | | | | | | |
| | | CAPSULE;ORAL | | | | | | | |
| | | TAMSULOSIN HYDROCHLORIDE | | | | | | | |
| | | @ | SANDOZ | 0.4MG | A078015 | 001 | Apr 27, 2010 | Jun | DISC |
| | | TAPENTADOL HYDROCHLORIDE | | | | | | | |
| | | SOLUTION;ORAL | | | | | | | |
| | | TAPENTADOL HYDROCHLORIDE | | | | | | | |
| | | | NOVITIUM PHARMA | EQ 20MG BASE/ML | A219119 | 001 | Jan 26, 2026 | Jan | NFTG |
| | | TABLET;ORAL | | | | | | | |
| | | NUCYNTA | | | | | | | |
| | AB | + | COLLEGIUM PHARM INC | EQ 50MG BASE | N022304 | 001 | Nov 20, 2008 | Jan | CFTG |
| | AB | + | | EQ 75MG BASE | N022304 | 002 | Nov 20, 2008 | Jan | CFTG |
| | AB | +! | | EQ 100MG BASE | N022304 | 003 | Nov 20, 2008 | Jan | CFTG |
| | | TAPENTADOL HYDROCHLORIDE | | | | | | | |
| | AB | | EPIC PHARMA LLC | EQ 50MG BASE | A214378 | 001 | Jan 27, 2026 | May | CAHN |
| | AB | | | EQ 75MG BASE | A214378 | 002 | Jan 27, 2026 | May | CAHN |
| | AB | | | EQ 100MG BASE | A214378 | 003 | Jan 27, 2026 | May | CAHN |
| | | @ | HIKMA | EQ 50MG BASE | A205057 | 001 | Feb 10, 2026 | May | DISC |

TABLET;ORAL
TAPENTADOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | | EQ 50MG BASE | A205057 | 001 | Feb 10, 2026 | Jan NEWA |
| | | @ | | EQ 75MG BASE | A205057 | 002 | Feb 10, 2026 | May DISC |
| | AB | | | EQ 75MG BASE | A205057 | 002 | Feb 10, 2026 | Jan NEWA |
| | | @ | | EQ 100MG BASE | A205057 | 003 | Feb 10, 2026 | May DISC |
| | AB | | | EQ 100MG BASE | A205057 | 003 | Feb 10, 2026 | Jan NEWA |
| | AB | | HUMANWELL | EQ 50MG BASE | A214378 | 001 | Jan 27, 2026 | Jan NFTG |
| | AB | | | EQ 75MG BASE | A214378 | 002 | Jan 27, 2026 | Jan NFTG |
| | AB | | | EQ 100MG BASE | A214378 | 003 | Jan 27, 2026 | Jan NFTG |
| | AB | | MSN | EQ 50MG BASE | A220865 | 001 | Sep 03, 2026 | Aug NEWA |
| | AB | | | EQ 75MG BASE | A220865 | 002 | Sep 03, 2026 | Aug NEWA |
| | AB | | | EQ 100MG BASE | A220865 | 003 | Sep 03, 2026 | Aug NEWA |

TAVABOROLE

SOLUTION;TOPICAL
TAVABOROLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | CIPLA | 5% | A212224 | 001 | Feb 09, 2021 | Jan DISC |
| >D> | AB | ! | ENCUBE | 5% | A211297 | 001 | Oct 13, 2020 | Oct CAHN |
| >A> | AB | ! | | 5% | A211297 | 001 | Oct 13, 2020 | Oct CAHN |
| | | @ | LUPIN | 5% | A212168 | 001 | Feb 08, 2021 | Feb DISC |
| | | @ | PADAGIS US | 5% | A211848 | 001 | Oct 13, 2020 | Mar DISC |

TAVAPADON

TABLET;ORAL
JUVMO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | + | ABBVIE | 5MG | N220415 | 002 | Sep 25, 2026 | Oct CHRS |
| >A> | | +! | | 5MG | N220415 | 002 | Sep 25, 2026 | Oct CHRS |
| | | + | | 5MG | N220415 | 002 | Sep 25, 2026 | Sep NEWA |
| | | + | | 10MG | N220415 | 003 | Sep 25, 2026 | Sep NEWA |
| >D> | | +! | | 15MG | N220415 | 004 | Sep 25, 2026 | Oct CHRS |
| >A> | | + | | 15MG | N220415 | 004 | Sep 25, 2026 | Oct CHRS |
| | | +! | | 15MG | N220415 | 004 | Sep 25, 2026 | Sep NEWA |

JUVMO (COPACKAGED)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | + | ABBVIE | 0.25MG;1MG | N220415 | 001 | Sep 25, 2026 | Oct CHRS |
| >A> | | +! | | 0.25MG;1MG | N220415 | 001 | Sep 25, 2026 | Oct CHRS |
| | | + | | 0.25MG;1MG | N220415 | 001 | Sep 25, 2026 | Sep NEWA |

TAZAROTENE

CREAM;TOPICAL
AVAGE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | +! | CHARTWELL RX | 0.1% | N021184 | 003 | Sep 30, 2002 | Sep CAHN |

TAZAROTENE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | COSETTE PHARMS NC | 0.05% | A208662 | 002 | Mar 10, 2025 | May CAHN |
| | AB | | | 0.1% | A208662 | 001 | Dec 22, 2017 | May CAHN |
| | AB | | SOLARIS PHARMA CORP | 0.05% | A214560 | 001 | Nov 24, 2025 | Jan CAHN |

TAZORAC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | +! | CHARTWELL RX | 0.05% | N021184 | 001 | Sep 29, 2000 | Sep CAHN |
| | AB | +! | | 0.1% | N021184 | 002 | Sep 29, 2000 | Sep CAHN |

GEL;TOPICAL
TAZAROTENE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | COSETTE PHARMS NC | 0.05% | A215433 | 001 | Sep 13, 2022 | May CAHN |
| | AB | | | 0.1% | A214136 | 001 | Sep 13, 2022 | May CAHN |

TAZORAC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | +! | CHARTWELL RX | 0.05% | N020600 | 001 | Jun 13, 1997 | Sep CAHN |
| | AB | +! | | 0.1% | N020600 | 002 | Jun 13, 1997 | Sep CAHN |

TAZEMETOSTAT HYDROBROMIDE

TABLET;ORAL
TAZVERIK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | + | EPIZYME INC | EQ 200MG BASE | N211723 | 001 | Jan 23, 2020 | May DISC |

TEBIPENEM PIVOXIL HYDROBROMIDE

TABLET;ORAL
UTEBZI

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | GLAXOSMITHKLINE | EQ 300MG BASE | N215960 | 001 | Jun 17, 2026 | Jun NEWA |

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE;INJECTION

NEUROLITE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | SHINE | N/A | N020256 | 001 | Nov 23, 1994 | Feb CAHN |

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION

CARDIOLITE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | +! | SHINE | N/A | N019785 | 001 | Dec 21, 1990 | Feb CAHN |

MIRALUMA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | SHINE | N/A | N019785 | 003 | May 23, 1997 | Feb CAHN |

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

TECHNELITE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | SHINE | 1-20 CI/GENERATOR | N017771 | 002 | Feb 12, 2014 | Feb CAHN |
| | @ | | 0.0083-2.7 CI/GENERATOR | N017771 | 001 | | Feb CAHN |

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

VIBATIV

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | APOTEX | EQ 250MG BASE/VIAL | N022110 | 001 | Sep 11, 2009 | Jul CAHN |
| | +! | | EQ 750MG BASE/VIAL | N022110 | 002 | Sep 11, 2009 | Jul CAHN |

TELMISARTAN

TABLET;ORAL

MICARDIS

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ + | BOEHRINGER INGELHEIM | 40MG | N020850 | 001 | Nov 10, 1998 | Jul DISC |

TELMISARTAN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ADAPTIS | 20MG | A205150 | 001 | Oct 30, 2015 | Sep CAHN |
| AB | | | 40MG | A205150 | 002 | Oct 30, 2015 | Sep CAHN |
| AB | ! | | 80MG | A205150 | 003 | Oct 30, 2015 | Sep CAHN |
| | @ | MICRO LABS | 20MG | A207016 | 001 | Oct 03, 2017 | Aug DISC |
| | @ | | 40MG | A207016 | 002 | Oct 03, 2017 | Aug DISC |
| | @ | | 80MG | A207016 | 003 | Oct 03, 2017 | Aug DISC |

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | AMNEAL PHARMS | 7.5MG | A203482 | 001 | May 23, 2016 | Jan CMFD |
| AB | | | 15MG | A203482 | 002 | May 23, 2016 | Jan CMFD |
| AB | | | 22.5MG | A203482 | 003 | May 23, 2016 | Jan CMFD |
| AB | | | 30MG | A203482 | 004 | May 23, 2016 | Jan CMFD |

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | NIVAGEN | 5MG | A213328 | 001 | Nov 23, 2021 | Aug CAHN |
| | @ | | 20MG | A213328 | 002 | Nov 23, 2021 | Aug CAHN |
| | @ | | 100MG | A213328 | 003 | Nov 23, 2021 | Aug CAHN |
| | @ | | 140MG | A213328 | 004 | Nov 23, 2021 | Aug CAHN |
| | @ | | 180MG | A213328 | 005 | Nov 23, 2021 | Aug CAHN |
| | @ | | 250MG | A213328 | 006 | Nov 23, 2021 | Aug CAHN |
| | @ | PHARMAZONE | 5MG | A205227 | 001 | Jun 29, 2016 | Sep CAHN |
| | @ | | 20MG | A205227 | 002 | Jun 29, 2016 | Sep CAHN |
| | @ | | 100MG | A205227 | 003 | Jun 29, 2016 | Sep CAHN |
| | @ | | 140MG | A205227 | 004 | Jun 29, 2016 | Sep CAHN |
| | @ | | 180MG | A205227 | 005 | Jun 29, 2016 | Sep CAHN |
| | @ | | 250MG | A205227 | 006 | Jun 29, 2016 | Sep CAHN |

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | EQ 1MG BASE | A074823 | 001 | Mar 30, 1998 | Sep CAHN |
| AB | | | EQ 2MG BASE | A074823 | 002 | Mar 30, 1998 | Sep CAHN |
| AB | | | EQ 5MG BASE | A074823 | 003 | Mar 30, 1998 | Sep CAHN |
| AB | | | EQ 10MG BASE | A074823 | 004 | Mar 30, 1998 | Sep CAHN |
| AB | | SENORES PHARMS | EQ 1MG BASE | A074823 | 001 | Mar 30, 1998 | Feb CAHN |
| AB | | | EQ 2MG BASE | A074823 | 002 | Mar 30, 1998 | Feb CAHN |
| AB | | | EQ 5MG BASE | A074823 | 003 | Mar 30, 1998 | Feb CAHN |
| AB | | | EQ 10MG BASE | A074823 | 004 | Mar 30, 1998 | Feb CAHN |

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | CIPLA | EQ 250MG BASE | A077137 | 001 | Jul 02, 2007 | May CMFD |
| | | @ | INVAGEN PHARMS | EQ 250MG BASE | A077533 | 001 | Jul 02, 2007 | Jun DISC |
| | AB | | PHARMAZONE | EQ 250MG BASE | A076390 | 001 | Jul 02, 2007 | Sep CAHN |

TERBUTALINE SULFATE

TABLET;ORAL

TERBUTALINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | TWI PHARMS | 2.5MG | A211832 | 001 | Jun 19, 2020 | Sep DISC |
| | | @ | | 5MG | A211832 | 002 | Jun 19, 2020 | Sep DISC |

TERCONAZOLE

CREAM;VAGINAL

TERCONAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | BX | +! | FOUGERA | 0.8% | N021735 | 001 | Oct 01, 2004 | Aug CAHN |

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | CONCORD BIOTECH LTD | 7MG | A218663 | 001 | Apr 07, 2025 | Feb CMFD |
| | AB | | | 14MG | A218663 | 002 | Apr 07, 2025 | Feb CMFD |
| | AB | | NEOCUBES PHARMA | 7MG | A218663 | 001 | Apr 07, 2025 | Sep CAHN |
| | AB | | | 14MG | A218663 | 002 | Apr 07, 2025 | Sep CAHN |

TERIPARATIDE

SOLUTION;SUBCUTANEOUS

TERIPARATIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AP | | DR REDDYS | 0.56MG/2.24ML (0.25MG/ML) | A214412 | 001 | Oct 23, 2026 | Oct NEWA |

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB1 | | ENCUBE | 25MG/2.5GM PACKET | A212984 | 003 | Jul 11, 2024 | Oct CAHN |
| >A> | AB1 | | | 25MG/2.5GM PACKET | A212984 | 003 | Jul 11, 2024 | Oct CAHN |
| >D> | AB1 | | | 50MG/5GM PACKET | A212984 | 001 | Nov 09, 2021 | Oct CAHN |
| >A> | AB1 | | | 50MG/5GM PACKET | A212984 | 001 | Nov 09, 2021 | Oct CAHN |

GEL, METERED;TRANSDERMAL

TESTOSTERONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | | ENCUBE | 1.62% (20.25MG/1.25GM ACTUATION) | A208620 | 001 | Apr 10, 2019 | Oct CAHN |
| >A> | AB | | | 1.62% (20.25MG/1.25GM ACTUATION) | A208620 | 001 | Apr 10, 2019 | Oct CAHN |
| >D> | AB1 | | | 12.5MG/1.25GM ACTUATION | A212984 | 002 | Feb 09, 2024 | Oct CAHN |
| >A> | AB1 | | | 12.5MG/1.25GM ACTUATION | A212984 | 002 | Feb 09, 2024 | Oct CAHN |

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AT | | ENCUBE | 30MG/1.5ML ACTUATION | A212301 | 001 | Jan 11, 2021 | Oct CAHN |
| >A> | AT | | | 30MG/1.5ML ACTUATION | A212301 | 001 | Jan 11, 2021 | Oct CAHN |
| | AT | | | 30MG/1.5ML ACTUATION | A212301 | 001 | Jan 11, 2021 | Jun CMFD |

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AO | | BPI LABS | 200MG/ML | A219478 | 001 | Sep 03, 2026 | Aug NEWA |
| | | @ | CAPLIN ONE LABS | 100MG/ML | A040615 | 001 | Aug 10, 2006 | Mar DISC |
| | AO | | | 100MG/ML | A040615 | 001 | Aug 10, 2006 | Jan CAHN |
| | | @ | | 200MG/ML | A040615 | 002 | Aug 10, 2006 | Mar DISC |
| | AO | | | 200MG/ML | A040615 | 002 | Aug 10, 2006 | Jan CAHN |

SOLUTION;INTRAMUSCULAR

AZMIRO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | AZURITY | 200MG/ML (200MG/ML) | N216318 | 001 | Jun 02, 2022 | Sep DISC |

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL

KYZATREX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | MARIUS | 50MG | N213953 | 004 | Aug 25, 2026 | Aug NEWA |

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | PIRAMAL | 12.5MG | A213316 | 001 | Jan 22, 2020 | Sep CAHN |
| AB | | | | 25MG | A213316 | 002 | Jan 22, 2020 | Sep CAHN |

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

TETRACYCLINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | | HIKMA | 250MG | A060768 | 001 | | Sep CAHN |
| | @ | | | 500MG | A060768 | 002 | | Sep CAHN |

THALIDOMIDE

CAPSULE;ORAL

THALIDOMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | | NATCO | 50MG | A213267 | 002 | Apr 24, 2026 | Apr NFTG |
| AB | | | | 100MG | A213267 | 003 | Apr 24, 2026 | Apr NFTG |
| AB | | | | 200MG | A213267 | 004 | Apr 24, 2026 | Apr NFTG |

THALOMID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | + | BRISTOL-MYERS | 50MG | N020785 | 001 | Jul 16, 1998 | Apr CFTG |
| AB | | + | | 100MG | N020785 | 002 | Jan 17, 2003 | Apr CFTG |
| AB | | +! | | 200MG | N020785 | 003 | Jan 17, 2003 | Apr CFTG |

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | + | SOLIS PHARMS | 80MG/15ML | A085186 | 001 | | Jan DISC |

THEOPHYLLINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | ! | PHARM ASSOC | 80MG/15ML | A206344 | 001 | Dec 16, 2016 | Jan CHRS |
| | | | | 80MG/15ML | A206344 | 001 | Dec 16, 2016 | Jan CTEC |

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AP | | HONG KONG | 100MG/ML | A213131 | 001 | Sep 25, 2026 | Oct CAHN |
| | AP | | | 100MG/ML | A213131 | 001 | Sep 25, 2026 | Sep NEWA |
| | AP | | MANKIND PHARMA | 100MG/ML | A220513 | 001 | Jul 31, 2026 | Jul NEWA |
| >A> | AP | | MEITHEAL | 100MG/ML | A213131 | 001 | Sep 25, 2026 | Oct CAHN |

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | | HENGRUI PHARMA | 15MG/VIAL | A209150 | 001 | May 04, 2018 | Apr DISC |

POWDER;INTRAVENOUS

TEPADINA AND SODIUM CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | +! | ADIENNE SA | 400MG | N208264 | 004 | Jan 15, 2026 | Jan NEWA |

SOLUTION;INTRAVENOUS

TEPYLUTE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | + | SHORLA | 15MG/1.5ML (10MG/ML) | N216984 | 001 | Jun 25, 2024 | Sep DISC |
| | @ | + | | 100MG/10ML (10MG/ML) | N216984 | 002 | Feb 26, 2025 | Sep DISC |

TICAGRELOR

TABLET;ORAL

TICAGRELOR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | | AMNEAL | 60MG | A208531 | 002 | Oct 28, 2025 | Mar DISC |
| AB | | | LAURUS | 60MG | A218869 | 001 | Aug 20, 2026 | Aug NEWA |
| AB | | | | 90MG | A218869 | 002 | Aug 20, 2026 | Aug NEWA |
| AB | | | MANKIND PHARMA | 60MG | A217679 | 001 | Feb 06, 2026 | Jan NEWA |
| AB | | | | 90MG | A217679 | 002 | Feb 06, 2026 | Jan NEWA |
| AB | | | MICRO LABS | 60MG | A208539 | 001 | Apr 27, 2026 | Apr NEWA |
| AB | | | | 90MG | A208539 | 002 | Apr 27, 2026 | Apr NEWA |
| AB | | | PHARMOBEDIENT | 60MG | A218869 | 001 | Aug 20, 2026 | Sep CAHN |
| AB | | | | 90MG | A218869 | 002 | Aug 20, 2026 | Sep CAHN |
| AB | | | ZHEJIANG JINGXIN | 60MG | A219006 | 001 | Mar 24, 2026 | Mar NEWA |
| AB | | | | 90MG | A219006 | 002 | Mar 24, 2026 | Mar NEWA |

TIGECYCLINE

POWDER;INTRAVENOUS

TIGECYCLINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ + | FRESENIUS KABI USA | 50MG/VIAL | N205645 | 001 | Dec 01, 2016 | Mar DISC |

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AT1 | ABBVIE | EQ 0.25% BASE | A074746 | 001 | Mar 25, 1997 | Aug CAHN |
| AT1 | | EQ 0.5% BASE | A074747 | 001 | Mar 25, 1997 | Aug CAHN |
| AT3 | J MOLNER | EQ 0.25% BASE | A212592 | 001 | Dec 13, 2021 | Jun CAHN |
| AT3 | | EQ 0.5% BASE | A212592 | 002 | Dec 13, 2021 | Jun CAHN |

TABLET;ORAL

TIMOLOL MALEATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | MYLAN | 5MG | A072668 | 002 | Jun 08, 1990 | Mar DISC |
| @ | | 20MG | A072668 | 001 | Jun 08, 1990 | Mar DISC |
| | RISING | 5MG | A207556 | 001 | May 02, 2019 | Mar CTEC |
| ! | | 20MG | A207556 | 003 | May 02, 2019 | Mar CHRS |
| | | 20MG | A207556 | 003 | May 02, 2019 | Mar CTEC |

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | UNIQUE | 250MG | A202489 | 001 | Oct 09, 2013 | Mar CAHN |
| AB | | 500MG | A202489 | 002 | Oct 09, 2013 | Mar CAHN |

TIOPRONIN

TABLET;ORAL

TIOCYSTIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| + | CASPER PHARMA LLC | 100MG | N212927 | 001 | Jun 02, 2026 | Jun NEWA |
| +! | | 200MG | N212927 | 002 | Jun 02, 2026 | Jun NEWA |

TABLET, DELAYED RELEASE;ORAL

TIOPRONIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | AMNEAL | 100MG | A216278 | 002 | Aug 29, 2025 | Mar DISC |
| @ | | 300MG | A216278 | 001 | Aug 15, 2023 | Mar DISC |

TIRATRICOL

TABLET, FOR SUSPENSION;ORAL

EMCITATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | RARE THYROID | 350MCG | N220963 | 001 | Sep 28, 2026 | Sep NEWA |

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS

MOUNJARO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | ELI LILLY AND CO | 10MG/2.4ML (4.17MG/ML) | N215866 | 013 | Jan 07, 2026 | Jan NEWA |
| +! | | 20MG/2.4ML (8.33MG/ML) | N215866 | 014 | Jan 07, 2026 | Jan NEWA |
| +! | | 30MG/2.4ML (12.5MG/ML) | N215866 | 015 | Jan 07, 2026 | Jan NEWA |
| +! | | 40MG/2.4ML (16.7MG/ML) | N215866 | 016 | Jan 07, 2026 | Jan NEWA |
| +! | | 50MG/2.4ML (20.8MG/ML) | N215866 | 017 | Jan 07, 2026 | Jan NEWA |
| +! | | 60MG/2.4ML (25MG/ML) | N215866 | 018 | Jan 07, 2026 | Jan NEWA |

MOUNJARO KWIKPEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | ELI LILLY AND CO | 10MG/2.4ML (4.17MG/ML) | N215866 | 019 | Jan 20, 2026 | Jan NEWA |
| +! | | 20MG/2.4ML (8.33MG/ML) | N215866 | 020 | Jan 20, 2026 | Jan NEWA |
| +! | | 30MG/2.4ML (12.5MG/ML) | N215866 | 021 | Jan 20, 2026 | Jan NEWA |
| +! | | 40MG/2.4ML (16.7MG/ML) | N215866 | 022 | Jan 20, 2026 | Jan NEWA |
| +! | | 50MG/2.4ML (20.8MG/ML) | N215866 | 023 | Jan 20, 2026 | Jan NEWA |
| +! | | 60MG/2.4ML (25MG/ML) | N215866 | 024 | Jan 20, 2026 | Jan NEWA |

ZEPBOUND

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | ELI LILLY AND CO | 10MG/2.4ML (4.17MG/ML) | N217806 | 013 | Jan 07, 2026 | Jan NEWA |
| +! | | 20MG/2.4ML (8.33MG/ML) | N217806 | 014 | Jan 07, 2026 | Jan NEWA |
| +! | | 30MG/2.4ML (12.5MG/ML) | N217806 | 015 | Jan 07, 2026 | Jan NEWA |
| +! | | 40MG/2.4ML (16.7MG/ML) | N217806 | 016 | Jan 07, 2026 | Jan NEWA |
| +! | | 50MG/2.4ML (20.8MG/ML) | N217806 | 017 | Jan 07, 2026 | Jan NEWA |
| +! | | 60MG/2.4ML (25MG/ML) | N217806 | 018 | Jan 07, 2026 | Jan NEWA |

ZEPBOUND KWIKPEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | ELI LILLY AND CO | 10MG/2.4ML (4.17MG/ML) | N217806 | 019 | Jan 20, 2026 | Jan NEWA |
| +! | | 20MG/2.4ML (8.33MG/ML) | N217806 | 020 | Jan 20, 2026 | Jan NEWA |
| +! | | 30MG/2.4ML (12.5MG/ML) | N217806 | 021 | Jan 20, 2026 | Jan NEWA |
| +! | | 40MG/2.4ML (16.7MG/ML) | N217806 | 022 | Jan 20, 2026 | Jan NEWA |
| +! | | 50MG/2.4ML (20.8MG/ML) | N217806 | 023 | Jan 20, 2026 | Jan NEWA |
| +! | | 60MG/2.4ML (25MG/ML) | N217806 | 024 | Jan 20, 2026 | Jan NEWA |

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | INGENUS PHARMS LLC | EQ 2MG BASE | A210267 | 001 | Mar 12, 2019 | Feb | CAHN |
| AB | | | EQ 4MG BASE | A210267 | 002 | Mar 12, 2019 | Feb | CAHN |
| AB | | | EQ 6MG BASE | A210267 | 003 | Mar 12, 2019 | Feb | CAHN |
| AB | | PHARMAZONE | EQ 4MG BASE | A213365 | 001 | May 13, 2024 | Sep | CAHN |
| AB | | | EQ 6MG BASE | A213365 | 002 | May 13, 2024 | Sep | CAHN |
| AB | | SENORES PHARMS | EQ 4MG BASE | A213365 | 001 | May 13, 2024 | Jan | CAHN |
| AB | | | EQ 6MG BASE | A213365 | 002 | May 13, 2024 | Jan | CAHN |

ZANAFLEX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | LEGACY | EQ 2MG BASE | N021447 | 001 | Aug 29, 2002 | Jun | CAHN |
| AB | +! | | EQ 4MG BASE | N021447 | 002 | Aug 29, 2002 | Jun | CAHN |
| AB | + | | EQ 6MG BASE | N021447 | 003 | Aug 29, 2002 | Jun | CAHN |
| AB | +! | LEGACY PHARMA USA | EQ 4MG BASE | N021447 | 002 | Aug 29, 2002 | Mar | CHRS |
| AB | + | | EQ 6MG BASE | N021447 | 003 | Aug 29, 2002 | Mar | CHRS |

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | ALLIED | EQ 2MG BASE | A207170 | 001 | Jan 26, 2017 | Sep | CAHN |
| @ | | | EQ 4MG BASE | A207170 | 002 | Jan 26, 2017 | Sep | CAHN |
| AB | | AUROBINDO PHARMA USA | EQ 2MG BASE | A076282 | 001 | Dec 16, 2003 | Sep | CMFD |
| AB | | | EQ 4MG BASE | A076282 | 002 | Dec 16, 2003 | Sep | CMFD |
| @ | | EVEREST LIFESCIENCES | EQ 2MG BASE | A207170 | 001 | Jan 26, 2017 | Sep | CAHN |
| @ | | | EQ 4MG BASE | A207170 | 002 | Jan 26, 2017 | Sep | CAHN |
| AB | | TP ANDA HOLDINGS | EQ 2MG BASE | A076281 | 001 | Oct 20, 2003 | Sep | CAHN |
| AB | | | EQ 4MG BASE | A076281 | 002 | Oct 20, 2003 | Sep | CAHN |

ZANAFLEX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | + | LEGACY | EQ 2MG BASE | N020397 | 002 | Feb 04, 2000 | Jun | CAHN |
| AB | +! | | EQ 4MG BASE | N020397 | 001 | Nov 27, 1996 | Jun | CAHN |

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | TEVA PHARMS USA | 300MG/4ML | A210915 | 001 | Jun 26, 2019 | Jul | DISC |

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | BAUSCH AND LOMB INC | 0.3% | A064052 | 001 | Nov 29, 1993 | May | CAHN |

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | BAXTER HLTHCARE CORP | EQ 40MG BASE/ML | A206965 | 001 | Jul 01, 2016 | Aug | DISC |
| AP | | EUGIA PHARMA | EQ 1.2GM BASE/VIAL | A217519 | 001 | Jun 21, 2023 | Apr | CMFD |
| AP | | HAINAN POLY | EQ 1.2GM BASE/VIAL | A217029 | 001 | Feb 01, 2023 | Jul | CAHN |

TOFACITINIB CITRATE

SOLUTION;ORAL

TOFACITINIB CITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | | AUSON | EQ 1MG BASE/ML | A219370 | 001 | Jun 09, 2026 | May | NEWA |
| AA | | HIKMA | EQ 1MG BASE/ML | A216878 | 001 | Sep 25, 2023 | May | CMFD |
| AA | | MSN | EQ 1MG BASE/ML | A217298 | 001 | Jun 03, 2026 | May | NEWA |
| AA | | PHARMACO | EQ 1MG BASE/ML | A219370 | 001 | Jun 09, 2026 | Aug | CAHN |
| AA | | SAPTALIS PHARMS | EQ 1MG BASE/ML | A218900 | 001 | Jun 09, 2026 | May | NEWA |
| AA | | SUN PHARM INDS INC | EQ 1MG BASE/ML | A218407 | 001 | Jun 03, 2026 | May | NEWA |

XELJANZ

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AA | +! | PFIZER | EQ 1MG BASE/ML | N213082 | 001 | Sep 25, 2020 | May | CTEC |

TABLET;ORAL

TOFACITINIB CITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AJANTA PHARMA LTD | EQ 10MG BASE | A212943 | 001 | Jun 01, 2021 | Apr | CMFD |
| AB | | APOTEX | EQ 5MG BASE | A218096 | 001 | Jun 03, 2026 | May | NEWA |
| AB | | | EQ 10MG BASE | A218096 | 002 | Jun 03, 2026 | May | NEWA |
| AB | | AUROBINDO PHARMA LTD | EQ 5MG BASE | A215356 | 001 | Jun 03, 2026 | May | NEWA |
| AB | | | EQ 10MG BASE | A215356 | 002 | Jun 03, 2026 | May | NEWA |
| AB | | BRECKENRIDGE | EQ 5MG BASE | A209633 | 001 | Jun 03, 2026 | May | NEWA |
| AB | | | EQ 10MG BASE | A209633 | 002 | Jun 03, 2026 | May | NEWA |
| AB | | CONCORD BIOTECH LTD | EQ 5MG BASE | A218821 | 001 | Jun 09, 2026 | May | NEWA |
| AB | | | EQ 10MG BASE | A218821 | 002 | Jun 09, 2026 | May | NEWA |
| AB | | MACLEODS PHARMS | EQ 5MG BASE | A219530 | 001 | Jun 03, 2026 | May | NEWA |
| AB | | | EQ 10MG BASE | A219530 | 002 | Jun 03, 2026 | May | NEWA |
| AB | | MICRO LABS | EQ 5MG BASE | A209738 | 001 | Mar 13, 2023 | Apr | CMFD |
| AB | | | EQ 10MG BASE | A209738 | 002 | Jun 03, 2026 | May | NEWA |

TABLET;ORAL
TOFACITINIB CITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | MSN | EQ 5MG BASE | A217299 | 001 | Jun 03, 2026 | May | NEWA |
| AB | | | EQ 10MG BASE | A217299 | 002 | Jun 03, 2026 | May | NEWA |
| AB | | SOMERSET THERAPS LLC | EQ 5MG BASE | A220137 | 001 | Jun 03, 2026 | May | NEWA |
| AB | | | EQ 10MG BASE | A220137 | 002 | Jun 03, 2026 | May | NEWA |
| AB | | SPECGX LLC | EQ 5MG BASE | A219395 | 001 | Jun 03, 2026 | May | NEWA |
| AB | | | EQ 10MG BASE | A219395 | 002 | Jun 03, 2026 | May | NEWA |
| AB | | YAOPHARMA CO LTD | EQ 5MG BASE | A215552 | 001 | Jun 09, 2026 | May | NEWA |
| AB | | | EQ 10MG BASE | A215552 | 002 | Jun 09, 2026 | May | NEWA |
| AB | | ZYDUS PHARMS | EQ 5MG BASE | A209829 | 001 | Mar 13, 2023 | Apr | CMFD |
| AB | | | EQ 10MG BASE | A209829 | 002 | Jun 05, 2026 | May | NEWA |

XELJANZ

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | PF PRISM CV | EQ 5MG BASE | N203214 | 001 | Nov 06, 2012 | Apr | CTEC |
| AB | +! | | EQ 10MG BASE | N203214 | 002 | May 30, 2018 | Apr | CTEC |

TABLET, EXTENDED RELEASE;ORAL
TOFACITINIB CITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AJANTA PHARMA LTD | EQ 11MG BASE | A219542 | 001 | Aug 19, 2025 | Apr | CMFD |
| | @ | | EQ 11MG BASE | A219542 | 001 | Aug 19, 2025 | Jan | DISC |
| >A> AB | | | EQ 22MG BASE | A219542 | 002 | Oct 19, 2026 | Oct | NEWA |
| AB | | APOTEX | EQ 11MG BASE | A220458 | 001 | Jun 03, 2026 | May | NEWA |
| >A> AB | | | EQ 22MG BASE | A220458 | 002 | Nov 09, 2026 | Oct | NEWA |
| AB | | AUROBINDO PHARMA LTD | EQ 11MG BASE | A218462 | 001 | Jun 03, 2024 | Apr | CMFD |
| AB | | DEXCEL | EQ 11MG BASE | A218668 | 001 | Dec 16, 2024 | Apr | CMFD |
| >A> AB | | | EQ 22MG BASE | A218668 | 002 | Nov 10, 2026 | Oct | NEWA |
| AB | | ORIENT PHARMA | EQ 11MG BASE | A219830 | 001 | Jun 09, 2026 | May | NEWA |
| AB | | SCIEGEN PHARMS | EQ 11MG BASE | A220972 | 001 | Jun 25, 2026 | Jun | NEWA |
| >A> AB | | | EQ 22MG BASE | A220972 | 002 | Nov 06, 2026 | Oct | NEWA |
| AB | | TEVA PHARMS USA | EQ 11MG BASE | A209813 | 001 | Aug 17, 2026 | Aug | NEWA |
| AB | | | EQ 22MG BASE | A209813 | 002 | Aug 17, 2026 | Aug | NEWA |
| AB | | ZYDUS PHARMS | EQ 11MG BASE | A214264 | 001 | Aug 19, 2021 | Apr | CMFD |
| AB | | | EQ 22MG BASE | A214264 | 002 | Aug 19, 2021 | Apr | CHRS |
| AB | ! | | EQ 22MG BASE | A214264 | 002 | Aug 19, 2021 | Apr | CMFD |

XELJANZ XR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | PFIZER | EQ 22MG BASE | N208246 | 002 | Dec 12, 2019 | Apr | CTEC |

## TOLCAPONE

TABLET;ORAL
TASMAR

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | + | BAUSCH | 100MG | N020697 | 001 | Jan 29, 1998 | Aug | DISC |
| | +! | | 100MG | N020697 | 001 | Jan 29, 1998 | Mar | CTEC |

TOLCAPONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | INGENUS PHARMS LLC | 100MG | A208937 | 001 | Aug 07, 2018 | Mar | DISC |
| AB | | | 100MG | A208937 | 001 | Aug 07, 2018 | Feb | CAHN |

## TOLMETIN SODIUM

CAPSULE;ORAL
TOLMETIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | PHARMAZONE | EQ 400MG BASE | A073290 | 001 | Nov 27, 1991 | Sep | CAHN |

TABLET;ORAL
TOLMETIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | | COSETTE PHARMS NC | EQ 600MG BASE | A074399 | 001 | Mar 28, 1996 | Jun | CAHN |
| @ | | | EQ 600MG BASE | A074729 | 001 | Feb 27, 1997 | Jun | CAHN |

## TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
DETROL LA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | + | UPJOHN | 2MG | N021228 | 001 | Dec 22, 2000 | Aug | DISC |
| @ | + | | 4MG | N021228 | 002 | Dec 22, 2000 | Aug | DISC |

TOLTERODINE TARTRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | ! | TORRENT | 4MG | A203016 | 002 | Aug 11, 2015 | Aug | CHRS |

TABLET;ORAL
TOLTERODINE TARTRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | UNIQUE | 1MG | A204721 | 001 | Jan 24, 2020 | Mar | CAHN |
| AB | | | 2MG | A204721 | 002 | Jan 24, 2020 | Mar | CAHN |

## TOLVAPTAN

TABLET;ORAL
JYNARQUE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB2 | +! | OTSUKA | 45MG | N204441 | 003 | Apr 23, 2018 | Aug | CTEC |
| AB2 | + | | 90MG | N204441 | 005 | Apr 23, 2018 | Aug | CTEC |

TABLET;ORAL
TOLVAPTAN

| | | | | | | |
|---|---|---|---|---|---|---|
| AB2 | ALKEM LABS LTD | 15MG | A220147 | 001 | Apr 21, 2026 | Apr NEWA |
| AB2 | | 30MG | A220147 | 002 | Apr 21, 2026 | Apr NEWA |
| AB2 | | 45MG | A220147 | 003 | Apr 21, 2026 | Aug CTEC |
| AB | | 45MG | A220147 | 003 | Apr 21, 2026 | Apr NEWA |
| AB2 | | 60MG | A220147 | 004 | Apr 21, 2026 | Apr NEWA |
| AB2 | | 90MG | A220147 | 005 | Apr 21, 2026 | Aug CTEC |
| AB | | 90MG | A220147 | 005 | Apr 21, 2026 | Apr NEWA |
| AB2 | APOTEX | 45MG | A218381 | 003 | Nov 10, 2025 | Aug CTEC |
| AB2 | | 90MG | A218381 | 005 | Nov 10, 2025 | Aug CTEC |
| AB2 | LUPIN | 45MG | A216063 | 003 | Apr 23, 2025 | Aug CTEC |
| AB2 | | 90MG | A216063 | 005 | Apr 23, 2025 | Aug CTEC |
| AB2 | TEVA PHARMS INC | 15MG | A216933 | 001 | Jul 21, 2026 | Jul NEWA |
| AB2 | | 30MG | A216933 | 002 | Jul 21, 2026 | Jul NEWA |
| AB2 | | 45MG | A216933 | 003 | Jul 21, 2026 | Aug CTEC |
| AB | | 45MG | A216933 | 003 | Jul 21, 2026 | Jul NEWA |
| AB2 | | 60MG | A216933 | 004 | Jul 21, 2026 | Jul NEWA |
| AB2 | | 90MG | A216933 | 005 | Jul 21, 2026 | Aug CTEC |
| AB | | 90MG | A216933 | 005 | Jul 21, 2026 | Jul NEWA |

TOPIRAMATE
CAPSULE;ORAL
TOPIRAMATE

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | PHARMAZONE | 15MG | A218642 | 001 | Oct 10, 2024 | Sep CAHN |
| AB | | 25MG | A218642 | 002 | Oct 10, 2024 | Sep CAHN |
| AB | SENORES PHARMS | 15MG | A218642 | 001 | Oct 10, 2024 | Jan CAHN |
| AB | | 25MG | A218642 | 002 | Oct 10, 2024 | Jan CAHN |
| AB | STRIDES PHARMA | 50MG | A078418 | 003 | Feb 02, 2026 | Jan NEWA |

CAPSULE, EXTENDED RELEASE;ORAL
TOPIRAMATE

| | | | | | | |
|---|---|---|---|---|---|---|
| AB1 | ASCENT PHARMS INC | 25MG | A217443 | 001 | Jan 12, 2026 | Jan NEWA |
| AB1 | | 50MG | A217443 | 002 | Jan 12, 2026 | Jan NEWA |
| AB1 | | 100MG | A217443 | 003 | Jan 12, 2026 | Jan NEWA |
| AB1 | | 200MG | A217443 | 004 | Jan 12, 2026 | Jan NEWA |
| AB1 | BIOCON PHARMA | 25MG | A220943 | 001 | Jul 22, 2026 | Jul NEWA |
| AB1 | | 50MG | A220943 | 002 | Jul 22, 2026 | Jul NEWA |
| AB1 | | 100MG | A220943 | 003 | Jul 22, 2026 | Jul NEWA |
| AB1 | | 200MG | A220943 | 004 | Jul 22, 2026 | Jul NEWA |
| AB1 | MICRO LABS | 25MG | A219183 | 001 | Sep 04, 2026 | Aug NEWA |
| AB1 | | 50MG | A219183 | 002 | Sep 04, 2026 | Aug NEWA |
| AB1 | | 100MG | A219183 | 003 | Sep 04, 2026 | Aug NEWA |
| AB1 | | 200MG | A219183 | 004 | Sep 04, 2026 | Aug NEWA |
| @ | RICONPHARMA LLC | 25MG | A220041 | 001 | May 26, 2026 | Jun DISC |
| AB2 | | 25MG | A220041 | 001 | May 26, 2026 | May NEWA |
| @ | | 50MG | A220041 | 002 | May 26, 2026 | Jun DISC |
| AB2 | | 50MG | A220041 | 002 | May 26, 2026 | May NEWA |
| @ | | 100MG | A220041 | 003 | May 26, 2026 | Jun DISC |
| AB2 | | 100MG | A220041 | 003 | May 26, 2026 | May NEWA |
| @ | | 150MG | A220041 | 004 | May 26, 2026 | Jun DISC |
| AB2 | | 150MG | A220041 | 004 | May 26, 2026 | May NEWA |
| @ | | 200MG | A220041 | 005 | May 26, 2026 | Jun DISC |
| AB2 | | 200MG | A220041 | 005 | May 26, 2026 | May NEWA |

TABLET;ORAL
TOPIRAMATE

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | AIPING PHARM INC | 25MG | A078499 | 001 | Jan 07, 2010 | Sep CMFD |
| AB | | 50MG | A078499 | 002 | Jan 07, 2010 | Sep CMFD |
| AB | | 100MG | A078499 | 003 | Jan 07, 2010 | Sep CMFD |
| AB | | 200MG | A078499 | 004 | Jan 07, 2010 | Sep CMFD |
| @ | PHARMACO | 25MG | A077733 | 001 | Mar 27, 2009 | Sep DISC |
| @ | | 50MG | A077733 | 002 | Mar 27, 2009 | Sep DISC |
| @ | | 100MG | A077733 | 003 | Mar 27, 2009 | Sep DISC |
| @ | | 200MG | A077733 | 004 | Mar 27, 2009 | Sep DISC |
| @ | PHARMAZONE | 25MG | A090353 | 001 | Sep 01, 2010 | Sep CAHN |
| @ | | 50MG | A090353 | 002 | Sep 01, 2010 | Sep CAHN |
| @ | | 100MG | A090353 | 003 | Sep 01, 2010 | Sep CAHN |
| @ | | 200MG | A090353 | 004 | Sep 01, 2010 | Sep CAHN |
| @ | SENORES PHARMS | 25MG | A090353 | 001 | Sep 01, 2010 | Jan CAHN |
| @ | | 50MG | A090353 | 002 | Sep 01, 2010 | Jan CAHN |
| @ | | 100MG | A090353 | 003 | Sep 01, 2010 | Jan CAHN |
| @ | | 200MG | A090353 | 004 | Sep 01, 2010 | Jan CAHN |
| @ | SUN PHARM | 25MG | A090278 | 001 | Mar 27, 2009 | Sep DISC |
| @ | | 50MG | A090278 | 002 | Mar 27, 2009 | Sep DISC |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | TABLET;ORAL | | | | | | |
| | | TOPIRAMATE | | | | | | |
| | | @ | | 100MG | A090278 | 003 | Mar 27, 2009 | Sep DISC |
| | | TOPOTECAN HYDROCHLORIDE | | | | | | |
| | | INJECTABLE;INJECTION | | | | | | |
| | | TOPOTECAN HYDROCHLORIDE | | | | | | |
| | AP | | INGENUS PHARMS LLC | EQ 4MG BASE/VIAL | A206962 | 001 | Nov 30, 2016 | Feb CAHN |
| | | SOLUTION;INTRAVENOUS | | | | | | |
| | | TOPOTECAN HYDROCHLORIDE | | | | | | |
| | | @ | NATCO PHARMA USA | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A206074 | 001 | Nov 24, 2017 | Mar CAHN |
| | | TORSEMIDE | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | TORSEMIDE | | | | | | |
| | AB | | HERITAGE | 5MG | A076894 | 001 | May 31, 2005 | Sep CAHN |
| | AB | | | 10MG | A076894 | 002 | May 31, 2005 | Sep CAHN |
| | AB | | | 20MG | A076894 | 003 | May 31, 2005 | Sep CAHN |
| | AB | | | 100MG | A076894 | 004 | May 31, 2005 | Sep CAHN |
| | AB | | MICRO LABS | 5MG | A217239 | 001 | May 01, 2026 | Apr NEWA |
| | AB | | | 10MG | A217239 | 002 | May 01, 2026 | Apr NEWA |
| | AB | | | 20MG | A217239 | 003 | May 01, 2026 | Apr NEWA |
| | | @ | STRIDES PHARMA INTL | 5MG | A076226 | 001 | May 27, 2003 | Jun DISC |
| | | @ | | 5MG | A090613 | 001 | Mar 22, 2011 | Jun DISC |
| | | @ | | 10MG | A076226 | 002 | May 27, 2003 | Jun DISC |
| | | @ | | 10MG | A090613 | 002 | Mar 22, 2011 | Jun DISC |
| | | @ | | 20MG | A076226 | 003 | May 27, 2003 | Jun DISC |
| | | @ | | 20MG | A090613 | 003 | Mar 22, 2011 | Jun DISC |
| | | @ | | 100MG | A076226 | 004 | May 27, 2003 | Jun DISC |
| | | @ | | 100MG | A090613 | 004 | Mar 22, 2011 | Jun DISC |
| | | TRABECTEDIN | | | | | | |
| >A> | | POWDER;INTRAVENOUS | | | | | | |
| >A> | | TRABECTEDIN | | | | | | |
| >A> | | +! | EVER | 1MG/VIAL | N219617 | 001 | Oct 01, 2026 | Oct NEWA |
| | | SOLUTION;INTRAVENOUS | | | | | | |
| | | EVDI | | | | | | |
| | | +! | APOTEX | 1MG/20ML (0.05MG/ML) | N220837 | 001 | May 01, 2026 | May NEWA |
| | | TRAMADOL HYDROCHLORIDE | | | | | | |
| | | SOLUTION;ORAL | | | | | | |
| | | QDOLO | | | | | | |
| | | @ + | ROSEMOUNT | 5MG/ML | N214044 | 001 | Sep 01, 2020 | Mar CAHN |
| | | TRAMADOL HYDROCHLORIDE | | | | | | |
| | | ! | NOVITIUM PHARMA | 5MG/ML | A219647 | 001 | Jun 26, 2026 | Jun NFTG |
| | | TABLET;ORAL | | | | | | |
| | | TRAMADOL HYDROCHLORIDE | | | | | | |
| | AB | | GRAVITI PHARMS | 25MG | A075968 | 003 | Jul 28, 2026 | Jul NEWA |
| | AB | | PHARMAZONE | 50MG | A090404 | 001 | Jan 31, 2011 | Sep CAHN |
| | AB | | RUBICON | 25MG | A208708 | 003 | Nov 27, 2023 | Mar CTEC |
| | AB | | RUBICON RESEARCH | 25MG | A208708 | 003 | Nov 27, 2023 | May CAHN |
| | AB | | | 50MG | A208708 | 001 | Jun 28, 2019 | May CAHN |
| | | | | 75MG | A208708 | 004 | Apr 04, 2024 | May CAHN |
| | AB | ! | | 100MG | A208708 | 002 | Jun 28, 2019 | May CAHN |
| | AB | | STRIDES PHARMA | 25MG | A202075 | 002 | Mar 23, 2026 | Mar NEWA |
| | | TRANDOLAPRIL | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | TRANDOLAPRIL | | | | | | |
| | | @ | PHARMAZONE | 1MG | A078493 | 001 | Aug 25, 2008 | Sep CAHN |
| | | @ | | 2MG | A078493 | 002 | Aug 25, 2008 | Sep CAHN |
| | | @ | | 4MG | A078493 | 003 | Aug 25, 2008 | Sep CAHN |
| | | @ | SENORES PHARMS | 1MG | A078493 | 001 | Aug 25, 2008 | Jan CAHN |
| | | @ | | 2MG | A078493 | 002 | Aug 25, 2008 | Jan CAHN |
| | | @ | | 4MG | A078493 | 003 | Aug 25, 2008 | Jan CAHN |

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | AM REGENT | 100MG/ML | A201885 | 001 | Aug 10, 2011 | Sep | DISC |
| AP | | PHARMOBEDIENT | 100MG/ML | A201580 | 001 | Jun 14, 2013 | Aug | CAHN |

TABLET;ORAL

LYSTEDA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | J MOLNER | 650MG | N022430 | 001 | Nov 13, 2009 | Jun | CAHN |

TRANEXAMIC ACID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | BIONPHARMA | 650MG | A219123 | 001 | Aug 19, 2025 | May | DISC |
| AB | | I 3 PHARMS | 650MG | A219702 | 001 | Jan 26, 2026 | Jan | NEWA |
| AB | | PHARMAZONE | 650MG | A219702 | 001 | Jan 26, 2026 | Sep | CAHN |
| >A> AB | | ZYDUS LIFESCIENCES | 650MG | A221213 | 001 | Oct 27, 2026 | Oct | NEWA |

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | OXFORD PHARMS | 25MG | A072193 | 002 | Sep 01, 2026 | Aug | NFTG |
| | ! | | 75MG | A072193 | 003 | Sep 01, 2026 | Aug | NFTG |

TRETINOIN

CREAM;TOPICAL

RETIN-A

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB1 | +! | BAUSCH | 0.05% | N017522 | 001 | | Jun | CAHN |
| AB | +! | | 0.1% | N017340 | 001 | | Jun | CAHN |

TRETINOIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB1 | | ALEMBIC | 0.05% | A214590 | 001 | Jun 11, 2026 | Jun | NEWA |
| >D> AB | | ENCUBE | 0.025% | A217831 | 001 | Jul 10, 2025 | Oct | CAHN |
| >A> AB | | | 0.025% | A217831 | 001 | Jul 10, 2025 | Oct | CAHN |
| >D> AB1 | | | 0.05% | A217832 | 001 | Mar 25, 2026 | Oct | CAHN |
| >A> AB1 | | | 0.05% | A217832 | 001 | Mar 25, 2026 | Oct | CAHN |
| AB1 | | | 0.05% | A217832 | 001 | Mar 25, 2026 | Mar | NEWA |
| >D> AB | | | 0.1% | A217833 | 001 | Feb 10, 2026 | Oct | CAHN |
| >A> AB | | | 0.1% | A217833 | 001 | Feb 10, 2026 | Oct | CAHN |
| AB | | | 0.1% | A217833 | 001 | Feb 10, 2026 | Jan | NEWA |
| AB | | ZYDUS LIFESCIENCES | 0.025% | A218560 | 001 | Sep 15, 2026 | Sep | NEWA |

GEL;TOPICAL

RETIN-A-MICRO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | +! | BAUSCH | 0.06% | N020475 | 004 | Oct 23, 2017 | Apr | CFTG |

TRETINOIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | AMNEAL | 0.08% | A217497 | 001 | May 14, 2026 | May | NEWA |
| >D> AB | | ENCUBE | 0.01% | A217588 | 001 | Mar 03, 2025 | Oct | CAHN |
| >A> AB | | | 0.01% | A217588 | 001 | Mar 03, 2025 | Oct | CAHN |
| >D> AB | | | 0.025% | A217587 | 001 | Mar 03, 2025 | Oct | CAHN |
| >A> AB | | | 0.025% | A217587 | 001 | Mar 03, 2025 | Oct | CAHN |

TRETINOIN MICROSPHERE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | | ENCUBE | 0.06% | A215609 | 002 | Apr 15, 2026 | Oct | CAHN |
| >A> AB | | | 0.06% | A215609 | 002 | Apr 15, 2026 | Oct | CAHN |
| AB | | | 0.06% | A215609 | 002 | Apr 15, 2026 | Apr | NFTG |
| >D> AB | | | 0.08% | A215609 | 001 | Aug 22, 2023 | Oct | CAHN |
| >A> AB | | | 0.08% | A215609 | 001 | Aug 22, 2023 | Oct | CAHN |

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | COSETTE PHARMS NC | 0.025% | A089797 | 001 | May 31, 1991 | May | CAHN |
| AT | | | 0.1% | A089798 | 001 | May 31, 1991 | May | CAHN |
| >D> AT | | ENCUBE | 0.1% | A208848 | 001 | Sep 18, 2017 | Oct | CAHN |
| >A> AT | | | 0.1% | A208848 | 001 | Sep 18, 2017 | Oct | CAHN |
| | @ + | PHARMOBEDIENT | 0.025% | N011601 | 003 | | Aug | CAHN |
| | @ + | | 0.1% | N011601 | 006 | | Aug | CAHN |

INJECTABLE;INJECTION

KENALOG-10

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | APOTHECON | 10MG/ML | N012041 | 001 | | May | CHRS |
| AB | +! | | 10MG/ML | N012041 | 001 | | Jan | CHRS |

TRIAMCINOLONE ACETONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | CAPLIN | 10MG/ML | A090166 | 001 | May 27, 2009 | Jan | CAHN |
| AB | ! | DR REDDYS | 10MG/ML | A218773 | 001 | Mar 12, 2025 | May | CHRS |

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | | COSETTE PHARMS NC | 0.1% | A089129 | 001 | Aug 14, 1986 | May | CAHN |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | LOTION;TOPICAL | | | | | | |
| | | | TRIAMCINOLONE ACETONIDE | | | | | | |
| >D> | | @ | ENCUBE | 0.1% | A204606 | 001 | Jul 07, 2016 | Oct | CAHN |
| >A> | | @ | | 0.1% | A204606 | 001 | Jul 07, 2016 | Oct | CAHN |
| | | @ | | 0.1% | A204606 | 001 | Jul 07, 2016 | May | CAHN |
| >D> | AT | ! | PHARMOBEDIENT | 0.1% | A088451 | 001 | Apr 03, 1985 | Oct | CHRS |
| >A> | AT | | | 0.1% | A088451 | 001 | Apr 03, 1985 | Oct | CHRS |
| >D> | AT | | QUAGEN | 0.1% | A213559 | 002 | Jul 01, 2020 | Oct | CHRS |
| >A> | AT | ! | | 0.1% | A213559 | 002 | Jul 01, 2020 | Oct | CHRS |
| | | | OINTMENT;TOPICAL | | | | | | |
| | | | TRIAMCINOLONE ACETONIDE | | | | | | |
| | AT | | COSETTE PHARMS NC | 0.025% | A089795 | 001 | Dec 23, 1988 | May | CAHN |
| | AT | | | 0.1% | A089796 | 001 | Dec 23, 1988 | May | CAHN |
| | | @ | | 0.5% | A208925 | 001 | Oct 06, 2017 | Jun | CAHN |
| >D> | AT | ! | ENCUBE | 0.05% | A212384 | 001 | Nov 29, 2019 | Oct | CAHN |
| >A> | AT | ! | | 0.05% | A212384 | 001 | Nov 29, 2019 | Oct | CAHN |
| >D> | AT | | | 0.1% | A205373 | 001 | May 13, 2016 | Oct | CAHN |
| >A> | AT | | | 0.1% | A205373 | 001 | May 13, 2016 | Oct | CAHN |
| >D> | | @ | | 0.5% | A208590 | 001 | Mar 03, 2017 | Oct | CAHN |
| >A> | | @ | | 0.5% | A208590 | 001 | Mar 03, 2017 | Oct | CAHN |
| | | @ | | 0.5% | A208590 | 001 | Mar 03, 2017 | May | CAHN |
| | AT | | PHARMAZONE | 0.05% | A213619 | 001 | Nov 10, 2020 | Sep | CAHN |
| | | | TRIANEX | | | | | | |
| | | @ | PHARMOBEDIENT | 0.05% | A089595 | 001 | Mar 23, 1995 | Sep | CAHN |
| | | | PASTE;DENTAL | | | | | | |
| | | | TRIAMCINOLONE ACETONIDE | | | | | | |
| | AT | | COSETTE PHARMS NC | 0.1% | A205592 | 001 | Jan 12, 2017 | May | CAHN |
| | | | TRIAMTERENE | | | | | | |
| | | | CAPSULE;ORAL | | | | | | |
| | | | TRIAMTERENE | | | | | | |
| >A> | AB | | RUBICON RESEARCH | 50MG | A220782 | 001 | Oct 28, 2026 | Oct | NEWA |
| >A> | AB | | | 100MG | A220782 | 002 | Oct 28, 2026 | Oct | NEWA |
| | AB | | TP ANDA HOLDINGS | 50MG | A211581 | 001 | Aug 19, 2019 | Sep | CAHN |
| | AB | | | 100MG | A211581 | 002 | Aug 19, 2019 | Sep | CAHN |
| | | | TRIAZOLAM | | | | | | |
| | | | TABLET;ORAL | | | | | | |
| | | | TRIAZOLAM | | | | | | |
| | | @ | BRECKENRIDGE | 0.125MG | A216890 | 001 | Nov 08, 2022 | Feb | DISC |
| | | @ | | 0.25MG | A216890 | 002 | Nov 08, 2022 | Feb | DISC |
| | AB | | INGENUS PHARMS LLC | 0.125MG | A214219 | 001 | Oct 20, 2020 | Feb | CAHN |
| | AB | | | 0.25MG | A214219 | 002 | Oct 20, 2020 | Feb | CAHN |
| | | | TRIENTINE HYDROCHLORIDE | | | | | | |
| | | | CAPSULE;ORAL | | | | | | |
| | | | TRIENTINE HYDROCHLORIDE | | | | | | |
| | | @ | PH HEALTH | 250MG | A210096 | 001 | Sep 25, 2019 | Jun | DISC |
| | | ! | RISING | 500MG | A212238 | 002 | Sep 22, 2023 | Jan | CHRS |
| | | @ | WATSON LABS TEVA | 250MG | A207567 | 001 | Feb 07, 2018 | May | DISC |
| | | | TRIFLUOPERAZINE HYDROCHLORIDE | | | | | | |
| | | | TABLET;ORAL | | | | | | |
| | | | TRIFLUOPERAZINE HYDROCHLORIDE | | | | | | |
| | | @ | PHARMOBEDIENT | EQ 1MG BASE | A040153 | 001 | Oct 25, 1996 | Sep | CAHN |
| | | @ | | EQ 2MG BASE | A040153 | 002 | Oct 25, 1996 | Sep | CAHN |
| | | @ | | EQ 5MG BASE | A040153 | 003 | Oct 25, 1996 | Sep | CAHN |
| | | @ | | EQ 10MG BASE | A040153 | 004 | Oct 25, 1996 | Sep | CAHN |
| | | @ | POM PHARMA | EQ 1MG BASE | A040153 | 001 | Oct 25, 1996 | Apr | CAHN |
| | | @ | | EQ 2MG BASE | A040153 | 002 | Oct 25, 1996 | Apr | CAHN |
| | | @ | | EQ 5MG BASE | A040153 | 003 | Oct 25, 1996 | Apr | CAHN |
| | | @ | | EQ 10MG BASE | A040153 | 004 | Oct 25, 1996 | Apr | CAHN |
| | | | TRIHEXYPHENIDYL HYDROCHLORIDE | | | | | | |
| | | | TABLET;ORAL | | | | | | |
| | | | TRIHEXYPHENIDYL HYDROCHLORIDE | | | | | | |
| | | @ | HIKMA | 2MG | A040337 | 002 | Feb 16, 2000 | Sep | CAHN |
| | | @ | | 5MG | A040337 | 001 | Feb 16, 2000 | Sep | CAHN |

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

TIGAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AP | +! | PH HEALTH | 100MG/ML | N017530 | 001 | | Oct CHRS |
| >A> | AP | + | | 100MG/ML | N017530 | 001 | | Oct CHRS |

TRIMETHOBENZAMIDE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AP | | BPI LABS | 100MG/ML | A219606 | 001 | Oct 16, 2025 | Oct CHRS |
| >A> | AP | ! | | 100MG/ML | A219606 | 001 | Oct 16, 2025 | Oct CHRS |

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | BIONPHARMA | 100MG | A221194 | 001 | Oct 23, 2026 | Oct NEWA |

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL

GYNE-SULF

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | COSETTE PHARMS NC | 3.7%;2.86%;3.42% | A088607 | 001 | Jun 09, 1986 | Jun CAHN |

VAGILIA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | COSETTE PHARMS NC | 3.7%;2.86%;3.42% | A088821 | 001 | Nov 09, 1987 | Jun CAHN |

>A> TRISODIUM CITRATE

>A> SOLUTION;EXTRACORPOREAL

>A> CIENBY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | +! | FRESENIUS MEDCL CARE | 40GM/1000ML (1500ML) | N219455 | 001 | Oct 19, 2026 | Oct NEWA |

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

TROPICAMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AT | | BAUSCH AND LOMB | 1% | A040064 | 001 | Jul 27, 1994 | May CAHN |

TROSPIUM CHLORIDE

TABLET;ORAL

TROSPIUM CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | CHARTWELL RX | 20MG | A215781 | 001 | Feb 16, 2022 | Sep CAHN |
| | AB | | ZAMEER PHARMS | 20MG | A215781 | 001 | Feb 16, 2022 | Jan CAHN |

UPADACITINIB

TABLET, EXTENDED RELEASE;ORAL

RINVOQ

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | + | ABBVIE | 15MG | N211675 | 001 | Aug 16, 2019 | Oct CFTG |
| >A> | AB | + | | 15MG | N211675 | 001 | Aug 16, 2019 | Oct CFTG |
| >A> | | + | | 15MG | N211675 | 001 | Aug 16, 2019 | Oct CTEC |
| >D> | | + | | 30MG | N211675 | 002 | Jan 14, 2022 | Oct CFTG |
| >A> | AB | + | | 30MG | N211675 | 002 | Jan 14, 2022 | Oct CFTG |
| >A> | | + | | 30MG | N211675 | 002 | Jan 14, 2022 | Oct CTEC |

>A> UPADACITINIB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | AUROBINDO PHARMA LTD | 15MG | A218866 | 001 | Oct 16, 2026 | Oct NFTG |
| >A> | | @ | | 15MG | A218866 | 001 | Oct 16, 2026 | Oct DISC |
| >A> | AB | | | 30MG | A218866 | 002 | Oct 16, 2026 | Oct NFTG |
| >A> | | @ | | 30MG | A218866 | 002 | Oct 16, 2026 | Oct DISC |

URSODIOL

CAPSULE;ORAL

URSODIOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ADAPTIS | 300MG | A212452 | 001 | Oct 30, 2019 | Sep CAHN |
| | AB | | ALLIED | 300MG | A214329 | 001 | Jul 28, 2021 | Jul CAHN |
| | | | LGM PHARMA | 200MG | A205789 | 001 | May 08, 2020 | Jun CHRS |
| | | | | 400MG | A205789 | 002 | May 08, 2020 | Jun CHRS |
| | AB | | PHARMAZONE | 300MG | A214329 | 001 | Jul 28, 2021 | Sep CAHN |
| | AB | | SENORES PHARMS | 300MG | A214329 | 001 | Jul 28, 2021 | Aug CAHN |
| | | | STRIDES PHARMA | 150MG | A210344 | 002 | Jan 16, 2026 | Jan NFTG |

VADADUSTAT

TABLET;ORAL

VAFSEO

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ + | AKEBIA | 450MG | N215192 | 003 | Mar 27, 2024 | Aug DISC |

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | ! | HETERO LABS LTD V | EQ 1GM BASE | A203047 | 002 | Apr 08, 2015 | Feb CHRS |

VALTREX

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | + | GLAXOSMITHKLINE | EQ 1GM BASE | N020487 | 002 | Jun 23, 1995 | Feb CHRS |

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | | ALEMBIC | 50MG/ML | A217267 | 001 | Oct 26, 2026 | Oct NEWA |
| | AB | | | MICRO LABS | 50MG/ML | A218838 | 001 | Mar 19, 2026 | Mar NEWA |

TABLET;ORAL

VALCYTE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | + | CHEPLAPHARM | EQ 450MG BASE | N021304 | 001 | Mar 29, 2001 | Aug DISC |

VALGANCICLOVIR HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | ! | HETERO LABS LTD V | EQ 450MG BASE | A205166 | 001 | Mar 18, 2016 | Aug CHRS |

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | | ADAPTIS | 250MG | A207611 | 001 | Aug 05, 2019 | Sep CAHN |

VALSARTAN

SOLUTION;ORAL

PREXXARTAN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | + | CARMEL BIOSCIENCES | 4MG/ML | N209139 | 001 | Dec 19, 2017 | Oct CTEC |
| >A> | AA | | + | | 4MG/ML | N209139 | 001 | Dec 19, 2017 | Oct CTEC |
| | AB | | + | | 4MG/ML | N209139 | 001 | Dec 19, 2017 | Jul CMFD |

VALSARTAN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | ! | NOVITIUM PHARMA | 4MG/ML | A214102 | 001 | Nov 02, 2021 | Oct CTEC |
| >A> | AA | | ! | | 4MG/ML | A214102 | 001 | Nov 02, 2021 | Oct CTEC |
| >D> | AB | | | RUBICON RESEARCH | 4MG/ML | A216460 | 001 | Jun 05, 2025 | Oct CTEC |
| >A> | AA | | | | 4MG/ML | A216460 | 001 | Jun 05, 2025 | Oct CTEC |
| | AB | | | | 4MG/ML | A216460 | 001 | Jun 05, 2025 | May CAHN |

TABLET;ORAL

VALSARTAN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | | ADAPTIS | 40MG | A205347 | 001 | Apr 09, 2018 | Sep CAHN |
| | AB | | | | 80MG | A205347 | 002 | Apr 09, 2018 | Sep CAHN |
| | AB | | | | 160MG | A205347 | 003 | Apr 09, 2018 | Sep CAHN |
| | AB | | | | 320MG | A205347 | 004 | Apr 09, 2018 | Sep CAHN |
| | AB | | | BOSTAL DRUG | 40MG | A205357 | 001 | Aug 11, 2026 | Jul NEWA |
| | AB | | | | 80MG | A205357 | 002 | Aug 11, 2026 | Jul NEWA |
| | AB | | | | 160MG | A205357 | 003 | Aug 11, 2026 | Jul NEWA |
| | AB | | | | 320MG | A205357 | 004 | Aug 11, 2026 | Jul NEWA |
| | AB | | | LAURUS | 40MG | A218897 | 001 | Apr 21, 2026 | Apr NEWA |
| | AB | | | | 80MG | A218897 | 002 | Apr 21, 2026 | Apr NEWA |
| | AB | | | | 160MG | A218897 | 003 | Apr 21, 2026 | Apr NEWA |
| | AB | | | | 320MG | A218897 | 004 | Apr 21, 2026 | Apr NEWA |
| | | @ | | LUPIN | 40MG | A201677 | 001 | Jan 05, 2015 | May DISC |
| | | @ | | | 80MG | A201677 | 002 | Jan 05, 2015 | May DISC |
| | | @ | | | 160MG | A201677 | 003 | Jan 05, 2015 | May DISC |
| | | @ | | | 320MG | A201677 | 004 | Jan 05, 2015 | May DISC |
| | AB | | | PHARMOBEDIENT | 40MG | A218897 | 001 | Apr 21, 2026 | Sep CAHN |
| | AB | | | | 80MG | A218897 | 002 | Apr 21, 2026 | Sep CAHN |
| | AB | | | | 160MG | A218897 | 003 | Apr 21, 2026 | Sep CAHN |
| | AB | | | | 320MG | A218897 | 004 | Apr 21, 2026 | Sep CAHN |
| | | @ | | RENATA | 40MG | A218169 | 001 | Aug 05, 2024 | Feb CAHN |
| | | @ | | | 80MG | A218169 | 002 | Aug 05, 2024 | Feb CAHN |
| | | @ | | | 160MG | A218169 | 003 | Aug 05, 2024 | Feb CAHN |
| | | @ | | | 320MG | A218169 | 004 | Aug 05, 2024 | Feb CAHN |
| | | @ | | SOMERSET THERAPS LLC | 40MG | A218169 | 001 | Aug 05, 2024 | Sep CAHN |
| | | @ | | | 80MG | A218169 | 002 | Aug 05, 2024 | Sep CAHN |
| | | @ | | | 160MG | A218169 | 003 | Aug 05, 2024 | Sep CAHN |
| | | @ | | | 320MG | A218169 | 004 | Aug 05, 2024 | Sep CAHN |

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | LUPIN | EQ 125MG BASE | A090439 | 001 | Jan 28, 2015 | May | DISC |
| @ | | EQ 250MG BASE | A090439 | 002 | Jan 28, 2015 | May | DISC |
| AB | PAI HOLDINGS | EQ 125MG BASE | A065478 | 001 | Apr 09, 2012 | Mar | CMFD |
| AB | | EQ 250MG BASE | A065478 | 002 | Apr 09, 2012 | Mar | CMFD |

FOR SOLUTION;ORAL

FIRVANQ KIT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | +! AZURITY | EQ 25MG BASE/ML | N208910 | 001 | Jan 26, 2018 | Apr | CTEC |
| AA | +! | EQ 50MG BASE/ML | N208910 | 002 | Jan 26, 2018 | Apr | CTEC |

VANCOMYCIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | ALKEM LABS LTD | EQ 25MG BASE/ML | A214913 | 001 | Nov 14, 2022 | Apr | CTEC |
| AA | | EQ 50MG BASE/ML | A214913 | 002 | Nov 14, 2022 | Apr | CTEC |
| AA | AUROBINDO PHARMA | EQ 25MG BASE/ML | A218130 | 001 | Aug 07, 2026 | Jul | NEWA |
| AA | | EQ 50MG BASE/ML | A218130 | 002 | Aug 07, 2026 | Jul | NEWA |

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | EUROFARMA | EQ 500MG BASE/VIAL | A065401 | 001 | Jun 30, 2008 | Feb | CAHN |
| AP | | EQ 1GM BASE/VIAL | A065401 | 002 | Jun 30, 2008 | Feb | CAHN |
| AP | HAINAN POLY | EQ 500MG BASE/VIAL | A212332 | 001 | Jun 12, 2019 | Jul | CAHN |
| AP | | EQ 1GM BASE/VIAL | A212332 | 002 | Jun 12, 2019 | Jul | CAHN |
| AP | | EQ 5GM BASE/VIAL | A215821 | 001 | Nov 18, 2021 | Jul | CAHN |
| AP | | EQ 10GM BASE/VIAL | A215821 | 002 | Nov 18, 2021 | Jul | CAHN |

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| ! | SAMSON MEDCL | EQ 100GM BASE | A091532 | 001 | Jan 06, 2016 | Jan | CHRS |
| | | EQ 100GM BASE | A091532 | 001 | Jan 06, 2016 | Jan | CTNA |

VARENICLINE TARTRATE

SPRAY;NASAL

TYRVAYA

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >A> +! | HARROW EYE | EQ 0.03MG BASE/SPRAY | N213978 | 001 | Oct 15, 2021 | Oct | CAHN |
| >D> +! | OYSTER POINT PHARMA | EQ 0.03MG BASE/SPRAY | N213978 | 001 | Oct 15, 2021 | Oct | CAHN |

TABLET;ORAL

VARENICLINE TARTRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | ADAPTIS | EQ 0.5MG BASE | A216615 | 001 | Apr 08, 2025 | Aug | CAHN |
| AB | | EQ 1MG BASE | A216615 | 002 | Apr 08, 2025 | Aug | CAHN |
| AB | PHARMAZONE | EQ 0.5MG BASE | A217115 | 001 | Jul 23, 2024 | Sep | CAHN |
| AB | | EQ 0.5MG BASE | A217151 | 001 | Jul 25, 2023 | Sep | CAHN |
| AB | | EQ 1MG BASE | A217115 | 002 | Jul 23, 2024 | Sep | CAHN |
| AB | | EQ 1MG BASE | A217151 | 002 | Jul 25, 2023 | Sep | CAHN |
| @ | PHARMOBEDIENT | EQ 0.5MG BASE | A202019 | 001 | Feb 28, 2024 | May | DISC |
| @ | | EQ 1MG BASE | A202019 | 002 | Feb 28, 2024 | Aug | DISC |
| AB | PIRAMAL | EQ 0.5MG BASE | A217115 | 001 | Jul 23, 2024 | Jan | CMFD |
| AB | | EQ 1MG BASE | A217115 | 002 | Jul 23, 2024 | Jan | CMFD |
| AB | SENORES PHARMS | EQ 0.5MG BASE | A217115 | 001 | Jul 23, 2024 | Sep | CAHN |
| AB | | EQ 0.5MG BASE | A217151 | 001 | Jul 25, 2023 | Sep | CAHN |
| AB | | EQ 1MG BASE | A217115 | 002 | Jul 23, 2024 | Sep | CAHN |
| AB | | EQ 1MG BASE | A217151 | 002 | Jul 25, 2023 | Sep | CAHN |
| AB | SOMERSET THERAPS LLC | EQ 0.5MG BASE | A219382 | 001 | Jul 06, 2026 | Jun | NEWA |
| AB | | EQ 1MG BASE | A219382 | 002 | Jul 06, 2026 | Jun | NEWA |
| AB | UMEDICA | EQ 0.5MG BASE | A218985 | 001 | Jan 09, 2026 | Jan | NEWA |
| AB | | EQ 1MG BASE | A218985 | 002 | Jan 09, 2026 | Jan | NEWA |

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOPRESSIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | EAGLE PHARMS | 20UNITS/ML (20UNITS/ML) | A211538 | 001 | Dec 15, 2021 | Mar | DISC |
| AP | SANDOZ | 20UNITS/ML (20UNITS/ML) | A212068 | 001 | May 06, 2026 | Apr | NEWA |
| AP | | 200UNITS/10ML (20UNITS/ML) | A212069 | 001 | May 06, 2026 | Apr | NFTG |

VASOPRESSIN IN DEXTROSE 5%

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | DR REDDYS | 40UNITS/100ML (0.4UNITS/ML) | A213988 | 002 | Jun 03, 2026 | May | NEWA |

VASOSTRICT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP +! | PH HEALTH | 200UNITS/10ML (20UNITS/ML) | N204485 | 002 | Dec 17, 2016 | Apr | CFTG |

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | ! | EUGIA PHARMA | 10MG/VIAL | A206670 | 001 | Dec 20, 2018 | May CHRS |
| AP | | ! | | 20MG/VIAL | A206670 | 002 | Dec 20, 2018 | May CHRS |
| AP | | | SUN PHARM | 10MG/VIAL | A079001 | 001 | Jun 17, 2009 | May CHRS |
| | | @ | | 20MG/VIAL | A079001 | 002 | Jun 17, 2009 | May DISC |

VENETOCLAX

TABLET;ORAL

VENCLEXTA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | + | ABBVIE | 10MG | N208573 | 001 | Apr 11, 2016 | May CFTG |
| AB | | + | | 50MG | N208573 | 002 | Apr 11, 2016 | May CFTG |
| AB | | +! | | 100MG | N208573 | 003 | Apr 11, 2016 | May CFTG |

VENETOCLAX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | | ALEMBIC | 10MG | A214747 | 001 | Oct 28, 2026 | Oct NEWA |
| >A> | AB | | | 50MG | A214747 | 002 | Oct 28, 2026 | Oct NEWA |
| >A> | AB | | | 100MG | A214747 | 003 | Oct 28, 2026 | Oct NEWA |
| | AB | | DR REDDYS | 10MG | A214733 | 001 | May 15, 2026 | May NFTG |
| | AB | | | 50MG | A214733 | 002 | May 15, 2026 | May NFTG |
| | AB | | | 100MG | A214733 | 003 | May 15, 2026 | May NFTG |

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | | ADAPTIS | EQ 37.5MG BASE | A203332 | 001 | Mar 12, 2020 | Sep CAHN |
| | AB | | | EQ 75MG BASE | A203332 | 002 | Mar 12, 2020 | Sep CAHN |
| | | | | EQ 100MG BASE | A203332 | 004 | Jul 14, 2026 | Sep CAHN |
| | AB | | | EQ 150MG BASE | A203332 | 003 | Mar 12, 2020 | Sep CAHN |
| | AB | | INVENTIA | EQ 37.5MG BASE | A203332 | 001 | Mar 12, 2020 | Jul CAHN |
| | AB | | | EQ 75MG BASE | A203332 | 002 | Mar 12, 2020 | Jul CAHN |
| | | | | EQ 100MG BASE | A203332 | 004 | Jul 14, 2026 | Jul CAHN |
| | AB | | | EQ 150MG BASE | A203332 | 003 | Mar 12, 2020 | Jul CAHN |
| | | | INVENTIA HLTHCARE | EQ 100MG BASE | A203332 | 004 | Jul 14, 2026 | Jul NFTG |
| | AB | | PLATINUM | EQ 37.5MG BASE | A201272 | 001 | Nov 23, 2018 | Apr CAHN |
| | AB | | | EQ 75MG BASE | A201272 | 002 | Nov 23, 2018 | Apr CAHN |
| | AB | | | EQ 150MG BASE | A201272 | 003 | Nov 23, 2018 | Apr CAHN |
| >A> | AB | | YICHANG HUMANWELL | EQ 37.5MG BASE | A220619 | 001 | Nov 06, 2026 | Oct NEWA |
| >A> | AB | | | EQ 75MG BASE | A220619 | 002 | Nov 06, 2026 | Oct NEWA |
| >A> | AB | | | EQ 150MG BASE | A220619 | 003 | Nov 06, 2026 | Oct NEWA |

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | ADAPTIS | EQ 75MG BASE | A213927 | 001 | Jan 21, 2021 | Mar DISC |
| | | @ | | EQ 150MG BASE | A209193 | 001 | Oct 31, 2019 | Sep DISC |
| | AB | | | EQ 150MG BASE | A209193 | 001 | Oct 31, 2019 | Sep CAHN |
| | | @ | | EQ 225MG BASE | A209193 | 002 | Oct 31, 2019 | Sep DISC |
| | AB | | | EQ 225MG BASE | A209193 | 002 | Oct 31, 2019 | Sep CAHN |
| | | @ | PHARMADAX | EQ 75MG BASE | A214423 | 001 | Jan 04, 2022 | Mar CAHN |
| | | @ | | EQ 150MG BASE | A214423 | 002 | Jan 04, 2022 | Mar CAHN |

VEPDEGESTRANT

TABLET;ORAL

VEPPANU

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + | ARVINAS OPERATIONS | 100MG | N219835 | 001 | May 01, 2026 | May NEWA |
| | | +! | | 200MG | N219835 | 002 | May 01, 2026 | May NEWA |
| | | + | RIGEL PHARMS | 100MG | N219835 | 001 | May 01, 2026 | Jun CAHN |
| | | +! | | 200MG | N219835 | 002 | May 01, 2026 | Jun CAHN |

VERAPAMIL HYDROCHLORIDE

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | | | KNACK | 2.5MG/ML | A220076 | 001 | Jul 22, 2026 | Jul NEWA |

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ | AMNEAL | 5MG/2ML (2.5MG/ML) | A210994 | 001 | Jul 13, 2018 | Mar DISC |
| | | @ | | 10MG/4ML (2.5MG/ML) | A210994 | 002 | Jul 13, 2018 | Mar DISC |
| | | @ | HOSPIRA | 5MG/2ML (2.5MG/ML) | A075136 | 001 | Oct 20, 1998 | Jun DISC |
| | | @ | | 10MG/4ML (2.5MG/ML) | A075136 | 001 | Oct 20, 1998 | Jun CPOT |

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | ADAPTIS | 500MG/PACKET | A214992 | 001 | May 13, 2021 | Aug | CAHN |
| @ | TEVA PHARMS USA | 500MG/PACKET | A209824 | 001 | Apr 23, 2018 | Jan | DISC |

VIGADRONE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AA | BORA | 500MG/PACKET | A210196 | 001 | Jun 21, 2018 | Jul | CAHN |

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | INGENUS PHARMS LLC | EQ 10MG BASE/ML | A208997 | 001 | Aug 05, 2019 | May | CAHN |

VORICONAZOLE

POWDER;INTRAVENOUS

VORICONAZOLE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | HAINAN POLY | 200MG/VIAL | A211661 | 001 | Nov 30, 2018 | Jul | CAHN |
| AP | ZHEJIANG NOVUS | 200MG/VIAL | A220078 | 001 | May 05, 2026 | Apr | NEWA |

XENON XE-133

GAS;INHALATION

XENON XE 133

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | SHINE | 10mCi/VIAL | N017284 | 001 | | Feb | CAHN |
| | | 20mCi/VIAL | N017284 | 002 | | Feb | CAHN |

ZALEPLON

CAPSULE;ORAL

ZALEPLON

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | HIKMA | 5MG | A078147 | 001 | Nov 25, 2008 | Sep | CAHN |
| @ | | 10MG | A078147 | 002 | Nov 25, 2008 | Sep | CAHN |

ZICONOTIDE ACETATE

INJECTABLE;INTRATHECAL

PRIALT

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | ESTEVE | 100MCG/1ML (100MCG/ML) | N021060 | 002 | Dec 28, 2004 | Apr | CAHN |
| @ | | 200MCG/2ML (100MCG/ML) | N021060 | 003 | Dec 28, 2004 | Apr | CAHN |
| +! | | 500MCG/20ML (25MCG/ML) | N021060 | 001 | Dec 28, 2004 | Apr | CAHN |
| +! | | 500MCG/5ML (100MCG/ML) | N021060 | 004 | Dec 28, 2004 | Apr | CAHN |

ZIDESAMTINIB

TABLET;ORAL

JIDEYTRO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| + | NUVALENT | 25MG | N220185 | 001 | Jul 22, 2026 | Jul | NEWA |
| +! | | 100MG | N220185 | 002 | Jul 22, 2026 | Jul | NEWA |

ZILGANERSEN SODIUM

SOLUTION;INTRATHECAL

ZANVASTRO

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | IONIS PHARMS INC | EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML) | N220210 | 001 | Sep 03, 2026 | Sep | NEWA |

ZILURGISERTIB FUMARATE

TABLET;ORAL

ATEBRIOZ

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | INCYTE CORP | EQ 25MG BASE | N221198 | 001 | Sep 25, 2026 | Sep | NEWA |
| +! | MIRUM | EQ 25MG BASE | N221198 | 001 | Sep 25, 2026 | Sep | CAHN |

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | STIRA | EQ 1MG ZINC/ML | A217625 | 001 | Apr 14, 2025 | Apr | CAHN |

ZINC SULFATE

SOLUTION;INTRAVENOUS

ZINC SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | NIVAGEN | EQ 10MG BASE/10ML (EQ 1MG BASE/ML) | A214597 | 001 | Jul 05, 2024 | Aug | CAHN |
| AP | | EQ 25MG BASE/5ML (EQ 5MG BASE/ML) | A214597 | 002 | Jul 05, 2024 | Aug | CAHN |
| AP | | EQ 30MG BASE/10ML (EQ 3MG BASE/ML) | A214597 | 003 | Jul 05, 2024 | Aug | CAHN |
| AP | STIRA | EQ 10MG BASE/10ML (EQ 1MG | A217624 | 001 | Jun 10, 2025 | Apr | CAHN |

SOLUTION;INTRAVENOUS
ZINC SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | | BASE/ML) | | | | |
| AP | | | EQ 25MG BASE/5ML (EQ 5MG BASE/ML) | A217624 | 002 | Jun 10, 2025 | Apr CAHN |
| AP | | | EQ 30MG BASE/10ML (EQ 3MG BASE/ML) | A217624 | 003 | Jun 10, 2025 | Apr CAHN |

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS
ZOLEDRONIC ACID

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | @ | ADAPTIS | EQ 4MG BASE/5ML | A208513 | 001 | May 15, 2019 | Aug CAHN |
| AP | | GLAND | EQ 4MG BASE/100ML | A219984 | 001 | Feb 05, 2026 | Jan NEWA |
| | @ | HOSPIRA INC | EQ 5MG BASE/100ML | A202837 | 001 | Apr 05, 2013 | Jan DISC |
| | @ | INGENUS PHARMS LLC | EQ 4MG BASE/5ML | A208968 | 001 | Feb 19, 2020 | Jun CAHN |

ZOLPIDEM TARTRATE

CAPSULE;ORAL
ZOLPIDEM TARTRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | ALMATICA | 7.5MG | N215721 | 001 | May 09, 2023 | May CFTG |
| AB | | UMEDICA LABS PVT | 7.5MG | A220717 | 001 | May 12, 2026 | May NFTG |

TABLET;ORAL
ZOLPIDEM TARTRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | PHARMAZONE | 5MG | A077214 | 001 | Apr 23, 2007 | Sep CAHN |
| | @ | | 5MG | A077985 | 001 | Apr 23, 2007 | Sep CAHN |
| AB | | | 10MG | A077214 | 002 | Apr 23, 2007 | Sep CAHN |
| | @ | | 10MG | A077985 | 002 | Apr 23, 2007 | Sep CAHN |
| | @ | SENORES PHARMS | 5MG | A077985 | 001 | Apr 23, 2007 | Jan CAHN |
| | @ | | 10MG | A077985 | 002 | Apr 23, 2007 | Jan CAHN |
| | @ | TEVA | 5MG | A076410 | 001 | Apr 23, 2007 | May DISC |
| | @ | | 10MG | A076410 | 002 | Apr 23, 2007 | May DISC |

TABLET, EXTENDED RELEASE;ORAL
ZOLPIDEM TARTRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | BRECKENRIDGE | 6.25MG | A213592 | 001 | Jun 04, 2020 | Jan CMFD |
| AB | | | 12.5MG | A213592 | 002 | Jun 04, 2020 | Jan CMFD |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **ACETAMINOPHEN** | | | | | | | |
| SUPPOSITORY;RECTAL | | | | | | | |
| ACEPHEN | | | | | | | |
| @ | COSETTE PHARMS NC | 120MG | A072218 | 001 | Mar 27, 1992 | May | CAHN |
| @ | | 325MG | A072344 | 001 | Mar 27, 1992 | May | CAHN |
| @ | | 650MG | A072237 | 001 | Mar 27, 1992 | May | CAHN |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| ACETAMINOPHEN | | | | | | | |
| | PHARMAZONE | 650MG | A215486 | 001 | Aug 25, 2021 | Sep | CAHN |
| **ACETAMINOPHEN; IBUPROFEN** | | | | | | | |
| TABLET;ORAL | | | | | | | |
| ACETAMINOPHEN AND IBUPROFEN | | | | | | | |
| | PHARMAZONE | 250MG;125MG | A216994 | 001 | Jul 10, 2023 | Sep | CAHN |
| **ACETAMINOPHEN; NAPROXEN SODIUM** | | | | | | | |
| TABLET;ORAL | | | | | | | |
| TYLENOL WITH NAPROXEN | | | | | | | |
| +! | KENVUE BRANDS | 325MG;110MG | N219962 | 001 | Jul 24, 2026 | Jul | NEWA |
| **ADAPALENE** | | | | | | | |
| GEL;TOPICAL | | | | | | | |
| ADAPALENE | | | | | | | |
| | RISING | 0.1% | A219565 | 001 | Jun 30, 2026 | Sep | CAHN |
| | THINQ PHARM-CRO PVT | 0.1% | A219565 | 001 | Jun 30, 2026 | Sep | CAHN |
| | UNIQUE | 0.1% | A219565 | 001 | Jun 30, 2026 | Jun | NEWA |
| **ADAPALENE; BENZOYL PEROXIDE** | | | | | | | |
| GEL;TOPICAL | | | | | | | |
| DIFFERIN EPIDUO | | | | | | | |
| +! | GALDERMA LABS LP | 0.1%;2.5% | N220736 | 001 | May 22, 2026 | May | NEWA |
| **ALCOHOL; CHLORHEXIDINE GLUCONATE** | | | | | | | |
| SOLUTION;TOPICAL | | | | | | | |
| AVAGARD | | | | | | | |
| +! | SOLVENTUM | 61%;1% | N021074 | 001 | Jun 07, 2001 | Apr | CAHN |
| **APRACLONIDINE HYDROCHLORIDE** | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| >A> BRYTLY | | | | | | | |
| >A> +! | ALCON LABS INC | EQ 0.125% BASE | N220341 | 001 | Oct 16, 2026 | Oct | NEWA |
| **AZELASTINE HYDROCHLORIDE** | | | | | | | |
| SPRAY, METERED;NASAL | | | | | | | |
| AZELASTINE HYDROCHLORIDE | | | | | | | |
| @ | AMNEAL | 0.2055MG/SPRAY | A216576 | 001 | Jun 05, 2024 | Feb | DISC |
| **CETIRIZINE HYDROCHLORIDE** | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| CETIRIZINE HYDROCHLORIDE ALLERGY | | | | | | | |
| | ONESOURCE | 10MG | A205291 | 001 | Jul 21, 2017 | Jul | CAHN |
| SOLUTION;ORAL | | | | | | | |
| CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY | | | | | | | |
| | PHARMAZONE | 5MG/5ML | A090474 | 002 | Mar 30, 2009 | Sep | CAHN |
| CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF | | | | | | | |
| | PHARMAZONE | 5MG/5ML | A090474 | 001 | Mar 30, 2009 | Sep | CAHN |
| TABLET;ORAL | | | | | | | |
| CETIRIZINE HYDROCHLORIDE ALLERGY | | | | | | | |
| @ | AMNEAL PHARMS NY | 5MG | A078780 | 001 | Jan 21, 2010 | Mar | DISC |
| @ | | 10MG | A078780 | 004 | Jan 21, 2010 | Mar | DISC |
| | PHARMAZONE | 5MG | A078933 | 001 | Jun 15, 2010 | Sep | CAHN |
| | | 10MG | A078933 | 002 | Jun 15, 2010 | Sep | CAHN |
| CETIRIZINE HYDROCHLORIDE HIVES | | | | | | | |
| | PHARMAZONE | 5MG | A078933 | 003 | Jun 15, 2010 | Sep | CAHN |
| | | 10MG | A078933 | 004 | Jun 15, 2010 | Sep | CAHN |
| CETIRIZINE HYDROCHLORIDE HIVES RELIEF | | | | | | | |
| @ | AMNEAL PHARMS NY | 5MG | A078780 | 003 | Jan 21, 2010 | Mar | DISC |
| @ | | 10MG | A078780 | 002 | Jan 21, 2010 | Mar | DISC |

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

DYNA-HEX 2

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | XTTRIUM | 2% | N019422 | 001 | Dec 17, 1985 | Feb | CTNA |

DYNA-HEX 4

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | XTTRIUM | 4% | N019125 | 001 | Dec 24, 1984 | Feb | CTNA |

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP S

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | SOLVENTUM | 2%;70% | N208288 | 001 | Aug 08, 2018 | Apr | CAHN |

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | ! | ENCUBE | 1% | A074165 | 001 | Jul 16, 1993 | Oct | CAHN |
| >A> | ! | | 1% | A074165 | 001 | Jul 16, 1993 | Oct | CAHN |
| | ! | | 1% | A074165 | 001 | Jul 16, 1993 | May | CAHN |

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

MUCINEX DM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| + | RECKITT BENCKISER | 30MG;600MG | N021620 | 002 | Apr 29, 2004 | Jun | CAHN |
| +! | | 60MG;1.2GM | N021620 | 001 | Apr 29, 2004 | Jun | CAHN |

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM

TABLET, EXTENDED RELEASE;ORAL

MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | RECKITT BENCKISER | 30MG;600MG;110MG | N217338 | 001 | Dec 22, 2025 | Jun | CAHN |

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| +! | RECKITT BENCKISER | EQ 30MG HYDROBROMIDE/5ML | N018658 | 001 | Oct 08, 1982 | Jun | CAHN |

DEXTROMETHORPHAN POLISTIREX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | AUROBINDO PHARMA LTD | EQ 30MG HYDROBROMIDE/5ML | A218417 | 001 | Apr 15, 2026 | Apr | NEWA |

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | ENCUBE | 1% | A210986 | 001 | Jan 27, 2020 | Oct | CAHN |
| >A> | | | 1% | A210986 | 001 | Jan 27, 2020 | Oct | CAHN |

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ONESOURCE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | A200888 | 001 | Mar 05, 2012 | Jul | CAHN |

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | AMNEAL PHARMS CO | 25MG;220MG | A209726 | 001 | Oct 23, 2018 | Mar | DISC |
| | MACLEODS PHARMS | 25MG;220MG | A211830 | 001 | Aug 22, 2019 | Sep | CAHN |

DOCOSANOL

CREAM;TOPICAL

DOCOSANOL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | KLM LABS PVT | 10% | A220017 | 001 | Jul 31, 2026 | Jul | NEWA |

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | PHARMAZONE | EQ 20MG BASE | A217264 | 001 | Sep 29, 2023 | Sep | CAHN |

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ | MYLAN | EQ 20MG BASE | A212088 | 001 | Jun 25, 2020 | Jun | DISC |

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | PHARMAZONE | 10MG | A217543 | 001 | Mar 08, 2023 | Sep | CAHN |
| | | 20MG | A217543 | 002 | Mar 08, 2023 | Sep | CAHN |

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | PHARMAZONE | 30MG | A079112 | 002 | Feb 08, 2012 | Sep | CAHN |
| @ | TEVA | 30MG | A076447 | 004 | Apr 13, 2011 | Mar | DISC |
| | TIME CAP LABS | 30MG | A079112 | 002 | Feb 08, 2012 | Mar | CAHN |

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | PHARMAZONE | 30MG | A079112 | 001 | Feb 08, 2012 | Sep | CAHN |
| @ | TEVA | 30MG | A076447 | 005 | Apr 13, 2011 | Mar | DISC |
| | TIME CAP LABS | 30MG | A079112 | 001 | Feb 08, 2012 | Mar | CAHN |

FEXOFENADINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | DR REDDYS | 60MG | A220413 | 001 | Jul 30, 2026 | Jul | NEWA |
| | | 180MG | A220413 | 002 | Jul 30, 2026 | Jul | NEWA |

FEXOFENADINE HYDROCHLORIDE ALLERGY

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | PHARMAZONE | 60MG | A079112 | 004 | Feb 08, 2012 | Sep | CAHN |
| | | 180MG | A079112 | 006 | Feb 08, 2012 | Sep | CAHN |
| @ | RISING | 60MG | A077081 | 006 | Jul 21, 2011 | Mar | DISC |
| @ | | 180MG | A077081 | 008 | Jul 21, 2011 | Mar | DISC |
| @ | TEVA | 60MG | A076447 | 006 | Apr 13, 2011 | Mar | DISC |
| @ | | 180MG | A076447 | 008 | Apr 13, 2011 | Mar | DISC |
| | TIME CAP LABS | 60MG | A079112 | 004 | Feb 08, 2012 | Mar | CAHN |
| | | 180MG | A079112 | 006 | Feb 08, 2012 | Mar | CAHN |

FEXOFENADINE HYDROCHLORIDE HIVES

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | PHARMAZONE | 60MG | A079112 | 003 | Feb 08, 2012 | Sep | CAHN |
| | | 180MG | A079112 | 005 | Feb 08, 2012 | Sep | CAHN |
| @ | RISING | 60MG | A077081 | 007 | Jul 21, 2011 | Mar | DISC |
| @ | | 180MG | A077081 | 009 | Jul 21, 2011 | Mar | DISC |
| @ | TEVA | 60MG | A076447 | 007 | Apr 13, 2011 | Mar | DISC |
| | TIME CAP LABS | 60MG | A079112 | 003 | Feb 08, 2012 | Mar | CAHN |
| | | 180MG | A079112 | 005 | Feb 08, 2012 | Mar | CAHN |

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | AUROBINDO PHARMA LTD | 180MG;240MG | A215232 | 001 | Apr 17, 2025 | Feb | CMFD |

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | GLENMARK PHARMS LTD | 0.05MG/SPRAY | A218742 | 001 | Mar 16, 2026 | Mar | NEWA |
| | GLENMARK SPECLT | 0.05MG/SPRAY | A218742 | 001 | Mar 16, 2026 | Apr | CAHN |
| | RUBICON RESEARCH | 0.05MG/SPRAY | A219060 | 001 | Aug 15, 2025 | May | CAHN |

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | PHARMAZONE | 600MG | A217780 | 001 | Aug 21, 2023 | Sep | CAHN |
| | | 1.2GM | A217780 | 002 | Aug 21, 2023 | Sep | CAHN |

MUCINEX

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| + | RECKITT BENCKISER | 600MG | N021282 | 001 | Jul 12, 2002 | Jun | CAHN |
| +! | | 1.2GM | N021282 | 002 | Dec 18, 2002 | Jun | CAHN |

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MUCINEX D

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| + | RECKITT BENCKISER | 600MG;60MG | N021585 | 001 | Jun 22, 2004 | Jun | CAHN |
| +! | | 1.2GM;120MG | N021585 | 002 | Jun 22, 2004 | Jun | CAHN |

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | ONESOURCE | EQ 200MG FREE ACID AND POTASSIUM SALT | A204469 | 001 | Mar 28, 2018 | Jul | CAHN |
| | PHARMAZONE | EQ 200MG FREE ACID AND POTASSIUM SALT | A079205 | 001 | Jun 26, 2009 | Sep | CAHN |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| SUSPENSION;ORAL | | | | | | | |
| IBUPROFEN | | | | | | | |
| | RUBICON RESEARCH | 100MG/5ML | A220239 | 001 | Mar 05, 2026 | Feb | NEWA |
| MOTRIN IB | | | | | | | |
| +! | KENVUE BRANDS | 200MG/10ML | N020516 | 002 | Jul 22, 2026 | Jul | NEWA |
| TABLET;ORAL | | | | | | | |
| IBUPROFEN | | | | | | | |
| @ | ALLIED | 200MG | A071870 | 001 | May 05, 1988 | Jul | CAHN |
| @ | AMNEAL PHARMS | 200MG | A079233 | 001 | Mar 18, 2014 | Apr | DISC |
| @ | AMNEAL PHARMS NY | 200MG | A071333 | 001 | Feb 17, 1987 | Mar | DISC |
| @ | CONTRACT PHARMACAL | 200MG | A071265 | 001 | Oct 15, 1986 | Sep | CAHN |
| @ | | 200MG | A071265 | 002 | Sep 10, 1987 | Sep | CAHN |
| | | 200MG | A072299 | 001 | Jul 01, 1988 | Sep | CAHN |
| @ | PH HEALTH | 200MG | A071229 | 001 | Apr 01, 1987 | May | DISC |
| @ | PHARMAZONE | 200MG | A071870 | 001 | May 05, 1988 | Sep | CAHN |
| | | 200MG | A091237 | 001 | Feb 08, 2011 | Sep | CAHN |
| | | 200MG | A091239 | 001 | Feb 01, 2011 | Sep | CAHN |
| @ | SENORES PHARMS | 200MG | A071870 | 001 | May 05, 1988 | Sep | CAHN |
| IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| IBUPROHM COLD AND SINUS | | | | | | | |
| @ | OHM LABS | 200MG;30MG | A074567 | 001 | Apr 17, 2001 | Jul | DISC |
| IODINE POVACRYLEX; ISOPROPYL ALCOHOL | | | | | | | |
| SPONGE;TOPICAL | | | | | | | |
| DURAPREP | | | | | | | |
| +! | SOLVENTUM | EQ 0.7% IODINE;74% (6ML) | N021586 | 001 | Sep 29, 2006 | Apr | CAHN |
| +! | | EQ 0.7% IODINE;74% (26ML) | N021586 | 002 | Sep 29, 2006 | Apr | CAHN |
| KETOTIFEN FUMARATE | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| KETOTIFEN FUMARATE | | | | | | | |
| @ | APOTEX INC | EQ 0.025% BASE | A077354 | 001 | May 09, 2006 | Apr | DISC |
| LOPERAMIDE HYDROCHLORIDE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| LOPERAMIDE HYDROCHLORIDE | | | | | | | |
| | ONESOURCE | 2MG | A213070 | 001 | Aug 11, 2021 | Jul | CAHN |
| | TARO | 2MG | A220722 | 001 | Sep 30, 2026 | Sep | NEWA |
| TABLET;ORAL | | | | | | | |
| LOPERAMIDE HYDROCHLORIDE | | | | | | | |
| | PHARMAZONE | 2MG | A220153 | 001 | Nov 17, 2025 | Sep | CAHN |
| LORATADINE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| LORATADINE | | | | | | | |
| @ | ONESOURCE | 10MG | A211926 | 001 | Jan 15, 2020 | Jul | CAHN |
| | PHARMAZONE | 10MG | A206214 | 001 | Sep 23, 2016 | Sep | CAHN |
| TABLET;ORAL | | | | | | | |
| LORATADINE | | | | | | | |
| | ADAPTIS | 10MG | A207569 | 001 | Mar 12, 2019 | Aug | CAHN |
| @ | ALLIED | 10MG | A075790 | 001 | Nov 07, 2008 | Jul | CAHN |
| | GUARDIAN DRUG | 10MG | A207569 | 001 | Mar 12, 2019 | Aug | CAHN |
| @ | PHARMAZONE | 10MG | A075790 | 001 | Nov 07, 2008 | Sep | CAHN |
| | | 10MG | A219223 | 001 | Nov 21, 2024 | Sep | CAHN |
| @ | SENORES PHARMS | 10MG | A075790 | 001 | Nov 07, 2008 | Sep | CAHN |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | | | |
| LORATADINE | | | | | | | |
| | INSTAPILL | 5MG | A212795 | 001 | Sep 18, 2020 | Feb | CAHN |
| | | 10MG | A213294 | 001 | Oct 30, 2020 | Feb | CAHN |
| LORATADINE; PSEUDOEPHEDRINE SULFATE | | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| LORATADINE AND PSEUDOEPHEDRINE SULFATE | | | | | | | |
| | DR REDDYS | 5MG;120MG | A220448 | 001 | Aug 06, 2026 | Jul | NEWA |
| >A> | | 10MG;240MG | A220432 | 001 | Oct 16, 2026 | Oct | NEWA |

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | +! | HISAMITSU PHARM CO | 3%;10% | N022029 | 002 | Nov 05, 2012 | Mar | CHRS |

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE 7

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | ENCUBE | 2% | A074164 | 001 | Mar 29, 1996 | Oct | CAHN |
| >A> | | | 2% | A074164 | 001 | Mar 29, 1996 | Oct | CAHN |
| | | | 2% | A074164 | 001 | Mar 29, 1996 | May | CAHN |

MICONAZOLE NITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | 2% | A074366 | 001 | Feb 22, 1996 | Jun | CAHN |

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | COSETTE PHARMS NC | 2%,200MG | A074926 | 001 | Apr 16, 1999 | May | CAHN |

MICONAZOLE 7 COMBINATION PACK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | COSETTE PHARMS NC | 2%,100MG | A076585 | 001 | Mar 26, 2004 | Jun | CAHN |

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | COSETTE PHARMS NC | 100MG | A073507 | 001 | Nov 19, 1993 | May | CAHN |
| | @ | | 100MG | A074414 | 001 | Apr 30, 1997 | Jun | CAHN |

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | AUROBINDO PHARMA LTD | 2% | A074767 | 001 | Feb 28, 1997 | Jul | CMFD |

MINOXIDIL (FOR WOMEN)

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | AUROBINDO PHARMA LTD | 2% | A074767 | 002 | Nov 25, 1997 | Jul | CMFD |

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

REXTOVY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | +! | AMPHASTAR PHARMS INC | 4MG/SPRAY | N208969 | 001 | Mar 07, 2023 | Oct | DISC |
| >A> | @ + | | 4MG/SPRAY | N208969 | 001 | Mar 07, 2023 | Oct | DISC |
| | +! | | 4MG/SPRAY | N208969 | 001 | Mar 07, 2023 | Jun | CMKT |

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | ONESOURCE | EQ 200MG BASE | A215472 | 001 | Aug 17, 2022 | Jul | CAHN |

TABLET;ORAL

NAPROXEN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | PHARMAZONE | 220MG | A090545 | 001 | Mar 16, 2011 | Sep | CAHN |

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

HABITROL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | DR REDDYS LABS SA | EQ 2MG BASE | A215276 | 001 | Jul 17, 2025 | Jul | CTNA |
| | | | EQ 4MG BASE | A215276 | 002 | Jul 17, 2025 | Jul | CTNA |

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | ALEMBIC | EQ 0.7% BASE | A217856 | 001 | Nov 03, 2026 | Oct | NEWA |
| | @ | FDC LTD | EQ 0.2% BASE | A217051 | 001 | Jul 14, 2025 | Feb | DISC |

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | AUROBINDO PHARMA LTD | EQ 20MG BASE | A213201 | 001 | Apr 28, 2023 | Sep | CMFD |

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | ! | P AND L | EQ 20MG BASE | A206582 | 001 | Jun 01, 2020 | Sep | CHRS |
| | | PHARMAZONE | EQ 20MG BASE | A218829 | 001 | Aug 07, 2025 | Sep | CAHN |

PRILOSEC OTC

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | ASTRAZENECA | EQ 20MG BASE | N021229 | 001 | Jun 20, 2003 | Sep | CHRS |

PERMETHRIN

LOTION;TOPICAL

PERMETHRIN

| | | | | | | |
|---|---|---|---|---|---|---|
| @ | PERRIGO NEW YORK | 1% | A076090 | 001 | Dec 20, 2001 | Feb DISC |

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

| | | | | | | |
|---|---|---|---|---|---|---|
| | ALLIED | 17GM/SCOOPFUL | A090812 | 001 | Oct 07, 2009 | Apr CAHN |
| | LNK INTL INC | 17GM/SCOOPFUL | A217505 | 001 | Jul 29, 2026 | Jul NEWA |
| | | 17GM/PACKET | A217505 | 002 | Jul 29, 2026 | Jul NEWA |
| | PHARMAZONE | 17GM/SCOOPFUL | A090812 | 001 | Oct 07, 2009 | Sep CAHN |
| | POINTVIEW HLDINGS | 17GM/SCOOPFUL | A090812 | 001 | Oct 07, 2009 | Jun CAHN |

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| @ | RISING | EQ 75MG BASE | A075497 | 001 | Jan 14, 2000 | Mar CAHN |

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | AUROBINDO PHARMA LTD | 0.055MG/SPRAY | A220110 | 001 | Aug 11, 2026 | Jul NEWA |

# DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

## CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2026

NO OCTOBER 2026 APPROVALS

# ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

# DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 2026 APPROVALS

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ABEMACICLIB - VERZENIO | | | | | | |
| N 208716 001 >A> | 11634426 | Jul 11, 2039 | U-4614 | | | |
| ABEMACICLIB - VERZENIO | | | | | | |
| N 208716 002 >A> | 11634426 | Jul 11, 2039 | U-4614 | | | |
| ABEMACICLIB - VERZENIO | | | | | | |
| N 208716 003 >A> | 11634426 | Jul 11, 2039 | U-4614 | | | |
| ABEMACICLIB - VERZENIO | | | | | | |
| N 208716 004 >A> | 11634426 | Jul 11, 2039 | U-4614 | | | |
| ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA | | | | | | |
| N 216793 001 | 11207311 | Jul 28, 2037 | U-2830 | | I-980 | Dec 12, 2028 |
| | 11207311 | Jul 28, 2037 | U-4368 | | | |
| | 11673877 | Mar 27, 2038 | DS DP U-2830 | | | |
| | 11673877 | Mar 27, 2038 | DS DP U-4368 | | | |
| | 11986468 | Jul 28, 2037 | U-2830 | | | |
| | 11986468 | Jul 28, 2037 | U-4368 | | | |
| | 11986469 | Jul 28, 2037 | U-2830 | | | |
| | 11986469 | Jul 28, 2037 | U-4368 | | | |
| | 11986470 | Jul 28, 2037 | U-4368 | | | |
| | 11992486 | Jul 28, 2037 | U-2830 | | | |
| | 11992486 | Jul 28, 2037 | U-4368 | | | |
| | 12383543 | Jul 28, 2037 | U-2830 | | | |
| | 12383543 | Jul 28, 2037 | U-4368 | | | |
| | 12734180 | Sep 30, 2043 | U-4608 | | | |
| | 12734180 | Sep 30, 2043 | U-4609 | | | |
| | 8071579 | Aug 12, 2027 | U-2830 | | | |
| | 8071579 | Aug 12, 2027 | U-4368 | | | |
| | 8143241 | Aug 12, 2027 | U-2830 | | | |
| | 8143241 | Aug 12, 2027 | U-4368 | | | |
| | 8859562 | Aug 04, 2031 | U-2830 | | | |
| | 8859562 | Aug 04, 2031 | U-4368 | | | |
| ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA | | | | | | |
| N 216793 002 | 11207311 | Jul 28, 2037 | U-2830 | | I-980 | Dec 12, 2028 |
| | 11207311 | Jul 28, 2037 | U-4368 | | | |
| | 11673877 | Mar 27, 2038 | DS DP U-2830 | | | |
| | 11673877 | Mar 27, 2038 | DS DP U-4368 | | | |
| | 11986468 | Jul 28, 2037 | U-2830 | | | |
| | 11986468 | Jul 28, 2037 | U-4368 | | | |
| | 11986469 | Jul 28, 2037 | U-2830 | | | |
| | 11986469 | Jul 28, 2037 | U-4368 | | | |
| | 11986470 | Jul 28, 2037 | U-4368 | | | |
| | 11992486 | Jul 28, 2037 | U-2830 | | | |
| | 11992486 | Jul 28, 2037 | U-4368 | | | |
| | 12383543 | Jul 28, 2037 | U-2830 | | | |
| | 12383543 | Jul 28, 2037 | U-4368 | | | |
| | 12734180 | Sep 30, 2043 | U-4608 | | | |
| | 12734180 | Sep 30, 2043 | U-4609 | | | |
| | 8071579 | Aug 12, 2027 | U-2830 | | | |
| | 8071579 | Aug 12, 2027 | U-4368 | | | |
| | 8143241 | Aug 12, 2027 | U-2830 | | | |
| | 8143241 | Aug 12, 2027 | U-4368 | | | |
| | 8859562 | Aug 04, 2031 | U-2830 | | | |
| | 8859562 | Aug 04, 2031 | U-4368 | | | |
| ACALABRUTINIB - CALQUENCE | | | | | | |
| N 210259 001 | 11166951 | Aug 11, 2035 | U-4426 | | D-200 | Feb 19, 2029 |
| | 11166951 | Aug 11, 2035 | U-4427 | | | |
| | 11166951 | Aug 11, 2035 | U-4428 | | | |
| | 11166951 | Aug 11, 2035 | U-4429 | | | |
| | 11166951 | Aug 11, 2035 | U-4430 | | | |
| | 11166951 | Aug 11, 2035 | U-4431 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| **ACALABRUTINIB MALEATE - CALQUENCE** | | | | | | | |
| N 216387 | 001 | 11166951 | Aug 11, 2035 | U-4426 | | D-200 | Feb 19, 2029 |
| | | 11166951 | Aug 11, 2035 | U-4427 | | | |
| | | 11166951 | Aug 11, 2035 | U-4428 | | | |
| | | 11166951 | Aug 11, 2035 | U-4429 | | | |
| | | 11166951 | Aug 11, 2035 | U-4430 | | | |
| | | 11166951 | Aug 11, 2035 | U-4431 | | | |
| **ACECLIDINE HYDROCHLORIDE - VIZZ** | | | | | | | |
| N 218585 | 001 | 12533347 | Oct 08, 2039 | U-3741 | | | |
| | | 12653779 | Jun 18, 2035 | U-3741 | | | |
| **ACETAMINOPHEN; NAPROXEN SODIUM - TYLENOL WITH NAPROXEN** | | | | | | | |
| N 219962 | 001 | | | | | NP | Jul 24, 2029 |
| **ACORAMIDIS HYDROCHLORIDE - ATTRUBY** | | | | | | | |
| N 216540 | 001 | 12539290 | Aug 16, 2039 | DP | | | |
| **ADAGRASIB - KRAZATI** | | | | | | | |
| N 216340 | 001 | 12653789 | Aug 21, 2043 | DP | | | |
| **ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CABTREO** | | | | | | | |
| N 216632 | 001 | 12616710 | Jul 31, 2040 | DP | | | |
| **AFICAMTEN - MYQORZO** | | | | | | | |
| N 219083 | 001 | 10836755 | Jan 18, 2039 | DS DP U-4371 | | | |
| | | 12370179 | Jul 15, 2042 | U-4371 | | | |
| **AFICAMTEN - MYQORZO** | | | | | | | |
| N 219083 | 002 | 10836755 | Jan 18, 2039 | DS DP U-4371 | | | |
| | | 12370179 | Jul 15, 2042 | U-4371 | | | |
| **AFICAMTEN - MYQORZO** | | | | | | | |
| N 219083 | 003 | 10836755 | Jan 18, 2039 | DS DP U-4371 | | | |
| | | 12370179 | Jul 15, 2042 | U-4371 | | | |
| **AFICAMTEN - MYQORZO** | | | | | | | |
| N 219083 | 004 | 10836755 | Jan 18, 2039 | DS DP U-4371 | | | |
| | | 12370179 | Jul 15, 2042 | U-4371 | | | |
| **ALBUTEROL SULFATE - ALBUTEROL SULFATE** | | | | | | | |
| A 219409 | 001 | | | | | CGT | Dec 19, 2026 |
| **ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K - MULTIPLE VITAMINS INJECTION ADULT** | | | | | | | | |
| A 210672 | 001 | | | | | CGT | Dec 01, 2026 |
| **AMIFAMPRIDINE PHOSPHATE - FIRDAPSE** | | | | | | | |
| N 208078 | 001 | | | | | ODE-553 | Sep 29, 2029 |
| **AMIKACIN SULFATE - ARIKAYCE KIT** | | | | | | | |
| N 207356 | 001 | 12616708 | May 15, 2035 | U-2414 | | | |
| **AMIODARONE HYDROCHLORIDE - NEXTERONE** | | | | | | | |
| N 022325 | 002 | 10117951 | Mar 13, 2029 | DP | | | |
| | | 8410077 | Mar 13, 2029 | DP | | | |
| | | 9200088 | Mar 13, 2029 | DP | | | |
| | | 9493582 | Feb 27, 2033 | DP | | | |
| | | 9750822 | Mar 13, 2029 | DP | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| **AMIODARONE HYDROCHLORIDE - NEXTERONE** | | | | | | |
| N 022325 003 | 10117951 | Mar 13, 2029 | DP | | | |
| | 8410077 | Mar 13, 2029 | DP | | | |
| | 9200088 | Mar 13, 2029 | DP | | | |
| | 9493582 | Feb 27, 2033 | DP | | | |
| | 9750822 | Mar 13, 2029 | DP | | | |
| **AMLODIPINE BENZOATE - KATERZIA** | | | | | | |
| N 211340 001 | 12721843 | Oct 06, 2037 | DP | | | |
| **AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK** | | | | | | |
| N 219423 003 | 12673047 | Jan 23, 2038 | DP | | | |
| **AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK** | | | | | | |
| N 215152 001 | 7977488 | Apr 10, 2030 | DS | | | |
| **AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5** | | | | | | |
| N 210526 001 | 12734132 | Sep 24, 2038 | | | U-3538 | |
| **AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10** | | | | | | |
| N 210526 002 | 12734132 | Sep 24, 2038 | | | U-3538 | |
| **AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15** | | | | | | |
| N 210526 003 | 12734132 | Sep 24, 2038 | | | U-3538 | |
| **AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20** | | | | | | |
| N 210526 004 | 12734132 | Sep 24, 2038 | | | U-3538 | |
| **APALUTAMIDE - ERLEADA** | | | | | | |
| N 210951 001 | 11723898 | Jan 14, 2041 | | | U-4449 | |
| | 12303497 | Jan 30, 2040 | | | U-4448 | |
| | 12303497 | Jan 30, 2040 | | | U-4494 | |
| | 8445507 | Feb 14, 2032 | DS DP | | U-2237 | |
| | 8445507 | Feb 14, 2032 | DS DP | | U-2624 | |
| | RE50642 | Sep 23, 2033 | | | U-4450 | |
| **APALUTAMIDE - ERLEADA** | | | | | | |
| N 210951 002 | 11723898 | Jan 14, 2041 | | | U-4449 | |
| | 12303497 | Jan 30, 2040 | | | U-4448 | |
| | 12303497 | Jan 30, 2040 | | | U-4494 | |
| >A> | 12746230 | Feb 15, 2044 | DP | | U-2237 | |
| >A> | 12746230 | Feb 15, 2044 | DP | | U-2624 | |
| | 8445507 | Feb 14, 2032 | DS DP | | U-2237 | |
| | 8445507 | Feb 14, 2032 | DS DP | | U-2624 | |
| | RE50642 | Sep 23, 2033 | | | U-4450 | |
| **APOMORPHINE HYDROCHLORIDE - ONAPGO** | | | | | | |
| N 214056 001 | | | | | >A> ODE-559 | Feb 03, 2032 |
| **APREMILAST - OTEZLA** | | | | | | |
| N 205437 001 | 12576034 | Nov 30, 2033 | DP | | U-1858 | |
| | 12576034 | Nov 30, 2033 | DP | | U-4290 | |
| | 12576034 | Nov 30, 2033 | DP | | U-4291 | |
| | 12576034*PED | May 30, 2034 | | | | |
| **APREMILAST - OTEZLA** | | | | | | |
| N 205437 002 | 12576034 | Nov 30, 2033 | DP | | U-1858 | |
| | 12576034 | Nov 30, 2033 | DP | | U-4290 | |
| | 12576034 | Nov 30, 2033 | DP | | U-4291 | |
| | 12576034*PED | May 30, 2034 | | | | |
| **APREMILAST - OTEZLA** | | | | | | |
| N 205437 003 | 12576034 | Nov 30, 2033 | DP | | U-1858 | |
| | 12576034 | Nov 30, 2033 | DP | | U-4290 | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 205437 003 | 12576034 | Nov 30, 2033 | DP U-4291 | | | |
| | 12576034*PED | May 30, 2034 | | | | |
| ARIMOCLOMOL CITRATE - MIPLYFFA | | | | | | |
| N 214927 001 | 11707456 | Nov 19, 2041 | DS DP U-4021 | | | |
| ARIMOCLOMOL CITRATE - MIPLYFFA | | | | | | |
| N 214927 002 | 11707456 | Nov 19, 2041 | DS DP U-4021 | | | |
| ARIMOCLOMOL CITRATE - MIPLYFFA | | | | | | |
| N 214927 003 | 11707456 | Nov 19, 2041 | DS DP U-4021 | | | |
| ARIMOCLOMOL CITRATE - MIPLYFFA | | | | | | |
| N 214927 004 | 11707456 | Nov 19, 2041 | DS DP U-4021 | | | |
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N 202971 001 | 12691056 | Apr 01, 2041 | U-3245 | | | |
| | 12691056 | Apr 01, 2041 | U-814 | | | |
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N 202971 002 | 12691056 | Apr 01, 2041 | U-3245 | | | |
| | 12691056 | Apr 01, 2041 | U-814 | | | |
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N 202971 003 | 12691056 | Apr 01, 2041 | U-3245 | | | |
| | 12691056 | Apr 01, 2041 | U-814 | | | |
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N 202971 004 | 12691056 | Apr 01, 2041 | U-3245 | | | |
| | 12691056 | Apr 01, 2041 | U-814 | | | |
| ARIPIPRAZOLE LAUROXIL - ARISTADA | | | | | | |
| N 207533 001 | 11097006 | Sep 19, 2033 | DP U-764 | | | |
| | 11969469 | Apr 06, 2034 | DP | | | |
| | 12629366 | Dec 06, 2032 | DP U-764 | | | |
| | 12653822 | Mar 19, 2035 | U-2402 | | | |
| ARIPIPRAZOLE LAUROXIL - ARISTADA | | | | | | |
| N 207533 002 | 11097006 | Sep 19, 2033 | DP U-764 | | | |
| | 11969469 | Apr 06, 2034 | DP | | | |
| | 12629366 | Dec 06, 2032 | DP U-764 | | | |
| | 12653822 | Mar 19, 2035 | U-2402 | | | |
| ARIPIPRAZOLE LAUROXIL - ARISTADA | | | | | | |
| N 207533 003 | 11097006 | Sep 19, 2033 | DP U-764 | | | |
| | 11969469 | Apr 06, 2034 | DP | | | |
| | 12629366 | Dec 06, 2032 | DP U-764 | | | |
| | 12653822 | Mar 19, 2035 | U-2402 | | | |
| ARIPIPRAZOLE LAUROXIL - ARISTADA | | | | | | |
| N 207533 004 | 11097006 | Sep 19, 2033 | DP U-764 | | | |
| | 11969469 | Apr 06, 2034 | DP | | | |
| | 12629366 | Dec 06, 2032 | DP U-764 | | | |
| | 12653822 | Mar 19, 2035 | U-2402 | | | |
| ARTESUNATE - ARTESUNATE | | | | | | |
| N 213036 001 | 12390442 | Feb 16, 2044 | U-4433 | | | |
| ARTICAINE HYDROCHLORIDE - CYKLX | | | | | | |
| N 218643 001 | 11096922 | Mar 27, 2039 | DP U-4423 | | | |
| | 11826347 | Mar 27, 2039 | DP U-4423 | | | |
| | 12403126 | Mar 27, 2039 | DP U-4422 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| **ASCORBIC ACID - ASCORBIC ACID** | | | | | | | |
| A 220873 001 | | | | | | >A> CGT | Apr 24, 2027 |
| **ASCORBIC ACID - ASCORBIC ACID** | | | | | | | |
| A 220873 002 | | | | | | >A> CGT | Apr 24, 2027 |
| **ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K - MULTIPLE VITAMINS INJECTION PEDIATRIC** | | | | | | | |
| A 210671 001 | | | | | | CGT | Dec 21, 2026 |
| **ATOGEPANT - QULIPTA** | | | | | | | |
| N 215206 001 | | 12622897 | Sep 27, 2042 | | U-4536 | | |
| | | 8754096 | Sep 28, 2035 | DS DP | U-3534 | | |
| **ATOGEPANT - QULIPTA** | | | | | | | |
| N 215206 002 | | 12622897 | Sep 27, 2042 | | U-4536 | | |
| | | 8754096 | Sep 28, 2035 | DS DP | U-3534 | | |
| **ATOGEPANT - QULIPTA** | | | | | | | |
| N 215206 003 | | 8754096 | Sep 28, 2035 | DS DP | U-3534 | | |
| **ATORVASTATIN CALCIUM - ATORVALIQ** | | | | | | | |
| N 213260 001 | | 12599553 | Jun 07, 2037 | DP | | | |
| | >A> | 12758492 | Jun 07, 2037 | DP | | | |
| **ATRASENTAN HYDROCHLORIDE - VANRAFIA** | | | | | | | |
| N 219208 001 | | 12521369 | Mar 02, 2041 | | U-3980 | | |
| | | 12582631 | Mar 25, 2043 | | U-3980 | | |
| **AVACINCAPTAD PEGOL SODIUM - IZERVAY** | | | | | | | |
| N 217225 001 | | 7579456 | Feb 14, 2027 | DS | | | |
| | >A> | 8236773 | Nov 11, 2027 | | U-3673 | | |
| | | 9617546 | Feb 14, 2027 | DS | U-3673 | | |
| **AVACOPAN - TAVNEOS** | | | | | | | |
| N 214487 001 | | 8906938 | Jan 06, 2034 | DS DP | | | |
| **AVAPRITINIB - AYVAKIT** | | | | | | | |
| N 212608 005 | >A> | 11999744 | Apr 10, 2040 | | U-3168 | | |
| | >A> | 11999744 | Apr 10, 2040 | | U-3506 | | |
| | >A> | 9200002 | Oct 15, 2034 | DS DP | U-3168 | | |
| | >A> | 9200002 | Oct 15, 2034 | DS DP | U-3506 | | |
| | >A> | 9944651 | Oct 15, 2034 | DS DP | U-3168 | | |
| | >A> | 9944651 | Oct 15, 2034 | DS DP | U-3506 | | |
| | >A> | 9994575 | Oct 15, 2034 | DS DP | U-3168 | | |
| | >A> | 9994575 | Oct 15, 2034 | DS DP | U-3506 | | |
| **AVATROMBOPAG MALEATE - DOPTELET** | | | | | | | |
| N 210238 001 | | | | | | ODE-548 | Jul 24, 2032 |
| **AVATROMBOPAG MALEATE - DOPTELET SPRINKLE** | | | | | | | |
| N 219696 001 | | | | | | ODE-548 | Jul 24, 2032 |
| **AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)** | | | | | | | |
| N 219616 001 | | 12509450 | Dec 29, 2042 | DP | | ODE-525 | May 08, 2032 |
| **AXITINIB - INLYTA** | | | | | | | |
| N 202324 001 | | 12534530 | Feb 03, 2035 | | U-4411 | | |
| | | 12534530 | Feb 03, 2035 | | U-4412 | | |
| | | 12534530*PED | Aug 03, 2035 | | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| AXITINIB - INLYTA | | | | | | | |
| N 202324 | 002 | 12534530 | Feb 03, 2035 | U-4411 | | | |
| | | 12534530 | Feb 03, 2035 | U-4412 | | | |
| | | 12534530*PED | Aug 03, 2035 | | | | |
| AZILSARTAN KAMEDOXOMIL - AZILSARTAN MEDOXOMIL | | | | | | | |
| A 214489 | 001 | | | | | PC | Dec 12, 2026 |
| AZILSARTAN KAMEDOXOMIL - AZILSARTAN MEDOXOMIL | | | | | | | |
| A 214489 | 002 | | | | | PC | Dec 12, 2026 |
| BALOXAVIR MARBOXIL - XOFLUZA | | | | | | | |
| N 210854 | 001 | 8987441 | Oct 24, 2032 | DS DP | | | |
| BALOXAVIR MARBOXIL - XOFLUZA | | | | | | | |
| N 210854 | 002 | 8987441 | Oct 24, 2032 | DS DP | | | |
| BALOXAVIR MARBOXIL - XOFLUZA | | | | | | | |
| N 210854 | 003 | 8987441 | Oct 24, 2032 | DS DP | | | |
| BALOXAVIR MARBOXIL - XOFLUZA | | | | | | | |
| N 214410 | 001 | 8987441 | Oct 24, 2032 | DS DP | | | |
| BALOXAVIR MARBOXIL - XOFLUZA | | | | | | | |
| N 214410 | 002 | 8987441 | Oct 24, 2032 | DS DP | | M-187 | Dec 19, 2027 |
| BALOXAVIR MARBOXIL - XOFLUZA | | | | | | | |
| N 214410 | 003 | 8987441 | Oct 24, 2032 | DS DP | | M-187 | Dec 19, 2027 |
| BARICITINIB - OLUMIANT | | | | | | | |
| N 207924 | 001 | >A> 11806555 | Nov 02, 2031 | U-4625 | | >A> NPP | Sep 25, 2029 |
| | | >A> 9737469 | Nov 02, 2031 | U-4625 | | | |
| BARICITINIB - OLUMIANT | | | | | | | |
| N 207924 | 002 | | | | | >A> NPP | Sep 25, 2029 |
| BARICITINIB - OLUMIANT | | | | | | | |
| N 207924 | 003 | >A> 11806555 | Nov 02, 2031 | U-4625 | | >A> NPP | Sep 25, 2029 |
| | | >A> 9737469 | Nov 02, 2031 | U-4625 | | | |
| BAXDROSTAT - BAXFENDY | | | | | | | |
| N 219878 | 001 | 9353081 | Feb 04, 2033 | DS DP | | NCE | May 15, 2031 |
| BAXDROSTAT - BAXFENDY | | | | | | | |
| N 219878 | 002 | 9353081 | Feb 04, 2033 | DS DP | | NCE | May 15, 2031 |
| BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - TRIMBOW | | | | | | | |
| N 219622 | 001 | 10159645 | Dec 23, 2030 | DP U-4538 | | NP | May 14, 2029 |
| | | 10617638 | Dec 23, 2034 | DP U-4538 | | | |
| | | 10806701 | Dec 23, 2030 | DP | | | |
| | | 11389401 | Dec 23, 2030 | DP | | | |
| | | 11590074 | Dec 23, 2030 | U-4538 | | | |
| | | 12357568 | Dec 23, 2030 | DP U-4538 | | | |
| BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - TRIMBOW | | | | | | | |
| N 219622 | 002 | 10159645 | Dec 23, 2030 | DP U-4538 | | NP | May 14, 2029 |
| | | 10617638 | Dec 23, 2034 | DP U-4538 | | | |
| | | 10806701 | Dec 23, 2030 | DP | | | |
| | | 11389401 | Dec 23, 2030 | DP | | | |
| | | 11590074 | Dec 23, 2030 | U-4538 | | | |
| | | 12357568 | Dec 23, 2030 | DP U-4538 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BEDAQUILINE FUMARATE - SIRTURO | | | | | | | |
| N 204384 | 001 | | | | | NPP | Jul 28, 2028 |
| BEDAQUILINE FUMARATE - SIRTURO | | | | | | | |
| N 204384 | 002 | | | | | NPP | Jul 28, 2028 |
| BELUMOSUDIL MESYLATE - REZUROCK | | | | | | | |
| N 214783 | 001 | >A> 12766143 | Jul 14, 2042 | U-4629 | | | |
| | | >A> 12766143 | Jul 14, 2042 | U-4630 | | | |
| BELZUTIFAN - WELIREG | | | | | | | |
| N 215383 | 001 | 10335388 | Apr 14, 2036 | U-4565 | | >A> I-1001 | Sep 24, 2029 |
| | | >A> 9908845 | Sep 05, 2034 | DS DP U-3201 | | I-994 | Jun 12, 2029 |
| | | >A> 9908845 | Sep 05, 2034 | DS DP U-4176 | | | |
| | | >A> 9908845 | Sep 05, 2034 | DS DP U-4195 | | | |
| | | >A> 9908845 | Sep 05, 2034 | DS DP U-4565 | | | |
| | | >A> 9908845 | Sep 05, 2034 | DS DP U-4637 | | | |
| | | >A> RE49948 | Sep 05, 2034 | DS DP U-3201 | | | |
| | | >A> RE49948 | Sep 05, 2034 | DS DP U-4176 | | | |
| | | >A> RE49948 | Sep 05, 2034 | DS DP U-4195 | | | |
| | | >A> RE49948 | Sep 05, 2034 | DS DP U-4565 | | | |
| | | >A> RE49948 | Sep 05, 2034 | DS DP U-4637 | | | |
| BENZGALANTAMINE GLUCONATE - ZUNVEYL | | | | | | | |
| N 218549 | 001 | 12551491 | Jul 23, 2045 | U-713 | | | |
| BENZGALANTAMINE GLUCONATE - ZUNVEYL | | | | | | | |
| N 218549 | 002 | 12551491 | Jul 23, 2045 | U-713 | | | |
| BENZGALANTAMINE GLUCONATE - ZUNVEYL | | | | | | | |
| N 218549 | 003 | 12551491 | Jul 23, 2045 | U-713 | | | |
| BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO | | | | | | | |
| N 214094 | 001 | 12545645 | Nov 01, 2039 | DS DP | | | |
| | | 12545645*PED | May 01, 2040 | | | | |
| | | 12545646 | Nov 01, 2039 | DS DP | | | |
| | | 12545646*PED | May 01, 2040 | | | | |
| | | 12545647 | Nov 01, 2039 | DS DP | | | |
| | | 12545647*PED | May 01, 2040 | | | | |
| | | 12552750 | Nov 01, 2039 | DS DP | | | |
| | | 12552750*PED | May 01, 2040 | | | | |
| | | 12590068 | Nov 01, 2039 | DS DP | | | |
| | | 12590068*PED | May 01, 2040 | | | | |
| | | 12590069 | Nov 01, 2039 | DS DP | | | |
| | | 12590069*PED | May 01, 2040 | | | | |
| BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO | | | | | | | |
| N 214094 | 002 | 12545645 | Nov 01, 2039 | DS DP | | | |
| | | 12545645*PED | May 01, 2040 | | | | |
| | | 12545646 | Nov 01, 2039 | DS DP | | | |
| | | 12545646*PED | May 01, 2040 | | | | |
| | | 12545647 | Nov 01, 2039 | DS DP | | | |
| | | 12545647*PED | May 01, 2040 | | | | |
| | | 12552750 | Nov 01, 2039 | DS DP | | | |
| | | 12552750*PED | May 01, 2040 | | | | |
| | | 12590068 | Nov 01, 2039 | DS DP | | | |
| | | 12590068*PED | May 01, 2040 | | | | |
| | | 12590069 | Nov 01, 2039 | DS DP | | | |
| | | 12590069*PED | May 01, 2040 | | | | |
| BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO | | | | | | | |
| N 219776 | 001 | 10125102 | Apr 07, 2035 | DS U-4535 | | | |
| | | 10125102*PED | Oct 07, 2035 | | | | |
| | | 10329260 | Mar 09, 2035 | DS | | | |
| | | 10329260*PED | Sep 09, 2035 | | | | |
| | | 10662160 | Nov 01, 2039 | DS U-4535 | | | |

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 219776 001 | 10662160*PED | May 01, 2040 | | | | |
| | 10689346 | Mar 09, 2035 | U-4535 | | | |
| | 10689346*PED | Sep 09, 2035 | | | | |
| | 11117867 | Nov 01, 2039 | DP U-4535 | | | |
| | 11117867*PED | May 01, 2040 | | | | |
| | 11230530 | Mar 09, 2035 | U-4535 | | | |
| | 11230530*PED | Sep 09, 2035 | | | | |
| | 11618733 | Nov 01, 2039 | U-4535 | | | |
| | 11618733*PED | May 01, 2040 | | | | |
| | 11708333 | Mar 09, 2035 | U-4535 | | | |
| | 11708333*PED | Sep 09, 2035 | | | | |
| | 12116346 | Mar 09, 2035 | DS | | | |
| | 12116346*PED | Sep 09, 2035 | | | | |
| | 12344585 | Nov 01, 2039 | U-4535 | | | |
| | 12344585*PED | May 01, 2040 | | | | |
| | 12545645 | Nov 01, 2039 | DS DP | | | |
| | 12545645*PED | May 01, 2040 | | | | |
| | 12545646 | Nov 01, 2039 | DS DP | | | |
| | 12545646*PED | May 01, 2040 | | | | |
| | 12545647 | Nov 01, 2039 | DS DP | | | |
| | 12545647*PED | May 01, 2040 | | | | |
| | 12552750 | Nov 01, 2039 | DS DP | | | |
| | 12552750*PED | May 01, 2040 | | | | |
| | 12590068 | Nov 01, 2039 | DS DP | | | |
| | 12590068*PED | May 01, 2040 | | | | |
| | 12590069 | Nov 01, 2039 | DS DP | | | |
| | 12590069*PED | May 01, 2040 | | | | |
| BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO | | | | | | |
| N 219776 002 | 10125102 | Apr 07, 2035 | DS U-4535 | | | |
| | 10125102*PED | Oct 07, 2035 | | | | |
| | 10329260 | Mar 09, 2035 | DS | | | |
| | 10329260*PED | Sep 09, 2035 | | | | |
| | 10662160 | Nov 01, 2039 | DS U-4535 | | | |
| | 10662160*PED | May 01, 2040 | | | | |
| | 10689346 | Mar 09, 2035 | U-4535 | | | |
| | 10689346*PED | Sep 09, 2035 | | | | |
| | 11117867 | Nov 01, 2039 | DP U-4535 | | | |
| | 11117867*PED | May 01, 2040 | | | | |
| | 11230530 | Mar 09, 2035 | U-4535 | | | |
| | 11230530*PED | Sep 09, 2035 | | | | |
| | 11618733 | Nov 01, 2039 | U-4535 | | | |
| | 11618733*PED | May 01, 2040 | | | | |
| | 11708333 | Mar 09, 2035 | U-4535 | | | |
| | 11708333*PED | Sep 09, 2035 | | | | |
| | 12116346 | Mar 09, 2035 | DS | | | |
| | 12116346*PED | Sep 09, 2035 | | | | |
| | 12344585 | Nov 01, 2039 | U-4535 | | | |
| | 12344585*PED | May 01, 2040 | | | | |
| | 12545645 | Nov 01, 2039 | DS DP | | | |
| | 12545645*PED | May 01, 2040 | | | | |
| | 12545646 | Nov 01, 2039 | DS DP | | | |
| | 12545646*PED | May 01, 2040 | | | | |
| | 12545647 | Nov 01, 2039 | DS DP | | | |
| | 12545647*PED | May 01, 2040 | | | | |
| | 12552750 | Nov 01, 2039 | DS DP | | | |
| | 12552750*PED | May 01, 2040 | | | | |
| | 12590068 | Nov 01, 2039 | DS DP | | | |
| | 12590068*PED | May 01, 2040 | | | | |
| | 12590069 | Nov 01, 2039 | DS DP | | | |
| | 12590069*PED | May 01, 2040 | | | | |
| BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO | | | | | | |
| N 219776 003 | 10125102 | Apr 07, 2035 | DS U-4535 | | | |
| | 10125102*PED | Oct 07, 2035 | | | | |
| | 10329260 | Mar 09, 2035 | DS | | | |
| | 10329260*PED | Sep 09, 2035 | | | | |
| | 10662160 | Nov 01, 2039 | DS U-4535 | | | |
| | 10662160*PED | May 01, 2040 | | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 219776 003 | 10689346 | Mar 09, 2035 | U-4535 | | | |
| | 10689346*PED | Sep 09, 2035 | | | | |
| | 11117867 | Nov 01, 2039 | DP U-4535 | | | |
| | 11117867*PED | May 01, 2040 | | | | |
| | 11230530 | Mar 09, 2035 | U-4535 | | | |
| | 11230530*PED | Sep 09, 2035 | | | | |
| | 11618733 | Nov 01, 2039 | U-4535 | | | |
| | 11618733*PED | May 01, 2040 | | | | |
| | 11708333 | Mar 09, 2035 | U-4535 | | | |
| | 11708333*PED | Sep 09, 2035 | | | | |
| | 12116346 | Mar 09, 2035 | DS | | | |
| | 12116346*PED | Sep 09, 2035 | | | | |
| | 12344585 | Nov 01, 2039 | U-4535 | | | |
| | 12344585*PED | May 01, 2040 | | | | |
| | 12545645 | Nov 01, 2039 | DS DP | | | |
| | 12545645*PED | May 01, 2040 | | | | |
| | 12545646 | Nov 01, 2039 | DS DP | | | |
| | 12545646*PED | May 01, 2040 | | | | |
| | 12545647 | Nov 01, 2039 | DS DP | | | |
| | 12545647*PED | May 01, 2040 | | | | |
| | 12552750 | Nov 01, 2039 | DS DP | | | |
| | 12552750*PED | May 01, 2040 | | | | |
| | 12590068 | Nov 01, 2039 | DS DP | | | |
| | 12590068*PED | May 01, 2040 | | | | |
| | 12590069 | Nov 01, 2039 | DS DP | | | |
| | 12590069*PED | May 01, 2040 | | | | |
| BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO | | | | | | |
| N 219776 004 | 10125102 | Apr 07, 2035 | DS U-4535 | | | |
| | 10125102*PED | Oct 07, 2035 | | | | |
| | 10329260 | Mar 09, 2035 | DS | | | |
| | 10329260*PED | Sep 09, 2035 | | | | |
| | 10662160 | Nov 01, 2039 | DS U-4535 | | | |
| | 10662160*PED | May 01, 2040 | | | | |
| | 10689346 | Mar 09, 2035 | U-4535 | | | |
| | 10689346*PED | Sep 09, 2035 | | | | |
| | 11117867 | Nov 01, 2039 | DP U-4535 | | | |
| | 11117867*PED | May 01, 2040 | | | | |
| | 11230530 | Mar 09, 2035 | U-4535 | | | |
| | 11230530*PED | Sep 09, 2035 | | | | |
| | 11618733 | Nov 01, 2039 | U-4535 | | | |
| | 11618733*PED | May 01, 2040 | | | | |
| | 11708333 | Mar 09, 2035 | U-4535 | | | |
| | 11708333*PED | Sep 09, 2035 | | | | |
| | 12116346 | Mar 09, 2035 | DS | | | |
| | 12116346*PED | Sep 09, 2035 | | | | |
| | 12344585 | Nov 01, 2039 | U-4535 | | | |
| | 12344585*PED | May 01, 2040 | | | | |
| | 12545645 | Nov 01, 2039 | DS DP | | | |
| | 12545645*PED | May 01, 2040 | | | | |
| | 12545646 | Nov 01, 2039 | DS DP | | | |
| | 12545646*PED | May 01, 2040 | | | | |
| | 12545647 | Nov 01, 2039 | DS DP | | | |
| | 12545647*PED | May 01, 2040 | | | | |
| | 12552750 | Nov 01, 2039 | DS DP | | | |
| | 12552750*PED | May 01, 2040 | | | | |
| | 12590068 | Nov 01, 2039 | DS DP | | | |
| | 12590068*PED | May 01, 2040 | | | | |
| | 12590069 | Nov 01, 2039 | DS DP | | | |
| | 12590069*PED | May 01, 2040 | | | | |
| BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO | | | | | | |
| N 219776 005 | | | | | >A> ODE* | Dec 03, 2027 |
| | | | | | >A> PED | Jun 03, 2028 |
| BETAMETHASONE DIPROPIONATE - SERNIVO | | | | | | |
| N 208079 001 | 12661489 | Nov 19, 2045 | U-4596 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BEXAGLIFLOZIN - BRENZAVVY | | | | | | | |
| N 214373 | 001 | 12594243 | Oct 05, 2041 | DP | | | |
| BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM - BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) | | | | | | | |
| N 221443 | 001 | 10071985 | Aug 17, 2037 | DS DP | | NCE | Dec 22, 2027 |
| | | 10385067 | Jun 19, 2035 | U-4602 | | NP | Aug 27, 2029 |
| | | 10654827 | Aug 17, 2037 | U-4602 | | | |
| | | 11267799 | Aug 16, 2038 | DS | | | |
| | | 9216996 | Dec 19, 2033 | DS DP | | | |
| | | 9708342 | Jun 19, 2035 | DS DP | | | |
| | | 9732092 | Dec 19, 2033 | DS DP | | | |
| | | 9951043 | Feb 28, 2034 | DS DP U-4602 | | | |
| BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY | | | | | | | |
| N 210251 | 001 | 12594244 | Nov 08, 2036 | DP U-257 | | ODE-540 | Jul 30, 2032 |
| BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY | | | | | | | |
| N 210251 | 002 | 12594244 | Nov 08, 2036 | DP U-257 | | ODE-540 | Jul 30, 2032 |
| BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM - BIXLENVO | | | | | | | |
| N 221104 | 001 | 10071985 | Aug 17, 2037 | DS DP | | NCE | Dec 22, 2027 |
| | | 10385067 | Jun 19, 2035 | U-4602 | | NP | Aug 27, 2029 |
| | | 10654827 | Aug 17, 2037 | U-4602 | | | |
| | | 11267799 | Aug 16, 2038 | DS | | | |
| | | 9216996 | Dec 19, 2033 | DS DP | | | |
| | | 9708342 | Jun 19, 2035 | DS DP | | | |
| | | 9732092 | Dec 19, 2033 | DS DP | | | |
| | | 9951043 | Feb 28, 2034 | DS DP U-4602 | | | |
| BINIMETINIB - MEKTOVI | | | | | | | |
| N 210498 | 001 | 7777050 | Mar 13, 2027 | DS DP | | | |
| BIRCH TRITERPENES - FILSUVEZ | | | | | | | |
| N 215064 | 001 | 8828444 | Jun 21, 2027 | DP | | | |
| BOSUTINIB MONOHYDRATE - BOSUTINIB MONOHYDRATE | | | | | | | |
| A 209543 | 001 | | | | | PC | Nov 23, 2026 |
| BOSUTINIB MONOHYDRATE - BOSUTINIB MONOHYDRATE | | | | | | | |
| A 209543 | 002 | | | | | PC | Nov 23, 2026 |
| BOSUTINIB MONOHYDRATE - BOSUTINIB MONOHYDRATE | | | | | | | |
| A 209624 | 001 | | | | | PC | Nov 23, 2026 |
| BREPOCITINIB TOSYLATE - LISRAYA | | | | | | | |
| N 220106 | 001 | 11197867 | Aug 19, 2035 | DS DP | | NCE | Aug 27, 2031 |
| | | 9663526 | Aug 19, 2035 | DS DP | | | |
| BRIMONIDINE TARTRATE - LUMIFY | | | | | | | |
| N 208144 | 001 | 12514857 | Jul 27, 2029 | U-2222 | | | |
| BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE | | | | | | | |
| N 218424 | 001 | 12311050 | Jul 27, 2029 | U-2222 | | | |
| | | 12514857 | Jul 27, 2029 | U-2222 | | | |
| BRIMONIDINE TARTRATE; CARBACHOL - YUVEZZI | | | | | | | |
| N 220142 | 001 | 12268662 | Nov 10, 2042 | DP U-3741 | | NP | Jan 28, 2029 |
| | | 12268662 | Nov 10, 2042 | DP U-4419 | | | |
| | | 12268662 | Nov 10, 2042 | DP U-4420 | | | |
| | | 8455494 | May 24, 2030 | U-3741 | | | |
| | | 8455494 | May 24, 2030 | U-4419 | | | |
| | | 8455494 | May 24, 2030 | U-4420 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BRINCIDOFOVIR - TEMBEXA | | | | | | | |
| N 214460 001 | | 9303051 | Jul 30, 2034 | DS DP U-3165 | | | |
| BRINCIDOFOVIR - TEMBEXA | | | | | | | |
| N 214461 001 | | 9303051 | Jul 30, 2034 | DS DP U-3165 | | | |
| BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE | | | | | | | |
| N 216579 001 | | 10716753 | May 28, 2030 | DP U-3203 | | I-988 | Apr 27, 2029 |
| | | 10716753 | May 28, 2030 | DP U-4513 | | | |
| | | 9415009 | May 28, 2030 | U-3203 | | | |
| | | 9415009 | May 28, 2030 | U-4513 | | | |
| BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE | | | | | | | |
| N 216579 002 | | 10716753 | May 28, 2030 | DP U-4513 | | NS | Apr 27, 2029 |
| | | 9415009 | May 28, 2030 | U-4513 | | | |
| BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE | | | | | | | |
| N 212122 002 | | 10716753 | May 28, 2030 | DP U-4503 | | NS | Apr 27, 2029 |
| | | 11331442 | Oct 05, 2038 | DP | | | |
| | | 11833292 | Oct 05, 2038 | DP | | | |
| | | 8324266 | May 28, 2030 | U-4503 | | | |
| | | 8703806 | May 28, 2030 | U-4503 | | | |
| | | 8808713 | May 28, 2030 | DP U-4503 | | | |
| | | 8815258 | Mar 17, 2031 | U-4503 | | | |
| | | 9415009 | May 28, 2030 | U-4503 | | | |
| | | 9463161 | May 28, 2030 | DP U-4503 | | | |
| BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE | | | | | | | |
| N 220290 001 | >A> | 10716753 | May 28, 2030 | DP U-4635 | >A> | NP | Oct 08, 2029 |
| | >A> | 11331442 | Oct 05, 2038 | DP | | | |
| | >A> | 11833292 | Oct 05, 2038 | DP | | | |
| | >A> | 8324266 | May 28, 2030 | U-4635 | | | |
| | >A> | 8703806 | May 28, 2030 | U-4635 | | | |
| | >A> | 8808713 | May 28, 2030 | DP U-4635 | | | |
| | >A> | 8815258 | Mar 17, 2031 | U-4635 | | | |
| | >A> | 9415009 | May 28, 2030 | U-4635 | | | |
| BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE | | | | | | | |
| N 220290 002 | >A> | 10716753 | May 28, 2030 | DP U-4503 | >A> | NP | Oct 08, 2029 |
| | >A> | 11331442 | Oct 05, 2038 | DP | | | |
| | >A> | 11833292 | Oct 05, 2038 | DP | | | |
| | >A> | 8324266 | May 28, 2030 | U-4503 | | | |
| | >A> | 8703806 | May 28, 2030 | U-4503 | | | |
| | >A> | 8808713 | May 28, 2030 | DP U-4503 | | | |
| | >A> | 8815258 | Mar 17, 2031 | U-4503 | | | |
| | >A> | 9415009 | May 28, 2030 | U-4503 | | | |
| BUMETANIDE - ENBUMYST | | | | | | | |
| N 219500 001 | | 12558330 | May 14, 2045 | DP U-4279 | | | |
| BUPIVACAINE - EXPAREL | | | | | | | |
| N 022496 001 | | 12728094 | Jul 02, 2044 | DP U-4152 | | | |
| | | 12728095 | Jul 02, 2044 | DP U-4152 | | | |
| BUPIVACAINE - EXPAREL | | | | | | | |
| N 022496 002 | | 12728094 | Jul 02, 2044 | DP U-4152 | | | |
| | | 12728095 | Jul 02, 2044 | DP U-4152 | | | |
| BUPRENORPHINE - SUBLOCADE | | | | | | | |
| N 209819 001 | | 12622904 | Nov 06, 2035 | U-4528 | | | |
| BUPRENORPHINE - SUBLOCADE | | | | | | | |
| N 209819 002 | | 12622904 | Nov 06, 2035 | U-4528 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY | | | | | | |
| N 215430 001 | 10058518 | Nov 05, 2034 | U-3419 | | I-913 | Apr 30, 2029 |
| | 10058518 | Nov 05, 2034 | U-4522 | | | |
| | 10064857 | Nov 05, 2034 | U-3419 | | | |
| | 10064857 | Nov 05, 2034 | U-4517 | | | |
| | 10080727 | Nov 05, 2034 | U-3419 | | | |
| | 10080727 | Nov 05, 2034 | U-4520 | | | |
| | 10092560 | Nov 05, 2034 | U-3419 | | | |
| | 10092560 | Nov 05, 2034 | U-4517 | | | |
| | 10092561 | Nov 05, 2034 | U-3419 | | | |
| | 10092561 | Nov 05, 2034 | U-4517 | | | |
| | 10105361 | Nov 05, 2034 | U-3419 | | | |
| | 10105361 | Nov 05, 2034 | U-4522 | | | |
| | 10251879 | Nov 05, 2034 | U-3419 | | | |
| | 10251879 | Nov 05, 2034 | U-4517 | | | |
| | 10463634 | Nov 05, 2034 | U-3419 | | | |
| | 10463634 | Nov 05, 2034 | U-4517 | | | |
| | 10512643 | Nov 05, 2034 | U-3419 | | | |
| | 10512643 | Nov 05, 2034 | U-4517 | | | |
| | 10596167 | Nov 05, 2034 | U-3419 | | | |
| | 10596167 | Nov 05, 2034 | U-4517 | | | |
| | 10780066 | Nov 05, 2034 | U-3419 | | | |
| | 10780066 | Nov 05, 2034 | U-4517 | | | |
| | 10786496 | Nov 05, 2034 | U-3419 | | | |
| | 10786496 | Nov 05, 2034 | U-4517 | | | |
| | 10806710 | Nov 05, 2034 | U-3419 | | | |
| | 10806710 | Nov 05, 2034 | U-4517 | | | |
| | 10881624 | Nov 05, 2034 | U-3419 | | | |
| | 10881624 | Nov 05, 2034 | U-4517 | | | |
| | 10966941 | Nov 05, 2034 | U-3419 | | | |
| | 10966941 | Nov 05, 2034 | U-4517 | | | |
| | 11007189 | Nov 05, 2034 | U-4516 | | | |
| | 11065248 | Nov 05, 2034 | U-3419 | | | |
| | 11065248 | Nov 05, 2034 | U-4517 | | | |
| | 11123344 | Nov 05, 2034 | U-3419 | | | |
| | 11123344 | Nov 05, 2034 | U-4517 | | | |
| | 11191739 | Nov 05, 2034 | DP U-3419 | | | |
| | 11191739 | Nov 05, 2034 | DP U-4516 | | | |
| | 11197839 | Nov 05, 2034 | DP U-3419 | | | |
| | 11197839 | Nov 05, 2034 | DP U-4516 | | | |
| | 11207281 | Nov 05, 2034 | U-3419 | | | |
| | 11207281 | Nov 05, 2034 | U-4537 | | | |
| | 11234946 | Nov 05, 2034 | U-3419 | | | |
| | 11234946 | Nov 05, 2034 | U-4526 | | | |
| | 11253492 | Nov 05, 2034 | U-3419 | | | |
| | 11253492 | Nov 05, 2034 | U-4526 | | | |
| | 11273133 | Nov 05, 2034 | U-3419 | | | |
| | 11273133 | Nov 05, 2034 | U-4526 | | | |
| | 11273134 | Nov 05, 2034 | U-3419 | | | |
| | 11273134 | Nov 05, 2034 | U-4517 | | | |
| | 11285118 | Nov 05, 2034 | U-3419 | | | |
| | 11285118 | Nov 05, 2034 | U-4526 | | | |
| | 11285146 | Nov 05, 2034 | U-3419 | | | |
| | 11285146 | Nov 05, 2034 | U-4517 | | | |
| | 11291638 | Nov 05, 2034 | U-3419 | | | |
| | 11291638 | Nov 05, 2034 | U-4517 | | | |
| | 11291665 | Nov 05, 2034 | U-3419 | | | |
| | 11291665 | Nov 05, 2034 | U-4517 | | | |
| | 11298352 | Nov 05, 2034 | U-3419 | | | |
| | 11298352 | Nov 05, 2034 | U-4517 | | | |
| | 11344544 | Nov 05, 2034 | U-3419 | | | |
| | 11344544 | Nov 05, 2034 | U-4517 | | | |
| | 11357744 | Nov 05, 2034 | U-3419 | | | |
| | 11357744 | Nov 05, 2034 | U-4517 | | | |
| | 11382874 | Nov 05, 2034 | U-3419 | | | |
| | 11382874 | Nov 05, 2034 | U-4517 | | | |
| | 11419867 | Nov 05, 2034 | U-3419 | | | |
| | 11419867 | Nov 05, 2034 | U-4517 | | | |
| | 11426370 | Nov 05, 2034 | U-3419 | | | |
| | 11426370 | Nov 05, 2034 | U-4526 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| N 215430 001 | | 11426401 | Nov 05, 2034 | U-3419 | | | |
| | | 11426401 | Nov 05, 2034 | U-4517 | | | |
| | | 11433067 | Nov 05, 2034 | DP U-3419 | | | |
| | | 11433067 | Nov 05, 2034 | DP U-4516 | | | |
| | | 11439636 | Nov 05, 2034 | U-3419 | | | |
| | | 11439636 | Nov 05, 2034 | U-4517 | | | |
| | | 11534414 | Nov 05, 2034 | DP U-3419 | | | |
| | | 11534414 | Nov 05, 2034 | DP U-4516 | | | |
| | | 11571417 | Nov 05, 2034 | U-3419 | | | |
| | | 11571417 | Nov 05, 2034 | U-4526 | | | |
| | | 11576909 | Nov 05, 2034 | U-3419 | | | |
| | | 11576909 | Nov 05, 2034 | U-4526 | | | |
| | | 11590124 | Nov 05, 2034 | U-3419 | | | |
| | | 11590124 | Nov 05, 2034 | U-4526 | | | |
| | | 11617747 | Nov 05, 2034 | U-3563 | | | |
| | | 11617747 | Nov 05, 2034 | U-4526 | | | |
| | | 12194005 | Jan 23, 2043 | U-4523 | | | |
| | | 12194036 | Apr 20, 2043 | U-4521 | | | |
| | | 12239642 | Jan 20, 2043 | U-4515 | | | |
| | | 12263161 | Jan 20, 2043 | U-4515 | | | |
| | | 12364674 | Jan 23, 2043 | U-4516 | | | |
| | | 12370154 | Feb 15, 2043 | U-4518 | | | |
| | | 12433884 | Jun 05, 2040 | U-4514 | | | |
| | | 12472155 | Feb 23, 2043 | U-4519 | | | |
| | | 12472156 | Jun 05, 2040 | U-4516 | | | |
| | | 12472174 | Jan 20, 2043 | U-4515 | | | |
| | | 12478622 | Jan 20, 2043 | U-4515 | | | |
| | | 12564587 | Jan 20, 2043 | U-4515 | | | |
| | | 12576078 | Jun 05, 2040 | U-4516 | | | |
| | | 12599576 | Feb 15, 2043 | U-4518 | | | |
| | | 12653795 | Nov 28, 2043 | U-4516 | | | |
| | | 12661408 | Jan 20, 2043 | U-3419 | | | |
| | | 12678506 | Jan 20, 2043 | DP | | | |
| | >A> | 12740949 | Feb 15, 2043 | U-4516 | | | |
| | | 8569328 | Jul 18, 2032 | DP U-3419 | | | |
| | | 8569328 | Jul 18, 2032 | DP U-4516 | | | |
| | | 9168234 | Nov 05, 2034 | U-3419 | | | |
| | | 9168234 | Nov 05, 2034 | U-4517 | | | |
| | | 9198905 | Nov 05, 2034 | U-3419 | | | |
| | | 9198905 | Nov 05, 2034 | U-4520 | | | |
| | | 9205083 | Nov 05, 2034 | U-3419 | | | |
| | | 9205083 | Nov 05, 2034 | U-4520 | | | |
| | | 9238032 | Nov 05, 2034 | U-3419 | | | |
| | | 9238032 | Nov 05, 2034 | U-4520 | | | |
| | | 9278095 | Nov 05, 2034 | U-3419 | | | |
| | | 9278095 | Nov 05, 2034 | U-4517 | | | |
| | | 9314462 | Nov 05, 2034 | U-3419 | | | |
| | | 9314462 | Nov 05, 2034 | U-4517 | | | |
| | | 9370513 | Nov 05, 2034 | U-3419 | | | |
| | | 9370513 | Nov 05, 2034 | U-4520 | | | |
| | | 9375429 | Nov 05, 2034 | U-3419 | | | |
| | | 9375429 | Nov 05, 2034 | U-4517 | | | |
| | | 9408815 | Nov 05, 2034 | U-3419 | | | |
| | | 9408815 | Nov 05, 2034 | U-4517 | | | |
| | | 9421176 | Nov 05, 2034 | U-3419 | | | |
| | | 9421176 | Nov 05, 2034 | U-4517 | | | |
| | | 9457023 | Nov 05, 2034 | U-3419 | | | |
| | | 9457023 | Nov 05, 2034 | U-4517 | | | |
| | | 9457025 | Nov 05, 2034 | U-3419 | | | |
| | | 9457025 | Nov 05, 2034 | U-4517 | | | |
| | | 9474731 | Nov 05, 2034 | U-3419 | | | |
| | | 9474731 | Nov 05, 2034 | U-4520 | | | |
| | | 9486450 | Nov 05, 2034 | U-3419 | | | |
| | | 9486450 | Nov 05, 2034 | U-4517 | | | |
| | | 9700528 | Nov 05, 2034 | U-3419 | | | |
| | | 9700528 | Nov 05, 2034 | U-4517 | | | |
| | | 9700553 | Nov 05, 2034 | U-3419 | | | |
| | | 9700553 | Nov 05, 2034 | U-4517 | | | |
| | | 9707191 | Nov 05, 2034 | U-3419 | | | |
| | | 9707191 | Nov 05, 2034 | U-4522 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| N 215430 | 001 | 9763932 | Nov 05, 2034 | U-3419 | | | |
| | | 9763932 | Nov 05, 2034 | U-4517 | | | |
| | | 9861595 | Nov 05, 2034 | U-3419 | | | |
| | | 9861595 | Nov 05, 2034 | U-4517 | | | |
| | | 9867819 | Nov 05, 2034 | U-3419 | | | |
| | | 9867819 | Nov 05, 2034 | U-4517 | | | |
| | | 9968568 | Nov 05, 2034 | U-3419 | | | |
| | | 9968568 | Nov 05, 2034 | U-4517 | | | |
| BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY | | | | | | | |
| N 215430 | 002 | 10058518 | Nov 05, 2034 | U-4522 | | I-913 | Apr 30, 2029 |
| | | 10064857 | Nov 05, 2034 | U-4517 | | | |
| | | 10080727 | Nov 05, 2034 | U-4520 | | | |
| | | 10092560 | Nov 05, 2034 | U-4517 | | | |
| | | 10092561 | Nov 05, 2034 | U-4517 | | | |
| | | 10105361 | Nov 05, 2034 | U-4522 | | | |
| | | 10251879 | Nov 05, 2034 | U-4517 | | | |
| | | 10463634 | Nov 05, 2034 | U-4517 | | | |
| | | 10512643 | Nov 05, 2034 | U-4517 | | | |
| | | 10780066 | Nov 05, 2034 | U-4517 | | | |
| | | 10881624 | Nov 05, 2034 | U-4517 | | | |
| | | 11007189 | Nov 05, 2034 | U-4516 | | | |
| | | 11207281 | Nov 05, 2034 | U-4537 | | | |
| | | 11234946 | Nov 05, 2034 | U-4526 | | | |
| | | 11253492 | Nov 05, 2034 | U-4526 | | | |
| | | 11273133 | Nov 05, 2034 | U-4526 | | | |
| | | 11273134 | Nov 05, 2034 | U-4517 | | | |
| | | 11285118 | Nov 05, 2034 | U-4526 | | | |
| | | 11285146 | Nov 05, 2034 | U-4517 | | | |
| | | 11291638 | Nov 05, 2034 | U-4517 | | | |
| | | 11291665 | Nov 05, 2034 | U-4517 | | | |
| | | 11298352 | Nov 05, 2034 | U-4517 | | | |
| | | 11344544 | Nov 05, 2034 | U-4517 | | | |
| | | 11382874 | Nov 05, 2034 | U-4517 | | | |
| | | 11419867 | Nov 05, 2034 | U-4517 | | | |
| | | 11426370 | Nov 05, 2034 | U-4526 | | | |
| | | 11571417 | Nov 05, 2034 | U-4526 | | | |
| | | 11590124 | Nov 05, 2034 | U-4526 | | | |
| | | 11617747 | Nov 05, 2034 | U-4526 | | | |
| | | 12433884 | Jun 05, 2040 | U-4514 | | | |
| | | 12472156 | Jun 05, 2040 | U-4516 | | | |
| | | 12472174 | Jan 20, 2043 | U-4515 | | | |
| | | 12576078 | Jun 05, 2040 | U-4516 | | | |
| | | 12678506 | Jan 20, 2043 | DP | | | |
| | >A> | 12740949 | Feb 15, 2043 | U-4516 | | | |
| | | 8569328 | Jul 18, 2032 | DP U-4516 | | | |
| | | 9168234 | Nov 05, 2034 | U-4517 | | | |
| | | 9198905 | Nov 05, 2034 | U-4520 | | | |
| | | 9205083 | Nov 05, 2034 | U-4520 | | | |
| | | 9238032 | Nov 05, 2034 | U-4520 | | | |
| | | 9278095 | Nov 05, 2034 | U-4517 | | | |
| | | 9314462 | Nov 05, 2034 | U-4517 | | | |
| | | 9370513 | Nov 05, 2034 | U-4520 | | | |
| | | 9375429 | Nov 05, 2034 | U-4517 | | | |
| | | 9408815 | Nov 05, 2034 | U-4517 | | | |
| | | 9421176 | Nov 05, 2034 | U-4517 | | | |
| | | 9457023 | Nov 05, 2034 | U-4517 | | | |
| | | 9457025 | Nov 05, 2034 | U-4517 | | | |
| | | 9474731 | Nov 05, 2034 | U-4520 | | | |
| | | 9486450 | Nov 05, 2034 | U-4517 | | | |
| | | 9700528 | Nov 05, 2034 | U-4517 | | | |
| | | 9700553 | Nov 05, 2034 | U-4517 | | | |
| | | 9707191 | Nov 05, 2034 | U-4522 | | | |
| | | 9763932 | Nov 05, 2034 | U-4517 | | | |
| | | 9861595 | Nov 05, 2034 | U-4517 | | | |
| | | 9867819 | Nov 05, 2034 | U-4517 | | | |
| | | 9968568 | Nov 05, 2034 | U-4517 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| CABAZITAXEL - JEVTANA KIT | | | | | | |
| N 201023 001 | 10583110 | Oct 27, 2030 | U-2753 | | | |
| | 10583110*PED | Apr 27, 2031 | | | | |
| | 10716777 | Oct 27, 2030 | U-2856 | | | |
| | 10716777*PED | Apr 27, 2031 | | | | |
| | 12453712 | Oct 27, 2030 | U-4334 | | | |
| | 12453712*PED | Apr 27, 2031 | | | | |
| CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT | | | | | | |
| N 212888 001 | 12636285 | Oct 01, 2040 | U-3348 | | | |
| | 12636286 | Oct 01, 2040 | U-3348 | | | |
| CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT | | | | | | |
| N 212888 002 | 12636285 | Oct 01, 2040 | U-3348 | | | |
| | 12636286 | Oct 01, 2040 | U-3348 | | | |
| CABOZANTINIB LAURYLSULFATE - OMCAZIO | | | | | | |
| N 220613 001 | 12064430 | Jun 13, 2039 | U-1480 | | | |
| | 12064430 | Jun 13, 2039 | U-2488 | | | |
| | 12415784 | Jan 30, 2044 | | | | |
| | 12516025 | Jan 30, 2044 | U-1480 | | | |
| | 12516025 | Jan 30, 2044 | U-2488 | | | |
| | 12516025 | Jan 30, 2044 | U-4131 | | | |
| | 12552567 | Jan 30, 2044 | U-1480 | | | |
| | 12552567 | Jan 30, 2044 | U-2488 | | | |
| | 12552567 | Jan 30, 2044 | U-4131 | | | |
| | 12552749 | Jan 30, 2044 | U-1480 | | | |
| | 12552749 | Jan 30, 2044 | U-2488 | | | |
| | 12552749 | Jan 30, 2044 | U-4131 | | | |
| | 12741938 | Jan 30, 2044 | DP | | | |
| CABOZANTINIB LAURYLSULFATE - OMCAZIO | | | | | | |
| N 220613 002 | 12064430 | Jun 13, 2039 | U-1480 | | | |
| | 12064430 | Jun 13, 2039 | U-2488 | | | |
| | 12415784 | Jan 30, 2044 | | | | |
| | 12516025 | Jan 30, 2044 | U-1480 | | | |
| | 12516025 | Jan 30, 2044 | U-2488 | | | |
| | 12516025 | Jan 30, 2044 | U-4131 | | | |
| | 12552567 | Jan 30, 2044 | U-1480 | | | |
| | 12552567 | Jan 30, 2044 | U-2488 | | | |
| | 12552567 | Jan 30, 2044 | U-4131 | | | |
| | 12552749 | Jan 30, 2044 | U-1480 | | | |
| | 12552749 | Jan 30, 2044 | U-2488 | | | |
| | 12552749 | Jan 30, 2044 | U-4131 | | | |
| | 12741938 | Jan 30, 2044 | DP | | | |
| CABOZANTINIB LAURYLSULFATE - OMCAZIO | | | | | | |
| N 220613 003 | 12064430 | Jun 13, 2039 | U-1480 | | | |
| | 12064430 | Jun 13, 2039 | U-2488 | | | |
| | 12415784 | Jan 30, 2044 | | | | |
| | 12516025 | Jan 30, 2044 | U-1480 | | | |
| | 12516025 | Jan 30, 2044 | U-2488 | | | |
| | 12516025 | Jan 30, 2044 | U-4131 | | | |
| | 12552567 | Jan 30, 2044 | U-1480 | | | |
| | 12552567 | Jan 30, 2044 | U-2488 | | | |
| | 12552567 | Jan 30, 2044 | U-4131 | | | |
| | 12552749 | Jan 30, 2044 | U-1480 | | | |
| | 12552749 | Jan 30, 2044 | U-2488 | | | |
| | 12552749 | Jan 30, 2044 | U-4131 | | | |
| | 12741938 | Jan 30, 2044 | DP | | | |
| CABOZANTINIB S-MALATE - CABOMETYX | | | | | | |
| N 208692 001 | | | | | ODE-530 | Mar 26, 2032 |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| CABOZANTINIB S-MALATE - CABOMETYX | | | | | | |
| N 208692 002 | | | | | ODE-530 | Mar 26, 2032 |
| CABOZANTINIB S-MALATE - CABOMETYX | | | | | | |
| N 208692 003 | | | | | ODE-530 | Mar 26, 2032 |
| CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV | | | | | | |
| N 212690 001 | 12582622 | Feb 22, 2041 | U-4044 | | | |
| CAMIZESTRANT - ETCAMAH | | | | | | |
| N 220359 001 | 10131663 | Oct 13, 2037 | DS DP | | NCE | Sep 04, 2031 |
| | 10590130 | Oct 13, 2037 | DS DP | | | |
| | 10961241 | Oct 13, 2037 | U-4607 | | | |
| | 12077530 | Oct 13, 2037 | U-4607 | | | |
| | 12364689 | Sep 18, 2041 | U-4606 | | | |
| | 12453729 | Oct 22, 2041 | DP | | | |
| CANNABIDIOL - EPIDIOLEX | | | | | | |
| N 210365 001 | 12661365 | Sep 24, 2042 | U-4573 | | | |
| | 12661365 | Sep 24, 2042 | U-4574 | | | |
| | 12661365 | Sep 24, 2042 | U-4575 | | | |
| CAPIVASERTIB - TRUQAP | | | | | | |
| N 218197 001 | 10039766 | Apr 16, 2033 | U-3762 | | I-991 | Jun 12, 2029 |
| | 10039766 | Apr 16, 2033 | U-4559 | | | |
| | 11236095 | Oct 10, 2028 | U-4559 | | | |
| | 9492453 | Oct 10, 2028 | U-4559 | | | |
| CAPIVASERTIB - TRUQAP | | | | | | |
| N 218197 002 | 10039766 | Apr 16, 2033 | U-3762 | | I-991 | Jun 12, 2029 |
| | 10039766 | Apr 16, 2033 | U-4559 | | | |
| | 11236095 | Oct 10, 2028 | U-4559 | | | |
| | 9492453 | Oct 10, 2028 | U-4559 | | | |
| CARBIDOPA; LEVODOPA - CREXONT | | | | | | |
| N 217186 001 | 12691074 | Oct 07, 2034 | DP | | | |
| CARBIDOPA; LEVODOPA - CREXONT | | | | | | |
| N 217186 002 | 12691074 | Oct 07, 2034 | DP | | | |
| CARBIDOPA; LEVODOPA - CREXONT | | | | | | |
| N 217186 003 | 12691074 | Oct 07, 2034 | DP | | | |
| CARBIDOPA; LEVODOPA - CREXONT | | | | | | |
| N 217186 004 | 12691074 | Oct 07, 2034 | DP | | | |
| CARFILZOMIB - KYPROLIS | | | | | | |
| N 202714 001 | 12636340 | Apr 29, 2041 | U-4551 | | | |
| | 12636340*PED | Oct 29, 2041 | | | | |
| CARFILZOMIB - KYPROLIS | | | | | | |
| N 202714 002 | 12636340 | Apr 29, 2041 | U-4551 | | | |
| | 12636340*PED | Oct 29, 2041 | | | | |
| CARFILZOMIB - KYPROLIS | | | | | | |
| N 202714 003 | 12636340 | Apr 29, 2041 | U-4551 | | | |
| | 12636340*PED | Oct 29, 2041 | | | | |
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | |
| N 204370 001 | 7737142 | Sep 17, 2029 | DS DP U-1750 | | M-14 | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2543 | | NPP | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2544 | | PED | Jun 18, 2029 |
| | 7737142 | Sep 17, 2029 | DS DP U-2545 | | PED | Jun 18, 2029 |
| | 7737142 | Sep 17, 2029 | DS DP U-3503 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 204370 001 | 7737142*PED | Mar 17, 2030 | | | | |
| | 7943621 | Dec 16, 2028 | DS DP | | | |
| | 7943621*PED | Jun 16, 2029 | | | | |
| | RE47350 | Jul 16, 2029 | U-1750 | | | |
| | RE47350 | Jul 16, 2029 | U-2543 | | | |
| | RE47350 | Jul 16, 2029 | U-2544 | | | |
| | RE47350 | Jul 16, 2029 | U-2545 | | | |
| | RE47350 | Jul 16, 2029 | U-3503 | | | |
| | RE47350*PED | Jan 16, 2030 | | | | |
| | RE49110 | Jul 16, 2029 | U-2543 | | | |
| | RE49110 | Jul 16, 2029 | U-2544 | | | |
| | RE49110 | Jul 16, 2029 | U-2545 | | | |
| | RE49110 | Jul 16, 2029 | U-3503 | | | |
| | RE49110*PED | Jan 16, 2030 | | | | |
| | RE49302 | Jul 16, 2029 | U-2543 | | | |
| | RE49302 | Jul 16, 2029 | U-2544 | | | |
| | RE49302 | Jul 16, 2029 | U-2545 | | | |
| | RE49302 | Jul 16, 2029 | U-3503 | | | |
| | RE49302*PED | Jan 16, 2030 | | | | |
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | |
| N 204370 002 | 7737142 | Sep 17, 2029 | DS DP U-1750 | | M-14 | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2543 | | NPP | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2544 | | PED | Jun 18, 2029 |
| | 7737142 | Sep 17, 2029 | DS DP U-2545 | | PED | Jun 18, 2029 |
| | 7737142 | Sep 17, 2029 | DS DP U-3503 | | | |
| | 7737142*PED | Mar 17, 2030 | | | | |
| | 7943621 | Dec 16, 2028 | DS DP | | | |
| | 7943621*PED | Jun 16, 2029 | | | | |
| | RE49110 | Jul 16, 2029 | U-2543 | | | |
| | RE49110 | Jul 16, 2029 | U-2544 | | | |
| | RE49110 | Jul 16, 2029 | U-2545 | | | |
| | RE49110 | Jul 16, 2029 | U-3503 | | | |
| | RE49110*PED | Jan 16, 2030 | | | | |
| | RE49302 | Jul 16, 2029 | U-2543 | | | |
| | RE49302 | Jul 16, 2029 | U-2544 | | | |
| | RE49302 | Jul 16, 2029 | U-2545 | | | |
| | RE49302 | Jul 16, 2029 | U-3503 | | | |
| | RE49302*PED | Jan 16, 2030 | | | | |
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | |
| N 204370 003 | 7737142 | Sep 17, 2029 | DS DP U-1750 | | M-14 | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2543 | | NPP | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2544 | | PED | Jun 18, 2029 |
| | 7737142*PED | Mar 17, 2030 | | | PED | Jun 18, 2029 |
| | 7943621 | Dec 16, 2028 | DS DP | | | |
| | 7943621*PED | Jun 16, 2029 | | | | |
| | RE49110 | Jul 16, 2029 | U-2543 | | | |
| | RE49110 | Jul 16, 2029 | U-2544 | | | |
| | RE49110 | Jul 16, 2029 | U-2545 | | | |
| | RE49110*PED | Jan 16, 2030 | | | | |
| | RE49302 | Jul 16, 2029 | U-2543 | | | |
| | RE49302 | Jul 16, 2029 | U-2544 | | | |
| | RE49302 | Jul 16, 2029 | U-2545 | | | |
| | RE49302 | Jul 16, 2029 | U-3503 | | | |
| | RE49302*PED | Jan 16, 2030 | | | | |
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | |
| N 204370 004 | 7737142 | Sep 17, 2029 | DS DP U-1750 | | M-14 | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2543 | | PED | Jun 18, 2029 |
| | 7737142 | Sep 17, 2029 | DS DP U-2544 | | | |
| | 7737142*PED | Mar 17, 2030 | | | | |
| | 7943621 | Dec 16, 2028 | DS DP | | | |
| | 7943621*PED | Jun 16, 2029 | | | | |
| | RE49110 | Jul 16, 2029 | U-2543 | | | |
| | RE49110 | Jul 16, 2029 | U-2544 | | | |
| | RE49110 | Jul 16, 2029 | U-2545 | | | |
| | RE49110*PED | Jan 16, 2030 | | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 204370 004 | RE49302 | Jul 16, 2029 | U-2543 | | | |
| | RE49302 | Jul 16, 2029 | U-2544 | | | |
| | RE49302 | Jul 16, 2029 | U-2545 | | | |
| | RE49302 | Jul 16, 2029 | U-3503 | | | |
| | RE49302*PED | Jan 16, 2030 | | | | |
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | |
| N 204370 005 | 7737142 | Sep 17, 2029 | DS DP U-2543 | | M-14 | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2544 | | NPP | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2545 | | PED | Jun 18, 2029 |
| | 7737142 | Sep 17, 2029 | DS DP U-3503 | | PED | Jun 18, 2029 |
| | 7737142*PED | Mar 17, 2030 | | | | |
| | 7943621 | Dec 20, 2028 | DS DP | | | |
| | 7943621*PED | Jun 20, 2029 | | | | |
| | RE47350 | Jul 16, 2029 | U-2543 | | | |
| | RE47350 | Jul 16, 2029 | U-2544 | | | |
| | RE47350 | Jul 16, 2029 | U-2545 | | | |
| | RE47350 | Jul 16, 2029 | U-3503 | | | |
| | RE47350*PED | Jan 16, 2030 | | | | |
| | RE49110 | Jul 16, 2029 | U-2543 | | | |
| | RE49110 | Jul 16, 2029 | U-2544 | | | |
| | RE49110 | Jul 16, 2029 | U-2545 | | | |
| | RE49110 | Jul 16, 2029 | U-3503 | | | |
| | RE49110*PED | Jan 16, 2030 | | | | |
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | |
| N 204370 006 | 7737142 | Sep 17, 2029 | DS DP U-2543 | | M-14 | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2544 | | NPP | Dec 18, 2028 |
| | 7737142 | Sep 17, 2029 | DS DP U-2545 | | PED | Jun 18, 2029 |
| | 7737142 | Sep 17, 2029 | DS DP U-3503 | | PED | Jun 18, 2029 |
| | 7737142*PED | Mar 17, 2030 | | | | |
| | 7943621 | Dec 20, 2028 | DS DP | | | |
| | 7943621*PED | Jun 20, 2029 | | | | |
| | RE47350 | Jul 16, 2029 | U-2543 | | | |
| | RE47350 | Jul 16, 2029 | U-2544 | | | |
| | RE47350 | Jul 16, 2029 | U-2545 | | | |
| | RE47350 | Jul 16, 2029 | U-3503 | | | |
| | RE47350*PED | Jan 16, 2030 | | | | |
| | RE49110 | Jul 16, 2029 | U-2543 | | | |
| | RE49110 | Jul 16, 2029 | U-2544 | | | |
| | RE49110 | Jul 16, 2029 | U-2545 | | | |
| | RE49110 | Jul 16, 2029 | U-3503 | | | |
| | RE49110*PED | Jan 16, 2030 | | | | |
| CEDAZURIDINE; DECITABINE - INQOVI | | | | | | |
| N 212576 001 | 12697347 | Dec 10, 2042 | U-4587 | | I-990 | May 13, 2029 |
| | 8268800 | Feb 12, 2034 | DS U-2864 | | | |
| | 8268800 | Feb 12, 2034 | DS U-2865 | | | |
| | 8268800 | Feb 12, 2034 | DS U-2866 | | | |
| | 8268800 | Feb 12, 2034 | DS U-2867 | | | |
| CEFEPIME HYDROCHLORIDE; ZIDEBACTAM - ZAYNICH | | | | | | |
| N 220787 001 | 8822450 | Aug 24, 2032 | DS DP | | NCE | May 29, 2031 |
| | 8853197 | Aug 24, 2032 | DS | | GAIN | May 29, 2036 |
| | 9132133 | Aug 24, 2032 | U-4558 | | | |
| | 9381200 | Aug 24, 2032 | DP | | | |
| | 9657021 | Oct 12, 2033 | DS | | | |
| | 9827235 | Aug 24, 2032 | DP U-4558 | | | |
| | 9834557 | Oct 12, 2033 | DS | | | |
| CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA | | | | | | |
| N 206829 001 | 10028963 | Sep 07, 2032 | U-2565 | | NPP | May 12, 2029 |
| | 10028963 | Sep 07, 2032 | U-2566 | | PED | Nov 12, 2029 |
| | 10028963 | Sep 07, 2032 | U-4542 | | | |
| | 10028963 | Sep 07, 2032 | U-4543 | | | |
| | 10028963*PED | Mar 07, 2033 | | | | |
| | 10125149 | Aug 14, 2035 | DP | | | |
| | 10125149*PED | Feb 14, 2036 | | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| N 206829 001 | | 10376496 | Sep 09, 2034 | U-2610 | | | |
| | | 10376496 | Sep 09, 2034 | U-2611 | | | |
| | | 10376496 | Sep 09, 2034 | U-4548 | | | |
| | | 10376496 | Sep 09, 2034 | U-4549 | | | |
| | | 10376496*PED | Mar 09, 2035 | | | | |
| | | 10420841 | Mar 14, 2034 | U-1672 | | | |
| | | 10420841 | Mar 14, 2034 | U-2631 | | | |
| | | 10420841 | Mar 14, 2034 | U-3360 | | | |
| | | 10420841 | Mar 14, 2034 | U-3361 | | | |
| | | 10420841 | Mar 14, 2034 | U-4546 | | | |
| | | 10420841 | Mar 14, 2034 | U-4547 | | | |
| | | 10420841*PED | Sep 14, 2034 | | | | |
| | | 10933053 | Sep 09, 2034 | U-3090 | | | |
| | | 10933053 | Sep 09, 2034 | U-3091 | | | |
| | | 10933053 | Sep 09, 2034 | U-4544 | | | |
| | | 10933053 | Sep 09, 2034 | U-4545 | | | |
| | | 10933053*PED | Mar 09, 2035 | | | | |
| | | 11278622 | Mar 14, 2034 | U-3335 | | | |
| | | 11278622 | Mar 14, 2034 | U-3336 | | | |
| | | 11278622 | Mar 14, 2034 | U-4542 | | | |
| | | 11278622 | Mar 14, 2034 | U-4543 | | | |
| | | 11278622*PED | Sep 14, 2034 | | | | |
| | | 7129232 | May 15, 2028 | DS DP U-1676 | | | |
| | | 7129232 | May 15, 2028 | DS DP U-3360 | | | |
| | | 7129232 | May 15, 2028 | DS DP U-3361 | | | |
| | | 7129232 | May 15, 2028 | DS DP U-36 | | | |
| | | 7129232 | May 15, 2028 | DS DP U-4542 | | | |
| | | 7129232 | May 15, 2028 | DS DP U-4543 | | | |
| | | 7129232 | May 15, 2028 | DS DP U-4547 | | | |
| | | 7129232 | May 15, 2028 | DS DP U-4550 | | | |
| | | 7129232*PED | Nov 15, 2028 | | | | |
| | | 8906898 | May 28, 2034 | DS DP | | | |
| | | 8906898*PED | Nov 28, 2034 | | | | |
| | | 8968753 | Mar 14, 2034 | U-1672 | | | |
| | | 8968753 | Mar 14, 2034 | U-1673 | | | |
| | | 8968753 | Mar 14, 2034 | U-3360 | | | |
| | | 8968753 | Mar 14, 2034 | U-3361 | | | |
| | | 8968753 | Mar 14, 2034 | U-4547 | | | |
| | | 8968753 | Mar 14, 2034 | U-4550 | | | |
| | | 8968753*PED | Sep 14, 2034 | | | | |
| | | 9320740 | Mar 14, 2034 | DP | | | |
| | | 9320740*PED | Sep 14, 2034 | | | | |
| | | 9724353 | Sep 07, 2032 | U-2565 | | | |
| | | 9724353 | Sep 07, 2032 | U-2566 | | | |
| | | 9724353 | Sep 07, 2032 | U-4542 | | | |
| | | 9724353 | Sep 07, 2032 | U-4543 | | | |
| | | 9724353*PED | Mar 07, 2033 | | | | |
| | | 9872906 | Mar 14, 2034 | DP | | | |
| | | 9872906*PED | Sep 14, 2034 | | | | |
| CELECOXIB - VYSCOXA | | | | | | | |
| N 211759 001 | | 12678405 | Sep 17, 2045 | DP | | | |
| CEVIMELINE HYDROCHLORIDE - EVOXAC | | | | | | | |
| N 221183 001 | >A> | 12558347 | May 20, 2045 | DP U-4634 | | | |
| CHENODIOL - CTEXLI | | | | | | | |
| N 219488 001 | | | | | | ODE-523 | Feb 21, 2032 |
| CHLORTHALIDONE - HEMICLOR | | | | | | | |
| N 218647 001 | | 12667554 | Sep 04, 2045 | DP | | | |
| CIPEPOFOL - CYPSEDO | | | | | | | |
| N 220482 001 | | 10729666 | May 06, 2034 | DP U-4599 | | NCE | Aug 27, 2031 |
| | | 9517988 | May 06, 2034 | DS U-4599 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| CITALOPRAM HYDROBROMIDE - CITALOPRAM HYDROBROMIDE | | | | | | |
| A 219985 001 | | | | | CGT | Sep 16, 2026 |
| CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ | | | | | | |
| N 209589 001 | 12576072 | Jun 23, 2034 | DP U-3261 | | | |
| CLADRIBINE - MAVENCLAD | | | | | | |
| N 022561 001 | 12533408 | Sep 10, 2041 | U-4395 | | | |
| | 12539329 | Sep 10, 2041 | U-4399 | | | |
| CLASCOTERONE - WINLEVI | | | | | | |
| N 213433 001 | 9433628 | Aug 26, 2031 | DS DP | | | |
| CLOBETASOL PROPIONATE - IMPOYZ | | | | | | |
| N 209483 001 | 11179465 | Aug 31, 2030 | DP U-1858 | | | |
| CLONIDINE HYDROCHLORIDE - ONYDA XR | | | | | | |
| N 217645 001 | 12576032 | Jul 28, 2041 | U-2357 | | | |
| CLONIDINE HYDROCHLORIDE - JAVADIN | | | | | | |
| N 220256 001 | 12721837 | Jul 15, 2042 | DP | | | |
| CLONIDINE HYDROCHLORIDE - QLONILIK | | | | | | |
| N 221094 001 | 12551466 | Aug 22, 2045 | DP U-4581 | | | |
| CLOTRIMAZOLE - CLOTIC | | | | | | |
| N 217628 001 | | | | | ODE-549 | Sep 26, 2032 |
| | | | | | GAIN | Sep 26, 2037 |
| COBICISTAT - TYBOST | | | | | | |
| N 203094 001 | | | | | NPP | Jun 20, 2028 |
| COBICISTAT - TYBOST | | | | | | |
| N 203094 002 | | | | | NS | Jun 20, 2028 |
| COLCHICINE - GLOPERBA | | | | | | |
| N 210942 001 | 12514819 | Nov 22, 2036 | U-2814 | | | |
| COPPER - MIUDELLA | | | | | | |
| N 218201 001 | 9180040 | Mar 22, 2034 | DP | | | |
| COPPER HISTIDINATE - ZYCUBO | | | | | | |
| N 211241 001 | | | | | NCE | Jan 12, 2031 |
| | | | | | ODE-520 | Jan 12, 2033 |
| CORTICOTROPIN - PURIFIED CORTROPHIN GEL | | | | | | |
| N 008975 002 | 12734217 | Oct 27, 2043 | DP U-3904 | | | |
| | 12734217 | Oct 27, 2043 | DP U-3905 | | | |
| | 12734217 | Oct 27, 2043 | DP U-3907 | | | |
| | 12734217 | Oct 27, 2043 | DP U-3912 | | | |
| | 12734217 | Oct 27, 2043 | DP U-3916 | | | |
| | 12734217 | Oct 27, 2043 | DP U-3924 | | | |
| CRINECERFONT - CRENESSITY | | | | | | |
| N 218808 001 | 12582634 | Jan 12, 2043 | DS | | | |
| CRINECERFONT - CRENESSITY | | | | | | |
| N 218808 002 | 12582634 | Jan 12, 2043 | DS | | | |
| CRINECERFONT - CRENESSITY | | | | | | |
| N 218808 003 | 12582634 | Jan 12, 2043 | DS | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| CRINECERFONT - CRENESSITY | | | | | | |
| N 218820 001 | 12582634 | Jan 12, 2043 | DS | | | |
| CYSTEINE HYDROCHLORIDE - NOURESS | | | | | | |
| N 212535 001 | 12569514 | Jan 15, 2039 | DP | | | |
| CYTARABINE; DAUNORUBICIN - VYXEOS | | | | | | |
| N 209401 001 | 10028912 | Oct 15, 2032 | DP U-3149 | | ODE-350 | Mar 30, 2028 |
| | 10028912 | Oct 15, 2032 | DP U-3150 | | PED | Sep 30, 2028 |
| | 10028912*PED | Apr 15, 2033 | | | | |
| | 10166184 | Oct 15, 2032 | DP U-3149 | | | |
| | 10166184*PED | Apr 15, 2033 | | | | |
| | 10835492 | Oct 15, 2032 | U-3150 | | | |
| | 10835492*PED | Apr 15, 2033 | | | | |
| | 7850990 | Jan 23, 2027 | DP U-3147 | | | |
| | 7850990*PED | Jul 23, 2027 | | | | |
| | 8022279 | Sep 14, 2027 | DP U-3147 | | | |
| | 8022279*PED | Mar 14, 2028 | | | | |
| | 8092828 | Apr 01, 2029 | U-3147 | | | |
| | 8092828*PED | Oct 01, 2029 | | | | |
| | 9271931 | Jan 23, 2027 | DP | | | |
| | 9271931*PED | Jul 23, 2027 | | | | |
| DANICOPAN - VOYDEYA | | | | | | |
| N 218037 001 | 9796741 | Mar 29, 2038 | DS U-3933 | | | |
| DANICOPAN - VOYDEYA | | | | | | |
| N 218037 002 | 9796741 | Mar 29, 2038 | DS U-3933 | | | |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211156 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211156 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211312 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211312 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211467 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211467 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211470 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211470 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211482 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211482 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211523 001 | | | | | PC | Oct 03, 2026 |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211523 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211541 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211541 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211545 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211545 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211560 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN - DAPAGLIFLOZIN | | | | | | |
| A 211560 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211479 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211479 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211479 003 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211479 004 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211491 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211491 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211491 003 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211563 001 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211563 002 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211563 003 | | | | | PC | Oct 03, 2026 |
| DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | |
| A 211563 004 | | | | | PC | Oct 03, 2026 |
| DAPTOMYCIN - DAPTOMYCIN | | | | | | |
| N 217415 001 | 12629337 | Jan 09, 2043 | DP | | | |
| DAPTOMYCIN - DAPTOMYCIN | | | | | | |
| N 217415 002 | 12629337 | Jan 09, 2043 | DP | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DARAXONRASIB - RASONQUE | | | | | | |
| N 220910 001 | 12280113 | Jan 24, 2042 | DS DP | | NCE | Aug 26, 2031 |
| | 12403196 | Sep 15, 2041 | DS DP | | | |
| DARAXONRASIB - RASONQUE | | | | | | |
| N 220910 002 | 12280113 | Jan 24, 2042 | DS DP | | NCE | Aug 26, 2031 |
| | 12403196 | Sep 15, 2041 | DS DP | | | |
| DARIDOREXANT HYDROCHLORIDE - QUVIVIQ | | | | | | |
| N 214985 001 | 9732075 | Jun 03, 2033 | DS DP U-620 | | | |
| DARIDOREXANT HYDROCHLORIDE - QUVIVIQ | | | | | | |
| N 214985 002 | 9732075 | Jun 03, 2033 | DS DP U-620 | | | |
| DAROLUTAMIDE - NUBEQA | | | | | | |
| N 212099 001 | 12329742 | Jun 17, 2042 | DP | | | |
| | 12611397 | Jul 02, 2040 | DP | | | |
| DASATINIB - PHYRAGO | | | | | | |
| N 216099 001 | 12544376 | Jan 22, 2041 | U-3767 | | | |
| | 12544376 | Jan 22, 2041 | U-3768 | | | |
| | 12544376 | Jan 22, 2041 | U-3769 | | | |
| | 12544376 | Jan 22, 2041 | U-3770 | | | |
| | 12544376 | Jan 22, 2041 | U-3771 | | | |
| | 12544376 | Jan 22, 2041 | U-3772 | | | |
| DASATINIB - PHYRAGO | | | | | | |
| N 216099 002 | 12544376 | Jan 22, 2041 | U-3767 | | | |
| | 12544376 | Jan 22, 2041 | U-3768 | | | |
| | 12544376 | Jan 22, 2041 | U-3769 | | | |
| | 12544376 | Jan 22, 2041 | U-3770 | | | |
| | 12544376 | Jan 22, 2041 | U-3771 | | | |
| | 12544376 | Jan 22, 2041 | U-3772 | | | |
| DASATINIB - PHYRAGO | | | | | | |
| N 216099 003 | 12544376 | Jan 22, 2041 | U-3767 | | | |
| | 12544376 | Jan 22, 2041 | U-3768 | | | |
| | 12544376 | Jan 22, 2041 | U-3769 | | | |
| | 12544376 | Jan 22, 2041 | U-3770 | | | |
| | 12544376 | Jan 22, 2041 | U-3771 | | | |
| | 12544376 | Jan 22, 2041 | U-3772 | | | |
| DASATINIB - PHYRAGO | | | | | | |
| N 216099 004 | 12544376 | Jan 22, 2041 | U-3767 | | | |
| | 12544376 | Jan 22, 2041 | U-3768 | | | |
| | 12544376 | Jan 22, 2041 | U-3769 | | | |
| | 12544376 | Jan 22, 2041 | U-3770 | | | |
| | 12544376 | Jan 22, 2041 | U-3771 | | | |
| | 12544376 | Jan 22, 2041 | U-3772 | | | |
| DASATINIB - PHYRAGO | | | | | | |
| N 216099 005 | 12544376 | Jan 22, 2041 | U-3767 | | | |
| | 12544376 | Jan 22, 2041 | U-3768 | | | |
| | 12544376 | Jan 22, 2041 | U-3769 | | | |
| | 12544376 | Jan 22, 2041 | U-3770 | | | |
| | 12544376 | Jan 22, 2041 | U-3771 | | | |
| | 12544376 | Jan 22, 2041 | U-3772 | | | |
| DASATINIB - PHYRAGO | | | | | | |
| N 216099 006 | 12544376 | Jan 22, 2041 | U-3767 | | | |
| | 12544376 | Jan 22, 2041 | U-3768 | | | |
| | 12544376 | Jan 22, 2041 | U-3769 | | | |
| | 12544376 | Jan 22, 2041 | U-3770 | | | |
| | 12544376 | Jan 22, 2041 | U-3771 | | | |
| | 12544376 | Jan 22, 2041 | U-3772 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE | | | | | | | |
| N 214231 | 001 | 10442847 | Mar 22, 2035 | DS DP | | NPP | Jun 18, 2029 |
| DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR) | | | | | | | |
| N 214231 | 002 | 10442847 | Mar 22, 2035 | DS DP | | NPP | Jun 18, 2029 |
| DEFIBROTIDE SODIUM - DEFITELIO | | | | | | | |
| N 208114 | 001 | 12529052 | Jun 22, 2032 | DP | | | |
| | | 12534722 | Jun 22, 2032 | DP | | | |
| DEGARELIX ACETATE - FIRMAGON | | | | | | | |
| N 022201 | 001 | 12514898 | Feb 20, 2029 | U-1978 | | | |
| | | 12533387 | Feb 20, 2029 | U-4417 | | | |
| DEGARELIX ACETATE - FIRMAGON | | | | | | | |
| N 022201 | 002 | 12514898 | Feb 20, 2029 | U-1978 | | | |
| | | 12533387 | Feb 20, 2029 | U-4417 | | | |
| DEHYDRATED ALCOHOL - DEHYDRATED ALCOHOL | | | | | | | |
| N 214988 | 001 | | | | | ODE-521 | Oct 23, 2032 |
| DELAFLOXACIN MEGLUMINE - BAXDELA | | | | | | | |
| N 208611 | 001 | 12558349 | Mar 14, 2034 | U-3967 | | | |
| DESMOPRESSIN ACETATE - DESMODA | | | | | | | |
| N 219873 | 001 | 12214010 | Apr 03, 2044 | DP | | | |
| | | 12343372 | Apr 03, 2044 | DP U-4432 | | | |
| DEUCRAVACITINIB - SOTYKTU | | | | | | | |
| N 214958 | 001 | 12521390 | Feb 11, 2043 | DP U-3434 | | I-986 | Mar 06, 2029 |
| | | 12521390 | Feb 11, 2043 | DP U-4451 | | | |
| | | 12734169 | Sep 18, 2040 | DP U-3434 | | | |
| | | 12734169 | Sep 18, 2040 | DP U-4452 | | | |
| | >A> | 12751948 | Sep 18, 2040 | DP U-3434 | | | |
| | >A> | 12751948 | Sep 18, 2040 | DP U-4452 | | | |
| | | RE47929 | Nov 07, 2033 | DS DP U-3434 | | | |
| | | RE47929 | Nov 07, 2033 | DS DP U-4452 | | | |
| DEUTETRABENAZINE - AUSTEDO XR | | | | | | | |
| N 216354 | 001 | 12589075 | Jun 10, 2041 | U-1995 | | | |
| | | 12589075 | Jun 10, 2041 | U-3055 | | | |
| | | 12599598 | Jun 10, 2041 | U-1995 | | | |
| | | 12599598 | Jun 10, 2041 | U-3055 | | | |
| DEUTETRABENAZINE - AUSTEDO XR | | | | | | | |
| N 216354 | 002 | 12589075 | Jun 10, 2041 | U-1995 | | | |
| | | 12589075 | Jun 10, 2041 | U-3055 | | | |
| | | 12599598 | Jun 10, 2041 | U-1995 | | | |
| | | 12599598 | Jun 10, 2041 | U-3055 | | | |
| DEUTETRABENAZINE - AUSTEDO XR | | | | | | | |
| N 216354 | 003 | 12589075 | Jun 10, 2041 | U-1995 | | | |
| | | 12589075 | Jun 10, 2041 | U-3055 | | | |
| | | 12599598 | Jun 10, 2041 | U-1995 | | | |
| | | 12599598 | Jun 10, 2041 | U-3055 | | | |
| DEUTETRABENAZINE - AUSTEDO XR | | | | | | | |
| N 216354 | 004 | 12589075 | Jun 10, 2041 | U-1995 | | | |
| | | 12589075 | Jun 10, 2041 | U-3055 | | | |
| | | 12599598 | Jun 10, 2041 | U-1995 | | | |
| | | 12599598 | Jun 10, 2041 | U-3055 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DEUTETRABENAZINE - AUSTEDO XR | | | | | | |
| N 216354 005 | 12589075 | Jun 10, 2041 | U-1995 | | | |
| | 12589075 | Jun 10, 2041 | U-3055 | | | |
| | 12599598 | Jun 10, 2041 | U-1995 | | | |
| | 12599598 | Jun 10, 2041 | U-3055 | | | |
| DEUTETRABENAZINE - AUSTEDO XR | | | | | | |
| N 216354 006 | 12589075 | Jun 10, 2041 | U-1995 | | | |
| | 12589075 | Jun 10, 2041 | U-3055 | | | |
| | 12599598 | Jun 10, 2041 | U-1995 | | | |
| | 12599598 | Jun 10, 2041 | U-3055 | | | |
| DEUTETRABENAZINE - AUSTEDO XR | | | | | | |
| N 216354 007 | 12589075 | Jun 10, 2041 | U-1995 | | | |
| | 12589075 | Jun 10, 2041 | U-3055 | | | |
| | 12599598 | Jun 10, 2041 | U-1995 | | | |
| | 12599598 | Jun 10, 2041 | U-3055 | | | |
| DEUTETRABENAZINE - AUSTEDO XR | | | | | | |
| N 216354 008 | 12589075 | Jun 10, 2041 | U-1995 | | | |
| | 12589075 | Jun 10, 2041 | U-3055 | | | |
| | 12599598 | Jun 10, 2041 | U-1995 | | | |
| | 12599598 | Jun 10, 2041 | U-3055 | | | |
| DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK | | | | | | |
| N 218730 001 | 10081621 | Mar 25, 2031 | DP U-4087 | | ODE-526 | Dec 20, 2031 |
| | 10081621 | Mar 25, 2031 | DP U-4468 | | ODE-536 | Mar 27, 2033 |
| | 10239867 | Apr 09, 2027 | DS DP U-4090 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-4464 | | | |
| | 11564916 | Aug 13, 2029 | U-4095 | | | |
| | 11564916 | Aug 13, 2029 | U-4466 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4096 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4465 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4090 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4464 | | | |
| | 11866450 | Feb 14, 2039 | U-4082 | | | |
| | 11866450 | Feb 14, 2039 | U-4463 | | | |
| | 11873300 | Aug 13, 2040 | DS DP U-4083 | | | |
| | 11873300 | Aug 13, 2040 | DS DP U-4462 | | | |
| | 8324242 | Aug 05, 2027 | U-4090 | | | |
| | 8324242 | Aug 05, 2027 | U-4464 | | | |
| | 8415387 | Nov 12, 2027 | U-4082 | | | |
| | 8415387 | Nov 12, 2027 | U-4463 | | | |
| | 8598181 | May 01, 2027 | U-4090 | | | |
| | 8598181 | May 01, 2027 | U-4463 | | | |
| | 9181192 | May 17, 2032 | DS DP U-4094 | | | |
| | 9181192 | May 17, 2032 | DS DP U-4472 | | | |
| | 9512079 | May 17, 2032 | DS DP U-4098 | | | |
| | 9512079 | May 17, 2032 | DS DP U-4471 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4080 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4470 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4080 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4469 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4082 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4463 | | | |
| DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK | | | | | | |
| N 218730 002 | 10081621 | Mar 25, 2031 | DP U-4087 | | ODE-526 | Dec 20, 2031 |
| | 10081621 | Mar 25, 2031 | DP U-4468 | | ODE-536 | Mar 27, 2033 |
| | 10206877 | Apr 14, 2035 | DP U-4092 | | | |
| | 10206877 | Apr 14, 2035 | DP U-4467 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-4090 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-4464 | | | |
| | 11564916 | Aug 13, 2029 | U-4095 | | | |
| | 11564916 | Aug 13, 2029 | U-4466 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4096 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4465 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4090 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 218730 002 | 11639347 | Apr 09, 2027 | DS DP U-4464 | | | |
| | 11866450 | Feb 14, 2039 | U-4082 | | | |
| | 11866450 | Feb 14, 2039 | U-4463 | | | |
| | 11873300 | Aug 13, 2040 | DS DP U-4083 | | | |
| | 11873300 | Aug 13, 2040 | DS DP U-4462 | | | |
| | 11951212 | Apr 14, 2035 | DP U-4089 | | | |
| | 11951212 | Apr 14, 2035 | DP U-4461 | | | |
| | 12186306 | Jan 10, 2043 | U-4088 | | | |
| | 12186306 | Jan 10, 2043 | U-4460 | | | |
| | 8324242 | Aug 05, 2027 | U-4090 | | | |
| | 8324242 | Aug 05, 2027 | U-4464 | | | |
| | 8415387 | Nov 12, 2027 | U-4082 | | | |
| | 8415387 | Nov 12, 2027 | U-4463 | | | |
| | 8598181 | May 01, 2027 | U-4090 | | | |
| | 8598181 | May 01, 2027 | U-4463 | | | |
| | 9181192 | May 17, 2032 | DS DP U-4094 | | | |
| | 9181192 | May 17, 2032 | DS DP U-4472 | | | |
| | 9512079 | May 17, 2032 | DS DP U-4098 | | | |
| | 9512079 | May 17, 2032 | DS DP U-4471 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4080 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4470 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4080 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4469 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4082 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4463 | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS | | | | | | |
| N 212994 001 | 9079928 | May 07, 2035 | DP | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS | | | | | | |
| N 212994 002 | 9079928 | May 07, 2035 | DP | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS | | | | | | |
| N 212994 003 | 9079928 | May 07, 2035 | DP | | | |
| DEXTROAMPHETAMINE - XELSTRYM | | | | | | |
| N 215401 001 | 12678504 | Mar 12, 2034 | DP U-4583 | | | |
| DEXTROAMPHETAMINE - XELSTRYM | | | | | | |
| N 215401 002 | 12678504 | Mar 12, 2034 | DP U-4583 | | | |
| DEXTROAMPHETAMINE - XELSTRYM | | | | | | |
| N 215401 003 | 12678504 | Mar 12, 2034 | DP U-4583 | | | |
| DEXTROAMPHETAMINE - XELSTRYM | | | | | | |
| N 215401 004 | 12678504 | Mar 12, 2034 | DP U-4583 | | | |
| DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM - MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM | | | | | | |
| N 217338 001 | 11278506 | Oct 11, 2036 | DP | | | |
| | 12257218 | Oct 11, 2036 | DP | | | |
| | 12370189 | Oct 11, 2036 | DP | | | |
| DIAZEPAM - VALTOCO | | | | | | |
| N 211635 001 | 12521400 | Mar 27, 2029 | DP | | | |
| | 12599611 | Jun 10, 2042 | U-4455 | | | |
| >A> | 12758561 | Mar 27, 2029 | DP | | | |
| DIAZEPAM - VALTOCO | | | | | | |
| N 211635 002 | 12521400 | Mar 27, 2029 | DP | | | |
| | 12599611 | Jun 10, 2042 | U-4455 | | | |
| >A> | 12758561 | Mar 27, 2029 | DP | | | |
| DIAZEPAM - VALTOCO | | | | | | |
| N 211635 003 | 12521400 | Mar 27, 2029 | DP | | | |
| | 12599611 | Jun 10, 2042 | U-4455 | | | |

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|---|
| N 211635 | 003 | >A> | 12758561 | Mar 27, 2029 | | DP | | | |
| DIAZOXIDE CHOLINE - VYKAT XR | | | | | | | | | |
| N 216665 | 001 | | | | | | | ODE-532 | Mar 26, 2032 |
| DIAZOXIDE CHOLINE - VYKAT XR | | | | | | | | | |
| N 216665 | 002 | | | | | | | ODE-532 | Mar 26, 2032 |
| DIAZOXIDE CHOLINE - VYKAT XR | | | | | | | | | |
| N 216665 | 003 | | | | | | | ODE-532 | Mar 26, 2032 |
| DICHLORPHENAMIDE - KEVEYIS | | | | | | | | | |
| N 011366 | 002 | >A> | 12758502 | Dec 23, 2043 | | U-4613 | | | |
| DICLOFENAC EPOLAMINE - LICART | | | | | | | | | |
| N 206976 | 001 | | | | | | | NPP | Mar 27, 2029 |
| DICLOFENAC SODIUM - ZUEINO | | | | | | | | | |
| N 218379 | 001 | >A> | 11110073 | Mar 23, 2038 | | DP U-4618 | | | |
| | | >A> | 11707443 | Dec 08, 2040 | | DP U-4618 | | | |
| | | >A> | 11850224 | Aug 10, 2038 | | DP U-4618 | | | |
| DIFAMILAST - ADQUEY | | | | | | | | | |
| N 219474 | 001 | | 10588893 | Dec 31, 2036 | DS | DP | | NCE | Feb 12, 2031 |
| | | | RE46792 | Mar 01, 2028 | DS | DP U-4445 | | | |
| DIFELIKEFALIN ACETATE - KORSUVA | | | | | | | | | |
| N 214916 | 001 | | 7402564 | Nov 12, 2032 | DS | DP U-3204 | | | |
| DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR) | | | | | | | | | |
| N 215400 | 001 | | 11083712 | Jun 30, 2039 | | DP U-2718 | | | |
| | | | 11083712 | Jun 30, 2039 | | DP U-4508 | | | |
| | | | 11541043 | Mar 20, 2039 | | DP | | | |
| | | | 12329749 | May 27, 2039 | | DP U-2718 | | | |
| | | | 12329749 | May 27, 2039 | | DP U-4508 | | | |
| | | | 12414941 | Aug 24, 2039 | | DP | | | |
| | | | 12533351 | Feb 26, 2039 | | DP | | | |
| DIHYDROERGOTAMINE MESYLATE - ATZUMI | | | | | | | | | |
| N 217901 | 001 | | 12594273 | Sep 24, 2033 | | DP | | | |
| DIMETHYL SULFOXIDE - DIMETHYL SULFOXIDE | | | | | | | | | |
| A 220173 | 001 | | | | | | | CGT | Mar 10, 2027 |
| DOCETAXEL - BEIZRAY | | | | | | | | | |
| N 218711 | 002 | | 11419842 | May 16, 2036 | | DP U-4027 | | | |
| | | | 11419842 | May 16, 2036 | | DP U-4028 | | | |
| | | | 11419842 | May 16, 2036 | | DP U-881 | | | |
| | | | 11419842 | May 16, 2036 | | DP U-937 | | | |
| | | | 11419842 | May 16, 2036 | | DP U-946 | | | |
| | | | 12090134 | May 16, 2036 | | DP U-4027 | | | |
| | | | 12090134 | May 16, 2036 | | DP U-4028 | | | |
| | | | 12090134 | May 16, 2036 | | DP U-881 | | | |
| | | | 12090134 | May 16, 2036 | | DP U-937 | | | |
| | | | 12090134 | May 16, 2036 | | DP U-946 | | | |
| | | | 12090135 | May 16, 2036 | | DP | | | |
| DOLUTEGRAVIR SODIUM - TIVICAY PD | | | | | | | | | |
| N 213983 | 001 | | | | | | | NPP | Aug 25, 2029 |
| | | | | | | | | PED | Feb 25, 2030 |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DONIDALORSEN SODIUM - DAWNZERA (AUTOINJECTOR) | | | | | | | |
| N 219407 | 001 | | | | | ODE-550 | Aug 21, 2032 |
| DORAVIRINE; ISLATRAVIR - IDVYNSO | | | | | | | |
| N 216964 | 001 | 7339053 | May 31, 2027 | DS | | NCE | Apr 20, 2031 |
| | | 8486975 | Aug 30, 2032 | DS DP U-4527 | | | |
| DORDAVIPRONE HYDROCHLORIDE - MODEYSO | | | | | | | |
| N 219876 | 001 | RE46290 | Aug 30, 2032 | U-4254 | | ODE-547 | Aug 06, 2032 |
| DOXECITINE; DOXRIBTIMINE - KYGEVVI | | | | | | | |
| N 219792 | 001 >A> | 12746287 | Sep 23, 2044 | U-4633 | | | |
| DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE | | | | | | | |
| N 219131 | 001 | 12721817 | Jan 13, 2046 | DP | | | |
| DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE | | | | | | | |
| N 219131 | 002 | 12721817 | Jan 13, 2046 | DP | | | |
| DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE | | | | | | | |
| N 219131 | 003 | 12721817 | Jan 13, 2046 | DP | | | |
| DUVELISIB - COPIKTRA | | | | | | | |
| N 211155 | 001 | 8193182 | Sep 24, 2032 | DS | | | |
| DUVELISIB - COPIKTRA | | | | | | | |
| N 211155 | 002 | 8193182 | Sep 24, 2032 | DS | | | |
| EDARAVONE - RADICAVA ORS | | | | | | | |
| N 215446 | 001 | 12527769 | Nov 12, 2041 | U-4111 | | | |
| | | 12569469 | Nov 12, 2041 | U-4111 | | | |
| | | 12599586 | Nov 01, 2039 | DP | | | |
| EFLORNITHINE HYDROCHLORIDE - IWILFIN | | | | | | | |
| N 215500 | 001 | 12582625 | Feb 12, 2036 | U-4444 | | | |
| ELAFIBRANOR - IQIRVO | | | | | | | |
| N 218860 | 001 | 12589086 | Mar 30, 2037 | U-4473 | | | |
| | | 12673035 | Mar 05, 2044 | DP U-1854 | | | |
| ELAMIPRETIDE HYDROCHLORIDE - FORZINITY | | | | | | | |
| N 215244 | 001 | 7576061 | Jan 20, 2027 | DS DP | | ODE-551 | Sep 19, 2032 |
| ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED) | | | | | | | |
| N 212273 | 001 | 10081621 | Mar 25, 2031 | DP U-3032 | | ODE-543 | Mar 27, 2033 |
| | | 10081621 | Mar 25, 2031 | DP U-3157 | | | |
| | | 10081621 | Mar 25, 2031 | DP U-4075 | | | |
| | | 10081621 | Mar 25, 2031 | DP U-4480 | | | |
| | | 10239867 | Apr 09, 2027 | DS DP U-3033 | | | |
| | | 10239867 | Apr 09, 2027 | DS DP U-3158 | | | |
| | | 10239867 | Apr 09, 2027 | DS DP U-4056 | | | |
| | | 10239867 | Apr 09, 2027 | DS DP U-4475 | | | |
| | | 10758534 | Oct 06, 2035 | DS DP U-3028 | | | |
| | | 10758534 | Oct 06, 2035 | DS DP U-3144 | | | |
| | | 10758534 | Oct 06, 2035 | DS DP U-4073 | | | |
| | | 10758534 | Oct 06, 2035 | DS DP U-4475 | | | |
| | | 10793547 | Dec 08, 2037 | DS DP U-3028 | | | |
| | | 10793547 | Dec 08, 2037 | DS DP U-3144 | | | |
| | | 10793547 | Dec 08, 2037 | DS DP U-4073 | | | |
| | | 10793547 | Dec 08, 2037 | DS DP U-4475 | | | |
| | | 11179367 | Dec 08, 2037 | DP U-3253 | | | |
| | | 11179367 | Dec 08, 2037 | DP U-4071 | | | |
| | | 11179367 | Dec 08, 2037 | DP U-4487 | | | |
| | | 11426407 | Oct 06, 2035 | DS DP U-3425 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 212273 001 | 11426407 | Oct 06, 2035 | DS DP U-4070 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-4475 | | | |
| | 11517564 | Dec 08, 2037 | DP U-3498 | | | |
| | 11517564 | Dec 08, 2037 | DP U-4067 | | | |
| | 11517564 | Dec 08, 2037 | DP U-4475 | | | |
| | 11564916 | Aug 13, 2029 | U-3525 | | | |
| | 11564916 | Aug 13, 2029 | U-4063 | | | |
| | 11564916 | Aug 13, 2029 | U-4491 | | | |
| | 11578062 | Mar 25, 2031 | DP U-3544 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4054 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4490 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-3587 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4056 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4475 | | | |
| | 12350262 | Jul 17, 2038 | U-4221 | | | |
| | 12350262 | Jul 17, 2038 | U-4475 | | | |
| | 12458635 | Aug 13, 2029 | DP U-4330 | | | |
| | 12458635 | Aug 13, 2029 | DP U-4486 | | | |
| | 8324242 | Aug 05, 2027 | U-3028 | | | |
| | 8324242 | Aug 05, 2027 | U-3144 | | | |
| | 8324242 | Aug 05, 2027 | U-4073 | | | |
| | 8324242 | Aug 05, 2027 | U-4475 | | | |
| | 8415387 | Nov 12, 2027 | U-3028 | | | |
| | 8415387 | Nov 12, 2027 | U-3144 | | | |
| | 8415387 | Nov 12, 2027 | U-4073 | | | |
| | 8415387 | Nov 12, 2027 | U-4475 | | | |
| | 8598181 | May 01, 2027 | U-3028 | | | |
| | 8598181 | May 01, 2027 | U-3144 | | | |
| | 8598181 | May 01, 2027 | U-4056 | | | |
| | 8598181 | May 01, 2027 | U-4475 | | | |
| | 9670163 | Dec 28, 2026 | DP U-3031 | | | |
| | 9670163 | Dec 28, 2026 | DP U-3155 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4078 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4477 | | | |
| | 9931334 | Dec 28, 2026 | DP U-3031 | | | |
| | 9931334 | Dec 28, 2026 | DP U-3155 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4078 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4479 | | | |
| | 9974781 | Apr 09, 2027 | DP U-3028 | | | |
| | 9974781 | Apr 09, 2027 | DP U-3144 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4073 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4475 | | | |
| ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED) | | | | | | |
| N 212273 002 | 10081621 | Mar 25, 2031 | DP U-3157 | | ODE-543 | Mar 27, 2033 |
| | 10081621 | Mar 25, 2031 | DP U-4075 | | | |
| | 10081621 | Mar 25, 2031 | DP U-4480 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-3158 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-4056 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-4475 | | | |
| | 10758534 | Oct 06, 2035 | DS DP U-3144 | | | |
| | 10758534 | Oct 06, 2035 | DS DP U-4073 | | | |
| | 10758534 | Oct 06, 2035 | DS DP U-4475 | | | |
| | 10793547 | Dec 08, 2037 | DS DP U-3144 | | | |
| | 10793547 | Dec 08, 2037 | DS DP U-4073 | | | |
| | 10793547 | Dec 08, 2037 | DS DP U-4475 | | | |
| | 11179367 | Dec 08, 2037 | DP U-3253 | | | |
| | 11179367 | Dec 08, 2037 | DP U-4071 | | | |
| | 11179367 | Dec 08, 2037 | DP U-4487 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-3425 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-4070 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-4475 | | | |
| | 11517564 | Dec 08, 2037 | DP U-3498 | | | |
| | 11517564 | Dec 08, 2037 | DP U-4069 | | | |
| | 11517564 | Dec 08, 2037 | DP U-4475 | | | |
| | 11564916 | Aug 13, 2029 | U-3525 | | | |
| | 11564916 | Aug 13, 2029 | U-4063 | | | |
| | 11564916 | Aug 13, 2029 | U-4491 | | | |
| | 11578062 | Mar 25, 2031 | DP U-3544 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 212273 002 | 11578062 | Mar 25, 2031 | DP U-4054 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4490 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-3587 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4056 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4475 | | | |
| | 12350262 | Jul 17, 2038 | U-4222 | | | |
| | 12350262 | Jul 17, 2038 | U-4475 | | | |
| | 12458635 | Aug 13, 2029 | DP U-4330 | | | |
| | 12458635 | Aug 13, 2029 | DP U-4486 | | | |
| | 8324242 | Aug 05, 2027 | U-3144 | | | |
| | 8324242 | Aug 05, 2027 | U-4073 | | | |
| | 8324242 | Aug 05, 2027 | U-4475 | | | |
| | 8415387 | Nov 12, 2027 | U-3144 | | | |
| | 8415387 | Nov 12, 2027 | U-4073 | | | |
| | 8415387 | Nov 12, 2027 | U-4475 | | | |
| | 8598181 | May 01, 2027 | U-3144 | | | |
| | 8598181 | May 01, 2027 | U-4056 | | | |
| | 8598181 | May 01, 2027 | U-4475 | | | |
| | 9670163 | Dec 28, 2026 | DP U-3155 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4078 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4477 | | | |
| | 9931334 | Dec 28, 2026 | DP U-3155 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4078 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4479 | | | |
| | 9974781 | Apr 09, 2027 | DP U-3144 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4073 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4475 | | | |
| ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED) | | | | | | |
| N 217660 001 | 10081621 | Mar 25, 2031 | DP U-3600 | | ODE-543 | Mar 27, 2033 |
| | 10081621 | Mar 25, 2031 | DP U-4065 | | | |
| | 10081621 | Mar 25, 2031 | DP U-4481 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-3590 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-4053 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-4476 | | | |
| | 10272046 | Feb 27, 2033 | DP U-3599 | | | |
| | 10272046 | Feb 27, 2033 | DP U-4062 | | | |
| | 10272046 | Feb 27, 2033 | DP U-4482 | | | |
| | 10758534 | Oct 06, 2035 | DS DP U-3589 | | | |
| | 10758534 | Oct 06, 2035 | DS DP U-4066 | | | |
| | 10758534 | Oct 06, 2035 | DS DP U-4476 | | | |
| | 10793547 | Dec 08, 2037 | DS DP U-3588 | | | |
| | 10793547 | Dec 08, 2037 | DS DP U-4066 | | | |
| | 10793547 | Dec 08, 2037 | DS DP U-4476 | | | |
| | 11147770 | Feb 27, 2033 | DP U-3598 | | | |
| | 11147770 | Feb 27, 2033 | DP U-4060 | | | |
| | 11147770 | Feb 27, 2033 | DP U-4483 | | | |
| | 11179367 | Dec 08, 2037 | DP U-3597 | | | |
| | 11179367 | Dec 08, 2037 | DP U-4059 | | | |
| | 11179367 | Dec 08, 2037 | DP U-4484 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-3595 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-4058 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-4476 | | | |
| | 11517564 | Dec 08, 2037 | DP U-3586 | | | |
| | 11517564 | Dec 08, 2037 | DP U-4057 | | | |
| | 11517564 | Dec 08, 2037 | DP U-4476 | | | |
| | 11564916 | Aug 13, 2029 | U-3585 | | | |
| | 11564916 | Aug 13, 2029 | U-4055 | | | |
| | 11564916 | Aug 13, 2029 | U-4485 | | | |
| | 11578062 | Mar 25, 2031 | DP U-3584 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4054 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4488 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-3583 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4053 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4476 | | | |
| | 11752106 | Feb 27, 2033 | DP U-3696 | | | |
| | 11752106 | Feb 27, 2033 | DP U-4052 | | | |
| | 11752106 | Feb 27, 2033 | DP U-4489 | | | |
| | 12214083 | Feb 27, 2033 | DP U-4141 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 217660 001 | 12214083 | Feb 27, 2033 | DP U-4492 | | | |
| | 12458635 | Aug 13, 2029 | DP U-4333 | | | |
| | 12458635 | Aug 13, 2029 | DP U-4493 | | | |
| | 8324242 | Aug 05, 2027 | U-3589 | | | |
| | 8324242 | Aug 05, 2027 | U-4066 | | | |
| | 8324242 | Aug 05, 2027 | U-4476 | | | |
| | 8415387 | Nov 12, 2027 | U-3589 | | | |
| | 8415387 | Nov 12, 2027 | U-4066 | | | |
| | 8415387 | Nov 12, 2027 | U-4476 | | | |
| | 8598181 | May 01, 2027 | U-3589 | | | |
| | 8598181 | May 01, 2027 | U-4066 | | | |
| | 8598181 | May 01, 2027 | U-4476 | | | |
| | 9670163 | Dec 28, 2026 | DP U-3591 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4068 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4478 | | | |
| | 9931334 | Dec 28, 2026 | DP U-3591 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4068 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4478 | | | |
| | 9974781 | Apr 09, 2027 | DP U-3589 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4066 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4476 | | | |
| ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED) | | | | | | |
| N 217660 002 | 10081621 | Mar 25, 2031 | DP U-3600 | | ODE-543 | Mar 27, 2033 |
| | 10081621 | Mar 25, 2031 | DP U-4065 | | | |
| | 10081621 | Mar 25, 2031 | DP U-4481 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-3590 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-4053 | | | |
| | 10239867 | Apr 09, 2027 | DS DP U-4476 | | | |
| | 10272046 | Feb 27, 2033 | DP U-3599 | | | |
| | 10272046 | Feb 27, 2033 | DP U-4062 | | | |
| | 10272046 | Feb 27, 2033 | DP U-4482 | | | |
| | 10758534 | Oct 06, 2035 | DS DP U-3589 | | | |
| | 10758534 | Oct 06, 2035 | DS DP U-4066 | | | |
| | 10758534 | Oct 06, 2035 | DS DP U-4476 | | | |
| | 10793547 | Dec 08, 2037 | DS DP U-3588 | | | |
| | 10793547 | Dec 08, 2037 | DS DP U-4066 | | | |
| | 10793547 | Dec 08, 2037 | DS DP U-4476 | | | |
| | 11147770 | Feb 27, 2033 | DP U-3598 | | | |
| | 11147770 | Feb 27, 2033 | DP U-4060 | | | |
| | 11147770 | Feb 27, 2033 | DP U-4483 | | | |
| | 11179367 | Dec 08, 2037 | DP U-3597 | | | |
| | 11179367 | Dec 08, 2037 | DP U-4059 | | | |
| | 11179367 | Dec 08, 2037 | DP U-4484 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-3595 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-4058 | | | |
| | 11426407 | Oct 06, 2035 | DS DP U-4476 | | | |
| | 11517564 | Dec 08, 2037 | DP U-3586 | | | |
| | 11517564 | Dec 08, 2037 | DP U-4057 | | | |
| | 11517564 | Dec 08, 2037 | DP U-4476 | | | |
| | 11564916 | Aug 13, 2029 | U-3585 | | | |
| | 11564916 | Aug 13, 2029 | U-4055 | | | |
| | 11564916 | Aug 13, 2029 | U-4485 | | | |
| | 11578062 | Mar 25, 2031 | DP U-3584 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4054 | | | |
| | 11578062 | Mar 25, 2031 | DP U-4488 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-3583 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4053 | | | |
| | 11639347 | Apr 09, 2027 | DS DP U-4476 | | | |
| | 11752106 | Feb 27, 2033 | DP U-3696 | | | |
| | 11752106 | Feb 27, 2033 | DP U-4052 | | | |
| | 11752106 | Feb 27, 2033 | DP U-4489 | | | |
| | 12214083 | Feb 27, 2033 | DP U-4141 | | | |
| | 12214083 | Feb 27, 2033 | DP U-4492 | | | |
| | 12350262 | Jul 17, 2038 | U-4220 | | | |
| | 12350262 | Jul 17, 2038 | U-4476 | | | |
| | 12458635 | Aug 13, 2029 | DP U-4333 | | | |
| | 12458635 | Aug 13, 2029 | DP U-4493 | | | |
| | 8324242 | Aug 05, 2027 | U-3589 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 217660 002 | 8324242 | Aug 05, 2027 | U-4066 | | | |
| | 8324242 | Aug 05, 2027 | U-4476 | | | |
| | 8415387 | Nov 12, 2027 | U-3589 | | | |
| | 8415387 | Nov 12, 2027 | U-4066 | | | |
| | 8415387 | Nov 12, 2027 | U-4476 | | | |
| | 8598181 | May 01, 2027 | U-3589 | | | |
| | 8598181 | May 01, 2027 | U-4066 | | | |
| | 8598181 | May 01, 2027 | U-4476 | | | |
| | 9670163 | Dec 28, 2026 | DP U-3591 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4068 | | | |
| | 9670163 | Dec 28, 2026 | DP U-4478 | | | |
| | 9931334 | Dec 28, 2026 | DP U-3591 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4068 | | | |
| | 9931334 | Dec 28, 2026 | DP U-4478 | | | |
| | 9974781 | Apr 09, 2027 | DP U-3589 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4066 | | | |
| | 9974781 | Apr 09, 2027 | DP U-4476 | | | |
| ELINZANETANT - LYNKUET | | | | | | |
| N 219469 001 | 12533358 | May 14, 2045 | U-4402 | | | |
| | 7683056 | Sep 15, 2027 | DS DP | | | |
| EMPAGLIFLOZIN - JARDIANCE | | | | | | |
| N 204629 001 | 12527810 | Apr 22, 2033 | U-4403 | | | |
| | 12527810*PED | Oct 22, 2033 | | | | |
| EMPAGLIFLOZIN - JARDIANCE | | | | | | |
| N 204629 002 | 12527810 | Apr 22, 2033 | U-4403 | | | |
| | 12527810*PED | Oct 22, 2033 | | | | |
| EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR | | | | | | |
| N 212614 001 | 12678442 | Apr 02, 2029 | DP | | | |
| | 12678442*PED | Oct 02, 2029 | | | | |
| EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR | | | | | | |
| N 212614 002 | 12678442 | Apr 02, 2029 | DP | | | |
| | 12678442*PED | Oct 02, 2029 | | | | |
| EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR | | | | | | |
| N 212614 003 | 12678442 | Apr 02, 2029 | DP | | | |
| | 12678442*PED | Oct 02, 2029 | | | | |
| EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR | | | | | | |
| N 212614 004 | 12678442 | Apr 02, 2029 | DP | | | |
| | 12678442*PED | Oct 02, 2029 | | | | |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY | | | | | | |
| N 206111 001 | 12527810 | Apr 22, 2033 | U-4403 | | | |
| | 12527810*PED | Oct 22, 2033 | | | | |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY | | | | | | |
| N 206111 002 | 12527810 | Apr 22, 2033 | U-4403 | | | |
| | 12527810*PED | Oct 22, 2033 | | | | |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY | | | | | | |
| N 206111 003 | 12527810 | Apr 22, 2033 | U-4403 | | | |
| | 12527810*PED | Oct 22, 2033 | | | | |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY | | | | | | |
| N 206111 004 | 12527810 | Apr 22, 2033 | U-4403 | | | |
| | 12527810*PED | Oct 22, 2033 | | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY | | | | | | | |
| N 208215 001 | | 12629338 | Jun 29, 2036 | DP | | ODE-556 | Jun 20, 2032 |
| | | 12648911 | Jun 29, 2036 | U-1259 | | | |
| | | 12648911 | Jun 29, 2036 | U-1663 | | | |
| | | 12661323 | Jun 29, 2036 | DP | | | |
| | | 12678408 | Jun 29, 2036 | DP | | | |
| EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY | | | | | | | |
| N 208215 002 | | 12661323 | Jun 29, 2036 | DP | | ODE-554 | Jan 07, 2029 |
| | | | | | | ODE-556 | Jun 20, 2032 |
| ENCORAFENIB - BRAFTOVI | | | | | | | |
| N 210496 001 | | | | | | I-997 | Feb 24, 2029 |
| ENCORAFENIB - BRAFTOVI | | | | | | | |
| N 210496 002 | | 10005761 | Aug 27, 2030 | U-2335 | | I-997 | Feb 24, 2029 |
| | | 10005761 | Aug 27, 2030 | U-2802 | | | |
| | | 10005761 | Aug 27, 2030 | U-2803 | | | |
| | | 10005761 | Aug 27, 2030 | U-3738 | | | |
| | | 10005761 | Aug 27, 2030 | U-4051 | | | |
| | | 10005761 | Aug 27, 2030 | U-4440 | | | |
| | | 10258622 | Nov 21, 2032 | U-2802 | | | |
| | | 10258622 | Nov 21, 2032 | U-4051 | | | |
| | | 10258622 | Nov 21, 2032 | U-4439 | | | |
| | | 8541575 | Feb 26, 2030 | DS DP U-2335 | | | |
| | | 8541575 | Feb 26, 2030 | DS DP U-2802 | | | |
| | | 8541575 | Feb 26, 2030 | DS DP U-2803 | | | |
| | | 8541575 | Feb 26, 2030 | DS DP U-3738 | | | |
| | | 8541575 | Feb 26, 2030 | DS DP U-4051 | | | |
| | | 8541575 | Feb 26, 2030 | DS DP U-4440 | | | |
| | | 9314464 | Jul 04, 2031 | U-2336 | | | |
| | | 9314464 | Jul 04, 2031 | U-2802 | | | |
| | | 9314464 | Jul 04, 2031 | U-2803 | | | |
| | | 9314464 | Jul 04, 2031 | U-3738 | | | |
| | | 9314464 | Jul 04, 2031 | U-4051 | | | |
| | | 9314464 | Jul 04, 2031 | U-4440 | | | |
| | | 9474754 | Aug 05, 2033 | U-2802 | | | |
| | | 9474754 | Aug 05, 2033 | U-4051 | | | |
| | | 9474754 | Aug 05, 2033 | U-4440 | | | |
| | | 9850230 | Aug 27, 2030 | U-2334 | | | |
| | | 9850230 | Aug 27, 2030 | U-2802 | | | |
| | | 9850230 | Aug 27, 2030 | U-2803 | | | |
| | | 9850230 | Aug 27, 2030 | U-3738 | | | |
| | | 9850230 | Aug 27, 2030 | U-4051 | | | |
| | | 9850230 | Aug 27, 2030 | U-4440 | | | |
| ENLICITIDE DECANOATE - LIPFENDRA | | | | | | | |
| N 220848 001 | | 11427616 | Feb 04, 2040 | DS DP U-4585 | | NCE | Jul 15, 2031 |
| ENSITRELVIR - XOCOVA | | | | | | | |
| N 220442 001 | | 11814368 | May 01, 2042 | DS DP U-4553 | | NCE | May 29, 2031 |
| | | 12559474 | May 01, 2042 | DS DP U-4553 | | | |
| | >A> | 12751955 | Feb 27, 2044 | DP | | | |
| | | 9150546 | Dec 12, 2030 | DS DP | | | |
| ENTRECTINIB - ROZLYTREK | | | | | | | |
| N 218550 001 | >A> | 10231965 | Feb 17, 2035 | U-4639 | | | |
| | >A> | 10398693 | Jul 18, 2038 | DP | | | |
| | >A> | 10561651 | Feb 19, 2035 | U-4639 | | | |
| | >A> | 10738037 | May 18, 2037 | DS DP U-4639 | | | |
| | >A> | 11091469 | May 18, 2037 | U-4639 | | | |
| | >A> | 12758544 | Jul 29, 2040 | DP U-4639 | | | |
| | >A> | 8299057 | Mar 10, 2032 | DS DP | | | |
| | >A> | 8673893 | Jul 08, 2028 | U-4639 | | | |
| | >A> | 9029356 | Jul 08, 2028 | DS DP | | | |
| | >A> | 9085558 | Jul 08, 2028 | DP | | | |
| | >A> | 9085565 | May 22, 2033 | DS DP | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| N 218550 001 | >A> | 9255087 | Jul 08, 2028 | U-4639 | | | |
| | >A> | 9616059 | Jul 08, 2028 | U-4639 | | | |
| | >A> | 9649306 | May 22, 2033 | U-4639 | | | |
| EPINEPHRINE - EPINEPHRINE | | | | | | | |
| N 215425 001 | | 12539283 | Jan 17, 2045 | DP | | | |
| EPLONTERSEN SODIUM - WAINUA | | | | | | | |
| N 217388 002 | | 10683499 | Aug 25, 2034 | DS DP U-2378 | | | |
| | | 9127276 | May 01, 2034 | DS | | | |
| | | 9181549 | May 01, 2034 | DS | | | |
| ERAVACYCLINE DIHYDROCHLORIDE - XERAVA | | | | | | | |
| N 211109 001 | | 8906887 | Aug 27, 2032 | DP | | | |
| ERAVACYCLINE DIHYDROCHLORIDE - XERAVA | | | | | | | |
| N 211109 002 | | 8906887 | Aug 27, 2032 | DP | | | |
| ERDAFITINIB - BALVERSA | | | | | | | |
| N 212018 001 | | 12678498 | Jun 13, 2036 | U-4584 | | | |
| ERDAFITINIB - BALVERSA | | | | | | | |
| N 212018 002 | | 12678498 | Jun 13, 2036 | U-4584 | | | |
| ERDAFITINIB - BALVERSA | | | | | | | |
| N 212018 003 | | 12678498 | Jun 13, 2036 | U-4584 | | | |
| ERTUGLIFLOZIN - STEGLATRO | | | | | | | |
| N 209803 001 | | 8080580 | Dec 19, 2031 | DS DP U-2214 | | | |
| ERTUGLIFLOZIN - STEGLATRO | | | | | | | |
| N 209803 002 | | 8080580 | Dec 19, 2031 | DS DP U-2214 | | | |
| ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET | | | | | | | |
| N 209806 001 | | 8080580 | Dec 19, 2031 | DS DP U-2214 | | | |
| ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET | | | | | | | |
| N 209806 002 | | 8080580 | Dec 19, 2031 | DS DP U-2214 | | | |
| ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET | | | | | | | |
| N 209806 003 | | 8080580 | Dec 19, 2031 | DS DP U-2214 | | | |
| ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET | | | | | | | |
| N 209806 004 | | 8080580 | Dec 19, 2031 | DS DP U-2214 | | | |
| ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN | | | | | | | |
| N 209805 001 | | 8080580 | Dec 19, 2031 | DS DP U-2214 | | | |
| ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN | | | | | | | |
| N 209805 002 | | 8080580 | Dec 19, 2031 | DS DP U-2214 | | | |
| ESOMEPRAZOLE MAGNESIUM - ESOMEPRAZOLE MAGNESIUM | | | | | | | |
| N 214278 001 | >A> | 10076494 | Dec 08, 2036 | DP | Y | | |
| | >A> | 10835488 | Dec 08, 2036 | DP | Y | | |
| ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE | | | | | | | |
| N 214846 001 | | 12551447 | Nov 05, 2042 | DP | | | |
| ETHINYL ESTRADIOL; NORELGESTROMIN - GWYN LO | | | | | | | |
| N 219990 001 | | | | | | NP | Jul 28, 2029 |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ETONOGESTREL - NEXPLANON | | | | | | | |
| N 021529 | 002 | | | | | D-199 | Jan 16, 2029 |
| ETRIPAMIL - CARDAMYST | | | | | | | |
| N 218571 | 001 | 10010522 | Jun 19, 2028 | U-38 | | | |
| | | 10010523 | Jun 19, 2028 | DS | | | |
| | | 10117848 | Apr 13, 2036 | DP U-4370 | | | |
| | | 12257224 | Jul 15, 2042 | U-4370 | | | |
| | | 9227918 | Jun 19, 2028 | DP | | | |
| | | 9463179 | Jun 19, 2028 | U-4370 | | | |
| FENFLURAMINE HYDROCHLORIDE - FINTEPLA | | | | | | | |
| N 212102 | 001 | >A> 12734137 | Sep 28, 2035 | U-4621 | | | |
| | | >A> 12734137 | Sep 28, 2035 | U-4622 | | | |
| | | >A> 12734137 | Sep 28, 2035 | U-4623 | | | |
| | | >A> 12734137 | Sep 28, 2035 | U-4624 | | | |
| FERRIC CARBOXYMALTOSE - INJECTAFER | | | | | | | |
| N 203565 | 001 | 7612109 | Feb 05, 2027 | DS DP | | | |
| FERRIC CARBOXYMALTOSE - INJECTAFER | | | | | | | |
| N 203565 | 002 | 7612109 | Feb 05, 2027 | DS DP | | | |
| FERRIC CARBOXYMALTOSE - INJECTAFER | | | | | | | |
| N 203565 | 003 | 7612109 | Feb 05, 2027 | DS DP | | | |
| FERRIC CARBOXYMALTOSE - INJECTAFER | | | | | | | |
| N 203565 | 004 | 7612109 | Feb 05, 2027 | DS DP | | | |
| FERRIC OXYHYDROXIDE - VELPHORO | | | | | | | |
| N 205109 | 002 | | | | | >A> NPP | Jul 01, 2027 |
| | | | | | | >A> PED | Jan 01, 2028 |
| FINERENONE - KERENDIA | | | | | | | |
| N 215341 | 001 | 8436180 | Aug 26, 2033 | DS DP | | I-998 | Sep 16, 2029 |
| FINERENONE - KERENDIA | | | | | | | |
| N 215341 | 002 | 8436180 | Aug 26, 2033 | DS DP | | I-998 | Sep 16, 2029 |
| FINERENONE - KERENDIA | | | | | | | |
| N 215341 | 003 | 8436180 | Aug 26, 2033 | DS DP | | I-998 | Sep 16, 2029 |
| FITUSIRAN SODIUM - QFITLIA | | | | | | | |
| N 219019 | 001 | RE50996 | Mar 22, 2033 | DS DP U-4165 | | | |
| FITUSIRAN SODIUM - QFITLIA | | | | | | | |
| N 219019 | 002 | RE50996 | Mar 22, 2033 | DS DP U-4165 | | | |
| FLIBANSERIN - ADDYI | | | | | | | |
| N 022526 | 001 | | | | | I-983 | Dec 13, 2028 |
| FLORETYROSINE F-18 - PIXCLARA | | | | | | | |
| N 218592 | 001 | | | | | NCE | Sep 11, 2031 |
| FLOROQUINITAU F-18 - TAUKLARIFY | | | | | | | |
| N 220496 | 001 | 10022461 | Jun 09, 2035 | U-4597 | | NCE | Aug 13, 2031 |
| | | 9808542 | Jun 09, 2035 | DS DP U-4597 | | | |
| FLURPIRIDAZ F-18 - FLYRCADO | | | | | | | |
| N 215168 | 001 | 12527884 | May 13, 2042 | DP U-4406 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FLUTICASONE FUROATE - ARNUITY ELLIPTA | | | | | | | |
| N 205625 | 001 | >A> RE51082 | Oct 11, 2030 | DP | | | |
| | | >A> RE51082*PED | Apr 11, 2031 | | | | |
| FLUTICASONE FUROATE - ARNUITY ELLIPTA | | | | | | | |
| N 205625 | 002 | >A> RE51082 | Oct 11, 2030 | DP | | | |
| | | >A> RE51082*PED | Apr 11, 2031 | | | | |
| FLUTICASONE FUROATE - ARNUITY ELLIPTA | | | | | | | |
| N 205625 | 003 | >A> RE51082 | Oct 11, 2030 | DP | | | |
| | | >A> RE51082*PED | Apr 11, 2031 | | | | |
| FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA | | | | | | | |
| N 209482 | 001 | >A> 8746242 | Oct 11, 2030 | DP | Y | | |
| | | >A> 8746242*PED | Apr 11, 2031 | | | | |
| | | >A> RE51082 | Oct 11, 2030 | DP | | | |
| | | >A> RE51082*PED | Apr 11, 2031 | | | | |
| FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA | | | | | | | |
| N 209482 | 002 | >A> 8746242 | Oct 11, 2030 | DP | Y | | |
| | | >A> 8746242*PED | Apr 11, 2031 | | | | |
| | | >A> RE51082 | Oct 11, 2030 | DP | | | |
| | | >A> RE51082*PED | Apr 11, 2031 | | | | |
| FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA | | | | | | | |
| N 204275 | 001 | >A> 8746242 | Oct 11, 2030 | DP | Y | | |
| | | >A> 8746242*PED | Apr 11, 2031 | | | | |
| | | >A> RE51082 | Oct 11, 2030 | DP | | | |
| | | >A> RE51082*PED | Apr 11, 2031 | | | | |
| FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA | | | | | | | |
| N 204275 | 002 | >A> RE51082 | Oct 11, 2030 | DP | | | |
| | | >A> RE51082*PED | Apr 11, 2031 | | | | |
| FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA | | | | | | | |
| N 204275 | 003 | >A> RE51082 | Oct 11, 2030 | DP | | | |
| | | >A> RE51082*PED | Apr 11, 2031 | | | | |
| FLUTICASONE PROPIONATE - FLUTICASONE PROPIONATE | | | | | | | |
| A 219602 | 001 | | | | | CGT | Sep 20, 2026 |
| FLUTICASONE PROPIONATE - XHANCE | | | | | | | |
| N 209022 | 001 | 12616806 | Feb 23, 2036 | U-4524 | | | |
| | | 12616806 | Feb 23, 2036 | U-4525 | | | |
| FOSFOMYCIN DISODIUM - CONTEPO | | | | | | | |
| N 212271 | 001 | 12702676 | Jan 30, 2039 | U-4331 | | NP | Oct 22, 2028 |
| | | | | | | GAIN | Oct 22, 2033 |
| FUROSEMIDE - FUROSCIX READYFLOW (AUTOINJECTOR) | | | | | | | |
| N 209988 | 002 | 11497755 | Jan 30, 2040 | DP | | | |
| | | 11559535 | Jan 30, 2040 | DP | | | |
| | | 11571434 | Jan 30, 2040 | DP | | | |
| | | 11998555 | Jan 30, 2040 | DP U-4589 | | | |
| | | 12048709 | Jan 30, 2040 | DP U-4588 | | | |
| | | 12491193 | Jan 30, 2040 | DP U-4588 | | | |
| | | 12491194 | Jan 30, 2040 | DP U-4588 | | | |
| | | 12491195 | Jan 30, 2040 | DP U-4588 | | | |
| | | 12491196 | Jan 30, 2040 | DP U-4588 | | | |
| | | 12491197 | Jan 30, 2040 | DP U-4588 | | | |
| FUROSEMIDE - LASIX ONYU | | | | | | | |
| N 217294 | 001 | 11246851 | Jan 03, 2040 | DP U-4576 | | | |
| | | 12318363 | Jan 03, 2040 | DP | | | |
| | | 12403120 | Jan 10, 2042 | DP U-4576 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| GADOPICLENOL - ELUCIREM | | | | | | |
| N 216986 001 | 12064487 | Jan 17, 2040 | U-4424 | | NPP | Feb 20, 2029 |
| | 8114863 | May 25, 2032 | DS DP | | | |
| GADOPICLENOL - ELUCIREM | | | | | | |
| N 216986 002 | 12064487 | Jan 17, 2040 | U-4424 | | NPP | Feb 20, 2029 |
| | 8114863 | May 25, 2032 | DS DP | | | |
| GADOPICLENOL - ELUCIREM | | | | | | |
| N 216986 003 | 12064487 | Jan 17, 2040 | U-4424 | | NPP | Feb 20, 2029 |
| | 8114863 | May 25, 2032 | DS DP | | | |
| GADOPICLENOL - ELUCIREM | | | | | | |
| N 216986 004 | 12064487 | Jan 17, 2040 | U-4424 | | NPP | Feb 20, 2029 |
| | 8114863 | May 25, 2032 | DS DP | | | |
| GADOPICLENOL - ELUCIREM | | | | | | |
| N 216986 005 | 12064487 | Jan 17, 2040 | U-4424 | | NPP | Feb 20, 2029 |
| | 8114863 | May 25, 2032 | DS DP | | | |
| GADOPICLENOL - ELUCIREM | | | | | | |
| N 216986 006 | 12064487 | Jan 17, 2040 | U-4424 | | NPP | Feb 20, 2029 |
| | 8114863 | May 25, 2032 | DS DP | | | |
| GADOPICLENOL - ELUCIREM | | | | | | |
| N 216986 007 | 12064487 | Jan 17, 2040 | U-4424 | | NPP | Feb 20, 2029 |
| | 8114863 | May 25, 2032 | DS DP | | | |
| GADOQUATRANE - AMBELVIST | | | | | | |
| N 219627 001 | 10137209 | May 30, 2036 | DS U-4424 | | NCE | Jun 12, 2031 |
| | 10722601 | May 30, 2036 | DS U-4424 | | | |
| | 11491245 | May 30, 2036 | DS | | | |
| | 11944690 | May 19, 2040 | DP | | | |
| | 12303573 | Nov 21, 2039 | DP | | | |
| | 12478696 | May 30, 2036 | DS | | | |
| GADOQUATRANE - AMBELVIST | | | | | | |
| N 219627 002 | 10137209 | May 30, 2036 | DS U-4424 | | NCE | Jun 12, 2031 |
| | 10722601 | May 30, 2036 | DS U-4424 | | | |
| | 11491245 | May 30, 2036 | DS | | | |
| | 11944690 | May 19, 2040 | DP | | | |
| | 12303573 | Nov 21, 2039 | DP | | | |
| | 12478696 | May 30, 2036 | DS | | | |
| GADOQUATRANE - AMBELVIST | | | | | | |
| N 219627 003 | 10137209 | May 30, 2036 | DS U-4424 | | NCE | Jun 12, 2031 |
| | 10722601 | May 30, 2036 | DS U-4424 | | | |
| | 11491245 | May 30, 2036 | DS | | | |
| | 11944690 | May 19, 2040 | DP | | | |
| | 12303573 | Nov 21, 2039 | DP | | | |
| | 12478696 | May 30, 2036 | DS | | | |
| GADOQUATRANE - AMBELVIST | | | | | | |
| N 219627 004 | 10137209 | May 30, 2036 | DS U-4424 | | NCE | Jun 12, 2031 |
| | 10722601 | May 30, 2036 | DS U-4424 | | | |
| | 11491245 | May 30, 2036 | DS | | | |
| | 11944690 | May 19, 2040 | DP | | | |
| | 12303573 | Nov 21, 2039 | DP | | | |
| | 12478696 | May 30, 2036 | DS | | | |
| GADOQUATRANE - AMBELVIST | | | | | | |
| N 219627 005 | 10137209 | May 30, 2036 | DS U-4424 | | NCE | Jun 12, 2031 |
| | 10722601 | May 30, 2036 | DS U-4424 | | | |
| | 11491245 | May 30, 2036 | DS | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|---|
| N 219627 | 005 | | 11944690 | May 19, 2040 | DP | | | | |
| | | | 12303573 | Nov 21, 2039 | DP | | | | |
| | | | 12478696 | May 30, 2036 | DS | | | | |
| GADOQUATRANE - AMBELVIST | | | | | | | | | |
| N 219627 | 006 | | 10137209 | May 30, 2036 | DS | U-4424 | | NCE | Jun 12, 2031 |
| | | | 10722601 | May 30, 2036 | DS | U-4424 | | | |
| | | | 11491245 | May 30, 2036 | DS | | | | |
| | | | 11944690 | May 19, 2040 | DP | | | | |
| | | | 12303573 | Nov 21, 2039 | DP | | | | |
| | | | 12478696 | May 30, 2036 | DS | | | | |
| GANAXOLONE - ZTALMY | | | | | | | | | |
| N 215904 | 001 | | 8318714 | Nov 28, 2031 | DP | | | | |
| GEDATOLISIB - REVTORPYK | | | | | | | | | |
| N 219908 | 001 | >A> | 12109308 | Jan 02, 2041 | DP | | | NCE | Jul 14, 2031 |
| | | >A> | 12350276 | Aug 31, 2042 | | U-4615 | | | |
| | | >A> | 8039469 | Dec 17, 2029 | DS | | | | |
| | | >A> | 8217036 | May 22, 2029 | | U-4616 | | | |
| | | >A> | 8575159 | May 22, 2029 | DS | | | | |
| | | >A> | 8748421 | May 22, 2029 | DS | U-4616 | | | |
| | | >A> | 9174963 | May 22, 2029 | DS | | | | |
| GEMCITABINE HYDROCHLORIDE - INLEXZO | | | | | | | | | |
| N 219683 | 001 | | 12576253 | Dec 17, 2030 | DP | | | | |
| | | | 12636300 | Nov 07, 2038 | | U-4552 | | | |
| GEPOTIDACIN MESYLATE - BLUJEPA | | | | | | | | | |
| N 218230 | 001 | | 12528809 | Dec 13, 2042 | DS DP | U-4361 | | | |
| | | | 12528809 | Dec 13, 2042 | DS DP | U-4408 | | | |
| GIVINOSTAT HYDROCHLORIDE - DUVYZAT | | | | | | | | | |
| N 217865 | 001 | | 12606519 | May 03, 2040 | DS DP | | | | |
| | | | 7329689 | Jan 15, 2027 | DS DP | | | | |
| GLASDEGIB MALEATE - DAURISMO | | | | | | | | | |
| N 210656 | 001 | | 8148401 | Nov 21, 2032 | DS DP | | | | |
| GLASDEGIB MALEATE - DAURISMO | | | | | | | | | |
| N 210656 | 002 | | 8148401 | Nov 21, 2032 | DS DP | | | | |
| GLUCAGON - BAQSIMI | | | | | | | | | |
| N 210134 | 001 | | | | | | | NPP | Mar 17, 2028 |
| HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE | | | | | | | | | |
| N 217812 | 001 | | 12653820 | Jan 10, 2043 | DP | U-4571 | | | |
| IBERDOMIDE HYDROCHLORIDE - ZENBEXUS | | | | | | | | | |
| N 221075 | 001 | | 11529339 | Sep 30, 2039 | | U-4598 | | NCE | Aug 13, 2031 |
| | | | 8518972 | Jun 05, 2031 | DS DP | | | | |
| | | | 9221788 | Sep 25, 2033 | DS | | | | |
| | | | 9629849 | Aug 08, 2033 | | U-4598 | | | |
| | | | 9828361 | Feb 10, 2031 | DS DP | | | | |
| | | | RE49647 | Oct 07, 2034 | DP | | | | |
| | | | RE50917 | Oct 07, 2034 | | U-4598 | | | |
| IBERDOMIDE HYDROCHLORIDE - ZENBEXUS | | | | | | | | | |
| N 221075 | 002 | | 11529339 | Sep 30, 2039 | | U-4598 | | NCE | Aug 13, 2031 |
| | | | 8518972 | Jun 05, 2031 | DS DP | | | | |
| | | | 9221788 | Sep 25, 2033 | DS | | | | |
| | | | 9629849 | Aug 08, 2033 | | U-4598 | | | |
| | | | 9828361 | Feb 10, 2031 | DS DP | | | | |
| | | | RE49647 | Oct 07, 2034 | DP | | | | |
| | | | RE50917 | Oct 07, 2034 | | U-4598 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| IBREXAFUNGERP CITRATE - BREXAFEMME | | | | | | | | |
| N 214900 | 001 | >A> | 8188085 | Jun 01, 2035 | DS DP U-3159 | | | |
| IBRUTINIB - IMBRUVICA | | | | | | | | |
| N 210563 | 001 | | 12551448 | Mar 03, 2036 | DP | | | |
| IBRUTINIB - IMBRUVICA | | | | | | | | |
| N 210563 | 002 | | 12551448 | Mar 03, 2036 | DP | | | |
| IBRUTINIB - IMBRUVICA | | | | | | | | |
| N 210563 | 003 | | 12551448 | Mar 03, 2036 | DP | | | |
| ICOTROKINRA HYDROCHLORIDE - ICOTYDE | | | | | | | | |
| N 220149 | 001 | | 11845808 | Jan 14, 2041 | DS U-4447 | | NCE | Mar 17, 2031 |
| | | | 11939361 | Nov 19, 2041 | DP U-4447 | | | |
| | | | 12552836 | Jul 12, 2039 | DS DP | | | |
| ILOPERIDONE - FANAPT | | | | | | | | |
| N 022192 | 001 | | 10563259 | Jul 24, 2030 | U-4562 | | | |
| | | | 10563259 | Jul 24, 2030 | U-4563 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4562 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4563 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4504 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4505 | | | |
| ILOPERIDONE - FANAPT | | | | | | | | |
| N 022192 | 002 | | 10563259 | Jul 24, 2030 | U-4562 | | | |
| | | | 10563259 | Jul 24, 2030 | U-4563 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4562 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4563 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4504 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4505 | | | |
| ILOPERIDONE - FANAPT | | | | | | | | |
| N 022192 | 003 | | 10563259 | Jul 24, 2030 | U-4562 | | | |
| | | | 10563259 | Jul 24, 2030 | U-4563 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4562 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4563 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4504 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4505 | | | |
| ILOPERIDONE - FANAPT | | | | | | | | |
| N 022192 | 004 | | 10563259 | Jul 24, 2030 | U-4562 | | | |
| | | | 10563259 | Jul 24, 2030 | U-4563 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4562 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4563 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4504 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4505 | | | |
| ILOPERIDONE - FANAPT | | | | | | | | |
| N 022192 | 005 | | 10563259 | Jul 24, 2030 | U-4562 | | | |
| | | | 10563259 | Jul 24, 2030 | U-4563 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4562 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4563 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4504 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4505 | | | |
| ILOPERIDONE - FANAPT | | | | | | | | |
| N 022192 | 006 | | 10563259 | Jul 24, 2030 | U-4562 | | | |
| | | | 10563259 | Jul 24, 2030 | U-4563 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4562 | | | |
| | | | 10570453 | Mar 28, 2028 | U-4563 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4504 | | | |
| | | | 12606869 | Sep 22, 2030 | U-4505 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ILOPERIDONE - FANAPT | | | | | | | |
| N 022192 | 007 | 10563259 | Jul 24, 2030 | U-4562 | | | |
| | | 10563259 | Jul 24, 2030 | U-4563 | | | |
| | | 10570453 | Mar 28, 2028 | U-4562 | | | |
| | | 10570453 | Mar 28, 2028 | U-4563 | | | |
| | | 12606869 | Sep 22, 2030 | U-4504 | | | |
| | | 12606869 | Sep 22, 2030 | U-4505 | | | |
| IMETELSTAT SODIUM - RYTELO | | | | | | | |
| N 217779 | 001 | 7494982 | Dec 27, 2026 | DS DP | | | |
| IMETELSTAT SODIUM - RYTELO | | | | | | | |
| N 217779 | 002 | 7494982 | Dec 27, 2026 | DS DP | | | |
| IMLUNESTRANT TOSYLATE - INLURIYO | | | | | | | |
| N 218881 | 001 | >A> 11634426 | Jul 11, 2039 | U-4619 | | | |
| INCLISIRAN SODIUM - LEQVIO | | | | | | | |
| N 214012 | 001 | 10125369 | Aug 18, 2034 | DS DP U-4249 | | I-985 | Feb 12, 2029 |
| | | 10125369 | Aug 18, 2034 | DS DP U-4413 | | NPP | Feb 12, 2029 |
| | | 10125369 | Aug 18, 2034 | DS DP U-4414 | | ODE-555 | Feb 12, 2033 |
| | | 10131907 | Aug 24, 2028 | DS DP U-4249 | | | |
| | | 10131907 | Aug 24, 2028 | DS DP U-4413 | | | |
| | | 10131907 | Aug 24, 2028 | DS DP U-4414 | | | |
| | | 10851377 | Aug 25, 2036 | U-4249 | | | |
| | | 10851377 | Aug 25, 2036 | U-4413 | | | |
| | | 10851377 | Aug 25, 2036 | U-4414 | | | |
| | | 8106022 | Dec 12, 2029 | DS DP U-4249 | | | |
| | | 8106022 | Dec 12, 2029 | DS DP U-4413 | | | |
| | | 8106022 | Dec 12, 2029 | DS DP U-4414 | | | |
| | | 8222222 | Dec 29, 2027 | U-4249 | | | |
| | | 8222222 | Dec 29, 2027 | U-4413 | | | |
| | | 8222222 | Dec 29, 2027 | U-4414 | | | |
| | | 8809292 | May 10, 2027 | DS DP U-4249 | | | |
| | | 8809292 | May 10, 2027 | DS DP U-4413 | | | |
| | | 8809292 | May 10, 2027 | DS DP U-4414 | | | |
| | | 8828956 | Dec 04, 2028 | DS DP U-4249 | | | |
| | | 8828956 | Dec 04, 2028 | DS DP U-4413 | | | |
| | | 8828956 | Dec 04, 2028 | DS DP U-4414 | | | |
| | | 9370582 | Dec 04, 2028 | DS DP U-4249 | | | |
| | | 9370582 | Dec 04, 2028 | DS DP U-4413 | | | |
| | | 9370582 | Dec 04, 2028 | DS DP U-4414 | | | |
| INDOCYANINE GREEN - INDOCYANINE GREEN | | | | | | | |
| A 219139 | 001 | | | | | CGT | Jan 31, 2027 |
| IOHEXOL - IOHEXOL | | | | | | | |
| A 217737 | 001 | | | | | CGT | Jul 26, 2026 |
| IOPAMIDOL - ISOVUE READI | | | | | | | |
| N 220583 | 001 | | | | >A> | I-975 | Oct 10, 2028 |
| IPRATROPIUM BROMIDE - IPRATROPIUM BROMIDE | | | | | | | |
| A 217953 | 001 | | | | | PC | Oct 13, 2026 |
| IPTACOPAN HYDROCHLORIDE - FABHALTA | | | | | | | |
| N 218276 | 001 | | | | | ODE-524 | Mar 20, 2032 |
| LAMOTRIGINE - SUBVENITE | | | | | | | |
| N 218879 | 001 | 12629377 | May 29, 2040 | DP U-4539 | | | |
| | | 12629377 | May 29, 2040 | DP U-4540 | | | |
| | | 12629377 | May 29, 2040 | DP U-4541 | | | |
| | | 12636289 | May 29, 2040 | DP | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LAMOTRIGINE HEMIFUMARATE - LAMLIQUE | | | | | | | |
| N 221109 | 001 | 12605388 | Feb 14, 2045 | DP | | | |
| LAMOTRIGINE HEMIFUMARATE - LAMLIQUE | | | | | | | |
| N 221109 | 002 | 12605388 | Feb 14, 2045 | DP | | | |
| LANDIOLOL HYDROCHLORIDE - RAPIBLYK | | | | | | | |
| N 217202 | 001 | | | | | NPP | Feb 13, 2029 |
| LANREOTIDE ACETATE - LANREOTIDE ACETATE | | | | | | | |
| A 218217 | 001 | | | | | CGT | Mar 20, 2027 |
| LANSOPRAZOLE - LANSOPRAZOLE | | | | | | | |
| N 208025 | 001 | >A> 11077055 | Apr 21, 2036 | DP | Y | | |
| | | >A> 11986554 | Apr 21, 2036 | DP | Y | | |
| LAZERTINIB MESYLATE - LAZCLUZE | | | | | | | |
| N 219008 | 001 | 12599606 | May 14, 2040 | U-4512 | | | |
| | | RE50528 | Oct 13, 2035 | DS DP U-3985 | | | |
| LAZERTINIB MESYLATE - LAZCLUZE | | | | | | | |
| N 219008 | 002 | 12599606 | May 14, 2040 | U-4511 | | | |
| | | RE50528 | Oct 13, 2035 | DS DP U-3985 | | | |
| LENACAPAVIR SODIUM - SUNLENCA | | | | | | | |
| N 215973 | 001 | 12594267 | Jul 15, 2039 | DP | | | |
| LENACAPAVIR SODIUM - SUNLENCA | | | | | | | |
| N 215974 | 001 | 10654827 | Aug 17, 2037 | U-3507 | | I-999 | Aug 27, 2029 |
| | | 10654827 | Aug 17, 2037 | U-4602 | | | |
| | | 9951043 | Feb 28, 2034 | DS DP U-3507 | | | |
| | | 9951043 | Feb 28, 2034 | DS DP U-4602 | | | |
| LENACAPAVIR SODIUM - YEZTUGO | | | | | | | |
| N 220018 | 001 | 12594267 | Jul 15, 2039 | DP | | | |
| LENIOLISIB PHOSPHATE - JOENJA | | | | | | | |
| N 217759 | 001 | | | | | NPP | Sep 11, 2029 |
| LENIOLISIB PHOSPHATE - JOENJA | | | | | | | |
| N 217759 | 002 | | | | | NCE | Mar 24, 2028 |
| | | | | | | NS | Sep 11, 2029 |
| | | | | | | ODE* | Mar 24, 2030 |
| LENIOLISIB PHOSPHATE - JOENJA | | | | | | | |
| N 217759 | 003 | | | | | NCE | Mar 24, 2028 |
| | | | | | | NS | Sep 11, 2029 |
| | | | | | | ODE* | Mar 24, 2030 |
| LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED) | | | | | | | |
| N 209935 | 001 | 10799506 | Apr 14, 2036 | DP | | I-951 | Sep 17, 2027 |
| | | 10799506*PED | Oct 14, 2036 | | | M-14 | Jul 01, 2029 |
| | | 12064434 | Apr 14, 2036 | DP | | PED | Mar 17, 2028 |
| | | 12064434*PED | Oct 14, 2036 | | | PED | Jan 01, 2030 |
| | | 12419894 | Apr 14, 2036 | DP | | | |
| | | 12419894*PED | Oct 14, 2036 | | | | |
| | | 12544380 | Aug 07, 2034 | U-3264 | | | |
| | | 12544380 | Aug 07, 2034 | U-3998 | | | |
| | | 12544380*PED | Feb 07, 2035 | | | | |
| | | 8324225 | Jun 17, 2028 | DS DP | | | |
| | | 8324225*PED | Dec 17, 2028 | | | | |
| | | 8415355 | Mar 13, 2031 | DS DP | | | |
| | | 8415355*PED | Sep 13, 2031 | | | | |
| | | 8685980 | May 25, 2030 | DS DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| N 209935 | 001 | | 8685980*PED | Nov 25, 2030 | | | | |
| | | | 8962630 | Dec 09, 2029 | U-2505 | | | |
| | | | 8962630 | Dec 09, 2029 | U-3264 | | | |
| | | | 8962630 | Dec 09, 2029 | U-3998 | | | |
| | | | 8962630*PED | Jun 09, 2030 | | | | |
| | | | 9193732 | Nov 09, 2031 | DS DP | | | |
| | | | 9193732*PED | May 09, 2032 | | | | |
| | | | 9416136 | Aug 20, 2029 | U-2505 | | | |
| | | | 9416136 | Aug 20, 2029 | U-3264 | | | |
| | | | 9416136 | Aug 20, 2029 | U-3998 | | | |
| | | | 9416136*PED | Feb 20, 2030 | | | | |
| | | | 9868739 | Nov 09, 2031 | U-2505 | | | |
| | | | 9868739 | Nov 09, 2031 | U-3264 | | | |
| | | | 9868739 | Nov 09, 2031 | U-3998 | | | |
| | | | 9868739*PED | May 09, 2032 | | | | |
| LEUCOVORIN CALCIUM - VYKOURA | | | | | | | | |
| N 220406 | 001 | | 12564592 | Dec 23, 2044 | DP | | | |
| LEUCOVORIN CALCIUM - VYKOURA | | | | | | | | |
| N 220406 | 002 | | 12564592 | Dec 23, 2044 | DP | | | |
| LEUCOVORIN CALCIUM - VYKOURA | | | | | | | | |
| N 220406 | 003 | | 12564592 | Dec 23, 2044 | DP | | | |
| LEUPROLIDE ACETATE - FENSOLVI KIT | | | | | | | | |
| N 213150 | 001 | >A> | 12751990 | Jun 25, 2039 | U-3611 | | | |
| LEUPROLIDE MESYLATE - CAMCEVI KIT | | | | | | | | |
| N 211488 | 001 | | 9572857 | Aug 02, 2029 | DP | | | |
| LEUPROLIDE MESYLATE - CAMCEVI ETM | | | | | | | | |
| N 219745 | 001 | | 10646572 | Jan 16, 2027 | DP | | | |
| | | | 11717555 | Jan 01, 2039 | DP | | | |
| | | | 12133878 | Dec 18, 2037 | DP | | | |
| | | | 9572857 | Aug 02, 2029 | DP | | | |
| | | | 9744207 | Jan 16, 2027 | DP | | | |
| LEVACETYLLEUCINE - AQNEURSA | | | | | | | | |
| N 219132 | 001 | | 12144792 | Apr 19, 2037 | U-4603 | | >A> I-1000 | Sep 18, 2029 |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | | |
| N 021924 | 002 | | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | | |
| N 021924 | 003 | | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | | |
| N 021924 | 004 | | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | | |
| N 021924 | 005 | | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | | |
| N 021924 | 006 | | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | | |
| N 021924 | 007 | | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | | |
| N 021924 | 008 | | 12564565 | Sep 26, 2044 | DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | |
| N 021924 009 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | |
| N 021924 010 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | |
| N 021924 011 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | |
| N 021924 012 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | |
| N 021924 013 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | |
| N 021924 014 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | |
| N 021924 015 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | |
| N 021924 016 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 001 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 002 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 003 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 004 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 005 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 006 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 007 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 008 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 009 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 010 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 011 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 012 | 12564565 | Sep 26, 2044 | DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 013 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 014 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT-SOL | | | | | | |
| N 206977 015 | 12564565 | Sep 26, 2044 | DP | | | |
| LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM | | | | | | |
| N 210632 001 | 12636270 | Dec 01, 2036 | DP | | | |
| LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM | | | | | | |
| N 210632 002 | 12636270 | Dec 01, 2036 | DP | | | |
| LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM | | | | | | |
| N 210632 003 | 12636270 | Dec 01, 2036 | DP | | | |
| LIDOCAINE - BONDLIDO | | | | | | |
| N 215029 001 | 8722065 | Nov 10, 2028 | DP | | | |
| LIDOCAINE; TETRACAINE - PLIAGLIS | | | | | | |
| N 021717 001 | 12558328 | Jan 14, 2031 | U-4421 | | | |
| LIFITEGRAST - XIIDRA | | | | | | |
| N 208073 001 | 7314938 | Jun 25, 2029 | DS DP | | | |
| LINACLOTIDE - LINZESS | | | | | | |
| N 202811 001 | | | | | NPP | Nov 04, 2028 |
| | | | | | PED | May 04, 2029 |
| LINACLOTIDE - LINZESS | | | | | | |
| N 202811 003 | 10702576 | Aug 11, 2031 | U-1516 | | NPP | May 21, 2029 |
| | 10702576 | Aug 11, 2031 | U-3644 | | | |
| | 10702576 | Aug 11, 2031 | U-4566 | | | |
| | 10702576*PED | Feb 11, 2032 | | | | |
| | 7304036 | Aug 30, 2026 | DS DP U-1516 | | | |
| | 7304036 | Aug 30, 2026 | DS DP U-3644 | | | |
| | 7304036 | Aug 30, 2026 | DS DP U-4566 | | | |
| | 7304036*PED | Feb 28, 2027 | | | | |
| | 8933030 | Feb 17, 2031 | DP U-1516 | | | |
| | 8933030 | Feb 17, 2031 | DP U-3644 | | | |
| | 8933030 | Feb 17, 2031 | DP U-4566 | | | |
| | 8933030*PED | Aug 17, 2031 | | | | |
| | 9708371 | Aug 16, 2033 | DP U-1516 | | | |
| | 9708371 | Aug 16, 2033 | DP U-3644 | | | |
| | 9708371 | Aug 16, 2033 | DP U-4566 | | | |
| | 9708371*PED | Feb 16, 2034 | | | | |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO | | | | | | |
| N 201281 001 | 12678442 | Apr 02, 2029 | DP | | | |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO | | | | | | |
| N 201281 002 | 12678442 | Apr 02, 2029 | DP | | | |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO | | | | | | |
| N 201281 003 | 12678442 | Apr 02, 2029 | DP | | | |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR | | | | | | |
| N 208026 001 | 12678442 | Apr 02, 2029 | DP | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR | | | | | | | |
| N 208026 | 002 | 12678442 | Apr 02, 2029 | DP | | | |
| LINERIXIBAT - LYNAVOY | | | | | | | |
| N 220295 | 001 | 9040518 | Sep 06, 2031 | DS DP | | NCE | Mar 17, 2031 |
| | | | | | | ODE-517 | Mar 17, 2033 |
| LIRAFUGRATINIB HYDROCHLORIDE - LYRFIGTU | | | | | | | |
| N 220425 | 001 | >A> 11780845 | May 12, 2040 | DS DP | | >A> NCE | Sep 23, 2031 |
| | | >A> 12152034 | Nov 18, 2041 | DS DP | | | |
| LIRAFUGRATINIB HYDROCHLORIDE - LYRFIGTU | | | | | | | |
| N 220425 | 002 | >A> 11780845 | May 12, 2040 | DS DP | | >A> NCE | Sep 23, 2031 |
| | | >A> 12152034 | Nov 18, 2041 | DS DP | | | |
| LISDEXAMFETAMINE DIMESYLATE - ARYNTA | | | | | | | |
| N 219847 | 001 | 12582620 | Apr 16, 2040 | DP | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 001 | 12472172 | Jul 29, 2041 | U-4438 | | NPP | Feb 25, 2029 |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 002 | 12472172 | Jul 29, 2041 | U-4438 | | NPP | Feb 25, 2029 |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 003 | 12472172 | Jul 29, 2041 | U-4438 | | NPP | Feb 25, 2029 |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 004 | 12472172 | Jul 29, 2041 | U-4438 | | NPP | Feb 25, 2029 |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 005 | | | | | NPP | Feb 25, 2029 |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 007 | 12472172 | Jul 29, 2041 | U-4438 | | NS | Feb 25, 2029 |
| | | 7932268 | Aug 19, 2027 | U-1316 | | | |
| LOMUSTINE - LOMUSTINE | | | | | | | |
| A 219265 | 001 | | | | | CGT | May 19, 2026 |
| LOMUSTINE - LOMUSTINE | | | | | | | |
| A 219265 | 002 | | | | | CGT | May 19, 2026 |
| LOMUSTINE - LOMUSTINE | | | | | | | |
| A 219265 | 003 | | | | | CGT | May 19, 2026 |
| LOSARTAN POTASSIUM - ARBLI | | | | | | | |
| N 218772 | 001 | 12605365 | Oct 07, 2041 | DP U-4159 | | | |
| | | 12605365 | Oct 07, 2041 | DP U-4160 | | | |
| LOTEPREDNOL ETABONATE - LOTEMAX SM | | | | | | | |
| N 208219 | 001 | 12589069 | Jan 26, 2036 | DP U-2764 | | | |
| LOTEPREDNOL ETABONATE; TOBRAMYCIN - LOTEPREDNOL ETABONATE AND TOBRAMYCIN | | | | | | | |
| A 217597 | 001 | | | | | CGT | Jul 14, 2026 |
| LUMASIRAN SODIUM - OXLUMO | | | | | | | |
| N 214103 | 001 | 12723247 | May 29, 2041 | DS DP U-2995 | | | |
| LUMATEPERONE TOSYLATE - CAPLYTA | | | | | | | |
| N 209500 | 001 | | | | | M-319 | Apr 24, 2029 |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LUMATEPERONE TOSYLATE - CAPLYTA | | | | | | |
| N 209500 002 | | | | | M-319 | Apr 24, 2029 |
| LUMATEPERONE TOSYLATE - CAPLYTA | | | | | | |
| N 209500 003 | | | | | M-319 | Apr 24, 2029 |
| LURBINECTEDIN - ZEPZELCA | | | | | | |
| N 213702 001 | >A> 12746240 | May 29, 2040 | U-4620 | | | |
| LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO | | | | | | |
| N 215833 001 | 10398791 | Mar 23, 2036 | DS DP | | I-996 | Jul 31, 2029 |
| | 10406240 | Aug 15, 2028 | DS DP U-4169 | | | |
| | 10406240 | Aug 15, 2028 | DS DP U-4593 | | | |
| | 10406240 | Aug 15, 2028 | DS DP U-4594 | | | |
| | 11318121 | Aug 15, 2028 | DS DP U-4169 | | | |
| | 11318121 | Aug 15, 2028 | DS DP U-4593 | | | |
| | 11318121 | Aug 15, 2028 | DS DP U-4594 | | | |
| | 11951190 | Nov 12, 2035 | U-4169 | | | |
| | 11951190 | Nov 12, 2035 | U-4593 | | | |
| | 11951190 | Nov 12, 2035 | U-4594 | | | |
| | 12208102 | Sep 18, 2041 | U-4169 | | | |
| | 12208102 | Sep 18, 2041 | U-4592 | | | |
| | 12208102 | Sep 18, 2041 | U-4593 | | | |
| MACIMORELIN ACETATE - MACRILEN | | | | | | |
| N 205598 001 | 8192719 | Oct 12, 2027 | U-2220 | | M-14 | Jul 23, 2029 |
| | 8192719*PED | Apr 12, 2028 | | | PED | Jan 23, 2030 |
| MACITENTAN - MACITENTAN | | | | | | |
| A 211026 001 | | | | | PC | Dec 03, 2026 |
| MACITENTAN - MACITENTAN | | | | | | |
| A 211120 001 | | | | | PC | Dec 03, 2026 |
| MACITENTAN - MACITENTAN | | | | | | |
| A 211187 001 | | | | | PC | Dec 03, 2026 |
| MACITENTAN - MACITENTAN | | | | | | |
| A 211224 001 | | | | | PC | Dec 03, 2026 |
| MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE | | | | | | |
| N 215344 001 | 12594298 | Jun 14, 2044 | DP | | | |
| MARALIXIBAT CHLORIDE - LIVMARLI | | | | | | |
| N 214662 001 | 12599602 | Feb 12, 2040 | U-3290 | | | |
| | 12599602 | Feb 12, 2040 | U-3974 | | | |
| MARIBAVIR - LIVTENCITY | | | | | | |
| N 215596 001 | 12527771 | Oct 11, 2043 | DS DP | | | |
| | 12661368 | Oct 27, 2031 | U-4572 | | | |
| MAVACAMTEN - CAMZYOS | | | | | | |
| N 214998 001 | >A> 9585883 | Jun 19, 2034 | U-3373 | | >A> NPP | Sep 30, 2029 |
| | >A> 9585883 | Jun 19, 2034 | U-4632 | | | |
| MAVACAMTEN - CAMZYOS | | | | | | |
| N 214998 002 | >A> 9585883 | Jun 19, 2034 | U-3373 | | >A> NPP | Sep 30, 2029 |
| | >A> 9585883 | Jun 19, 2034 | U-4632 | | | |
| MAVACAMTEN - CAMZYOS | | | | | | |
| N 214998 003 | >A> 9585883 | Jun 19, 2034 | U-3373 | | >A> NPP | Sep 30, 2029 |
| | >A> 9585883 | Jun 19, 2034 | U-4632 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| MAVACAMTEN - CAMZYOS | | | | | | | |
| N 214998 | 004 | >A> 9585883 | Jun 19, 2034 | U-3373 | | >A> NPP | Sep 30, 2029 |
| | | >A> 9585883 | Jun 19, 2034 | U-4632 | | | |
| MAVACAMTEN - CAMZYOS | | | | | | | |
| N 214998 | 005 | >A> 9585883 | Jun 19, 2034 | U-4632 | | >A> NCE | Apr 28, 2027 |
| | | >A> RE50050 | Apr 28, 2036 | DS DP | | >A> NS | Sep 30, 2029 |
| MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO | | | | | | | |
| N 215431 | 001 | 10265399 | Apr 11, 2036 | U-4509 | | | |
| | | 10265400 | Apr 11, 2036 | U-4509 | | | |
| | | 10307484 | Apr 11, 2036 | U-4509 | | | |
| | | 10369225 | Apr 11, 2036 | U-4356 | | | |
| | | 10456471 | Apr 11, 2036 | U-4509 | | | |
| | | 11266657 | Apr 11, 2036 | U-1719 | | | |
| | | 11433078 | Apr 11, 2036 | U-1719 | | | |
| | | 11433079 | Apr 11, 2036 | U-1719 | | | |
| | | 11944683 | Apr 11, 2036 | U-1719 | | | |
| | | 12005118 | Jan 25, 2043 | U-1719 | | | |
| | | 12544383 | Mar 10, 2045 | U-1719 | | | |
| | | 12551488 | May 28, 2040 | U-1719 | | | |
| | | 12551489 | May 28, 2040 | U-1719 | | | |
| | | 12611413 | Dec 29, 2041 | U-1719 | | | |
| | | 12616752 | May 18, 2038 | U-4510 | | | |
| | | 12685736 | May 09, 2040 | U-1719 | | | |
| | | 12691123 | Apr 11, 2036 | U-1719 | | | |
| MEROPENEM; VABORBACTAM - VABOMERE | | | | | | | |
| N 209776 | 001 | 12533342 | Apr 06, 2039 | U-3421 | | | |
| METAXALONE - METAXALONE | | | | | | | |
| N 022503 | 001 | 12485111 | May 14, 2043 | DP U-4453 | | | |
| METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR | | | | | | | |
| N 200678 | 001 | | | | | M-14 | Oct 11, 2027 |
| METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR | | | | | | | |
| N 200678 | 002 | | | | | M-14 | Oct 11, 2027 |
| METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR | | | | | | | |
| N 200678 | 003 | | | | | M-14 | Oct 11, 2027 |
| METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | | | | | | | |
| A 202388 | 001 | | | | | PC | Nov 24, 2026 |
| METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | | | | | | | |
| A 202388 | 002 | | | | | PC | Nov 24, 2026 |
| METHOTREXATE - JYLAMVO | | | | | | | |
| N 212479 | 001 | 12605385 | Oct 25, 2035 | DP | | | |
| MIGALASTAT HYDROCHLORIDE - GALAFOLD | | | | | | | |
| N 208623 | 001 | 12594268 | May 23, 2041 | U-2371 | | | |
| | | 12599594 | Jul 19, 2036 | U-2371 | | | |
| | | 12599595 | Apr 28, 2028 | U-2371 | | | |
| MILSAPERIDONE - BYSANTI | | | | | | | |
| N 220358 | 001 | 10563259 | Jul 24, 2030 | U-4436 | | NCE | Feb 20, 2031 |
| | | 10563259 | Jul 24, 2030 | U-4437 | | | |
| | | 10570453 | Mar 28, 2028 | U-4436 | | | |
| | | 10570453 | Mar 28, 2028 | U-4437 | | | |
| | | 12478619 | May 31, 2044 | U-4434 | | | |
| | | 12478619 | May 31, 2044 | U-4435 | | | |
| | | 12606869 | Sep 22, 2030 | U-4506 | | | |
| | | 12606869 | Sep 22, 2030 | U-4507 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 220358 001 | 8999638 | Oct 28, 2030 | U-4436 | | | |
| | 8999638 | Oct 28, 2030 | U-4437 | | | |
| | 9072742 | Jan 16, 2031 | U-4436 | | | |
| | 9072742 | Jan 16, 2031 | U-4437 | | | |
| | 9074254 | Dec 28, 2031 | U-4436 | | | |
| | 9074254 | Dec 28, 2031 | U-4437 | | | |
| | 9074255 | Dec 17, 2030 | U-4436 | | | |
| | 9074255 | Dec 17, 2030 | U-4437 | | | |
| | 9074256 | Feb 10, 2031 | U-4436 | | | |
| | 9074256 | Feb 10, 2031 | U-4437 | | | |
| | 9157121 | Apr 05, 2030 | U-4436 | | | |
| | 9157121 | Apr 05, 2030 | U-4437 | | | |
| MILSAPERIDONE - BYSANTI | | | | | | |
| N 220358 002 | 10563259 | Jul 24, 2030 | U-4436 | | NCE | Feb 20, 2031 |
| | 10563259 | Jul 24, 2030 | U-4437 | | | |
| | 10570453 | Mar 28, 2028 | U-4436 | | | |
| | 10570453 | Mar 28, 2028 | U-4437 | | | |
| | 12478619 | May 31, 2044 | U-4434 | | | |
| | 12478619 | May 31, 2044 | U-4435 | | | |
| | 12606869 | Sep 22, 2030 | U-4506 | | | |
| | 12606869 | Sep 22, 2030 | U-4507 | | | |
| | 8999638 | Oct 28, 2030 | U-4436 | | | |
| | 8999638 | Oct 28, 2030 | U-4437 | | | |
| | 9072742 | Jan 16, 2031 | U-4436 | | | |
| | 9072742 | Jan 16, 2031 | U-4437 | | | |
| | 9074254 | Dec 28, 2031 | U-4436 | | | |
| | 9074254 | Dec 28, 2031 | U-4437 | | | |
| | 9074255 | Dec 17, 2030 | U-4436 | | | |
| | 9074255 | Dec 17, 2030 | U-4437 | | | |
| | 9074256 | Feb 10, 2031 | U-4436 | | | |
| | 9074256 | Feb 10, 2031 | U-4437 | | | |
| | 9157121 | Apr 05, 2030 | U-4436 | | | |
| | 9157121 | Apr 05, 2030 | U-4437 | | | |
| MILSAPERIDONE - BYSANTI | | | | | | |
| N 220358 003 | 10563259 | Jul 24, 2030 | U-4436 | | NCE | Feb 20, 2031 |
| | 10563259 | Jul 24, 2030 | U-4437 | | | |
| | 10570453 | Mar 28, 2028 | U-4436 | | | |
| | 10570453 | Mar 28, 2028 | U-4437 | | | |
| | 12478619 | May 31, 2044 | U-4434 | | | |
| | 12478619 | May 31, 2044 | U-4435 | | | |
| | 12606869 | Sep 22, 2030 | U-4506 | | | |
| | 12606869 | Sep 22, 2030 | U-4507 | | | |
| | 8999638 | Oct 28, 2030 | U-4436 | | | |
| | 8999638 | Oct 28, 2030 | U-4437 | | | |
| | 9072742 | Jan 16, 2031 | U-4436 | | | |
| | 9072742 | Jan 16, 2031 | U-4437 | | | |
| | 9074254 | Dec 28, 2031 | U-4436 | | | |
| | 9074254 | Dec 28, 2031 | U-4437 | | | |
| | 9074255 | Dec 17, 2030 | U-4436 | | | |
| | 9074255 | Dec 17, 2030 | U-4437 | | | |
| | 9074256 | Feb 10, 2031 | U-4436 | | | |
| | 9074256 | Feb 10, 2031 | U-4437 | | | |
| | 9157121 | Apr 05, 2030 | U-4436 | | | |
| | 9157121 | Apr 05, 2030 | U-4437 | | | |
| MILSAPERIDONE - BYSANTI | | | | | | |
| N 220358 004 | 10563259 | Jul 24, 2030 | U-4436 | | NCE | Feb 20, 2031 |
| | 10563259 | Jul 24, 2030 | U-4437 | | | |
| | 10570453 | Mar 28, 2028 | U-4436 | | | |
| | 10570453 | Mar 28, 2028 | U-4437 | | | |
| | 12478619 | May 31, 2044 | U-4434 | | | |
| | 12478619 | May 31, 2044 | U-4435 | | | |
| | 12606869 | Sep 22, 2030 | U-4506 | | | |
| | 12606869 | Sep 22, 2030 | U-4507 | | | |
| | 8999638 | Oct 28, 2030 | U-4436 | | | |
| | 8999638 | Oct 28, 2030 | U-4437 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 220358 004 | 9072742 | Jan 16, 2031 | U-4436 | | | |
| | 9072742 | Jan 16, 2031 | U-4437 | | | |
| | 9074254 | Dec 28, 2031 | U-4436 | | | |
| | 9074254 | Dec 28, 2031 | U-4437 | | | |
| | 9074255 | Dec 17, 2030 | U-4436 | | | |
| | 9074255 | Dec 17, 2030 | U-4437 | | | |
| | 9074256 | Feb 10, 2031 | U-4436 | | | |
| | 9074256 | Feb 10, 2031 | U-4437 | | | |
| | 9157121 | Apr 05, 2030 | U-4436 | | | |
| | 9157121 | Apr 05, 2030 | U-4437 | | | |
| MILSAPERIDONE - BYSANTI | | | | | | |
| N 220358 005 | 10563259 | Jul 24, 2030 | U-4436 | | NCE | Feb 20, 2031 |
| | 10563259 | Jul 24, 2030 | U-4437 | | | |
| | 10570453 | Mar 28, 2028 | U-4436 | | | |
| | 10570453 | Mar 28, 2028 | U-4437 | | | |
| | 12478619 | May 31, 2044 | U-4434 | | | |
| | 12478619 | May 31, 2044 | U-4435 | | | |
| | 12606869 | Sep 22, 2030 | U-4506 | | | |
| | 12606869 | Sep 22, 2030 | U-4507 | | | |
| | 8999638 | Oct 28, 2030 | U-4436 | | | |
| | 8999638 | Oct 28, 2030 | U-4437 | | | |
| | 9072742 | Jan 16, 2031 | U-4436 | | | |
| | 9072742 | Jan 16, 2031 | U-4437 | | | |
| | 9074254 | Dec 28, 2031 | U-4436 | | | |
| | 9074254 | Dec 28, 2031 | U-4437 | | | |
| | 9074255 | Dec 17, 2030 | U-4436 | | | |
| | 9074255 | Dec 17, 2030 | U-4437 | | | |
| | 9074256 | Feb 10, 2031 | U-4436 | | | |
| | 9074256 | Feb 10, 2031 | U-4437 | | | |
| | 9157121 | Apr 05, 2030 | U-4436 | | | |
| | 9157121 | Apr 05, 2030 | U-4437 | | | |
| MILSAPERIDONE - BYSANTI | | | | | | |
| N 220358 006 | 10563259 | Jul 24, 2030 | U-4436 | | NCE | Feb 20, 2031 |
| | 10563259 | Jul 24, 2030 | U-4437 | | | |
| | 10570453 | Mar 28, 2028 | U-4436 | | | |
| | 10570453 | Mar 28, 2028 | U-4437 | | | |
| | 12478619 | May 31, 2044 | U-4434 | | | |
| | 12478619 | May 31, 2044 | U-4435 | | | |
| | 12606869 | Sep 22, 2030 | U-4506 | | | |
| | 12606869 | Sep 22, 2030 | U-4507 | | | |
| | 8999638 | Oct 28, 2030 | U-4436 | | | |
| | 8999638 | Oct 28, 2030 | U-4437 | | | |
| | 9072742 | Jan 16, 2031 | U-4436 | | | |
| | 9072742 | Jan 16, 2031 | U-4437 | | | |
| | 9074254 | Dec 28, 2031 | U-4436 | | | |
| | 9074254 | Dec 28, 2031 | U-4437 | | | |
| | 9074255 | Dec 17, 2030 | U-4436 | | | |
| | 9074255 | Dec 17, 2030 | U-4437 | | | |
| | 9074256 | Feb 10, 2031 | U-4436 | | | |
| | 9074256 | Feb 10, 2031 | U-4437 | | | |
| | 9157121 | Apr 05, 2030 | U-4436 | | | |
| | 9157121 | Apr 05, 2030 | U-4437 | | | |
| MILSAPERIDONE - BYSANTI | | | | | | |
| N 220358 007 | 10563259 | Jul 24, 2030 | U-4436 | | NCE | Feb 20, 2031 |
| | 10563259 | Jul 24, 2030 | U-4437 | | | |
| | 10570453 | Mar 28, 2028 | U-4436 | | | |
| | 10570453 | Mar 28, 2028 | U-4437 | | | |
| | 12478619 | May 31, 2044 | U-4434 | | | |
| | 12478619 | May 31, 2044 | U-4435 | | | |
| | 12606869 | Sep 22, 2030 | U-4506 | | | |
| | 12606869 | Sep 22, 2030 | U-4507 | | | |
| | 8999638 | Oct 28, 2030 | U-4436 | | | |
| | 8999638 | Oct 28, 2030 | U-4437 | | | |
| | 9072742 | Jan 16, 2031 | U-4436 | | | |
| | 9072742 | Jan 16, 2031 | U-4437 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 220358 007 | 9074254 | Dec 28, 2031 | U-4436 | | | |
| | 9074254 | Dec 28, 2031 | U-4437 | | | |
| | 9074255 | Dec 17, 2030 | U-4436 | | | |
| | 9074255 | Dec 17, 2030 | U-4437 | | | |
| | 9074256 | Feb 10, 2031 | U-4436 | | | |
| | 9074256 | Feb 10, 2031 | U-4437 | | | |
| | 9157121 | Apr 05, 2030 | U-4436 | | | |
| | 9157121 | Apr 05, 2030 | U-4437 | | | |
| MINOCYCLINE HYDROCHLORIDE - ZILXI | | | | | | |
| N 213690 001 | 12661407 | Oct 01, 2030 | U-1631 | | | |
| MINOCYCLINE HYDROCHLORIDE - EMROSI | | | | | | |
| N 219015 001 | 12594252 | Jan 07, 2039 | U-4043 | | | |
| MIRDAMETINIB - GOMEKLI | | | | | | |
| N 219379 001 | 11819487 | Feb 17, 2041 | U-4590 | | | |
| | 12011424 | Feb 17, 2041 | U-4595 | | | |
| | 12295925 | Feb 17, 2041 | U-4590 | | | |
| | 12324791 | Mar 16, 2043 | U-4591 | | | |
| | 12661330 | Feb 05, 2044 | U-4130 | | | |
| MIRDAMETINIB - GOMEKLI | | | | | | |
| N 219379 002 | 11066358 | Feb 17, 2041 | DS DP | | NCE | Feb 11, 2030 |
| | 11084780 | Feb 17, 2041 | DS | | ODE* | Feb 11, 2032 |
| | 11453641 | Feb 17, 2041 | U-4130 | | | |
| | 11571402 | Feb 17, 2041 | DP | | | |
| | 11806321 | Feb 17, 2041 | U-4130 | | | |
| | 11819487 | Feb 17, 2041 | U-4590 | | | |
| | 11883375 | Mar 16, 2043 | U-4130 | | | |
| | 12029711 | Mar 15, 2044 | DP U-4130 | | | |
| | 12037306 | Feb 17, 2041 | U-4130 | | | |
| | 12220390 | Mar 16, 2043 | U-4130 | | | |
| | 12257215 | Mar 16, 2043 | U-4130 | | | |
| | 12263146 | Feb 17, 2041 | U-4130 | | | |
| | 12295925 | Feb 17, 2041 | U-4590 | | | |
| | 12324791 | Mar 16, 2043 | U-4591 | | | |
| | 12357597 | Feb 17, 2041 | U-4130 | | | |
| | 12390430 | Oct 10, 2044 | U-4130 | | | |
| | 12661330 | Feb 05, 2044 | U-4130 | | | |
| MIRDAMETINIB - GOMEKLI | | | | | | |
| N 219379 003 | 11066358 | Feb 17, 2041 | DS DP | | NCE | Feb 11, 2030 |
| | 11084780 | Feb 17, 2041 | DS | | ODE* | Feb 11, 2032 |
| | 11453641 | Feb 17, 2041 | U-4130 | | | |
| | 11571402 | Feb 17, 2041 | DP | | | |
| | 11806321 | Feb 17, 2041 | U-4130 | | | |
| | 11819487 | Feb 17, 2041 | U-4590 | | | |
| | 12029711 | Mar 15, 2044 | DP U-4130 | | | |
| | 12037306 | Feb 17, 2041 | U-4130 | | | |
| | 12220390 | Mar 16, 2043 | U-4130 | | | |
| | 12263146 | Feb 17, 2041 | U-4130 | | | |
| | 12295925 | Feb 17, 2041 | U-4590 | | | |
| | 12324791 | Mar 16, 2043 | U-4591 | | | |
| | 12357597 | Feb 17, 2041 | U-4130 | | | |
| | 12390430 | Oct 10, 2044 | U-4130 | | | |
| | 12661330 | Feb 05, 2044 | U-4130 | | | |
| MIRDAMETINIB - GOMEKLI | | | | | | |
| N 219389 001 | 11819487 | Feb 17, 2041 | U-4590 | | | |
| | 12011424 | Feb 17, 2041 | U-4595 | | | |
| | 12295925 | Feb 17, 2041 | U-4590 | | | |
| | 12324791 | Mar 16, 2043 | U-4591 | | | |
| | 12661330 | Feb 05, 2044 | U-4130 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| MIRDAMETINIB - GOMEKLI | | | | | | | |
| N 219389 | 002 | 11819487 | Feb 17, 2041 | U-4590 | | | |
| | | 12295925 | Feb 17, 2041 | U-4590 | | | |
| | | 12324791 | Mar 16, 2043 | U-4591 | | | |
| | | 12661330 | Feb 05, 2044 | U-4130 | | | |
| MITAPIVAT SULFATE - PYRUKYND | | | | | | | |
| N 216196 | 001 | RE49582 | Apr 11, 2035 | DS DP | | | |
| MITAPIVAT SULFATE - PYRUKYND | | | | | | | |
| N 216196 | 002 | RE49582 | Apr 11, 2035 | DS DP | | | |
| MITAPIVAT SULFATE - PYRUKYND | | | | | | | |
| N 216196 | 003 | RE49582 | Apr 11, 2035 | DS DP | | | |
| MITAPIVAT SULFATE - AQVESME | | | | | | | |
| N 216196 | 004 | 10632114 | May 03, 2032 | U-4391 | | NCE | Feb 17, 2027 |
| | | 11254652 | Nov 21, 2038 | DS DP | | NP | Dec 23, 2028 |
| | | 11878049 | Jul 31, 2041 | U-4390 | | ODE-522 | Dec 23, 2032 |
| | | 9193701 | Oct 26, 2032 | U-4393 | | | |
| | | 9682080 | May 03, 2032 | U-4392 | | | |
| | | RE49582 | Apr 11, 2035 | DS DP | | | |
| MITOMYCIN - ZUSDURI | | | | | | | |
| N 215793 | 001 | 12740940 | Jul 25, 2044 | U-4605 | | | |
| MOMELOTINIB DIHYDROCHLORIDE - OJJAARA | | | | | | | |
| N 216873 | 001 | 12576089 | Aug 21, 2039 | U-4441 | | | |
| | | 8486941 | Jan 03, 2035 | DS DP U-1201 | | | |
| MOMELOTINIB DIHYDROCHLORIDE - OJJAARA | | | | | | | |
| N 216873 | 002 | 12576089 | Aug 21, 2039 | U-4441 | | | |
| | | 8486941 | Jan 03, 2035 | DS DP U-1201 | | | |
| MOMELOTINIB DIHYDROCHLORIDE - OJJAARA | | | | | | | |
| N 216873 | 003 | 12576089 | Aug 21, 2039 | U-4441 | | | |
| | | 8486941 | Jan 03, 2035 | DS DP U-1201 | | | |
| MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS | | | | | | | |
| N 211746 | 001 | 12653833 | Nov 21, 2044 | DP U-4564 | | NPP | Jul 07, 2029 |
| MOXIDECTIN - MOXIDECTIN | | | | | | | |
| N 210867 | 001 | | | | | ODE-528 | Feb 07, 2032 |
| NALOXONE HYDROCHLORIDE - REZENOPY | | | | | | | |
| N 215487 | 001 | 12514854 | Feb 05, 2041 | U-4397 | | | |
| | | 12622903 | Feb 05, 2041 | DP | | | |
| NAVEPEGRITIDE - YUVIWEL | | | | | | | |
| N 219164 | 001 | 10835578 | Jan 05, 2037 | DS DP U-4425 | | NCE | Feb 27, 2031 |
| | | 11154593 | Jan 05, 2037 | DS DP U-4425 | | ODE-516 | Feb 27, 2033 |
| | | 11224661 | Jan 05, 2037 | DS DP | | | |
| | | 11311604 | Jan 05, 2037 | DS DP U-4425 | | | |
| | | 11389510 | Jan 05, 2037 | DS DP | | | |
| | | 11389511 | Jan 05, 2037 | DP U-4425 | | | |
| | | 11413351 | Jan 05, 2037 | DS DP | | | |
| | | 12083182 | Jan 05, 2037 | U-4425 | | | |
| | | 12156917 | Jan 05, 2037 | U-4425 | | | |
| | | 12239689 | Jan 05, 2037 | U-4425 | | | |
| | | 12377133 | Nov 12, 2042 | DP U-4425 | | | |
| | >A> | 12758617 | Jan 05, 2037 | U-4425 | | | |
| | | 8906847 | Apr 30, 2031 | DS DP U-4425 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| NAVEPEGRITIDE - YUVIWEL | | | | | | | |
| N 219164 002 | | 10835578 | Jan 05, 2037 | DS DP U-4425 | | NCE | Feb 27, 2031 |
| | | 11154593 | Jan 05, 2037 | DS DP U-4425 | | ODE-516 | Feb 27, 2033 |
| | | 11224661 | Jan 05, 2037 | DS DP | | | |
| | | 11311604 | Jan 05, 2037 | DS DP U-4425 | | | |
| | | 11389510 | Jan 05, 2037 | DS DP | | | |
| | | 11389511 | Jan 05, 2037 | DP U-4425 | | | |
| | | 11413351 | Jan 05, 2037 | DS DP | | | |
| | | 12083182 | Jan 05, 2037 | U-4425 | | | |
| | | 12156917 | Jan 05, 2037 | U-4425 | | | |
| | | 12239689 | Jan 05, 2037 | U-4425 | | | |
| | | 12377133 | Nov 12, 2042 | DP U-4425 | | | |
| | >A> | 12758617 | Jan 05, 2037 | U-4425 | | | |
| | | 8906847 | Apr 30, 2031 | DS DP U-4425 | | | |
| NAVEPEGRITIDE - YUVIWEL | | | | | | | |
| N 219164 003 | | 10835578 | Jan 05, 2037 | DS DP U-4425 | | NCE | Feb 27, 2031 |
| | | 11154593 | Jan 05, 2037 | DS DP U-4425 | | ODE-516 | Feb 27, 2033 |
| | | 11224661 | Jan 05, 2037 | DS DP | | | |
| | | 11311604 | Jan 05, 2037 | DS DP U-4425 | | | |
| | | 11389510 | Jan 05, 2037 | DS DP | | | |
| | | 11389511 | Jan 05, 2037 | DP U-4425 | | | |
| | | 11413351 | Jan 05, 2037 | DS DP | | | |
| | | 12083182 | Jan 05, 2037 | U-4425 | | | |
| | | 12156917 | Jan 05, 2037 | U-4425 | | | |
| | | 12239689 | Jan 05, 2037 | U-4425 | | | |
| | | 12377133 | Nov 12, 2042 | DP U-4425 | | | |
| | >A> | 12758617 | Jan 05, 2037 | U-4425 | | | |
| | | 8906847 | Apr 30, 2031 | DS DP U-4425 | | | |
| NEDOSIRAN SODIUM - RIVFLOZA | | | | | | | |
| N 215842 001 | | | | | | ODE-531 | Mar 27, 2032 |
| NEDOSIRAN SODIUM - RIVFLOZA | | | | | | | |
| N 215842 002 | | | | | | ODE-531 | Mar 27, 2032 |
| NEDOSIRAN SODIUM - RIVFLOZA | | | | | | | |
| N 215842 003 | | | | | | ODE-531 | Mar 27, 2032 |
| NERANDOMILAST - JASCAYD | | | | | | | |
| N 218764 001 | | 11406638 | Oct 22, 2038 | U-4297 | | I-979 | Dec 19, 2028 |
| | | 11406638 | Oct 22, 2038 | U-4373 | | ODE-546 | Oct 07, 2032 |
| | | 11813266 | Oct 22, 2038 | U-4292 | | | |
| | | 11813266 | Oct 22, 2038 | U-4372 | | | |
| NERANDOMILAST - JASCAYD | | | | | | | |
| N 218764 002 | | 11406638 | Oct 22, 2038 | U-4297 | | I-979 | Dec 19, 2028 |
| | | 11406638 | Oct 22, 2038 | U-4373 | | ODE-546 | Oct 07, 2032 |
| | | 11813266 | Oct 22, 2038 | U-4292 | | | |
| | | 11813266 | Oct 22, 2038 | U-4372 | | | |
| NILOTINIB - CAVHANZA | | | | | | | |
| N 217379 001 | | 11389450 | Jan 29, 2041 | U-4556 | | | |
| | | 11389450 | Jan 29, 2041 | U-4557 | | | |
| | | 11559485 | Apr 30, 2041 | DP | | | |
| | | 12016861 | Jan 29, 2041 | U-4554 | | | |
| | | 12016861 | Jan 29, 2041 | U-4555 | | | |
| | | 12029740 | Jan 29, 2041 | DP | | | |
| | >A> | 12751950 | Jan 29, 2041 | U-4627 | | | |
| | >A> | 12751950 | Jan 29, 2041 | U-4628 | | | |
| NILOTINIB - CAVHANZA | | | | | | | |
| N 217379 002 | | 11389450 | Jan 29, 2041 | U-4556 | | | |
| | | 11389450 | Jan 29, 2041 | U-4557 | | | |
| | | 11559485 | Apr 30, 2041 | DP | | | |
| | | 12016861 | Jan 29, 2041 | U-4554 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| N 217379 002 | | 12016861 | Jan 29, 2041 | U-4555 | | | |
| | | 12029740 | Jan 29, 2041 | DP | | | |
| | >A> | 12751950 | Jan 29, 2041 | U-4627 | | | |
| | >A> | 12751950 | Jan 29, 2041 | U-4628 | | | |
| NILOTINIB TARTRATE - DANZITEN | | | | | | | |
| N 219293 001 | | 12629369 | Feb 18, 2040 | DP | | | |
| NILOTINIB TARTRATE - DANZITEN | | | | | | | |
| N 219293 002 | | 12629369 | Feb 18, 2040 | DP | | | |
| NIROGACESTAT HYDROBROMIDE - OGSIVEO | | | | | | | |
| N 217677 001 | | 12599587 | Jul 08, 2042 | DP | | | |
| NIROGACESTAT HYDROBROMIDE - OGSIVEO | | | | | | | |
| N 217677 002 | | 12599587 | Jul 08, 2042 | DP | | | |
| NIROGACESTAT HYDROBROMIDE - OGSIVEO | | | | | | | |
| N 217677 003 | | 12599587 | Jul 08, 2042 | DP | | | |
| NITISINONE - HARLIKU | | | | | | | |
| N 209449 004 | | | | | | ODE-529 | Jun 10, 2032 |
| NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | | | | | | | |
| N 214313 001 | | 12714681 | Mar 08, 2041 | DP | | | |
| NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | | | | | | | |
| N 214313 002 | | 12714681 | Mar 08, 2041 | DP | | | |
| NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | | | | | | | |
| N 215700 004 | | 10888534 | Apr 26, 2039 | DP | | | |
| | | RE49422 | Feb 26, 2035 | DP | | | |
| | | RE49443 | Feb 26, 2035 | DP | | | |
| NUSINERSEN SODIUM - SPINRAZA | | | | | | | |
| N 209531 002 | | 7838657 | Jul 11, 2027 | DS DP | | NS | Mar 27, 2029 |
| | | 8361977 | Dec 23, 2030 | DS DP | | | |
| | | 8980853 | Nov 24, 2030 | U-1941 | | | |
| | | 9717750 | Jun 17, 2030 | U-1942 | | | |
| | | 9717750 | Jun 17, 2030 | U-1943 | | | |
| | | 9717750 | Jun 17, 2030 | U-2093 | | | |
| | | 9717750 | Jun 17, 2030 | U-2094 | | | |
| NUSINERSEN SODIUM - SPINRAZA | | | | | | | |
| N 209531 003 | | 7838657 | Jul 11, 2027 | DS DP | | NS | Mar 27, 2029 |
| | | 8361977 | Dec 23, 2030 | DS DP | | | |
| | | 8980853 | Nov 24, 2030 | U-1941 | | | |
| | | 9717750 | Jun 17, 2030 | U-1942 | | | |
| | | 9717750 | Jun 17, 2030 | U-1943 | | | |
| | | 9717750 | Jun 17, 2030 | U-2093 | | | |
| | | 9717750 | Jun 17, 2030 | U-2094 | | | |
| OCTREOTIDE ACETATE - OCTREOTIDE ACETATE | | | | | | | |
| A 216589 001 | | | | | | CGT | Aug 02, 2026 |
| OCTREOTIDE ACETATE - OCTREOTIDE ACETATE | | | | | | | |
| A 216589 002 | | | | | | CGT | Jul 27, 2026 |
| OCTREOTIDE ACETATE - OCTREOTIDE ACETATE | | | | | | | |
| A 216589 003 | | | | | | CGT | Jul 27, 2026 |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ODEVIXIBAT - BYLVAY | | | | | | | |
| N 215498 001 | | 12508234 | Jun 20, 2039 | U-3186 | | | |
| | | 12508234 | Jun 20, 2039 | U-3648 | | | |
| | | 12545705 | Nov 08, 2031 | U-3186 | | | |
| | | 12545705 | Nov 08, 2031 | U-3648 | | | |
| | | 9694018 | Mar 18, 2034 | U-3186 | | | |
| | | 9694018 | Mar 18, 2034 | U-3648 | | | |
| ODEVIXIBAT - BYLVAY | | | | | | | |
| N 215498 002 | | 12508234 | Jun 20, 2039 | U-3186 | | | |
| | | 12508234 | Jun 20, 2039 | U-3648 | | | |
| | | 12545705 | Nov 08, 2031 | U-3186 | | | |
| | | 12545705 | Nov 08, 2031 | U-3648 | | | |
| | | 9694018 | Mar 18, 2034 | U-3186 | | | |
| | | 9694018 | Mar 18, 2034 | U-3648 | | | |
| ODEVIXIBAT - BYLVAY | | | | | | | |
| N 215498 003 | | 12508234 | Jun 20, 2039 | U-3186 | | | |
| | | 12508234 | Jun 20, 2039 | U-3648 | | | |
| | | 12545705 | Nov 08, 2031 | U-3186 | | | |
| | | 12545705 | Nov 08, 2031 | U-3648 | | | |
| | | 9694018 | Mar 18, 2034 | U-3186 | | | |
| | | 9694018 | Mar 18, 2034 | U-3648 | | | |
| ODEVIXIBAT - BYLVAY | | | | | | | |
| N 215498 004 | | 12508234 | Jun 20, 2039 | U-3186 | | | |
| | | 12508234 | Jun 20, 2039 | U-3648 | | | |
| | | 12545705 | Nov 08, 2031 | U-3186 | | | |
| | | 12545705 | Nov 08, 2031 | U-3648 | | | |
| | | 9694018 | Mar 18, 2034 | U-3186 | | | |
| | | 9694018 | Mar 18, 2034 | U-3648 | | | |
| OLANZAPINE - WELTRUZA | | | | | | | |
| N 219007 001 | >A> | 10646443 | Mar 20, 2038 | U-543 | | | |
| | >A> | 11813359 | Oct 05, 2038 | DP | | | |
| | >A> | 12220418 | Jan 10, 2044 | U-543 | | | |
| | >A> | 9023897 | Apr 05, 2033 | DP | | | |
| OLANZAPINE - WELTRUZA | | | | | | | |
| N 219007 002 | >A> | 10646443 | Mar 20, 2038 | U-543 | | | |
| | >A> | 11813359 | Oct 05, 2038 | DP | | | |
| | >A> | 12220418 | Jan 10, 2044 | U-543 | | | |
| | >A> | 9023897 | Apr 05, 2033 | DP | | | |
| OLANZAPINE - WELTRUZA | | | | | | | |
| N 219007 003 | >A> | 10646443 | Mar 20, 2038 | U-543 | | | |
| | >A> | 11813359 | Oct 05, 2038 | DP | | | |
| | >A> | 12220418 | Jan 10, 2044 | U-543 | | | |
| | >A> | 9023897 | Apr 05, 2033 | DP | | | |
| OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI | | | | | | | |
| N 213378 001 | | 10300054 | May 31, 2033 | DP U-3140 | | | |
| | | 10300054 | May 31, 2033 | DP U-3141 | | | |
| OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI | | | | | | | |
| N 213378 002 | | 10300054 | May 31, 2033 | DP U-3140 | | | |
| | | 10300054 | May 31, 2033 | DP U-3141 | | | |
| OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI | | | | | | | |
| N 213378 003 | | 10300054 | May 31, 2033 | DP U-3140 | | | |
| | | 10300054 | May 31, 2033 | DP U-3141 | | | |
| OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI | | | | | | | |
| N 213378 004 | | 10300054 | May 31, 2033 | DP U-3140 | | | |
| | | 10300054 | May 31, 2033 | DP U-3141 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR) | | | | | | | |
| N 218614 | 001 | 12509684 | May 01, 2034 | U-4050 | | I-992 | Jun 24, 2029 |
| | | 12509684 | May 01, 2034 | U-4580 | | | |
| | | 9157082 | Apr 27, 2032 | U-4050 | | | |
| | | 9157082 | Apr 27, 2032 | U-4580 | | | |
| OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR) | | | | | | | |
| N 218614 | 002 | 12509684 | May 01, 2034 | U-4580 | | NS | Jun 24, 2029 |
| | | 9127276 | May 01, 2034 | DS | | | |
| | | 9157082 | Apr 27, 2032 | U-4580 | | | |
| | | 9163239 | May 01, 2034 | DS | | | |
| | | 9181549 | May 01, 2034 | DS | | | |
| OMADACYCLINE TOSYLATE - NUZYRA | | | | | | | |
| N 209816 | 001 | | | | | M-320 | May 13, 2029 |
| OMADACYCLINE TOSYLATE - NUZYRA | | | | | | | |
| N 209817 | 001 | | | | | M-320 | May 13, 2029 |
| OMAVELOXOLONE - SKYCLARYS | | | | | | | |
| N 216718 | 001 | >A> 8993640 | Feb 28, 2037 | DS DP | | | |
| OMEPRAZOLE - OMEPRAZOLE | | | | | | | |
| N 022032 | 001 | 12599565 | Jan 31, 2030 | DP | | | |
| OPICAPONE - ONGENTYS | | | | | | | |
| N 212489 | 001 | 8168793 | Apr 07, 2032 | DS DP U-3869 | | | |
| OPICAPONE - ONGENTYS | | | | | | | |
| N 212489 | 002 | 8168793 | Apr 07, 2032 | DS DP U-3869 | | | |
| ORFORGLIPRON CALCIUM - FOUNDAYO | | | | | | | |
| N 220934 | 001 | RE50455 | Sep 26, 2037 | DS DP U-4474 | | NCE | Apr 01, 2031 |
| ORFORGLIPRON CALCIUM - FOUNDAYO | | | | | | | |
| N 220934 | 002 | RE50455 | Sep 26, 2037 | DS DP U-4474 | | NCE | Apr 01, 2031 |
| ORFORGLIPRON CALCIUM - FOUNDAYO | | | | | | | |
| N 220934 | 003 | RE50455 | Sep 26, 2037 | DS DP U-4474 | | NCE | Apr 01, 2031 |
| ORFORGLIPRON CALCIUM - FOUNDAYO | | | | | | | |
| N 220934 | 004 | RE50455 | Sep 26, 2037 | DS DP U-4474 | | NCE | Apr 01, 2031 |
| ORFORGLIPRON CALCIUM - FOUNDAYO | | | | | | | |
| N 220934 | 005 | RE50455 | Sep 26, 2037 | DS DP U-4474 | | NCE | Apr 01, 2031 |
| ORFORGLIPRON CALCIUM - FOUNDAYO | | | | | | | |
| N 220934 | 006 | RE50455 | Sep 26, 2037 | DS DP U-4474 | | NCE | Apr 01, 2031 |
| ORITAVANCIN DIPHOSPHATE - ORBACTIV | | | | | | | |
| N 206334 | 001 | 12514899 | Aug 29, 2029 | U-4398 | | | |
| ORITAVANCIN DIPHOSPHATE - KIMYRSA | | | | | | | |
| N 214155 | 001 | 12514899 | Aug 29, 2029 | U-4398 | | | |
| OSILODROSTAT PHOSPHATE - ISTURISA | | | | | | | |
| N 212801 | 001 | 10709691 | Oct 12, 2035 | U-4529 | | ODE-535 | Apr 15, 2032 |
| | | 8314097 | May 20, 2033 | DS DP | | | |
| | | 8609862 | Jan 13, 2031 | U-4529 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| OSILODROSTAT PHOSPHATE - ISTURISA | | | | | | |
| N 212801 002 | 10709691 | Oct 12, 2035 | U-4529 | | ODE-535 | Apr 15, 2032 |
| | 8314097 | May 20, 2033 | DS DP | | | |
| | 8609862 | Jan 13, 2031 | U-4529 | | | |
| OSILODROSTAT PHOSPHATE - ISTURISA | | | | | | |
| N 212801 003 | | | | | ODE-535 | Apr 15, 2032 |
| OSIMERTINIB MESYLATE - TAGRISSO | | | | | | |
| N 208065 001 | | | | | >A> ODE-557 | Feb 16, 2031 |
| | | | | | >A> ODE-558 | Sep 25, 2031 |
| OSIMERTINIB MESYLATE - TAGRISSO | | | | | | |
| N 208065 002 | | | | | >A> ODE-557 | Feb 16, 2031 |
| | | | | | >A> ODE-558 | Sep 25, 2031 |
| OXYCODONE - XTAMPZA ER | | | | | | |
| N 208090 001 | 7771707 | Oct 09, 2028 | DP | | | |
| OXYCODONE - XTAMPZA ER | | | | | | |
| N 208090 002 | 7771707 | Oct 09, 2028 | DP | | | |
| OXYCODONE - XTAMPZA ER | | | | | | |
| N 208090 003 | 7771707 | Oct 09, 2028 | DP | | | |
| OXYCODONE - XTAMPZA ER | | | | | | |
| N 208090 004 | 7771707 | Oct 09, 2028 | DP | | | |
| OXYCODONE - XTAMPZA ER | | | | | | |
| N 208090 005 | 7771707 | Oct 09, 2028 | DP | | | |
| OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ | | | | | | |
| N 212520 001 | 12605363 | Dec 16, 2039 | DP | | | |
| | 12648930 | Dec 16, 2039 | U-2849 | | | |
| PAFOLACIANINE SODIUM - CYTALUX | | | | | | |
| N 214907 001 | 9061057 | Nov 29, 2035 | DS DP U-3291 | | | |
| PALBOCICLIB - IBRANCE | | | | | | |
| N 207103 001 | | | | | I-995 | Jun 24, 2029 |
| PALBOCICLIB - IBRANCE | | | | | | |
| N 207103 002 | | | | | I-995 | Jun 24, 2029 |
| PALBOCICLIB - IBRANCE | | | | | | |
| N 207103 003 | | | | | I-995 | Jun 24, 2029 |
| PALBOCICLIB - IBRANCE | | | | | | |
| N 212436 001 | | | | | I-995 | Jun 24, 2029 |
| PALBOCICLIB - IBRANCE | | | | | | |
| N 212436 002 | | | | | I-995 | Jun 24, 2029 |
| PALBOCICLIB - IBRANCE | | | | | | |
| N 212436 003 | | | | | I-995 | Jun 24, 2029 |
| PALOVAROTENE - SOHONOS | | | | | | |
| N 215559 001 | 10864194 | Aug 16, 2037 | U-3676 | | | |
| PALOVAROTENE - SOHONOS | | | | | | |
| N 215559 002 | 10864194 | Aug 16, 2037 | U-3676 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PALOVAROTENE - SOHONOS | | | | | | | |
| N 215559 | 003 | 10864194 | Aug 16, 2037 | U-3676 | | | |
| PALOVAROTENE - SOHONOS | | | | | | | |
| N 215559 | 004 | 10864194 | Aug 16, 2037 | U-3676 | | | |
| PALOVAROTENE - SOHONOS | | | | | | | |
| N 215559 | 005 | 10864194 | Aug 16, 2037 | U-3676 | | | |
| PALTUSOTINE HYDROCHLORIDE - PALSONIFY | | | | | | | |
| N 219070 | 001 | | | | | ODE-537 | Sep 25, 2032 |
| PALTUSOTINE HYDROCHLORIDE - PALSONIFY | | | | | | | |
| N 219070 | 002 | | | | | ODE-537 | Sep 25, 2032 |
| PEGCETACOPLAN - EMPAVELI | | | | | | | |
| N 215014 | 001 | | | | | ODE-533 | Jul 28, 2032 |
| | | | | | | ODE-539 | Jul 28, 2032 |
| PEGCETACOPLAN - SYFOVRE | | | | | | | |
| N 217171 | 001 | 12528836 | Oct 07, 2036 | U-4394 | | | |
| PEMETREXED DIPOTASSIUM - AXTLE | | | | | | | |
| N 210661 | 001 | 12721811 | Jun 25, 2045 | DP | | | |
| PEMETREXED DIPOTASSIUM - AXTLE | | | | | | | |
| N 210661 | 002 | 12721811 | Jun 25, 2045 | DP | | | |
| PEMIGATINIB - PEMAZYRE | | | | | | | |
| N 213736 | 001 | 12552792 | Oct 03, 2040 | DS DP | | | |
| PEMIGATINIB - PEMAZYRE | | | | | | | |
| N 213736 | 002 | 12552792 | Oct 03, 2040 | DS DP | | | |
| PEMIGATINIB - PEMAZYRE | | | | | | | |
| N 213736 | 003 | 12552792 | Oct 03, 2040 | DS DP | | | |
| PERAMPANEL - PERAMPANEL | | | | | | | |
| A 218152 | 001 | | | | | PC | Jun 14, 2026 |
| PERFLUOROHEXYLOCTANE - MIEBO | | | | | | | |
| N 216675 | 001 | 10682315 | Sep 29, 2036 | U-4586 | | | |
| | | 12005033 | Sep 12, 2033 | U-4586 | | | |
| | | 12128010 | Sep 29, 2036 | DP | | | |
| | | RE50060 | Jun 21, 2037 | U-4586 | | | |
| PHENOBARBITAL SODIUM - SEZABY | | | | | | | |
| N 215910 | 001 | 12636254 | Apr 07, 2042 | DP U-3779 | | | |
| PHENTOLAMINE MESYLATE - RYZUMVI | | | | | | | |
| N 217064 | 001 >A> | 12016841 | Oct 25, 2039 | U-4641 | | | |
| | | 12201615 | Oct 25, 2039 | U-3804 | | | |
| | | 12576066 | Oct 25, 2039 | U-3804 | | | |
| | | 12576067 | Oct 25, 2039 | U-3804 | | | |
| | | 12721810 | Jan 31, 2034 | DP | | | |
| | | 12734126 | Jan 31, 2034 | U-4604 | | | |
| PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | | | | | | | |
| N 216830 | 001 | 12564561 | Aug 08, 2044 | DP | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PIFLUFOLASTAT F-18 - PYLARIFY TRUVU | | | | | | | |
| N 220089 | 001 | 10947197 | Jun 09, 2037 | DS DP U-3317 | | NCE | May 26, 2026 |
| | | 11851407 | Jun 09, 2037 | DS DP U-3317 | | | |
| | | 12070513 | Jul 31, 2029 | DS DP U-3317 | | | |
| | | 8487129 | Nov 07, 2027 | DS DP | | | |
| | | 8778305 | Sep 21, 2030 | DS DP U-3317 | | | |
| | | 9861713 | Jul 31, 2029 | DS DP U-3317 | | | |
| PIMAVANSERIN TARTRATE - NUPLAZID | | | | | | | |
| N 207318 | 001 | 7601740 | Apr 29, 2030 | DS DP | | M-14 | Apr 27, 2029 |
| | | 7601740*PED | Oct 29, 2030 | | | PED | Oct 27, 2029 |
| | | 7732615 | Jun 03, 2028 | DS DP | | | |
| | | 7732615*PED | Dec 03, 2028 | | | | |
| PIMAVANSERIN TARTRATE - NUPLAZID | | | | | | | |
| N 207318 | 002 | 10517860 | Mar 23, 2037 | U-1974 | | M-14 | Apr 27, 2029 |
| | | 10517860*PED | Sep 23, 2037 | | | PED | Oct 27, 2029 |
| | | 10953000 | Mar 23, 2037 | U-1974 | | | |
| | | 10953000*PED | Sep 23, 2037 | | | | |
| | | 7601740 | Apr 29, 2030 | DS DP | | | |
| | | 7601740*PED | Oct 29, 2030 | | | | |
| | | 7732615 | Jun 03, 2028 | DS DP | | | |
| | | 7732615*PED | Dec 03, 2028 | | | | |
| PIMAVANSERIN TARTRATE - NUPLAZID | | | | | | | |
| N 210793 | 001 | 10449185 | Aug 27, 2038 | DP | | M-14 | Apr 27, 2029 |
| | | 10449185*PED | Feb 27, 2039 | | | PED | Oct 27, 2029 |
| | | 10646480 | Aug 27, 2038 | DP | | | |
| | | 10646480*PED | Feb 27, 2039 | | | | |
| | | 10849891 | Aug 27, 2038 | DP U-1974 | | | |
| | | 10849891*PED | Feb 27, 2039 | | | | |
| | | 11452721 | Aug 27, 2038 | DP | | | |
| | | 11452721*PED | Feb 27, 2039 | | | | |
| | | 7601740 | Apr 29, 2030 | DS DP | | | |
| | | 7601740*PED | Oct 29, 2030 | | | | |
| | | 7732615 | Jun 03, 2028 | DS DP | | | |
| | | 7732615*PED | Dec 03, 2028 | | | | |
| PIMOZIDE - PIMOZIDE | | | | | | | |
| A 219897 | 001 | | | | | CGT | Oct 18, 2026 |
| PIMOZIDE - PIMOZIDE | | | | | | | |
| A 219897 | 002 | | | | | CGT | Oct 18, 2026 |
| PIRTOBRUTINIB - JAYPIRCA | | | | | | | |
| N 216059 | 001 | >A> 10464905 | Dec 16, 2036 | U-3518 | | >A> I-1005 | Oct 02, 2029 |
| | | >A> 10464905 | Dec 16, 2036 | U-4362 | | I-981 | Dec 02, 2028 |
| | | >A> 10464905 | Dec 16, 2036 | U-4636 | | ODE-518 | Dec 03, 2032 |
| | | >A> 10695323 | Dec 16, 2036 | DS DP U-3518 | | | |
| | | >A> 10695323 | Dec 16, 2036 | DS DP U-4362 | | | |
| | | >A> 10695323 | Dec 16, 2036 | DS DP U-4636 | | | |
| | | >A> 10918622 | Dec 16, 2036 | U-3518 | | | |
| | | >A> 10918622 | Dec 16, 2036 | U-4362 | | | |
| | | >A> 10918622 | Dec 16, 2036 | U-4636 | | | |
| | | >A> 12220401 | Dec 16, 2036 | DS DP U-3518 | | | |
| | | >A> 12220401 | Dec 16, 2036 | DS DP U-4362 | | | |
| | | >A> 12220401 | Dec 16, 2036 | DS DP U-4636 | | | |
| PIRTOBRUTINIB - JAYPIRCA | | | | | | | |
| N 216059 | 002 | >A> 10464905 | Dec 16, 2036 | U-3518 | | >A> I-1005 | Oct 02, 2029 |
| | | >A> 10464905 | Dec 16, 2036 | U-4362 | | I-981 | Dec 02, 2028 |
| | | >A> 10464905 | Dec 16, 2036 | U-4636 | | ODE-518 | Dec 03, 2032 |
| | | >A> 10695323 | Dec 16, 2036 | DS DP U-3518 | | | |
| | | >A> 10695323 | Dec 16, 2036 | DS DP U-4362 | | | |
| | | >A> 10695323 | Dec 16, 2036 | DS DP U-4636 | | | |
| | | >A> 10918622 | Dec 16, 2036 | U-3518 | | | |
| | | >A> 10918622 | Dec 16, 2036 | U-4362 | | | |

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| N 216059 002 | >A> | 10918622 | Dec 16, 2036 | U-4636 | | | |
| | >A> | 12220401 | Dec 16, 2036 | DS DP U-3518 | | | |
| | >A> | 12220401 | Dec 16, 2036 | DS DP U-4362 | | | |
| | >A> | 12220401 | Dec 16, 2036 | DS DP U-4636 | | | |
| PITOLISANT HYDROCHLORIDE - WAKIX | | | | | | | |
| N 211150 001 | | | | | | ODE-519 | Feb 13, 2033 |
| PITOLISANT HYDROCHLORIDE - WAKIX | | | | | | | |
| N 211150 002 | | | | | | ODE-519 | Feb 13, 2033 |
| PLOZASIRAN SODIUM - REDEMPLO | | | | | | | |
| N 219947 001 | | | | | | ODE-541 | Nov 18, 2032 |
| POMALIDOMIDE - POMALIDOMIDE | | | | | | | |
| A 210111 001 | | | | | | PC | Aug 29, 2026 |
| POMALIDOMIDE - POMALIDOMIDE | | | | | | | |
| A 210111 002 | | | | | | PC | Aug 29, 2026 |
| POMALIDOMIDE - POMALIDOMIDE | | | | | | | |
| A 210111 003 | | | | | | PC | Aug 29, 2026 |
| POMALIDOMIDE - POMALIDOMIDE | | | | | | | |
| A 210111 004 | | | | | | PC | Aug 29, 2026 |
| PONESIMOD - PONVORY | | | | | | | |
| N 213498 001 | | 12728116 | Dec 24, 2044 | U-4610 | | | |
| PONESIMOD - PONVORY | | | | | | | |
| N 213498 010 | | 12728116 | Dec 24, 2044 | U-4610 | | | |
| POSACONAZOLE - NOXAFIL | | | | | | | |
| N 205053 001 | | | | | | NPP | Jan 27, 2029 |
| POSACONAZOLE - NOXAFIL | | | | | | | |
| N 205596 001 | | 9023790 | Jul 04, 2031 | DP U-1698 | | NPP | Jan 27, 2029 |
| | | 9023790 | Jul 04, 2031 | DP U-3160 | | | |
| | | 9023790 | Jul 04, 2031 | DP U-3171 | | | |
| | | 9023790 | Jul 04, 2031 | DP U-4415 | | | |
| | | 9023790 | Jul 04, 2031 | DP U-4416 | | | |
| | | 9358297 | Jun 24, 2031 | DP U-3160 | | | |
| | | 9358297 | Jun 24, 2031 | DP U-3171 | | | |
| | | 9358297 | Jun 24, 2031 | DP U-4415 | | | |
| | | 9358297 | Jun 24, 2031 | DP U-4416 | | | |
| POSACONAZOLE - NOXAFIL POWDERMIX KIT | | | | | | | |
| N 214770 001 | | | | | | I-984 | Jan 27, 2029 |
| POTASSIUM CHLORIDE - POTASSIUM CHLORIDE | | | | | | | |
| N 206814 001 | | 12539314 | Mar 07, 2039 | DP | | | |
| | | 12728138 | Mar 07, 2039 | DP | | | |
| POTASSIUM CHLORIDE - POTASSIUM CHLORIDE | | | | | | | |
| N 206814 002 | | 12539314 | Mar 07, 2039 | DP | | | |
| | | 12728138 | Mar 07, 2039 | DP | | | |
| POTASSIUM CHLORIDE - POKONZA | | | | | | | |
| N 206814 003 | | 12728138 | Mar 07, 2039 | DP | | | |
| POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | | | | | | | |
| N 218343 001 | | 11925661 | Oct 12, 2041 | DP U-4185 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PRALSETINIB - GAVRETO | | | | | | | |
| N 213721 | 001 | 12448366 | Jul 07, 2042 | DS | | | |
| | | 12539303 | Apr 03, 2039 | U-2828 | | | |
| | | 12655128 | Nov 01, 2036 | DS DP | | | |
| | | 12692251 | Apr 19, 2043 | DP | | | |
| PRETOMANID - PRETOMANID | | | | | | | |
| N 212862 | 001 | | | | | ODE-253 | Aug 14, 2026 |
| | | | | | | GAIN | Aug 14, 2031 |
| PRITELIVIR MESYLATE - HOVILPRI | | | | | | | |
| N 221154 | 001 | >A> 8784887 | Jul 18, 2029 | DP | | | |
| | | >A> 9119786 | Sep 26, 2032 | DP | | | |
| | | >A> 9340535 | Sep 26, 2032 | DS DP U-4638 | | | |
| | | >A> 9889124 | Sep 26, 2032 | DS DP U-4638 | | | |
| | | >A> RE49697 | Sep 26, 2032 | DS DP U-4638 | | | |
| PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH | | | | | | | |
| N 213972 | 001 | 12544337 | Dec 23, 2039 | DP U-4026 | | | |
| PROPRANOLOL HYDROCHLORIDE - PROPRANOLOL HYDROCHLORIDE | | | | | | | |
| A 219165 | 001 | | | | | CGT | Feb 15, 2027 |
| RALTEGRAVIR POTASSIUM - RALTEGRAVIR POTASSIUM | | | | | | | |
| A 217990 | 001 | | | | >A> | PC | May 01, 2027 |
| RELACORILANT - LIFYORLI (COPACKAGED) | | | | | | | |
| N 220641 | 001 | 10456392 | May 24, 2033 | U-4457 | | NCE | Mar 25, 2031 |
| | | 11285145 | May 26, 2041 | U-4457 | | | |
| | | 11285145 | May 26, 2041 | U-4458 | | | |
| | | 11285145 | May 26, 2041 | U-4459 | | | |
| | | 11464764 | Apr 14, 2040 | DP | | | |
| | | 11576907 | May 24, 2033 | DS DP U-4457 | | | |
| | | 11576907 | May 24, 2033 | DS DP U-4458 | | | |
| | | 11576907 | May 24, 2033 | DS DP U-4459 | | | |
| | | 11925626 | Dec 18, 2039 | DP | | | |
| | | 12152028 | Dec 22, 2041 | DP U-4457 | | | |
| | | 12152028 | Dec 22, 2041 | DP U-4458 | | | |
| | | 12152028 | Dec 22, 2041 | DP U-4459 | | | |
| | | 12514849 | Dec 18, 2039 | DP | | | |
| | | 12589094 | May 26, 2041 | U-4457 | | | |
| | | 12589094 | May 26, 2041 | U-4458 | | | |
| | | 12589094 | May 26, 2041 | U-4459 | | | |
| | | 8859774 | May 24, 2033 | DS DP | | | |
| | | 9273047 | May 24, 2033 | U-4457 | | | |
| | | 9273047 | May 24, 2033 | U-4458 | | | |
| | | 9273047 | May 24, 2033 | U-4459 | | | |
| RELUGOLIX - ORGOVYX | | | | | | | |
| N 214621 | 001 | 12629370 | Sep 29, 2037 | U-3020 | | | |
| REMDESIVIR - VEKLURY | | | | | | | |
| N 214787 | 001 | 10065958 | Nov 18, 2032 | DS | | NPP | Feb 28, 2027 |
| | | 10065958*PED | May 18, 2033 | | | PED | Aug 28, 2027 |
| REMDESIVIR - VEKLURY | | | | | | | |
| N 214787 | 002 | 10065958 | Nov 18, 2032 | DS | | NPP | Feb 28, 2027 |
| | | 10065958*PED | May 18, 2033 | | | PED | Aug 28, 2027 |
| REMIBRUTINIB - RHAPSIDO | | | | | | | |
| N 218436 | 001 | 12419889 | Jan 19, 2043 | U-4281 | >A> | I-1002 | Oct 06, 2029 |
| | | >A> 12751949 | Dec 09, 2043 | DS DP U-4611 | | | |
| | | >A> 12751949 | Dec 09, 2043 | DS DP U-4612 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| RESMETIROM - REZDIFFRA | | | | | | |
| N 217785 001 | 12661359 | Jan 28, 2042 | U-4568 | | | |
| | 12667575 | Feb 04, 2045 | U-4567 | | | |
| | 7452882 | Sep 12, 2027 | DS DP | | | |
| RESMETIROM - REZDIFFRA | | | | | | |
| N 217785 002 | 12661359 | Jan 28, 2042 | U-4568 | | | |
| | 12667575 | Feb 04, 2045 | U-4567 | | | |
| | 7452882 | Sep 12, 2027 | DS DP | | | |
| RESMETIROM - REZDIFFRA | | | | | | |
| N 217785 003 | 12661359 | Jan 28, 2042 | U-4568 | | | |
| | 7452882 | Sep 12, 2027 | DS DP | | | |
| REVUMENIB CITRATE - REVUFORJ | | | | | | |
| N 218944 001 | 12564590 | Dec 18, 2042 | DP U-4045 | | | |
| | 12564590 | Dec 18, 2042 | DP U-4327 | | | |
| REVUMENIB CITRATE - REVUFORJ | | | | | | |
| N 218944 002 | 12564590 | Dec 18, 2042 | DP U-4045 | | | |
| | 12564590 | Dec 18, 2042 | DP U-4327 | | | |
| REVUMENIB CITRATE - REVUFORJ | | | | | | |
| N 218944 003 | 12564590 | Dec 18, 2042 | DP U-4045 | | | |
| | 12564590 | Dec 18, 2042 | DP U-4327 | | | |
| REZAFUNGIN ACETATE - REZZAYO | | | | | | |
| N 217417 001 | 8722619 | May 09, 2036 | DS DP U-3566 | | | |
| RIBOCICLIB SUCCINATE - KISQALI | | | | | | |
| N 209092 001 | 10799506 | Apr 14, 2036 | DP | | I-950 | Sep 17, 2027 |
| | 10799506*PED | Oct 14, 2036 | | | M-14 | Jul 01, 2029 |
| | 12064434 | Apr 14, 2036 | DP | | PED | Mar 17, 2028 |
| | 12064434*PED | Oct 14, 2036 | | | PED | Jan 01, 2030 |
| | 12419894 | Apr 14, 2036 | DP | | | |
| | 12419894*PED | Oct 14, 2036 | | | | |
| | 12544379 | Aug 07, 2034 | U-3975 | | | |
| | 12544379*PED | Feb 07, 2035 | | | | |
| | 12544380 | Aug 07, 2034 | U-4404 | | | |
| | 12544380 | Aug 07, 2034 | U-4405 | | | |
| | 12544380*PED | Feb 07, 2035 | | | | |
| | 8324225 | Jun 17, 2028 | DS DP | | | |
| | 8324225*PED | Dec 17, 2028 | | | | |
| | 8415355 | Mar 13, 2031 | DS DP | | | |
| | 8415355*PED | Sep 13, 2031 | | | | |
| | 8685980 | May 25, 2030 | DS DP | | | |
| | 8685980*PED | Nov 25, 2030 | | | | |
| | 8962630 | Dec 09, 2029 | U-1981 | | | |
| | 8962630 | Dec 09, 2029 | U-2355 | | | |
| | 8962630 | Dec 09, 2029 | U-2356 | | | |
| | 8962630 | Dec 09, 2029 | U-3265 | | | |
| | 8962630 | Dec 09, 2029 | U-3266 | | | |
| | 8962630 | Dec 09, 2029 | U-3975 | | | |
| | 8962630 | Dec 09, 2029 | U-3999 | | | |
| | 8962630*PED | Jun 09, 2030 | | | | |
| | 9193732 | Nov 09, 2031 | DS DP | | | |
| | 9193732*PED | May 09, 2032 | | | | |
| | 9416136 | Aug 20, 2029 | U-1981 | | | |
| | 9416136 | Aug 20, 2029 | U-2355 | | | |
| | 9416136 | Aug 20, 2029 | U-2356 | | | |
| | 9416136 | Aug 20, 2029 | U-3265 | | | |
| | 9416136 | Aug 20, 2029 | U-3266 | | | |
| | 9416136 | Aug 20, 2029 | U-3975 | | | |
| | 9416136 | Aug 20, 2029 | U-3999 | | | |
| | 9416136*PED | Feb 20, 2030 | | | | |
| | 9868739 | Nov 09, 2031 | U-1981 | | | |
| | 9868739 | Nov 09, 2031 | U-2355 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| N 209092 | 001 | 9868739 | Nov 09, 2031 | U-2356 | | | |
| | | 9868739 | Nov 09, 2031 | U-3265 | | | |
| | | 9868739 | Nov 09, 2031 | U-3266 | | | |
| | | 9868739 | Nov 09, 2031 | U-3975 | | | |
| | | 9868739 | Nov 09, 2031 | U-3999 | | | |
| | | 9868739*PED | May 09, 2032 | | | | |
| RILZABRUTINIB - WAYRILZ | | | | | | | |
| N 219685 | 001 | | | | | ODE-552 | Aug 29, 2032 |
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 001 | 12503469 | Feb 18, 2034 | DP U-2834 | | | |
| | | 12503469 | Feb 18, 2034 | DP U-2835 | | | |
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 002 | 12503469 | Feb 18, 2034 | DP U-2834 | | | |
| | | 12503469 | Feb 18, 2034 | DP U-2835 | | | |
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 003 | 12503469 | Feb 18, 2034 | DP U-2834 | | | |
| | | 12503469 | Feb 18, 2034 | DP U-2835 | | | |
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 004 | 12503469 | Feb 18, 2034 | DP U-2834 | | | |
| | | 12503469 | Feb 18, 2034 | DP U-2835 | | | |
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 005 | 12503469 | Feb 18, 2034 | DP U-2834 | | | |
| | | 12503469 | Feb 18, 2034 | DP U-2835 | | | |
| RIPRETINIB - QINLOCK | | | | | | | |
| N 213973 | 001 | 12708617 | Dec 30, 2040 | U-3219 | | | |
| RISPERIDONE - UZEDY | | | | | | | |
| N 213586 | 003 | >A> 12746197 | Mar 17, 2042 | U-4214 | | | |
| RISPERIDONE - UZEDY | | | | | | | |
| N 213586 | 005 | >A> 12746197 | Mar 17, 2042 | U-4214 | | | |
| RISPERIDONE - UZEDY | | | | | | | |
| N 213586 | 006 | >A> 12746197 | Mar 17, 2042 | U-4214 | | | |
| RISPERIDONE - UZEDY | | | | | | | |
| N 213586 | 007 | >A> 12746197 | Mar 17, 2042 | U-4214 | | | |
| RITLECITINIB TOSYLATE - LITFULO | | | | | | | |
| N 215830 | 001 | >A> 12758554 | Jan 19, 2044 | DP | | | |
| RIVAROXABAN - YULZETY | | | | | | | |
| N 221033 | 001 | >A> 12648950 | Aug 06, 2044 | DP | | | |
| RIVAROXABAN - YULZETY | | | | | | | |
| N 221033 | 002 | >A> 12648950 | Aug 06, 2044 | DP | | | |
| RIZATRIPTAN BENZOATE - RIZAFILM | | | | | | | |
| N 205394 | 002 | 9301948 | Jul 30, 2034 | DP | | | |
| ROFLUMILAST - ZORYVE | | | | | | | |
| N 215985 | 001 | 11129818 | Aug 25, 2037 | U-3408 | | NPP | Jun 29, 2029 |
| | | 11129818 | Aug 25, 2037 | U-3712 | | | |
| | | 11129818 | Aug 25, 2037 | U-4578 | | | |
| | | 11819496 | Jun 07, 2037 | U-3748 | | | |
| | | 11819496 | Jun 07, 2037 | U-4578 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 215985 001 | 11992480 | Jun 07, 2037 | U-4578 | | | |
| | 12005051 | Jun 07, 2037 | U-4578 | | | |
| | 12310956 | Jun 07, 2037 | U-4578 | | | |
| | 12697329 | Jun 07, 2037 | DP | | | |
| | 9907788 | Jun 07, 2037 | U-3408 | | | |
| | 9907788 | Jun 07, 2037 | U-3712 | | | |
| | 9907788 | Jun 07, 2037 | U-4578 | | | |
| ROFLUMILAST - ZORYVE | | | | | | |
| N 215985 002 | 12697329 | Jun 07, 2037 | DP | | | |
| ROFLUMILAST - ZORYVE | | | | | | |
| N 215985 003 | 12685727 | Jun 07, 2037 | U-4301 | | | |
| | 12697329 | Jun 07, 2037 | DP | | | |
| ROFLUMILAST - ZORYVE | | | | | | |
| N 217242 001 | 12697329 | Jun 07, 2037 | DP | | | |
| ROMIDEPSIN - ROMIDEPSIN | | | | | | |
| A 219099 001 | | | | | CGT | Dec 07, 2026 |
| RUCAPARIB CAMSYLATE - RUBRACA | | | | | | |
| N 209115 001 | | | | | I-982 | Dec 17, 2028 |
| RUCAPARIB CAMSYLATE - RUBRACA | | | | | | |
| N 209115 002 | | | | | I-982 | Dec 17, 2028 |
| RUCAPARIB CAMSYLATE - RUBRACA | | | | | | |
| N 209115 003 | | | | | I-982 | Dec 17, 2028 |
| RUSFERTIDE ACETATE - MIMRYLO | | | | | | |
| N 220605 001 | 10030061 | Mar 17, 2034 | DS DP | | NCE | Aug 28, 2031 |
| | 10442846 | Mar 17, 2034 | DS DP U-4600 | | | |
| | 10501515 | Mar 17, 2034 | DS U-4600 | | | |
| | 11807674 | Mar 17, 2034 | DP U-4600 | | | |
| | 12269856 | Mar 17, 2034 | U-4600 | | | |
| | 9822157 | Mar 17, 2034 | DS DP | | | |
| RUSFERTIDE ACETATE - MIMRYLO | | | | | | |
| N 220605 002 | 10030061 | Mar 17, 2034 | DS DP | | NCE | Aug 28, 2031 |
| | 10442846 | Mar 17, 2034 | DS DP U-4600 | | | |
| | 10501515 | Mar 17, 2034 | DS U-4600 | | | |
| | 11807674 | Mar 17, 2034 | DP U-4600 | | | |
| | 12269856 | Mar 17, 2034 | U-4600 | | | |
| | 9822157 | Mar 17, 2034 | DS DP | | | |
| RUSFERTIDE ACETATE - MIMRYLO | | | | | | |
| N 220605 003 | 10030061 | Mar 17, 2034 | DS DP | | NCE | Aug 28, 2031 |
| | 10442846 | Mar 17, 2034 | DS DP U-4600 | | | |
| | 10501515 | Mar 17, 2034 | DS U-4600 | | | |
| | 11807674 | Mar 17, 2034 | DP U-4600 | | | |
| | 12269856 | Mar 17, 2034 | U-4600 | | | |
| | 9822157 | Mar 17, 2034 | DS DP | | | |
| RUSFERTIDE ACETATE - MIMRYLO | | | | | | |
| N 220605 004 | 10030061 | Mar 17, 2034 | DS DP | | NCE | Aug 28, 2031 |
| | 10442846 | Mar 17, 2034 | DS DP U-4600 | | | |
| | 10501515 | Mar 17, 2034 | DS U-4600 | | | |
| | 11807674 | Mar 17, 2034 | DP U-4600 | | | |
| | 12269856 | Mar 17, 2034 | U-4600 | | | |
| | 9822157 | Mar 17, 2034 | DS DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| RUSFERTIDE ACETATE - MIMRYLO | | | | | | |
| N 220605 005 | 10030061 | Mar 17, 2034 | DS DP | | NCE | Aug 28, 2031 |
| | 10442846 | Mar 17, 2034 | DS DP U-4600 | | | |
| | 10501515 | Mar 17, 2034 | DS U-4600 | | | |
| | 11807674 | Mar 17, 2034 | DP U-4600 | | | |
| | 12269856 | Mar 17, 2034 | U-4600 | | | |
| | 9822157 | Mar 17, 2034 | DS DP | | | |
| RUXOLITINIB PHOSPHATE - OPZELURA | | | | | | |
| N 215309 001 | 12544381 | May 20, 2031 | DP | | | |
| | 12564593 | May 20, 2031 | DP | | | |
| | 12589096 | Sep 04, 2040 | U-3505 | | | |
| RUXOLITINIB PHOSPHATE - JAKAFI XR | | | | | | |
| N 217180 001 | 10016429 | Jun 12, 2028 | U-3226 | | ODE* | Sep 22, 2028 |
| | 10016429 | Jun 12, 2028 | U-3230 | | PED | Mar 22, 2029 |
| | 10016429*PED | Dec 12, 2028 | | | | |
| | 10874616 | Nov 14, 2033 | DP | | | |
| | 10874616*PED | May 14, 2034 | | | | |
| | 11213528 | Jun 12, 2028 | DP | | | |
| | 11213528*PED | Dec 12, 2028 | | | | |
| | 11337927 | Jan 17, 2034 | U-3226 | | | |
| | 11337927 | Jan 17, 2034 | U-3227 | | | |
| | 11337927 | Jan 17, 2034 | U-3228 | | | |
| | 11337927 | Jan 17, 2034 | U-3230 | | | |
| | 11337927*PED | Jul 17, 2034 | | | | |
| | 11576864 | Nov 14, 2033 | U-3226 | | | |
| | 11576864 | Nov 14, 2033 | U-3227 | | | |
| | 11576864 | Nov 14, 2033 | U-3228 | | | |
| | 11576864 | Nov 14, 2033 | U-3230 | | | |
| | 11576864*PED | May 14, 2034 | | | | |
| | 11576865 | Nov 14, 2033 | DP U-3226 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3227 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3228 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3230 | | | |
| | 11576865*PED | May 14, 2034 | | | | |
| | 11744832 | Dec 12, 2026 | U-3226 | | | |
| | 11744832 | Dec 12, 2026 | U-3230 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3226 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3227 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3228 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3230 | | | |
| | 11896717*PED | May 14, 2034 | | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3227 | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3228 | | | |
| | 7598257*PED | Jun 24, 2028 | | | | |
| | 8415362 | Dec 24, 2027 | DS DP | | | |
| | 8415362*PED | Jun 24, 2028 | | | | |
| | 8530485 | Dec 12, 2026 | DP | | | |
| | 8722693 | Jun 12, 2028 | DS DP | | | |
| | 8722693*PED | Dec 12, 2028 | | | | |
| | 8822481 | Jun 12, 2028 | U-3226 | | | |
| | 8822481 | Jun 12, 2028 | U-3227 | | | |
| | 8822481 | Jun 12, 2028 | U-3228 | | | |
| | 8822481 | Jun 12, 2028 | U-3230 | | | |
| | 8822481*PED | Dec 12, 2028 | | | | |
| | 8829013 | Jun 12, 2028 | U-3227 | | | |
| | 8829013 | Jun 12, 2028 | U-3228 | | | |
| | 8829013*PED | Dec 12, 2028 | | | | |
| | 9079912 | Dec 12, 2026 | U-3226 | | | |
| | 9079912 | Dec 12, 2026 | U-3227 | | | |
| | 9079912 | Dec 12, 2026 | U-3228 | | | |
| | 9079912 | Dec 12, 2026 | U-3230 | | | |
| | 9206187 | Dec 12, 2026 | U-3227 | | | |
| | 9206187 | Dec 12, 2026 | U-3228 | | | |
| | 9814722 | Dec 12, 2026 | U-3226 | | | |
| | 9814722 | Dec 12, 2026 | U-3230 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| RUXOLITINIB PHOSPHATE - JAKAFI XR | | | | | | |
| N 217180 002 | 10016429 | Jun 12, 2028 | U-3226 | | ODE* | Sep 22, 2028 |
| | 10016429 | Jun 12, 2028 | U-3230 | | PED | Mar 22, 2029 |
| | 10016429*PED | Dec 12, 2028 | | | | |
| | 10874616 | Nov 14, 2033 | DP | | | |
| | 10874616*PED | May 14, 2034 | | | | |
| | 11213528 | Jun 12, 2028 | DP | | | |
| | 11213528*PED | Dec 12, 2028 | | | | |
| | 11337927 | Jan 17, 2034 | U-3226 | | | |
| | 11337927 | Jan 17, 2034 | U-3227 | | | |
| | 11337927 | Jan 17, 2034 | U-3228 | | | |
| | 11337927 | Jan 17, 2034 | U-3230 | | | |
| | 11337927*PED | Jul 17, 2034 | | | | |
| | 11576864 | Nov 14, 2033 | U-3226 | | | |
| | 11576864 | Nov 14, 2033 | U-3227 | | | |
| | 11576864 | Nov 14, 2033 | U-3228 | | | |
| | 11576864 | Nov 14, 2033 | U-3230 | | | |
| | 11576864*PED | May 14, 2034 | | | | |
| | 11576865 | Nov 14, 2033 | DP U-3226 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3227 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3228 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3230 | | | |
| | 11576865*PED | May 14, 2034 | | | | |
| | 11744832 | Dec 12, 2026 | U-3226 | | | |
| | 11744832 | Dec 12, 2026 | U-3230 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3226 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3227 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3228 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3230 | | | |
| | 11896717*PED | May 14, 2034 | | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3227 | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3228 | | | |
| | 7598257*PED | Jun 24, 2028 | | | | |
| | 8415362 | Dec 24, 2027 | DS DP | | | |
| | 8415362*PED | Jun 24, 2028 | | | | |
| | 8530485 | Dec 12, 2026 | DP | | | |
| | 8722693 | Jun 12, 2028 | DS DP | | | |
| | 8722693*PED | Dec 12, 2028 | | | | |
| | 8822481 | Jun 12, 2028 | U-3226 | | | |
| | 8822481 | Jun 12, 2028 | U-3227 | | | |
| | 8822481 | Jun 12, 2028 | U-3228 | | | |
| | 8822481 | Jun 12, 2028 | U-3230 | | | |
| | 8822481*PED | Dec 12, 2028 | | | | |
| | 8829013 | Jun 12, 2028 | U-3227 | | | |
| | 8829013 | Jun 12, 2028 | U-3228 | | | |
| | 8829013*PED | Dec 12, 2028 | | | | |
| | 9079912 | Dec 12, 2026 | U-3226 | | | |
| | 9079912 | Dec 12, 2026 | U-3227 | | | |
| | 9079912 | Dec 12, 2026 | U-3228 | | | |
| | 9079912 | Dec 12, 2026 | U-3230 | | | |
| | 9206187 | Dec 12, 2026 | U-3227 | | | |
| | 9206187 | Dec 12, 2026 | U-3228 | | | |
| | 9814722 | Dec 12, 2026 | U-3226 | | | |
| | 9814722 | Dec 12, 2026 | U-3230 | | | |
| RUXOLITINIB PHOSPHATE - JAKAFI XR | | | | | | |
| N 217180 003 | 10016429 | Jun 12, 2028 | U-3226 | | ODE* | Sep 22, 2028 |
| | 10016429 | Jun 12, 2028 | U-3230 | | PED | Mar 22, 2029 |
| | 10016429*PED | Dec 12, 2028 | | | | |
| | 10874616 | Nov 14, 2033 | DP | | | |
| | 10874616*PED | May 14, 2034 | | | | |
| | 11213528 | Jun 12, 2028 | DP | | | |
| | 11213528*PED | Dec 12, 2028 | | | | |
| | 11337927 | Jan 17, 2034 | U-3226 | | | |
| | 11337927 | Jan 17, 2034 | U-3227 | | | |
| | 11337927 | Jan 17, 2034 | U-3228 | | | |
| | 11337927 | Jan 17, 2034 | U-3230 | | | |
| | 11337927*PED | Jul 17, 2034 | | | | |
| | 11576864 | Nov 14, 2033 | U-3226 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 217180 003 | 11576864 | Nov 14, 2033 | U-3227 | | | |
| | 11576864 | Nov 14, 2033 | U-3228 | | | |
| | 11576864 | Nov 14, 2033 | U-3230 | | | |
| | 11576864*PED | May 14, 2034 | | | | |
| | 11576865 | Nov 14, 2033 | DP U-3226 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3227 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3228 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3230 | | | |
| | 11576865*PED | May 14, 2034 | | | | |
| | 11744832 | Dec 12, 2026 | U-3226 | | | |
| | 11744832 | Dec 12, 2026 | U-3230 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3226 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3227 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3228 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3230 | | | |
| | 11896717*PED | May 14, 2034 | | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3227 | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3228 | | | |
| | 7598257*PED | Jun 24, 2028 | | | | |
| | 8415362 | Dec 24, 2027 | DS DP | | | |
| | 8415362*PED | Jun 24, 2028 | | | | |
| | 8530485 | Dec 12, 2026 | DP | | | |
| | 8722693 | Jun 12, 2028 | DS DP | | | |
| | 8722693*PED | Dec 12, 2028 | | | | |
| | 8822481 | Jun 12, 2028 | U-3226 | | | |
| | 8822481 | Jun 12, 2028 | U-3227 | | | |
| | 8822481 | Jun 12, 2028 | U-3228 | | | |
| | 8822481 | Jun 12, 2028 | U-3230 | | | |
| | 8822481*PED | Dec 12, 2028 | | | | |
| | 8829013 | Jun 12, 2028 | U-3227 | | | |
| | 8829013 | Jun 12, 2028 | U-3228 | | | |
| | 8829013*PED | Dec 12, 2028 | | | | |
| | 9079912 | Dec 12, 2026 | U-3226 | | | |
| | 9079912 | Dec 12, 2026 | U-3227 | | | |
| | 9079912 | Dec 12, 2026 | U-3228 | | | |
| | 9079912 | Dec 12, 2026 | U-3230 | | | |
| | 9206187 | Dec 12, 2026 | U-3227 | | | |
| | 9206187 | Dec 12, 2026 | U-3228 | | | |
| | 9814722 | Dec 12, 2026 | U-3226 | | | |
| | 9814722 | Dec 12, 2026 | U-3230 | | | |
| RUXOLITINIB PHOSPHATE - JAKAFI XR | | | | | | |
| N 217180 004 | 10016429 | Jun 12, 2028 | U-3226 | | ODE* | Sep 22, 2028 |
| | 10016429 | Jun 12, 2028 | U-3230 | | PED | Mar 22, 2029 |
| | 10016429*PED | Dec 12, 2028 | | | | |
| | 10874616 | Nov 14, 2033 | DP | | | |
| | 10874616*PED | May 14, 2034 | | | | |
| | 11213528 | Jun 12, 2028 | DP | | | |
| | 11213528*PED | Dec 12, 2028 | | | | |
| | 11337927 | Jan 17, 2034 | U-3226 | | | |
| | 11337927 | Jan 17, 2034 | U-3227 | | | |
| | 11337927 | Jan 17, 2034 | U-3228 | | | |
| | 11337927 | Jan 17, 2034 | U-3230 | | | |
| | 11337927*PED | Jul 17, 2034 | | | | |
| | 11576864 | Nov 14, 2033 | U-3226 | | | |
| | 11576864 | Nov 14, 2033 | U-3227 | | | |
| | 11576864 | Nov 14, 2033 | U-3228 | | | |
| | 11576864 | Nov 14, 2033 | U-3230 | | | |
| | 11576864*PED | May 14, 2034 | | | | |
| | 11576865 | Nov 14, 2033 | DP U-3226 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3227 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3228 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3230 | | | |
| | 11576865*PED | May 14, 2034 | | | | |
| | 11744832 | Dec 12, 2026 | U-3226 | | | |
| | 11744832 | Dec 12, 2026 | U-3230 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3226 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3227 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3228 | | | |

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 217180 004 | 11896717 | Nov 14, 2033 | DP U-3230 | | | |
| | 11896717*PED | May 14, 2034 | | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3227 | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3228 | | | |
| | 7598257*PED | Jun 24, 2028 | | | | |
| | 8415362 | Dec 24, 2027 | DS DP | | | |
| | 8415362*PED | Jun 24, 2028 | | | | |
| | 8530485 | Dec 12, 2026 | DP | | | |
| | 8722693 | Jun 12, 2028 | DS DP | | | |
| | 8722693*PED | Dec 12, 2028 | | | | |
| | 8822481 | Jun 12, 2028 | U-3226 | | | |
| | 8822481 | Jun 12, 2028 | U-3227 | | | |
| | 8822481 | Jun 12, 2028 | U-3228 | | | |
| | 8822481 | Jun 12, 2028 | U-3230 | | | |
| | 8822481*PED | Dec 12, 2028 | | | | |
| | 8829013 | Jun 12, 2028 | U-3227 | | | |
| | 8829013 | Jun 12, 2028 | U-3228 | | | |
| | 8829013*PED | Dec 12, 2028 | | | | |
| | 9079912 | Dec 12, 2026 | U-3226 | | | |
| | 9079912 | Dec 12, 2026 | U-3227 | | | |
| | 9079912 | Dec 12, 2026 | U-3228 | | | |
| | 9079912 | Dec 12, 2026 | U-3230 | | | |
| | 9206187 | Dec 12, 2026 | U-3227 | | | |
| | 9206187 | Dec 12, 2026 | U-3228 | | | |
| | 9814722 | Dec 12, 2026 | U-3226 | | | |
| | 9814722 | Dec 12, 2026 | U-3230 | | | |
| RUXOLITINIB PHOSPHATE - JAKAFI XR | | | | | | |
| N 217180 005 | 10016429 | Jun 12, 2028 | U-3226 | | ODE* | Sep 22, 2028 |
| | 10016429 | Jun 12, 2028 | U-3230 | | PED | Mar 22, 2029 |
| | 10016429*PED | Dec 12, 2028 | | | | |
| | 10874616 | Nov 14, 2033 | DP | | | |
| | 10874616*PED | May 14, 2034 | | | | |
| | 11213528 | Jun 12, 2028 | DP | | | |
| | 11213528*PED | Dec 12, 2028 | | | | |
| | 11337927 | Jan 17, 2034 | U-3226 | | | |
| | 11337927 | Jan 17, 2034 | U-3227 | | | |
| | 11337927 | Jan 17, 2034 | U-3228 | | | |
| | 11337927 | Jan 17, 2034 | U-3230 | | | |
| | 11337927*PED | Jul 17, 2034 | | | | |
| | 11576864 | Nov 14, 2033 | U-3226 | | | |
| | 11576864 | Nov 14, 2033 | U-3227 | | | |
| | 11576864 | Nov 14, 2033 | U-3228 | | | |
| | 11576864 | Nov 14, 2033 | U-3230 | | | |
| | 11576864*PED | May 14, 2034 | | | | |
| | 11576865 | Nov 14, 2033 | DP U-3226 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3227 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3228 | | | |
| | 11576865 | Nov 14, 2033 | DP U-3230 | | | |
| | 11576865*PED | May 14, 2034 | | | | |
| | 11744832 | Dec 12, 2026 | U-3226 | | | |
| | 11744832 | Dec 12, 2026 | U-3230 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3226 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3227 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3228 | | | |
| | 11896717 | Nov 14, 2033 | DP U-3230 | | | |
| | 11896717*PED | May 14, 2034 | | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3227 | | | |
| | 7598257 | Dec 24, 2027 | DS DP U-3228 | | | |
| | 7598257*PED | Jun 24, 2028 | | | | |
| | 8415362 | Dec 24, 2027 | DS DP | | | |
| | 8415362*PED | Jun 24, 2028 | | | | |
| | 8530485 | Dec 12, 2026 | DP | | | |
| | 8722693 | Jun 12, 2028 | DS DP | | | |
| | 8722693*PED | Dec 12, 2028 | | | | |
| | 8822481 | Jun 12, 2028 | U-3226 | | | |
| | 8822481 | Jun 12, 2028 | U-3227 | | | |
| | 8822481 | Jun 12, 2028 | U-3228 | | | |
| | 8822481 | Jun 12, 2028 | U-3230 | | | |

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 217180 005 | 8822481*PED | Dec 12, 2028 | | | | |
| | 8829013 | Jun 12, 2028 | U-3227 | | | |
| | 8829013 | Jun 12, 2028 | U-3228 | | | |
| | 8829013*PED | Dec 12, 2028 | | | | |
| | 9079912 | Dec 12, 2026 | U-3226 | | | |
| | 9079912 | Dec 12, 2026 | U-3227 | | | |
| | 9079912 | Dec 12, 2026 | U-3228 | | | |
| | 9079912 | Dec 12, 2026 | U-3230 | | | |
| | 9206187 | Dec 12, 2026 | U-3227 | | | |
| | 9206187 | Dec 12, 2026 | U-3228 | | | |
| | 9814722 | Dec 12, 2026 | U-3226 | | | |
| | 9814722 | Dec 12, 2026 | U-3230 | | | |
| SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA | | | | | | |
| N 022350 001 | | | | | M-14 | Oct 11, 2027 |
| SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA | | | | | | |
| N 022350 002 | | | | | M-14 | Oct 11, 2027 |
| SEBETRALSTAT - EKTERLY | | | | | | |
| N 219301 001 | | | | | ODE-534 | Jul 03, 2032 |
| SELADELPAR LYSINE - LIVDELZI | | | | | | |
| N 217899 001 | 10272058 | Mar 13, 2038 | U-1854 | | | |
| | 7301050 | Aug 02, 2027 | DS DP | | | |
| | 7709682 | Sep 13, 2027 | DS | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 001 | 10821108 | Dec 01, 2036 | DP U-2992 | | NPP | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 002 | 10821108 | Dec 01, 2036 | DP U-2992 | | NPP | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 003 | 10821108 | Dec 01, 2036 | DP U-2992 | | NPP | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 207947 003 | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 004 | 10821108 | Dec 01, 2036 | DP U-2992 | | NPP | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 005 | 10821108 | Dec 01, 2036 | DP U-2992 | | NPP | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 006 | 10821108 | Dec 01, 2036 | DP U-2992 | | NPP | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 007 | 10821108 | Dec 01, 2036 | DP U-2992 | | NPP | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 008 | 10821108 | Dec 01, 2036 | DP U-2992 | | NPP | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 207947 008 | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 010 | 10821108 | Dec 01, 2036 | DP U-2992 | | NS | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 011 | 10821108 | Dec 01, 2036 | DP U-2992 | | NS | May 23, 2029 |
| | 10821108*PED | Jun 01, 2037 | | | PED | Nov 23, 2029 |
| | 10828298 | Dec 01, 2036 | DP U-2991 | | | |
| | 10828298*PED | Jun 01, 2037 | | | | |
| | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 214275 001 | 7205302 | Oct 31, 2026 | DS DP U-1797 | | | |
| | 7205302*PED | Apr 30, 2027 | | | | |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 8791122*PED | Feb 01, 2031 | | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9173881*PED | Feb 12, 2030 | | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| | 9284280*PED | Dec 25, 2030 | | | | |
| SELINEXOR - XPOVIO | | | | | | |
| N 212306 001 | 10519139 | Aug 14, 2035 | DS DP U-2584 | | | |
| | 10519139 | Aug 14, 2035 | DS DP U-3018 | | | |
| | 11746102 | Aug 14, 2035 | U-2584 | | | |
| | 11746102 | Aug 14, 2035 | U-3018 | | | |
| | 11753401 | Aug 14, 2035 | DP U-2584 | | | |
| | 11753401 | Aug 14, 2035 | DP U-3018 | | | |
| | 11787771 | Jul 26, 2032 | U-2584 | | | |
| | 11787771 | Jul 26, 2032 | U-2855 | | | |
| | 11787771 | Jul 26, 2032 | U-3018 | | | |
| | 12291508 | Jul 26, 2032 | U-2584 | | | |
| | 12291508 | Jul 26, 2032 | U-3018 | | | |
| | 9079865 | Jul 26, 2032 | U-2584 | | | |
| | 9079865 | Jul 26, 2032 | U-3018 | | | |
| SELINEXOR - XPOVIO | | | | | | |
| N 212306 002 | 10519139 | Aug 14, 2035 | DS DP U-2584 | | | |
| | 10519139 | Aug 14, 2035 | DS DP U-3018 | | | |
| | 11746102 | Aug 14, 2035 | U-2584 | | | |
| | 11746102 | Aug 14, 2035 | U-3018 | | | |
| | 11753401 | Aug 14, 2035 | DP U-2584 | | | |
| | 11753401 | Aug 14, 2035 | DP U-3018 | | | |
| | 11787771 | Jul 26, 2032 | U-2584 | | | |
| | 11787771 | Jul 26, 2032 | U-3018 | | | |
| | 12291508 | Jul 26, 2032 | U-2584 | | | |
| | 12291508 | Jul 26, 2032 | U-3018 | | | |

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 212306 002 | 9079865 | Jul 26, 2032 | U-2584 | | | |
| | 9079865 | Jul 26, 2032 | U-3018 | | | |
| SELINEXOR - XPOVIO | | | | | | |
| N 212306 003 | 10519139 | Aug 14, 2035 | DS DP U-2584 | | | |
| | 10519139 | Aug 14, 2035 | DS DP U-3018 | | | |
| | 11746102 | Aug 14, 2035 | U-2584 | | | |
| | 11746102 | Aug 14, 2035 | U-3018 | | | |
| | 11753401 | Aug 14, 2035 | DP U-2584 | | | |
| | 11753401 | Aug 14, 2035 | DP U-3018 | | | |
| | 11787771 | Jul 26, 2032 | U-2584 | | | |
| | 11787771 | Jul 26, 2032 | U-3018 | | | |
| | 12291508 | Jul 26, 2032 | U-2584 | | | |
| | 12291508 | Jul 26, 2032 | U-3018 | | | |
| | 9079865 | Jul 26, 2032 | U-2584 | | | |
| | 9079865 | Jul 26, 2032 | U-3018 | | | |
| SELINEXOR - XPOVIO | | | | | | |
| N 212306 004 | 10519139 | Aug 14, 2035 | DS DP U-2584 | | | |
| | 10519139 | Aug 14, 2035 | DS DP U-3018 | | | |
| | 11746102 | Aug 14, 2035 | U-2584 | | | |
| | 11746102 | Aug 14, 2035 | U-3018 | | | |
| | 11753401 | Aug 14, 2035 | DP U-2584 | | | |
| | 11753401 | Aug 14, 2035 | DP U-3018 | | | |
| | 11787771 | Jul 26, 2032 | U-2584 | | | |
| | 11787771 | Jul 26, 2032 | U-3018 | | | |
| | 12291508 | Jul 26, 2032 | U-2584 | | | |
| | 12291508 | Jul 26, 2032 | U-3018 | | | |
| | 9079865 | Jul 26, 2032 | U-2584 | | | |
| | 9079865 | Jul 26, 2032 | U-3018 | | | |
| SELINEXOR - XPOVIO | | | | | | |
| N 212306 005 | 10519139 | Aug 14, 2035 | DS DP U-2584 | | | |
| | 10519139 | Aug 14, 2035 | DS DP U-3018 | | | |
| | 11746102 | Aug 14, 2035 | U-2584 | | | |
| | 11746102 | Aug 14, 2035 | U-3018 | | | |
| | 11753401 | Aug 14, 2035 | DP U-2584 | | | |
| | 11753401 | Aug 14, 2035 | DP U-3018 | | | |
| | 11787771 | Jul 26, 2032 | U-2584 | | | |
| | 11787771 | Jul 26, 2032 | U-3018 | | | |
| | 12291508 | Jul 26, 2032 | U-2584 | | | |
| | 12291508 | Jul 26, 2032 | U-3018 | | | |
| | 9079865 | Jul 26, 2032 | U-2584 | | | |
| | 9079865 | Jul 26, 2032 | U-3018 | | | |
| SELUMETINIB SULFATE - KOSELUGO | | | | | | |
| N 213756 001 | | | | | ODE-545 | Nov 19, 2032 |
| SELUMETINIB SULFATE - KOSELUGO | | | | | | |
| N 213756 002 | | | | | ODE-545 | Nov 19, 2032 |
| SELUMETINIB SULFATE - KOSELUGO | | | | | | |
| N 219943 001 | | | | | ODE* | Nov 19, 2032 |
| SELUMETINIB SULFATE - KOSELUGO | | | | | | |
| N 219943 002 | | | | | ODE* | Nov 19, 2032 |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 209637 001 | 9457154 | Sep 29, 2027 | DP | Y | | |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 209637 002 | 12295988 | Oct 10, 2038 | U-1852 | | | |
| | 12569543 | Apr 28, 2037 | U-4446 | | | |
| | 9457154 | Sep 29, 2027 | DP | Y | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 209637 003 | 12569543 | Apr 28, 2037 | U-4446 | | | |
| | 9457154 | Sep 29, 2027 | DP | Y | | |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 209637 004 | 12295988 | Oct 10, 2038 | U-1852 | | | |
| | 12569543 | Apr 28, 2037 | U-4446 | | | |
| | 9457154 | Sep 29, 2027 | DP | Y | | |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 209637 005 | 10888605 | Aug 24, 2038 | DP U-1852 | | | |
| | 11318191 | Feb 17, 2041 | DP U-1852 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4561 | | | |
| | 11752198 | Aug 24, 2038 | DP U-1852 | | | |
| | 12214017 | Aug 24, 2038 | DP U-1852 | | | |
| | 12569543 | Apr 28, 2037 | U-4446 | | | |
| | 8129343 | Dec 05, 2031 | DS DP U-3355 | | | |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 209637 006 | 10888605 | Aug 24, 2038 | DP U-1852 | | | |
| | 11318191 | Feb 17, 2041 | DP U-1852 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4561 | | | |
| | 11752198 | Aug 24, 2038 | DP U-1852 | | | |
| | 12214017 | Aug 24, 2038 | DP U-1852 | | | |
| | 12569543 | Apr 28, 2037 | U-4446 | | | |
| | 8129343 | Dec 05, 2031 | DS DP U-3355 | | | |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 209637 007 | 10335462 | Jun 21, 2033 | U-1852 | | | |
| | 10888605 | Aug 24, 2038 | DP U-1852 | | | |
| | 11318191 | Feb 17, 2041 | DP U-1852 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4561 | | | |
| | 11752198 | Aug 24, 2038 | DP U-1852 | | | |
| | 12214017 | Aug 24, 2038 | DP U-1852 | | | |
| | 12295988 | Oct 10, 2038 | U-1852 | | | |
| | 12569543 | Apr 28, 2037 | U-4446 | | | |
| | 8129343 | Dec 05, 2031 | DS DP U-3355 | | | |
| SEMAGLUTIDE - RYBELSUS | | | | | | |
| N 213051 001 | 11033499 | Jun 19, 2033 | DP U-2628 | | | |
| | 12514822 | May 02, 2034 | U-2628 | | | |
| | 12594326 | Mar 15, 2033 | DP | | | |
| SEMAGLUTIDE - RYBELSUS | | | | | | |
| N 213051 002 | 11033499 | Jun 19, 2033 | DP U-2628 | | | |
| | 12514822 | May 02, 2034 | U-2628 | | | |
| | 12594326 | Mar 15, 2033 | DP | | | |
| SEMAGLUTIDE - RYBELSUS | | | | | | |
| N 213051 003 | 11033499 | Jun 19, 2033 | DP U-2628 | | | |
| | 12514822 | May 02, 2034 | U-2628 | | | |
| | 12594326 | Mar 15, 2033 | DP | | | |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 213051 004 | 11033499 | Jun 19, 2033 | DP U-2628 | | | |
| | 12514822 | May 02, 2034 | U-2628 | | | |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 213051 005 | 11033499 | Jun 19, 2033 | DP U-2628 | | | |
| | 12514822 | May 02, 2034 | U-2628 | | | |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 213051 006 | 11033499 | Jun 19, 2033 | DP U-2628 | | | |
| | 12514822 | May 02, 2034 | U-2628 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 215256 005 | 12551536 | Oct 10, 2038 | U-4418 | | | |
| SEMAGLUTIDE - WEGOVY HD | | | | | | |
| N 215256 006 | 10888605 | Aug 24, 2038 | DP U-4418 | | NS | Mar 19, 2029 |
| | 11318191 | Feb 17, 2041 | DP U-4418 | | | |
| | 11752198 | Aug 24, 2038 | DP U-4418 | | | |
| | 12029779 | Oct 10, 2038 | U-4418 | | | |
| | 12214017 | Aug 24, 2038 | DP U-4418 | | | |
| | 12551536 | Oct 10, 2038 | U-4418 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 9764003 | Jun 21, 2033 | U-4418 | | | |
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 215256 007 | 10888605 | Aug 24, 2038 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4443 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4560 | | | |
| | 11478533 | May 13, 2040 | U-3861 | | | |
| | 11752198 | Aug 24, 2038 | DP U-3162 | | | |
| | 12029779 | Oct 10, 2038 | U-3162 | | | |
| | 12214017 | Aug 24, 2038 | DP U-3162 | | | |
| | 12551536 | Oct 10, 2038 | U-4418 | | | |
| | 12569543 | Apr 28, 2037 | U-4443 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 9764003 | Jun 21, 2033 | U-3161 | | | |
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 215256 008 | 10888605 | Aug 24, 2038 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4443 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4560 | | | |
| | 11478533 | May 13, 2040 | U-3861 | | | |
| | 11752198 | Aug 24, 2038 | DP U-3162 | | | |
| | 12029779 | Oct 10, 2038 | U-3162 | | | |
| | 12214017 | Aug 24, 2038 | DP U-3162 | | | |
| | 12551536 | Oct 10, 2038 | U-4418 | | | |
| | 12569543 | Apr 28, 2037 | U-4443 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 9764003 | Jun 21, 2033 | U-3161 | | | |
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 215256 009 | 10888605 | Aug 24, 2038 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4443 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4560 | | | |
| | 11478533 | May 13, 2040 | U-3861 | | | |
| | 11752198 | Aug 24, 2038 | DP U-3162 | | | |
| | 12029779 | Oct 10, 2038 | U-3162 | | | |
| | 12214017 | Aug 24, 2038 | DP U-3162 | | | |
| | 12551536 | Oct 10, 2038 | U-4418 | | | |
| | 12569543 | Apr 28, 2037 | U-4443 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 9764003 | Jun 21, 2033 | U-3161 | | | |
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 215256 010 | 10888605 | Aug 24, 2038 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4443 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4560 | | | |
| | 11478533 | May 13, 2040 | U-3861 | | | |
| | 11752198 | Aug 24, 2038 | DP U-3162 | | | |
| | 12029779 | Oct 10, 2038 | U-3162 | | | |
| | 12214017 | Aug 24, 2038 | DP U-3162 | | | |
| | 12551536 | Oct 10, 2038 | U-4418 | | | |
| | 12569543 | Apr 28, 2037 | U-4443 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 9764003 | Jun 21, 2033 | U-3161 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 215256 011 | 10888605 | Aug 24, 2038 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-3162 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4443 | | | |
| | 11318191 | Feb 17, 2041 | DP U-4560 | | | |
| | 11478533 | May 13, 2040 | U-3861 | | | |
| | 11752198 | Aug 24, 2038 | DP U-3162 | | | |
| | 12029779 | Oct 10, 2038 | U-3162 | | | |
| | 12214017 | Aug 24, 2038 | DP U-3162 | | | |
| | 12551536 | Oct 10, 2038 | U-4418 | | | |
| | 12569543 | Apr 28, 2037 | U-4443 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 9764003 | Jun 21, 2033 | U-3161 | | | |
| SEMAGLUTIDE - WEGOVY FLEXTOUCH | | | | | | |
| N 215256 012 | 11478533 | May 13, 2040 | U-3861 | | I-935 | Mar 08, 2027 |
| | 12029779 | Oct 10, 2038 | U-3162 | | I-973 | Aug 15, 2028 |
| | 12551536 | Oct 10, 2038 | U-4418 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 9764003 | Jun 21, 2033 | U-3161 | | | |
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 218316 001 | 10278923 | May 02, 2034 | U-4389 | | I-935 | Mar 08, 2027 |
| | 11033499 | Jun 19, 2033 | DP U-4496 | | NP | Dec 22, 2028 |
| | 11382957 | Dec 16, 2031 | DP | | | |
| | 11833248 | Feb 01, 2039 | DP U-4387 | | | |
| | 12239739 | May 02, 2034 | U-4388 | | | |
| | 12396953 | Feb 01, 2039 | DP U-4387 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 8536122 | Mar 20, 2026 | DS DP | | | |
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 218316 002 | 10278923 | May 02, 2034 | U-4389 | | I-935 | Mar 08, 2027 |
| | 11033499 | Jun 19, 2033 | DP U-4496 | | NP | Dec 22, 2028 |
| | 11382957 | Dec 16, 2031 | DP | | | |
| | 11833248 | Feb 01, 2039 | DP U-4387 | | | |
| | 12239739 | May 02, 2034 | U-4388 | | | |
| | 12396953 | Feb 01, 2039 | DP U-4387 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 8536122 | Mar 20, 2026 | DS DP | | | |
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 218316 003 | 10278923 | May 02, 2034 | U-4389 | | I-935 | Mar 08, 2027 |
| | 11033499 | Jun 19, 2033 | DP U-4496 | | NP | Dec 22, 2028 |
| | 11382957 | Dec 16, 2031 | DP | | | |
| | 11833248 | Feb 01, 2039 | DP U-4387 | | | |
| | 12239739 | May 02, 2034 | U-4388 | | | |
| | 12396953 | Feb 01, 2039 | DP U-4387 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 8536122 | Mar 20, 2026 | DS DP | | | |
| | 9278123 | Dec 16, 2031 | DP U-4389 | | | |
| SEMAGLUTIDE - WEGOVY | | | | | | |
| N 218316 004 | 10278923 | May 02, 2034 | U-4389 | | I-935 | Mar 08, 2027 |
| | 11033499 | Jun 19, 2033 | DP U-4496 | | NP | Dec 22, 2028 |
| | 11382957 | Dec 16, 2031 | DP | | | |
| | 11833248 | Feb 01, 2039 | DP U-4387 | | | |
| | 12239739 | May 02, 2034 | U-4388 | | | |
| | 12396953 | Feb 01, 2039 | DP U-4387 | | | |
| | 8129343 | Dec 05, 2031 | DS DP | | | |
| | 8536122 | Mar 20, 2026 | DS DP | | | |
| | 9278123 | Dec 16, 2031 | DP U-4389 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| SEPIAPTERIN - SEPHIENCE | | | | | | |
| N 219666 001 | | | | | ODE-542 | Jul 28, 2032 |
| SEPIAPTERIN - SEPHIENCE | | | | | | |
| N 219666 002 | | | | | ODE-542 | Jul 28, 2032 |
| SETMELANOTIDE ACETATE - IMCIVREE | | | | | | |
| N 213793 001 | | | | | I-987 | Mar 19, 2029 |
| SEVABERTINIB - HYRNUO | | | | | | |
| N 219972 001 | 10428063 | Oct 10, 2035 | DS DP | | >A> ODE-560 | Nov 19, 2032 |
| | 12679836 | Nov 14, 2043 | DS DP U-4582 | | >A> ODE-561 | Sep 09, 2033 |
| SILDENAFIL CITRATE - VYBRIQUE | | | | | | |
| N 210858 001 | 11123287 | Dec 16, 2033 | DP | | NP | Dec 16, 2028 |
| SILDENAFIL CITRATE - VYBRIQUE | | | | | | |
| N 210858 002 | 11123287 | Dec 16, 2033 | DP | | NP | Dec 16, 2028 |
| SILDENAFIL CITRATE - VYBRIQUE | | | | | | |
| N 210858 003 | 11123287 | Dec 16, 2033 | DP | | NP | Dec 16, 2028 |
| SILDENAFIL CITRATE - VYBRIQUE | | | | | | |
| N 210858 004 | 11123287 | Dec 16, 2033 | DP | | NP | Dec 16, 2028 |
| SIPONIMOD - MAYZENT | | | | | | |
| N 209884 001 | 12533340 | Apr 23, 2036 | U-4407 | | | |
| SIPONIMOD - MAYZENT | | | | | | |
| N 209884 002 | 12533340 | Apr 23, 2036 | U-4407 | | | |
| SIPONIMOD - MAYZENT | | | | | | |
| N 209884 003 | 12533340 | Apr 23, 2036 | U-4407 | | | |
| SIROLIMUS - HYFTOR | | | | | | |
| N 213478 001 | 12740970 | Apr 11, 2045 | DP | | | |
| SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE | | | | | | |
| A 202387 001 | | | | | PC | Nov 24, 2026 |
| SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE | | | | | | |
| A 202387 002 | | | | | PC | Nov 24, 2026 |
| SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE | | | | | | |
| A 202387 003 | | | | | PC | Nov 24, 2026 |
| SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE | | | | | | |
| A 202425 001 | | | | | PC | Nov 24, 2026 |
| SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE | | | | | | |
| A 202425 002 | | | | | PC | Nov 24, 2026 |
| SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE | | | | | | |
| A 202425 003 | | | | | PC | Nov 24, 2026 |
| SODIUM OXYBATE - LUMRYZ | | | | | | |
| N 214755 001 | 12728110 | Jul 21, 2037 | DP | | | |
| SODIUM OXYBATE - LUMRYZ | | | | | | |
| N 214755 002 | 12728110 | Jul 21, 2037 | DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| SODIUM OXYBATE - LUMRYZ | | | | | | | |
| N 214755 | 003 | 12728110 | Jul 21, 2037 | DP | | | |
| SODIUM OXYBATE - LUMRYZ | | | | | | | |
| N 214755 | 004 | 12728110 | Jul 21, 2037 | DP | | | |
| SOFPIRONIUM BROMIDE - SOFDRA | | | | | | | |
| N 217347 | 001 | 12703682 | May 22, 2040 | DS DP | | | |
| | | 8628759 | Nov 13, 2027 | U-2398 | | | |
| SONROTOCLAX - BEQALZI | | | | | | | |
| N 220711 | 001 | 11420968 | Apr 29, 2039 | DS DP | | NCE | May 13, 2031 |
| SONROTOCLAX - BEQALZI | | | | | | | |
| N 220711 | 002 | 11420968 | Apr 29, 2039 | DS DP | | NCE | May 13, 2031 |
| SONROTOCLAX - BEQALZI | | | | | | | |
| N 220711 | 003 | 11420968 | Apr 29, 2039 | DS DP | | NCE | May 13, 2031 |
| SONROTOCLAX - BEQALZI | | | | | | | |
| N 220711 | 004 | 11420968 | Apr 29, 2039 | DS DP | | NCE | May 13, 2031 |
| SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE | | | | | | | |
| N 022306 | 001 | 12569183 | Apr 05, 2039 | U-4456 | | | |
| | | 12740947 | Aug 14, 2038 | U-2769 | | | |
| SPARSENTAN - FILSPARI | | | | | | | |
| N 216403 | 001 | 12714697 | Oct 13, 2037 | U-3993 | | I-989 | Apr 13, 2029 |
| | | 9662312 | Mar 29, 2030 | U-4495 | | | |
| | | 9993461 | Mar 29, 2030 | U-3269 | | | |
| | | 9993461 | Mar 29, 2030 | U-3993 | | | |
| | | 9993461 | Mar 29, 2030 | U-4495 | | | |
| SPARSENTAN - FILSPARI | | | | | | | |
| N 216403 | 002 | 12714697 | Oct 13, 2037 | U-3993 | | I-989 | Apr 13, 2029 |
| | | 9662312 | Mar 29, 2030 | U-4495 | | | |
| | | 9993461 | Mar 29, 2030 | U-3269 | | | |
| | | 9993461 | Mar 29, 2030 | U-3993 | | | |
| | | 9993461 | Mar 29, 2030 | U-4495 | | | |
| SUVOREXANT - BELSOMRA | | | | | | | |
| N 204569 | 001 | 12599610 | May 29, 2033 | DP | | | |
| SUVOREXANT - BELSOMRA | | | | | | | |
| N 204569 | 002 | 12599610 | May 29, 2033 | DP | | | |
| SUVOREXANT - BELSOMRA | | | | | | | |
| N 204569 | 003 | 12599610 | May 29, 2033 | DP | | | |
| SUVOREXANT - BELSOMRA | | | | | | | |
| N 204569 | 004 | 12599610 | May 29, 2033 | DP | | | |
| TADALAFIL - TADLIQ | | | | | | | |
| N 214522 | 001 | 12691120 | Dec 24, 2038 | DP U-3397 | | | |
| | | 12697338 | Dec 24, 2038 | DP U-3397 | | | |
| | | 12708626 | Dec 24, 2038 | DP U-3397 | | | |
| | | 12721849 | Dec 24, 2038 | DP U-3397 | | | |
| | | 12734175 | Dec 24, 2038 | DP | | | |
| TAFAMIDIS - VYNDAMAX | | | | | | | |
| N 212161 | 001 | >A> 7214695 | Dec 19, 2027 | DS DP | | | |
| | | >A> 7214696 | Dec 19, 2027 | U-2524 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TAFAMIDIS MEGLUMINE - VYNDAQEL | | | | | | | |
| N 211996 001 | >A> | 7214695 | Dec 19, 2027 | DS DP | | | |
| | >A> | 7214696 | Dec 19, 2027 | U-2524 | | | |
| TAFENOQUINE SUCCINATE - ARAKODA | | | | | | | |
| N 210607 001 | | 12616689 | Dec 02, 2035 | U-2582 | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 211651 001 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 211651 002 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 211651 003 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 211651 004 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 211651 005 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 211651 006 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 217439 001 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 217439 002 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 217439 003 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 217439 004 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 217439 005 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALAZOPARIB TOSYLATE - TALZENNA | | | | | | | |
| N 217439 006 | | 8012976 | Oct 16, 2032 | DS DP | | | |
| TALETRECTINIB ADIPATE - IBTROZI | | | | | | | |
| N 219713 001 | | | | | | ODE-544 | Jun 11, 2032 |
| TAPINAROF - VTAMA | | | | | | | |
| N 215272 001 | | 10195160 | May 23, 2036 | DP | | | |
| | | 12569453 | Dec 18, 2039 | U-4048 | | | |
| TAVAPADON - JUVMO (COPACKAGED) | | | | | | | |
| N 220415 001 | >A> | 10093655 | Jun 23, 2034 | U-219 | | >A> NCE | Sep 25, 2031 |
| | >A> | 10421744 | Jun 23, 2034 | U-219 | | | |
| | >A> | 9107923 | Jun 23, 2034 | DS DP | | | |
| | >A> | 9527831 | Jun 23, 2034 | DS DP | | | |
| TAVAPADON - JUVMO | | | | | | | |
| N 220415 002 | >A> | 10093655 | Jun 23, 2034 | U-219 | | >A> NCE | Sep 25, 2031 |
| | >A> | 10421744 | Jun 23, 2034 | U-219 | | | |
| | >A> | 9107923 | Jun 23, 2034 | DS DP | | | |
| | >A> | 9527831 | Jun 23, 2034 | DS DP | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|---|
| TAVAPADON - JUVMO | | | | | | | | | |
| N 220415 | 003 | >A> | 10093655 | Jun 23, 2034 | | U-219 | | >A> NCE | Sep 25, 2031 |
| | | >A> | 10421744 | Jun 23, 2034 | | U-219 | | | |
| | | >A> | 9107923 | Jun 23, 2034 | DS | DP | | | |
| | | >A> | 9527831 | Jun 23, 2034 | DS | DP | | | |
| TAVAPADON - JUVMO | | | | | | | | | |
| N 220415 | 004 | >A> | 10093655 | Jun 23, 2034 | | U-219 | | >A> NCE | Sep 25, 2031 |
| | | >A> | 10421744 | Jun 23, 2034 | | U-219 | | | |
| | | >A> | 9107923 | Jun 23, 2034 | DS | DP | | | |
| | | >A> | 9527831 | Jun 23, 2034 | DS | DP | | | |
| TEBIPENEM PIVOXIL HYDROBROMIDE - UTEBZI | | | | | | | | | |
| N 215960 | 001 | | 10889587 | Feb 06, 2038 | DS | DP U-4570 | | NCE | Jun 17, 2031 |
| | | | 12226403 | Dec 15, 2037 | | DP U-4569 | | GAIN | Jun 17, 2036 |
| TECHNETIUM TC-99M LABELED CARBON - TECHNEGAS KIT | | | | | | | | | |
| N 022335 | 001 | | 7722856 | Feb 24, 2031 | | U-4442 | | | |
| TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT | | | | | | | | | |
| N 202207 | 001 | >A> | 12404349 | Oct 03, 2043 | DS | DP | | | |
| TENAPANOR HYDROCHLORIDE - IBSRELA | | | | | | | | | |
| N 211801 | 001 | | 12539299 | Nov 26, 2042 | | DP | | | |
| TENAPANOR HYDROCHLORIDE - XPHOZAH | | | | | | | | | |
| N 213931 | 001 | | 12539299 | Nov 26, 2042 | | DP | | | |
| TENAPANOR HYDROCHLORIDE - XPHOZAH | | | | | | | | | |
| N 213931 | 002 | | 12539299 | Nov 26, 2042 | | DP | | | |
| TENAPANOR HYDROCHLORIDE - XPHOZAH | | | | | | | | | |
| N 213931 | 003 | | 12539299 | Nov 26, 2042 | | DP | | | |
| TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY | | | | | | | | | |
| N 208464 | 001 | | | | | | | NPP | Mar 27, 2027 |
| TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) | | | | | | | | | |
| N 209863 | 001 | | 12629483 | Aug 07, 2035 | | DP | | | |
| TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) | | | | | | | | | |
| N 209863 | 002 | | 12629483 | Aug 07, 2035 | | DP | | | |
| TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) | | | | | | | | | |
| N 209863 | 003 | | 12629483 | Aug 07, 2035 | | DP | | | |
| TESTOSTERONE UNDECANOATE - JATENZO | | | | | | | | | |
| N 206089 | 001 | | 12605391 | Apr 12, 2039 | | U-1103 | | | |
| TESTOSTERONE UNDECANOATE - JATENZO | | | | | | | | | |
| N 206089 | 002 | | 12605391 | Apr 12, 2039 | | U-1103 | | | |
| TESTOSTERONE UNDECANOATE - JATENZO | | | | | | | | | |
| N 206089 | 003 | | 12605391 | Apr 12, 2039 | | U-1103 | | | |
| TESTOSTERONE UNDECANOATE - TLANDO | | | | | | | | | |
| N 208088 | 001 | | 12691057 | Apr 28, 2041 | | DP U-4194 | | | |
| THIOTEPA - TEPADINA AND SODIUM CHLORIDE | | | | | | | | | |
| N 208264 | 004 | | 9931458 | May 31, 2037 | | DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| THIOTEPA - TEPYLUTE | | | | | | | | |
| N 216984 | 001 | | 12622921 | Aug 16, 2041 | U-4530 | | | |
| THIOTEPA - TEPYLUTE | | | | | | | | |
| N 216984 | 002 | | 12622921 | Aug 16, 2041 | U-4530 | | | |
| TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF | | | | | | | | |
| N 207981 | 001 | | 12728130 | Feb 03, 2037 | DP U-3657 | | | |
| | | | 12728130 | Feb 03, 2037 | DP U-3658 | | | |
| TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF | | | | | | | | |
| N 207981 | 002 | | 12728130 | Feb 03, 2037 | DP U-3657 | | | |
| | | | 12728130 | Feb 03, 2037 | DP U-3658 | | | |
| TIRATRICOL - EMCITATE | | | | | | | | |
| N 220963 | 001 | >A> | 12611383 | Jul 07, 2045 | DP U-4617 | | >A> NCE | Sep 28, 2031 |
| TIRBANIBULIN - KLISYRI | | | | | | | | |
| N 213189 | 001 | | 12667576 | Mar 12, 2038 | U-4577 | | | |
| TIRZEPATIDE - MOUNJARO (AUTOINJECTOR) | | | | | | | | |
| N 215866 | 001 | | 12343382 | Jul 22, 2039 | U-4229 | | NPP | Dec 19, 2028 |
| | | | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | | | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | | | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | | | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | | | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | | | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | | | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | | | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | | | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | | | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | | | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO (AUTOINJECTOR) | | | | | | | | |
| N 215866 | 002 | | 12343382 | Jul 22, 2039 | U-4229 | | NPP | Dec 19, 2028 |
| | | | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | | | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | | | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | | | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | | | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | | | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | | | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | | | 12616740 | Jul 22, 2039 | U-4501 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 215866 002 | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO (AUTOINJECTOR) | | | | | | |
| N 215866 003 | 12343382 | Jul 22, 2039 | U-4229 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO (AUTOINJECTOR) | | | | | | |
| N 215866 004 | 12343382 | Jul 22, 2039 | U-4229 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO (AUTOINJECTOR) | | | | | | |
| N 215866 005 | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 215866 005 | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO (AUTOINJECTOR) | | | | | | |
| N 215866 006 | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 007 | 12343382 | Jul 22, 2039 | U-4229 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 008 | 12343382 | Jul 22, 2039 | U-4229 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 009 | 12343382 | Jul 22, 2039 | U-4229 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 010 | 12343382 | Jul 22, 2039 | U-4229 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 215866 010 | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 011 | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 012 | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12453755 | Jun 14, 2039 | U-4375 | | | |
| | 12453755 | Jun 14, 2039 | U-4376 | | | |
| | 12453755 | Jun 14, 2039 | U-4377 | | | |
| | 12453755 | Jun 14, 2039 | U-4378 | | | |
| | 12453755 | Jun 14, 2039 | U-4379 | | | |
| | 12453755 | Jun 14, 2039 | U-4380 | | | |
| | 12453755 | Jun 14, 2039 | U-4381 | | | |
| | 12453755 | Jun 14, 2039 | U-4382 | | | |
| | 12453755 | Jun 14, 2039 | U-4383 | | | |
| | 12453755 | Jun 14, 2039 | U-4384 | | | |
| | 12453755 | Jun 14, 2039 | U-4385 | | | |
| | 12453755 | Jun 14, 2039 | U-4386 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4533 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4534 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 013 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 215866 013 | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 014 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 015 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 016 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 017 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO | | | | | | |
| N 215866 018 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 215866 018 | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO KWIKPEN | | | | | | |
| N 215866 019 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO KWIKPEN | | | | | | |
| N 215866 020 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO KWIKPEN | | | | | | |
| N 215866 021 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO KWIKPEN | | | | | | |
| N 215866 022 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | NPP | Dec 19, 2028 |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| TIRZEPATIDE - MOUNJARO KWIKPEN | | | | | | |
| N 215866 023 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | | |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - MOUNJARO KWIKPEN | | | | | | |
| N 215866 024 | 12295987 | Dec 30, 2041 | U-4192 | | NCE | May 13, 2027 |
| | 12295987 | Dec 30, 2041 | U-4193 | | | |
| | 12343382 | Jul 22, 2039 | U-4229 | | | |
| | 12343382 | Jul 22, 2039 | U-4230 | | | |
| | 12343382 | Jul 22, 2039 | U-4231 | | | |
| | 12343382 | Jul 22, 2039 | U-4232 | | | |
| | 12343382 | Jul 22, 2039 | U-4400 | | | |
| | 12343382 | Jul 22, 2039 | U-4401 | | | |
| | 12616740 | Jul 22, 2039 | U-4500 | | | |
| | 12616740 | Jul 22, 2039 | U-4501 | | | |
| | 12616740 | Jul 22, 2039 | U-4502 | | | |
| | 9474780 | May 13, 2036 | DS DP U-4374 | | | |
| TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR) | | | | | | |
| N 217806 001 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR) | | | | | | |
| N 217806 002 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR) | | | | | | |
| N 217806 003 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR) | | | | | | |
| N 217806 004 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 217806 004 | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR) | | | | | | |
| N 217806 005 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR) | | | | | | |
| N 217806 006 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 007 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 008 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 009 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 010 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 011 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 012 | 12343382 | Jul 22, 2039 | U-4227 | | | |
| | 12343382 | Jul 22, 2039 | U-4228 | | | |
| | 12343382 | Jul 22, 2039 | U-4409 | | | |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4531 | | | |
| | 12629404 | Jun 14, 2039 | DP U-4532 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 013 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 014 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 015 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 016 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 017 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND | | | | | | |
| N 217806 018 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND KWIKPEN | | | | | | |
| N 217806 019 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| N 217806 019 | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND KWIKPEN | | | | | | |
| N 217806 020 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND KWIKPEN | | | | | | |
| N 217806 021 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND KWIKPEN | | | | | | |
| N 217806 022 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND KWIKPEN | | | | | | |
| N 217806 023 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |
| | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | 9474780 | May 13, 2036 | DS DP | | | |
| TIRZEPATIDE - ZEPBOUND KWIKPEN | | | | | | |
| N 217806 024 | 12343382 | Jul 22, 2039 | U-4227 | | I-958 | Dec 20, 2027 |
| | 12343382 | Jul 22, 2039 | U-4228 | | M-82 | Oct 18, 2027 |
| | 12343382 | Jul 22, 2039 | U-4409 | | NCE | May 13, 2027 |
| | 12343382 | Jul 22, 2039 | U-4410 | | | |
| | 12453758 | Jul 22, 2039 | U-4308 | | | |
| | 12453758 | Jul 22, 2039 | U-4309 | | | |
| | 12453758 | Jul 22, 2039 | U-4310 | | | |
| | 12453758 | Jul 22, 2039 | U-4311 | | | |
| | 12616740 | Jul 22, 2039 | U-4497 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| N 217806 024 | | 12616740 | Jul 22, 2039 | U-4498 | | | |
| | | 12616740 | Jul 22, 2039 | U-4499 | | | |
| | | 9474780 | May 13, 2036 | DS DP | | | |
| TIVOZANIB HYDROCHLORIDE - FOTIVDA | | | | | | | |
| N 212904 001 | >A> | 12778944 | Nov 05, 2039 | U-4640 | | | |
| TIVOZANIB HYDROCHLORIDE - FOTIVDA | | | | | | | |
| N 212904 002 | >A> | 12778944 | Nov 05, 2039 | U-4640 | | | |
| TRABECTEDIN - EVDI | | | | | | | |
| N 220837 001 | | 12303506 | Feb 18, 2043 | DP | | | |
| TRADIPITANT - NEREUS | | | | | | | |
| N 220152 001 | | 10772880 | Mar 04, 2036 | U-4396 | | | |
| | | 10821099 | Mar 04, 2036 | U-4396 | | | |
| | | 11324735 | Mar 04, 2036 | U-4396 | | | |
| | | 12318375 | Aug 09, 2036 | U-4396 | | | |
| TREOSULFAN - GRAFAPEX | | | | | | | |
| N 214759 001 | | 7199162 | Oct 12, 2026 | U-4142 | | | |
| TREOSULFAN - GRAFAPEX | | | | | | | |
| N 214759 002 | | 7199162 | Oct 12, 2026 | U-4142 | | | |
| TREPROSTINIL - TYVASO | | | | | | | |
| N 022387 001 | >A> | 12734143 | Apr 16, 2041 | U-3749 | | | |
| TREPROSTINIL - TYVASO DPI | | | | | | | |
| N 214324 001 | | 12679811 | Mar 14, 2034 | U-1849 | | | |
| | | 12679811 | Mar 14, 2034 | U-3749 | | | |
| | >A> | 12740954 | Apr 16, 2041 | U-3749 | | | |
| TREPROSTINIL - TYVASO DPI | | | | | | | |
| N 214324 002 | | 12679811 | Mar 14, 2034 | U-1849 | | | |
| | | 12679811 | Mar 14, 2034 | U-3749 | | | |
| | >A> | 12740954 | Apr 16, 2041 | U-3749 | | | |
| TREPROSTINIL - TYVASO DPI | | | | | | | |
| N 214324 003 | | 12679811 | Mar 14, 2034 | U-1849 | | | |
| | | 12679811 | Mar 14, 2034 | U-3749 | | | |
| | >A> | 12740954 | Apr 16, 2041 | U-3749 | | | |
| TREPROSTINIL - TYVASO DPI | | | | | | | |
| N 214324 004 | | 12679811 | Mar 14, 2034 | U-1849 | | | |
| | | 12679811 | Mar 14, 2034 | U-3749 | | | |
| | >A> | 12740954 | Apr 16, 2041 | U-3749 | | | |
| TREPROSTINIL - TYVASO DPI | | | | | | | |
| N 214324 005 | | 12679811 | Mar 14, 2034 | U-1849 | | | |
| | | 12679811 | Mar 14, 2034 | U-3749 | | | |
| | >A> | 12740954 | Apr 16, 2041 | U-3749 | | | |
| TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR | | | | | | | |
| N 215760 001 | | 12662445 | May 03, 2039 | DS DP U-4262 | | | |
| TRIHEPTANOIN - DOJOLVI | | | | | | | |
| N 213687 001 | | 12551461 | Nov 14, 2034 | DP | | | |
| | >A> | 12766123 | Nov 14, 2034 | U-4631 | | | |
| | >A> | 12766124 | Nov 14, 2034 | U-4631 | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| TRILACICLIB DIHYDROCHLORIDE - COSELA | | | | | | |
| N 214200 001 | 12527798 | Dec 05, 2037 | U-3504 | | | |
| TROFINETIDE - DAYBUE | | | | | | |
| N 217026 001 | 11370755 | Aug 03, 2040 | DS DP | | NCE | Mar 10, 2028 |
| | 11370755*PED | Feb 03, 2041 | | | ODE-425 | Mar 10, 2030 |
| | 11827600 | Jul 12, 2042 | DS DP U-3556 | | PED | Sep 10, 2028 |
| | 11827600*PED | Jan 12, 2043 | | | PED | Sep 10, 2030 |
| | 12492167 | Jul 12, 2042 | DS DP U-3556 | | | |
| | 12492167*PED | Jan 12, 2043 | | | | |
| | 9212204 | Jan 27, 2032 | U-3556 | | | |
| | 9212204*PED | Jul 27, 2032 | | | | |
| TROFINETIDE - DAYBUE STIX | | | | | | |
| N 219884 001 | 11370755 | Aug 03, 2040 | DS DP | | NCE | Mar 10, 2028 |
| | 11370755*PED | Feb 03, 2041 | | | ODE* | Mar 10, 2030 |
| | 11827600 | Jul 12, 2042 | DS DP U-3556 | | PED | Sep 10, 2028 |
| | 11827600*PED | Jan 12, 2043 | | | PED | Sep 10, 2030 |
| | 12492167 | Jul 12, 2042 | DS DP U-3556 | | | |
| | 12492167*PED | Jan 12, 2043 | | | | |
| | 9212204 | Jan 27, 2032 | U-3556 | | | |
| | 9212204*PED | Jul 27, 2032 | | | | |
| TROFINETIDE - DAYBUE STIX | | | | | | |
| N 219884 002 | 11370755 | Aug 03, 2040 | DS DP | | NCE | Mar 10, 2028 |
| | 11370755*PED | Feb 03, 2041 | | | ODE* | Mar 10, 2030 |
| | 11827600 | Jul 12, 2042 | DS DP U-3556 | | PED | Sep 10, 2028 |
| | 11827600*PED | Jan 12, 2043 | | | PED | Sep 10, 2030 |
| | 12492167 | Jul 12, 2042 | DS DP U-3556 | | | |
| | 12492167*PED | Jan 12, 2043 | | | | |
| | 9212204 | Jan 27, 2032 | U-3556 | | | |
| | 9212204*PED | Jul 27, 2032 | | | | |
| TROFINETIDE - DAYBUE STIX | | | | | | |
| N 219884 003 | 11370755 | Aug 03, 2040 | DS DP | | NCE | Mar 10, 2028 |
| | 11370755*PED | Feb 03, 2041 | | | ODE* | Mar 10, 2030 |
| | 11827600 | Jul 12, 2042 | DS DP U-3556 | | PED | Sep 10, 2028 |
| | 11827600*PED | Jan 12, 2043 | | | PED | Sep 10, 2030 |
| | 12492167 | Jul 12, 2042 | DS DP U-3556 | | | |
| | 12492167*PED | Jan 12, 2043 | | | | |
| | 9212204 | Jan 27, 2032 | U-3556 | | | |
| | 9212204*PED | Jul 27, 2032 | | | | |
| TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY | | | | | | |
| N 216158 001 | 12558317 | Oct 29, 2039 | DP | | | |
| TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY | | | | | | |
| N 216158 002 | 12558317 | Oct 29, 2039 | DP | | | |
| TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY | | | | | | |
| N 216158 003 | 12558317 | Oct 29, 2039 | DP | | | |
| TUCATINIB - TUKYSA | | | | | | |
| N 213411 001 | 8648087 | Apr 17, 2034 | DS DP | | >A> I-1003 | Oct 07, 2029 |
| TUCATINIB - TUKYSA | | | | | | |
| N 213411 002 | 8648087 | Apr 17, 2034 | DS DP | | >A> I-1003 | Oct 07, 2029 |
| UPADACITINIB - RINVOQ | | | | | | |
| N 211675 001 | 12570664 | Oct 17, 2036 | U-4454 | | ODE-538 | Apr 28, 2032 |
| VADADUSTAT - VAFSEO | | | | | | |
| N 215192 001 | 12569474 | Jun 04, 2034 | U-3876 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| VADADUSTAT - VAFSEO | | | | | | |
| N 215192 002 | 12569474 | Jun 04, 2034 | U-3876 | | | |
| VADADUSTAT - VAFSEO | | | | | | |
| N 215192 003 | 12569474 | Jun 04, 2034 | U-3876 | | | |
| VAMOROLONE - AGAMREE | | | | | | |
| N 215239 001 | 8334279 | Apr 23, 2034 | U-3747 | | | |
| VARENICLINE TARTRATE - TYRVAYA | | | | | | |
| N 213978 001 | 12576080 | Oct 19, 2035 | U-1900 | | | |
| | 12653824 | Oct 19, 2035 | DP | | | |
| VEPDEGESTRANT - VEPPANU | | | | | | |
| N 219835 001 | 10647698 | Jan 30, 2038 | DS DP | | NCE | May 01, 2031 |
| | 10899742 | Dec 01, 2037 | U-4278 | | | |
| | 11597720 | Dec 01, 2037 | DS DP U-4278 | | | |
| VEPDEGESTRANT - VEPPANU | | | | | | |
| N 219835 002 | 10647698 | Jan 30, 2038 | DS DP | | NCE | May 01, 2031 |
| | 10899742 | Dec 01, 2037 | U-4278 | | | |
| | 11597720 | Dec 01, 2037 | DS DP U-4278 | | | |
| VERICIGUAT - VERQUVO | | | | | | |
| N 214377 001 | | | | | D-198 | Jan 21, 2029 |
| VERICIGUAT - VERQUVO | | | | | | |
| N 214377 002 | | | | | D-198 | Jan 21, 2029 |
| VERICIGUAT - VERQUVO | | | | | | |
| N 214377 003 | | | | | D-198 | Jan 21, 2029 |
| VIGABATRIN - VIGAFYDE | | | | | | |
| N 217684 001 | 12576054 | Jun 08, 2043 | DP | | | |
| VIMSELTINIB - ROMVIMZA | | | | | | |
| N 219304 001 | 12509443 | Apr 30, 2045 | DP | | | |
| | 12528787 | Dec 06, 2044 | DS DP | | | |
| | 12551483 | Dec 06, 2044 | DP | | | |
| | 12582655 | Dec 23, 2039 | U-4145 | | | |
| | 12617775 | Dec 06, 2044 | DS DP | | | |
| | 12643883 | Dec 06, 2044 | DS DP | | | |
| | 12686672 | Apr 30, 2045 | DP | | | |
| VIMSELTINIB - ROMVIMZA | | | | | | |
| N 219304 002 | 12509443 | Apr 30, 2045 | DP | | | |
| | 12528787 | Dec 06, 2044 | DS DP | | | |
| | 12551483 | Dec 06, 2044 | DP | | | |
| | 12582655 | Dec 23, 2039 | U-4145 | | | |
| | 12617775 | Dec 06, 2044 | DS DP | | | |
| | 12643883 | Dec 06, 2044 | DS DP | | | |
| | 12686672 | Apr 30, 2045 | DP | | | |
| VIMSELTINIB - ROMVIMZA | | | | | | |
| N 219304 003 | 12509443 | Apr 30, 2045 | DP | | | |
| | 12528787 | Dec 06, 2044 | DS DP | | | |
| | 12551483 | Dec 06, 2044 | DP | | | |
| | 12582655 | Dec 23, 2039 | U-4145 | | | |
| | 12617775 | Dec 06, 2044 | DS DP | | | |
| | 12643883 | Dec 06, 2044 | DS DP | | | |
| | 12686672 | Apr 30, 2045 | DP | | | |

# PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| VOCLOSPORIN - LUPKYNIS | | | | | | | |
| N 213716 001 | | 7332472 | Oct 17, 2027 | DS DP U-3056 | | | |
| VONOPRAZAN FUMARATE - VOQUEZNA | | | | | | | |
| N 215151 001 | | 7977488 | Apr 10, 2030 | DS | | | |
| VONOPRAZAN FUMARATE - VOQUEZNA | | | | | | | |
| N 215151 002 | | 7977488 | Apr 10, 2030 | DS | | | |
| VOSORITIDE - VOXZOGO | | | | | | | |
| N 214938 001 | >A> | 10646550 | Aug 01, 2036 | U-3927 | | | |
| | | 12514906 | Aug 01, 2036 | DP U-3927 | | | |
| | | 8198242 | Jun 11, 2035 | DS DP U-3927 | | | |
| VOSORITIDE - VOXZOGO | | | | | | | |
| N 214938 002 | >A> | 10646550 | Aug 01, 2036 | U-3927 | | | |
| | | 12514906 | Aug 01, 2036 | DP U-3927 | | | |
| | | 8198242 | Jun 11, 2035 | DS DP U-3927 | | | |
| VOSORITIDE - VOXZOGO | | | | | | | |
| N 214938 003 | >A> | 10646550 | Aug 01, 2036 | U-3927 | | | |
| | | 12514906 | Aug 01, 2036 | DP U-3927 | | | |
| | | 8198242 | Jun 11, 2035 | DS DP U-3927 | | | |
| VUTRISIRAN SODIUM - AMVUTTRA | | | | | | | |
| N 215515 001 | | | | | | ODE-527 | Mar 20, 2032 |
| ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET | | | | | | | |
| N 216386 001 | | 8481546 | Jun 26, 2034 | DS DP U-3555 | | | |
| ZIDESAMTINIB - JIDEYTRO | | | | | | | |
| N 220185 001 | | 11542278 | May 05, 2041 | DS DP | | NCE | Jul 22, 2031 |
| | | 12043626 | Sep 30, 2042 | DS DP | | | |
| | | 12054498 | May 05, 2041 | U-4579 | | | |
| | | 12630560 | Sep 30, 2042 | U-4579 | | | |
| ZIDESAMTINIB - JIDEYTRO | | | | | | | |
| N 220185 002 | | 11542278 | May 05, 2041 | DS DP | | NCE | Jul 22, 2031 |
| | | 12043626 | Sep 30, 2042 | DS DP | | | |
| | | 12054498 | May 05, 2041 | U-4579 | | | |
| | | 12630560 | Sep 30, 2042 | U-4579 | | | |
| ZIFTOMENIB - KOMZIFTI | | | | | | | |
| N 220305 001 | | 12521396 | Jul 16, 2044 | DP | | | |
| ZILGANERSEN SODIUM - ZANVASTRO | | | | | | | |
| N 220210 001 | | 11786546 | May 20, 2041 | DS DP U-4601 | | | |
| ZILURGISERTIB FUMARATE - ATEBRIOZ | | | | | | | |
| N 221198 001 | >A> | 10710980 | Jul 18, 2037 | DS DP | >A> | NCE | Sep 25, 2031 |
| | >A> | 10947218 | Jul 18, 2037 | U-4626 | | | |
| | >A> | 12466808 | May 24, 2039 | DS DP U-4626 | | | |
| ZOLIFLODACIN - NUZOLVENCE | | | | | | | |
| N 219491 001 | | 8658641 | Jun 20, 2030 | DS | | | |
| | | 8889671 | Jan 21, 2034 | DS U-4369 | | | |
| | | 9040528 | Oct 13, 2029 | U-4369 | | | |
| | | 9187495 | Jan 21, 2034 | DS U-4369 | | | |
| | | 9540394 | Jan 21, 2034 | U-4369 | | | |
| | | 9839641 | Jan 21, 2034 | U-4369 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2026

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ZONISAMIDE - ZONISADE | | | | | | |
| N 214273 001 | 12685723 | Aug 18, 2038 | DP | | | |

# PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 46TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm